<SEC-DOCUMENT>0001410578-24-001519.txt : 20240819
<SEC-HEADER>0001410578-24-001519.hdr.sgml : 20240819
<ACCEPTANCE-DATETIME>20240819160705
ACCESSION NUMBER:		0001410578-24-001519
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		99
FILED AS OF DATE:		20240819
DATE AS OF CHANGE:		20240819

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PSYENCE BIOMEDICAL LTD.
		CENTRAL INDEX KEY:			0001985062
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-281644
		FILM NUMBER:		241220471

	BUSINESS ADDRESS:	
		STREET 1:		121 RICHMOND STREET WEST PENTHOUSE
		STREET 2:		SUITE 1300
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5H 2K1
		BUSINESS PHONE:		27744604171

	MAIL ADDRESS:	
		STREET 1:		121 RICHMOND STREET WEST PENTHOUSE
		STREET 2:		SUITE 1300
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5H 2K1
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>pbm-20240331xf1.htm
<DESCRIPTION>F-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 8/19/2024 7:07:56 PM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: 9b826869-a1fb-46e0-8d21-d8739a3370a2 -->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pbm="http://www.psyence.com/20240331" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="dei:EntityCentralIndexKey" id="Tc_RFvFL2GgeUuceS88mbiQjA_2_1">0001985062</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="dei:EntityEmergingGrowthCompany" id="Tc_s9Hfb1wgCkiM6ZGrHI_0uA_3_1">true</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="dei:EntityExTransitionPeriod" id="Tc_1j4CdkyFU0q7femyEQfxZA_4_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="dei:AmendmentFlag" id="Tc_l1v8oTwaGUSYK_npxsIYUg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" id="Hidden_XxB_F4KMEE25cXOfcM4pEQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="INF" name="pbm:NumberOfWarrantsOutstanding" id="Hidden_s2yDhvbquUGMuaS1WGntNA">13070000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ" decimals="INF" name="pbm:NumberOfWarrantsIssued" id="Hidden_x8bw_yf0B0-hUxug_gXzGw">12500000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ" decimals="INF" name="pbm:NumberOfWarrantsOutstanding" id="Hidden_zlOG_EIIqEixGctRvHNJ-A">570000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="INF" name="ifrs-full:NumberOfSharesOutstanding" id="Hidden_t5Q4ViJtT0a_n3x8PTtDQg">13390659</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_xeKCbUv1EkKwDZisFjFScw" name="pbm:ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" id="Hidden_8zLKxnneHEOziY32s6_j8Q">P35D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_z-3r1zgdRUar9YFq_BAsYw" name="pbm:ThresholdPeriodForVolumeWeightedAveragePrice" id="Hidden_bgTt3-yaZkufZ6GsyM4Hmw">P30D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="dei:DocumentType" id="Hidden_dYH7SUvFfk6sgj6PCvfaJA">F-1</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pbm-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_z-3r1zgdRUar9YFq_BAsYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_15_2024_To_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_t2bpJrv-CEWvzpwrJA9aDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-15</xbrli:startDate><xbrli:endDate>2024-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_xeKCbUv1EkKwDZisFjFScw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_23_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_1M028Mwq5kytRxpB_bSdUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">pbm:BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_EDSUwdQ36UKTQvA2QAr00A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_0wYG8t1HXE-O2rRhbaBJaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MgMsfnVGck2AmUnYInyYOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_bvPGj60BfUSrD5EMG-60sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_TE-tT_L3DE-Ydn-lI9Eu5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Hjb5c9ngrEaYgdmgugFj6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_ThirdPartyAdvisorsMember_mC8mvXWyOki084m60qbTKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:ThirdPartyAdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_KTMtplbPx0WC_t5qQhav6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_RC1H4ZLwU0apeImJQBE_dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_15_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_AFjT0Vhi0UeLxeHCocK_EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">pbm:BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_25_2024_To_1_25_2024_eZQ4RlMJqUmySF9gmBlrAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_pbm_IfrsTaxPeriodAxis_pbm_TaxYear2044Member_WwE4lXg6VE6ETeoIPfEQ6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="pbm:IfrsTaxPeriodAxis">pbm:TaxYear2044Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_pbm_IfrsTaxPeriodAxis_pbm_IndefinitePeriodMember_X0xZ3jp2mkq_3uYS8sNVww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember><xbrldi:explicitMember dimension="pbm:IfrsTaxPeriodAxis">pbm:IndefinitePeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_RIjV61siK0uleVe4MSXSMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ay66gT7zZ0uREQ7yRI0cAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pbm:ReverseTakeoverTransactionWithNcacAxis">pbm:NcacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember_T_SrbOBOBUmz9DO4DYwbFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:UnaffiliatedThirdPartyInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember__hvPDjzjLUyCCDf5J2hfyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:UnaffiliatedThirdPartyInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_16_2024_To_6_16_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_Kkk9C124KESJe8OR92o3TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-16</xbrli:startDate><xbrli:endDate>2024-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_lrZq_P2lj0W1n0ER5UZe2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pbm:ReverseTakeoverTransactionWithNcacAxis">pbm:NcacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_LZT5nK0-7UestTgckCLkuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pbm:ReverseTakeoverTransactionWithNcacAxis">pbm:NcacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ZZfEBp5vhECip57BNE-wtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_EyC98DIUWkSnV6ZsDXjDuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_15_2024_To_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_TVvUizpQt0O2JuSrfGUeqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-15</xbrli:startDate><xbrli:endDate>2024-01-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_w3jAzl07ZUOTF5NYOWIMug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_snyZUpSh_k-8or2abjhYpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_T9W7od1CnEWSc0EL6UeLCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">pbm:BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_H47wk_lCv0mLLYxNgeLpyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">pbm:BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_WarrantsIssuedOnJanuary252024Member_Ge_kREe1AE-p07ojtGFkCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:WarrantsIssuedOnJanuary252024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_fldBCEgE6kSkrzCFgPayzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:DebtIssuedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o-z_ZS_GkkqdhTX8BnXnaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:DebtIssuedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_cEdgQ5bJd06uTqKWAeXLww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_CBu0LGH96Uq1bwkLGIZIlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_0Qw1JPRffk-sFJICGMRYNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_-EyNTF-GgkaIrUlPa35XIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_Se9-CIpcRkaZzb8oP9NClQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_569tQMQIbUuCRwNdZsHxOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_SZy8rGHGj06aGJODffVKug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_srt_StatementScenarioAxis_pbm_UntilFirstResetDateMember_xUD9ygGdy0ikpiUdFa3HuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pbm:UntilFirstResetDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_srt_StatementScenarioAxis_pbm_OnSecondResetDateMember_xTV-TVOmlEOSuiCCH637yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pbm:OnSecondResetDateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2023_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_wL0j3sQ_P02l4cmD5Xha0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_dOTID6jPYEuNrAYNswuBQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-20</xbrli:startDate><xbrli:endDate>2024-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RzTFDy0njUmWjdXWuxBKzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-20</xbrli:startDate><xbrli:endDate>2024-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_GWT3zleBVUqWPPvqxVkOFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_w55DsmyS8EihPG7FoizvZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-15</xbrli:startDate><xbrli:endDate>2024-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_21_2023_To_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_4lNLIUCIGkWdqrARdGf_Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-21</xbrli:startDate><xbrli:endDate>2023-08-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_FIOBwMXOW0G4Rh9Kg-g5zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_8aaTSxqRuk2-CUB0EpgfuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:HistoricalDailyVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_0n6lL7b98kK_7fXZv3ARAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:HistoricalAnnualVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_DiscountRateSharesMeasurementInputMember_T-qLZ5GLyUqYuqKzU6A99Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:DiscountRateSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_DiscountRateCashMeasurementInputMember_9zeIuNj3jkeNuHkmFUSZww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:DiscountRateCashMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_AnnualInterestRateMeasurementInputMember_rlp9Ay7neEuAWClA72ZtUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:AnnualInterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_ifrs-full_ConstantPrepaymentRateMeasurementInputMember_OOYtrkOvCkOAIWIIs2K24g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:ConstantPrepaymentRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_kXEDmraaCEyS6VFHtQQhVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedLifeMeasurementInputMember_VCLVBTHMYEOISLzWk8xClg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExpectedLifeMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedDividendYieldMeasurementInputMember_SJAHRg26zES9xeoq_XHY8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExpectedDividendYieldMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExercisePriceMeasurementInputMember_MsEFN7RVDUWdk_1PcKNO4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExercisePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Z65vDr3AykS8Ay5XjpdTIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_iwqqB_9GUE6i4oPg6dByJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_mklxx0Juv0KNIx9Swl1rqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedLifeMeasurementInputMember_4vaXn8GAh0W1rO5og87law"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExpectedLifeMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedDividendYieldMeasurementInputMember_VFv-YHMmsUK_zTq5IChJuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExpectedDividendYieldMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExercisePriceMeasurementInputMember_xlkc7XKVtk2Kga0Muvve7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExercisePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_nDnNEVpGr0yCKCdSdpxUUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_C7czhwq_XUix_v98K7IvfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-05</xbrli:startDate><xbrli:endDate>2023-10-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_-EfQBvs7Lka4G6nGPl75Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_Rt33JWhG7ku7cESAe2Q9TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-25</xbrli:startDate><xbrli:endDate>2024-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PysenceBiomedIICorpMember_G26BZFrZI02CLYH9Vu0ViA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">pbm:PysenceBiomedIICorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PsyenceAustraliaPtyLtd.Member_6XWCmWdVH0epdAirb_PHmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">pbm:PsyenceAustraliaPtyLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_NewcourtAcquistionCorpMember_RS2hbyZeVE21RshMW0SvfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">pbm:NewcourtAcquistionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_1QeYdHjl3EWi94YMiSvNOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_ipePrLsiFUeta9xYIvy-Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_xjrxvVhFRE2AUu-5qZqFxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_BDylPQLgv0aDtOticTwZeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Y8ha6ksYVkK1MvnJV2HJKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_zZkoynDJMUmruO9PlmDnHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-15</xbrli:startDate><xbrli:endDate>2024-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_17_2024_To_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_TakD6semK0yRl952XvE8qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_31_2024_To_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_n_9pkBhIOEaocJLzvCa1KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-31</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember_P86XfCLzD0iMCh0cmIVomA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:UnaffiliatedThirdPartyInvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_DRqwp1PzKECgohUZ8NbYwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_G3Bu9s5MGkyw9paFYnaXQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RxOFqjiYkk-14gPIVMGVgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_BJrV3lqLKEyRyjAj25AV4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_WCUD7D3O30eL671BNA5zOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_dXrtFPMS3U-OLj3sZ1COaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_p40vy71k1EO-ouLsmL1rWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_Q5QpV3tf5Ea3fIz2QATK7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pbm:ThirdPartyAdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_hsBM3S00RUmiCZS-VgNMhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pbm:ThirdPartyAdvisorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_3f-lrQXd4E6JrxjlD7INuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_qlM5Q3rZkUqmLNL6sPVskw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3QvCsKmuG0iNZ278OZUdsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_H4W4G8XGKUi_LOkR72lsQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:WarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pbm:IfrsClassOfWarrantOrRightAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PublicWarrantsMember_dwZDj5CY_kWj6NkZwas54g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:WarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pbm:IfrsClassOfWarrantOrRightAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PublicWarrantsMember_ZIGv0avMc0GYY8eOD0yDqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:WarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pbm:IfrsClassOfWarrantOrRightAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_0tIdiQ7fUEKkoN3p-hLo-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:WarrantLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="pbm:IfrsClassOfWarrantOrRightAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_0gDwTd2QTkau6NL_MH7NiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_a6DRGR0kP0CtkXqAEpTHbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsPromissoryNoteMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1MqeGaZQTkmZ9uo64ysG4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsPromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_5wmoOjA370-BDjmpcYZTtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsPromissoryNoteMember_9ScKY7OBvU6qJkoGTvZzKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsPromissoryNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_DrXtvzbxdUuHFqH8Mzx6Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_9W7HSkN-ZEWhSSTlLJLMYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_GVpNsIbN90GJv-LofUYMOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_gpUJ9iKr40yfgmBdIh8i8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_fZwi28Ln9kCZ-qKFXmRfrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Am2J6wS5NU2pK_QwXcD3tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_h3aSU-K3ukq60Id9Kf0N4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:DebtIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_aKXOxKCzikiefTsqg-KknQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:DebtIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_HzIBP-BDS0iBcUlFJmYxvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_AmT7G0GxkU2kHfFmvoXWyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Pj4XiiixQkW2C1vuJhevIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_fDdHxo-EdE-nSoM7ApAHWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4Ep3QBgg9E-C5EIM6WXlUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_tuvfzSbZYUSwJW82QolpRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_I2azYclQNUyISbz7ooT7Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_c2lWJEMjh0WThzeAGu23wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_5KKmfXcG5UWbCL--sLIg7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_Dw3sdk3PW0qHioYev-uYqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_-XClE6sYLESe4Ac51L39fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_XpSCtJGVFEW3JU9sTAbAHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_1-dfoVe4v0uYJUHIYSGRgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_ebbDbrQcZkK0zv4fy_SFHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_nAJQDxrBpkSuuvZsO96n0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_pbm_LoanLiabilityMember_Bfg_MzgGgE248VkLkaHv1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">pbm:LoanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_ComputerEquipmentMember_7jZCSqZ_9UaOraMsvT_DUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_ifrs-full_GeographicalAreasAxis_country_AU_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_oXkJbW1flU65sYmCYJGLPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_pbm_LoanLiabilityMember_IYWYvzYJfU2ryBzR65Zllg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">pbm:LoanLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_tIiRp3n8-02l_21JjlykGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_sCiZc0LkzEif6BGm_OtlfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_gwAintdcuUyQ_JwYJbceZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_srt_StatementScenarioAxis_pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_miXMAYbfxkOSULYF69B0Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pbm:NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_srt_StatementScenarioAxis_pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_5hN9t5cHDkWZRJOTiq9-ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pbm:NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_nExNeJnlAkCUbDgmBzFjag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_PM6a_iQxqU-pxFt4cy2t8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_xbkoUUMcMU-zQH04gc1B7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_nXcMNI1ydUezo0_dxGEwgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_Ov4A1NkLkEa1t15pEcI7Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_ieM9jWT5V0m51QaeqASX4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="pbm:ReverseTakeoverTransactionWithNcacAxis">pbm:NcacMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_3_31_2022_JQf3C7gGZUeF0m5KrvQUIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA__NbCY8cPYUCtxWf2hnkGgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_GeographicalAreasAxis_country_CA_ipl1RTFCVU6OA2u7sgwd-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_ZRqYyGoYrU2C6-I2Wd8ynA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001985062</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Options_7uzaMjMwKkiCpqW1np5Gkw"><xbrli:measure>pbm:Options</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_AUD_jW69VxHF6ECitQL_0ZsRRw"><xbrli:measure>iso4217:AUD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A"><xbrli:measure>pbm:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Y_GuMP1MngLk2rtbNTk6zhew"><xbrli:measure>pbm:Y</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_efa13061_2f59_40e0_9628_740364a2ece9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As filed with the Securities and Exchange Commission on August 19, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Registration No.&#160;333-</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:2pt 0pt 0pt 0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:4.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Form&#160;</b><span style="-sec-ix-hidden:Hidden_dYH7SUvFfk6sgj6PCvfaJA;"><b style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:bold;">F-1</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">REGISTRATION STATEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNDER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">THE SECURITIES ACT OF 1933</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="dei:EntityRegistrantName" id="Narr_EV0phqS2LEax6jJgabd8IQ"><b style="font-weight:bold;">Psyence Biomedical&#160;Ltd.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><i style="font-style:italic;">(Exact Name of Registrant as Specified in Its Charter)</i></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:29.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Ontario, Canada</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:29.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">2834</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.46%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Not Applicable</b></p></td></tr><tr><td style="vertical-align:top;width:32.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">(State or Other Jurisdiction of <br/>Incorporation or Organization)</p></td><td style="vertical-align:top;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:29.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(Primary Standard Industrial<br/>Classification Code Number)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S.&#160;Employer<br/>Identification Number)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">121 Richmond Street West</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Penthouse Suite 1300</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Toronto, Ontario MK5 2K1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:3pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Telephone: + 1 (416) 346-7764</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Puglisi&#160;&amp; Associates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">850 Library Ave., Suite&#160;204</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Newark, Delaware 19711</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Telephone: (302) 738-6680</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-style:italic;font-weight:bold;">Copies to:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Ari Edelman</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Edelman Advisory LLC</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">400 Rella Boulevard, Suite 165</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Suffern, New York 10901</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(845) 533-3435</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Approximate date of commencement of proposed sale of the securities to the public: </b>As soon as practicable after this Registration Statement becomes effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">If this form is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">If this form is a post-effective amendment filed pursuant to Rule&#160;462(c)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">If this Form&#160;is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act&#160;of&#160;1933.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">Emerging growth company&#160;<span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:0pt;margin:0pt;">If an emerging growth company that prepares its financial statements in accordance with U.S.&#160;GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><span style="font-size:9pt;">&#8224;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:2pt;margin-top:0pt;text-align:justify;"><span style="font-size:9pt;">The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&#160;5, 2012.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 2pt 0pt;"><b style="font-weight:bold;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1284411d_bfbc_451e_9757_64f49fe1cd34"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 36pt;"><b style="color:#d2232a;font-weight:bold;">PRELIMINARY PROSPECTUS, SUBJECT TO COMPLETION, DATED AUGUST 19, 2024</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 36pt;"><b style="color:#ff0000;font-weight:bold;background:#ffffff;">The information in this prospectus is not complete and may be changed. We may not issue these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 36pt;"><b style="font-weight:bold;">Psyence Biomedical&#160;Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 36pt;"><b style="font-weight:bold;">50,575,028 Common Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 54pt;">This prospectus relates to the potential offer and sale, from time to time, of an aggregate of 50,575,028 common shares, no par value (&#8220;<b style="font-weight:bold;">Common Shares</b>&#8221;), of Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada (&#8220;<b style="font-weight:bold;">Psyence</b>,&#8221; the &#8220;<b style="font-weight:bold;">Company</b>,&#8221; &#8220;<b style="font-weight:bold;">we</b>,&#8221; &#8220;<b style="font-weight:bold;">us</b>&#8221; or &#8220;<b style="font-weight:bold;">our</b>&#8221;) by the selling securityholders named in this prospectus (each a &#8220;<b style="font-weight:bold;">Selling Securityholder</b><span style="white-space:pre-wrap;">&#8221;), consisting of  (i) an aggregate of up to 50,375,000 Common Shares issuable by the Company to White Lion Capital, LLC (&#8220;</span><b style="font-weight:bold;">White Lion</b>&#8221;) as described herein, (ii) 3,000 Common Shares issued to Donohoe Advisory Associates LLC in full and final settlement of accrued service and advisory fees, (iii) 25,000 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery and (iv) an additional 172,028 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 54pt;">The Common Shares being offered by this prospectus represent vastly more than the number of our outstanding Common Shares, and the sales of such Common Shares, or the perception that those sales might occur, could depress the market price of our Common Shares and could impair our ability to raise capital through the sale of additional equity securities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 54pt;">Certain Common Shares to which this prospectus relates may be issued to White Lion pursuant to the Common Shares Purchase Agreement, dated July 25, 2024, by and between us and White Lion (the &#8220;<b style="font-weight:bold;">White Lion Purchase Agreement</b>&#8221;), establishing an equity line of credit. Such Common Shares include (a) up to 50,000,000 Common Shares that we may elect, in our sole discretion, to issue and sell to White Lion from time to time during the White Lion Commitment Period (as defined below) under the White Lion Purchase Agreement (assuming the shares to be issued are sold at a price of $0.50 per share and (b) 375,000 Common Shares (the &#8220;<b style="font-weight:bold;">Commitment Shares</b>&#8221;) issuable to White Lion as consideration for entering into the White Lion Purchase Agreement (assuming the shares to be issued are sold at a price of $0.50 per share). See &#8220;<i style="font-style:italic;">Selling Securityholders&#8212;The White Lion Transaction</i>&#8221; below for a description of the White Lion Purchase Agreement and for additional information regarding White Lion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 54pt;">The actual number of Common Shares issuable to White Lion will vary depending on the then-current market price of Common Shares sold to White Lion under the White Lion Purchase Agreement and are subject to the further limitations set forth in the White Lion Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 54pt;"><span style="white-space:pre-wrap;">We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of Common Shares by the Selling Securityholders. Additionally, we will not receive any proceeds from the issuance or sale of the Commitment Shares. However, we may receive gross proceeds of up to $25.0 million from the sale of our Common Shares to White Lion pursuant to the White Lion Purchase Agreement after the date of this prospectus.  The actual proceeds from White Lion may be less than this amount, depending on the number of Common Shares sold and the price at which the Common Shares are sold.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 54pt;">The Selling Securityholders may sell or otherwise dispose of the Common Shares described in this prospectus in a number of different ways and at varying prices. See &#8220;<i style="font-style:italic;">Plan of Distribution</i>&#8221; for more information about how the Selling Securityholders may sell or otherwise dispose of the Common Shares being registered pursuant to this prospectus. White Lion is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act. Each of the other Selling Securityholders may also be deemed an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 54pt;">The Selling Securityholders will pay all brokerage fees and commissions and similar expenses attributable to the sales of Common Shares. We will pay the expenses (except brokerage fees and commissions and similar expenses) incurred in registering the Common Shares offered hereby, including legal and accounting fees. See &#8220;<i style="font-style:italic;">Plan of Distribution</i>.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 54pt;">You should read this prospectus and any prospectus supplement or amendment carefully before investing in our securities. Our Common Shares trade on the Nasdaq Global Market under the symbol &#8220;PBM,&#8221; and certain of our warrants (the &#8220;<b style="font-weight:bold;">Public Warrants</b>&#8221;) trade on the Nasdaq Capital Market under the symbol &#8220;PBMWW.&#8221; On August 15, 2024, the last reported sales price of our Common Shares was $0.5093 per share and the last reported sales price of our Public Warrants was $0.0202 per Public Warrant.</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">We are a &#8220;foreign private issuer,&#8221; and an &#8220;emerging growth company&#8221; each as defined under the federal securities laws, and, as such, we are subject to reduced public company reporting requirements. See the section entitled &#8220;Prospectus Summary &#8212; Implications of Being an Emerging Growth Company and a Foreign Private Issuer&#8221; for additional information.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Investing in our securities involves a high degree of risk. You should purchase our securities only if you can afford to lose your entire investment. See the section entitled </b><span style="font-style:italic;font-weight:bold;">&#8220;Risk Factors,&#8221;</span><b style="font-weight:bold;"> which begins on page </b><span style="font-weight:bold;">25</span><b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined whether this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The date of this Prospectus is              , 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="TOC"></a><a id="_15008470_3c06_4396_82a3_dd7abf358439"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#ABOUTTHISPROSPECTUS_291984"><span style="font-style:normal;font-weight:normal;">About This Prospectus</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#FUNCTIONALANDREPORTINGCURRENCY_207982"><span style="font-style:normal;font-weight:normal;">Functional and Reporting Currency</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#INDUSTRYANDMARKETDATA_97820"><span style="font-style:normal;font-weight:normal;">Industry and Market Data</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#TRADEMARKSTRADENAMESANDSERVICEMARKS_9740"><span style="font-style:normal;font-weight:normal;">Trademarks, Trade Names and Service Marks</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#FREQUENTLYUSEDTERMS_119527"><span style="font-style:normal;font-weight:normal;">Frequently Used Terms</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PROSPECTUSSUMMARY_109598"><span style="font-style:normal;font-weight:normal;">Prospectus Summary</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PRICERANGEOFSECURITIESANDDIVIDENDS_89890"><span style="font-style:normal;font-weight:normal;">Price Range of Securities and Dividends</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">22</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#CAPITALIZATION_55609"><span style="font-style:normal;font-weight:normal;">Capitalization</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">23</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#DILUTION_343151"><span style="font-style:normal;font-weight:normal;">Dilution</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">24</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#RISKFACTORS_959159"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">25</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"><span style="font-style:normal;font-weight:normal;">Cautionary Note&#160;Regarding Forward-Looking Statements</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#USEOFPROCEEDS_470856"><span style="font-style:normal;font-weight:normal;">Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#SELLINGSHAREHOLDERS_643747"><span style="font-style:normal;font-weight:normal;">Selling Securityholders</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">56</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#PLANOFDISTRIBUTION_734861"><span style="font-style:normal;font-weight:normal;">Plan of Distribution</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#MANAGEMENTSDISCUSSIONANDANALYSISOFFINANC"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#BUSINESS_90630"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">65</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#MANAGEMENT_134401"><span style="font-style:normal;font-weight:normal;">Management</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#EXECUTIVEANDDIRECTORCOMPENSATION_302028"><span style="font-style:normal;font-weight:normal;">Director and Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">102</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#CERTAINRELATIONSHIPSANDRELATEDPERSONTRAN"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Person Transactions</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">109</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#BENEFICIALOWNERSHIPOFSECURITIES_464764"><span style="font-style:normal;font-weight:normal;">Beneficial Ownership of Securities</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">111</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#DESCRIPTIONOFSECURITIES_579886"><span style="font-style:normal;font-weight:normal;">Description of Securities</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">113</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#CERTAINMATERIALUSFEDERALINCOMETAXCONSIDE"><span style="font-style:normal;font-weight:normal;">Certain Material U.S Federal Income Tax Considerations</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">117</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#MATERIALCANADIANTAXCONSIDERATIONS_127128"><span style="font-style:normal;font-weight:normal;">Material Canadian Tax Considerations</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">121</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#EXPENSESRELATINGTOTHISOFFERING_33177"><span style="font-style:normal;font-weight:normal;">Expenses Related To This Offering</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">123</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#LEGALMATTERS_548671"><span style="font-style:normal;font-weight:normal;">Legal Matters</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">123</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#EXPERTS_102440"><span style="font-style:normal;font-weight:normal;">Experts</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">123</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#WHEREYOUCANFINDADDITIONALINFORMATION_564"><span style="font-style:normal;font-weight:normal;">Where You Can Find Additional Information</span></a></p></td><td style="vertical-align:bottom;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">123</p></td></tr><tr><td style="vertical-align:bottom;width:87.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><a href="#INDEXTOFINANCIALSTATEMENTS_783580"><span style="font-style:normal;font-weight:normal;">Index to Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">F-1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_63ed050f_d5e9_4769_86d3_86b84293f0dd"></a><a id="ABOUTTHISPROSPECTUS_291984"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ABOUT THIS&#160;PROSPECTUS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This prospectus is part of a registration statement on Form&#160;F-1 filed by Psyence with the U.S.&#160;Securities and Exchange Commission (the &#8220;<b style="font-weight:bold;">SEC</b>&#8221;), pursuant to which the Selling Securityholders may, from time to time, sell Common Shares through any means described in the section entitled &#8220;<i style="font-style:italic;">Plan of Distribution</i>.&#8221; More specific terms of any securities that the Selling Securityholders offer and sell may be provided in a prospectus supplement that describes, among other things, the specific amounts and prices of the Common Shares being offered and the terms of the offering. We will not receive any proceeds from the sale by the Selling Securityholders of the securities offered by them described in this prospectus. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A prospectus supplement may also add, update or change information included in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. You should rely only on the information contained in this prospectus and any applicable prospectus supplement. See the section entitled <i style="font-style:italic;">&#8220;Where You Can Find More Information.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or any accompanying prospectus supplement we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus or any applicable prospectus supplement. This prospectus is not an offer to sell our securities, and it is not soliciting an offer to buy our securities, in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate only as of the date on the front of those documents, regardless of the time of delivery of this prospectus or any applicable prospectus supplement. Our business, financial condition, results of operations and prospects may have changed since those dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;<i style="font-style:italic;">Where You Can Find More Information</i>.&#8221;</p><a id="_3db1d163_9f2e_46c0_9783_2491522f0a85"></a><a id="FUNCTIONALANDREPORTINGCURRENCY_207982"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FUNCTIONAL AND REPORTING CURRENCY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s management believes that the U.S.&#160;dollar is the currency of the primary economic environment in which it operates. Thus, the functional and reporting currency for Psyence is the U.S.&#160;dollar.</p><a id="_fbf6ae45_292d_42a1_b451_62471fa67cc1"></a><a id="INDUSTRYANDMARKETDATA_97820"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDUSTRY AND MARKET DATA</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In this prospectus, we present industry data, information and statistics regarding Psyence&#8217;s industry, business and the markets in which Psyence competes as well as publicly available information, industry and general publications and research and studies conducted by third parties. This information is supplemented where necessary with Psyence&#8217;s own internal estimates and information obtained from discussions with its customers, taking into account publicly available information about other industry participants and Psyence&#8217;s management&#8217;s judgment where information is not publicly available. This information appears in &#8220;Prospectus Summary,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Business&#8221; and other sections of this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry and general publications, government data and similar sources that we believe to be reliable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. While we have compiled, extracted and reproduced industry data from these sources, we have not independently verified the data. Industry publications, research, studies and forecasts generally state that the information they contain has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. Forecasts </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and other forward-looking information obtained from these sources are subject to the same qualifications and uncertainties as the other forward-looking statements in this prospectus. These forecasts and forward-looking information are subject to uncertainty and risk due to a variety of factors, including those described under &#8220;<i style="font-style:italic;">Risk Factors</i>.&#8221; These and other factors could cause results to differ materially from those expressed in any forecasts or estimates.</p><a id="_a63237be_17d2_45d1_a943_264eb85b5b56"></a><a id="TRADEMARKSTRADENAMESANDSERVICEMARKS_9740"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TRADEMARKS, TRADE NAMES AND SERVICE MARKS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This prospectus includes trademarks, tradenames and service marks, certain of which belong to Psyence and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus appear without the <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, TM and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our or their rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a3b55b6d_d875_4675_81d5_75aabca75757"></a><a id="FREQUENTLYUSEDTERMS_119527"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FREQUENTLY USED TERMS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise stated or unless the context otherwise requires in this document:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Articles of Incorporation&#8221; means the Company&#8217;s Articles of Incorporation, as registered on June&#160;29, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Board&#8221; means the board of directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Biomed II&#8221; or &#8220;Psyence II&#8221; means Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Business Combination&#8221; means the business combination transaction pursuant to which, among other things, (i)&#160;Parent contributed Biomed II to the Company in a share for share exchange and (ii)&#160;immediately thereafter, Merger Sub merged with and into NCAC, with NCAC being the surviving company in the merger and each outstanding NCAC Ordinary Share being converted into the right to receive one Common Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Business Combination Agreement&#8221; means the Amended and Restated Business Combination Agreement, dated as of July&#160;31, 2023, as amended on November&#160;9, 2023, by and among NCAC, Sponsor, Parent, the Company, Merger Sub, Psyence Biomed Corp. and Biomed II.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Cantor&#8221; means Cantor Fitzgerald&#160;&amp; Co.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;CCM&#8221; means Cohen&#160;&amp; Company Capital Markets, a division of J.V.B. Financial Group LLC, an affiliate of a passive member of the Sponsor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Closing&#8221; means the consummation of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Closing Date&#8221; means January&#160;25, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Code&#8221; means the Internal Revenue Code of 1986, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Common Shares&#8221; means the common shares of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Company Exchange&#8221; means the exchange in which Parent contributed Biomed II to the Company in a share for share exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Continental&#8221; means Continental Stock Transfer&#160;&amp; Trust Company, our transfer agent and warrant agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Effective Time&#8221; means the effective time of the Merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Exchange Act&#8221; means the Securities Exchange Act of 1934, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;IFRS&#8221; means the International Financial Reporting Standards issued by the International Accounting Standards Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;IPO&#8221; means NCAC&#8217;s initial public offering of NCAC Public Units, consummated on October&#160;22, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;JOBS Act&#8221; means the Jumpstart Our Business Startups Act of 2012, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Lock-Up Agreement&#8221; means the lock-up agreement, dated as of January&#160;25, 2024, by and among the Company, NCAC and certain shareholders of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Merger&#8221; means the merger in which Merger Sub merged with and into NCAC, with NCAC being the surviving company in the merger and each outstanding NCAC Ordinary Share being converted into the right to receive one Common Share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Merger Sub&#8221; means Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a direct and wholly owned subsidiary of the Company.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Nasdaq&#8221; means The Nasdaq Stock Market&#160;LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC&#8221; means Newcourt Acquisition Corp, a Cayman Islands exempted company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Class&#160;A Ordinary Shares&#8221; means NCAC&#8217;s Class&#160;A Ordinary Shares, par value $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Class&#160;B Ordinary Shares&#8221; means NCAC&#8217;s Class&#160;B Ordinary Shares, par value $0.0001 per share, which were converted into NCAC Class&#160;A Ordinary Shares on a one-for-one-basis on October&#160;20, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Ordinary Shares&#8221; means the NCAC Class&#160;A Ordinary Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Private Placement Shares&#8221; means the NCAC Class&#160;A Ordinary Shares included in the NCAC Private Placement Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Private Placement Units&#8221; means the units, each unit consisting of one NCAC Private Placement Share and one-half of one NCAC Private Placement Warrant, purchased in a private placement in connection with the IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Private Placement Warrants&#8221; means the warrants to purchase NCAC Ordinary Shares underlying the NCAC Private Placement Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Public Shareholders&#8221; means the holders of NCAC Public Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Public Shares&#8221; means NCAC Class&#160;A Ordinary Shares issued as part of the NCAC Public Units sold in the IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Public Units&#8221; means the 25,000,000 units issued in connection with the IPO, each of which consists of one NCAC Class&#160;A Ordinary Share and one-half of one NCAC Public Warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Public Warrants&#8221; means the warrants included in the NCAC Public Units sold in the IPO, each of which is exercisable for one NCAC Class&#160;A Ordinary Share, in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Units&#8221; means the NCAC Public Units and the NCAC Private Placement Units, collectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;NCAC Warrants&#8221; means the NCAC Public Warrants and the NCAC Private Placement Warrants, collectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;OBCA&#8221; means the Business Corporations Act (Ontario).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Original Business Combination Agreement&#8221; means that certain Business Combination Agreement entered into on January&#160;9, 2023 by and among, NCAC, the Sponsor, Parent and Psyence Biomed Corp.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Parent&#8221; or &#8220;PGI&#8221; means Psyence Group&#160;Inc., a corporation organized under the laws of Ontario, Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;PCAOB&#8221; means the Public Company Accounting Oversight Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Private Warrants&#8221; means the former NCAC Private Placement Warrants, which were converted at the Effective Time into a right to acquire one Common Share on substantially the same terms as were in effect immediately prior to the Effective Time under the terms of the Warrant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Psyence&#8221; or the &#8220;Company&#8221; means Psyence Biomedical,&#160;Ltd., a corporation organized under the laws of Ontario, Canada, and where context warrants, including its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Public Warrants&#8221; means the former NCAC Public Warrants, which were converted at the Effective Time into a right to acquire one Common Share on substantially the same terms as were in effect immediately prior to the Effective Time under the terms of the Warrant Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;SEC&#8221; means the U.S. Securities and Exchange Commission.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Securities Act&#8221; means the Securities Act of 1933, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Sponsor&#8221; means Newcourt SPAC Sponsor LLC, a Delaware limited liability company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Sponsor Support Agreement&#8221; means the support agreement, dated as of January&#160;18, 2024, by and among the Sponsor and the officers and directors of NCAC, in their capacities as shareholders of NCAC, NCAC and Psyence, pursuant to which such shareholders of NCAC agreed to, among other things, vote in favor of the Business Combination and other related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Structuring Shares&#8221; means the 3,000,000 Common Shares that are payable to certain investors (the &#8220;<b style="font-weight:bold;">Investors</b>&#8221;) as a structuring fee pursuant the Securities Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Trading Market&#8221; means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTCQB, or the OTCQX (or any successors to any of the foregoing).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Treasury Regulations&#8221; means the regulations, including proposed and temporary regulations, promulgated under the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Trust Account&#8221; means the trust account that held the net proceeds of the sale of the NCAC Public Units in the IPO and the sale of the NCAC Private Placement Units.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Underwriting Agreement&#8221; means the Underwriting Agreement, dated October&#160;19, 2021, entered into at the time of the IPO by and between NCAC and Cantor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;U.S. GAAP&#8221; means generally accepted accounting principles in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;VWAP&#8221; means for any date, the price determined by the first of the following clauses that applies: (a) if the Common Shares are then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Shares for such date (or the nearest preceding date) on the Trading Market on which the Common Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)); provided, however, that if the Common Shares are then listed or quoted on more than one Trading Market, then the Trading Market for purposes of any calculations to be made pursuant to the terms of the First Tranche Notes shall be the Trading Market selected by the Investors in their sole discretion, (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Shares are then reported in the &#8220;Pink Sheets&#8221; published by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Shares so reported, or (d) in all other cases, the fair market value of a Common Share as determined by an independent appraiser selected in good faith by the Investors and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Warrant Agreement&#8221; means the warrant agreement, dated October&#160;19, 2021, by and between NCAC and Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, governing NCAC&#8217;s warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Warrants&#8221; means the Private Warrants and the Public Warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Warrant Shares&#8221; means the Common Shares issuable upon exercise of the Warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><a id="_19e4dea2_e58c_4482_a5c8_e1ba0701d045"></a><a id="PROSPECTUSSUMMARY_109598"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PROSPECTUS SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our securities. You should read this entire prospectus carefully, including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The securities being offered by this prospectus represent vastly more than the number of our outstanding Common Shares, and the sales of such securities, or the perception that those sales might occur, could depress the market price of our Common Shares and could impair our ability to raise capital through the sale of additional equity securities. See &#8220;Risk Factors &#8211; The securities being offered in this prospectus represent a substantial percentage of our outstanding Common Shares, and the sales of such shares, or the perception that these sales could occur, could cause the market price of our Common Shares to decline significantly&#8221;.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Overview</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a life science biotechnology company that, through our operating subsidiary, Biomed II, is developing natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. We have commenced the clinical trial process to evaluate the safety and efficacy of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We strive to set the global standard for excellence and consistency in drug development using nature-based psilocybin products. Psyence&#8217;s priority is developing pharmaceutical grade psilocybin to help heal psychological trauma and the diagnosable disorders that can result therefrom, including AjD, alcohol use disorder (&#8220;<b style="font-weight:bold;">AUD</b>&#8221;), other substance use disorders (&#8220;<b style="font-weight:bold;">SUDs</b>&#8221;), anxiety, depression, post-traumatic stress disorder (&#8220;<b style="font-weight:bold;">PTSD</b>&#8221;), and grief and bereavement, especially in the context of palliative care. Our focus includes therapeutic protocols for medical and scientific research including observational studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate is PEX010, a capsule containing 25mg naturally sourced psilocybin and which is being used in our Phase IIb Study. Psyence has entered into a license agreement (the &#8220;<b style="font-weight:bold;">Research IP Agreement</b>&#8221;) with Filament Health Corp., a Canadian company that produces natural psilocybin capsules and the proprietary owner of PEX010 (&#8220;<b style="font-weight:bold;">Filament</b>&#8221;), for the licensing of PEX010 with respect to Psyence&#8217;s designated fields of use: anxiety and depression, including associated ailments, such as PTSD, stress, grief, and adjustment disorder within the context of palliative care. See &#8220;&#8212; <i style="font-style:italic;">Licensing of PEX010</i>&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have contracted iNGEN&#363; Pty Ltd (&#8220;<b style="font-weight:bold;">iNGEN&#363;</b>&#8221;), a contract research organization (&#8220;<b style="font-weight:bold;">CRO</b>&#8221;)&#160;in Australia that specializes in the study of psychedelics, to conduct a Phase&#160;IIb double-blind, randomized, low-dose controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder (&#8220;<b style="font-weight:bold;">AjD</b>&#8221;) due to incurable cancer (the &#8220;<b style="font-weight:bold;">Phase IIb Study</b>&#8221;). Outsourcing the study to a CRO assists the company in operating in a more capital efficient manner without the overhead of handling in-house.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase IIb Study&#160;- Palliative Care Clinical Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;9, 2023, Psyence and iNGEN&#363; signed a letter of intent to further develop Psyence&#8217;s licensed natural psilocybin drug product, starting with a Phase&#160;IIb Study in order to lead a pre-IND meeting with the FDA. The product to be used in this Phase&#160;IIb Study will be the proprietary botanical drug candidate PEX010 (25mg), which Psyence sources from Filament. The planned randomized double-blind study will evaluate the use of psilocybin-assisted psychotherapy versus psychotherapy alone and will test 84 patients utilizing the HAM A scale as the primary endpoint, which is an FDA validated endpoint, and safety data will be collected throughout the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For safety, there are no specific endpoints as all safety findings are captured as adverse events. The primary and secondary efficacy endpoints are all established in the protocol before it is reviewed and approved by the Ethics Committee before the study can start.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The HAM-A is a rating scale developed to measure the severity of anxiety symptoms and is widely used in both clinical and research settings. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental </p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). During the Phase II Study, the HAM-A scale will be used to measure change in anxiety levels over time as the primary endpoint.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The 84-patient Phase IIb Study being conducted by the CRO, iNGEN&#363;, in Australia is the one that has been referred to in discussions with the FDA in the pre-IND process, which is in the late planning stage, and estimated to commence enrollment in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The estimated costs of this Phase IIb Study were initially $5,575,000 made on the basis of milestones completed. Included in this original estimate were costs for 75 participants; an end of Phase II meeting preparation and attendance after the completion of the Phase IIb study with the FDA as well as psychotherapy training, psychotherapy sessions and therapist fees for participants. Subsequently, the Phase IIb Study was increased to 84 patients, and we anticipate the estimated cost of this study to be increased by approximately&#160;5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;15, 2022, we received full approval of a study (the &#8220;<b style="font-weight:bold;">UK Trial</b>&#8221;) in the United Kingdom from the UK Medicines and Healthcare products Regulatory Agency (&#8220;<b style="font-weight:bold;">MHRA</b>&#8221;)&#160;using natural psilocybin in the field of palliative care with oncology patients. For this study, we had partnered with Clerkenwell Clinics Limited (&#8220;<b style="font-weight:bold;">Clerkenwell Health</b>&#8221;), which would have been responsible for jointly designing and delivering the UK Trial. Following such approval, we opted to forego proceeding with the UK Trial in order to pursue the opportunity to conduct the Phase&#160;IIb Study in Australia, as Psyence could benefit from the Australian Federal Government&#8217;s Research&#160;&amp; Development tax incentive program, which could provide up to a 43.5% rebate on Psyence&#8217;s R&amp;D expenses in Australia, making it a more cost-effective endeavor. In addition, the Phase&#160;IIb Study adds a dose-finding arm, which allows us to accelerate our development strategy, seeking input from the FDA with our pre-IND application. On March&#160;5, 2024, Psyence received full approval of the Phase IIb Study from to the Australian Human Research Ethics Committees (HRECs), the body responsible for the review of research proposals involving human participants to ensure that they are ethically acceptable. If the outcome of the Phase IIb Study is positive, we believe we may be able to proceed directly to a Phase III trial in the United States, subject to FDA review and the opening of an IND; however, there is no guarantee that the FDA will accept data from trials conducted outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Licensing of PEX010</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April&#160;2022, Psyence entered into the Research IP Agreement with Filament for the licensing of PEX010 and its associated intellectual property, as well as for the supply of PEX010 for the specific intention of the clinical development of the product, and ultimately, for the marketing authorization for PEX010&#8217;s use in palliative care patients. Pursuant to the Research IP Agreement, Filament grants to Psyence an irrevocable, royalty free, worldwide license (with the right to sub-license, subject to certain restrictions) to use and distribute PEX010 and certain related intellectual property (such as delivery mechanism, preparation methods and know-how) solely for use in connection with pre-clinical and clinical studies and trials to be conducted in Canada, the UK and world-wide in the treatment of anxiety and depression, including associated ailments, such as PTSD, stress, grief, and adjustment disorder within the context of palliative care. This license is granted in respect of the clinical trial phase of Psyence&#8217;s activities, specifically phase II clinical trials which, at present, consists of the Phase IIb Study. The license is granted on an exclusive basis solely within the territory of the UK with respect to the designated fields of use, and Psyence has a right of first refusal to extend its exclusive license beyond the territory of the UK. Psyence does not have any rights to use PEX010 for any profit-making or commercial purposes under the Research IP Agreement. Any results of testing, research, conduct of and any information derived from the clinical studies and trials using PEX010 shall be the sole property of Psyence. Under the Research IP Agreement, Filament is entitled to receive milestone payments of up to CAD$250,000 in aggregate based on four distinct phase II clinical trial milestones to be achieved by Psyence. Should Psyence pursue a second or multiple indications, such aggregate milestone payments will increase accordingly. For the&#160;year ended March&#160;31, 2024, Psyence incurred $167,306 costs under the Research IP Agreement related to milestone payments, which was accounted for as research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to the licensing rights described above, per the terms of the Research IP Agreement, Filament has undertaken to support Psyence&#8217;s clinical trial efforts through the supply of the required quantities of PEX010 to Psyence, for no additional charge, based on Psyence&#8217;s good faith forecasts of its needs. Filament will also create and provide such information, assistance and support for the execution of the dossiers,&#160;IMBP and other documents required to conduct Psyence&#8217;s clinical trials in accordance with the&#160;trial schedules. The license term is 5&#160;years, expiring in April&#160;2027, however the license may be terminated early (a)&#160;by either party upon notice to the other party, where Psyence notifies Filament in writing that all of its clinical trials have been completed or abandoned; (b)&#160;by a party upon notice to the other party, if the other party becomes subject to bankruptcy proceedings; (c)&#160;by a party if the other party commits a breach of a material term of the Research IP Agreement and fails to remedy such breach; or (d)&#160;by a party upon notice to the other party, if the other party has a licence, permit or approval revoked by competent authorities which compromises its ability </p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">to grant the licenses contemplated in the Research IP Agreement or its ability to perform under the Research IP Agreement. On July&#160;22, 2024, the parties concluded an addendum to the Research IP Agreement (&#8220;<b style="font-weight:bold;">Filament Addendum</b>&#8221;) whereby Filament undertook to provide a sufficient supply of PEX010 to Psyence in order to facilitate the substitution of an alternative drug candidate for use in Phase III trials and for commercialization purposes following the conclusion of the Phase IIb Study (&#8220;<b style="font-weight:bold;">Proposed End Product</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, Psyence entered into a royalty-bearing, binding term sheet for the commercial licensing of intellectual property (with the right to sub-license) from Filament, which was subject to the terms of a definitive license agreement, and granted Psyence the worldwide right to commercialize PEX010 within the designated fields of use, being anxiety and depression, including associated ailments, such as PTSD, stress, grief, and adjustment disorder within the context of palliative care. The term sheet remained subject to further negotiations between the parties and the execution of a subsequent definitive agreement within a predefined time period. Following further discussions, Psyence and Filament mutually agreed to terminate the term sheet by way of the Filament Addendum. Psyence is engaging two alternative suppliers of drug product for its pivotal Phase III studies as well as for future studies in other indications. Filament agreed to continue to support the supply PEX010 for the upcoming Phase IIb Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence is in the final stages of negotiating supply agreements, as well as licensing agreements for the use of third-party intellectual property, with two licensed suppliers operating in the United Kingdom and North America. Psyence intends to provide further updates on such agreements as they are executed, however, there can be no guarantees that such agreements will be finalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence has not performed any pre-clinical or clinical trials on PEX010. PEX010 is owned and has undergone clinical trials directed by Filament. PEX010 has received regulatory approval to proceed into Phase I and II clinical trials in several jurisdictions worldwide. The FDA, Health Canada, MHRA, and the EMA have reviewed the chemistry, manufacturing, and controls and quality information of PEX010 through its associated filed DMFs/ IMPDs. The DMF for PEX010 is also on file with the Therapeutic Goods Administration (the &#8220;<b style="font-weight:bold;">TGA</b>&#8221;) in Australia. In addition to clinical trials, PEX010 is also already being administered to real-world patients via the Health Canada Special Access Program (&#8220;<b style="font-weight:bold;">SAP</b>&#8221;). Through the SAP, PEX010 is being prescribed for end of life distress as well as Major Depressive Disorder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of July&#160;17, 2024, 156 doses of PEX010 have been administered to 132 patients. Despite the serious condition of many of these patients, no serious adverse events or unexpected adverse events have been reported in any SAP administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Relationships with Third Parties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s Australian-based research and development will be conducted by its CRO partner, iNGEN&#363;, in Australia. As stated above, Filament&#8217;s PEX010 will serve as the product candidate under investigation during the Phase&#160;IIb Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s R&amp;D capabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s CEO (Dr.&#160;Neil Maresky) and Medical Director (Dr.&#160;Clive Ward-Able) are both medically trained physicians with close to 60&#160;years of experience between them within the pharmaceutical industry related to R&amp;D and the commercialization of new products. This experience provides the foundations for an excellent understanding of the clinical development, regulatory and commercialization needs of various pharmaceutical markets to design the optimal development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence plans on working with various CROs and consultancy agencies to prepare and operationalize their protocols for the various phases of the clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Competitive Environment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are currently no pharmaceutical agents with regulatory approval for the treatment of AjD within palliative care or any other arena. The current treatment of AjD is empirical, with either psychotherapy or off- label pharmacological agents, such as anti-depressants or anxiolytics, or a combination of both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We believe that the competitive landscape analysis of other commercial psychedelic-assisted treatments in clinical trials strongly suggests that Psyence&#8217;s clinical asset has a first-mover advantage in both the palliative care and cancer-related AjD market upon approval. PEX010 and its associated IP has been licensed to Psyence, giving it exclusivity for the indications of anxiety and depression within the context of palliative care in the UK and exclusive commercialization rights in the same indications and fields of </p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">use in the UK, EU and US. Psyence plans to expand their targeted indication of cancer-related AjD to address different types of AjD and other secondary indications both in a palliative and non-palliative context.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">White Lion Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 25, 2024, the Company entered into a Common Shares Purchase Agreement (the &#8220;<b style="font-weight:bold;">White Lion Purchase Agreement</b>&#8221;) with White Lion Capital, LLC (&#8220;<b style="font-weight:bold;">White Lion</b>&#8221;) and a related Registration Rights Agreement (the &#8220;<b style="font-weight:bold;">RRA</b>&#8221;). Pursuant to the White Lion Purchase Agreement, the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to $25,000,000 in aggregate gross purchase price of newly issued Common Shares, subject to certain limitations and conditions set forth in the White Lion Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the satisfaction of certain customary conditions including, without limitation, the effectiveness of a registration statement registering the resale of the shares issuable pursuant to the White Lion Purchase Agreement, the Company&#8217;s right to sell shares to White Lion commenced on the date of the execution of White Lion Purchase Agreement and extends until the earlier of (i) White Lion having purchased Common Shares equal to $25,000,000 and (ii) two years from the date of execution of the White Lion Purchase Agreement (the &#8220;<b style="font-weight:bold;">Commitment Period</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the Commitment Period, subject to the terms and conditions of the White Lion Purchase Agreement, the Company may exercise its right to sell its Common Shares. The Company may deliver a Fixed Purchase Notice (as such term is defined in the White Lion Purchase Agreement), pursuant to which the Company can require White Lion to purchase up to a number of Common Shares equal to the lesser of (i) $250,000 or (ii) 50% of Average Daily Trading Volume (as such term is defined in the White Lion Purchase Agreement). The Company may also deliver a Rapid Purchase Notice (as such term is defined in the White Lion Purchase Agreement), pursuant to which the Company may require White Lion to purchase up to a number of Common Shares equal to the lesser of (i) 30% of the Average Daily Trading Volume and (ii) $4,000,000 divided by the highest closing price of the Common Shares over the most recent five business days immediately prior to the receipt of the notice. White Lion may waive such limits under any notice at its discretion and purchase additional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The price to be paid by White Lion for any shares that the Company requires White Lion to purchase will depend on the type of purchase notice that the Company delivers. For shares being issued pursuant to a Fixed Purchase Notice, the purchase price per share will be equal to 90% of the lowest VWAP (as defined in the White Lion Purchase Agreement) of the Common Shares that occurs during the five consecutive business days prior to the purchase notice. For shares being issued pursuant to a Rapid Purchase Notice, the purchase price per share will be equal to the lowest traded price on the date that the notice is delivered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No purchase notice shall result in White Lion beneficially owning (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder) more than 4.99% (subject to increase, in the sole discretion of White Lion, to 9.99%) of the number of Common Shares outstanding immediately prior to the issuance of Common Shares issuable pursuant to a purchase notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has the right to terminate the White Lion Purchase Agreement in the event of a material breach of the White Lion Purchase Agreement by White Lion. The White Lion Purchase Agreement also automatically terminates upon the earlier of (i) the end of the Commitment Period and (ii) the date that the Company commences a voluntary bankruptcy proceeding, a custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In consideration for the commitments of White Lion, as described above, the Company has agreed that it will issue to White Lion Common Shares (&#8220;<b style="font-weight:bold;">Commitment Shares</b>&#8221;) in an amount equal to (i) $187,500 divided by (ii) the closing price of the Common Shares on, (A) with respect to half of the Commitment Shares, the business day prior to the filing of the registration statement pursuant to the RRA and (B) with respect to the other half of the Commitment Shares, the business day prior to the 90th day following the filing of the registration statement pursuant to the RRA. The Commitment Shares will be fully earned by White Lion regardless of termination of the White Lion Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Concurrently with the Common Shares Purchase Agreement, the Company entered into the RRA with White Lion, pursuant to which the Company agreed to file, within 30 days following the execution of the White Lion Purchase Agreement, a resale registration </p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">statement with the SEC covering the resale by White Lion of the maximum number of shares permitted to be included therein in accordance with applicable SEC rules, regulations and interpretations and the Commitment Shares. The RRA also contains usual and customary damages provisions for failure to file and failure to have the registration statement declared effective by the SEC within the time periods specified therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The White Lion Purchase Agreement and the RRA contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Issuances of Shares to Vendors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 29, 2024, the Company issued 3,000 Common Shares issued to Donohoe Advisory Associates LLC in full and final settlement of accrued service and advisory fees. On May 29, 2024, the Company issued 25,000 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery. On August 12, 2024, the Company issued an additional 172,028 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Addendum to Securities Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On August 15, 2024, the Company entered into a first addendum (the &#8220;Addendum&#8221;) to the Securities Purchase Agreement, dated January 15, 2024, and related agreements, with the holders of the Company&#8217;s senior convertible notes. The Addendum shall become effective upon the issuance of certain securities by the Company to such holders by no later than August 27, 2024, as described below. Pursuant to the Addendum, the holders shall convert all outstanding First Tranche Notes and Second Tranche Notes at the applicable conversion price. The holders have also waived their respective rights to call an event of default with respect to certain deficiencies or to pursue any rights in connection therewith.  Pursuant to the Addendum, the conversion price of the portion of the Second Tranche Note not drawn down prior to August 13, 2024, and Third Tranche Note and Fourth Tranche Note, shall, at all times, be subject to a conversion floor of $0.50. In addition, (i) the Company is no longer restricted from issuing securities pursuant to the White Lion Purchase Agreement or pursuant to any future issuance at no less than $0.50 per share and (ii) the Company is no longer restricted from registering for resale any shares issued pursuant to the White Lion Purchase Agreement or pursuant to any future issuance of common shares at no less than $0.50 per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In consideration for the waiver and abandonment of the holders&#8217; claims and entitlements as contemplated in the Addendum, the Company shall pay the holders a fee in connection with future offerings as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>a cash fee equal to 50% of the aggregate gross proceeds raised at each closing of any future offering until $655,625.00 has been paid to the Holders; provided, however, that 50% of such fee may be paid in the form of common shares, in lieu of cash, at a price of $0.50 per share, in the event that within two months from the effective date of the Addendum the aggregate gross amount raised in any future offerings is less than $5,000,000;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>the Company shall issue to the holders or their respective designees 1,000,000 common shares; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</span></span>the Company shall issue to the holders or their respective designees warrants to purchase 500,000 common shares, with an exercise price of $0.50 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Such shares and warrants (and the shares underlying such warrants) shall be subject to the registration rights agreement previously entered into between the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, effective as of the effective date of the Addendum, the Holders have consented to the release from lock-up of 500,000 common shares held by Parent. In addition, effective as of five days following the Holders&#8217; conversion of outstanding Notes, the Holders have consented to the release from lock-up of an additional 500,000 common shares held by Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Nasdaq Notices</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On March 11, 2024, the Company received two letters from the listing qualifications department staff of The Nasdaq Stock Market (&#8220;<b style="font-weight:bold;">Nasdaq</b>&#8221;), one notifying the Company (the &#8220;<b style="font-weight:bold;">MVLS Notice</b>&#8221;) that for the last 30 consecutive business days, the Company&#8217;s </p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Market Value of Listed Securities (&#8220;<b style="font-weight:bold;">MVLS</b>&#8221;) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the &#8220;<b style="font-weight:bold;">Market Value Standard</b>&#8221;), and the other notifying the Company (the &#8220;<b style="font-weight:bold;">MVPHS Notice</b>&#8221;) that for the last 30 consecutive business days, the Company&#8217;s Market Value of Publicly Held Shares (&#8220;<b style="font-weight:bold;">MVPHS</b>&#8221;) was below the minimum of $15 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C) (the &#8220;<b style="font-weight:bold;">MVPHS Standard</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The MVLS Notice and the MVPHS Notice are only notifications of deficiencies and have no immediate effect on the listing of the Company&#8217;s securities. The Company&#8217;s securities continue to trade on Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days, or until September 9, 2024, to regain compliance with the Market Value Standard and the MVPHS Standard. The MVLS Notice states that to regain compliance, the Company&#8217;s MVLS must close at $50 million or more for a minimum of ten consecutive business days during the compliance period ending September 9, 2024, at which time Nasdaq will provide written notification that the Company has achieved compliance under the Market Value Standard and the matter will be closed. The MVPHS Notice states that to regain compliance, the Company&#8217;s MVPHS must close at $15 million or more for a minimum of ten consecutive business days during the compliance period ending September 9, 2024, at which time Nasdaq will provide written notification that the Company has achieved compliance under the MVPHS Standard and the matter will be closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company intends to actively monitor its MVLS and MVPHS and will evaluate available options to regain compliance with the Nasdaq continued listing standards. However, there can be no assurance that the Company will be able to regain compliance under the Market Value Standard and the MVPHS Standard, or will otherwise be in compliance with other Nasdaq listing criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 27, 2024, the Company Received a notification letter from the staff of Nasdaq notifying the Company that the&#160;Company&#8217;s closing&#160;bid price per share was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the&#160;minimum bid&#160;price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the &#8220;<b style="font-weight:bold;">Minimum Bid&#160;Price Rule</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq provided the Company with 180 calendar days, or until December 24, 2024 (the &#8220;<b style="font-weight:bold;">Compliance Period</b>&#8221;), to regain compliance with the&#160;Minimum Bid&#160;Price Rule. If at any time during the Compliance Period, the closing bid price per share of the Company&#8217;s common shares is at least $1.00 for a minimum of ten (10) consecutive business days, Nasdaq will provide the Company a written confirmation of compliance with the&#160;Minimum Bid&#160;Price Rule and the matter will be closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event the Company does not regain compliance with the&#160;Minimum Bid&#160;Price Rule by December 24, 2024, the Company may be eligible for additional time. To qualify, the Company must submit, no later than December 24, 2024, an on-line transfer application and submit a non-refundable $5,000 application fee. The Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effecting a reverse stock split, if necessary. As part of its review process, the Staff will make a determination of whether the Staff believes the Company will be able to cure this deficiency. If the Staff concludes that the Company will not be able to cure the deficiency, or if the Company determines not to submit a transfer application or make the required representation, Nasdaq will provide notice that the Company&#8217;s securities will be subject to delisting. If the Company chooses to implement a reverse stock split, it must complete the split no later than ten (10) business days prior to December 24, 2024, or the expiration of the second compliance period if granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The Nasdaq notification letter does not result in the immediate delisting of the Company&#8217;s common shares, and the common shares will continue to trade uninterrupted under the symbol &#8220;PBM.&#8221; The Company intends to consider its available options to resolve the Company&#8217;s noncompliance with the&#160;Minimum Bid&#160;Price Rule.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Consummation of the Business Combination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January&#160;25, 2024, we consummated the transactions contemplated by the Business Combination Agreement, pursuant to which (i)&#160;Parent contributed Biomed II to the Company in a share for share exchange, (ii)&#160;following the Company Exchange, Merger Sub merged with and into NCAC, with NCAC being the surviving company in the Merger, and each outstanding ordinary share of NCAC was converted into the right to receive one Common Share of the Company, and (iii)&#160;each outstanding warrant to purchase </p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">NCAC Class&#160;A Ordinary Shares was converted into a warrant to acquire one Common Share on substantially the same terms as were in effect immediately prior to the Effective Time under their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Securities Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;15, 2024, in connection with the Business Combination, the Company and Biomed II entered into the Securities Purchase Agreement with the Investors and the Sponsor, relating to up to four senior secured convertible notes obligations under which are guaranteed by certain assets of the Company and Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up to $12,500,000 in exchange for up to $10,000,000 in subscription amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The two First Tranche Notes, for an aggregate of $3,125,000, were delivered by the Company to the Investors on January&#160;25, 2024, in exchange for an aggregate of $2,500,000 in financing, which occurred substantially concurrently with, and was contingent upon, the consummation of the Business Combination. On the original issuance date of the First Tranche Notes, interest began accruing at 8.0% per annum based on the outstanding principal amount of the First Tranche Notes, and is payable&#160;monthly in arrears in cash or in Common Shares (at the Conversion Price). The initial Conversion Price of the First Tranche Notes&#160;was $10.00; provided, however, that such Conversion Price is subject to certain adjustments according to the terms and reset dates included in the First Tranche Notes&#160;and may be reduced to a Conversion&#160;Floor of $1.00, until the First Reset Date (as such term is defined in the First Tranche Notes), then to $0.50 on the Second Reset Date (as such term is defined in the First Tranche Notes) and to $0 thereafter. The provisions relating to the reset dates are as follows: Downward adjustments in the conversion price occur on five reset dates. The First Reset Date occurs five days prior to the date on which the Registration Statement of which this prospectus forms a part is declared effective. The Second Reset Date occurs on April 25, 2024, which is the three-month anniversary of the closing of the Business Combination. The third reset date (the &#8220;<b style="font-weight:bold;">Third Reset Date</b>&#8221;) occurs on July 25, 2024, which is the six-month anniversary of the closing of the Business Combination. The fourth reset date (the &#8220;<b style="font-weight:bold;">Fourth Reset Date</b>&#8221;) occurs on October 25, 2024, which is the nine-month anniversary of the closing of the Business Combination. The fifth reset date (the &#8220;<b style="font-weight:bold;">Fifth Reset Date</b>&#8221; and collectively with the First Reset Date, the Second Reset Date, the Third Reset Date and the Fourth Reset Date, the &#8220;<b style="font-weight:bold;">Reset Dates</b>&#8221;) occurs on January 25, 2025, which is the 12-month anniversary of the closing of the Business Combination. On each of the Reset Dates, the conversion price of the First Tranche Notes will be reset to the lower of (i) the $10.00 initial conversion price of the First Tranche Notes and (ii) the average daily VWAP for the previous ten Trading Days prior to such applicable Reset Date, but in no event less than the Conversion Floor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the downward adjustments made to the conversion price on each of the Reset Dates, the conversion price of the First Tranche Notes will also be adjusted in connection with the conversion of the First Tranche Notes, or the determination of the payment of interest in Common Shares, upon a conversion or a payment of interest, at any time after the date of the closing of the Business Combination and prior to the First Reset Date, in the event that at such date the Investors have not recouped at least an aggregate of $5,000,000 of their investments, to the lower of (i) $10.00 and (ii) the lowest daily VWAP of the Common Shares, during the period from the date of the closing of the Business Combination until the earlier of (a) the date of conversion or payment of interest or (b) the First Reset Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, if the average VWAP for the 30 Trading Days (the &#8220;<b style="font-weight:bold;">30-day VWAP</b>&#8221;) after a conversion is lower than the conversion price on the date of conversion, the Company is also required make a &#8220;make whole payment&#8221; in cash or Common Shares, at its election but subject to certain limitations, as described in the First Tranche Notes, determined as follows: The &#8220;make whole payment&#8221; equals the difference between (i) the principal amount converted on the date of conversion divided by 30-day VWAP and (ii) the principal amount converted divided by the conversion price on the date of conversion. The &#8220;make whole payment&#8221; is due no later than 35 Trading Days after the applicable date of conversion. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May&#160;31, 2024, the Notes (the &#8220;<b style="font-weight:bold;">Initial Second Tranche Notes</b>&#8221;) for the initial portion of the second tranche of the Financing (the &#8220;<b style="font-weight:bold;">Second Tranche</b>&#8221;), for a total of $312,500 of principal in exchange for a total of $250,000 in subscription amounts, were issued to the Investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June&#160;14, 2024, the Company issued two additional Notes&#160;(the &#8220;<b style="font-weight:bold;">First Subsequent Second Tranche Notes</b>&#8221;, and together with the Initial Second Tranche Notes&#160;and the Second Subsequent Second Tranche Notes&#160;(as defined below), the &#8220;<b style="font-weight:bold;">Second Tranche Notes</b>&#8221;) for an additional portion of the Second Tranche, for an aggregate total of $312,500 principal in exchange for $250,000 provided by the Investors. The Investors were not obligated to fund any of the Second Tranche because the Company was not in compliance with all of the covenants under the Securities Purchase Agreement. Notwithstanding the foregoing, the Investors agreed to fund an additional portion of the Second Tranche on such date and may continue to do so at its discretion.</p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2024, the Company issued two additional Notes&#160;(the &#8220;<b style="font-weight:bold;">Second Subsequent Second Tranche Notes</b>&#8221;) for an additional portion of the Second Tranche, for an aggregate total of $625,000 principal in exchange for $500,000 provided by the Investors. The Investors were not obligated to fund any of the Second Tranche because the Company was not in compliance with all of the covenants under the Securities Purchase Agreement. Notwithstanding the foregoing, the Investors agreed to fund an additional portion of the Second Tranche on such date and may continue to do so at its discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Second Tranche Notes&#160;are substantially the same as the First Tranche Notes, except that the conversion floor and first and second reset dates have been removed, as these applicable dates have passed. Interest on the Subsequent Second Tranche Notes&#160;accrues at 8.0% per annum, based on the outstanding principal amount of the Subsequent Second Tranche Notes, and is payable&#160;monthly in arrears in cash or in the Common Shares (at the applicable conversion price).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The initial conversion price for the Second Tranche Notes&#160;is the lowest daily VWAP during the period commencing on January&#160;25, 2024 until the earlier of (i)&#160;the date of conversion of the Second Tranche Notes&#160;and (ii)&#160;the date on which the registration statement for the shares underlying the First Tranche Note&#160;is declared effective (or May&#160;14, 2024) and is subject to reset on July&#160;25, 2024, October&#160;25, 2024, January&#160;25, 2025 in respect of the Initial Second Tranche Note&#160;and the First Subsequent Second Tranche Note&#160;and July&#160;25, 2024, October&#160;25, 2024, January&#160;25, 2025, July&#160;25, 2025, October&#160;25, 2025 in respect of the Second Subsequent Second Tranche Note, at which time the conversion price will be reset to the lower of (i)&#160;the initial conversion price and (ii)&#160;the average daily VWAP for the previous ten (10)&#160;trading&#160;days prior to such reset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Providing any financing with respect to the Third Tranche Notes&#160;and the Fourth Tranche Notes&#160;is at the sole discretion of the Investors. With respect to any financing relating to the Third Tranche Notes, the Investors may issue a commitment letter to the Company on or before the 30<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;day following the last funding of the Second Tranche Financing, assuming that the Second Tranche Financing has been provided. With respect to the Fourth Tranche Notes, the Investors may issue a commitment letter to the Company on or before the 90<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup>&#160;day after the last funding of the Second Tranche Financing, assuming that the Second Tranche Financing is provided. The Third Tranche Notes&#160;would be in an aggregate principal amount of $3,125,000 and would be delivered in exchange for an additional $2,500,000 in financing. This would be the same for the Fourth Tranche Notes. Additionally, in consideration of the willingness of the Investors to enter into the transactions that are the subject of the Securities Purchase Agreement and the Notes, including providing the financing, Psyence Biomedical agreed that it or certain of its shareholders would pay the Investors a structuring fee by delivering to the Investors an aggregate of 3,000,000 Structuring Shares. At the initial closing of the financing under the terms of the Securities Purchase Agreement, and concurrent with the closing of the Business Combination, 1,300,000 of the Structuring Shares were delivered to the Investors. The remaining 1,700,000 Structuring Shares are subject to the terms of Call Option Agreements, by and among the Investors and certain members of the Sponsor, pursuant to which such Common Shares are deliverable to the Investors no later than two business&#160;days after requested by the Investors; provided that no amounts shall be requested at any time that the Investors own in excess of 9.9% of the Company. Pursuant to the provisions of the Call Option Agreements, the Investors have been granted the option to require Tabula and Launchpad to each sell to the Investors such remaining 1,700,000 Structuring Shares they own at a price of $0.0001 per Common Share. The number of Common Shares which the Investors may purchase pursuant to the terms of the Call Option Agreements are subject to adjustments for share dividends and split ups. As of the date of this prospectus, the Investors have purchased all of the 1,700,000 Structuring Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to secure the repayment of the Notes&#160;by the Company and Biomed II, pursuant to the terms and conditions of a General Security Agreement, dated January&#160;25, 2024 (the &#8220;<b style="font-weight:bold;">Security Agreement</b>&#8221;), each agreed to grant to the Investors a security interest, subject to certain exceptions, in all of the Collateral (as such term is defined in the Security Agreement) in each of their possessions, including a pledge of all equity securities owned by either of them, provided that no Common Shares are pledged equity securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a Guaranty, dated January&#160;25, 2024. Biomed II also agreed to guaranty all of the Company&#8217;s obligations to the Investors under the Notes&#160;including, without limitation, payment of all installments of principal and interest thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In connection with the foregoing, on January&#160;25, 2024, the Company and the Investors entered into a registration rights agreement (the &#8220;<b style="font-weight:bold;">Registration Rights Agreement</b>&#8221;), pursuant to which the Company has agreed to file a registration statement covering the resale of the Common Shares issuable upon conversion of the First Tranche Notes&#160;(the &#8220;<b style="font-weight:bold;">Initial Resale Registration Statement</b>&#8221;) and any additional registration statements required to be filed to register the resale of the Common Shares issuable upon any of the other Notes, as applicable, and to use its best efforts to have the Initial Resale Registration Statement and such registration statement(s), as applicable, declared effective by the SEC as soon as practicable, but in no event later than the applicable Effectiveness Deadline (as defined in the Registration Rights Agreement for such applicable registration statement). Such Initial Resale Registration Statement was declared effective by the SEC on May 14, 2024 and is being amended by this Post-Effective Amendment. The Registration Rights </p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement contains certain penalty provisions, subject to certain conditions and cure periods, for the Company failing to (i)&#160;file a registration statement by certain deadlines set forth in the Registration Rights Agreement, (ii)&#160;cause a registration statement to be declared effective by certain deadlines set forth in the Registration Rights Agreement, (iii)&#160;maintain certain circumstances and conditions allowing the resale of certain securities or (iv)&#160;satisfy the requirements of Rule&#160;144(c)(1)&#160;under the Exchange Act if a registration statement is not effective. The Registration Rights Agreement also provides the Investors with customary piggyback registration rights under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the foregoing, on January&#160;25, 2024, NCAC and the Company entered into a lock-up agreement with certain shareholders of the Company (the &#8220;<b style="font-weight:bold;">Lock-Up Agreement</b>&#8221;), pursuant to which such shareholders agreed not to, during the period (the &#8220;<b style="font-weight:bold;">Lock-Up Period</b>&#8221;) commencing from the Closing and ending on the earliest of (x)&#160;one hundred eighty (180)&#160;days after the Closing; provided, however, that in the event that the Investors delay investment of the Subscription Amounts (as defined in the Securities Purchase Agreement) with respect to the Second Tranche Note&#160;(as defined in the Securities Purchase Agreement) due to the occurrence of an event outlined in Section&#160;2.1(b)&#160;of the Securities Purchase Agreement, such period shall be extended by 60&#160;days or such earlier date as the deficiency is resolved, and (y)&#160;subsequent to the Closing, the date on which the Company consummates a liquidation, merger, share exchange or other similar transaction with an unaffiliated third party that results in all of Psyence Biomedical&#8217;s shareholders having the right to exchange the Common Shares for cash, securities or other property, (i)&#160;lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares issued or issuable to the applicable shareholder pursuant to their respective agreements (&#8220;<b style="font-weight:bold;">Restricted Securities</b>&#8221;), (ii)&#160;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii)&#160;publicly disclose the intention to do any of the foregoing, whether any such transaction described in clauses (i), (ii)&#160;or (iii)&#160;above is to be settled by delivery of Restricted Securities or other securities, in cash or otherwise (any of the foregoing described in clauses (i), (ii)&#160;or (iii), a &#8220;<b style="font-weight:bold;">Prohibited Transfer</b>&#8221;). The lock-up provisions provide for certain exemptions for transfers to permitted transferees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing descriptions of the Securities Purchase Agreement, the Guaranty, the Registration Rights Agreement, the General Security Agreement, the Lock-Up Agreement and the Note&#160;are qualified in their entirety by the full text of such agreements (or their forms), which are incorporated by reference as Exhibit&#160;2.3, Exhibit&#160;10.1, Exhibit&#160;10.12, Exhibit&#160;10.13, Exhibit&#160;10.14 and Exhibit&#160;10.15 to the Post-Effective Amendment, respectively and are incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment to CCM Engagement Letter</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, NCAC and CCM entered into an amendment to engagement letter (the &#8220;<b style="font-weight:bold;">CCM Amendment</b>&#8221;), which amended that certain Engagement Letter dated as of February&#160;9, 2023, by and among NCAC and CCM (the &#8220;<b style="font-weight:bold;">Initial Engagement Letter</b>&#8221;). Pursuant to the CCM Amendment, NCAC agreed to pay CCM a revised transaction fee, in lieu of (i)&#160;$982,500 owed to CCM as deferred underwriting commission and (ii)&#160;fees outstanding under the Initial Engagement Letter, in connection with the Business Combination in an amount equal to 150,000 CCM Fee Shares, plus reimbursable expenses incurred as of the Closing Date, which was paid from NCAC&#8217;s trust account at the Closing of the Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the obligation to deliver the CCM Fee Shares to CCM, the terms of the CCM Amendment also include registration rights obligations on the part of the Company, which include obligations to use reasonable best efforts to file a resale registration statement covering the CCM Fee Shares and to maintain the effectiveness thereof while CCM continues to hold the CCM Fee Shares, in accordance with the terms of the CCM Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing description of the CCM Amendment is qualified in its entirety by the full text of the CCM Amendment, which is incorporated by reference as Exhibit&#160;10.9 to the Post-Effective Amendment and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Modified Cantor Deferred Underwriting Fee Payment Obligations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Underwriting Agreement, dated as of October&#160;19, 2021 (as amended or modified, the &#8220;<b style="font-weight:bold;">Underwriting Agreement</b>&#8221;), entered into in connection with NCAC&#8217;s IPO, NCAC previously agreed to pay to Cantor, in Cantor&#8217;s capacity as representative of the underwriters, deferred underwriting commissions in an aggregate amount of $5,567,500 (reflecting Cantor&#8217;s portion of the $6,550,000 deferred underwriting commission, after giving effect to the waiver of 50% of the original $13,100,000 deferred underwriting fee) (the &#8220;<b style="font-weight:bold;">Cantor Deferred Fee</b>&#8221;).</p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, NCAC and Cantor, in consideration of redemption levels by NCAC public shareholders, among other factors, entered into that certain fee modification agreement (the &#8220;<b style="font-weight:bold;">Cantor Fee Modification Agreement</b>&#8221;), pursuant to which, among other things, Cantor agreed to accept, in lieu of payment of the Cantor Deferred Fee in cash at the Closing, an aggregate of 150,000 Cantor Fee Shares, payable and delivered, at Closing at an effective price of $10.00 resulting from a waiver of a portion of the Cantor Deferred Fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the Company&#8217;s obligation to deliver the Cantor Fee Shares to Cantor, free and clear of specified restrictions, the terms of the Cantor Fee Modification Agreement also include registration rights obligations on the part of the Company, which include obligations to use commercially reasonable efforts to file a resale registration statement covering the Cantor Fee Shares and to maintain the effectiveness thereof while Cantor continues to hold the Cantor Fee Shares, in each case in accordance with the terms of the Cantor Fee Modification Agreement. The Cantor Fee Modification Agreement also includes a penalty provision that will require the Company to deliver to Cantor $5,567,500 in cash in the event that Cantor is unable to timely sell or transfer Cantor Fee Shares or the shares and warrants purchased in the private placement by Cantor in connection with NCAC&#8217;s IPO, due to continuing restrictions thereunder resulting from a failure by the Company to satisfy certain post-closing registration-related covenants and agreements in accordance with terms of the Cantor Fee Modification Agreement, following notice and reasonable opportunity to cure on the part of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing description of the Cantor Fee Modification Agreement is qualified in its entirety by the full text of the Cantor Fee Modification Agreement, which is incorporated by reference as Exhibit&#160;10.10 to the Post-Effective Amendment and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MWE Fee Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, NCAC and MWE entered into that certain fee agreement (the &#8220;<b style="font-weight:bold;">MWE Fee Agreement</b>&#8221;). Pursuant to the MWE Fee Agreement, NCAC agreed to pay MWE a fee (the &#8220;<b style="font-weight:bold;">MWE Amended Fee</b>&#8221;) for the legal services provided by MWE to NCAC, in lieu of outstanding legal fees due to MWE. The MWE Fee Agreement provides that the MWE Amended Fee is comprised of (i)&#160;$100,000 due upon the Closing, (ii)&#160;an additional $100,000, payable on or prior to the 90<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> day after the Closing and (iii)&#160;125,000 MWE Fee Shares, payable and delivered, at Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the obligation to deliver the MWE Amended Fee, the terms of the MWE Fee Agreement also include registration rights obligations on the part of the Company, which include obligations to use commercially reasonable efforts to file a resale registration statement covering the MWE Fee Shares and to maintain the effectiveness thereof while MWE continues to hold the MWE Fee Shares, in accordance with the terms of the MWE Fee Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EGS Fee Modification Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;26, 2024, the Company and EGS entered into that certain fee modification agreement (the &#8220;<b style="font-weight:bold;">EGS Fee Modification Agreement</b>&#8221;), pursuant to which the Company paid to EGS, for services provided prior to the Closing, (i)&#160;$50,000 upon the Closing, (ii)&#160;$50,000 payable to EGS within ninety (90)&#160;days following the Closing, and (iii)&#160; 100,000 Common Shares, which were issued promptly following the date upon which the SEC declared the Initial Registration Statement effective (the &#8220;<b style="font-weight:bold;">Issuance Date</b>&#8221;). Additionally, the Company paid EGS (i)&#160;$25,000 in connection with the filing of the Initial Registration Statement and (ii)&#160;50,000 Common Shares, to be issued upon the Issuance Date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments to RNA Engagement Letter</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, NCAC and RNA Advisors, LLC, entered into that certain amendment to engagement letter (the &#8220;<b style="font-weight:bold;">RNA Amendment</b>&#8221;), which amended that certain Engagement Letter dated as of February&#160;2, 2023, by and among NCAC and RNA. Pursuant to the RNA Amendment, NCAC agreed to pay RNA a revised transaction fee (the &#8220;<b style="font-weight:bold;">RNA Amended Fee</b>&#8221;) in connection with the Business Combination, comprised of (i)&#160;$25,000 due upon the Closing, (ii)&#160;an additional $25,000, payable on or prior to the 90<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> day after the Closing and (iii)&#160;21,000 RNA Fee Shares, payable and delivered, at Closing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the obligation to deliver the RNA Amended Fee, the terms of the RNA Amendment also include registration rights obligations on the part of the Company, which include obligations to use reasonable best efforts to file a resale registration statement covering the RNA Fee Shares and to maintain the effectiveness thereof while RNA continues to hold the RNA Fee Shares, in accordance with the terms of the RNA Amendment.</p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendments to Maxim Engagement Letter</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, NCAC and Maxim entered into that certain amendment to engagement letter (the &#8220;<b style="font-weight:bold;">Maxim Amendment</b>&#8221;), which amended that certain Engagement Letter dated as of April&#160;28, 2023, by and among Parent and Maxim. Pursuant to the Maxim Amendment, Parent agreed to pay Maxim a revised transaction fee in connection with the Business Combination in an amount equal to 150,000 Maxim Fee Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the obligation to deliver the Maxim Fee Shares to Maxim, the terms of the Maxim Amendment also include registration rights obligations on the part of the Company, which include obligations to use reasonable best efforts to file a resale registration statement covering the Maxim Fee Shares and to maintain the effectiveness thereof while Maxim continues to hold the Maxim Fee Shares, in accordance with the terms of the Maxim Amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing description of the Maxim Amendment is qualified in its entirety by the full text of the Maxim Amendment, which is filed as Exhibit&#160;10.11 to the Post-Effective Amendment and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lock-Ups</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Closing, the following parties are subject to lock-ups as set forth below: the Sponsor, MWE, NCAC, J.V.B., Cantor, Maxim, EGS and RNA (each, a &#8220;<b style="font-weight:bold;">Lock-Up Party</b>&#8221;) entered into lock-up arrangements which are substantially identical to each other, pursuant to which the applicable Lock-Up Party agreed not to, during the period (the &#8220;<b style="font-weight:bold;">Lock-Up Period</b>&#8221;) commencing from the Closing and ending on the earliest of (x)&#160;one hundred eighty (180)&#160;days after the Closing; provided, however, that in the event that the Investors delay investment of the Subscription Amounts (as defined in the Securities Purchase Agreement) with respect to the Second Tranche Note&#160;(as defined in the Securities Purchase Agreement) due to the occurrence of an event outlined in Section&#160;2.1(b)&#160;of the Securities Purchase Agreement, such period shall be extended by 60&#160;days or such earlier date as the deficiency is resolved, and (y)&#160;subsequent to the Closing, the date on which the Company consummates a liquidation, merger, share exchange or other similar transaction with an unaffiliated third party that results in all of the Company&#8217;s shareholders having the right to exchange the Common Shares for cash, securities or other property, (i)&#160;lend, offer, pledge, hypothecate, encumber, donate, assign, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares issued or issuable to the applicable Lock-Up Party pursuant to their respective agreements (&#8220;<b style="font-weight:bold;">Restricted Securities</b>&#8221;), (ii)&#160;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Restricted Securities, or (iii)&#160;publicly disclose the intention to do any of the foregoing, whether any such transaction described in clauses (i), (ii)&#160;or (iii)&#160;above is to be settled by delivery of Restricted Securities or other securities, in cash or otherwise (any of the foregoing described in clauses (i), (ii)&#160;or (iii), a &#8220;<b style="font-weight:bold;">Prohibited Transfer</b>&#8221;). The lock-up provisions provide for certain exemptions for transfers to permitted transferees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Exchange</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May&#160;16, 2024, Psyence entered into a Warrant Exchange Agreement (the &#8220;<b style="font-weight:bold;">Warrant Exchange Agreement</b>&#8221;) with an unaffiliated third-party investor (the &#8220;<b style="font-weight:bold;">Holder</b>&#8221;) of Public Warrants. Pursuant to the Warrant Exchange Agreement, the Company issued to the Holder 660,000 Common Shares (the &#8220;<b style="font-weight:bold;">Exchange Shares</b>&#8221;) in exchange for the surrender and cancellation of 660,000 Public Warrants held by the Holder (the &#8220;<b style="font-weight:bold;">Holder&#8217;s Warrants</b>&#8221;) (such transactions, collectively, the &#8220;<b style="font-weight:bold;">Exchange</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing description of the Warrant Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the Warrant Exchange Agreement, which is incorporated by reference as Exhibit&#160;10.18 to this Post-Effective Amendment and incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The issuance by the Company of the Exchange Shares in the Exchange was made in reliance upon the exemption from the registration requirements provided by Section&#160;3(a)(9)&#160;of the Securities Act. The Company did not receive any cash proceeds from the issuance of the Exchange Shares pursuant to the Exchange.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Headquarters and Operational Office</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s headquarters address is 121 Richmond Street West, Penthouse Suite&#160;1300, Toronto, Ontario, M5H 2K1, Canada. The Company has an operational office in South Africa at Unit A210 The Old Biscuit Mill, 373-375 Albert Road, Woodstock, Cape Town, 7925.</p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign Private Issuer Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a foreign private issuer within the meaning of the rules&#160;under the Exchange&#160;Act. As such, we are exempt from certain provisions applicable to United&#160;States domestic public companies. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not required to provide as many Exchange Act reports, or as frequently, as a domestic public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">for interim reporting, we are permitted to comply solely with our home country requirements, which are less rigorous than the rules that apply to domestic public companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not required to provide the same level of disclosure on certain issues, such as executive compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are exempt from provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not required to comply with the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not required to comply with Section 16 of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and establishing insider liability for profits realized from any &#8220;short-swing&#8221; trading transaction.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will be required to file an annual report on Form&#160;20-F within four&#160;months of the end of each fiscal&#160;year. In addition, we intend to publish our results on a semi-annual basis as press releases, distributed pursuant to the rules&#160;and regulations of the Nasdaq. Press releases relating to financial results and material events will also be furnished to the SEC on Form&#160;6-K.&#160;However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S.&#160;domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S.&#160;domestic issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nasdaq listing rules&#160;provide that a foreign private issuer may follow the practices of its home country, which for us is Canada, rather than the Nasdaq rules&#160;as to certain corporate governance requirements, including the requirement that the issuer have a majority of independent directors and certain audit committee, compensation committee and nominating and corporate governance committee requirements, the requirement to disclose third party director and nominee compensation and the requirement to distribute annual and interim reports. A foreign private issuer that follows a home country practice in lieu of one or more of the listing rules&#160;shall disclose in its annual reports filed with the SEC each requirement that it does not follow and describe the home country practice followed by the issuer in lieu of such requirements. Currently, the Company does not plan to rely on the home country practice exemption with respect to its corporate governance other than the quorum requirement for shareholder meetings and with respect to Nasdaq shareholder approval rules. Our bylaws provide that two shareholders holding 25% of the voting shares constitutes a quorum, as contrasted with the Nasdaq requirement of one-third of a company&#8217;s outstanding voting securities. If the Company chooses to take advantage of other home country practice in the future, its shareholders may be afforded less protection than they otherwise would enjoy under Nasdaq corporate governance listing standards applicable to U.S.&#160;domestic issuers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Implications of Being an Emerging Growth Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a company with less than US$1.235 billion in revenue for the last fiscal&#160;year, we qualify as an &#8220;emerging growth company&#8221; pursuant to the Jumpstart Our Business Startups Act&#160;of&#160;2012, as amended (the &#8220;<b style="font-weight:bold;">JOBS Act</b>&#8221;). An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&#160;404 of the Sarbanes-Oxley Act&#160;of&#160;2002, or Section&#160;404, in the assessment of the emerging growth company&#8217;s internal control over financial reporting. The JOBS Act also provides that an emerging growth company does not need to comply with any new or revised financial accounting standards until such date that a private company is otherwise required to comply with such new or revised accounting standards. We intend to take advantage of certain of these exemptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We will remain an emerging growth company until the earliest of (i)&#160;the last&#160;day of our fiscal&#160;year during which we have total annual gross revenues of at least US$1.235 billion; (ii)&#160;the last&#160;day of our fiscal&#160;year following the fifth anniversary of the date of the </p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">first sale of our common equity securities pursuant to an effective registration statement under the Securities Act; (iii)&#160;the date on which we have, during the previous three&#160;year period, issued more than $1.0&#160;billion in non-convertible debt; or (iv)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange&#160;Act, which would occur if the market value of our Common Shares that are held by non-affiliates exceeds $700&#160;million as of the last business&#160;day of our most recently completed second fiscal quarter and we have been publicly reporting for at least 12&#160;months. Once we cease to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risk Factor Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business is subject to numerous risks and uncertainties, including those highlighted in the section entitled &#8220;<i style="font-style:italic;">Risk Factors</i>,&#8221; that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business. In particular, the following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could cause a decline in the price of shares of our securities and result in a loss of all or a portion of your investment:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a clinical-stage biotechnology company and have incurred significant losses since our inception. We anticipate that we will incur significant losses for the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence has a limited operating history and expects a number of factors to cause its operating results to fluctuate on an annual basis, which may make it difficult to predict the future performance of Psyence.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence has never generated revenue and may never be profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company will require substantial additional funding to achieve its business goals, and if it is unable to obtain this funding when needed and on acceptable terms, it could be forced to delay, limit or terminate its product development efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The psychedelic therapy and biotechnology industries are undergoing rapid growth and substantial change, which has resulted in an increase in competitors, consolidation and formation of strategic relationships. Acquisitions or other consolidating transactions could harm Psyence in a number of ways, including by losing strategic partners if they are acquired by or enter into relationships with a competitor, losing customers, revenue and market share, or forcing Psyence to expend greater resources to meet new or additional competitive threats, all of which could harm Psyence&#8217;s operating results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Current and future preclinical and clinical studies will be conducted outside the United States, and the FDA may not accept data from such studies to support any NDAs submitted after completing the applicable developmental and regulatory prerequisites (absent an IND).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">There is a high rate of failure for product candidates proceeding through clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because the results of preclinical studies and earlier clinical trials are not necessarily predictive of future results, Psyence may not have favorable results in its planned and future clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Negative results from clinical trials or studies of others and adverse safety events involving Psyence&#8217;s psychedelic analogs could have a material adverse effect on Psyence&#8217;s business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Supply chain interruptions could delay Psyence in the process of developing its product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of, or commercialize, our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing our product candidates, if approved. If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or technology from third parties or, in certain cases, we fail to meet certain development deadlines, we could lose license rights that are important to our business.</span></td></tr></table></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We (or iNGEN&#363; in conducting our clinical trials) will depend on enrollment of patients in our clinical trials for our product candidates. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our prospective products will be subject to the various federal and state laws and regulations relating to health and safety and failure to comply with, or changes in, these laws or regulations could have an adverse impact on our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are expensive, time-consuming, uncertain and susceptible to change, delay or termination. The results of clinical trials are open to differing interpretations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence may be subject to federal, state and foreign healthcare laws and regulations and implementation of or changes to such healthcare laws and regulations could adversely affect Psyence&#8217;s business and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Serious adverse events or other safety risks could require Psyence to abandon development and preclude, delay or limit approval of its current or future product candidates, limit the scope of any approved label or market acceptance, or cause the recall or loss of marketing approval of products that are already marketed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence may voluntarily suspend or terminate a clinical trial if at any time its believes that any of its product candidates presents an unacceptable risk to participants, if preliminary data demonstrates that the product candidate is unlikely to receive regulatory approval or unlikely to be successfully commercialized, or if sufficient funds to proceed to the next phases of clinical trials are not raised.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The success of Psyence&#8217;s product candidates and future approved products, if any, is subject to a number of constantly-evolving state and federal laws, regulations, and enforcement policies pertaining to psilocybin containing products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may seek fast track and breakthrough therapy designations or priority review for one or more of our product candidates, but we might not receive such designation or priority review, and even if we do, such designation or priority review may not lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates. Even if a product qualifies for such designation or priority review, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may seek approval of our product candidates, where applicable, under the FDA&#8217;s accelerated approval pathway. This pathway may not lead to a faster development, regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The psychedelic therapy industry and market are relatively new, and this industry and market may not continue to exist or grow as anticipated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Negative public opinion and perception of the psychedelic industry could adversely impact Psyence&#8217;s ability to operate and Psyence&#8217;s growth strategy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The expansion of the use of psychedelics in the medical industry may require new clinical research into effective medical therapies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The psychedelic therapy industry is difficult to quantify and investors will be reliant on their own estimates of the accuracy of market data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence may not be able to adequately protect or enforce its intellectual property rights, which could harm its competitive position.</span></td></tr></table></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If third parties claim that intellectual property owned or used by Psyence infringes upon their intellectual property, Psyence&#8217;s operating profits could be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If Psyence is not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of its products could be significantly diminished.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The securities being offered in this prospectus represent vastly more than the number of our outstanding Common Shares, and the sales of such shares, or the perception that these sales could occur, could cause the market price of our Common Shares to decline significantly, which could impair our ability to raise capital through the sale of additional equity securities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It is not possible to predict the actual number of shares we will sell under the White Lion Purchase Agreement to White Lion, or the actual gross proceeds resulting from those sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Investors who buy shares in this offering at different times will likely pay different prices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The issuance of shares to White Lion and sales of a substantial number of our securities in the public market by White Lion and/or by our existing shareholders could cause the price of our Common Shares to fall.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have broad discretion in the use of the net proceeds we receive from the sale of shares to White Lion and may not use them effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Certain of our shareholders purchased their respective Common Shares at prices lower than the current market price for our Common Shares and may therefore experience a positive rate of return on their investment, even if our public shareholders, who invested approximately $10.00 per Common Share, would experience a negative rate of return on their investment.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we fail to meet applicable continued listing requirements, Nasdaq may delist our Common Shares from trading, in which case the liquidity and market price of our Common Shares could decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price and trading volume of the Common Shares may be volatile and could decline significantly.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Public Warrants are exercisable for Common Shares, which would increase the number of shares eligible for future resale in the public market and result in dilution to its shareholders.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The requirements of being a public company may strain the Company&#8217;s resources, divert the Company management&#8217;s attention and affect the Company&#8217;s ability to attract and retain qualified board members.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company qualifies as a foreign private issuer within the meaning of the rules under the Exchange Act, and as such the Company is exempt from certain provisions applicable to United States domestic public companies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence currently reports financial results under IFRS, which differs in certain significant respects from U.S. GAAP.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because the Company is incorporated under the laws of Canada, the Company conducts substantially all of its operations and a majority of its directors and executive officers reside outside of the United States.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">It is not expected that the Company will pay dividends in the foreseeable future.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div></div><div style="max-width:100%;position:relative;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:26pt 5.22% 0pt 5.22%;padding:10pt 0.65% 10pt 0.65%;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The Offering</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Securities offered by the Selling Securityholders</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Up to 50,575,028 Common Shares, consisting of (i) up to 50,000,000 Common Shares that may be issued by us to White Lion pursuant to the White Lion Purchase Agreement, (ii) 375,000 Commitment Shares issuable to White Lion as consideration for entering into the White Lion Purchase Agreement, (iii) 3,000 Common Shares issued to Donohoe Advisory Associates LLC in full and final settlement of accrued service and advisory fees, (iv) 25,000 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery and (v) an additional 172,028 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery.</p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Common Shares outstanding prior to this offering</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">16,696,571 (as of August 15, 2024)</p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Common Shares outstanding following this offering</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Up to 16,696,571 (based on the total shares outstanding as of August 15, 2024)</p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Terms of the offering</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Each Selling Securityholder will determine when and how it will dispose of the Common Shares registered for resale under this prospectus. See &#8220;<i style="font-style:italic;">Plan of Distribution</i>&#8221;.</p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Use of proceeds</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">We will not receive any of the proceeds from the resale of the Common Shares by the Selling Securityholders. However, we may receive up to $25,000,000 in gross proceeds under the White Lion Purchase Agreement from sales of Common Shares that we may elect to make to White Lion pursuant to the White Lion Purchase Agreement, if any, from time to time in our sole discretion, during the White Lion Commitment Period. However, we will not receive any proceeds from the issuance of the Commitment Shares. The proceeds from White Lion that we receive under the White Lion Purchase Agreement, if any, are currently expected to be used for general corporate purposes, including working capital. Accordingly, we retain broad discretion over the use of the net proceeds from the sale of our Common Shares under the White Lion Purchase Agreement. The precise amount and timing of the application of such proceeds will depend upon our liquidity needs and the availability and cost of other capital over which we have little or no control. As of the date hereof, we cannot specify with certainty the particular uses for the net proceeds from the sales of Common Shares, if any to White Lion under the White Lion Purchase Agreement. See &#8220;<i style="font-style:italic;">Use of Proceeds</i>.&#8221; We will incur all costs associated with this prospectus and the registration statement of which it is a part.</p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Risk factors</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Before investing in our securities, you should carefully read and consider the information set forth in &#8220;<i style="font-style:italic;">Risk Factors</i>&#8221; beginning on page 24.</p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:35.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Nasdaq ticker symbols</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:62.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#8220;PBM&#8221; and &#8220;PBMWW&#8221;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="margin-left:5.22%;margin-right:5.22%;max-width:100%;padding-left:0.65%;padding-right:0.65%;position:relative;"><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:89.54%;border:0;margin:30pt 5.23% 30pt 5.23%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c387c44f_b4e4_4434_b8d1_75efc2d7f8c9"></a><a id="PRICERANGEOFSECURITIESANDDIVIDENDS_89890"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PRICE RANGE OF SECURITIES AND DIVIDENDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Price Range of Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Common Shares trade on the Nasdaq Global Market under the symbol &#8220;PBM,&#8221; and certain of our Public Warrants trade on the Nasdaq Capital Market under the symbol &#8220;PBMWW.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing price of our Common Shares and Public Warrants as reported by Nasdaq on August 15, 2024, was $0.5093 and $0.0202, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Dividends</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence has not paid any cash dividends on its shares to date and does not intend to pay cash dividends in the foreseeable future. The payment of cash dividends in the future will be dependent upon the Company&#8217;s revenue and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends is within the discretion of the Board. Further, our ability to declare dividends may be limited by the terms of financing or other agreements entered into by us or our subsidiaries from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c60b119e_dd68_47ce_9283_e5907be17a00"></a><a id="CAPITALIZATION_55609"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAPITALIZATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the capitalization of the Company as of August 13, 2024:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on an actual basis; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">on an as adjusted basis to give effect to the issuance of the additional 50,575,028 Common Shares we are registering on behalf of the Selling Securityholders (in addition to the 16,696,571 outstanding shares).</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Actual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;Adjusted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Psyence Group Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Former Members of Sponsor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,455,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,455,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cantor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">337,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">337,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CCM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">183,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">183,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing Investors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">472,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">472,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other Third Party Advisors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">646,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">646,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Public Shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,603,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,603,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">White Lion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">50,375,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:71.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total shares outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">16,696,571</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">67,071,571</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Type of Debts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Actual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pro Forma As adjusted</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">US$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">US$</p></td></tr><tr><td style="vertical-align:bottom;width:69.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Guaranteed bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Recourse liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,203,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,203,091</p></td></tr><tr><td style="vertical-align:bottom;width:69.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total Indebtedness</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,203,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,203,091</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The information set forth in the section titled &#8220;<i style="font-style:italic;">Prospectus Summary&#160;&#8211; Recent Developments&#160;&#8211; Consummation of the Business Combination&#160;&#8211; Securities Purchase Agreement</i>&#8221; is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8bcea2a4_bd74_4e86_97b2_58ee65422f79"></a><a id="DILUTION_343151"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DILUTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are registering for resale 50,575,028 common shares held by the Selling Securityholders. Sales of substantial amounts of common shares in the public market, or the perception that such sales might occur, could adversely affect the market price of our common shares, and the market value of our other securities. We cannot predict if and when Selling Securityholders may sell such common shares in the public markets. Furthermore, in the future, we may issue additional common shares or other equity or debt securities convertible into common shares. Any such issuance could result in substantial dilution to our existing shareholders and could cause our share price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7de9960e_a37b_45e6_a7e4_26d0f27916f9"></a><a id="RISKFACTORS_959159"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">RISK FACTORS</p><a id="Investinginoursecurities_307766"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our securities involves a high degree of risk. You should carefully consider the following information about these </i><i style="font-style:italic;">risks, together with the other information appearing elsewhere in this prospectus, including our financial statements, the notes thereto and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our securities. The occurrence of any of the following risks could have a material adverse effect on our business, reputation, financial condition, results of operations and future growth prospects, as well as our ability to accomplish our strategic objectives. As a result, the trading price of our securities could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and the market price of our securities.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Business and Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are a clinical-stage biotechnology company and have incurred significant losses since our inception. We anticipate that we will incur significant losses for the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Investment in biotechnology product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate effectiveness or an acceptable safety profile, gain regulatory approval and become commercially viable. All of Psyence&#8217;s product candidates will require substantial additional capital expenditures and development time, including extensive clinical research and resources, before it would be able to apply for and then receive marketing authorization and begin generating revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its inception, Psyence has invested most of its resources in establishing strategic partnerships, securing intellectual property licensing rights, advancing its clinical trial program, raising capital, building its management team and providing general and administrative support for these operations. Psyence has incurred losses in each&#160;year since its inception and expects to incur significant losses for the foreseeable future. Psyence&#8217;s net loss for the&#160;years ended March&#160;31, 2023 and March&#160;31, 2024 was $3.12 million and $50.96 million, respectively. The March 31, 2024 net loss was driven by the deemed listing expense of $41.48 million which consisted of a deemed consideration amount of $37.3 million for the 7,794,659 shares issued to NCAC shareholders at a fair value of $4.79 per share and $4.1 million for the net liabilities acquired. To date, no products have been approved for commercial sale and Psyence has not generated any revenue. Psyence has financed operations solely through the sale of equity securities and convertible debt financings. Psyence continues to incur significant research and development and other expenses related to ongoing operations and expects to incur losses for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the numerous risks and uncertainties associated with the development of its product candidates, Psyence is unable to predict the timing or amount of its expenses, or when it will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, its expenses could increase beyond current expectations if Psyence is required by the Therapeutic Goods Administration in Australia (&#8220;<b style="font-weight:bold;">TGA</b>&#8221;), the U.S. Food and Drug Administration (&#8220;<b style="font-weight:bold;">FDA</b>&#8221;), the European Medicines Agency (&#8220;<b style="font-weight:bold;">EMA</b>&#8221;), Medicines and Healthcare products Regulatory Agency in the UK (&#8220;<b style="font-weight:bold;">MHRA</b>&#8221;), or other comparable foreign regulatory authorities, to perform preclinical studies or clinical trials in addition to those that Psyence currently anticipates, or if there are any delays in any of Psyence&#8217;s or its future collaborators&#8217; clinical trials or the development of the existing product candidates and any other product candidates that Psyence may identify. Even if Psyence&#8217;s existing product candidates or any future product candidates that Psyence may identify are approved for commercial sale, Psyence anticipates incurring significant costs associated with commercializing any approved product and ongoing compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Psyence has a limited operating history and expects a number of factors to cause its operating results to fluctuate on an annual basis, which may make it difficult to predict the future performance of Psyence.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence is a clinical stage biotechnology development company with a limited operating history. Consequently, any predictions made about Psyence&#8217;s future success or viability may not be as accurate as they could be if Psyence had a longer operating history and additional definitive partnership agreements in place. Psyence&#8217;s operating results are expected to significantly fluctuate from quarter-to-quarter or&#160;year-to-year due to a variety of factors, many of which are beyond its control. Factors relating to Psyence&#8217;s business that may contribute to these fluctuations include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delays or issues in finding, and establishing successful business arrangements with, pharmaceutical and product development partners to assist in moving its product candidates through the development and commercialization processes;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in the commencement, enrolment and timing of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of its preclinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential side effects of its product candidates that could delay or prevent approval or license-out agreements or cause an approved product candidate to be eliminated;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply chain interruptions, which could delay Psyence in the process of developing its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to obtain additional funding to develop its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to attract and retain talented and experienced personnel to manage its business effectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition from existing psychedelic analogs companies or new psychedelic analogs companies that continue to emerge;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assuming market authorization has been obtained for our product candidates, the ability of patients or healthcare providers to obtain coverage or sufficient reimbursement for such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to adhere to clinical study requirements directly or with third parties such as clinical research organizations (&#8220;</span><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CROs</b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its dependency on third-party manufacturers to manufacture products and key ingredients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to establish or maintain collaborations, licensing or other transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to defend against any challenges to its intellectual property, including claims of patent infringement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to enforce its intellectual property rights against potential competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to secure additional intellectual property protection for its product candidates and associated manufacturing methods currently under development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a biological or chemical effect that Psyence does not predict;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse economic circumstances; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential liability claims;</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, the results of any historical financial periods should not be relied upon as indications of future operating performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Psyence has never generated revenue and may never be profitable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence may never be able to develop or commercialize marketable products or achieve profitability. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which Psyence gains regulatory approval, the accepted price for the product, the acceptance of the product by physicians and patients, the ability to obtain reimbursement at any price and whether Psyence owns the commercial rights for that territory. Psyence&#8217;s growth strategy depends on its ability to generate revenue. In addition, if the number of addressable patients is not as anticipated, the indication or intended use approved by regulatory authorities is narrower than expected, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, Psyence may not generate significant revenue from sales of such products, even if approved. Even if Psyence is able to generate revenue from the sale of any approved products, Psyence may not become profitable and may need to obtain additional funding to continue operations. Even if Psyence were to achieve profitability in the future, it may not be able to sustain profitability in subsequent periods.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s failure to achieve sustained profitability would depress the value of the Company and could impair its ability to raise capital, expand the business, diversify its research and development pipeline, market its product candidates, if approved, and pursue or continue operations. Psyence&#8217;s prior losses, combined with expected future losses, have had and will continue to have an adverse effect on shareholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company will require substantial additional funding to achieve its business goals, and if it is unable to obtain this funding when needed and on acceptable terms, it could be forced to delay, limit or terminate its product development efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s clinical trial and product development pipeline currently consists of an approved Phase IIb Study in Australia. We have also obtained approval from the MHRA to conduct a Phase IIa study in the UK, which was not initiated due to certain cost-effective incentives provided by Australia. Once the Phase IIb Study in Australia is completed, a Phase III pivotal study program will begin, of which the size and number of trials will depend on the results of the Phase IIb Study, the advice given to Psyence from the regulatory authorities and whether the FDA will assess the program as being fast-tracked or eligible as a breakthrough therapy. If the assessment is the latter, the Phase III program could be smaller than anticipated and less than the usual required two pivotal studies to support market authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence intends to submit the NDA requesting assessment via the 505(b)(2)&#160;pathway. A 505(b)(2)&#160;application is an NDA that contains full reports of investigations of safety and effectiveness, where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference or use, including, for example, the agency&#8217;s finding of safety and/or effectiveness for a listed drug or published literature. This could potentially allow for a shorter development program along with less data that is developed by Psyence, as compared to a regular NDA submission. Despite the usage of psilocybin for decades, there have been relatively few studies pertaining to psilocybin products due to the ban on the research into psychedelics. However, recently, academic institutions have been allowed to conduct such studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conducting clinical trials and developing biopharmaceutical products is expensive and time consuming, and we expect to require substantial additional capital to conduct research, preclinical studies and clinical trials for the current and future trials, seek regulatory approvals for our product candidates and launch and commercialize any products for which Psyence may receive regulatory approval, including building our own commercial sales, marketing and distribution organization. Our management and strategic decision makers have not made decisions regarding the future allocation of certain resources among Psyence&#8217;s pipeline of trials, but continue to evaluate the needs and opportunities with respect to each of these trials routinely and on a case-by-case basis. Because the outcome of any preclinical or clinical development and regulatory approval process is highly uncertain (including the size and quantum of the Phase III registrational program), Psyence cannot reasonably estimate the actual amounts necessary to successfully complete the development, regulatory approval process and potential commercialization of its product candidates and any future product candidates it may identify.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence expects that the cash provided in the PIPE Financing, assuming all tranches are consummated, together with Psyence&#8217;s existing cash, will be sufficient to fund operations beyond 12 months following the Closing Date. However, Psyence&#8217;s operating plan may change as a result of many factors currently unknown, including but not limited to the additional tranches of the PIPE Financing not being funded, and Psyence may need to seek additional funds sooner than planned, through public or private equity or debt financings, sales of assets or programs, other sources, such as strategic collaborations or license and development agreements, or a combination of these approaches. Even if Psyence believes that its funds are sufficient for its current or future operating plans, it may, subject to obtaining the necessary contractual consents, opportunistically seek additional capital if market conditions are favorable or for specific strategic considerations. Psyence&#8217;s spending will vary based on new and ongoing product development and business development activities. Any such additional fundraising efforts for Psyence may divert management from their day-to-day activities, which may adversely affect Psyence&#8217;s ability to develop and commercialize product candidates that Psyence may identify and pursue. Moreover, such financing may result in dilution to shareholders, imposition of debt covenants and repayment obligations, or other restrictions that may affect Psyence&#8217;s business. Changing circumstances, some of which may be beyond Psyence&#8217;s control, could cause Psyence to consume capital significantly faster than currently anticipated, and Psyence may need to seek additional funds sooner than planned. Psyence&#8217;s future funding requirements, both short-term and long-term, will depend on many factors, including, but not limited:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the time and cost necessary to complete ongoing and planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and cost of meeting regulatory requirements established by the TGA, FDA, the EMA, the MHRA and other comparable foreign regulatory authorities;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress, timing, scope and costs of preclinical studies, clinical trials and other related activities for ongoing and planned clinical trials, and potential future clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of obtaining clinical and commercial supplies of raw materials and drug products for Psyence&#8217;s product candidates, as applicable, and any other product candidates Psyence may identify and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence&#8217;s ability to successfully identify and negotiate acceptable terms for third-party supply and contract manufacturing agreements with contract manufacturing organizations (&#8220;</span><b style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CMOs</b><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities for any of Psyence&#8217;s product candidates that receive marketing approval, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities, or entering into strategic collaborations with third parties to leverage or access these capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount and timing of sales and other revenues from Psyence&#8217;s product candidates, if approved, including the sales price and the availability of coverage and adequate third-party reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cash requirements of developing Psyence&#8217;s programs and Psyence&#8217;s ability and willingness to finance their continued development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cash requirements of any future acquisitions or discovery of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the time and cost necessary to respond to technological and market developments, including other products that may compete with one or more of Psyence&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply chain interruptions, which could delay Psyence in the process of developing its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of acquiring, licensing or investing in intellectual property rights, products, product candidates and businesses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of maintaining, expanding and protecting Psyence&#8217;s intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to attract, hire and retain qualified personnel as Psyence expands research and development and establishes a commercial infrastructure; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of operating as a public company in the United States and maintaining a listing on Nasdaq.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence cannot be certain that additional funding will be available on acceptable terms, or at all. Market volatility resulting from the COVID-19 pandemic and the related U.S. and global economic impact or other factors could also adversely impact the ability to access funds as and when needed. If adequate funds are not available to Psyence on a timely basis, Psyence may be required to delay, limit or terminate one or more research or development programs or trials or the potential commercialization of any approved products or be unable to expand operations or otherwise capitalize on business opportunities, as desired, which could materially affect Psyence&#8217;s business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">We depend on our current key personnel and our ability to attract and retain employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future growth and success depends on our ability to recruit, retain, manage and motivate our employees. We are highly dependent on our current management and scientific personnel, including Dr.&#160;Neil Maresky (Chief Executive Officer), Jody Aufrichtig (Executive Chairman), Warwick Corden-Lloyd (Chief Financial Officer), Dr.&#160;Clive Ward-Able (Medical Director) and Taryn Vos (General Counsel). The inability to hire or retain experienced management personnel could adversely affect our ability to execute our business plan and harm our operating results. Due to the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified scientific, technical and managerial personnel. The competition for qualified personnel in the pharmaceutical field is intense and we may be unable to continue to attract and retain qualified personnel necessary for the development of our business or to recruit suitable replacement personnel.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our historical financial results may not be representative of our results as a separate, stand-alone company.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of the historical financial information we have included in this prospectus has been derived from the financial statements and accounting records of Parent and does not necessarily reflect what our financial position, results of operations or cash flows would have been had we been a separate, stand-alone company during the periods presented. The historical information does not necessarily indicate what our results of operations, financial position, cash flows or costs and expenses will be in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The psychedelic therapy and biotechnology industries are undergoing rapid growth and substantial change, which has resulted in an increase in competitors, consolidation and formation of strategic relationships. Acquisitions or other consolidating transactions could harm Psyence in a number of ways, including by losing strategic partners if they are acquired by or enter into relationships with a competitor, losing customers, revenue and market share, or forcing Psyence to expend greater resources to meet new or additional competitive threats, all of which could harm Psyence&#8217;s operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The psychedelic therapy and biotechnology industries are intensely competitive and subject to rapid and significant technological change. Psyence has competitors in Canada, the United States, Europe and other jurisdictions, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical and generic drug companies and universities and other research institutions. Many of its competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations than it does. Large pharmaceutical companies, in particular, have extensive experience in, and substantial capital resources for, conducting research, molecular derivative development, obtaining regulatory approvals, obtaining intellectual property protection and establishing key relationships. These companies also have significantly greater sales and marketing capabilities and experience in completing collaborative transactions in Psyence&#8217;s target markets with leading companies and research institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s competitors may introduce new psychedelic analogs or develop technological advances that compete with Psyence. Psyence cannot predict the timing or impact of competitors introducing new psychedelic analogs or technological advances. Such competing psychedelic analogs may be safer, more effective, more effectively marketed, licensed or sold or have lower prices or superior performance features than Psyence&#8217;s psychedelic analogs, and this could negatively impact Psyence&#8217;s business and results of operations. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the psychedelic analogs that Psyence develops obsolete. As a result of any of these factors, Psyence&#8217;s competitors may succeed in obtaining patent protection or discovering, developing and commercializing psychedelic analogs before Psyence does or may develop psychedelic analogs that are deemed to be more effective or gain greater market acceptance than those of Psyence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative transactions with large, established companies. In addition, many universities and private and public research institutions may become active in the development of novel compounds. Psyence&#8217;s competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and psychedelic analogs that are more effective or less costly than any of the psychedelic analogs that Psyence is currently developing or that it may develop, which could render its psychedelic analogs obsolete or non-competitive. If Psyence&#8217;s competitors&#8217; market psychedelic analogs that are more effective, safer or less expensive or that reach the market sooner than Psyence&#8217;s psychedelic analogs, if any, Psyence may not achieve commercial success. In addition, because of its limited resources, it may be difficult for Psyence to stay abreast of the rapid changes in each technology. If Psyence fails to stay at the forefront of technological change, it may be unable to compete effectively. Technological advances or products developed by its competitors may render its technologies or psychedelic analogs obsolete, less competitive or not economical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Current and future preclinical and clinical studies will be conducted outside the United States, and the FDA may not accept data from such studies to support any NDAs submitted after completing the applicable developmental and regulatory prerequisites (absent an IND).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Psyence is conducting a preclinical and a clinical study outside the United States. Psyence has received full approval of a study in the UK from the MHRA, which was not initiated due to certain cost-effective incentives provided by Australia. Psyence has received full approval from the Australian Human Research Ethics Committees (HRECs), the body responsible for the review of research proposals involving human participants to ensure that they are ethically acceptable. The protocol under review in Australia will be reviewed as part of a Pre-IND (Investigational New Drug) application by the FDA. To the extent Psyence does not conduct these clinical trials under an IND, the FDA may not accept data from such trials. Although the FDA may accept data from clinical trials conducted outside the United States that are not conducted under an IND, the FDA&#8217;s acceptance of these data is subject to certain </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">conditions. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles and all applicable FDA regulations. The trial population must also adequately represent the intended U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. There can be no guarantee that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from such clinical trials, this would likely result in the need for additional trials and the completion of additional regulatory steps, which would be costly and time-consuming and could delay or permanently halt the development of Psyence&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">There is a high rate of failure for product candidates proceeding through clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence has no registered products on the market, and its new potential psilocybin-based product candidates are currently either in the preclinical or clinical development phase. Psyence&#8217;s ability to achieve and sustain profitability with respect to its product candidates in which psilocybin is featured as the active pharmaceutical ingredient depends on obtaining regulatory approvals for and, if approved, successfully commercializing, its product candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of its current or future product candidates, Psyence or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety, purity and potency of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, there is a high rate of failure for product candidates proceeding through clinical trials. Psyence may suffer significant setbacks in its clinical trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving promising results in earlier trials. Further, even if Psyence views the results of a clinical trial to be positive, applicable international regulatory authorities may disagree with Psyence&#8217;s interpretation of the data. In the event that Psyence obtains negative results from clinical trials for product candidates or other problems related to potential chemistry, manufacturing and control issues or other hurdles occur and its current or future product candidates are not approved, Psyence may not be able to generate sufficient revenue or obtain financing to continue its operations, its ability to execute on its current business plan may be materially impaired and its reputation in the industry and in the investment community might be significantly damaged. In addition, Psyence&#8217;s inability to properly design, commence and complete clinical trials may negatively impact the timing and results of its clinical trials and ability to seek approvals for its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The testing, marketing and manufacturing of any new drug product for use in the U.S. will require approval from the FDA. Psyence cannot predict with any certainty the amount of time necessary to obtain such FDA approval and whether any such approval will ultimately be granted. Preclinical and clinical trials may reveal that one or more product candidates are ineffective or unsafe, in which event further development of such product candidates could be seriously delayed or terminated. Moreover, obtaining approval for certain product candidates may require testing on human subjects of substances whose effects on humans are not fully understood or documented. Delays in obtaining FDA or any other necessary regulatory approvals of any proposed drug and failure to receive such approvals would have an adverse effect on the drug&#8217;s potential commercial success and on Psyence&#8217;s business, prospects, financial condition and results of operations. In addition, it is possible that a proposed drug may be found to be ineffective or unsafe due to conditions or facts that arise after development has been completed and regulatory approvals have been obtained. In this event, Psyence may be required to withdraw such proposed drug from the market. To the extent that its success will depend on any regulatory approvals from government authorities outside of the U.S. that perform roles similar to that of the FDA, uncertainties similar to those stated above will also exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because the results of preclinical studies and earlier clinical trials are not necessarily predictive of future results, Psyence may not have favorable results in its planned and future clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Successful development of therapeutic products is highly uncertain and is dependent on numerous factors, many of which are beyond Psyence&#8217;s control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical or clinical study results that may show the product to be less effective than desired (e.g., the study failed to meet Psyence&#8217;s primary objectives) or to have harmful or problematic side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data analysis or regulatory requests for additional preclinical or clinical data or unexpected safety or manufacturing issues;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing costs, pricing, or reimbursement issues or other factors that make the product not economical; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proprietary rights of others and their competing products and technologies that may prevent the product from being commercialized.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any positive results from preclinical testing of Psyence&#8217;s prospective product candidates may not necessarily be predictive of the results from planned or future clinical trials for such product candidates. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results in preclinical and early clinical development, and Psyence cannot be certain that it will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings while clinical trials were underway or safety or efficacy observations in clinical trials, including adverse events. If Psyence fails to produce positive results in its planned clinical trials for its product candidates as described in the section titled &#8220;Business&#8221;, or its future clinical trials, the development timeline and regulatory approval and commercialization prospects for such product candidates, and, correspondingly, Psyence&#8217;s business and financial prospects, would be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Negative results from clinical trials or studies of others and adverse safety events involving Psyence&#8217;s psychedelic analogs could have a material adverse effect on Psyence&#8217;s business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, studies or clinical trials on medical-grade psilocybin mushroom products may be conducted or sponsored by academics, research institutions or others, including government agencies. The publication of negative results of studies or clinical trials related to Psyence&#8217;s proposed products or the therapeutic areas in which Psyence&#8217;s proposed products will compete could have a material adverse effect on Psyence&#8217;s business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Supply chain interruptions could delay Psyence in the process of developing its product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are few licensed suppliers of input materials for the manufacture of Psyence&#8217;s product candidates. Any loss of stored materials or facilities through fire, theft or other causes could have an adverse effect on Psyence&#8217;s ability to procure the product candidate materials and continue product development activities. Furthermore, Psyence is largely dependent on Filament, for the supply of PEX010 (a capsule containing 25mg naturally sourced psilocybin and product being used in Psyence&#8217;s Phase IIb Study), and any interruption in Filament&#8217;s supply chain (or the supply chain of any other suppliers engaged by Pyence) will lead to delays in Psyence&#8217;s drug development timelines. Furthermore, Filament, as well as any other suppliers engaged by Pyence, will be required to continue to meet regulatory requirements applicable to the PEX010 product candidate and maintain GMP compliant standards which dictate the minimum requirements for the methods, facilities and controls used in manufacturing, processing and packing of a drug product. There can be no assurances that Filament or any CMOs will be able to meet Psyence&#8217;s timetable and requirements or carry out their contractual obligations in accordance with the applicable regulations. In addition, the drug product supplied to Psyence may not meet its specifications and quality policies and procedures nor may they be able to supply the drug product in commercial quantities when the time comes. If Psyence is unable to arrange for alternative third-party supply sources on commercially reasonable terms or in a timely manner, it may delay the development of its product candidates and could have a material adverse effect on Psyence&#8217;s business operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, the failure of CMOs to operate in compliance with GMP or other applicable quality related regulations could result in, among other things, certain product liability claims in the event such failure to comply results in defective products that caused injury or harm. In general, Psyence&#8217;s dependence upon third parties for the supply of Psyence&#8217;s drug product may adversely affect profit margins and Psyence&#8217;s ability to develop and deliver viable end products on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Psyence&#8217;s proprietary information, or that of its strategic business partners, may be lost or Psyence may suffer security breaches.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of its business, Psyence collects and stores sensitive data, including valuable and commercially sensitive intellectual property, clinical trial data, proprietary business information and that of Psyence&#8217;s strategic business partners, as well as the personally identifiable information of clinical trial subjects, employees and patients, in and on Psyence&#8217;s networks. Despite security measures, information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise Psyence&#8217;s networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, disruption of operations, damage to Psyence&#8217;s reputation, and cause a loss of confidence in Psyence&#8217;s ability to conduct clinical trials, which could adversely affect Psyence&#8217;s business, prospects, financial condition and results of operations.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Costs associated with compliance with numerous laws and regulations could impact our financial results. In addition, we could become subject to increased enforcement and/or litigation risks associated with the psychedelic therapeutics industry.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The manufacture, labeling and distribution of products containing psilocybin or other psychedelic analogs is governed by various federal, state and local agencies. To the extent we are able to successfully commercialize any of our currently contemplated product candidates via the FDA&#8217;s NDA approval pathway, the presence of psychedelic analogs as active or inactive ingredients, as applicable, may give rise to heightened regulatory scrutiny and greater risk of consumer litigation, either of which could further restrict the permissible scope of our marketing claims about such products or our ability to sell them in the United States at all. The shifting compliance environment and the need to build and maintain robust systems to comply with different psychedelic-related regulations in jurisdictions may increase costs and/or the risk that we may violate one or more applicable regulatory requirements. If our operations, or any of our activities or prospective products, are found to be in violation of any such laws or any other governmental regulations that apply to the manufacture, distribution, or sale of prescription drug products, generally, and to products containing psychedelic analogs, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business or our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with any applicable regulatory requirements, relating to psilocybin or otherwise, may result in, among other things, injunctions, product withdrawals, recalls, product seizures, fines and criminal prosecutions. Additionally, advertising and labeling laws are often enforced by governmental officials, and any action based on potentially misleading or deceptive advertising is often followed by costly class-action complaints under consumer-protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Psyence may acquire businesses or products, or form additional strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence may acquire additional businesses or products, form additional strategic alliances, or create joint ventures with third parties that it believes will complement or augment its existing business. Any of these relationships may require Psyence to incur non-recurring and other charges, increase Psyence&#8217;s near and long-term expenditures, issue securities that dilute Psyence&#8217;s existing shareholders or disrupt Psyence&#8217;s management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. If Psyence acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if it is unable to successfully integrate them with its existing operations and company culture. Psyence may encounter numerous difficulties in developing, manufacturing, and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent it from realizing their expected benefits or enhancing its business. There is no assurance that, following any such acquisition, Psyence will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on its business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect to spend a substantial amount of capital in the development and manufacturing of our product candidates, and we will need substantial additional financing to do so. In particular, we will require substantial additional financing to enable commercial production of our product candidates and initiate and complete registrational trials for multiple products in multiple regions. Further, if approved, we will require significant additional capital in order to launch and commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2024, we had USD$762,799 in cash and cash equivalents and restricted cash. Changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may also need to raise additional capital sooner than we currently anticipate if we choose to expand more rapidly than we presently plan. In any event, we will require additional capital for the further development and commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our securities to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, future changes in regulations, changes in legal status of psilocybin-containing products, more vigorous enforcement thereof or other unanticipated events could require extensive changes to Psyence&#8217;s operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of Psyence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of, or commercialize, our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence relies on iNGEN&#363; to conduct clinical development activities with Psyence&#8217;s product candidates, which activities involve trial design, regulatory submissions, clinical patient recruitment, clinical trial monitoring, clinical data management and analysis, safety monitoring and project management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we expect to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, CDMOs and strategic partners to conduct our preclinical studies under agreements with us and in connection with our clinical trials. We expect to have to negotiate budgets and contracts with CROs, trial sites and CDMOs, which may result in delays to our development timelines and increase costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. As a result, we have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices (&#8220;<b style="font-weight:bold;">GCPs</b>&#8221;), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. Additionally, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing our product candidates, if approved. If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or technology from third parties or, in certain cases, we fail to meet certain development deadlines, we could lose license rights that are important to our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not currently own any patents, and we are heavily reliant upon a number of license agreements under which we are granted rights to intellectual property that are important to our business and we may need or choose to enter into additional license agreements in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specifically, our business and active Phase IIb Study is highly dependent on the Research IP Agreement with Filament, which expires in April&#160;2027 and covers the Phase IIb Study only. Until we develop our own product candidates, the termination, non-renewal or hinderance of use of the license granted under the Research IP Agreement could have a material adverse effect on our ability to develop our product candidates. Furthermore, following the completion of the Phase IIb Study, we will be required to enter into agreements with alternative suppliers for the supply and licensing of alternative drug products for use in our pivotal Phase III studies in palliative care, and there can be no guarantees that such agreements will be finalized. The Company continues to evaluate its bridging program into Phase III in this regard, which bridging program will require regulatory agency approval, and there can be no guarantees that such approvals will be obtained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our existing license agreements impose, and we expect that future license agreements will impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Our business could suffer, for example, if any current or future licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to sublicense patent and other rights to third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our obligation to pursue, or license others to pursue, development of indications we are not currently pursuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to transfer or assign the license; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of termination.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We may enter into additional licenses to third-party intellectual property that are necessary or useful to our business. Our current licenses and any future licenses that we may enter into may impose various royalty payment, milestone, and other obligations on us. Under some license agreements, we may not control prosecution of the licensed intellectual property, or may not have the first right to enforce the intellectual property. In those cases, we may not be able to adequately influence patent prosecution or enforcement, or </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">prevent inadvertent lapses of coverage due to failure to pay maintenance fees. If we fail to comply with any of our obligations under a current or future license agreement, the licensor may allege that we have breached our license agreement, and may accordingly seek to terminate our license. Termination of any of our current or future licenses could result in our loss of the right to use the licensed intellectual property, which could materially adversely affect our ability to develop and commercialize a product candidate or product, if approved, as well as harm our competitive business position and our business prospects. Under some license agreements, termination may also result in the transfer of or granting in rights under certain of our intellectual property and information related to the product candidate being developed under the license, such as regulatory information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The agreements under which we license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if our licensors fail to abide by the terms of the license, if the licensors fail to prevent infringement by third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms, our business could suffer. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similarly, if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to seek alternative options, such as developing new product candidates with design-around technologies, which may require more time and investment, or abandon development of the relevant research programs or product candidates and our business, financial condition, results of operations and prospects could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We (or iNGEN&#363; in conducting our clinical trials) will depend on enrollment of patients in our clinical trials for our product candidates. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Identifying and qualifying patients to participate in clinical trials of our product candidates will be critical to our success. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The enrollment of patients depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients with the disease or condition being studied;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks and benefits of the product candidate in the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating or drugs that may be used off-label for these indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population required for analysis of the trial&#8217;s primary and secondary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to study sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials for similar therapies or other new therapeutics not involving psychedelic therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions to health care systems caused by the coronavirus pandemic or outbreaks of other infections;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before completion of their treatment; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other public health factors, including the coronavirus pandemic or outbreaks of other infections.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, because our product candidates represent a departure from more commonly used methods for AjD treatment, potential study participants and their doctors may be inclined to use conventional therapies, such as pure psychotherapy, rather than participate in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these clinical trials and adversely affect our ability to advance the development of our product candidates. In addition, many of the factors that may lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Psyence&#8217;s insurance coverage may be inadequate or expensive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s business is subject to a number of risks and hazards generally, including adverse clinical trial results, accidents, labor disputes and changes in the regulatory environment. Such occurrences could result in damage to assets, personal injury or death, environmental damage, delays in operations, monetary losses and possible legal liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s insurance may not cover all the potential risks associated with its operations. Psyence may also be unable to maintain insurance to cover these risks at economically feasible premiums. Insurance coverage may not be available (or generally available on acceptable terms) or may not be adequate to cover any resulting liability. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large retention, or deductible, or co-insurance requirements, could have an adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Certain significant personnel may allocate their time to other businesses, which may cause conflicts of interest in their determination as to how much time to devote to our affairs and potentially competitive fiduciary and pecuniary interests that conflict with our interests.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of Psyence&#8217;s directors and officers do not devote their full time to the affairs of Psyence and certain of Psyence&#8217;s directors and officers are also directors, officers and shareholders of other biotechnology and research and development companies or other public companies in general, and as a result they may find themselves in a position where their duty to another company conflicts with their duty to Psyence. Although Psyence has policies which address such potential conflicts and the Business Corporations Act (Ontario) has provisions governing directors in the event of such a conflict, there is no assurance that any such conflicts will be resolved in favor of Psyence. If any such conflicts are not resolved in favor of Psyence, Psyence may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have received&#160;research and development incentives&#160;from the Australian government. If we don&#8217;t qualify for future&#160;research and development incentives, we may encounter difficulties in funding research and development projects, which could harm our operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have previously received a research and development (R&amp;D) cash rebate through the Australian Government&#8217;s Research and Development Tax Incentive program, which provides up to a 43.5% rebate on qualifying R&amp;D expenses in Australia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">For Psyence Australia Pty&#160;Ltd.&#8217;s fiscal&#160;year ended June&#160;30, 2023, our subsidiary, Psyence Australia Pty&#160;Ltd., received a cash refund of AUD $1,336,622. To receive this research and development cash rebate, we qualified for certain conditions under the R&amp;D Tax Incentive legislation (Income Tax Assessment Act 1997 (Cth), Division 355) in Australia including, but not limited to, having a company incorporated under Australian law, all R&amp;D activities being conducted solely within Australia; the Company&#8217;s aggregated </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">group turnover not being equal to, or more than, AU$20M for relevant period; all R&amp;D activities are conducted by, or will be conducted for, the Company; and all CRO expenditures have been physically undertaken in Australia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Entitlement to tax benefits under the Research and Development Tax Incentive for eligible R&amp;D purposes is based on an annual application to the Australian Government. We believe that we continue to be eligible for the tax benefits. If these tax benefits are reduced, cancelled, or discontinued, or if we fail to meet certain conditions, we may encounter difficulties funding further R&amp;D projects, which could harm our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Regulatory Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The research and development, studying, manufacturing, packaging, labeling, advertising and distribution of Psyence&#8217;s planned product candidates are subject to regulation by one or more governmental authorities, and various agencies of the federal, provincial, state and localities in which Psyence intends to commercialize its products. These governmental authorities may attempt to regulate any of its products that fall within their jurisdiction. Such governmental authorities may not accept the evidence of safety for any ingredients that Psyence may want to market, may determine that a particular product or product ingredient presents an unacceptable health risk and may determine that a particular statement of nutritional support that Psyence wants to use is an unacceptable claim. Such a determination would prevent Psyence from marketing particular products or using certain statements of nutritional support on its products. Psyence also may be unable to disseminate third-party literature that supports its products if the third-party literature fails to satisfy certain requirements. In addition, governmental authorities could require Psyence to remove a particular product from the market. Any recall or removal would result in additional costs to Psyence, including lost revenues from any products that it is required to remove from the market, any of which could be material. Any such product recalls or removals could lead to liability, substantial costs and reduced growth prospects, all of which could be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our prospective products will be subject to the various federal and state laws and regulations relating to health and safety and failure to comply with, or changes in, these laws or regulations could have an adverse impact on our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are in the process of developing an investigational new drug for which we intend to pursue FDA approval via the New Drug Application (&#8220;<b style="font-weight:bold;">NDA</b>&#8221;) process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with our development and future commercialization (if applicable) of the above- described prospective products, we and each contemplated product candidate are subject to the Federal Food Drug and Cosmetic Act (FDCA). The FDCA is intended to assure the consumer, in part, that drugs and devices are safe and effective for their intended uses and that all labeling and packaging is truthful, informative, and not deceptive. The FDCA and FDA regulations define the term &#8220;drug,&#8221; in part, by reference to its intended use, as &#8220;articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease&#8221; and &#8220;articles (other than food) intended to affect the structure or any function of the body of man or other animals.&#8221; Therefore, almost any ingested or topical or injectable product that, through its label or labeling (including internet websites, promotional pamphlets, and other marketing material), that is claimed to be beneficial for such uses will be regulated by FDA as a drug. The definition also includes components of drugs, such as active pharmaceutical ingredients. Drugs must generally either receive premarket approval by FDA through the NDA process or conform to a &#8220;monograph&#8221; for a particular drug category, as established by FDA&#8217;s Over-the-Counter (OTC) Drug Review. If the FDA does not award premarket approval for our product candidates through the NDA process, this could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA will accept data from studies performed in other countries, as long as the study complies with GCP and ICH guidelines. FDA will review the Phase IIb protocol prior to the start of the study to provide advice on what and how aspects of the trial will be captured. Advice from a pre-IND meeting with the FDA was received in July&#160;2023, which informed the Phase IIb Study design and may also inform the phase III program we plan to do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials are expensive, time-consuming, uncertain and susceptible to change, delay or termination. The results of clinical trials are open to differing interpretations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Clinical testing is expensive, time consuming, and uncertain as to outcome and may be more costly than anticipated due various factors including, but not limited to, regulatory environment, legal compliance, supply and demand of services and inflationary costs. </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, or at all. Failures in connection with one or more clinical trials can occur at any stage of testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory agencies may analyze or interpret the results of clinical trials differently than Psyence. Even if the results of the clinical trials are favorable, the clinical trials for the product candidates are expected to continue for several&#160;years and may take significantly longer to complete. Events that may prevent successful or timely completion of clinical development include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with regulatory authorities on trial design and other trial related matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement on acceptable terms with prospective third party service providers assisting the CROs in the conduct of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or perceived lack of effectiveness of the product candidate during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discovery of serious or unexpected toxicities or side effects experienced by trial participants or other safety issues, such as drug interactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected rates of subject recruitment and enrollment rates in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in retaining subjects for the entire duration of applicable clinical studies (as study subjects may withdraw at any time due to adverse side effects from the therapy, insufficient efficacy, fatigue with the clinical trial process, death or for any other reason;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or inability in manufacturing or obtaining sufficient quantities of materials for use in clinical trials due to regulatory and manufacturing constraints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inadequacy of or changes in manufacturing process or product candidate formulation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining and maintaining regulatory authorizations, including &#8220;clinical holds&#8221; or delays requiring suspension or termination of a trial by a regulatory agency, such as the TGA, before or after a trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in applicable regulatory policies and regulation, including changes to requirements imposed on the extent, nature or timing of studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainty regarding proper dosing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay or failure to supply product for use in clinical trials which conforms to regulatory specification;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable results from ongoing pre-clinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of the CRO, or other third-party contractors to comply with all contractual requirements or to perform their services in a timely or acceptable manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by Psyence, its employees, the CRO or its employees to comply with all applicable regulatory requirements relating to the conduct of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scheduling conflicts with participating clinicians and clinical institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to design appropriate clinical trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory concerns with administering a psychoactive product, generally, and the potential for abuse;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">insufficient data to support regulatory approval;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of medical investigators to follow our clinical protocols; or difficulty in maintaining contact with patients during or after treatment, which may result in incomplete data.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Psyence may be subject to federal, state and foreign healthcare laws and regulations and implementation of or changes to such healthcare laws and regulations could adversely affect Psyence&#8217;s business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If Psyence successfully completes the requisite preclinical and clinical testing, makes the required regulatory submissions and obtains any corresponding authorizations or licenses (as applicable), fulfills all other applicable development-related regulatory obligations, and, eventually, obtains FDA approval to market one or more of its current or future product candidates in the United States, Psyence will be subject to certain healthcare laws and regulations. In Australia, the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could impact Psyence&#8217;s ability to commercialize Psyence&#8217;s product candidates. If Psyence were found to be in violation of any of these laws or any other federal, state or foreign regulations, Psyence may be subject to administrative, civil and/or criminal penalties, damages, fines, individual imprisonment, exclusion from federal health care programs and the restructuring of its operations. Any of these could have a material adverse effect on its business and financial results. Since many of these laws have not been fully interpreted by the courts, there is an increased risk that Psyence may be found in violation of one or more of their provisions. Any action against Psyence for violation of these laws, even if Psyence is ultimately successful in its defense, will cause Psyence to incur significant legal expenses and divert management&#8217;s attention away from the operation of the business. In addition, in many foreign countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to government control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Serious adverse events or other safety risks could require Psyence to abandon development and preclude, delay or limit approval of its current or future product candidates, limit the scope of any approved label or market acceptance, or cause the recall or loss of marketing approval of products that are already marketed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of Psyence&#8217;s current or future product candidates, prior to or after any approval for commercial sale, cause serious or unexpected side effects, or are associated with other safety risks such as misuse, abuse or diversion, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may interrupt, delay or halt clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may deny regulatory approval of future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require certain labeling statements, such as warnings or contraindications or limitations on the indications for use, and/or impose restrictions on distribution;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval, require more onerous labeling statements, or require Psyence to recall any product that is approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence may be required to change the way the product is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence&#8217;s relationships with its collaboration partners may suffer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence could be sued and held liable for harm caused to patients; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence&#8217;s reputation could suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates, if approved, and could significantly harm our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Psyence may voluntarily suspend or terminate a clinical trial if at any time its believes that any of its product candidates presents an unacceptable risk to participants, if preliminary data demonstrates that the product candidate is unlikely to receive regulatory approval or unlikely to be successfully commercialized, or if sufficient funds to proceed to the next phases of clinical trials are not raised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After obtaining the requisite regulatory authorizations to commence or advance clinical trials, Psyence may voluntarily suspend or terminate any of its clinical trials for any number of reasons, including if it believes that a product candidate&#8217;s use, or a person&#8217;s exposure to such product candidate, may cause adverse health consequences or death. In addition, regulatory agencies may at any time recommend the temporary or permanent discontinuation of a clinical trial or request that Psyence cease using investigators in the clinical trials if the agency believes that a clinical trial is not being conducted in accordance with applicable regulatory requirements, or that it presents an unacceptable safety risk to participants. If Psyence elects or is forced to suspend or terminate a clinical trial of any of its product candidates, the commercial prospects for that product will be harmed and its ability to generate product revenue from such product candidate may be delayed or eliminated. Furthermore, any of these events may result in labeling statements such as warnings or contraindications. In addition, such events or labeling could prevent Psyence or its partners from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing its future product candidates and impair its ability to generate revenue from the commercialization of these product candidates either by Psyence or by its collaboration partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The clinical trial is divided into stages and progression of each stage is dependent on governmental approval to proceed to the next stage being furnished by Psyence. Accordingly, if Psyence believes that it does not have sufficient funds to progress with the next phases of the clinical trials, or for any other reason, Psyence is entitled to exercise this discretion in accordance with applicable laws and regulatory compliance and approvals, taking patient risk and safety into account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The success of Psyence&#8217;s product candidates and future approved products, if any, is subject to a number of constantly-evolving state and federal laws, regulations, and enforcement policies pertaining to psilocybin containing products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Local, state, federal, and international psilocybin laws and regulations remain highly restrictive and subject to evolving interpretations, which could require Psyence to incur substantial costs associated with compliance requirements. Psyence seeks independent local legal opinions confirming the lawfulness of Psyence&#8217;s existing and proposed activities as well as its compliance with legal, regulatory and governmental developments as they pertain to and affect Psyence&#8217;s operations. In addition, violations of these laws, or allegations of such violations, could disrupt Psyence&#8217;s business and result in a material adverse effect on Psyence&#8217;s operations. In addition, it is possible that regulations may be enacted in the future that will be directly applicable to Psyence&#8217;s proposed business regarding the administration of psilocybin or psilocybin-assisted psychotherapy. Psyence cannot predict the nature of any future laws, regulations, interpretations, or applications, nor can it determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on its activities in the psychedelics industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that Psyence&#8217;s product candidates containing psilocybin (as the active pharmaceutical ingredient) will be approved for commercialization in Australia, the U.S. or any other target jurisdiction at any time in the near or distant future. Any regulations the FDA issues relating to the sale, marketing, and/or other activities involving administration of psilocybin or psilocybin-assisted psychotherapy could have a material adverse effect on Psyence&#8217;s business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek fast track and breakthrough therapy designations or priority review for one or more of our product candidates, but we might not receive such designation or priority review, and even if we do, such designation or priority review may not lead to a faster development or regulatory review or approval process, and does not assure FDA approval of our product candidates. Even if a product qualifies for such designation or priority review, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek fast track, breakthrough therapy, and/or regenerative medicine advanced therapy designations or priority review for one or more of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The FDA may issue a fast track designation to a product candidate if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic may request that the FDA designate the biologic as a fast track product at any time during the clinical development of the product. For fast track products, sponsors may have greater interactions </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with the FDA during product development. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. However, the FDA&#8217;s goal for reviewing a BLA fast track application under the Prescription Drug User Fee Act (&#8220;<b style="font-weight:bold;">PDUFA</b>&#8221;) does not begin until the last section of the application is submitted. Fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fast track designation, priority review, and breakthrough therapy designation are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for any such designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of such designation may expedite the development or approval process, but do not change the standards for approval. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek approval of our product candidates, where applicable, under the FDA&#8217;s accelerated approval pathway. This pathway may not lead to a faster development, regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">A product may be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and generally provides a meaningful advantage over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, (&#8220;<b style="font-weight:bold;">IMM</b>&#8221;) that is reasonably likely to predict an effect on IMM or other clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as IMM. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;<b style="font-weight:bold;">FDORA</b>&#8221;), the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of accelerated approval was granted. FDORA also requires sponsors to send updates to the FDA every 180&#160;days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send the necessary updates to the FDA, or if such post-approval studies fail to verify the drug&#8217;s predicted clinical benefit. Under FDORA, the FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress. In addition, the FDA currently requires, unless otherwise informed by the agency, pre-approval of promotional materials for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product. Thus, even if we seek to utilize the accelerated approval pathway, we may not be able to obtain accelerated approval and, even if we do, we may not experience a faster development, regulatory review or approval process for that product. There can be no assurance that the FDA would allow any of the product candidates we may develop to proceed on an accelerated approval pathway, and even if the FDA did allow such pathway, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">at all. Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained. Receiving accelerated approval does not assure that the product&#8217;s accelerated approval will eventually be converted to a traditional approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Relating to the Psychedelic Therapy Market and Biotechnology Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The psychedelic therapy industry and market are relatively new, and this industry and market may not continue to exist or grow as anticipated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence operates its business in a relatively new industry and market. In addition to being subject to general business risks, Psyence must continue to build brand awareness in this industry and market through significant investments in its strategy, operational capacity, quality assurance and compliance with regulations. In addition, there is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated or function and evolve in a manner consistent with management&#8217;s expectations and assumptions. Any event or circumstance that adversely affects the psychedelic therapy industry and market could have a material adverse effect on Psyence&#8217;s business, financial conditions and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psilocybin is considered scientifically to be the safest of the psychedelics and/or drugs of abuse potential. In fact, psilocybin has been described as being anti-addictive and has been studied for the use in substance addictive disorders, such as alcohol use disorder, smoking cessation and opioid addiction. Notwithstanding the foregoing, the psychedelic therapy market will face specific marketing challenges given the products&#8217; status as a controlled substance, which has resulted in past and current public perception that the products have negative health and lifestyle effects and have the potential to cause physical and social harm due to psychoactive and potentially addictive effects. Any marketing efforts by Psyence would need to overcome this perception to build consumer confidence, brand recognition and goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Negative public opinion and perception of the psychedelic industry could adversely impact Psyence&#8217;s ability to operate and Psyence&#8217;s growth strategy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Consumer perception of Psyence&#8217;s products may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of naturally derived, medicinal-grade psilocybin mushroom products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the naturally derived medicinal-grade psilocybin mushroom market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for Psyence&#8217;s envisaged products and Psyence&#8217;s business, results of operations, financial condition and cash flows. Psyence&#8217;s dependence upon consumer perception means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on Psyence, the demand for Psyence&#8217;s products, and Psyence&#8217;s business, results of operations, financial condition and cash flows. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of naturally derived medicinal-grade psilocybin mushroom in general, or Psyence&#8217;s products specifically, or associating the consumption of naturally derived medicinal-grade psilocybin mushroom&#8217;s negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers&#8217; failure to consume such products appropriately or as directed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The expansion of the use of psychedelics in the medical industry may require new clinical research into effective medical therapies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Research in the UK, Canada, Australia and internationally regarding the medical benefits, viability, safety, efficacy, addictiveness, dosing and social acceptance of psychedelic and psychoactive products remains in early stages. There have been relatively few clinical trials on the benefits of such products. Although Psyence believes that the articles, reports and studies support its beliefs regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of psychedelic and psychoactive products, future research and clinical trials may prove such statements to be incorrect, or could raise concerns regarding, and perceptions relating to, psychedelic and psychoactive products. Future research studies and clinical trials may draw opposing conclusions to those stated in this prospectus or reach negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing, social acceptance or other facts and perceptions related to psychedelic and psychoactive products, which could have a material </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">adverse effect on the demand for Psyence&#8217;s product candidate and psychedelic therapies and a material adverse effect on Psyence&#8217;s business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The psychedelic therapy industry is difficult to quantify and investors will be reliant on their own estimates of the accuracy of market data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the psychedelic therapy industry is in a nascent stage with uncertain boundaries, there is a lack of information about comparable companies available for potential investors to analyze in deciding whether to invest in Psyence and, few, if any, established companies whose business model Psyence can follow or upon whose success Psyence can build. Accordingly, investors will have to rely on their own estimates in deciding whether to invest in Psyence. There can be no assurance that Psyence&#8217;s estimates are accurate or that the market size is sufficiently large for its business to grow as projected, which may negatively impact its financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Psyence may not be able to adequately protect or enforce its intellectual property rights, which could harm its competitive position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence relies upon a combination of patent, copyright, trademark and trade secret laws, as well as nondisclosure agreements, know-how of the scientific team, and other methods, to protect its proprietary technologies and processes. The strengths of patents in the pharmaceutical field involve complex legal and scientific questions and can be uncertain. Where appropriate, Psyence will seek patent protection for certain aspects of its products and technology. Filing, prosecuting and defending patents in a wide range of countries can be prohibitively expensive. If Psyence fails to adequately protect its intellectual property, it may face competition from companies who attempt to create a generic product to compete with its future product candidates. Psyence may also face competition from companies who develop a substantially similar product to its future product candidates that are not covered by any patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While Psyence will apply for a number of patents upon the discovery or creation of something novel, there can be no assurances that any patents will be issued. Specifically, naturally occurring substances arising from botanical sources, e.g Psilocybin, cannot be patented. As such, we will be required to rely on other processes such as extraction, purification, or formulation in order to establish patents and such processes are not guaranteed to receive issued patents. Even if patents are issued, the claims allowed may not be sufficiently broad to protect all of Psyence&#8217;s intellectual property. In addition, any future patents issued to Psyence may be challenged, invalidated or circumvented. As such, any rights granted under these patents may not provide Psyence with meaningful protection. If Psyence&#8217;s patents do not adequately protect its intellectual property, competitors may be able to offer products similar to Psyence&#8217;s products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence will be further dependent, to an extent, on Filament&#8217;s wholly-owned subsidiary, Psilo Scientific&#160;LTD. (&#8220;<b style="font-weight:bold;">Psilo</b>&#8221;), to maintain and defend the intellectual property currently being licensed to Psyence under the Research IP Agreement, and which is relevant for use in Psyence&#8217;s Phase IIb Study. Any failure on the part of Psilo or Filament, as applicable, to adequately maintain or defend its intellectual property will have a direct effect on the viability of Psyence&#8217;s Australian palliative care clinical trial initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s strategy is to patent technologies with commercial potential in jurisdictions with significant commercial opportunities. However, patent protection may not be available for some of the products or technologies Psyence is developing, such as in the areas of methods of treatment (which are not patentable in most jurisdictions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent positions of pharmaceutical products are complex and uncertain. The scope and extent of patent protection for future product candidates are particularly uncertain. Protection of Psyence&#8217;s future product candidates will be sought in respect of, among other things, composition-of-matter for specific formulations, methods of use, and delivery mechanisms, bearing in mind that patent protection is not available for naturally derived psilocybin alone. If any of Psyence&#8217;s products are approved and marketed for an indication for which it does not have an issued or licensed patent, Psyence&#8217;s ability to use a patent to prevent a competitor from commercializing a non-branded version of its commercial products for that non- patented indication could be significantly impaired or even eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Many companies have encountered significant problems in protecting, defending and enforcing intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property rights, particularly those relating to pharmaceuticals, which could make it difficult for Psyence to stop the infringement of patents or marketing of competing products in violation of its proprietary rights generally. Proceedings to </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">enforce patent rights in foreign jurisdictions may not be successful, could result in substantial cost and divert Psyence&#8217;s efforts and attention from other aspects of its business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If third parties claim that intellectual property owned or used by Psyence infringes upon their intellectual property, Psyence&#8217;s operating profits could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the pharmaceutical industry. Psyence may, from time to time, be notified of claims that Psyence is infringing upon patents, trademarks, copyrights or other intellectual property rights owned by third parties, and Psyence cannot provide assurances that other companies will not, in the future, pursue such infringement claims against it, its commercial partners or any third-party proprietary technologies it has licensed. If Psyence were found to infringe upon a patent or other intellectual property right, or if Psyence failed to obtain or renew a license under a patent or other intellectual property right from a third party, or if a third party that Psyence were licensing technologies from was found to infringe upon a patent or other intellectual property rights of another third party, Psyence may be required to pay damages, suspend the manufacture of certain products or reengineer or rebrand its products, if feasible, or it may be unable to enter certain new product markets. Any such claims could also be expensive and time-consuming to defend and divert management&#8217;s attention and resources. Psyence&#8217;s competitive position could suffer as a result. In addition, if Psyence has declined or failed to enter into a valid non-disclosure or assignment agreement for any reason, Psyence may not own the intellectual property, and its products may not be adequately protected. Thus, Psyence cannot guarantee that any of its future product candidates, or its commercialization thereof, does not and will not infringe any third party&#8217;s intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. We are not aware of any third-party proprietary rights that our planned products will infringe or misappropriate, but we have not conducted any freedom to operate study as we are in the earliest stages of development. We thus cannot guarantee that our product candidates, or manufacture or use of our product candidates, will not infringe third-party patents. Furthermore, a third party may claim that we are using inventions covered by the third party&#8217;s patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and scientific personnel. Some of these third parties may be better capitalized and have more resources than us. There is a risk that a court would decide that we are infringing the third party&#8217;s patents and would order us to stop the activities covered by the patents. In that event, we may not have a viable way around the patent and may need to halt commercialization of our product candidates. In addition, there is a risk that a court will order us to pay the other party damages for having violated the other party&#8217;s patents. In addition, we may be obligated to indemnify our licensors and collaborators against certain intellectual property infringement claims brought by third parties, which could require us to expend additional resources. The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are sued for patent infringement, we would need to demonstrate that our product candidates or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the U.S., proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and diversion of management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than us or the third parties from whom we license intellectual property because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If Psyence is not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of its products could be significantly diminished.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence relies, to an extent, on trade secrets to protect its proprietary licensed intellectual property, especially where it does not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Psyence relies in part on confidentiality agreements and restraints of trade with its current and former employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers, vendors and other advisors, as well as similar confidentiality protections benefiting its strategic partners and licensors to protect Psyence&#8217;s owned and licensed trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, Psyence cannot guarantee that it, nor its strategic and business partners, have executed these agreements with each party that may have or have had access to owned and licensed trade secrets. Any party with whom Psyence or strategic and business partners have executed such an agreement may breach that agreement and disclose proprietary information, including owned and licensed trade secrets, and adequate remedies for such breaches may not be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the U.S. are less willing or unwilling to protect trade secrets. If any of Psyence&#8217;s owned or licensed trade secrets were to be lawfully obtained or independently developed by a competitor, Psyence would have no right to prevent them, or those to whom they disclose such trade secrets, from using that technology or information to compete with it. If any of Psyence&#8217;s owned and licensed trade secrets were to be disclosed to or independently developed by a competitor or other third-party, Psyence&#8217;s competitive position would be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Ownership of Our Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">The securities being offered in this prospectus represent vastly more than the number of our outstanding Common Shares, and the sales of such shares, or the perception that these sales could occur, could cause the market price of our Common Shares to decline significantly could impair our ability to raise capital through the sale of additional equity securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This prospectus relates to the offer and sale from time to time by the Selling Securityholders named in this prospectus, or their permitted transferees, from time to time. The sale of Common Shares by the Selling Securityholders, or the perception that these sales could occur, could depress the market price of our Common Shares could impair our ability to raise capital through the sale of additional equity securities. A Selling Securityholder may still have an incentive to sell our Common Shares because it may still experience a positive rate of return on the securities it purchased, or was issued, due to the differences in the purchase prices it paid for our Common Shares and the public trading price of our Common Shares. While a Selling Securityholder may, on average, experience a positive rate of return based on the current market price of the Common Shares it purchased, public securityholders may not experience a similar rate of return on the Common Shares they purchased if there is such a decline in price and due to differences in the purchase prices and the current market price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">It is not possible to predict the actual number of shares we will sell under the White Lion Purchase Agreement to White Lion, or the actual gross proceeds resulting from those sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to certain limitations in the White Lion Purchase Agreement and compliance with applicable law, we have the discretion to deliver notices to White Lion at any time throughout the White Lion Commitment Period. The number of shares ultimately offered for sale by White Lion under this prospectus is dependent upon the number of shares we elect to sell to White Lion under the White Lion Purchase Agreement. The actual number of shares that are sold to White Lion may depend on a number of factors, including the market price and market liquidity of our Common Stock during the Commitment Period. Actual gross proceeds may be less than $25.0 million, which may impact our future liquidity. Because the price per share of each share sold to White Lion will fluctuate during the Commitment Period, it is not currently possible to predict the number of shares that will be sold or the actual gross proceeds to be raised in connection with those sales, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Investors who buy shares in this offering at different times will likely pay different prices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Investors who purchase Common Shares in this offering at different times will likely pay different prices, and so may experience different levels of dilution and different outcomes in their investment results. In connection with the White Lion Purchase Agreement, we will have discretion, subject to market demand, to vary the timing, prices, and numbers of Common Shares sold to White Lion. Similarly, White Lion may sell such shares at different times and at different prices. Investors may experience a decline in the value of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the shares they purchase from White Lion in this offering as a result of sales made by us in future transactions to White Lion at prices lower than the prices such investors paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">The issuance of shares to White Lion may cause substantial dilution to our existing shareholders, and the sale of such shares acquired by White Lion could cause the price of our Common Shares to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are registering for resale by White Lion up to 50,375,000 Common Shares. After White Lion has acquired shares under the White Lion Purchase Agreement, it may sell all, some or none of those shares. Sales to White Lion by us pursuant to the White Lion Purchase Agreement may result in substantial dilution to the interests of other holders of our Common Shares. The sale of a substantial number of shares to White Lion could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise desire. The number of Common Shares ultimately offered for resale by White Lion under this prospectus is dependent upon the number of Common Shares issued to White Lion pursuant to the White Lion Purchase Agreement. Depending on a variety of factors, including market liquidity of our Common Shares, the issuance of shares to White Lion may cause the trading price of our Common Shares to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">We have broad discretion in the use of the net proceeds we receive from the sale of shares to White Lion and may not use them effectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management will have broad discretion in the application of the proceeds we receive from White Lion, if any, including for the purposes described in &#8220;<i style="font-style:italic;">Use of Proceeds</i>&#8221;, and you will not have the opportunity as part of your investment decision to assess whether our management is using the proceeds appropriately. Because of the number and variability of factors that will determine our use of our proceeds from White Lion under the White Lion Purchase Agreement, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business and cause the price of our Common Shares to decline. Pending their use, we may invest the proceeds from White Lion in short-term, investment grade, interest-bearing securities. These investments may not yield a favorable return to our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future sales&#160;of our securities by existing holders could cause our stock price to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we or our existing holders sell, or indicate an intent to sell, substantial amounts of our Common Shares or securities convertible into our Common Shares in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our Common Shares, even if there is no relationship between such sales and the performance of our business. We also intend to register all Common Shares that we may issue under our Incentive Plan. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we fail to meet applicable continued listing requirements, Nasdaq may&#160;delist&#160;our Common Shares from trading, in which case the liquidity and market price of our Common Shares could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that we will be able to meet the continued listing standards of Nasdaq in the future. On March 11, 2024, we received two letters from the Nasdaq staff, one notifying the Company that for the last 30 consecutive business days, the Company&#8217;s Market Value of Listed Securities was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A), and the other notifying the Company that for the last 30 consecutive business days, the Company&#8217;s Market Value of Publicly Held Shares was below the minimum of $15 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C). Additionally, on June 27, 2024, we received a notification letter from the Nasdaq staff notifying the Company that the Company&#8217;s closing bid price per share was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). If we fail to comply with the applicable listing standards and Nasdaq delists our Common Shares, we and our shareholders could face significant material adverse consequences, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited availability of market quotations for our Common Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced liquidity for our Common Shares;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination that our Common Shares are &#8220;penny stock&#8221;, which would require brokers trading in our Common Shares to adhere to more stringent rules&#160;and possibly result in a reduced level of trading activity in the secondary trading market for our Common Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a limited amount of news about us and analyst coverage of us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8239;a decreased ability for us to issue additional equity securities or obtain additional equity or debt financing in the future.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The National Securities Markets Improvement Act&#160;of&#160;1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Because our Common Shares and Public Warrants are listed on Nasdaq, such securities are covered securities. Although the states are preempted from regulating the sale of our securities, the federal statute does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then the states can regulate or bar the sale of covered securities in a particular case. Further, if we were no longer listed on Nasdaq, our securities would not be covered securities and we would be subject to regulations in each state in which we offer our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price and trading volume of the Common Shares may be volatile and could decline significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The stock markets, including Nasdaq, on which the Company lists its securities, have from time to time experienced significant price and volume fluctuations. Even if an active, liquid and orderly trading market develops and is sustained for the Common Shares, the market prices of the Common Shares may be volatile and could decline significantly. In addition, the trading volumes in the Common Shares may fluctuate and cause significant price variations to occur. There can be no assurance that the market prices of the Common Shares will not fluctuate widely or decline significantly in the future in response to a number of factors, including, among others, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the realization of any of the risk factors presented in this prospectus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated differences in our estimates, or in the estimates of analysts, for the Company&#8217;s revenues, results of operations, cash flows, liquidity or financial condition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by the Company or its competitors of significant business developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquisitions or expansion plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s involvement in litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sale of Common Shares or other securities in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the Company&#8217;s industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading volume of Common Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual, potential or perceived control, accounting or reporting problems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting principles, policies and guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, including but not limited to those resulting from infectious diseases, health epidemics and pandemics (including but not limited to the COVID-19 pandemic), natural disasters, war, acts of terrorism or responses to these events; and</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic and market conditions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock markets have experienced extreme price and volume fluctuations. Broad market and industry factors may materially harm the market price of the Common Shares, regardless of our operating performance. In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted against that company. If the Company were involved in any similar litigation it could incur substantial costs and our management&#8217;s attention and resources could be diverted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our Warrants are exercisable for Common Shares, which would increase the number of shares eligible for future resale in the public market and result in dilution to our shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An aggregate of 12,410,000 Common Shares are issuable upon exercise of Warrants, including 11,840,000 Common Shares issuable upon exercise of Public Warrants and 570,000 Common shares issuable upon exercise of Private Warrants. These Warrants are currently exercisable. The exercise price of these Warrants is $11.50 per share. To the extent such Warrants are exercised, 12,410,000 additional Common Shares will be issued, representing approximately 75.1% of our current outstanding Common Shares and could result in dilution to the holders of Common Shares and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market or the fact that such Warrants may be exercised could adversely affect the market price of Common Shares. Notwithstanding the foregoing, because the closing price of our Common Shares on the Nasdaq Global Market was $0.6194 on July&#160;29, 2024, all of the Warrants are currently &#8220;out-of-the-money&#8221; and it is unlikely that any of the Warrants will be exercised by holders anytime in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">We may be subject to penalties under the Registration Rights Agreement since the registration statement of which this prospectus forms a part was not declared effective in a timely manner, which could include liquidated damages, the acceleration of repayment under the First Tranche Notes and other penalties, which would materially and adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the Securities Purchase Agreement, on January 25, 2024, the Company and the Investors entered into the Registration Rights Agreement, pursuant to which the Company agreed to file the Initial Resale Registration Statement covering the resale of the Common Shares issuable upon conversion of the First Tranche Notes and any additional registration statements required to be filed to register the resale of the Common Shares issuable upon any of the other Notes, as applicable, and to use its best efforts to have the Initial Resale Registration Statement and such registration statement(s), as applicable, declared effective by the SEC as soon as practicable, but in no event later than the applicable Effectiveness Deadline (as defined in the Registration Rights Agreement for such applicable registration statement). With respect to the Initial Resale Registration Statement, the Effectiveness Deadline was the earlier of the (A) 60th calendar day after the closing date of the First Tranche Notes, or March 25, 2024 and (B) 2nd business day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that such registration statement will not be reviewed or will not be subject to further review. Such Initial Resale Registration Statement was declared effective by the SEC on May 14, 2024 and is being amended by this Post-Effective Amendment. The Registration Rights Agreement contains certain penalty provisions, subject to certain conditions and cure periods, if the Company fails to (i) file a registration statement by certain deadlines set forth in the Registration Rights Agreement, (ii) cause a registration statement to be declared effective by certain deadlines set forth in the Registration Rights Agreement, (iii) maintain certain circumstances and conditions allowing the resale of certain securities, or (iv) satisfy the requirements of Rule 144(c)(1) under the Exchange Act if a registration statement is not effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, the First Tranche Notes provide for acceleration in certain instances in connection with certain events of default, including failure to cause the Initial Resale Registration Statement to become effective by the Effectiveness Deadline. Upon such event of default, the outstanding principal amount of the First Tranche Notes, accrued but unpaid interest through acceleration, plus liquidated damages and other amounts owing in respect thereof through the date of acceleration, became, at the Investors&#8217; election, immediately due and payable in cash. As of July 1, 2024, the total outstanding principal amount of the First Tranche Notes, accrued but unpaid interest through acceleration, plus liquidated damages and other amounts owing in respect thereof, that would be due immediately and in cash should the Company receive a notice of default from the Investors would be approximately $2 million. We have not yet received a notice of default from the Investors. Any acceleration of any of our outstanding indebtedness or requirement to pay liquidated damages or other penalties, would materially and adversely affect our business, and could affect our ability to continue as a going concern.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research, publish inaccurate or unfavorable research or cease publishing research about the Company, its share price and trading volume could decline significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for Common Shares depends, in part, on the research and reports that securities or industry analysts publish about the Company or its business. The Company may be unable to sustain coverage by well-regarded securities and industry analysts. If either none or only a limited number of securities or industry analysts maintain coverage of the Company, or if these securities or industry analysts are not widely respected within the general investment community, the demand for Common Shares could decrease, which might cause its share price and trading volume to decline significantly. In the event that the Company obtains securities or industry analyst coverage or, if one or more of the analysts who cover the Company downgrade their assessment of the Company or publish inaccurate or unfavorable research about the Company&#8217;s business, the market price and liquidity for Common Shares could be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The requirements of being a public company may strain the Company&#8217;s resources, divert the Company management&#8217;s attention and affect the Company&#8217;s ability to attract and retain qualified board members.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred and will continue to incur additional legal, accounting and other expenses since becoming a public company. The Company is subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Act, the Nasdaq listing requirements and other applicable securities rules&#160;and regulations. These expenses may increase even more if the Company no longer qualifies as an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a)&#160;of the Securities Act. The Exchange Act requires that we file annual and other material reports with respect to our businesses, financial condition, and results of operations. In addition, we must establish the corporate infrastructure necessary for operating a public company, which may divert our management&#8217;s attention from implementing our growth strategy, which could delay or slow the implementation of our business strategies, and in turn negatively impact our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. The Company expects these laws and regulations to increase its legal and financial compliance costs and to render some activities more time-consuming and costly, although the Company is currently unable to estimate these costs with any degree of certainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s management team has limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly complex laws pertaining to public companies. The Company&#8217;s management team may not successfully or efficiently manage the transition to being a public company subject to significant regulatory oversight and reporting obligations under the federal securities laws and regulations and the continuous scrutiny of securities analysts and investors. The need to establish the corporate infrastructure demanded of a public company may divert the management&#8217;s attention from implementing its growth strategy, which could prevent the Company from improving its business, financial condition and results of operations. Furthermore, the Company expects these rules&#160;and regulations to make it more difficult and more expensive for the Company to maintain director and officer liability insurance, and consequently the Company may be required to incur substantial costs to obtain such coverage. These additional obligations could have a material adverse effect on its business, financial condition, results of operations and prospects. These factors could also make it more difficult for the Company to attract and retain qualified members of its Board, particularly to serve on the Company&#8217;s audit committee, compensation committee and nominating and corporate governance committee, and qualified executive officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of disclosure of information in this prospectus and in filings required of a public company, the Company&#8217;s business and financial condition will become more visible, which may result in threatened or actual litigation, including by competitors and other third parties. If such claims are successful, the Company&#8217;s business and operating results could be adversely affected, and, even if the claims do not result in litigation or are resolved in the Company&#8217;s favor, these claims, and the time and resources necessary to resolve them, could have an adverse effect on its business, financial condition, results of operations and prospects.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company is an &#8220;emerging growth company,&#8221; and it cannot be certain if the reduced SEC reporting requirements applicable to emerging growth companies will make the Company&#8217;s Common Shares less attractive to investors, which could have a material and adverse effect on the Company, including its growth prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is an &#8220;emerging growth company&#8221; as defined in the JOBS Act. The Company will remain an &#8220;emerging growth company&#8221; until the earliest to occur of (i)&#160;the last day of the fiscal&#160;year (a)&#160;following the fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective registration statement under the Securities Act, (b)&#160;in which the Company has total annual gross revenue of at least $1.235 billion or (c)&#160;in which the Company is deemed to be a large accelerated filer, which means the market value of Common Shares held by non-affiliates exceeds $700 million as of the last business day of the Company&#8217;s prior second fiscal quarter, and (ii)&#160;the date on which the Company issued more than $1.0 billion in non-convertible debt during the prior three-year period. The Company intends to take advantage of exemptions from various reporting requirements that are applicable to most other non &#8220;emerging growth companies&#8221; including, but not limited to, an exemption from the provisions of Section&#160;404(b)&#160;of the Sarbanes-Oxley Act requiring that the Company&#8217;s independent registered public accounting firm provide an attestation report on the effectiveness of its internal control over financial reporting and reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, even after the Company no longer qualifies as an &#8220;emerging growth company,&#8221; as long as the Company continues to qualify as a foreign private issuer under the Exchange Act, the Company will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including, but not limited to, (i)&#160;the rules&#160;under the Exchange Act requiring the filing of quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K with the SEC; (ii)&#160;the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; (iii)&#160;the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iv)&#160;the selective disclosure rules&#160;by issuers of material nonpublic information under Regulation FD As a result, the Company shareholders may not have access to certain information they deem important. The Company cannot predict if investors will find Common Shares less attractive because it relies on these exemptions. If some investors do find Common Shares less attractive as a result, there may be a less active trading market and share price for Common Shares may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company qualifies as a foreign private issuer within the meaning of the rules&#160;under the Exchange Act, and as such the Company is exempt from certain provisions applicable to United States domestic public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the Company qualifies as a foreign private issuer under the Exchange Act, the Company is exempt from certain provisions of the securities rules&#160;and regulations in the United States that are applicable to U.S. domestic issuers, including, but not limited to: (i)&#160;the rules&#160;under the Exchange Act requiring the filing of quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K with the SEC; (ii)&#160;the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect of a security registered under the Exchange Act; (iii)&#160;the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iv)&#160;the selective disclosure rules&#160;by issuers of material nonpublic information under Regulation FD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is required to file an annual report on Form&#160;20-F within four&#160;months of the end of each fiscal&#160;year. Press releases relating to financial results and material events will also be furnished to the SEC on Form&#160;6-K. However, the information the Company is required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers. Accordingly, if you continue to hold Common Shares, you may receive less or different information about the Company than you would receive about a U.S. domestic public company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Company may lose its foreign private issuer status which would then require it to comply with the domestic reporting regime of the Exchange Act and cause us to incur significant additional legal, accounting and other expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As discussed above, the Company is a foreign private issuer and therefore is not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act and may take advantage of certain exemptions to Nasdaq&#8217;s corporate governance rules. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter, and, accordingly, the next determination will be made with respect to the Company on September&#160;30, 2024. In the future, the Company would lose its foreign private issuer status if (1)&#160;more than 50% of its outstanding voting securities are owned by U.S. residents and (2)&#160;a majority of its directors or executive officers are U.S. citizens or residents, or it </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">fails to meet additional requirements necessary to avoid loss of foreign private issuer status. If the Company loses its foreign private issuer status, it will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. The Company would also have to mandatorily comply with U.S. federal proxy requirements, and its officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section&#160;16 of the Exchange Act. In addition, it would lose its ability to rely upon exemptions from certain corporate governance requirements under the listing rules&#160;of Nasdaq. As a U.S. listed public company that is not a foreign private issuer, the Company could incur significant additional legal, accounting and other expenses that it will not incur as a foreign private issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Psyence currently reports financial results under IFRS, which differs in certain significant respects from U.S. GAAP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence currently reports financial results under IFRS. There are and there may in the future be certain significant material differences between IFRS and U.S. GAAP. As a result, financial information and reported earnings of Psyence for historical or future periods could be significantly different if they were prepared in accordance with U.S. GAAP. In addition, the Company does not intend to provide a reconciliation between IFRS and U.S. GAAP unless it is required under applicable law. As a result, you may not be able to meaningfully compare our financial statements under IFRS with those of companies that prepare financial statements under U.S. GAAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are classified as a passive foreign investment company, United States taxpayers who own our Common Shares may have adverse United States federal income tax consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A non-U.S. corporation such as ourselves will be classified as a passive foreign investment company, which is known as a PFIC, for any taxable&#160;year if, for such&#160;year, either</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">At least 75% of our gross income for the&#160;year is passive income; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The average&#160;percentage of our assets (determined at the end of each quarter) during the taxable&#160;year which produces passive income or which are held for the production of passive income is at least 50%.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Passive income generally includes dividends, interest, rents, royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are determined to be a PFIC for any taxable&#160;year (or portion thereof) that is included in the holding period of a U.S. taxpayer who holds our Common Shares, the U.S. taxpayer may be subject to increased U.S. federal income tax liability and may be subject to additional reporting requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Depending on the amount of our cash and other assets held for the production of passive income, it is possible that, for our current taxable&#160;year or for any subsequent&#160;year, more than 50% of our assets may be assets which produce passive income. We will make this determination following the end of any particular tax&#160;year. Although the law in this regard is unclear, we treat our consolidated affiliated entities as being owned by us for United States federal income tax purposes, not only because we exercise effective control over the operation of such entities but also because we are entitled to substantially all of their economic benefits, and, as a result, we consolidate their operating results in our consolidated financial statements. For purposes of the PFIC analysis, in general, a non-U.S. corporation is deemed to own its pro rata share of the gross income and assets of any entity in which it is considered to own, directly or indirectly, at least 25% of the equity by value. Our status as a PFIC is a fact-intensive determination made on an annual basis, and no opinion of counsel has or will be provided regarding our classification as a PFIC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For a more detailed discussion of the application of the PFIC rules&#160;to us and the consequences to U.S. taxpayers who own our Common Shares if we were determined to be a PFIC, see &#8220;<i style="font-style:italic;">Certain Material U.S. Federal Income Tax Considerations&#160;&#8212; Passive Foreign Investment Company</i>.&#8221;</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because the Company is incorporated under the laws of Canada, the Company conducts substantially all of its operations and a majority of its directors and executive officers reside outside of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company is a corporation incorporated under the laws of Canada, and conducts a majority of its operations through its subsidiary, Biomed II, outside the United States. Substantially all of the Company&#8217;s assets are located outside the United States. A majority of the Company&#8217;s officers and directors reside outside the United States and a substantial portion of the assets of those persons are located outside of the United States. As a result, it could be difficult or impossible for you to bring an action against the Company or against these individuals outside of the United States in the event that you believe that your rights have been infringed upon under the applicable securities laws or otherwise and it will be difficult to effect service of process within the United States upon the Company&#8217;s officers or directors, or enforce judgments obtained in United States courts against the Company&#8217;s officers or directors. Even if you are successful in bringing an action of this kind, the laws of Ontario could render you unable to enforce a judgment against the Company&#8217;s assets or the assets of the Company&#8217;s directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Articles of Incorporation and certain Canadian legislation contain provisions that may have the effect of delaying or preventing a change in control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Certain provisions of the Articles of Incorporation, together or separately, could discourage potential acquisition proposals, delay or prevent a change in control and limit the price that certain investors may be willing to pay for our common shares. For instance, our Articles of Incorporation contain provisions that establish certain advance notice procedures for nomination of candidates for election as directors at shareholders&#8217; meetings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition, a non-Canadian must file an application for review with the Minister responsible for the Investment Canada Act and obtain approval of the Minister prior to acquiring control of a &#8220;Canadian Business&#8221; within the meaning of the Investment Canada Act, where prescribed financial thresholds are exceeded. Finally, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). The Competition Act (Canada) establishes a pre-merger notification regime for certain types of merger transactions that exceed certain statutory shareholding and financial thresholds. Transactions that are subject to notification cannot be closed until the required materials are filed and the applicable statutory waiting period has expired or been waived by the Commissioner. The Commissioner of Competition still retains the authority under the Competition Act (Canada) to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us, whether or not it is subject to mandatory notification. Otherwise, there are no limitations either under the laws of Canada or Ontario, or in our articles on the rights of non-Canadians to hold or vote our common shares. Any of these provisions may discourage a potential acquirer from proposing or completing a transaction that may have otherwise presented a premium to our shareholders. We cannot predict whether investors will find our company and our Common Shares less attractive because we are governed by foreign laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">It is not expected that the Company will pay dividends in the foreseeable future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">It is expected that the Company will retain most, if not all, of its available funds and any future earnings to fund the development and growth of its business. In addition, the Company is a holding company and its subsidiaries are located abroad. Part&#160;of the Company&#8217;s primary internal sources of funds to meet its cash needs will be its share of the dividends, if any, paid by the Company&#8217;s subsidiaries. The distribution of dividends to the Company from the subsidiaries in certain markets where the Company operates is subject to restrictions imposed by the applicable laws and regulations in these markets. As a result, it is not expected that the Company will pay any cash dividends in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board has complete discretion as to whether to distribute dividends. Even if the Board decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on the future results of operations and cash flow, capital requirements and surplus, the amount of distributions, if any, received by the Company from subsidiaries, the Company&#8217;s financial condition, contractual restrictions and other factors deemed relevant by the Board. There is no guarantee that the Common Shares will appreciate in value or that the trading price of the Common Shares will not decline. Holders of the Common Shares should not rely on an investment in Common Shares as a source for any future dividend income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a6ca106f_b8b2_4955_bae9_2b6d1ff7c355"></a><a id="CAUTIONARYNOTEREGARDINGFORWARDLOOKINGSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or the negative of these terms or other similar expressions. Forward-looking statements include, without limitation, the company&#8217;s expectations concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments, operational performance, future market conditions or economic performance and developments in the capital and credit markets and expected future financial performance, as well as any information concerning possible or assumed future results of operations of the Company as set forth in this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Forward-looking statements involve a number of risks, uncertainties and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability of Psyence Biomedical to realize the benefits expected from the Business Combination (as defined below) and to maintain the listing of the Common Shares or the Warrants on Nasdaq;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks that the Business Combination disrupts current plans of Psyence Biomedical or diverts management&#8217;s attention from Psyence Biomedical&#8217;s ongoing business operations and potential difficulties in Psyence Biomedical&#8217;s employee retention as a result of the Business Combination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">volatility in the price of the securities of the Company due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company operates, variations in performance across competitors, changes in laws and regulations affecting the Company&#8217;s business and changes in the Company&#8217;s capital structure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psyence Biomedical&#8217;s success in retaining or recruiting, or changes required in, its officers, key employees or directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">factors relating to the business, operations and financial performance of the Company, including, but not limited to:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s ability to achieve successful clinical results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company currently has no products approved for commercial sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s ability to obtain regulatory approval for its product candidates, and any related restrictions or limitations of any approved products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s ability to obtain licensing of third-party intellectual property rights for future discovery and development of the Company&#8217;s product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s ability to commercialize product candidates and achieve market acceptance of such product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s success is dependent on product candidates which it licenses from third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s success is dependent on the supply of materials necessary to perform its clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to respond to general economic conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has incurred significant losses since inception, and it expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company requires substantial additional capital to finance its operations, and if it is unable to raise such capital when needed or on acceptable terms, it may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s ability to develop and maintain effective internal controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumptions regarding interest rates and inflation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition and competitive pressures from other companies worldwide in the industries in which the Company operates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation and the ability to adequately protect the Company&#8217;s intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foregoing list of factors is not exhaustive. Forward-looking statements are not guarantees of future performance. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Company&#8217;s Reports on Form&#160;20-F, Current Reports on Form&#160;6-K and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. The forward-looking statements in this document represent the views of the Company as of the date of this document. Subsequent events and developments may cause that view to change. Readers are cautioned not to put undue reliance on forward-looking statements, and all forward-looking statements in this document are qualified by these cautionary statements. The Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations. The inclusion of any statement in this document does not constitute an admission by the Company or any other person that the events or circumstances described in such statement are material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6f320341_3945_4cae_80b1_f728c5091f46"></a><a id="USEOFPROCEEDS_470856"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">USE OF PROCEEDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the Common Shares offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their own accounts. We will not receive any of the proceeds from the resale of the Common Shares by the Selling Securityholders. However, we may receive up to $25,000,000 in gross proceeds under the White Lion Purchase Agreement from sales of Common Shares that we may elect to make to White Lion pursuant to the White Lion Purchase Agreement, if any, from time to time in our sole discretion, during the White Lion Commitment Period. However, we will not receive any proceeds from the issuance of the Commitment Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The proceeds from White Lion that we receive under the White Lion Purchase Agreement, if any, are currently expected to be used for general corporate purposes, including working capital. Accordingly, we retain broad discretion over the use of the net proceeds from the sale of our Common Shares under the White Lion Purchase Agreement. The precise amount and timing of the application of such proceeds will depend upon our liquidity needs and the availability and cost of other capital over which we have little or no control. As of the date hereof, we cannot specify with certainty the particular uses for the net proceeds from the sales of Common Shares, if any to White Lion under the White Lion Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will incur all costs associated with this prospectus and the registration statement of which it is a part.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the Common Shares offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their own accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><a id="_004aceb1_d074_4b09_8688_787c84a5ce96"></a><a id="SELLINGSHAREHOLDERS_643747"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SELLING SECURITYHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This prospectus relates to the possible resale from time to time by (i) White Lion of any or all of the Common Shares that may be issued by us to White Lion under the White Lion Purchase Agreement (ii) 3,000 Common Shares issued to Donohoe Advisory Associates LLC in full and final settlement of accrued service and advisory fees, (iii) 25,000 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery and (iv) an additional 172,028 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery. We are registering Common Shares pursuant to the provisions of the RRA we entered into with White Lion on July 25, 2024 in order to permit White Lion to offer the shares for resale from time to time. Except for the transactions contemplated by the White Lion Purchase Agreement and the RRA or as otherwise disclosed in this prospectus, White Lion has not had any material relationship with us within the past three years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below presents information regarding each Selling Securityholder and the Common Shares that it may offer from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Securityholders, and reflects holdings as of August 15, 2024. The number of shares in the column &#8220;Maximum Number of Common Shares to be Offered Pursuant to this Prospectus&#8221; represents all of the Common Shares that the Selling Securityholders may offer under this prospectus. The Selling Securityholders may sell some, all or none of its shares in this offering. We do not know how long the Selling Securityholders will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Securityholders regarding the sale of any of the shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes Common Shares with respect to which a Selling Securityholder has voting and investment power. The percentage of Common Shares beneficially owned by each Selling Securityholder prior to the offering shown in the table below is based on an aggregate of 16,696,571 Common Shares outstanding on August 15, 2024. Because the purchase price of the Common Shares issuable under the White Lion Purchase Agreement is determined on the Closing Date with respect to each purchase, the number of shares that may actually be sold by the Company under the White Lion Purchase Agreement may be fewer than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the Selling Securityholders pursuant to this prospectus.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:23.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Common&#160;Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Owned&#160;Prior&#160;to</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Offering</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum&#160;Number&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Common&#160;Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">to&#160;be&#160;Offered&#160;Pursuant&#160;to</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">this&#160;Prospectus</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;Shares&#160;of</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Common&#160;Shares</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">Owned&#160;After&#160;Offering</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">Name of Selling Securityholder</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.77%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percent</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:23.05%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">White Lion Capital LLC<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.77%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">50,375,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:23.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Donohoe Advisory Associates LLC<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:23.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Outside The Box Capital Inc.<sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"> (6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">197,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">197,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Represents beneficial ownership of less than 1% of the outstanding shares of our Common Shares.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that White Lion may be required to purchase under the White Lion Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the White Lion Purchase Agreement, the satisfaction of which are entirely outside of White Lion&#8217;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the purchase of Common Shares is subject to certain agreed upon maximum amount limitations set forth in the White Lion Purchase Agreement. Also, the White Lion Purchase Agreement prohibits us from issuing and selling any Common Shares to White Lion to the extent such shares, when aggregated with all other Common Shares then beneficially owned by White Lion, would cause White Lion&#8217;s beneficial ownership of our Common Shares to exceed the 4.99% Beneficial Ownership Limitation. The White Lion Purchase Agreement also prohibits us from issuing or selling our Common Shares under the White Lion Purchase Agreement in excess of the 19.99% Exchange Cap, unless we obtain shareholder approval to do so, or unless the Exchange Cap limitation would not apply under applicable Nasdaq rules. Neither the Beneficial Ownership Limitation nor the Exchange Cap (to the extent applicable under Nasdaq rules) may be amended or waived under the White Lion Purchase Agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Applicable percentage ownership is based on 16,696,571 Common Shares outstanding as of August 15, 2024.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assumes the sale of all shares being offered pursuant to this prospectus.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The business address of White Lion is 17631 Ventura Blvd., Suite 1008, Encino, CA 91316. White Lion&#8217;s principal business is that of a private investor. Dmitriy Slobodskiy Jr., Yash Thukral, Sam Yaffa, and Nathan Yee are the managing principals of White Lion. Therefore, each of Slobodskiy Jr., Thukral, Yaffa, and Yee may be deemed to have sole voting control and investment discretion over securities beneficially owned directly by White Lion and, indirectly, by White Lion. We have been advised that White Lion is not a member of the Financial Industry Regulatory Authority, or FINRA, or an independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Slobodskiy Jr., Thukral, Yaffa, and Yee as to beneficial ownership of the securities beneficially owned directly by White Lion and, indirectly, by White Lion.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The business address of Donohoe Advisory Associates LLC is 9801 Washingtonian Blvd., Suite 340 Gaithersburg, MD 20878. Donohoe Advisory Associates LLC is managed by David A. Donohoe, Jr., who has voting and dispositive control over the securities held by the named Selling Securityholder.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The business address of Outside The Box Capital LLC is 2202 Green Orchard Place Oakville ON L6H 4V4 Canada. Jason Coles has voting and dispositive control over the securities held by the named Selling Securityholder. Jason Coles disclaims beneficial ownership of any shares other than to the extent he may have a pecuniary interest therein, directly or indirectly.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The White Lion Transaction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 25, 2024, the Company entered into the White Lion Purchase Agreement with White Lion and the RRA. Pursuant to the White Lion Purchase Agreement, the Company has the right, but not the obligation, to require White Lion to purchase, from time to time, up to $25,000,000 in aggregate gross purchase price of newly issued Common Shares, subject to certain limitations and conditions set forth in the White Lion Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the satisfaction of certain customary conditions including, without limitation, the effectiveness of a registration statement registering the resale of the shares issuable pursuant to the White Lion Purchase Agreement, the Company&#8217;s right to sell shares to White Lion commenced on the date of the execution of Purchase Agreement and extends until the earlier of (i) White Lion having purchased Common Shares equal to $25,000,000 and (ii) two years from the date of execution of the White Lion Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the Commitment Period, subject to the terms and conditions of the White Lion Purchase Agreement, the Company may exercise its right to sell its Common Shares. The Company may deliver a Fixed Purchase Notice (as such term is defined in the White Lion Purchase Agreement), pursuant to which the Company can require White Lion to purchase up to a number of Common Shares equal to the lesser of (i) $250,000 or (ii) 50% of Average Daily Trading Volume (as such term is defined in the White Lion Purchase Agreement). The Company may also deliver a Rapid Purchase Notice (as such term is defined in the White Lion Purchase Agreement), pursuant to which the Company may require White Lion to purchase up to a number of Common Shares equal to the lesser of (i) 30% of the Average Daily Trading Volume and (ii) $4,000,000 divided by the highest closing price of the Common Shares over the most recent five business days immediately prior to the receipt of the notice. White Lion may waive such limits under any notice at its discretion and purchase additional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The price to be paid by White Lion for any shares that the Company requires White Lion to purchase will depend on the type of purchase notice that the Company delivers. For shares being issued pursuant to a Fixed Purchase Notice, the purchase price per share will be equal to 90% of the lowest VWAP (as defined in the White Lion Purchase Agreement) of the Common Shares that occurs during the five consecutive business days prior to the purchase notice. For shares being issued pursuant to a Rapid Purchase Notice, the purchase price per share will be equal to the lowest traded price on the date that the notice is delivered.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No purchase notice shall result in White Lion beneficially owning (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder) more than 4.99% (subject to increase, in the sole discretion of White Lion, to 9.99%) of the number of Common Shares outstanding immediately prior to the issuance of Common Shares issuable pursuant to a purchase notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has the right to terminate the White Lion Purchase Agreement in the event of a material breach of the White Lion Purchase Agreement by White Lion. The White Lion Purchase Agreement also automatically terminates upon the earlier of (i) the end of the Commitment Period and (ii) the date that the Company commences a voluntary bankruptcy proceeding, a custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In consideration for the commitments of White Lion, as described above, the Company has agreed that it will issue to White Lion Commitment Shares in an amount equal to (i) $187,500 divided by (ii) the closing price of the Common Shares on, (A) with respect to half of the Commitment Shares, the business day prior to the filing of the registration statement pursuant to the RRA and (B) with respect to the other half of the Commitment Shares, the business day prior to the 90th day following the filing of the registration statement pursuant to the RRA. The Commitment Shares will be fully earned by White Lion regardless of termination of the White Lion Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the Common Shares Purchase Agreement, the Company entered into the RRA with White Lion, pursuant to which the Company agreed to file, within 30 days following the execution of the White Lion Purchase Agreement, a resale registration statement with the SEC covering the resale by White Lion of the maximum number of shares permitted to be included therein in accordance with applicable SEC rules, regulations and interpretations and the Commitment Shares. The RRA also contains usual and customary damages provisions for failure to file and failure to have the registration statement declared effective by the SEC within the time periods specified therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The White Lion Purchase Agreement and the RRA contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d59c5a15_f009_4bea_89cc_cea2306c6aeb"></a><a id="PLANOFDISTRIBUTION_734861"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">PLAN OF DISTRIBUTION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Common Shares offered by this prospectus are being offered by the Selling Securityholders. The shares may be sold or distributed from time to time by the Selling Securityholders directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of the shares offered by this prospectus could be effected in one or more of the following methods:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ordinary brokers&#8217; transactions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transactions involving cross or block trades;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">through brokers, dealers, or underwriters who may act solely as agents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;at the market&#8221; into an existing market for our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in privately negotiated transactions; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any combination of the foregoing.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s registration or qualification requirement is available and complied with.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">White Lion is an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act. Each of the other Selling Securityholders may also be deemed an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">White Lion has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our Common Shares that it may acquire from us pursuant to the White Lion Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. White Lion has informed us that each such broker-dealer may receive commissions from White Lion and, if so, such commissions will not exceed customary brokerage commissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Brokers, dealers, underwriters or agents participating in the distribution of the shares offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Securityholders through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of Common Shares sold by the Selling Securityholders may be less than or in excess of customary commissions. Neither we nor the Selling Securityholders can presently estimate the amount of compensation that any agent will receive from any purchasers of Common Shares sold by the Selling Securityholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We know of no existing arrangements between the Selling Securityholders or any other shareholder, broker, dealer, underwriter or agent relating to the sale or distribution of the Common Shares offered by this prospectus. Cohen Capital Markets LLC, a division of J.V.B. Financial Group, LLC, is acting as a broker with respect to any issuance of Common Shares by the Company to White Lion and will receive a commission in connection with any such issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this prospectus by a Selling Securityholder, including the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by such Selling Securityholder, any compensation paid by such Selling Securityholder to any such brokers, dealers, underwriters or agents, and any other required information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We also have agreed to indemnify White Lion and certain other persons against certain liabilities in connection with the offering of shares offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">amounts required to be paid in respect of such liabilities. White Lion has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by White Lion specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We estimate that the total expenses for the offering will be approximately $50,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">White Lion has represented to us that at no time prior to the date of the White Lion Purchase Agreement has White Lion, any of its affiliates or any entity managed or controlled by White Lion engaged in or effected, directly or indirectly, for its own principal account, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our Common Shares that establishes a net short position with respect to our Common Shares. White Lion has agreed that, during the Commitment Term, none of White Lion, any of its affiliates nor any entity managed or controlled by White Lion will enter into or effect, directly or indirectly, any of the foregoing transactions for its own principal account or for the principal account of any other such entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have advised White Lion that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes White Lion, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This offering will terminate on the date that all shares of our Common Shares offered by this prospectus have been sold by the Selling Securityholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Common Shares are currently listed on The Nasdaq Capital Market under the symbol &#8220;PBM&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_97469d67_da78_450f_a0fe_78d5c5da558d"></a><a id="MANAGEMENTSDISCUSSIONANDANALYSISOFFINANC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL<br/>CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context otherwise requires, all references in this section to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to the business of Psyence Biomedical&#160;Ltd. and its subsidiaries following the consummation of the Business Combination.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our historical condensed consolidated audited financial statements for the&#160;years ended March&#160;31, 2023 and March&#160;31, 2024 and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this prospectus.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The numbers presented here have been translated to USD and are presented in USD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence Biomedical&#160;Ltd. (the &#8220;Company&#8221; or &#8220;PBM&#8221;), is the world&#8217;s first life science biotechnology company traded on Nasdaq (NASDAQ: PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The Company is working towards developing safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. The Company is initially focused on mental health disorders in the context of Palliative Care. The Company is currently conducting research through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Operating Results</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Sales and marketing costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended March&#160;31, 2024, we incurred sales and marketing costs of $80,603, consisting primarily of expenses for investor relations, travel, conferences, content, promotional materials and website design costs. For the&#160;year ended March&#160;31, 2023, sales and marketing costs of $7,029 were incurred, consisting of costs to create awareness of the Company and its activities, due to its recent establishment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended March 31, 2024, we incurred research and development costs of $954,593 (March 31, 2023: $1,608,895). This consisted of $785,720 (March 31, 2023: $1,373,985) of costs related to the clinical trial for the treatment of adjustment disorder, $167,306 (March 31, 2023: $170,213) for the formulation and licensing of PEX010 and $1,567 (March 31, 2023: $64,697) for general research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and administration costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended March&#160;31, 2024, we incurred general and administrative costs of $557,904 (March&#160;31, 2023: $366,435), which consisted of bank fees, salaries and wages and operational costs. General and administrative costs increased during the&#160;year ended March&#160;31, 2024 in comparison to the&#160;year ended March&#160;31, 2023 as result of an increase in payroll related costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Professional and consulting fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the year ended March 31, 2024, professional and consulting fees totaled $1,158,484 (March 31, 2023: $1,252,510). This consisted of $848,955 (March 31, 2023: $826,550) paid to consultants for business strategies, financial and administrative services, legal fees of $105,962 (March 31,2023: $250,730) paid to legal practitioners for various corporate matters, and $203,567 (March 31, 2023: $175,230) for audit fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The professional and consulting fees for the period increased from the preceding&#160;year due to the Business Combination.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Gains and Losses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended March&#160;31, 2024 and 2023, the Company earned interest income of $2,134 and $1,554, respectively, and had a foreign exchange loss of $2,696 and foreign exchange gain of $26,912, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Rebate</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended March&#160;31, 2024 the Company received its first R&amp;D rebate from the Australian tax office (ATO). The Company received $879,344 as other income. This amount represents 43.5% of R&amp;D expenditure incurred in Australia which was refunded by the ATO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Listing Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our securities became listed on Nasdaq in January 2024 through a Business Combination which had the accounting treatment of a reverse take-over. The deemed listing expense associated with the Business Combination was $41,481,605 and other transaction costs incurred was $2,461,026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since incorporation, our operations have been financed from investment by our shareholders, a loan advance based off our eligibility to receive a rebate from the Australian Tax Office and the rebate from the Australian Tax Office. Our main use for liquidity is funding scientific research, clinical studies, salaries and professional and consulting fees. Our ability to fund operations and to make planned cash flows are subject to prevailing economic conditions, regulatory and financial, business, and other factors, some of which are beyond our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2024, we had a cash balance of including restricted cash of $762,799 and negative working capital of $10,978,027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s current expenditure obligations include milestone-related commitments for the Phase IIb palliative care clinical trial. The Company expects to continue funding these projects with available cash and cash equivalents, and therefore, is subject to risks including, but not limited to, an inability to raise additional funds through the issuance of equity, debt instruments or similar means of financing to support the Company&#8217;s continued development, including operating requirements and to meet its liabilities and commitments at they become due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has experienced operating losses and cash outflows from operations since incorporation and by nature of its business, will require ongoing financing to continue its research and development operations. The Company&#8217;s ability to access both public and private capital is dependent upon, among other things, general and sectoral market conditions and the capital markets generally, market perceptions about the Company and its business operations, and the trading prices of the Company&#8217;s securities from time to time. There can be no assurance that additional funds can be raised upon terms acceptable to the Company, or at all, as funding for early-stage companies remain challenging generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s primary capital needs are funds to advance its research and development activities and for working capital purposes. These activities include staffing, pre-clinical studies, clinical trials, professional and consulting fees and general and administrative costs. There are uncertainties regarding the Company&#8217;s ability to continue as a going concern. There is no assurance that additional capital or other types of financing will be available if needed or that these financings will be on terms at least as favorable for the Company as those previously obtained, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and comprehensive loss as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">incurred. Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting </b><b style="font-weight:bold;">Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results may differ from these estimates. The Company&#8217;s management reviews these estimates, judgments, and assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical accounting policies as these require a high level of subjectivity and judgement and could have a material impact on Psyence&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audited financial statements included elsewhere in this prospectus have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management routinely plans future activities including forecasting future cash flows and forming judgements collectively with directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Judgement is required in determining if the Company&#8217;s has sufficient cash reserves, together with all other available information, to continue as a going concern for a period of at least twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2024 the Company has concluded that a material uncertainty exists that casts significant doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Quantitative and Qualitative Disclosures About Financial Instruments and Financial Risk Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management, as well as monitoring. Our Board has overall responsibility for the establishment and oversight of the Company&#8217;s risk management framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Credit risk arises from cash and cash equivalents held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions. The Company also assesses the credit quality of counterparties, taking into account their financial position, past experience and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company&#8217;s main source of funding has been through investments from its parent. The Company&#8217;s access to financing is always uncertain and there can be no assurance of continued access to significant equity or debt funding on terms satisfactory to the Company, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Foreign exchange risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company operates internationally and is exposed to foreign exchange risk from the South African Rand, Great British Pound, Australian Dollar and United States Dollar. Foreign exchange risk arises from transactions as well as recognized financial assets and liabilities denominated in foreign currencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A 10% adverse change in exchange rate would have resulted in a loss of $4,139 as of March&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Management mitigates the risk of adverse exchange rate movements by holding funds in US dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Interest rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Capital Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s objectives when managing its capital are to safeguard its ability to continue as a going concern, to meet its capital expenditures for its continued operations, and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, issue debt, or acquire or dispose of assets. The Company is not subject to externally imposed capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Management reviews its capital management approach on an ongoing basis. The Company considers its shareholders&#8217; equity balance as capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have no obligations, assets or liabilities, which would be considered off-balance sheet arrangements as of March 31, 2024. We do not participate in transactions that create relationships with entities or financial partnerships, often referred to as variable interest entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Contractual Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">JOBS Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April&#160;5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as an &#8220;emerging growth company&#8221; and under the JOBS Act are allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non- emerging growth companies. As such, our financial statements may not be comparable to companies that comply with public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an &#8220;emerging growth company,&#8221; we choose to rely on such exemptions we may not be required to, among other things, (i)&#160;provide an auditor&#8217;s attestation report on our system of internal control over financial reporting pursuant to Section&#160;404 of the Sarbanes-Oxley Act, (ii)&#160;provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii)&#160;comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis) and (iv)&#160;disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of executive compensation to median employee compensation. These exemptions will apply for a period of five&#160;years following the completion of our IPO or until we are no longer an &#8220;emerging growth company,&#8221; whichever is earlier.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5c223cb0_f89e_4521_a596_d9128db7c12a"></a><a id="BUSINESS_90630"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">BUSINESS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">The following terms, as used in this section shall have the following meanings:</i></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:72.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 27pt;">AjD</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:72.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustment Disorder</p></td></tr><tr><td style="vertical-align:bottom;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 27pt;">PEX010</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:72.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capsule containing 25mg naturally sourced psilocybin</p></td></tr><tr><td style="vertical-align:bottom;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 27pt;">PAP</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:72.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Psilocybin Assisted Psychotherapy</p></td></tr><tr><td style="vertical-align:bottom;width:24.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 27pt;">API</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:72.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Active Pharmaceutical Ingredient</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Corporate History and Development</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Business Combination</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024 (the &#8220;<b style="font-weight:bold;">Closing Date</b>&#8221;), Psyence Biomedical&#160;Ltd., a corporation organized under the laws of Ontario, Canada (&#8220;<b style="font-weight:bold;">Psyence</b>,&#8221; &#8220;<b style="font-weight:bold;">Psyence Biomedical</b>&#8221; or the &#8220;<b style="font-weight:bold;">Company</b>&#8221;), consummated the previously announced business combination pursuant to the Amended and Restated Business Combination Agreement (as amended, the &#8220;<b style="font-weight:bold;">Business Combination Agreement</b>&#8221;), dated as of July&#160;31, 2023, by and among the Company, Newcourt Acquisition Corp, a Cayman Islands exempted company (&#8220;<b style="font-weight:bold;">NCAC</b>&#8221;), Newcourt SPAC Sponsor LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">Sponsor</b>&#8221;), Psyence Group&#160;Inc., a corporation organized under the laws of Ontario, Canada (&#8220;<b style="font-weight:bold;">Parent</b>&#8221;), Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a direct and wholly owned subsidiary of Pubco (&#8220;<b style="font-weight:bold;">Merger Sub</b>&#8221;), Psyence Biomed Corp., a corporation continued under the laws of Ontario, Canada (&#8220;<b style="font-weight:bold;">Original Target</b>&#8221;), and Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (&#8220;<b style="font-weight:bold;">Biomed II</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following transactions occurred pursuant to the terms of the Business Combination Agreement (collectively, the &#8220;<b style="font-weight:bold;">Business Combination</b>&#8221;) at the effective time of the Merger (the &#8220;<b style="font-weight:bold;">Effective Time</b>&#8221;):</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Parent contributed Biomed II to the Company in a share for share exchange (the &#8220;<b style="font-weight:bold;">Company Exchange</b>&#8221;).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Following the Company Exchange, Merger Sub merged with and into NCAC, with NCAC being the surviving company in the merger (the &#8220;Merger&#8221;) and each outstanding ordinary share of NCAC was converted into the right to receive one common share of the Company (&#8220;<b style="font-weight:bold;">Common Share</b>&#8221;).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Each outstanding warrant to purchase NCAC Class&#160;A ordinary shares was converted into a warrant to acquire one Common Share (the &#8220;<b style="font-weight:bold;">Warrants</b>&#8221;) on substantially the same terms as were in effect immediately prior to the Effective Time under their terms.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;15, 2024 and January&#160;23, 2024, the parties to the Business Combination Agreement entered into letter agreements (the &#8220;<b style="font-weight:bold;">Closing Letter Agreements</b>&#8221;) pursuant to which, among other things, the Company, Parent, Biomed II, Original Target and Merger Sub (collectively, the &#8220;<b style="font-weight:bold;">Psyence Parties</b>&#8221;) agreed, (X)&#160;on a conditional basis, to waive the closing conditions contained in the Business Combination Agreement that, at or prior to the Closing, (i)&#160;NCAC shall have no less than $20,000,000, net of liabilities, as of the Closing (the &#8220;<b style="font-weight:bold;">Minimum Cash Condition</b>&#8221;) and (ii)&#160;the PIPE Investment in the PIPE Investment Amount shall have occurred or shall be ready to occur substantially concurrently with the Closing (the &#8220;<b style="font-weight:bold;">PIPE Investment Condition</b>&#8221;) and (Y)&#160;to waive certain deliverables under Section&#160;3.6 of the Business Combination Agreement (the &#8220;<b style="font-weight:bold;">Closing Deliverables</b>&#8221;). Upon the closing of the Business Combination (&#8220;<b style="font-weight:bold;">Business Combination</b>&#8221;), the Psyence Parties waived in full the Closing Deliverables, the Minimum Cash Condition and the PIPE Investment Condition. Although we did not satisfy the PIPE Investment Condition, we were able to close on a convertible debt PIPE financing with the Investors, in an aggregate principal amount of $3,125,000, with an original issue discount of 20%, for gross proceeds in the aggregate amount of $2,500,000 (the &#8220;<b style="font-weight:bold;">PIPE Financing</b>&#8221;). While the First Tranche Notes&#160;issued by us to the Investors in the PIPE Financing are initially convertible into Common Shares at a conversion price of $10.00, due to the several adjustment provisions in the conversion price under the terms of the First Tranche Notes, and the applicable Conversion Floor, the documents entered into in connection with the PIPE Financing required us to register for resale, on behalf of the Investors, an amount of Common Shares equal to the aggregate principal amount of the First Tranche Notes&#160;converted at an assumed conversion price of $0.50 and multiplied by 300% of the result thereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Investors were also issued, as a structuring fee, an additional 1,300,000 Common Shares and entered into call option agreements (collectively, the &#8220;<b style="font-weight:bold;">Call Option Agreements</b>&#8221;) with Tabula Rasa Limited, which was the sole manager of Sponsor (&#8220;<b style="font-weight:bold;">Tabula</b>&#8221;), and Launchpad Capital Opportunities Fund LP, which was a member of the Sponsor (&#8220;<b style="font-weight:bold;">Launchpad</b>&#8221;), pursuant to which </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the Investors may purchase up to an additional 1,700,000 Common Shares (in the aggregate) from Tabula and Launchpad, at a purchase price of $0.0001 per Common Share (such 3,000,000 Common Shares collectively referred to hereafter as the &#8220;<b style="font-weight:bold;">Structuring Shares</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Common Shares and the Warrants are traded on The Nasdaq Stock Market LLC (&#8220;<b style="font-weight:bold;">Nasdaq</b>&#8221;) under the symbols &#8220;PBM&#8221; and &#8220;PBMWW,&#8221; respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence Biomedical Ltd was incorporated as a corporation under the laws of Ontario, Canada on June&#160;29, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Psyence Group,&#160;Inc.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the completion of the Business Combination (as defined below), we were the therapeutics division of Psyence Group,&#160;Inc., a life science biotechnology company listed on the Canadian Securities Exchange (CSE:PSYG), with a focus on natural psychedelics. We refer to Psyence Group,&#160;Inc. and its subsidiaries and affiliates prior to the consummation of the Business Combination as the &#8220;Psyence Group.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Psyence Group was created through various corporate transactions, including a prior business combination of Mindhealth Corp. with Cardinal Capital Partners&#160;Inc., a public company, in January&#160;2021, resulting in the Psyence Group&#8217;s public listing in Canada. MindHealth Biomed Corp. (&#8220;<b style="font-weight:bold;">MindHealth</b>&#8221;) was a private corporation incorporated under the laws of British Columbia on May&#160;21, 2020. Mind Health (Pty) Ltd (&#8220;<b style="font-weight:bold;">MindHealth Lesotho</b>&#8221;) is a private entity incorporated under the laws of the Kingdom of Lesotho, which in May&#160;2020, was granted permission by the Minister of Health (Lesotho) to import, cultivate, produce, manufacture and export psilocybin mushrooms. The governmentally licensed commercial psilocybin cultivation and production facilities operated by MindHealth Lesotho under the name &#8220;Psyence Production&#8221; are situated in the Kingdom of Lesotho. On May&#160;22, 2020, MindHealth Lesotho became a subsidiary of MindHealth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combination, the Psyence Group had three key divisions: Psyence Therapeutics, Psyence Function and Psyence Production.&#160;Pursuant to the Business Combination, the Psyence Therapeutics business was separated from the Psyence Group and became a wholly-owned subsidiary of the Company, while the other two divisions of the Psyence Group (Psyence Production and Psyence Function) remained under the Psyence Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Canadian Restructuring</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the date of the Business Combination Agreement, (i)&#160;Parent formed Biomed II and Psyence Biomedical as wholly-owned subsidiaries, (ii)&#160;promptly after entering into the Business Combination Agreement, Parent and the Original Target, a corporation continued under the laws of Ontario, Canada, were amalgamated, and thereafter (iii)&#160;Parent (x)&#160;transferred the shares of Psyence Australia Pty&#160;Ltd. and its related business assets to Biomed II while (y)&#160;retaining the shares of Good Psyence (Pty) Ltd (RF) (South Africa), Psyence Jamaica Ltd (Jamaica), Psyence UK Group&#160;Ltd., Psyence Therapeutics Corp. (Ontario, Canada), Mind Health (Pty) Ltd (Lesotho), and Psyence South Africa (Pty) Ltd (South Africa) (collectively, the &#8220;<b style="font-weight:bold;">Excluded Assets</b>&#8221;) (such transactions, collectively, the &#8220;<b style="font-weight:bold;">Canadian Restructuring</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our registered address and principal executive office is 121 Richmond Street West, Penthouse Suite&#160;1300, Toronto, Ontario M5H 2K1, and our telephone number is +1 (416) 346-7764.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our U.S. transfer agent and registrar&#160;is Continental Stock Transfer&#160;&amp; Trust Company, located at 1 State Street, 30th Floor, New York, NY 10004.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We file reports and other information with the SEC pursuant to the SEC&#8217;s rules&#160;and regulations that apply to foreign private issuers. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our electronic filings are available for viewing on the SEC&#8217;s website at http:// www.sec.gov). The website address of the Company is <i style="font-style:italic;">www.psyencebiomed.com</i>. The information contained on the website does not form a part of, and is not incorporated by reference into, this prospectus.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a life science biotechnology company that, through our operating subsidiary, Biomed II, is developing natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. We have commenced the clinical trial process to evaluate the safety and efficacy of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We strive to set the global standard for excellence and consistency in drug development using nature-based psilocybin products. Psyence&#8217;s priority is developing pharmaceutical grade psilocybin to help heal psychological trauma and the diagnosable disorders that can result therefrom, including AjD, alcohol use disorder (&#8220;<b style="font-weight:bold;">AUD</b>&#8221;), other substance use disorders (&#8220;<b style="font-weight:bold;">SUDs</b>&#8221;), anxiety, depression, post-traumatic stress disorder (&#8220;<b style="font-weight:bold;">PTSD</b>&#8221;), and grief and bereavement, especially in the context of palliative care. Our focus includes therapeutic protocols for medical and scientific research including observational studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate is PEX010, a capsule containing 25mg naturally sourced psilocybin and which is being used in our Phase IIb Study. Psyence has entered into the Research IP Agreement with Filament, a Canadian company that produces natural psilocybin capsules and the proprietary owner of PEX010, for the licensing of PEX010 with respect to Psyence&#8217;s designated fields of use: anxiety and depression, including associated ailments, such as PTSD, stress, grief, and adjustment disorder within the context of palliative care. See &#8220;&#8212; <i style="font-style:italic;">Licensing of PEX010</i>&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have contracted iNGEN&#363;, a CRO&#160;in Australia that specializes in the study of psychedelics, to conduct a Phase&#160;IIb double-blind, randomized, low-dose controlled clinical trial to assess the efficacy and safety of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. Outsourcing the study to a CRO assists the company in operating in a more capital efficient manner without the overhead of handling in-house.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Corporate Structure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence Biomedical conducts its operations through its subsidiaries based in Ontario and Australia and also owns a subsidiary in the Cayman Islands, as listed below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Proportion</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ordinary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Held by</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Country of Incorporation and Place of Business</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Psyence&#160;Biomedical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Psyence Biomed II Corp</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ontario, Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:30.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Psyence Australia Pty Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indirect 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:30.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Newcourt Acquisition Corp</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:44.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cayman Islands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Indirect 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:360pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The diagram below depicts a current version of Psyence Biomedical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pbm-20240331xf1009.jpg" alt="Graphic" style="display:inline-block;height:360pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:435.92pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to certain of the informational filing requirements of the Exchange Act. Since the Company is a &#8220;foreign private issuer,&#8221; it is exempt from the rules&#160;and regulations under the Exchange Act prescribing the furnishing and content of proxy statements, and the officers, directors and principal shareholders of the Company are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section&#160;16 of the Exchange Act with respect to their purchase and sale of Common Shares. In addition, the Company is not required to file reports and financial statements with the SEC as frequently or as promptly as U.S. public companies whose securities are registered under the Exchange Act. However, the Company is required to file with the SEC an Annual Report on Form&#160;20-F containing financial statements audited by an independent accounting firm. The SEC also maintains a website at www.sec.gov that contains reports and other information that the Company files with or furnishes electronically to the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The website address of the Company is <i style="font-style:italic;">www. psyencebiomed.com</i>. The information contained on the website does not form a part of, and is not incorporated by reference into, this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Phase IIb Study&#160;- Palliative Care Clinical Trial</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;9, 2023, Psyence and iNGEN&#363; signed a letter of intent to further develop Psyence&#8217;s licensed natural psilocybin drug product, starting with a Phase&#160;IIb Study in order to lead a pre-IND meeting with the FDA. The product to be used in this Phase&#160;IIb Study will be the proprietary botanical drug candidate PEX010 (25mg), which Psyence sources from Filament. The planned randomized double-blind study will evaluate the use of psilocybin-assisted psychotherapy versus psychotherapy alone and will test 84 patients utilizing the HAM A scale as the primary endpoint, which is an FDA validated endpoint, and safety data will be collected throughout the study.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For safety, there are no specific endpoints as all safety findings are captured as adverse events. The primary and secondary efficacy endpoints are all established in the protocol before it is reviewed and approved by the Ethics Committee before the study can start.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The HAM-A is a rating scale developed to measure the severity of anxiety symptoms and is widely used in both clinical and research settings. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). During the Phase II Study, the HAM-A scale will be used to measure change in anxiety levels over time as the primary endpoint.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The 84-patient Phase IIb Study being conducted by the CRO, iNGEN&#363;, in Australia is the one that has been referred to in discussions with the FDA in the pre-IND process, which is in the late planning stage, and estimated to commence enrollment in the second half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimated costs of this Phase IIb Study were initially $5,575,000 made on the basis of milestones completed. Included in this original estimate were costs for 75 participants; an end of Phase II meeting preparation and attendance after the completion of the Phase IIb study with the FDA as well as psychotherapy training, psychotherapy sessions and therapist fees for participants. Subsequently, the Phase IIb Study was increased to 84 patients, and we anticipate the estimated cost of this study to be increased by approximately&#160;5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September&#160;15, 2022, we received full approval of a study (the &#8220;<b style="font-weight:bold;">UK Trial</b>&#8221;) in the United Kingdom from the UK Medicines and Healthcare products Regulatory Agency (&#8220;<b style="font-weight:bold;">MHRA</b>&#8221;)&#160;using natural psilocybin in the field of palliative care with oncology patients. For this study, we had partnered with Clerkenwell Clinics Limited (&#8220;<b style="font-weight:bold;">Clerkenwell Health</b>&#8221;), which would have been responsible for jointly designing and delivering the UK Trial. Following such approval, we opted to forego proceeding with the UK Trial in order to pursue the opportunity to conduct the Phase&#160;IIb Study in Australia, as Psyence could benefit from the Australian Federal Government&#8217;s Research&#160;&amp; Development tax incentive program, which could provide up to a 43.5% rebate on Psyence&#8217;s R&amp;D expenses in Australia, making it a more cost-effective endeavor. In addition, the Phase&#160;IIb Study adds a dose-finding arm, which allows us to accelerate our development strategy, seeking input from the FDA with our pre-IND application. On March 5, 2024, Psyence received full approval of the Phase IIb Study from to the Australian Human Research Ethics Committees (HRECs), the body responsible for the review of research proposals involving human participants to ensure that they are ethically acceptable. If the outcome of the Phase IIb Study is positive, we believe we may be able to proceed directly to a Phase III trial in the United States, subject to FDA review and the opening of an IND; however, there is no guarantee that the FDA will accept data from trials conducted outside of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Licensing of PEX010</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April&#160;2022, Psyence entered into the Research IP Agreement with Filament for the licensing of PEX010 and its associated intellectual property, as well as for the supply of PEX010 for the specific intention of the clinical development of the product, and ultimately, for the marketing authorization for PEX010&#8217;s use in palliative care patients. Pursuant to the Research IP Agreement, Filament grants to Psyence an irrevocable, royalty free, worldwide license (with the right to sub-license, subject to certain restrictions) to use and distribute PEX010 and certain related intellectual property (such as delivery mechanism, preparation methods and know-how) solely for use in connection with pre-clinical and clinical studies and trials to be conducted in Canada, the UK and world-wide in the treatment of anxiety and depression, including associated ailments, such as PTSD, stress, grief, and adjustment disorder within the context of palliative care. This license is granted in respect of the clinical trial phase of Psyence&#8217;s activities, specifically phase II clinical trials which, at present, consists of the Phase IIb Study. The license is granted on an exclusive basis solely within the territory of the UK with respect to the designated fields of use, and Psyence has a right of first refusal to extend its exclusive license beyond the territory of the UK. Psyence does not have any rights to use PEX010 for any profit-making or commercial purposes under the Research IP Agreement. Any results of testing, research, conduct of and any information derived from the clinical studies and trials using PEX010 shall be the sole property of Psyence. Under the Research IP Agreement, Filament is entitled to receive milestone payments of up to CAD$250,000 in aggregate based on four distinct phase II clinical trial milestones to be achieved by Psyence. Should Psyence pursue a second or multiple indications, such aggregate milestone payments will increase accordingly. For the&#160;year ended March&#160;31, 2024, Psyence incurred $167,306 costs under the Research IP Agreement related to milestone payments, which was accounted for as research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In addition to the licensing rights described above, per the terms of the Research IP Agreement, Filament has undertaken to support Psyence&#8217;s clinical trial efforts through the supply of the required quantities of PEX010 to Psyence, for no additional charge, </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">based on Psyence&#8217;s good faith forecasts of its needs. Filament will also create and provide such information, assistance and support for the execution of the dossiers,&#160;IMBP and other documents required to conduct Psyence&#8217;s clinical trials in accordance with the&#160;trial schedules. The license term is 5&#160;years, expiring in April&#160;2027, however the license may be terminated early (a)&#160;by either party upon notice to the other party, where Psyence notifies Filament in writing that all of its clinical trials have been completed or abandoned; (b)&#160;by a party upon notice to the other party, if the other party becomes subject to bankruptcy proceedings; (c)&#160;by a party if the other party commits a breach of a material term of the Research IP Agreement and fails to remedy such breach; or (d)&#160;by a party upon notice to the other party, if the other party has a licence, permit or approval revoked by competent authorities which compromises its ability to grant the licenses contemplated in the Research IP Agreement or its ability to perform under the Research IP Agreement. On July&#160;22, 2024, the parties concluded an addendum to the Research IP Agreement (&#8220;<b style="font-weight:bold;">Filament Addendum</b>&#8221;) whereby Filament undertook to provide a sufficient supply of PEX010 to Psyence in order to facilitate the substitution of an alternative drug candidate for use in Phase III trials and for commercialization purposes following the conclusion of the Phase IIb Study (&#8220;<b style="font-weight:bold;">Proposed End Product</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, Psyence entered into a royalty-bearing, binding term sheet for the commercial licensing of intellectual property (with the right to sub-license) from Filament, which was subject to the terms of a definitive license agreement, and granted Psyence the worldwide right to commercialize PEX010 within the designated fields of use, being anxiety and depression, including associated ailments, such as PTSD, stress, grief, and adjustment disorder within the context of palliative care. The term sheet remained subject to further negotiations between the parties and the execution of a subsequent definitive agreement within a predefined time period. Following further discussions, Psyence and Filament mutually agreed to terminate the term sheet by way of the Filament Addendum. Psyence is engaging two alternative suppliers of drug product for its pivotal Phase III studies as well as for future studies in other indications. Filament agreed to continue to support the supply PEX010 for the upcoming Phase IIb Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence is in the final stages of negotiating supply agreements, as well as licensing agreements for the use of third-party intellectual property, with two licensed suppliers operating in the United Kingdom and North America. Psyence intends to provide further updates on such agreements as they are executed, however, there can be no guarantees that such agreements will be finalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence has not performed any pre-clinical or clinical trials on PEX010. PEX010 is owned and has undergone clinical trials directed by Filament. PEX010 has received regulatory approval to proceed into Phase I and II clinical trials in several jurisdictions worldwide. The FDA, Health Canada, MHRA, and the EMA have reviewed the chemistry, manufacturing, and controls and quality information of PEX010 through its associated filed DMFs/ IMPDs. The DMF for PEX010 is also on file with the Therapeutic Goods Administration (the &#8220;<b style="font-weight:bold;">TGA</b>&#8221;) in Australia. In addition to clinical trials, PEX010 is also already being administered to real-world patients via the Health Canada Special Access Program (&#8220;<b style="font-weight:bold;">SAP</b>&#8221;). Through the SAP, PEX010 is being prescribed for end of life distress as well as Major Depressive Disorder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to clinical trial exposures, PEX010 is also being administered to real-world patients via the Health Canada Special Access Program (SAP). Through the SAP, PEX010 is being prescribed for End of life Distress as well as Major Depressive Disorder. As of July 17, 2024, 156 doses of PEX010 have been administered to 132 patients. Despite the serious condition of many of these patients, no serious adverse events or unexpected adverse events have been reported in any SAP administration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Relationships with Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s Australian-based research and development will be conducted by its CRO partner, iNGEN&#363;, in Australia. As stated above, Filament&#8217;s PEX010 will serve as the product candidate under investigation during the Phase&#160;IIb Study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s R&amp;D capabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s CEO (Dr.&#160;Neil Maresky) and Medical Director (Dr.&#160;Clive Ward-Able) are both medically trained physicians with close to 60&#160;years of experience between them within the pharmaceutical industry related to R&amp;D and the commercialization of new products. This experience provides the foundations for an excellent understanding of the clinical development, regulatory and commercialization needs of various pharmaceutical markets to design the optimal development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence plans on working with various CROs and consultancy agencies to prepare and operationalize their protocols for the various phases of the clinical development program.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence engages a team of lawyers and advisors that helps strengthen the protection of its IP&#160;assets. As psilocybin is a naturally occurring substance, it cannot be patented. However, patents may be granted on formulations, methods of use, compositions of matter and formulation processes, provided that such items are novel, non-obvious and have significant improvements to existing inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s IP strategy is built around:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Establishing and maintaining a competitive advantage on formulation, dosage and administration of psilocybin, as well as psychedelic-assisted therapy modules for palliative care indications; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ensuring business flexibility through directing its research in areas which maintain freedom to operate (relative to third party patent positions) and secures the most favorable commercial terms in agreements with other companies in collaborating on later research, and the commercialization of Psyence&#8217;s IP assets.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence has a specialist, experienced in-house team focused on delivery of this strategy, including internationally recognized patent professionals working directly with Psyence&#8217;s board on these issues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Specific actions are being taken towards delivery of this strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ongoing patent landscaping on the competitor patent landscape. Psyence has completed a patent landscaping review and has ongoing patent watching searches in place on the back of this to identify any new filings made in this space;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Actively considering potential patent filings, with the intention to identify, file, prosecute and eventually maintain Psyence&#8217;s patent portfolio. This patent portfolio is intended to be built out incrementally across the proprietary formulation and treatment technologies that are under development by Psyence;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Active management of key know-how and trade secrets (in order to supplement the patent portfolio); and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Thoughtful negotiation of in-licensing arrangements of third-party IP rights that can enhance or accelerate the building of our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence does not currently hold any patents. PEX010 is protected by a portfolio of patents comprising five patent families. A patent family is a group of patent applications covering the same or similar technical content, or a group of patents registered in several countries to protect an invention. This occurs when a patent application is made in one country and then obtains priority. This priority is then extended to numerous countries. In other words, applications in a family are related to each other through priority claims. Filament holds a worldwide, exclusive, and sub-licensable license from its wholly-owned subsidiary, Psilo, for the intellectual property portfolio relating to PEX010, and Psilo is responsible for maintaining and defending the intellectual property currently being sub-licensed to Psyence under the Research IP Agreement, and which is relevant for use in Psyence&#8217;s proposed Australian palliative care clinical trial. Below is a summary of the five patent families that are relevant to Psyence&#8217;s licenses granted by Filament based on the most recent information made available to us by Filament.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filament patent family 1 is focused on extraction methods, and consists of eleven (11) total granted patents, of which six (6) were issued by the Canadian Intellectual Property Office (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">CIPO</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and five (5) were issued by the United States Patent and Trademark Office (&#8220;</span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">USPTO</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), as well as thirteen (13) pending patent applications. Issued patents in this family are scheduled to expire twenty years from the earliest nonprovisional filing date, which in this case indicates an expiry date in July of 2040.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filament patent family 2 is focused on purification processes, and consists of one (1) granted Canadian patent as well as five (5) patent applications. Issued patents in this family are scheduled to expire twenty years from the earliest nonprovisional filing date, which in this case indicates an expiry date in October of 2040.</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filament patent family 3 is focused on the standardization processes, and consists of one (1) allowed patent application and five (5) pending patent applications. Issued patents in this family are scheduled to expire twenty years from the earliest nonprovisional filing date, which in this case indicates an expiry date in December of 2040.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filament patent family 4 is focused on chemical processes for stabilizing psychoactive alkaloids. This family consists of two (2) granted patents, of which one was issued by the CIPO and one was issued by the USPTO, as well as eleven (11) pending applications. Issued patents in this family are scheduled to expire twenty years from the earliest nonprovisional filing date, which in this case indicates an expiry date in December of 2040.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Filament patent family 5 is focused on methods and formulations for delivering psychoactive alkaloids. This family consists of six granted patents, of which five (5) were issued by the CIPO and one (1) was issued by the USPTO, as well as four pending patent applications. Issued patents in this family are scheduled to expire twenty years from the earliest nonprovisional filing date, which in this case indicates an expiry date in March of 2041.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A summary table of Filament&#8217;s patent portfolio relevant to Psyence&#8217;s licenses is provided below based on the most recent information made available to us by Filament:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Internal</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date/</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:Times New Roman;font-weight:bold;">&#9679;</b><b style="font-weight:bold;">@</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:1.49%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Family</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction*</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Appl.&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Wingdings';font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-AUNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psychedelic fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Dec-22; 2021291583</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-BRNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psychedelic fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>BR</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Jul-21; 112022025777</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-CADIV1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3123908</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Ethanol extraction of psychoactive compounds from psilocybin fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">29-Jul-20 (exam requested 5-Jul-21); 3123908</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">22-Mar-22</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-CADIV2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3124367</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aqueous extraction of psychoactive compounds from psilocybin fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">29-Jul-20 (exam requested 9-Jul-21); 3124367</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">26-Apr-22</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-CANE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3161623</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psychedelic fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Jun-21 (exam requested 13-May-22); 3161623</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">4-Apr-23</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-CANP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3088384</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psilocybin fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">29-Jul-20; 3088384</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3-Aug-21</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">7</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-EPNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psychedelic fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>EP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">6-Jan-23; EP20210827107</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">8</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-ILNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psychedelic fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>IL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">30-Oct-22; 297791</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">9</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-JMPC</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psilocybin fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>JM</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">29-Sep-21; 18/2/000123</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">10</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-MXNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psychedelic fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>MX</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Dec-22; MX/a/2022/016531</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">11</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-USCON1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">US11510952</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Ethanol extraction of psychoactive compounds from psilocybin fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">28-Jan-22; 17587731</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">29-Nov-22;</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">12</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-USCON2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">US11571450</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Aqueous extraction of psychoactive compounds from psilocybin fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">17-Mar-22; 17697798</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">7-Feb-23;</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">13</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001a-USPC</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">US11382942</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Extraction of psychoactive compounds from psilocybin fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">17-Jun-21; 17351149</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">12-Jul-22;</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">14</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-AUNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methanol-based extraction of psychoactive alkaloids from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Dec-22; 2021291726</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Internal</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date/</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:Times New Roman;font-weight:bold;">&#9679;</b><b style="font-weight:bold;">@</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:1.49%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Family</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction*</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Appl.&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Wingdings';font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">15</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-BRNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methanol-based extraction of psychoactive alkaloids from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>BR</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Dec-22; CA2021050823; BR112022025778</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-CADIV1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Hydro-methanol extraction of psychoactive compounds from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Jun-21 (exam requested 28-Apr-23); 3198238</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">17</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-CANE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3163795</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methanol-based extraction of psychoactive alkaloids from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">13-Jun-23 (exam requested 3-Jun-22); 3163795</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">13-Jun-23</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">18</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-CANP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3089455</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methanol-based extraction of psychoactive compounds from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">7-Aug-20 (exam requested 5-Jul-21); 3089455</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">5-Jul-22</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">19</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-EPNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><span style="font-family:'Wingdings';"><br/></span>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methanol-based extraction of psychoactive alkaloids from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>EP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">6-Jan-23; EP20210825822</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">20</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-ILNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methanol-based extraction of psychoactive alkaloids from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>IL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">24-Nov-22; 298561</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">21</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-MXNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methanol-based extraction of psychoactive alkaloids from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>MX</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Dec-22; MX/a/2022/016530</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">22</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001b-USNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methanol-based extraction of psychoactive alkaloids from fungus</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">15-Jun-22; 17841323</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A;</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">23</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001c-USCON1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">11642385</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Basic extraction of psychoactive compounds from psychoactive organisms</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">23-Mar-22; 17702701</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">9-May-23;</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">24</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU001c-USNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">11331357</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Methods and compositions comprising psychoactive compounds from psychoactive organisms</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">15-Jun-21; 17348697</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">17-May-22</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">25</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU002-AUNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Process for obtaining a purified psychoactive alkaloid solution</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">5-Dec-22; 2021290454</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">26</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU002-BRNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Process for obtaining a purified psychoactive alkaloid solution</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>BR</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Dec-22; BR112022025782</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">27</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU002-CANP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3097246</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Process for obtaining a purified psychoactive alkaloid solution</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">23-Oct-20</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">28-Mar-23</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">28</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU002-EPNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Process for obtaining a purified psychoactive alkaloid solution</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>EP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">6-Jan-23; EP20210881426</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">29</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU002-ILNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Process for obtaining a purified psychoactive alkaloid solution</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>IL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">25-Dec-22; 299448</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">30</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU002-MXNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Process for obtaining a purified psychoactive alkaloid solution</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">MX</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">13-Apr-23; MX/a/2023/004350</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">31</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU003-AUNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Standardized psychoactive alkaloid extract composition</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">19-Dec-22; 2022291410</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">32</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU003-BRNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Standardized psychoactive alkaloid extract composition</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>BR</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Dec-22; CA2021050813; BR112022025780</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">33</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU003-CANP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Standardized psychoactive alkaloid extract composition</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">18-Dec-20; 3103707</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">34</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU003-EPNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Standardized psychoactive alkaloid extract composition</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>EP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">6-Jan-23; EP20210825817</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">35</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU003-ILNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Standardized psychoactive alkaloid extract composition</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>IL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">25-Dec-22; 299449</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Internal</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date/</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:Times New Roman;font-weight:bold;">&#9679;</b><b style="font-weight:bold;">@</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:1.49%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Family</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction*</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Appl.&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Wingdings';font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">36</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU003-MXNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Standardized psychoactive alkaloid extract composition</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>MX</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Dec-22; MX/a/2022/016533</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">37</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-AUDIV1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">19-Dec-22; 2022291416</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">38</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-AUDIV2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Predominantly phosphorylated psychoactive alkaloid extraction using alkali</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">19-Dec-22; 2022291413</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">39</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-AUDIV3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Psychoactive alkaloid extraction and composition with controlled dephosphorylation</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">19-Dec-22; 2022291414</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">40</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-AUNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Psychoactive alkaloid extraction and composition with inhibited dephosphorylation</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>AU</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">19-Dec-22; 2022291411</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">41</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-CADIV1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">14-Jun-21 (exam requested 25-Jul-22); 3169140</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">42</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-CADIV2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Predominantly phosphorylated psychoactive alkaloid extraction using alkali</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">14-Jun-21 (exam requested 7-Sep-22); 3173030</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">43</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-CANE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3137016</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Psychoactive alkaloid extraction and composition with inhibited dephosphorylation</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Aug-22 (exam requested 29-Oct-21); 3137016</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Aug-22</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">44</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-CANP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Psychoactive alkaloid extraction and composition with controlled dephosphorylation</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">4-Dec-20; 3101765</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">45</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-ILDIV1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Dephosphorylation-controlled extraction of phosphorylatable psychoactive alkaloids</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>IL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">25-Dec-22; 299450</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">46</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-ILDIV2</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Predominantly phosphorylated psychoactive alkaloid extraction using alkali</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>IL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">25-Dec-22; 299451</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">47</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-ILDIV3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Psychoactive alkaloid extraction and composition with controlled dephosphorylation</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>IL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">25-Dec-22; 299452</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">48</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-ILNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Psychoactive alkaloid extraction and composition with inhibited dephosphorylation</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>IL</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">25-Dec-22; 299453</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">49</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU004-USNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>4</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">US11298388</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Psychoactive alkaloid extraction and composition with controlled dephosphorylation</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">23-Sep-21; 17483601</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">12-Apr-22</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">50</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005a-CADIV1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Process for transmucosal psychoactive alkaloid composition</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">24-Mar-21 (exam requested 18-Apr-23); 3197443</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">51</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005a-CANE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3152326</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Preparation of transmucosal psychoactive alkaloid composition</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">29-Nov-21 (exam requested 12-Mar-22); 3152326</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">9-May-23</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">52</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005a-CANP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Transmucosal psychoactive alkaloid composition and preparation thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">24-Mar-21; 3113240</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:10.35pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Internal</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reference</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Date/</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-family:Times New Roman;font-weight:bold;">&#9679;</b><b style="font-weight:bold;">@</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:1.49%;border-bottom:1.5pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Family</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction*</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Appl.&#160;No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Issue&#160;Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:3.45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Wingdings';font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:middle;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:bottom;white-space:nowrap;width:10.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">53</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005a-USNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Transmucosal psychoactive alkaloid composition and preparation thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">14-Jun-22; 17840482</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">54</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005b-CANP</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3123774</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Allowed</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Transdermal psychoactive alkaloid composition and preparation thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1-Jul-21; 3123774</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Forecasted Issue Date: 8-Aug-23</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">55</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005b-USNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Transdermal psychoactive alkaloid composition and preparation thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">28-Jun-23; 18259697</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">56</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005c-CANE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3161491</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Allowed</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vaporizable psychoactive alkaloid composition and preparation thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">22-Dec-21 (exam requested 3-Jun-22); 3161491</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">25-Jul-23</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">57</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005c-USNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Pending</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Vaporizable psychoactive alkaloid composition and preparation thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">14-Jun-22; 17840502</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">N/A</p></td></tr><tr><td style="vertical-align:top;width:3.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">58</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005d-CANE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3157550</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Injectable psychoactive alkaloid composition and preparation thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>CA</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">17-Dec-21 (exam requested 27-Apr-22); 3157550</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">3-Jan-23</p></td></tr><tr><td style="vertical-align:top;width:3.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">59</p></td><td style="vertical-align:top;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">PSU005d-USNE</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>5</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">US11491138</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issued</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Injectable psychoactive alkaloid composition and preparation thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:Times New Roman;">&#9679;</span><br/>US</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">16-Mar-22; 17/696,584</p></td><td style="vertical-align:top;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:0.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">18-Nov-22</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Legend: CA: Canada; IL: Israel, AU: Australia; US: United States; BR: Brazil; MX: Mexico; EP: Europe; PCT: Patent Cooperation Treaty International Patent System; JM: Jamaica</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Competitive Environment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are currently no pharmaceutical agents with regulatory approval for the treatment of AjD within palliative care or any other arena. The current treatment of AjD is empirical, with either psychotherapy or off-label pharmacological agents, such as anti-depressants or anxiolytics, or a combination of both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the competitive landscape analysis of other commercial psychedelic-assisted treatments in clinical trials strongly suggests that Psyence&#8217;s clinical asset has a first-mover advantage in both the palliative care and cancer-related AjD market upon approval. PEX010 and its associated IP has been licensed to Psyence, giving it exclusivity for the indications of anxiety and depression within the context of palliative care in the UK for R&amp;D purposes. Psyence plans to expand their targeted indication of cancer-related AjD to address different types of AjD and other secondary indications both in a palliative and non-palliative context.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2019, the FDA designated psilocybin therapy as &#8220;breakthrough therapy&#8221; for the treatment of severe depressive disorder. This precedent provides the possibility that psilocybin-based drug candidates, such as the Proposed End Product, may be eligible for a number of processes that could result in expedited marketing approval of such psilocybin-based drug candidates, such as Fast Track, Accelerated Approval, Priority Review and Breakthrough Status. Breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence intends to submit the NDA requesting assessment via the 505(b)(2)&#160;pathway. A 505(b)(2)&#160;application is an NDA that contains full reports of investigations of safety and effectiveness, where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference or use, including, for example, the agency&#8217;s finding of safety and/or effectiveness for a listed drug or published literature. This could potentially allow for a shorter development program along with less data that is developed by Psyence, as compared to a regular NDA submission. Despite the usage of psilocybin for decades, there have been relatively few studies pertaining to psilocybin products due to the ban on the research into psychedelics. However, recently, academic institutions have been allowed to conduct such studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A breakthrough therapy designation conveys all of the fast track program features (see below for more details on fast track designation), more intensive FDA guidance on an efficient drug development program, an organizational commitment involving senior managers, and eligibility for rolling review and priority review.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, even if we are granted an accelerated approval pathway, that may or may not lead to a faster development or regulatory review or approval process and may or may not increase the likelihood that our other product candidate will receive marketing approval. The European Medicines Agency (EMA) PRIME program, similar to the Food and Drug Administration (FDA) breakthrough therapy designation program, was launched in March&#160;2016 to enhance support for the development of medicines that target an unmet medical need. PRIME and the U.S. breakthrough therapy designation share the same objective (timely patient access to innovative medicines).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Business Objectives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence intends to further expand the development of its product candidates for additional indications. While Psyence&#8217;s initial focus will be on the development of PEX010 for the treatment of AjD in patients with a recent diagnosis of cancer in its Phase IIb Study and the development of the Proposed End Product thereafter, indication expansion will focus on other causes of AjD potentially leading to an increased opportunity within the indication. Further indications will be considered once the AjD program is ongoing in areas such as Alcohol Use Disorder and potentially with the use of other in-licensed candidates, however no such agreements have been reached at this stage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Psyence&#8217;s Psilocybin Asset</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to accelerate clinical development of a palliative care, psilocybin-based asset, Psyence has initially licensed Filament Health&#8217;s proprietary botanical drug candidate, PEX010, and its associated IP. Filament has developed innovative technology to extract and standardize stable doses of natural compounds from mushrooms. PEX010 is currently covered by up to ten patents (five patents by the USPTO and five by the Canadian Intellectual Property Office). The product candidate has also previously received authorization from the FDA and Health Canada to enter into Phase&#160;1 and Phase&#160;2 human clinical trials. The license granted to Psyence in respect of the early trial phases grants Psyence exclusivity in the UK to use PEX010 in future Phase 2 clinical trials for the indications of depression and anxiety, including associated ailments, such as PTSD, stress, grief, and AjD within the context of palliative care. Pursuant to the license, Psyence will own all the data, results of testing, research, any information and any other IP derived or arising from any clinical trials, with the exclusion of IP related to the manufacture, processing or production of the Filament input material, which will vest in Filament.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PEX010 is a pharmaceutical-grade, natural psilocybin drug candidate. It is an oral capsule containing 25mg of naturally derived psilocybin. PEX010 will be used as an adjunct to psychotherapy for the treatment of AjD due to an incurable cancer diagnosis versus psychotherapy alone within a palliative care context.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of PEX010</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PEX010 is extracted and purified from the psilocybes species of mushroom. Psilocybin is rapidly metabolized in the body to form psilocin, a psychoactive molecule. There has recently been a resurgence in the study of the use of psychedelics in a multitude of potential indications such as depression, anxiety disorders, PTSD, addictions and within palliative care, which is the focus area for Psyence&#8217;s development of PEX010.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PEX010 is being tested in patients with a recent terminal cancer diagnosis and who have developed AjD which can severely affect their quality of life as well as those closely related to them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Natural versus synthetic psilocybin</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Naturally extracting psychedelic compounds for medicinal use has the exciting opportunity of exploring the &#8216;entourage effect&#8217;, which refers to the synergistic interaction of two or more psychoactive molecules that are present in low concentrations in the final product after psilocybin extraction, resulting in a smoother, more tolerable onset and offset of the psychedelic experience. There are other active molecules within the mushrooms that have psychedelic effects, although less than psilocybin (see diagram below). A small amount of these additional active molecules is contained in the extracts derived from natural mushrooms, which contribute to the entourage effect. In the case of &#8216;magic mushrooms,&#8217; psychedelic effects are achieved either by ingesting natural psilocybin-containing extracts or engineered formulations of psilocybin derivatives. It is important to note that the pharmacological properties of the psilocybin molecule remain unchanged whether the drug is synthetically or naturally derived. Current synthetic versions of psilocybin exist as distinct polymorphic structures and are synthesized via reactions using certain substrates and enzymes </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:288pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">that direct the production of psilocybin. Naturally derived psilocybin is obtained by cultivating and processing psilocybin-containing mushrooms into a crude API for further use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">What distinguishes naturally derived psilocybin formulations from synthetic formulations is the potential to explore the &#8216;entourage effect&#8217; by varying the amounts of different tryptamines yielded in the host mushroom during the growing process. The &#8216;entourage effect&#8217; has important ramifications for the overall therapeutic effectiveness of psilocybin-assisted psychotherapy due to the potential of modulating the psychedelic effects and the neuroplastic processes, which help form connections between multiple neurons, typically induced by psilocybin. This is because the subjective effects derived from the type or intensity of &#8216;mystical experiences&#8217; occasioned by psilocybin, might additionally contribute to the overall effectiveness of the treatment. Whilst this area of research is still largely unexplored, a few preclinical studies have shown that different species of magic mushrooms procure nuanced changes in psychedelic experiences due to their differing levels of psilocybin, psilocin and other tryptamine derivatives. As the psilocybin industry continues to evolve, we believe that it is likely that there will be demand for both naturally derived psilocybin formulations as well as synthetic psilocybin (and derivatives) due to both the increasing demand in psilocybin-based research and more importantly, patient accessibility of psilocybin medicines. Whole Psilocybe mushrooms contain tryptamine derivatives that may contribute to a synergistic therapeutic effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="pbm-20240331xf1011.jpg" alt="Graphic" style="display:inline-block;height:288pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:373.21pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Figure 1 Source: ChemDraw</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psilocybin, 3-[2-(Dimethylamino)ethyl]-1 H-indol-4-yl dihydrogen phosphate is a naturally occurring tryptamine derivative found in over 100 species of mushrooms.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup>&#160;Psilocybin quickly dephosphorylates into psilocin upon ingestion. Psilocin is a partial-agonist of serotonin receptors in the brain. Tryptamine derivatives and serotonin share many similarities in their chemical structure. Psilocin binds with high affinity to the serotonin 2A receptors (5-HT2A).<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup></p><div style="font-family:'Times New Roman','Times','serif';font-size:9.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup> Daniel J, Haberman M. Clinical potential of psilocybin as a treatment for mental health conditions. Ment Health Clin. 2017;7:24&#160;&#8211; 28</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> PubChem. Psilocybine. https://pubchem.ncbi.nlm.nih.gov/compound/Psilocybine. Accessed 25 February&#160;2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Psilocybin reliably induces profound changes in sensory perception, emotion, thought, and sense of self, characterized by marked alterations in all mental functions, including perception, mood, volition, cognition and self-experience.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>&#160;These profound changes are often referred to as &#8220;mystical-type&#8221; experiences. Measures of mystical-type experience occurring during psilocybin treatment have been repeatedly observed to predict later effects on behavior and emotions, including reductions in depressive and anxious symptoms.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4,5</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Oral psilocybin has about a 50% bioavailability and psilocin is detectable in plasma within 15 minutes of administration of the parent compound.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6,7</sup>&#160;The half-life of psilocin in blood is 2-3 hours. Onset of noticeable psychoactive effects for a 25 mg dose typically occur within one hour, peaks at two hours after a dose and finishes at six hours after the dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The investigational medicinal product PEX010 is a capsule for oral administration that contains the herbal drug substance PYEX; a Psilocybe cubensis mushroom extract containing Psilocybin 9[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate). The drug product PEX010 is manufactured with the drug substance PYEX (12.5-14.0% psilocybin), excipients, and hydroxypropyl methylcellulose capsules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Indication and Treatments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Adjustment Disorder</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Incurable cancer is predictably associated with challenges and burdens that may lead to symptoms of depression, demoralization, and fears of suffering, dependency, and mortality.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">8</sup>&#160;Up to 50% of individuals with advanced cancer report symptoms that are sufficiently severe to reach clinical levels, exacerbating physical symptoms and impairing quality of life.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">9,10</sup>&#160;Multiple physical symptoms, dramatic alteration in support needs and personal relationships, difficulty navigating a complex health care system, and the threat of impending mortality all may constitute pathways to distress.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">11</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">AjD is defined in International Classification of Diseases 11th&#160;Revision (ICD-11) as a maladaptive reaction, which usually emerges within one&#160;month of a significant life-stressor, such as illness, family or partnership problems, job-related issues, or financial difficulties.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">14</sup>&#160;There are two core categories of symptoms that characterize AjD: a preoccupation with the stressor or its consequences, and failure to adapt. Preoccupation includes recurring distressing thoughts about the stressor, constant worry, and rumination. Failure to adapt describes a generalized stress-response (e.g., sleep disturbances or concentration problems) that results in significant impairment in social, interpersonal, occupational, educational, or other significant areas of functioning.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">3</sup> Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25:1434&#8201;&#8211;&#8201;1452.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">4 </sup>MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25:1453&#8201;&#8211;&#8201;1461.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">5 </sup>Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165&#8201;&#8211;&#8201;1180.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">6 </sup>Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, et al. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017;56:1543&#8211;1554.</p><a id="_Hlk174595876"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">7 </sup>Hasler F, Bourquin D, Brenneisen R, B&#228;r T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 1997;72:175&#8201;&#8211;&#8201;184.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">8 </sup>Lo C, Zimmermann C, Rydall A, Walsh A, Jones JM, Moore MJ, et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. J Clin Oncol. 2010;28:3084&#8201;&#8211;&#8201;3089.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">9 </sup>Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol. 2000;18:893&#8201;&#8211;&#8201;903.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">10 </sup>Delgado-Guay M, Parsons HA, Li Z, Palmer JL, Bruera E. Symptom distress in advanced cancer patients with anxiety and depression in the palliative care setting. Support Care Cancer. 2009;17:573&#8201;&#8211;&#8201;579.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">11 </sup>Rodin G, Lo C, Mikulincer M, Donner A, Gagliese L, Zimmermann C. Pathways to distress: the multiple determinants of depression, hopelessness, and the desire for hastened death in metastatic cancer patients. Soc Sci Med. 2009;68:562&#8201;&#8211;&#8201;569.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12 </sup>Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82:1904&#8201;&#8211;&#8201;1908.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13 </sup>Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and AjD in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160&#8201;&#8211;&#8201;174.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">14 </sup>Maercker A, Brewin CR, Bryant RA, Cloitre M, van Ommeren M, Jones LM, et al. Diagnosis and classification of disorders specifically associated with stress: proposals for ICD-11. World Psychiatry. 2013;12:198&#8201;&#8211;&#8201;206.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">AjD is also defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) diagnostic criteria,<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">15</sup>&#160;and while there is great overlap with the definition and symptomatology compared to the ICD 11 classification, the DSM definition separates AjD into 6 different subtypes, Both the ICD and DSM have had substantial impact on global psychiatric practice and research. While the DSM has been used more often in research around the world,<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">16</sup>&#160;a study of nearly 5,000 psychiatrists in 44 countries demonstrated that the majority of psychiatrists outside the U.S. utilize ICD classifications in their daily clinical practice.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">17</sup>&#160;The DSM-5 conceptualizes AjD as a stress-related syndrome in a separate chapter of &#8220;Trauma and Stress Related Disorders&#8221;,<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">18</sup>&#160;representing the most significant change from DSM-IV.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">19</sup>&#160;However, the current diagnostic construct is crucially dependent on an exclusion criterion, so that a diagnosis of AjD is rarely applicable when another mental disorder is present.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Treatment Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Traditional Treatments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Evidence suggests that addressing psychosocial, emotional, and physical symptoms early in the cancer trajectory, through such steps as palliative care or psychological interventions, may positively influence survival outcomes.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">20,21,22,23</sup>&#160;Comorbid depression with cancer leads to worsened quality of life, increased sensitivity to pain, difficulties with treatment, communication difficulties, caregiver burnout, increased risk of suicide, longer periods of hospitalization, and a reduced expectation of survival.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">24,25,26,27,28</sup>&#160;The National Institute for Clinical Excellence Palliative Cancer Care Guidelines<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">29</sup>&#160;recommend that if experiencing more severe types of psychological distress&#8201;&#8212;&#8201;which would include moderate to severe AjD&#8201;&#8212;&#8201;patients should be offered specialist psychological interventions such as psychotherapy, including cognitive behavioral therapy (&#8220;<b style="font-weight:bold;">CBT</b>&#8221;).</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">15 </sup>Casey P, Doherty A. AjD: implications for ICD-11 and DSM-5. Br J Psychiatry. 2012;201:90&#8201;&#8211;&#8201;92.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">16 </sup>Clark LA, Cuthbert B, Lewis-Fern&#225;ndez R, Narrow WE, Reed GM. Three Approaches to Understanding and Classifying Mental Disorder: ICD-11, DSM-5, and the National Institute of Mental Health&#8217;s Research Domain Criteria (RDoC). Psychol Sci Public Interest. 2017;18:72&#8201;&#8211;&#8201;145.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">17 </sup>Reed GM, Mendon&#231;a Correia J, Esparza P, Saxena S, Maj M. The WPA-WHO Global Survey of psychiatrists&#8217; attitudes towards mental disorders classification. World Psychiatry. 2011;10:118&#8201;&#8211;&#8201;131.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">18 </sup>Kangas M. DSM-5 Trauma and Stress-Related Disorders: Implications for Screening for Cancer-Related Stress. Front Psychiatry. 2013;4:122.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">19 </sup>Strain JJ, Friedman MJ. Considering AjDs as stress response syndromes for DSM-5. Depress Anxiety. 2011;28:818&#8201;&#8211;&#8201;823.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">20 </sup>Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733&#8201;&#8211;&#8201;742.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">21 </sup>Bakitas MA, Tosteson TD, Li Z, Lyons KD, Hull JG, Li Z, et al. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. J Clin Oncol. 2015;33:1438&#8201;&#8211;&#8201;1445.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">22 </sup>Giese-Davis J, Collie K, Rancourt KMS, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29:413&#8201;&#8211;&#8201;420.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">23 </sup>Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003;54:269&#8201;&#8211;&#8201;282.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">24 </sup>Skarstein J, Aass N, Foss&#229; SD, Skovlund E, Dahl AA. Anxiety and depression in cancer patients: relation between the Hospital Anxiety and Depression Scale and the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. J Psychosom Res. 2000;49:27&#8201;&#8211;&#8201;34.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">25 </sup>Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Centre for Reviews and Dissemination (UK); 2009.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">26 </sup>Prieto JM, Blanch J, Atala J, Carreras E, Rovira M, Cirera E, et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002;20:1907&#8201;&#8211;&#8201;1917.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">27 </sup>Misono S, Weiss NS, Fann JR, Redman M, Yueh B. Incidence of suicide in persons with cancer. J Clin Oncol. 2008;26:4731&#8201;&#8211;&#8201;4738.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">28 </sup>Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326&#8201;&#8211;&#8201;1327.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">29 </sup>Nice N. Improving supportive and palliative care for adults with cancer. London: NICE. 2004. 2004.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Psilocybin-assisted psychotherapy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CBT has been shown to improve anxiety in patients diagnosed with incurable cancer, but appears to be less effective at improving depressive symptoms.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">30</sup>&#160;Several recently published trials have examined the efficacy of psilocybin, a classic serotonergic psychedelic drug that induces its acute subjective effects through the agonism of serotonin 2A (5-HT2A) receptors, to treat depression and anxiety in patients with life&#160;-threatening cancer, amongst other psychiatric conditions.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">31,32,33,34</sup>&#160;Psilocybin-assisted psychotherapy is a course of therapy involving single or multiple sessions in which a dose of psilocybin is administered in conjunction with psychotherapy, delivered by a suitably trained therapist in a controlled setting. This intervention consists of three therapy stages: (1)&#160;preparation, (2)&#160;dosing session(s), and (3)&#160;integration, which allow for a more patient-centric approach compared to other therapy models. The pharmacological effects of psilocybin, in synergy with the psychotherapy, are considered to give rise to increased neuroplasticity, which facilitates rapid and deep psychological transformation that may accelerate and augment the effects of the psychotherapy process.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">34</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PAP has been demonstrated in various academic studies to cause expeditious, substantial, and sustained improvements in cancer-related anxiety and depression, existential distress, quality of life, and orientation toward death.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">32,33</sup>&#160;For example, in an academic study32&#160;of 29 patients with cancer-related depression and anxiety, at the 6.5-month follow up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60-80% of participants continued with clinically significant reductions in depression or anxiety respectively), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">35</sup>&#160;In another study of 51 patients,<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">33</sup>&#160;similar results were reported. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the &#8220;high&#8221; experience resulting from the psilocybin, with over 80% endorsing moderately or greater increased well-being/life satisfaction.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">36,37,38,39,40,41,42</sup></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">30 </sup>Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther. 2006;44:1&#8201;&#8211;&#8201;25.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">31 </sup>Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384:1402&#8201;&#8211;&#8201;1411.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">32 </sup>Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71&#8201;&#8211;&#8201;78.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">33 </sup>Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30:1181&#8201;&#8211;&#8201;1197.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">34 </sup>Brouwer A, Carhart-Harris RL. Pivotal mental states. J Psychopharmacol. 2021;35:319&#8201;&#8211;&#8201;352.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">35 </sup>Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont&#233; KL, Guss J, et al. Long-term follow-up of PAP for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34:155&#8201;&#8211;&#8201;166.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">36 </sup>Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619&#8201;&#8211;&#8201;627.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">37 </sup>Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399&#8201;&#8211;&#8201;408.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">38 </sup>Davis AK, Barrett FS, May&#160;DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of PAP on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78:481&#8201;&#8211;&#8201;489.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">39 </sup>Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin- assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29:289&#8201;&#8211;&#8201;299.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">40 </sup>Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983&#8201;&#8211;&#8201;992.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">41 </sup>Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67:1735&#8201;&#8211;&#8201;1740.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">42 </sup>Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30:1181&#8201;&#8211;&#8201;1197.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A number of factors provide rationale for focusing on patients with AjD following a diagnosis of incurable cancer as the target population. The size of the cancer population, which generally makes up approximately 30% of target country palliative patients, provides justification for research, in regard to both the magnitude of needs and the access to participant recruitment. Additionally, previous clinical trials have demonstrated the feasibility and efficacy of PAP for people with depression and anxiety symptoms, both within and outside of the palliative care setting, highlighting the versatility and universality of this intervention. Moreover, the sustained reductions in anxiety and depression amongst palliative care patients suggest the longevity of positive outcomes mediated by PAP and the potential to dramatically improve patient quality of life, in what remains of their life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Classic psychedelics, a term referring to naturally&#160;-derived psychedelics including mescaline, lysergic acid diethylamide and psilocybin, all share a common mechanism of action via the serotonergic pathways. Psilocybin is a prodrug that, when ingested, is metabolized into the psychoactive compound psilocin. Psilocin acts as a partial agonist at the serotonergic 5-HT2A receptor, and research has demonstrated that activation of the 5-HT2A receptor subtype is integral to the mechanism of action leading to subjective psychedelic experience.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">43,44,45,46,47</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>The pharmacological effects of psilocybin, in synergy with psychotherapy, are considered to give rise to increased neuroplasticity and create a &#8216;pivotal mental state,&#8217; which facilitates rapid and deep psychological transformation that may accelerate and augment the effects of the psychotherapy process.<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">34</sup>&#160;This is thought to underlie the transdiagnostic efficacy of PAP for a wide range of difficult to treat psychiatric conditions, including treatment-resistant depression, PTSD, substance use disorders, psychological distress with a life-threatening illness and obsessive-compulsive disorder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Studies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In recent palliative care clinical trials conducted at New York School of Medicine and Johns Hopkins University School of Medicine, in which participants received PAP at doses of 22 mg/70 kg, 30 mg/70 kg, and 0.3 mg/kg, no serious adverse events (&#8220;<b style="font-weight:bold;">SAEs</b>&#8221;)&#160;were reported. Adverse effects of PAP amongst participants had all been previously described for psilocybin and were mild and transient, and included physical discomfort, psychological discomfort, increased systolic and diastolic blood pressure without criteria for medical intervention, increased heart rate with a mild sympathomimetic effect, nausea and vomiting, transient anxiety and headaches or migraines. None of the participants experienced prolonged psychosis or hallucinogen persisting perception disorder (&#8220;<b style="font-weight:bold;">HPPD</b>&#8221;).</p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">43 </sup>Willins DL, Meltzer HY. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther. 1997;282:699&#8201;&#8211;&#8201;706.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">44 </sup>Glennon RA, Teitler M, Sanders-Bush E. Hallucinogens and serotonergic mechanisms. NIDA Res Monogr. 1992;119:131&#8201;&#8211;&#8201;135.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">45 </sup>Vollenweider FX, Vollenweider-Scherpenhuyzen MF, B&#228;bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897&#8201;&#8211;&#8201;3902.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">46 </sup>Ray TS. Psychedelics and the human receptorome. PLoS One. 2010;5:e9019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">47 </sup>Gonz&#225;lez-Maeso J, Weisstaub NV, Zhou M, Chan P,&#160;Ivic L, Ang R, et al. Hallucinogens Recruit&#160;Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior. Neuron. 2007;53:439&#8201;&#8211;&#8201;452.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There are currently five registered studies investigating the efficacy of PAP to treat depression, anxiety and demoralization in patients with incurable illnesses:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Study</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Study Design</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:31.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Yvan Beaussant from the Dana-Farber Cancer Institute (NCT04950608).</p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Open-label, single-arm pilot study&#8201;&#8212;&#8201;<i style="font-style:italic;">Recruiting</i></p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Safety and efficacy of a fixed 25 mg psilocybin dose and psychotherapy in hospice care patients with demoralization and existential distress</p></td></tr><tr><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Maryland Oncology Hematology (NCT04593563).</p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 2, open-label, single-arm study&#8201;&#8212;&#8201;<i style="font-style:italic;">Active, not recruiting</i></p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Safety and efficacy of a fixed 25 mg dose of psilocybin to treat MDD in 30 patients with malignant neoplasm</p></td></tr><tr><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">University of Utah (NCT04522804).</p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Open-label study, single-arm&#8201;&#8212;&#8201;<i style="font-style:italic;">Recruiting</i></p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Safety and tolerability of psilocybin in cancer patients assessed by the number and severity of Adverse Events (&#8220;AEs&#8221;), and the feasibility to recruit, enroll and consent patients with a cancer diagnosis or hematologic malignancy to the study</p></td></tr><tr><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">St Vincent&#8217;s Hospital in Melbourne (U1111-1237-8914).</p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 2 parallel 2-part study, where part 1 is a randomized, controlled trial comparing an active placebo of 100 mg Niacin with 25 mg psilocybin, and part 2 is an open-label single-arm study of 25 mg of psilocybin&#8201;&#8212;&#8201; <i style="font-style:italic;">Recruiting</i></p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assess the efficacy of PAP to treat depression and/or anxiety associated with an incurable illness diagnosis</p></td></tr><tr><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">University of Nebraska.</p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Phase 1, open-label, single-arm study&#8201;&#8212;&#8201;<i style="font-style:italic;">Not yet recruiting</i></p></td><td style="vertical-align:top;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exploratory pilot study of palliadelic treatment to reduce psychological distress and improve quality of life in persons with pancreatobiliary cancer, with a parallel assessment of healthcare utilization and family wellbeing</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Known and Potential Risks of Psilocybin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Abuse Potential</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, there have been no confirmed reports of an overdose of pharmaceutical psilocybin. Currently, psilocybin is placed in Schedule&#160;1 in the UK Misuse of Drugs Regulations&#160;2001, defined as having no medical use, possessing high abuse liability, and lack of accepted safety when used under medical supervision. However, in preclinical studies using non-human primates, psilocybin, mescaline and N,N-Dimethyltryptamine did not serve as positive reinforcers in 3,4-Methylenedioxy methamphetamine (MDMA) experienced rhesus monkeys. This suggests that non-human primates do not find the psychoactive effects of the 5-HT2A receptor agonists addictive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Analysis of long-term follow-up data from eight pooled experimental trials with healthy volunteers indicated no subsequent drug abuse, no changes to overall drug consumption habits (including alcohol, nicotine, cannabis and MDMA) or functional impairment following exposure to psilocybin in the laboratory. Where changes in drug consumption habits were noted, most respondents described decreased consumption, particularly with reference to psilocybin use. Large-scale survey research indicates that hallucinogens are selected as a primary substance of abuse in only a fraction of responders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In clinical studies with psilocybin, exposing individuals with either no history of hallucinogen use, or a history of minimal use (less than ten times in total and not within the previous five&#160;years) have not resulted in reported instances of subsequent illicit hallucinogen abuse. Additionally, studies have shown side effects that are potentially predictive of low abuse potential, such as </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">elevations in fear and anxiety. Based on available literature, it is not expected that either psilocybin-na&#239;ve or experienced individuals will develop dependence after exposure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Safety</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psilocybin has been found to be of very low toxicity in humans and research animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In recent palliative care clinical trials conducted at New York School of Medicine and Johns Hopkins University School of Medicine, in which participants received PAP at a dose of 22 mg/70 kg, 30 mg/70 kg, and 0.3 mg/kg, no serious adverse events (&#8220;<b style="font-weight:bold;">SAEs</b>&#8221;) were reported. Adverse effects of PAP amongst participants had all been previously described for psilocybin and were mild and transient, and included physical discomfort, psychological discomfort, increased systolic and diastolic blood pressure without criteria for medical intervention, increased heart rate with a mild sympathomimetic effect, nausea and vomiting, transient anxiety and headaches or migraines. None of the participants experienced prolonged psychosis or hallucinogen persisting perception disorder (&#8220;<b style="font-weight:bold;">HPPD</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> The clinical safety of psilocybin has been extensively studied in open-label and double-blind, controlled trials, both as a single agent and as adjunctive treatment in a number of clinical and non-clinical adult populations. Dosing regimens used in previous clinical trials with psilocybin have ranged from 0.014 mg/kg to 0.6 mg/kg, administered orally as either a single dose, or multiple doses weeks apart. Thousands of participants have received psilocybin under controlled conditions in a clinical setting for various indications, with results published in peer-reviewed journals. Knowledge gained from previous clinical trials with psilocybin and discussions with researchers leading other randomized control trials in this area has directed the design of Psyence&#8217;s planned Phase&#160;IIb Study.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psilocybin (also known as &#8216;magic mushrooms&#8217;) is rated as one of the least harmful recreational drugs. Commonly cited risks include prolonged psychotic reactions, flashback phenomena/HPPD, and bad trips. Prolonged psychotic responses are extremely rare in clinical studies with psilocybin (&lt;1%), even at very high doses, and none have been reported in modern studies or studies with patients. The risk of flashback phenomena is minimal (or even negligible), and no cases have been observed in other studies with psilocybin. Periods of psychological challenge (for example, increased anxiety) are more commonly reported, but may be predictive of positive clinical outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Psilocybin Related Adverse Events by Incidence (at 25 mg)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:35.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:normal;width:35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Common</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">&gt;20%</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:35.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less common</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">&lt;15%</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rare</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">&lt; 2%</b></p></td></tr><tr><td style="vertical-align:top;width:25.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1)</p></td><td style="vertical-align:top;white-space:normal;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">1)</p></td><td style="vertical-align:top;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">1)</p></td></tr><tr><td style="vertical-align:top;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Increased anxiety, particularly at the onset of the drug effects</p></td><td style="vertical-align:top;white-space:normal;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Paranoia or suspiciousness.</p></td><td style="vertical-align:top;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">HPPD/flashbacks</p></td></tr><tr><td style="vertical-align:top;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2)</p></td><td style="vertical-align:top;white-space:normal;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">2)</p></td><td style="vertical-align:top;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">2)</p></td></tr><tr><td style="vertical-align:top;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Mild-moderate increase in heart rate</p></td><td style="vertical-align:top;white-space:normal;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Nausea</p></td><td style="vertical-align:top;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Worsening of mental state after the drug experience</p></td></tr><tr><td style="vertical-align:top;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">3)</p></td><td style="vertical-align:top;white-space:normal;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">3)</p></td><td style="vertical-align:top;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Visual hallucinations</p></td><td style="vertical-align:top;white-space:normal;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Dizziness</p></td><td style="vertical-align:top;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4)</p></td><td style="vertical-align:top;white-space:normal;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">4)</p></td><td style="vertical-align:top;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Transient headaches, lasting for one to two days (maximum) post-dosing</p></td><td style="vertical-align:top;white-space:normal;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">A &#8216;bad trip&#8217; i.e. negative thoughts and mood during the acute drug effects</p></td><td style="vertical-align:top;white-space:normal;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:normal;width:35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">It is not uncommon for people to experience some negative psychological content during a psilocybin &#8216;trip&#8217;, particularly if they suffer from ongoing psychological distress, as is characteristic of depression. Typically, this is managed by ensuring good preparation </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">before, support during, and integration after the experience. While challenging episodes have been relatively commonly reported in previous trials, some of these have contributed to a psychological &#8216;breakthrough&#8217; on the part of the participant. Recent evidence indicates that challenging psychological experiences can produce therapeutic benefits, improving psychological well-being in the long-term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Negative aftereffects of challenging psychological experiences under psychedelics are thought to be a consequence of inadequate &#8216;set and setting&#8217; and post-session integration work&#8201;&#8212;&#8201;and they may also relate to the duration of the challenging period. In the Phase&#160;IIb Study and further studies, such risks will be reduced via thorough psychological preparation and integration, good patient-staff rapport and a positive, supportive environment. Challenging experiences/periods will be managed principally through psychological support, but oral and injectable lorazepam and olanzapine, as rescue medications, will be available. These would only be used in cases of severe panic that were unresponsive to psychological intervention, and where the patient&#8217;s behavior was putting themselves and/or staff in danger. Consent for such medication will be sought from the patient ahead of study participation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before, during and after the dosing session, patients will receive psychological support from therapists who have been specifically trained to deliver PAP in the context of research studies, including clinical trials. An onsite psychiatrist will also be available to support where needed. Monitoring of participants&#8217; vital signs, behavior and mood will be conducted prior to the psilocybin being administered, and prior to the participant being discharged. On the dosing day, patients will only be allowed to return home only once the study psychiatrist is confident they are fit to do so, and authorizes the patient&#8217;s release. 24-hour emergency contact numbers will be provided for a member of the study team, and localized support and crisis services will also be provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the psychoactive nature of psilocybin, the safety of participants in clinical trials can be enhanced by testing psilocybin within a &#8220;set and setting&#8221; protocol. By addressing the set (the emotional, cognitive, behavioral states, mindset and expectations of study participants just prior to psilocybin exposure) and setting (the physical environment in which the exposure occurs) of the experience, the risk of the subject reporting an event which is distressing or injuring themselves can be reduced. This approach generally incorporates three components: (1)&#160;preparation, (2)&#160;drug session and (3)&#160;post&#160;-session meetings to integrate the classic psychedelic experience.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the preparation phase, participants undergo pre-exposure sessions designed to build rapport with the therapist who will be present during the drug dosing session and to identify personal themes and struggles that might be especially likely to impact the session experience. The drug session itself is conducted by a trained therapist (the gender of which is selected by the participant) and an appropriately trained member of the study team, who are present throughout the session. Sessions are typically conducted in a room designed to be quiet, comfortable, and aesthetically pleasing, and participants are encouraged to wear eyeshades and listen to a program of music through headphones during the drug exposure to aid them in focusing their attention inwards. In the third phase, participants are engaged in a series of drug-free therapy sessions to discuss their dosing session experience thoroughly, with the goal of maximizing its therapeutic benefit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Suicide</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">While most trials with psilocybin have demonstrated reduced suicidality following dosing, one recent large-scale study conducted by Compass Pathways with 233 participants on the efficacy of psilocybin in a treatment-resistant depression (TRD) population reported that suicidal ideation and intentional self-injury were seen in all treatment groups, as is common in TRD studies. Most cases occurred more than a week after the COMP360 psilocybin session. There was no mean worsening of suicidal ideation scores on the MADRS scale in any treatment group. Suicidal behaviors were reported at least one&#160;month after COMP360 administration for three non-responders in the 25mg arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">It is important to note that subjects with AjD and patients with a terminal cancer diagnosis are also at increased risk of suicide. As such, in the Psyence Phase IIb Study, the risk of suicide and other AE&#8217;s will be assessed by thorough and regular screening using the Sheehan-Suicide Tracking Scale (S-STS) at every study visit. Participants with suicidal tendencies and histories of suicide attempts will be excluded from the study. The study psychiatrist and psychotherapist contact details will be provided to patients in case of emergency, in addition to providing localized information for support services and crisis management. A standard operating procedure for dealing with both AEs and any unexpected suicide attempt has been prepared. As such, we believe that the risk of suicide and other AEs will be reduced by thoroughly screening participants for any suicidal tendencies, by excluding patients with histories of suicide attempts and by regular monitoring of suicidal ideation and behavior.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 9pt 0pt;">Target Population and Market&#8201;&#8212;&#8201;Palliative Care Patients</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Previous trials have demonstrated that PAP is well tolerated in samples of palliative care patients, with no SAEs. Recruitment of palliative care participants may require screening of large samples in order to achieve the intended sample size. In previous PAP trials with palliative care participants, 10%-27% of screened individuals were enrolled in the study. Recruitment for trials of psychiatric disorders is complex, as such conditions may affect motivation and adherence, relating to both the physical and mental health of participants with a cancer diagnosis. Moreover, there is an exogenous risk of participant death during the trial for clinical trials in the palliative care setting. Similarly, as cancer may metastasize further, diligence must be paid to exclude participants with metastatic cancer to the brain, considering the potential impact on cognitive function. Together, this indicates that the success of recruitment and screening relies on the selection of participants with appropriate life expectancy, extent of cancer, and post-diagnosis time for the inclusion/exclusion criteria in PAP trials with palliative care patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 0pt;"><span style="white-space:pre-wrap;"> Targeted Market for First Indication (AjD in Patients with a Terminal Cancer Diagnosis)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The total Palliative Care Market is large, with an expected robust CAGR of 9.4% over the next 7&#160;years. The figures below are drawn from commissioned market research performed by Insight Ace Analytic (insightaceanalytic.com) in September&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">The total market value was calculated using two approaches simultaneously; namely top-down and bottom-up approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In the top-down approach, the total market revenue is calculated by conducting the parent market analysis for deducing the revenue for global palliative care market revenue. Analyst perspective and subject-matter-expert based heuristic form of market sizing also plays an integral role in this step. For forecasting the current estimates, the following key sources were considered:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">American Cancer Society International Association for Hospice &amp; Palliative Care,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">UK Palliative Medicine Association National Hospice and Palliative Care Organization (NHPCO),</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Worldwide Hospice Palliative Care Alliance (WHPCA), International Association for Hospice &amp; Palliative Care (IAHPC),</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Investor presentation of palliative care providers,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Psychedelic drug development companies,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Hospice care providers and associations</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Worldpopulationreview gco.,iarc.fr, webmed.com, acsjournals,.onlinelibrary.wiley.com, NCBI, www.cancer.org, ecancer.org, canadian-cancer-statistics-2021, www150.statcan.gc.ca cancer.ca, canceratlas.cancer.org, bmcmedicine, biomedcentral.com, www.who.int, ascopubs.org, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.jpsmjournal.com,OECD</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">In the bottom-up approach, we used different mathematical models to estimate the market sizes of different economies and segments, which we then summed up to define the total market. The key data points that enabled the estimation of global palliative care market are as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Palliative Care Service Revenues from major service providers</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Palliative care different disease and treatment penetration by region and key countries</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">As a part of the market engineering, both &#8216;top-down&#8217; as well as &#8216;bottom-up&#8217; approaches were extensively utilized along with data triangulation models to derive&#160;&amp; verify the market sizes&#160;&amp; forecast through 2028. Market forecast was performed through proprietary software that analyses various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provided accuracy in different market segments in the report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">A holistic approach was used to ensure that the granular and uncommon parameters were taken into consideration to ensure accurate results. The information from the paid databases were further combined to the raw data in order to standardize it.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Data validation is the most crucial stage of the research process. Primary interviews were conducted to validate the data and analysis, which provides first-hand information on the market dynamics, outlook, and growth parameters. Industry experts validate the estimates, which helps the company to cement the on-going research study and primary research includes online surveys and telephonic interviews with different distributors and manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pbm-20240331xf1017.jpg" alt="Graphic" style="display:inline-block;height:236.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:410.19pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 2 The estimated&#160;year of launch of the Proposed End Product in the treatment of Adjustment Disorder in palliative care patients is 2027. Robust growth of the total palliative care market continues through 2030.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="pbm-20240331xf1018.jpg" alt="Graphic" style="display:inline-block;height:221.22pt;width:431.19pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:253.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Figure 3 Robust growth in the palliative market across major regions of the world continue through 2030</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="pbm-20240331xf1019.jpg" alt="Graphic" style="display:inline-block;height:185.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:432.69pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Figure 4 The initial indication within the cancer segment of palliative care is about 37% of the total market which provides a large segment of other chronic illnesses to be targeted with label expansion opportunities.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="pbm-20240331xf1020.jpg" alt="Graphic" style="display:inline-block;height:253.46pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:449.94pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:237.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Figure 5 There will be approximately 2.25&#160;million patients in North America and Europe with distress related to cancer in 2030</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><img src="pbm-20240331xf1021.jpg" alt="Graphic" style="display:inline-block;height:236.97pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:449.94pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Figure 6 This table gives a directional indication of what the size of the revenue could be with very conservative estimates of&#160;percentage of number of cancer patients with distress on PAP and the costs charged for PAP or just the psilocybin. Growth in&#160;percentage market obtained will be dependent on awareness and ability to provide PAP in sufficient clinics. Whichever scenario is considered, the Serviceable Obtainable Market could be three times higher when other chronic disease sources of distress are available.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Business Model</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psilocybin-assisted psychotherapy, once approved, will have to be delivered to patients in a guided manner over a period of 6&#8201;&#8211;&#8201;8 weeks, including the intention setting meetings, the psychedelic event (dosing session) and the subsequent integration meetings. This implies having trained guides who will spend a long time with patients over the course of the PAP, suitable clinic settings and psychologists&#8217; oversight.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The final business model for the provision of the Proposed End Product will depend on a number of aspects, including the final outcomes of the studies, the indication(s)&#160;that will be allowed by the regulatory agencies and the state of the environment and market to provide psychedelic therapy at the time of approval. It is expected that the number of clinics available to be able to provide PAP will increase dramatically once the first psychedelic is approved for any indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our possible business models will take into consideration of whether to merely supply the the Proposed End Product for clinics to administer, through including a premium price for the intellectual property of a proprietary PAP, to enter into partnerships with clinics to administer PAP, or even to own dedicated clinics for administration of PAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The target audience for the initial indication will be oncology sites, including their oncologists and other health care professionals to create awareness of the effectiveness of PAP for terminal cancer patients who have AjD. The principal marketing message will be to offer patients a better quality of life for their remaining&#160;years with a single administration of the Proposed End Product within a PAP. It has been shown that patients in palliative care who are less anxious or depressed utilize fewer healthcare resources, which is an aspect that will help justify the costs of the PAP.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Legal and Regulatory Framework</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Current Regulatory Landscape of Target Markets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Psyence will focus on the initial countries and regions to perform their clinical development and to commercialize the final product, being North America (US&#160;&amp; Canada), EU, UK and Australia. Introductions into other regions will be contemplated at a later phase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">In the United States, foods, drugs and dietary supplements are subject to extensive regulation. The U.S. Food, Drug, and Cosmetic Act (the &#8220;<b style="font-weight:bold;">FDCA</b>&#8221;) and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacturing, storage, recordkeeping, approval, labelling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. We must ensure that all promotion and marketing, distribution, and labeling of any pharmaceutical products comply with the U.S. regulations, including the FDCA and the U.S. Food and Drug Administration (the&#160;&#8220;<b style="font-weight:bold;">FDA</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Psilocybin and psilocin are strictly controlled under the U.S. Controlled Substances Act (&#8220;<b style="font-weight:bold;">CSA</b>&#8221;) as Schedule&#160;I substances. By definition, Schedule&#160;I substances have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Schedule&#160;I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, security requirements and criteria for importation. Anyone wishing to conduct research on substances listed in Schedule&#160;I under the CSA must register with the DEA and obtain DEA approval of the research proposal. A majority of state laws in the United States also classify psilocybin and psilocin as Schedule&#160;I controlled substances. For any product containing psilocybin or any Schedule&#160;I substance to be available for commercial marketing in the United States, such substance must be rescheduled, or the product itself must be scheduled, by the DEA to Schedule&#160;II,&#160;III,&#160;IV or V. Scheduling determinations by the DEA are dependent on FDA approval of a substance or a specific formulation of a substance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Prescription drugs are classified and regulated under the federal Food and Drugs Act (Canada). Labeling, marketing and selling of any prescription drug must comply with Health Canada. The regulations in the European Union are similar to those in the U.S. and Canada.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">Psyence will focus the phase IIb portion of its clinical development program in Australia. The TGA is Australia&#8217;s government authority responsible for evaluating, assessing and monitoring products that are defined as therapeutic goods, and the use of therapeutic goods supplied in clinical trials in Australia under the therapeutic goods legislation. Such legislation includes The Therapeutic Goods Act 1989 (&#8220;<b style="font-weight:bold;">TG Act</b>&#8221;), Regulations and Orders which set out the requirements for inclusion of therapeutic goods in the Australian Register of Therapeutic Goods (ARTG).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">For a prescription medicine to be registered in the ARTG, a sponsor of the product (usually a pharmaceutical company such as Psyence) is required to submit a dossier of evidence on the clinical efficacy, safety and manufacturing quality for evaluation by the TGA. Clinical trials of medicines and biologicals regulated under the Clinical Trial Notification (CTN) or Clinical Trial Approval (CTA) schemes are subject to the TGA&#8217;s Good Clinical Practice (GCP) Inspection Program. The TGA has issued a handbook which provides guidance on the legislative, regulatory and good clinical practice (GCP) requirements when conducting clinical trials in Australia using &#8216;unapproved&#8217; therapeutic goods in order to assist trial sponsors, Human Research Ethics Committees (HRECs), investigators and approving authorities (institutions) in understanding their roles and responsibilities under the therapeutic goods legislation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Until recently, psilocybin was included in Schedule 9 (Prohibited Substances) of the Poisons Standard which, because of interaction with state and territory regulation, largely restricted the lawful supply of goods containing psilocybin to clinical trial settings only. However, effective as of July&#160;1, 2023, the TGA made the decision to down schedule psilocybin to Schedule 8 in the Poisons Standard when used in respect of certain conditions, namely for the treatment of treatment-resistant depression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">To import products that contain a controlled substance (such as psilocybin), the importer requires both an exemption, approval or authority under the TG Act and a license and/or permit to import from the Office of Drug Control under the Customs (Prohibited Imports) Regulations 1956. Licenses and permits to&#160;import psilocybin are only granted by the Office of Drug Control where the use of the substance is permitted by the relevant state or territory under their respective medicines and poisons legislation and the use of the of psilocybin is to be prescribed by an Authorized Prescriber or for an authorized clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence will monitor the evolution of Australia&#8217;s regulations as they pertain to psilocybin and the conduct of clinical trials in Australia.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulatory Changes on the Horizon for Therapeutic Psychedelics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 6pt 0pt;">With the reintroduction of the Breakthrough Therapies Act in March&#160;2023, there appears to be momentum to develop a legal-regulatory framework for therapeutic psychedelics. Congress also announced on November&#160;17, 2022, the bipartisan Congressional Psychedelics Advancing Clinical Treatments Caucus (the PACT Caucus). The PACT Caucus will focus on exploring psychedelic research to alleviate the U.S. mental health crisis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_00aeda85_f938_4ce8_9676_43ae8ab1fd8b"></a><a id="MANAGEMENT_134401"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">MANAGEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following sets forth certain information, as of the date of this prospectus, concerning the directors and executive officers of the Company. All executive officers are appointed by the Board to serve in their roles. Each executive officer is appointed for such term as may be prescribed by the Board or until a successor has been chosen and qualified or until such officer&#8217;s death, resignation or removal.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:65.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position(s)</b></p></td></tr><tr><td style="vertical-align:bottom;width:25%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Jody Aufrichtig</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:65.99%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board and Strategic Business Development Officer</p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dr. Neil Maresky</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">60</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Warwick Corden-Lloyd</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">45</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial officer</p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Marc Balkin</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">49</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Christopher (Chris) Bull</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">55</p></td><td style="vertical-align:top;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dr. Seth Feuerstein</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Executive Officers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dr. Neil Maresky </span>has served as the Company&#8217;s Chief Executive Officer since January 25, 2024 and Director since June 29, 2023. Dr. Maresky has also served as Parent&#8217;s chief executive officer and director from July 1, 2021 until his resignation in March 2024. Dr. Maresky brings more than 25 years of enterprise leadership and biopharmaceutical expertise and currently oversees the strategy and operations of Psyence. From 2010 to 2021, Dr. Maresky, spent more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs. Dr. Maresky is a South African trained doctor. In Canada, he has held various executive leadership positions in &#8220;Big Pharma&#8221;, including leading research and development and driving scientific strategy at Bayer Pharmaceuticals (1998-2002) as well as Wyeth Pharmaceuticals (2002-2008), where he was interim President and general manager in 2008. Dr. Maresky is a South African trained doctor where he was trained in emergency room medicine and cardiology, and practiced as a family physician. In the mid-1990s, Dr. Maresky emigrated to Canada and began his career in the pharmaceutical industry. During the course of his career, Dr. Maresky has positively impacted the health of millions of patients across Canada. With extensive experience and relationships with academic institutions, health authorities and decision-making bodies across Canada, Dr. Maresky has contributed to many innovative medical therapies and technologies, including over 50 approvals of new medicines and new indications. One of Dr. Maresky&#8217;s most recent achievements was the approval of the AstraZeneca Covid-19 vaccine by Health Canada. Dr. Maresky holds a Medical Degree M.B.,B.Ch. from the University of Witwatersrand (1987).Dr. Maresky is an experienced research scientist and entrepreneur, and has experience in both big pharma and technology driven startups, both at the board and operating levels, in a broad variety of areas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Warwick Corden-Lloyd</span> has served as the Chief Financial Officer of the Company since January&#160;25, 2024. Mr.&#160;Corden-Lloyd has also served as Chief Financial Officer of Parent from May&#160;21, 2020 until his resignation in January 2024. Mr.&#160;Corden-Lloyd is a Chartered Accountant and Certified Project Manager. He has over 19&#160;years of experience working in public accounting, consulting and listed financial services companies in the UK, US and South Africa. Mr.&#160;Corden-Lloyd has listed company financial and regulatory reporting experience in international and emerging markets. From May&#160;2020 to January&#160;2021, Mr.&#160;Corden-Lloyd was the Corporate Finance Advisor and Chief Financial Officer of MindHealth Biomed Corp, the predecessor company prior to Parent. Mr.&#160;Corden-Lloyd was previously the Vice President of Operations and Finance at Canopy Growth Africa, (a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: WEED) from May&#160;2019 to May&#160;2020. Whilst at Canopy Growth, he oversaw the Finance, Legal, Supply Chain, Human Resources, Quality Assurance and Regulatory, Project Management and Country Manager divisions. Prior to that he was Head of Financial Accounting at Capitec Bank, South Africa&#8217;s largest customer retail bank, from February&#160;2015 to May&#160;2019 where he was responsible for managing the financial and regulatory reporting, budgeting and financial accounting for the bank. Before working at Capitec Bank, he worked for PricewaterhouseCoopers International Limited in South Africa, US and the UK and for The Bank of New York Mellon Corporation in the UK. Mr.&#160;Corden-Lloyd received a Bachelor of Accounting from the University of Stellenbosch, South Africa in 2002, a Bachelor of Accounting Honours from the University of Natal, South Africa in 2003 and registered with the South African Institute of Chartered Accountants in 2006. He is also registered with The Institute of Chartered Accountants in England and Wales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Jody Aufrichtig</span>&#160;has served as Strategic Business Development Officer and Chairman of the Board since January&#160;25, 2024, and a Director of Parent since <span style="color:#231f20;">May&#160;21, 2020</span>. He has served in the same roles at Parent since May&#160;21, 2020. Mr.&#160;Aufrichtig is a chartered accountant and experienced entrepreneur with extensive experience in emerging markets. Mr.&#160;Aufrichtig is the founder of MindHealth Biomed Corp and has built multiple award-winning businesses and created substantial shareholder value in cannabis, commercial and residential property, private equity, tourism, leisure and other industries. Prior to founding MindHealth Biomed Corp, he was the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Managing Director of Canopy Growth Africa (a wholly owned subsidiary of Canopy Growth Corporation (NYSE: CGC / TSX: WEED)) from May&#160;2018 until he led a management buyout of the African operations in April&#160;2020. Mr.&#160;Aufrichtig founded Daddy Cann Lesotho (Pty) Limited in July&#160;2017 and was granted a license by the Ministry of Health (Lesotho) to cultivate, manufacture, supply, hold, import, export and transport cannabis. Daddy Cann Lesotho (Pty) Limited was subsequently acquired by Canopy Growth Corporation in May&#160;2018. In 2000, Mr.&#160;Aufrichtig co-founded Indigo Properties, a business focused on commercial and residential property, tourism and leisure. Mr.&#160;Aufrichtig holds a Bachelor of Accounting and a Bachelor of Accounting Honours from the University of Cape Town, South Africa and is registered with the South African Institute of Chartered Accountants. He is well-qualified to serve as a director because of his extensive commercial and corporate experience in a broad variety of areas including finance and mergers and acquisitions and has served as a director and chairman of other publicly traded companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Marc Balkin </span>has served as a director of the Company since January&#160;25, 2024. He served as the Chief Executive Officer and served as a member of the board of directors of NCAC from March&#160;2021 until January&#160;25, 2024. Mr.&#160;Balkin is a founder of Balkin and Co, an advisory firm that has advised private equity firms and family offices on mergers, acquisitions and investments in Africa since 2015. Clients have included HP Bet (part of the family office of Dr.&#160;Hasso Plattner, a founder and current Chairman of SAP), Omidyar Network (part of the family office of Pierre Omidyar, the founder of eBay) and Rand Merchant Bank. Prior to founding Balkin and Co, Mr.&#160;Balkin was the Managing Partner of Hasso Plattner Ventures Africa, a Venture Fund in which Dr.&#160;Plattner was the key limited partner. Mr.&#160;Balkin also held responsibility for managing the Emerging Market portfolio of private equity and venture capital assets of Dr.&#160;Plattner&#8217;s family office. Mr.&#160;Balkin is currently a partner at DiGame, a growth fund focused on Africa and the Middle East in which the key investor is Abu Dhabi Investment Counsel (&#8220;<b style="font-weight:bold;">ADIC</b>&#8221;). Mr.&#160;Balkin represents DiGame on the board of direct-to-consumer asset manager 10X Investments. Since 2004, Mr.&#160;Balkin has served on and chaired a range of venture capital and private equity fund investment committees as the representative of the limited partners or investors. These include Enablis, First National Bank Vumela Fund, Telkom Future Makers and Alithea IDF. Between 2000 and 2007, Mr.&#160;Balkin was the founding partner of O2 Capital, a private equity fund manager for the Msele Nedventures Fund. The LPs in the fund included a range of development finance institutions such as Proparco (France), DEG (Germany) and IDC (South Africa) and the fund invested primarily in technology businesses in South Africa. Mr.&#160;Balkin obtained his BA in 1995 and his LLB in 1997 from University of Witwatersrand in Johannesburg. He is well-qualified to serve as a director because of his experience at board and committee level as well as his legal, finance and financial markets background.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chris Bull</span>&#160;has served as a director of the Company since January&#160;25, 2024 and has served as a strategic advisor of Parent since December&#160;2022. Chris is a qualified chemical engineer, attorney, patent attorney and Certified Licensing Professional&#174;. Over his thirty&#160;year career, Mr.&#160;Bull has been an investor, director, founder and advisor to a range of successful companies in Europe and North America with novel technologies in the fields of pharmaceuticals, biotechnology, food sciences, chemical processing, and extraction technologies. Mr.&#160;Bull has served as a Chairman and director of a venture capital firm (Knife Capital). Mr.&#160;Bull has also been recognized through receipt of a number of international awards, including IAM Strategy 300,&#160;IAM Patent 1000,&#160;IAM Licensing 250; Euromoney Expert Guides: World&#8217;s Leading Patent Attorneys; Chambers and Partners&#8217; Global Guide to the World&#8217;s Leading Lawyers Legal 500 Guide to Outstanding Lawyers, in recognition of his skills in relation to the development and execution of venture capital investment, patent and intellectual property strategies for high-technology companies. He is well-qualified to serve as a director because of his prior Chairman and director experience and his chemical engineering, attorney and patent attorney qualifications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dr.&#160;Seth Feuerstein</span>&#160;has served as a director of the Company since January&#160;25, 2024. Dr.&#160;Feuerstein has expertise across multiple areas of medicine including Suicide Prevention, Technology and Suicide, Telehealth, Social Media and Mental Health, Digital Medicine, Suicide, Digital Health, Digital Therapeutics, Healthcare Innovation, Emerging Medical Technologies, forensic psychiatry, technology transfer, technology investment, intellectual property and the intersection of technology, law and medicine. He is a founding board member of the Center for Biomedical and Interventional Technology at Yale and Executive Director of the Center for Digital Health,&#160;Innovation and Excellence. He has been teaching at the Yale School of Medicine, Department of Psychiatry, since 2004 and is the faculty advisor for Innovation in Healthcare at the medical school. He works across multiple sectors in healthcare including health insurance, healthcare startups, healthcare investing, clinical care delivery innovation and early stage emerging medical technologies. He is the founder and CEO of Oui Therapeutics,&#160;Inc. Since 2019, which is developing a prescription digital therapeutic for suicide attempt reduction. Dr.&#160;Feuerstein has been appointed senior advisor/Highly Qualified Advisor (HQE) for the Department of Defense, advising on behavioral health innovation, since June&#160;2019. From 2014 to August&#160;2018, he was the chief medical and innovation officer at Magellan Healthcare. He has also co-founded and/or held leadership roles in a number of biotechnology and healthcare companies. Dr.&#160;Feuerstein received his Bachelor of Science from Cornell University, a J.D. from New York University School of Law, and an M.D. from New York University School of Medicine. We believe that Dr.&#160;Feuerstein is well-qualified to serve on the Board as result of his prior board experience and extensive experience in the fields of psychiatry and biotechnology.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have structured our corporate governance in a manner we believe will closely align our interests with those of our shareholders. Notable features of this corporate governance include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a majority of independent directors on our Board, and our independent directors will meet regularly in executive sessions without the presence of our corporate officers or non-independent directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have an audit committee that consists of three independent directors, at least one of whom qualifies as an &#8220;audit committee financial expert&#8221; as defined by the SEC; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have implemented a range of other corporate governance practices, including implementing a robust director education program.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Number and Terms of Office of Officers and Directors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our officers are appointed by the board of directors. Our board of directors is authorized to appoint officers as it deems appropriate. Our Board currently consists of 5 members, and pursuant to our Articles of Incorporation, may consist of a maximum of 10 members and a minimum of 3 members.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Independence of our Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Three of our five directors are independent directors and our Board has an independent audit committee. The Board determines which members are &#8220;independent.&#8221; The Board has determined that each of Messrs.&#160;Balkin, Bull and Feuerstein is &#8220;independent&#8221; as such term is defined under the Exchange Act and the rules&#160;of Nasdaq.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Committees of the Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board directs the management of our business and affairs and conducts its business through meetings of the Board and standing committees. The Company has audit, compensation and nominating and governance committees, each of which operates under a written charter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, from time to time, special committees may be established under the direction of the Board when the Board deems it necessary or advisable to address specific issues. Current copies of the Company&#8217;s committee charters will be posted on the Company&#8217;s website, as required by applicable SEC and Nasdaq rules. The information on or available through any of such website is not deemed incorporated in this prospectus and does not form part of this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Audit Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our audit committee (the &#8220;<b style="font-weight:bold;">Audit Committee</b>&#8221;) consists of Marc Balkin, Chris Bull and Dr.&#160;Seth Feuerstein. Mr.&#160;Balkin is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. Mr.&#160;Balkin serves as the chairperson of the Audit Committee. Each member of the Audit Committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the Board will examine each Audit Committee member&#8217;s scope of experience and the nature of their employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted an audit committee charter, which details the principal functions of the Audit Committee, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating the independence and performance of, and assesses the qualifications of, our independent auditor, and engages such independent auditor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving the plan and fees for the annual audit, quarterly reviews, tax and other audit-related services, and approves in advance any non-audit service to be provided by the independent auditor;</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring the independence of the independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing the financial statements to be included in our Annual Report on Form 20-F and Current Reports on Form 6-K and reviews with management and the independent auditors the results of the annual audit and reviews of our quarterly financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing all aspects of our systems of internal accounting control and corporate governance functions on behalf of the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving in advance any proposed related-party transactions and report to the full Board on any approved transactions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">providing oversight assistance in connection with legal, ethical and risk management compliance programs established by management and our Board, including Sarbanes-Oxley Act implementation, and makes recommendations to our Board of directors regarding corporate governance issues and policy decisions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Compensation Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our compensation committee (the &#8220;<b style="font-weight:bold;">Compensation Committee</b>&#8221;) consists of Marc Balkin, Chris Bull and Dr.&#160;Seth Feuerstein. The chair of the compensation committee is Chris Bull.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Compensation Committee is governed by a written charter approved by the Board. The charter of the Compensation Committee permits the Compensation Committee to engage outside consultants and to consult with human resources consultants when appropriate to assist in carrying out its responsibilities. Compensation consultants have not been engaged by the Company to recommend or assist in determining the amount or form of compensation for any current executive officers or directors of the Company. The Compensation Committee may also obtain advice and assistance from internal or external legal, accounting, or other advisers selected by the Compensation Committee. Our Compensation Committee is responsible for overseeing and making recommendations to our board of our directors regarding the salaries and other compensation of our executive officers and general employees and providing assistance and recommendations with respect to our compensation policies and practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nominating and Corporate Governance Committee</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our nominating and corporate governance committee (the &#8220;<b style="font-weight:bold;">Nominating and Corporate Governance Committee</b>&#8221;) consists of Marc Balkin, Chris Bull and Dr. Seth Feuerstein. The chair of the Nominating and Corporate Governance Committee is Marc Balkin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Nominating and Corporate Governance Committee is governed by a written charter approved by the Board. Our Nominating and Corporate Governance Committee is responsible for identifying and proposing new potential director nominees to the Board for consideration and reviewing our corporate governance policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Code of Ethics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have adopted a code of ethics that applies to all of our executive officers, directors and employees in accordance with the rules&#160;of the Nasdaq and the SEC. The code of ethics codifies the business and ethical principles that govern all aspects of our business. You will be able to review these documents by accessing our public filings at the SEC&#8217;s website at www.sec.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Governance Practices and Foreign Private Issuer Status</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company is a foreign private issuer within the meaning of the rules&#160;under the Exchange Act and, as such, the Company is permitted to follow the corporate governance practices of its home country in lieu of the corporate governance standards of Nasdaq applicable to U.S. domestic companies. For example, the Company is not required to file periodic reports and financial statements with the SEC as frequently or within the same time frames as U.S. companies with securities registered under the Exchange Act, although it may elect to file certain periodic reports and financial statements with the SEC on a voluntary basis on the forms used by U.S. domestic issuers. The Company is not required to comply with Regulation&#160;FD, which imposes restrictions on&#160;the selective </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">disclosure of material information to shareholders. In addition, the Company&#8217;s officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions of Section&#160;16 of the Exchange Act and the rules&#160;under the Exchange Act with respect to their purchases and sales of the Company&#8217;s securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, as a &#8220;foreign private issuer&#8221;, the Company is permitted to follow certain home-country corporate governance practices in lieu of certain Nasdaq requirements. A foreign private issuer must disclose in its annual reports filed with the SEC each Nasdaq requirement with which it does not comply followed by a description of its applicable home country practice. The Company currently intends to follow some, but not all, of the corporate governance requirements of Nasdaq. With respect to the corporate governance requirements of the Company that it does follow, the Company cannot give assurances that it will continue to follow such corporate governance requirements in the future, and may therefore in the future, rely on available Nasdaq exemptions that would allow the Company to follow its home country practice. Unlike the requirements of Nasdaq, the Company is not required, under the corporate governance practice and requirements in Ontario, to have its board consist of a majority of independent directors, nor is the Company required to have a compensation committee, a nominating or a corporate governance committee consisting entirely of independent directors, or to have regularly scheduled executive sessions with only independent directors each&#160;year. Such home country practices may afford less protection to holders of Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company intends to rely on this &#8220;foreign private issuer exemption&#8221; with respect to the quorum requirement for shareholder meetings and with respect to Nasdaq shareholder approval rules. Whereas under the corporate governance rules&#160;of Nasdaq, a quorum requires the presence, in person or by proxy, of holders of at least 331&#8725;3% of the total issued and outstanding voting power of our shares at each general meeting, pursuant to our bylaws, the quorum required for a general meeting will consist of at least two shareholders present in person or by proxy who hold or represent at least 25% of the total outstanding voting power of our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Limitation on Liability and Indemnification of Officers and Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;136 of the Business Corporations Act (Ontario) (the &#8220;<b style="font-weight:bold;">OBCA</b>&#8221;) governs the indemnification of directors and officers of a corporation and provides that a corporation may indemnify a director or officer of the corporation, a former director or officer of the corporation or another individual who acts or acted at the corporation&#8217;s request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the corporation or other entity. A corporation shall not indemnify an individual unless the individual acted honestly and in good faith with a view to the best interests of the corporation or, as the case may be, to the best interests of the other entity for which the individual acted as a director or officer or in a similar capacity at the corporation&#8217;s request. If the matter is a criminal or administrative action or proceeding that is enforced by a monetary penalty, a corporation shall not indemnify an individual unless the individual had reasonable grounds for believing that the individual&#8217;s conduct was lawful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into indemnification agreements with each director and officer of the Company in accordance with the provisions of the OBCA cited above, which are incorporated into such agreements. Under the indemnification agreements the termination of any proceedings by any judgment, order, settlement, conviction or the entering of a nolle prosequi does not, by itself, create a presumption that the individual did not act honestly and in good faith and with a view to the best interests of the corporation or that the individual had reasonable cause to believe that his or her conduct was unlawful. To the extent permissible by law, there shall be a presumption that the individual acted honestly and in good faith and with a view to the best interests of the corporation and that the individual had no reasonable cause to believe that his or her conduct was unlawful in the absence of fraud unless a question of law is involved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Non-Employee Director Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In connection with the consummation of the Business Combination, the Board has adopted a non-employee director compensation policy designed to align compensation with the Company&#8217;s business objectives and the creation of shareholder value, while enabling the Company to attract and retain directors to contribute to the Company&#8217;s long-term success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Equity Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company&#8217;s Compensation Committee approved the named executive officers&#8217; compensation at its first meeting. Following the Business Combination, compensation arrangements for the Company&#8217;s executive officers was determined based on the </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">compensation policies, programs and procedures established by the Compensation Committee, which entailed: (i) for directors and executive officers (a) market related base annual salaries or fees, (b) annual cash bonuses based on a target percentage of such base annual salaries or fees based on the achievement of performance metrics approved by the Compensation Committee, (c) a sign-on award in the form of RSUs, which may be converted into Common Shares and which are subject to a trading lock-up period as well as a clawback policy and (d) long-term equity awards in the form of RSUs based on a multiple of such base annual salaries or fees, and (ii) for non-executive directors (y) a fixed monthly fee and (z) long-term equity awards in the form of RSUs based on a multiple of such fixed monthly fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For information regarding share options granted to Psyence&#8217;s directors and executive officers, see the section entitled &#8220;&#8212; Equity Incentive Plans&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into indemnification agreements with each of its officers and directors. Under these agreements, the Company may agree to indemnify its directors against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">The 2023 Equity Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted the Psyence Biomedical&#160;Ltd. 2023 Equity Incentive Plan (as amended by the Board on June&#160;28, 2024), which is referred to herein as the &#8220;Incentive Plan.&#8221; The following is a summary of the material features of the Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Purpose</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the Incentive Plan is to enhance the ability of the Company to attract, retain, and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities that are intended to motivate high levels of performance and align the interests of directors, employees, and consultants with those of the Company&#8217;s shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Eligibility</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Persons eligible to participate in the Incentive Plan are employees, non-employee directors, and consultants of the Company and its subsidiaries as selected from time to time by the plan administrator in its discretion, including prospective employees, non-employee directors and consultants. Any awards granted to such a prospect before the individual&#8217;s start date may not become vested or exercisable, and no shares may be issued to such individual, before the date the individual first commences performance of services with the Company or its subsidiaries. As of the date of this prospectus, approximately 11 individuals are eligible to participate in the Incentive Plan, which includes approximately 2 officers, 4 non-employee directors, and 5 consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Administration</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Incentive Plan will be administered by the Board, the Compensation Committee of the Board, or such other similar committee pursuant to the terms of the Incentive Plan. The plan administrator, which initially will be the Compensation Committee of the Board, will have full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms and conditions of each award, subject to the provisions of the Incentive Plan. The plan administrator may delegate to one or more officers of the Company, the authority to grant awards to individuals who are not subject to the reporting and other provisions of Section&#160;16 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Share Reserve</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of the Common Shares that may be issued under the Incentive Plan is equal to 15% of the aggregate number of the Common Shares issued and outstanding immediately after the Closing (calculated on a fully-diluted basis), or 2,008,599 Common Shares. All of the shares initially available under the Incentive Plan may be issued upon the exercise of equity incentives.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The number of shares available for issuance under the Incentive Plan also will include an automatic annual increase, or the evergreen feature, on the first day of each calendar&#160;year, beginning January&#160;1, 2025 and ceasing as described below, equal to the lesser of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a number of the Common Shares equal to 1% of the aggregate number of the Common Shares issued and outstanding as of December 31 of the immediately preceding calendar year; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such number of the Common Shares as the plan administrator may determine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares issuable under the Incentive Plan may be authorized, but unissued, or reacquired the Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shares underlying any awards under the Incentive Plan that are forfeited, cancelled, held back upon exercise of a share option or settlement of an award to cover the exercise price or tax withholding satisfied without the issuance of the Common Shares or otherwise terminated (other than by exercise) will be added back to the shares available for issuance under the Incentive Plan and, to the extent permitted under</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Section&#160;422 of the Code and the Treasury Regulations promulgated thereunder, the shares that may be issued as incentive stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Types of Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Incentive Plan provides for the grant of share options, share appreciation rights, restricted shares, restricted share units, and other stock-based awards (collectively, &#8220;awards&#8221;). Unless otherwise set forth in an individual award agreement, each award shall vest over a three (3)&#160;year period, with one-third (1/3) of the award vesting on the first annual anniversary of the date of grant and the remaining portion of the award vesting annually thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Share Options. The Incentive Plan permits the granting of both options intended to qualify as incentive stock options under Section&#160;422 of the Code and share options that do not so qualify. Share options granted under the Incentive Plan will be nonqualified options if they fail to qualify as incentive stock options or exceed the annual limit on incentive stock options. Incentive stock options may only be granted to employees of the Company and its subsidiaries. Nonqualified options may be granted to any persons eligible to receive awards under the Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The exercise price of each share option will be determined by the plan administrator, but such exercise price may not be less than 100% of the fair market value of one the Common Share on the date of grant (which shall be the volume weighted average trading price during the thirty (30) preceding&#160;days) or, in the case of an incentive stock option granted to a 10% or greater shareholder, 110% of such share&#8217;s fair market value. The term of each share option will be fixed by the plan administrator and may not exceed ten (10)&#160;years from the date of grant (or five (5)&#160;years for an incentive stock option granted to a 10% or greater shareholder). The plan administrator will determine at what time or times each share option may be exercised, including the ability to accelerate the vesting of such share options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Upon exercise of a share option, the exercise price must be paid in full either in cash, check or, surrender of other the Common Shares which meet the conditions established by the plan administrator to avoid adverse accounting consequences to the Company. Subject to applicable law and approval of the plan administrator, the exercise price may also be made by means of a broker-assisted cashless exercise. In addition, the plan administrator may permit nonqualified options to be exercised using a &#8220;net exercise&#8221; arrangement that reduces the number of shares issued to the optionee by the largest whole number of shares with fair market value that does not exceed the aggregate exercise price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Share Appreciation Rights. The plan administrator may award share appreciation rights subject to such conditions and restrictions as it may determine. Share appreciation rights entitle the recipient to the Common Shares or cash, equal to the value of the appreciation in the Company&#8217;s share price over the exercise price, as set by the plan administrator. The term of each share appreciation right will be fixed by the plan administrator and may not exceed ten&#160;years from the date of grant. The plan administrator will determine at what time or times each share appreciation right may be exercised, including the ability to accelerate the vesting of such share appreciation rights.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted Shares. A restricted share award is an award of the Common Shares that vests in accordance with the terms and conditions established by the plan administrator. The plan administrator will determine the persons to whom grants of restricted share awards are made, the number of restricted shares to be awarded, the price (if any) to be paid for the restricted shares, the time or times within which restricted share awards may be subject to forfeiture, the vesting schedule and rights to acceleration thereof, and all other terms and conditions of restricted share awards. Unless otherwise provided in the applicable award agreement, a participant generally will have the rights and privileges of a shareholder as to such restricted shares, including without limitation the right to vote such restricted shares and the right to receive dividends, if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted Share Units. Restricted share units are the right to receive the Common Shares at a future date in accordance with the terms of such grant upon the attainment of certain conditions specified by the plan administrator. Restrictions or conditions could include, but are not limited to, the attainment of performance goals, continuous service with the Company or its subsidiaries, the passage of time or other restrictions or conditions. The plan administrator determines the persons to whom grants of restricted share units are made, the number of restricted share units to be awarded, the time or times within which awards of restricted share units may be subject to forfeiture, the vesting schedule, and rights to acceleration thereof, and all other terms and conditions of the restricted share unit awards. The value of the restricted share units may be paid in Common Shares, cash, other securities, other property, or a combination of the foregoing, as determined by the plan administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of restricted share units will have no voting rights. Prior to settlement or forfeiture, restricted share units awarded under the Incentive Plan may, at the plan administrator&#8217;s discretion, provide for a right to dividend equivalents. Such right entitles the holder to be credited with an amount equal to all dividends paid on one Common Share while each restricted share unit is outstanding. Dividend equivalents may be converted into additional restricted share units. Settlement of dividend equivalents may be made in the form of cash, Common Shares, other securities, other property, or a combination of the foregoing. Prior to distribution, any dividend equivalents shall be subject to the same conditions and restrictions as the restricted share units to which they are payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other Share-Based Awards. Other share-based awards may be granted either alone, in addition to, or in tandem with, other awards granted under the Incentive Plan and/or cash awards made outside of the Incentive Plan. The plan administrator shall have authority to determine the persons to whom and the time or times at which other share-based awards will be made, the amount of such other share-based awards, and all other conditions, including any dividend and/or voting rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Prohibition on Repricing</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except for an adjustment pursuant to the terms of the Incentive Plan or a repricing approved by shareholders, in no case may the plan administrator (i)&#160;amend an outstanding share option or share appreciation right to reduce the exercise price of the award, (ii)&#160;cancel, exchange, or surrender an outstanding share option or share appreciation right in exchange for cash or other awards for the purpose of repricing the award, or (iii)&#160;cancel, exchange, or surrender an outstanding share option or share appreciation right in exchange for a share option or share appreciation right with an exercise price that is less than the exercise price of the original award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Tax Withholding</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Participants in the Incentive Plan are responsible for the payment of any federal, state, or local taxes that the Company or its subsidiaries are required by law to withhold upon the exercise of share options or share appreciation rights or vesting of other awards. The plan administrator may cause any tax withholding obligation of the Company or its subsidiaries to be satisfied, in whole or in part, by the applicable entity withholding from the Common Shares to be issued pursuant to an award a number of shares with an aggregate fair market value that would satisfy the withholding amount due. The plan administrator may also require any tax withholding obligation of the Company or its subsidiaries to be satisfied, in whole or in part, by an arrangement whereby a certain number of the Common Shares issued pursuant to any award are immediately sold and proceeds from such sale are remitted to the Company or its subsidiaries in an amount that would satisfy the withholding amount due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Equitable Adjustments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of a merger, consolidation, recapitalization, share split, reverse share split, reorganization, split-up, spin-off, combination, repurchase or other change in corporate structure affecting the Common Shares, the maximum number and kind of shares reserved for issuance or with respect to which awards may be granted under the Incentive Plan will be adjusted to reflect such event, and the plan administrator will make such adjustments as it deems appropriate and equitable in the number, kind, and exercise price of the Common Shares covered by outstanding awards made under the Incentive Plan.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Change in Control</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of any proposed change in control (as defined in the Incentive Plan), the plan administrator will take any action as it deems appropriate, which action may include, without limitation, the following: (i)&#160;the continuation of any award, if the Company is the surviving corporation; (ii)&#160;the assumption of any award by the surviving corporation or its parent or subsidiary; (iii)&#160;the substitution by the surviving corporation or its parent or subsidiary of equivalent awards; (iv)&#160;accelerated vesting of the award, with all performance objectives and other vesting criteria deemed achieved at targeted levels, and a limited period during which to exercise the award prior to closing of the change in control, or (v)&#160;settlement of any award for the change in control price (less, to the extent applicable, the per share exercise price). Unless determined otherwise by the plan administrator, in the event that the successor corporation refuses to assume or substitute for the award, a participant shall fully vest in and have the right to exercise the award as to all the Common Shares covered by the award, including those that would not otherwise be vested or exercisable, all applicable restrictions will lapse, and all performance objectives and other vesting criteria will be deemed achieved at targeted levels.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Transferability of Awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless determined otherwise by the plan administrator, an award may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner, except to a participant&#8217;s estate or legal representative, and may be exercised, during the lifetime of the participant, only by the participant. If the plan administrator makes an award transferable, such award will contain such additional terms and conditions as the plan administrator deems appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Term</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Incentive Plan became effective when adopted by the Board, and, unless terminated earlier, the Incentive Plan will continue in effect for a term of ten (10)&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Amendment and Termination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board may amend or terminate the Incentive Plan at any time. Any such termination will not affect outstanding awards. No amendment or termination of the Incentive Plan will materially impair the rights of any participant, unless mutually agreed otherwise between the participant and the Company. Approval of the shareholders shall be required for any amendment, where required by applicable law, as well as (i)&#160;to increase the number of shares available for issuance under the Incentive Plan and (ii)&#160;to change the persons or class of persons eligible to receive awards under the Incentive Plan. We have opted out of Nasdaq requirements to receive shareholder approval in connection with an amendment to the Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Form&#160;S-8</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 30, 2024, the Company filed with the SEC a registration statement on Form&#160;S-8 covering the Common Shares issuable under the Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Material United States Federal Income Tax Considerations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a general summary under current law of the material U.S. federal income tax considerations related to awards and certain transactions under the Incentive Plan, based upon the current provisions of the Code and Treasury Regulations promulgated thereunder. This summary deals with the general U.S. federal income tax principles that apply and is provided only for general information. It does not describe all U.S. federal tax consequences under the Incentive Plan, nor does it describe state, local, or foreign income tax consequences or employment tax consequences. The rules&#160;governing the tax treatment of such awards are quite technical, so the following discussion of tax consequences is necessarily general in nature and is not complete. In addition, statutory provisions are subject to change, as are their interpretations, and their application may vary in individual circumstances. This summary is not intended as tax advice to participants, who should consult their own tax advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Incentive Plan is not qualified under the provisions of Section&#160;401(a)&#160;of the Code and is not subject to any of the provisions of the U.S. Employee Retirement Income Security Act of 1974, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the Company or its subsidiaries to realize the benefit of any tax deductions described below depends on generation of taxable income as well as the requirement of reasonableness and the satisfaction of tax reporting obligations.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Incentive Stock Options. No taxable income is generally realized by the optionee upon the grant or exercise of an incentive stock option. If the Common Shares issued to an optionee pursuant to the exercise of an incentive stock option are sold or transferred after two&#160;years from the date of grant and after one&#160;year from the date of exercise, then generally (i)&#160;upon sale of such shares, any amount realized in excess of the option exercise price (the amount paid for the shares) will be taxed to the optionee as a long- term capital gain, and any loss sustained will be a long-term capital loss, and (ii)&#160;neither the Company nor its subsidiaries will be entitled to any deduction for U.S. federal income tax purposes; provided that such incentive stock option otherwise meets all of the technical requirements of an incentive stock option. The exercise of an incentive stock option will give rise to an item of tax preference that may result in alternative minimum tax liability for the optionee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Common Shares acquired upon the exercise of an incentive stock option are disposed of prior to the expiration of the two-year and one-year holding periods described above (a &#8220;disqualifying disposition&#8221;), generally (i)&#160;the optionee will realize ordinary income in the&#160;year of disposition in an amount equal to the excess (if any) of the fair market value of the Common Shares at exercise (or, if less, the amount realized on a sale of such the Common Shares) over the option exercise price thereof, and (i)&#160;the Company or its subsidiaries will be entitled to deduct such amount. Special rules&#160;will apply where all or a portion of the exercise price of the incentive stock option is paid by tendering the Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If an incentive stock option is exercised at a time when it no longer qualifies for the tax treatment described above, the share option is treated as a nonqualified option. Generally, an incentive stock option will not be eligible for the tax treatment described above if it is exercised more than three&#160;months following termination of employment (or one&#160;year, in the case of termination of employment by reason of disability). In the case of termination of employment by reason of death, the three-month rule&#160;does not apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nonqualified Options. No income is generally realized by the optionee at the time a nonqualified option is granted. Generally, (i)&#160;at exercise, ordinary income is realized by the optionee in an amount equal to the difference between the option exercise price and the fair market value of the Common Shares issued on the date of exercise, and the Company or its subsidiaries receive a tax deduction for the same amount, and (ii)&#160;at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long- term capital gain or loss depending on how long the Common Shares have been held. Special rules&#160;will apply where all or a portion of the exercise price of the nonqualified option is paid by tendering the Common Shares. Upon exercise, the optionee will also be subject to Social Security taxes on the excess of the fair market value of the Common Shares over the exercise price of the share option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Share Appreciation Rights, Restricted Shares, Restricted Share Units, and Other Share-Based Awards. The current U.S. federal income tax consequences of other awards authorized under the Incentive Plan generally follow certain basic patterns: (i)&#160;share appreciation rights are taxed and deductible in substantially the same manner as nonqualified options; (ii)&#160;nontransferable restricted shares subject to a substantial risk of forfeiture result in income recognition equal to the excess of the fair market value of the Common Shares over the price paid, if any, only at the time the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant through a Code Section&#160;83(b)&#160;election); and (iii)&#160;restricted share units, dividend equivalents, and other share or cash based awards are generally subject to tax at the time of payment. the Company or its subsidiaries generally should be entitled to a U.S. federal income tax deduction in an amount equal to the ordinary income recognized by the participant at the time the participant recognizes such income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The participant&#8217;s basis for the determination of gain or loss upon the subsequent disposition of the Common Shares acquired from a share appreciation right, restricted share award, restricted share unit, or other share-based award will be the amount paid for such shares plus any ordinary income recognized when the shares were originally delivered, and the participant&#8217;s capital gain holding period for those shares will begin on the day after they are transferred to the participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parachute Payments. The vesting of any portion of an award that is accelerated due to the occurrence of a change in control (such as a sale event) may cause all or a portion of the payments with respect to such accelerated awards to be treated as &#8220;parachute payments&#8221; as defined in the Code. Any such parachute payments may be non-deductible to either the Company or its subsidiaries, in whole or in part, and may subject the recipient to a non-deductible 20% U.S. federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Section&#160;409A. The foregoing description assumes that Section&#160;409A of the Code does not apply to an award under the Incentive Plan. In general, share options and share appreciation rights are exempt from Section&#160;409A if the exercise price per share is at least equal to the fair market value per share of the underlying share at the time the share option or share appreciation right was granted. </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Restricted share awards are not generally subject to Section&#160;409A. Restricted share units are subject to Section&#160;409A unless they are settled within two and one-half&#160;months after the end of the later of (1)&#160;the end of the Company&#8217;s fiscal&#160;year in which vesting occurs or (2)&#160;the end of the calendar&#160;year in which vesting occurs. If an award is subject to Section&#160;409A and the provisions for the exercise or settlement of that award do not comply with Section&#160;409A, then the participant would be required to recognize ordinary income whenever a portion of the award vested (regardless of whether it had been exercised or settled). This amount would also be subject to a 20% U.S. federal tax and premium interest in addition to the U.S. federal income tax at the participant&#8217;s usual marginal rate for ordinary income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">New Plan Benefits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No awards have been previously granted under the Incentive Plan. The awards that are to be granted to any participant or group of participants are indeterminable at the date of this prospectus because participation and the types of awards that may be granted under the Incentive Plan are subject to the discretion of the plan administrator. Consequently, no new plan benefits table is included in this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_b7403b81_4988_40bd_8fc3_5cf733b28c9f"></a><a id="EXECUTIVEANDDIRECTORCOMPENSATION_302028"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DIRECTOR AND EXECUTIVE COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context otherwise requires, any reference in this section of this prospectus to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or &#8220;Psyence&#8221; refers to Psyence Biomed Corp. and its consolidated subsidiaries prior to the consummation of the Business Combination and to Psyence Biomedical&#160;Ltd. and its consolidated subsidiaries following the Business Combination.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following tables and discussions relate to the compensation paid to or earned by our executive officers and directors who were serving during the financial&#160;year ended March&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Neil Maresky currently serves as chief executive officer of the Company following his resignation as chief executive officer of the Parent. Warwick Corden-Lloyd currently serves as chief financial officer of the Company following his resignation as chief financial officer of the Parent. Jody Aufrichtig currently serves as Director and Executive Chairman of the Parent<i style="font-style:italic;"> </i>and the Company&#8217;s Director and Strategic Business Development Officer. Dr.&#160;Maresky, Mr.&#160;Corden-Lloyd and Mr.&#160;Aufrichtig are referred to collectively in this information statement as our &#8220;named executive officers.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the Business Combination, Psyence was part of the Psyence Group and not an independent company and, as such, the historical compensation shown below was determined by Parent. Following the Business Combination, compensation arrangements for the Company&#8217;s executive officers were determined based on the compensation policies, programs and procedures established by the Compensation Committee, which entailed: (i) for executive directors and officers (a) market related base annual salaries or fees, (b) annual cash bonuses based on a target percentage of such base annual salaries or fees based on the achievement of performance metrics approved by the Compensation Committee, (c) a sign-on award in the form of RSUs, which may be converted into Common Shares and which are subject to a trading lock-up period as well as a clawback policy and (d) long-term equity awards in the form of RSUs based on a multiple of such base annual salaries or fees, and (ii) for non-executive directors (y) a fixed monthly fee and (z) long-term equity awards in the form of RSUs based on a multiple of such fixed monthly fee. The Company&#8217;s Compensation Committee approved the named executive officers&#8217; compensation at its first meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary Compensation Table</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the compensation awarded to, earned by, or paid to our named executive officers for the fiscal&#160;year ended March&#160;31, 2024 and March 31, 2023. The average exchange rate used to convert amounts in this table from Canadian dollars to USD for 2024 are reported based on a rate of 1.3481 and for 2023 are reported based on a rate of 1.3230:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nonequity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incentive plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">All other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Salary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Bonus</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name and principal position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$)(2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$)(3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$)</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Neil Maresky</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.86%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">(Chief Executive Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 231,228</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1)</p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 70,458</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 55,000</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 356,686</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 192,171</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 75,721</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 43,068</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 310,960</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Jody Aufrichtig</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">(Executive Chairman)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 110,302</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1)</p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 31,924</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 42,773</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 184,999</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 85,036</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26,463</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,982</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 124,481</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Warwick Corden Lloyd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">(Chief Financial Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 98,346</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(1)</p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,395</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,588</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 123,329</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 85,036</span></p></td><td style="vertical-align:top;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,980</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,017</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 103,033</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">This includes salary earned from April 1, 2023 to January 25, 2024 as part of Psyence prior to the Business Combination and salary earned from January 26, 2024 to March 31, 2024 from the Company.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The amounts reported in the &#8220;Option awards&#8221; column represent the aggregate grant date fair value of the stock options granted to the named executive officers by Parent during 2023 computed in accordance with IFRS. The option awards value was calculated using the Black-Scholes valuation model. The options vested as follows: 50% on March 31, 2023 and 50% on September 30, 2023. Note that the amounts reported in these columns reflect the accounting cost for these stock options and do not correspond to the actual economic value that may be received by the named executive officers from the stock options.</p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The amounts reported in the &#8220;Stock awards&#8221; column represent the aggregate grant date fair value of the restricted stock units (RSUs) granted to the named executive officers by Parent during 2023 computed in accordance with IFRS. The stock awards value was based on the share price on the date of grant of RSUs. The RSUs vest as follows: 33.33% on March 31, 2024, 33.33% on March 31, 2025 and 33.34% on March 31, 2026. Note that the amounts reported in these columns reflect the accounting cost for these RSUs and do not correspond to the actual economic value that may be received by the named executive officers from the stock RSUs.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Other than as set forth in the foregoing table, the named executive officers and directors have not received compensation pursuant to any standard arrangement for the compensation of directors for their services in their capacity as directors, including any additional amounts payable for committee participation or special assignments, any other arrangement, in addition to, or in lieu of, any standard arrangement, for the compensation of directors in their capacity as directors, or any arrangement for the compensation of directors for services as consultants or experts.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Share Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Outstanding Equity Awards at Fiscal&#160;Year-End</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March 31, 2024, our executive officers have not received any equity awards from the Company, but as described above, have previously received equity awards from Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">Parent 2021 Stock Option Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Parent&#8217;s stock option plan (the &#8220;<b style="font-weight:bold;">Stock Option Plan</b>&#8221;) was adopted on November&#160;9, 2021 and was confirmed by the Parent&#8217;s shareholders on December&#160;9, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The purpose of the Stock Option Plan is to provide Parent with a share-related mechanism to enable Parent to attract, retain and motivate qualified directors, officers, employees and other service providers, to reward directors, officers, employees and other service providers for their contribution toward the long-term goals of Parent, and to enable and encourage such individuals to acquire shares of Parent as long-term investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Stock Option Plan is a &#8220;rolling&#8221; plan that limits the number of stock options that may be granted pursuant to the plan to a number equal to 10% of Parent&#8217;s issued and outstanding common shares, calculated at the date of the stock option grant. Share incentives granted under any share incentive plans of Parent will not have a bearing on the number of shares that may be subject to option under the Stock Option Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Eligible Persons. </b>Only executives (including directors and officers) employees, and consultants of Parent or its subsidiaries are eligible to receive stock options under the Stock Option Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Limitations. </b>The Stock Option Plan contains the following limitations:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the maximum number of shares which may be reserved for issuance to any one person under the Stock Option Plan must not exceed five&#160;percent (5%) of the issued shares (determined at the date the option was granted) in a twelve (12)&#160;month period, unless Parent first obtains any required disinterested shareholder approval of this plan;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the number of shares granted to any one Consultant (as defined in the Stock Option Plan) under the Stock Option Plan together with all other security based compensation arrangements in a twelve (12)&#160;month period must not exceed two&#160;percent (2%) of the issued shares of Parent;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the aggregate number of options granted to an option holder providing services that include investor relations activities under the Stock Option Plan must not exceed two&#160;percent (2%) of the issued shares of Parent in any twelve (12)&#160;month period, calculated at the date the option was granted; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the aggregate number of shares (i)&#160;issued to insiders under the Stock Option Plan within a twelve-month period, and (ii)&#160;issuable to insiders of the Company at any time under the plan, together with all of Parent&#8217;s other security based compensation arrangements, shall not exceed ten&#160;percent (10%) of the total number of shares then outstanding, unless Parent has first obtained disinterested shareholder approval of the plan, pursuant to applicable law or stock exchange rules&#160;(but only if the law or stock exchange rules&#160;require such approval).</p></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Term of the Options. </b>The expiry date of an option must be no later than the tenth anniversary of the grant date. Any shares subject to an option which for any reason is cancelled or terminated without having been exercised shall again be available for grants under the Stock Option Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Exercise Price. </b>The exercise price at which an option holder may purchase a share upon exercising their option shall be determined by the price determined by Parent and shall be set out in the option agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">Additional provisions included in the Stock Option Plan are as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A provision permitting the personal representative of an option holder who has become disabled to exercise the option on or before the date which is the earlier of one year following the termination of employment, engagement or appointment as a director or officer and the applicable expiry date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A provision permitting the personal representative of an option holder who ceased to be employed by Parent by reason of a disability and who dies within six months after their termination to exercise the option on or before the date which is the earlier of one year following the death of such option holder and the applicable expiry date;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A broad ability for Parent to cause stock options to terminate on an accelerated basis without the consent of option holders, in order to facilitate certain transactions that might be beneficial to PGI; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">An ability to grant stock options to investor relations consultants.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Black-out Period. </b>The Stock Option Plan provides that any options expiring during a disclosure &#8220;black-out period&#8221; will benefit from a 10-day extension beyond the end of the black-out period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Transferability. </b>Options are generally non-assignable and non-transferable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;"><b style="font-weight:bold;">Powers of the Board. </b>The Stock Option Plan permits Parent&#8217;s board of directors to appoint a committee (the &#8220;<b style="font-weight:bold;">Committee</b>&#8221;) whose purpose is to administer the plan. The Committee (or the Board if no Committee is in place) may also:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine all questions arising in connection with the administration, interpretation and application of the plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">correct any defect, supply any information or reconcile any inconsistency in the plan in such manner and to such extent as shall be deemed necessary or advisable to carry out the purposes of the plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prescribe, amend, and rescind rules and regulations relating to the administration of the plan;</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 9pt 0pt;">do the following with respect to the granting of options:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine the executives, employees or consultants to whom options shall be granted, based on the eligibility criteria set out in this plan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine the terms of the option to be granted to an option holder including, without limitation, the grant date, expiry dates, exercise price and vesting schedule (which need not be identical with the terms of any other option);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine when options shall be granted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:9pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine the number of shares subject to each option; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accelerate the vesting schedule of any option previously granted, subject to certain limitations.</span></td></tr></table><div style="margin-top:9pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 9pt 0pt;"><i style="font-weight:normal;">Parent Restricted Share Unit Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Parent&#8217;s restricted share unit plan (the &#8220;<b style="font-weight:bold;">RSU Plan</b>&#8221;) was originally adopted on August&#160;13, 2021 and underwent certain amendments on December&#160;9, 2021. Parent&#8217;s board of directors subsequently amended the plan on February&#160;16, 2022, with effect from March&#160;1, 2022. The RSU Plan is designed to provide certain directors, officers, consultants and other key employees (collectively, an &#8220;<b style="font-weight:bold;">Eligible Person</b>&#8221;) of Parent and its related entities with the opportunity to acquire restricted share&#160;units (&#8220;<b style="font-weight:bold;">RSUs</b>&#8221;) of PGI. The acquisition of RSUs allows an Eligible Person to participate in the long-term success of the Company thus promoting the alignment of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 9pt 0pt;">an Eligible Persons. The RSU Plan provides that the aggregate number of shares reserved for issuance pursuant to awards granted, at any time, shall not exceed 7.5% of the issued and outstanding shares in the capital of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Eligible Persons. </b>All employees, officers, directors, management company employees or consultants (as defined in the RSU Plan) of Parent and its related entities are eligible to participate in the RSU Plan (as &#8220;<b style="font-weight:bold;">Participants</b>&#8221;), and the Company reserves the right to restrict eligibility or otherwise limit the number of persons eligible for participation as Participants in the RSU Plan. Eligibility to participate as a Participant in the RSU Plan does not confer upon any person a right to receive an award of RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Subject to certain restrictions, the board of directors or its appointed Committee (as defined in the RSU Plan) can, from time to time, award RSUs to Eligible Persons. RSUs will be credited to an account maintained for each Participant on the books of Parent as of the award date. The number of RSUs to be credited to each Participant&#8217;s account shall be determined at the discretion of the board of directors and pursuant to the terms of the RSU Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Rolling Plan. </b>The aggregate number of shares that may be reserved for issuance under the RSU Plan at any time shall not exceed 7.5% of Parent&#8217;s outstanding shares. This 7.5% limit shall not include the number of shares reserved for issuance under any other incentive plans of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Vesting. </b>The Board or the Committee may, in its sole discretion, determine the time during which RSUs shall vest (except that no RSU, or portion thereof, may vest after the expiry date) and whether there shall be any other conditions or performance criteria to vesting. In the absence of any determination by the Board or the Committee to the contrary, RSUs will vest and be payable as to one third (1/3) of the total number of RSUs granted on each of the first, second and third anniversaries of the date or dates on which an award of RSUs is made to a Participant (computed in each case to the nearest whole RSU), provided that in all cases payment in satisfaction of a RSU shall occur prior to the Outside Payment Date (which, in respect of a RSU, means December&#160;31 of the calendar&#160;year in which the expiry date of the RSUs occurs). Notwithstanding the foregoing, the Committee may, in its sole discretion at any time or in the RSU agreement in respect of any RSUs granted, accelerate, or provide for the acceleration of vesting (in whole or in part) of RSUs previously granted. The award value of any RSU shall be determined as of the applicable vesting date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Transferability. </b>RSUs and all other rights, benefits or interests in the plan are non-transferable and may not be pledged or assigned or encumbered in any way and are not subject to attachment or garnishment, except that if a Participant dies the legal representatives of the Participant will be entitled to receive the amount of any payment otherwise payable to the Participant hereunder in accordance with the provisions of the RSU Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Limitations. </b>Unless Parent has first obtained disinterested shareholder approval of the plan, the RSU Plan limits the total number of shares issuable at any time to insiders of PGI, when combined with all other shares issuable to insiders under any security based compensation arrangement, to 10% of the total number of issued and outstanding equity securities of Parent. Unless Parent has first obtained disinterested shareholder approval of the plan, it further limits the total number of shares issuable to insiders during any one&#160;year period under the plan, when combined with all other shares issuable to insiders under any security based compensation arrangement, to 10% of the total number of issued and outstanding equity securities of Parent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">No RSU may be issued to anyone engaged to perform investor relations activities for Parent. In no event can the issuance of RSUs, when combined with any grant made pursuant to any other security based compensation arrangement, result in: (i)&#160;any one person being granted share-based compensation awards equaling or exceeding 5% of the issued shares, within a 12&#160;month period; and (ii)&#160;any one consultant in a 12&#160;month period being granted share-based compensation equaling or exceeding 2% of the issued shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Resignation, Termination, Engagement, Death or Disability. </b>Upon the voluntary resignation or the termination for cause of a Participant, all of the Participant&#8217;s RSUs which remain vested, but unexercised or unvested in the Participant&#8217;s Account shall be forfeited without any entitlement to such Participant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Generally, if a Participant dies, or their employment or engagement terminates with the Company due to total disability, while employed or retained by the Company, or while an officer or director, the expiry date of any vested or unvested RSUs held by the Participant at the date of death or date of termination due to total disability, which have not yet been subject to an exercise notice and subsequent award payout, shall be amended to the earlier of (i)&#160;one (1)&#160;year after the date of death or date of termination due to total disability, and (ii)&#160;the expiry date of such award, except that in the event the expiration of the award is earlier than one (1)&#160;year after the date of death or date of termination due to total disability, the expiry date shall be up to one (1)&#160;year after the date of death or date of termination due to total disability as determined by the Board.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Change of Control</b>. Subject to any provision to the contrary contained in an RSU agreement or other written agreement (such as an agreement of employment) between the Company and a Participant, if a change of control takes place, all issued and outstanding RSUs shall vest (whether or not then vested) and the vesting date shall be the date which is immediately prior to the time such change of control takes place, or at such earlier time as may be established by the Board or the Committee, in its absolute discretion, prior to the time such change of control takes place.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Credit For Dividends</b>. Within ten (10)&#160;days following the declaration and payment of dividends on PGI&#8217;s common shares, the Board may determine to make a cash payment to a Participant in respect of outstanding RSUs credited to the Participant&#8217;s Account, which shall be calculated in accordance with the RSU Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Terms of RSUs. </b>Subject to an earlier expiry date as may be determined by the Board and set out in the RSU agreement, RSUs will expire either at the earlier of the tenth anniversary of the date of the RSU grant and such earlier expiry date as may be determined by the Board, in its sole discretion, and set out in the applicable RSU Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Adjustments and Reorganizations. </b>In the event of any dividend paid in shares, share subdivision, combination or exchange of shares, merger, consolidation, spin-off, or other distribution of PGI assets to shareholders, or any other change in the capital of PGI affecting shares, the Board, in its sole and absolute discretion, will make, with respect to the number of RSUs outstanding under this Plan, any proportionate adjustments as it considers appropriate to reflect that change.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><i style="font-weight:normal;">2023 Equity Incentive Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">For a description of the material terms of the 2023 Equity Incentive Plan, see &#8220;Management&#160;&#8211; Equity Incentive Plans.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Employment, Consulting and Management Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of the date of this prospectus, the Company had the following employment, consulting and management agreements in place with its named executive officers:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jody Aufrichtig &#8211; Executive Chairman &amp; Chief Development Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company, its wholly-owned subsidiary, Biomed II, Jody Aufrichtig (as principal) and Aquacap Limited (as consultant) entered into a consulting agreement dated January 25, 2024 (the &#8220;<b style="font-weight:bold;">Aufrichtig Agreement</b>&#8221;), pursuant to which Mr. Aufrichtig shall perform the services of the Executive Chairman of the Board and Chief Development Officer. Mr. Aufrichtig&#8217;s base fee is $200,000 per annum. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Mr. Aufrichtig shall be eligible to receive 200,000 restricted share units (&#8220;<b style="font-weight:bold;">RSUs</b>&#8221;) as an initial award, which may be converted into Common Shares. Any Common Shares issued pursuant thereto will be subject to a lock - up period ending January 25, 2025, and a clawback at the option of the Company should Mr. Aufrichtig&#8217;s appointment be terminated by the Company for cause (as defined in his agreement) or should Mr. Aufrichtig resign without good reason (as defined in his agreement). For each completed fiscal year of the Company, Mr. Aufrichtig shall be eligible to receive an annual cash bonus based on a target bonus opportunity of 50% to 100% of Mr. Aufrichtig&#8217;s annual base fee, based on the achievement of performance metrics approved by the Compensation Committee. Mr. Aufrichtig will further be entitled to 304,118 RSUs, which will be granted no earlier than July 25, 2024 and shall vest in tranches. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Mr. Aufrichtig or the Company may terminate the Aufrichtig Agreement at any time upon no less than sixty (60) days&#8217; written notice to the other party. Additionally, the Company may terminate the Aufrichtig Agreement at any time without prior notice, for cause, subject to a ten business day cure period by Mr. Aufrichtig.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company may terminate the Aufrichtig Agreement without cause, or in relation to a change of control at any time and Mr. Aufrichtig may terminate the Aufrichtig Agreement for good reason (as defined in the agreement), and in each such case the Company shall pay Mr. Aufrichtig severance pay (in lieu of notice) equal to 12 months of Mr. Aufrichtig&#8217;s base fee (as at the date of notice of termination) plus an additional amount equal to the aggregate annual bonuses paid to Mr. Aufrichtig over the preceding 12 months (from the date of notice of termination) plus a prorated payment on account of any annual bonus targets already met by Mr. Aufrichtig as of the date of notice of termination for all active services rendered up to that date (calculated at target). Mr. Aufrichtig shall be entitled to exercise any vested stock options until the earlier of 1) the option expiry date or 2) a date which is 12 months from the effective date of termination, and if so required, the Company shall extend the option expiry date accordingly. </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In the event of termination by the Company for cause or by Mr. Aufrichtig without good reason, Mr. Aufrichtig shall not be entitled to any severance pay or any other payments, and none of the unvested equity incentives granted to Mr. Aufrichtig shall vest. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Mr. Aufrichtig shall not be entitled to any minimum termination entitlements required by the <i style="font-style:italic;">Ontario Employment Standards Act, 2000</i> (&#8220;<b style="font-weight:bold;">ESA</b>&#8221;), and no minimum termination entitlements contemplated in the ESA shall apply to the Aufrichtig Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">All equity incentives granted to Mr. Aufrichtig will be subject to accelerated vesting upon a change of control, upon termination by the Company without cause, or death of Mr. Aufrichtig.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Dr. Neil Maresky &#8211; Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company, its wholly-owned subsidiary, Biomed II, and Dr. Neil Maresky entered into an employment agreement dated January 25, 2024 (the &#8220;<b style="font-weight:bold;">Maresky Agreement</b>&#8221;), pursuant to which he shall perform the services of Chief Executive Officer of the Company on a full time basis in consideration for a base salary of $360,000.00 per annum. Dr. Maresky shall be entitled to an initial award of 200,000 RSUs. Any Common Shares issued pursuant thereto will be subject to a lock-up period ending January 25, 2025, and a clawback at the option of the Company should Dr. Maresky&#8217;s appointment be terminated by the Company for cause or should Dr. Maresky resign without good reason. For each completed fiscal year of the Company, Dr. Maresky shall be eligible to receive an annual cash bonus based on a target bonus opportunity of 50% to 100% of Dr. Maresky&#8217;s annual base salary, based on the achievement of performance metrics approved by the Compensation Committee. Dr. Maresky will further be entitled to 547,412 RSUs, which will be granted no earlier than July 25, 2024 and shall vest in tranches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company may terminate the Maresky Agreement without cause, or in relation to a change of control at any time and Dr. Maresky may terminate the Maresky Agreement for good reason (as defined in the agreement), and in each such case the Company shall pay Dr. Maresky severance pay (in lieu of notice) equal to 24 months of Dr. Maresky&#8217;s base salary (as at the date of notice of termination) plus an additional amount equal to the aggregate annual bonuses paid to Dr. Maresky over the preceding 12 months (from the date of notice of termination) plus a prorated payment on account of any annual bonus targets already met by Dr. Maresky as of the date of notice of termination for all active services rendered up to that date (calculated at target). Dr. Maresky shall be entitled to exercise any vested stock options until the earlier of 1) the option expiry date or 2) a date which is 12 months from the effective date of termination, and if so required, the Company shall extend the option expiry date accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of termination by the Company for cause or by Dr. Maresky without good reason, Dr. Maresky shall not be entitled to any severance pay or any other payments, and none of the unvested equity incentives granted to Dr. Maresky shall vest. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All equity incentives granted to Dr. Maresky will be subject to accelerated vesting upon a change of control, upon termination by the Company without cause, or death of Dr. Maresky. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr. Maresky shall be entitled to continuation of benefits (if any) for the minimum period required by the ESA and the greater of: (A) all other minimum requirements of the ESA and (B) the severance pay and other payments set out in the Maresky Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Warwick Corden-Lloyd &#8211; Chief Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company, its wholly-owned subsidiary, Biomed II, Warwick Corden-Lloyd (as principal) and CordenLloyd Consulting (Pty) Ltd (as consultant, and an entity controlled by Mr. Corden-Lloyd) entered into a consulting agreement dated January 25, 2024 (the &#8220;<b style="font-weight:bold;">Corden-Lloyd Agreement</b>&#8221;), pursuant to which Mr. Corden-Lloyd shall perform the services of Chief Financial Officer of the Company in consideration for a base fee of $180,000 per annum. Mr. Corden-Lloyd shall be entitled to 80,000 RSUs as an initial award. Any Common Shares issued pursuant thereto will be subject to a lock - up period ending January 25, 2025, and a clawback at the option of the Company should Mr. Corden-Lloyd&#8217;s appointment be terminated by the Company for cause or should Mr. Corden-Lloyd resign without good reason. For each completed fiscal year of the Company, Mr. Corden-Lloyd shall be eligible to receive an annual cash bonus based on a target bonus opportunity of 30% to 80% of Mr. Corden-Lloyd&#8217;s annual base fee, based on the achievement of performance metrics approved by the Compensation Committee. Mr. Corden-Lloyd will further be entitled to 171,299 RSUs, which will be granted no earlier than July 25, 2024 and shall vest in tranches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company may terminate the Corden-Lloyd Agreement without cause, or in relation to a change of control at any time and Mr. Corden-Lloyd may terminate the Corden-Lloyd Agreement for good reason (as defined in the agreement), and in each such case the Company shall pay Mr. Corden-Lloyd severance pay (in lieu of notice) equal to 12 months of Mr. Corden-Lloyd&#8217;s base fee (as at </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the date of notice of termination) plus an additional amount equal to the aggregate annual bonuses paid to Mr. Corden-Lloyd over the preceding 12 months (from the date of notice of termination) plus a prorated payment on account of any annual bonus targets already met by Mr. Corden-Lloyd as of the date of notice of termination for all active services rendered up to that date (calculated at target). Mr. Corden-Lloyd shall be entitled to exercise any vested stock options until the earlier of 1) the option expiry date or 2) a date which is 12 months from the effective date of termination, and if so required, the Company shall extend the option expiry date accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event of termination by the Company for cause or by Mr. Corden-Lloyd without good reason, Mr. Corden-Lloyd shall not be entitled to any severance pay or any other payments, and none of the unvested equity incentives granted to Mr. Corden-Lloyd shall vest. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Mr. Corden-Lloyd shall not be entitled to any minimum termination entitlements required by the <i style="font-style:italic;">Ontario Employment Standards Act, 2000</i> (&#8220;<b style="font-weight:bold;">ESA</b>&#8221;), and no minimum termination entitlements contemplated in the ESA shall apply to the Corden-Lloyd Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All equity incentives granted to Mr. Corden - Lloyd will be subject to accelerated vesting upon a change of control, upon termination by the Company without cause, or death of Mr. Corden - Lloyd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Christopher Bull, Marc Balkin, Dr Seth Feuerstein&#160;&#8211; Letters of Appointment (Non-Executive Directors)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each of Christopher Bull, Marc Balkin, and Dr Seth Feuerstein have entered into letters of appointment on identical terms in their positions as non-executive directors (&#8220;<b style="font-weight:bold;">NED</b>&#8221;). Each NED&#8217;s appointment under this letter is for an initial term commencing January&#160;25, 2024 until the date of the first annual general meeting of the Company, unless terminated earlier by either party giving to the other one&#160;month&#8217;s prior written notice. Each NED&#8217;s appointment is further subject to the Company&#8217;s articles of association, and re-election to the board by the Company&#8217;s shareholders at the first annual general meeting of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each NED is compensated for their services as a non-executive director in accordance with the compensation, annual bonus and long-term incentive policy adopted by the Board on February&#160;2, 2024, as supplemented by the performance metrics to be approved by the Compensation Committee of the Company in accordance with the Company&#8217;s rules&#160;and policies governing performance and bonus schemes (still to be adopted). Each of Mr.&#160;Balkin and Dr.&#160;Feuerstein earn US$2,500 per&#160;month / US$&#8206;30,000.00 per annum and have been allocated 45,618 RSU&#8217;s as equity / long-term incentive awards, and Mr. Bull earns &#163;6,250 per&#160;month / &#163;75,000 per annum and has been allocated 155,191 RSUs as equity / long-term incentive awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e0278b0f_537c_432c_9b5d_a590e517f964"></a><a id="CERTAINRELATIONSHIPSANDRELATEDPERSONTRAN"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024,&#160;the Company issued an unsecured convertible promissory&#160;note to Parent&#160;(the &#8220;<b style="font-weight:bold;">PGI&#160;Note</b>&#8221;), in the principal amount of $1,610,657, which is equal to the total amount owed to Parent in connection with loans the Parent had previously made to the Company. The PGI&#160;Note&#160;bears no interest, and (i)&#160;$150,000 of the principal balance of the PGI&#160;Note&#160;was payable on the date of the Closing and (ii)&#160;$1,460,657 of the principal balance of the PGI&#160;Note&#160;will be payable on the date that is the one-year anniversary after the Business Combination, or January&#160;25, 2025. On or prior to the maturity date, at the option of PGI, any amounts outstanding under the PGI&#160;Note&#160;may be converted into securities of the Company or securities of its affiliate, at a conversion price and with terms to be mutually agreed; provided however, such conversion price and terms shall not be less favorable to the conversion price and terms agreed by the parties to the NCAC Replacement Note&#160;(as described below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024,&#160;NCAC issued an unsecured convertible promissory&#160;note&#160;to the Sponsor (the &#8220;<b style="font-weight:bold;">NCAC Replacement&#160;Note</b>&#8221;), in the principal amount of $1,615,501, which is equal to the total amount owed to Sponsor under certain existing promissory notes previously issued by NCAC to the Sponsor (the &#8220;<b style="font-weight:bold;">Existing Notes</b>&#8221;). The NCAC Replacement&#160;Note&#160;bears no interest, and (i)&#160;$100,000 of the principal balance of the NCAC Replacement&#160;Note&#160;was payable on the date of the Closing and (ii)&#160;$1,515,501 of the principal balance of the NCAC Replacement&#160;Note&#160;will be payable on the date that is the one-year anniversary after the Business Combination, or January&#160;25, 2025. On or prior to the maturity date, at the option of Sponsor, any amounts outstanding under the NCAC Replacement&#160;Note&#160;may be converted into securities of the Company or securities of its affiliate, at a conversion price and with terms to be mutually agreed; provided however, such conversion price and terms shall not be less favorable to the conversion price and terms agreed by the parties to the PGI Note. Upon receipt by Sponsor of the NCAC Replacement&#160;Note, any and all obligations owing by NCAC under the Existing Notes&#160;was satisfied and discharged in full and the respective Existing Notes&#160;immediately and automatically terminated and will be of no further effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Equity Incentive Plans</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Management &#8201;&#8212;&#8201;Equity Incentive Plans.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Employment Agreements and Indemnification Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See <i style="font-style:italic;">&#8220;Executive Compensation&#8201;&#8212;&#8201; Employment, Consulting and Management Agreements&#8221;</i> and <i style="font-style:italic;">&#8220;Management&#160;&#8211; Limitation on Liability and Indemnification of Officers and Directors.&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Related Party Transaction Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board has adopted a written related party transaction policy, which sets forth the policies and procedures for the review and approval or ratification or related person transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A &#8220;Related Person Transaction&#8221; is a transaction, arrangement or relationship in which the Company or any of its subsidiaries was, is or will be a participant, the amount of which involved exceeds $120,000, and in which any related person had, has or will have a direct or indirect material interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A &#8220;Related Person&#8221; means:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any person who is, or at any time during the applicable period was, one of the Company&#8217;s officers or one of the Company&#8217;s directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any person who is known by the Company to be the beneficial owner of more than five percent (5%) of its voting stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, daughter-in-law, brother-in-law or sister-in-law of a director, officer or a beneficial owner of more than five percent (5%) of its voting stock, and any person (other than a tenant or employee) sharing the household of such director, officer or beneficial owner of more than five percent (5%) of its voting stock; and</span></td></tr></table></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any firm, corporation or other entity in which any of the foregoing persons is a partner or principal or in a similar position or in which such person has a ten percent (10%) or greater beneficial ownership interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has policies and procedures designed to minimize potential conflicts of interest arising from any dealings it may have with its affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time. Specifically, pursuant to its charter, the audit committee will have the responsibility to review related party transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_3c8ee9c3_780d_4e42_9a36_9097c10a8c46"></a><a id="BENEFICIALOWNERSHIPOFSECURITIES_464764"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">BENEFICIAL OWNERSHIP OF SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information regarding the beneficial ownership of Common Shares on the date of this prospectus, based on information obtained from the persons named below, by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person known by Psyence to be the beneficial owner of more than 5% of the outstanding Common Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of Psyence&#8217;s executive officers and directors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all of Psyence&#8217;s executive officers and directors as a group.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated, Psyence believes that all persons named in the tables below have sole voting and investment power with respect to all shares beneficially owned by them. Except as otherwise noted herein, the number and&#160;percentage of Common Shares beneficially owned is determined in accordance with Rule&#160;13d-3&#160;of the Exchange&#160;Act, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rule, beneficial ownership includes any Common Shares as to which the holder has sole or shared voting power or investment power and also any Common Shares which the holder has the right to acquire within 60&#160;days of the date of this prospectus through the exercise of any option, warrant, convertible security or other right. As of the date of this prospectus, there were 16,696,571 Common Shares issued and outstanding.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;of Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of Beneficial Owner(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">5% Holders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Launchpad Entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,567,638</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(2)</p></td><td style="vertical-align:top;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tabula Rasa Limited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 932,791</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">(3)</p></td><td style="vertical-align:top;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Psyence Group Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;">5,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 29.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Directors and Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dr. Neil Maresky</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warwick Corden-Lloyd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Jody Aufrichtig</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marc Balkin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Christopher (Chris) Bull</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dr. Seth Feuerstein</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">All Directors and Executive Officers as a group (six individuals)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Notes:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Unless otherwise noted, the business address of each of those listed in the table above is 121 Richmond Street West, Penthouse Suite&#160;1300, Toronto, Ontario M5H 2K1.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Consists of (i)&#160;192,500 Common Shares and 35,000 private placement warrants exercisable into Common Shares held by Launchpad Capital Opportunities Fund LP (Series&#160;1), (ii)&#160;98,263 Common Shares and 17,866 private placement warrants exercisable into Common Shares held by Launchpad Capital Fund I LP, (iii)&#160;25,487 Common Shares and 4,634 private placement warrants exercisable into Common Shares held by Launchpad Capital Fund I-B LP and (iv)&#160;1,193,888 Common Shares held by Launchpad Ignition Holdings&#160;LLC. Patel and Ryan Gilbert may be deemed the beneficial owners of the securities held by Launchpad Ignition Holdings LLC and to have voting and dispositive control over such securities. Messrs.&#160;Patel and Gilbert disclaim beneficial ownership of any shares other than to the extent each may have a pecuniary interest therein, directly or indirectly. The address of the Launchpad Entities is 15 Dos Posos, Orinda, CA. 94563. Jurgen van de Vyver may be deemed the beneficial owner of the securities held by Launchpad Capital Fund I-B LP, Launchpad Capital Fund I LP and Launchpad Capital Opportunities Fund LP (Series&#160;1) and to have voting and dispositive control over such securities. Mr.&#160;van de Vyver disclaims beneficial ownership of any shares other than to the extent he may have a pecuniary interest therein, directly or indirectly.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Consists of (i)&#160;864,791 Common Shares and (ii)&#160;68,000 private placement warrants exercisable into Common Shares held by Tabula Rasa. The address of Tabula Rasa Limited is PO Box 146, Road Town, Tortola, British Virgin Islands.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the knowledge of the Company, we are not directly or indirectly owned or controlled by any other corporation, by any foreign government or by any other natural or legal person either severally or jointly. As far as is known to the Company, there are no arrangements the operation of which may, at a subsequent date, result in a change in control of the Company.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To the knowledge of the Company, there were no significant changes in the&#160;percentage ownership held by any other major beneficial shareholders during the past three fiscal&#160;years. Major shareholders of the Company do not have different voting rights from other shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Rule 144</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Rule&#160;144, a person who has beneficially owned restricted Common Shares of Psyence for at least six&#160;months would be entitled to sell their securities provided that (i)&#160;such person is not deemed to have been one of Psyence&#8217;s affiliates at the time of, or at any time during the three&#160;months preceding, a sale and (ii)&#160;Psyence is subject to the Exchange&#160;Act periodic reporting requirements for at least three&#160;months before the sale and have filed all required reports under Section&#160;13 or 15(d)&#160;of the Exchange&#160;Act during the 12&#160;months (or such shorter period as we were required to file reports) preceding the sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Persons who have beneficially owned restricted Common Shares or warrants for at least six&#160;months but who are Psyence&#8217;s affiliates at the time of, or at any time during the three&#160;months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month&#160;period only a number of securities that does not exceed the greater of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1% of the total number of Common Shares then outstanding); or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the average weekly reported trading volume of the Common Shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales by Psyence&#8217;s affiliates under Rule&#160;144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the present Psyence shareholders will be able to sell shares either pursuant to the registration statement of which this prospectus is a part or, commencing three&#160;months after Psyence becomes a reporting company, which will be prior to the Closing date, pursuant to Rule&#160;144, although Psyence&#8217;s executive officer and directors and other affiliate will be subject to the limitation described above with respect to sales pursuant to Rule&#160;144. These restrictions do not affect sales pursuant to this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_452c81c9_3f99_4085_98f6_364eefd89068"></a><a id="DESCRIPTIONOFSECURITIES_579886"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DESCRIPTION OF SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following description of the material terms of the securities of the Company includes a summary of specified provisions of the Articles of Incorporation and amended and restated by-laws (&#8220;</i><span style="font-style:italic;font-weight:bold;">bylaws</span><i style="font-style:italic;">&#8221;) of the Company. This description is qualified by reference to the Articles of Incorporation and by-laws, copies of which are attached as exhibits to the registration statement of which this prospectus forms a part and incorporated in this prospectus by reference. In this section, the terms &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; refer to the Company, and all capitalized terms used in this section are as defined in the Articles of Incorporation and bylaws, unless elsewhere defined herein.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the rights of our Common Shares as set forth in our Articles of Incorporation and bylaws and certain related sections of the OBCA. This summary does not purport to be complete and is qualified in its entirety by the full text of the Articles of Incorporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our authorized share capital consists of an unlimited number of Common Shares, each without par value. We currently have 16,696,571 issued and outstanding Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following description of our share capital and provisions of our Articles of Incorporation and bylaws are summaries of material terms and provisions and are qualified by reference to our Articles of Incorporation and bylaws, copies of which have been filed with the SEC as exhibits to the registration statement of which this prospectus is a part. The description of our Common Shares reflects amendments to our Articles of Incorporation and bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The holders of our Common Shares are entitled to one vote for each share held at any meeting of shareholders. The holders of our Common Shares are entitled to receive dividends as and when declared by our Board. In the event of our liquidation, dissolution or winding-up or other distribution of our assets among our shareholders, the holders of our Common Shares are entitled to share pro rata in the distribution of the balance of our assets. There are no preemptive, redemption, purchase or conversion rights attaching to our Common Shares. There are no sinking fund provisions applicable to our Common Shares. Our Common Shares are issued in fully registered form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each Warrant is exercisable to purchase one Common Share. The Warrants will expire on January&#160;25, 2029, at 5:00&#160;p.m., New York City time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Public Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each the Public Warrant shall entitle the registered holder thereof to purchase one whole Common Share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on February&#160;24, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company will not be obligated to deliver any Common Shares pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the Common Shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue Common Shares upon exercise of a warrant unless Common Shares issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Public Warrants and the Common Shares issuable upon exercise of the Public Warrants have been registered on the Form&#160;F-4 filed in connection with the Business Combination. The Company will use its best efforts to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. Notwithstanding the above, if the Common Shares are at the time of any exercise of a warrant not listed on a </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">national securities exchange such that it satisfies the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1)&#160;of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9)&#160;of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a registration statement, but the Company will be required to use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once the warrants become exercisable, we may call the warrants for redemption:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in whole and not in part;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at a price of US$0.01 per warrant;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon not less than 30 days&#8217; prior written notice of redemption (the &#8220;30-day redemption period&#8221;) to each warrant holder; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if, and only if, the reported last sale price of Common Shares equals or exceeds US$18.00 per share for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption to the warrant holders.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If and when the warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise its warrant prior to the scheduled redemption date. However, the price of Common Shares may fall below the US$18.00 redemption trigger price as well as the US$11.50 warrant exercise price after the redemption notice is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we call the warrants for redemption as described above, our management will have the option to require any holder that wishes to exercise its warrant to do so on a &#8220;cashless basis.&#8221; This redemption feature may differ from the warrant redemption features used by other blank check companies. In determining whether to require all holders to exercise their warrants on a &#8220;cashless basis,&#8221; our management will consider, among other factors, our cash position, the number of warrants that are outstanding and the dilutive effect on our shareholders of issuing the maximum number of Common Shares issuable upon the exercise of our warrants. If our management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of Common Shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Common Shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market value&#8221; (defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported last sale price of the Common Shares for the 10 trading&#160;days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. As an example, if we elect to call the warrants for redemption on a &#8220;cashless basis&#8221; in accordance with the redemption criteria described above and the &#8220;fair market value&#8221; is determined to be US$18.00 per share, then a holder of warrants for the purchase of 100 shares of our Common Shares would receive 36 shares of our Common Shares upon such exercise. The &#8220;fair market value&#8221; for these purposes may be higher or lower than the US$18.00 redemption trigger price and will only be determinable when we elect to send a notice of redemption to holders of the warrants. If a holder does not exercise his or her warrants within the redemption period, then he or she will be forced to accept the nominal redemption price of US$0.01 per warrant which, at the time the outstanding warrants are called for redemption, is likely to be substantially less than the market value of such warrants. If we call our warrants for redemption and our Private Warrants and their permitted transferees would still be entitled to exercise their Private Warrants for cash or on a cashless basis using the same formula described above that other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis, as described in more detail below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder may specify) of the Common Shares outstanding immediately after giving effect to such exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If the number of outstanding Common Shares is increased by a share dividend payable in Common Shares, or by a split-up of Common Shares or other similar event, then, on the effective date of such share dividend, sub-division or similar event, the number of Common Shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding Common </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Shares. A rights offering to holders of Common Shares entitling holders to purchase Common Shares at a price less than the fair market value will be deemed a share dividend of a number of Common Shares equal to the product of (i)&#160;the number of Common Shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Common Shares) multiplied by (ii)&#160;one (1)&#160;minus the quotient of (x)&#160;the price per share of Common Shares paid in such rights offering divided by (y)&#160;the fair market value. For these purposes (i)&#160;if the rights offering is for securities convertible into or exercisable for Common Shares, in determining the price payable for Common Shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;fair market value means the volume weighted average price of Common Shares as reported during the ten (10)&#160;trading day period ending on the trading day prior to the first date on which the Common Shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if the Company, at any time while the warrants are outstanding and unexpired, pays a dividend or make a distribution in cash, securities or other assets to the holders of Common Shares on account of such Common Shares (or other shares of the Company&#8217;s capital stock into which the warrants are convertible), other than (a)&#160;as described above, (b)&#160;certain ordinary cash dividends, or (c)&#160;to satisfy the redemption rights of the holders of Common Shares in connection with a proposed initial business combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Common Shares in respect of such event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the number of outstanding Common Shares is decreased by a consolidation, combination, reverse stock split or reclassification of Common Shares or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of Common Shares issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Whenever the number of Common Shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of Common Shares purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of Common Shares so purchasable immediately thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In case of any reclassification or reorganization of the outstanding Common Shares (other than those described above or that solely affects the par value of such Common Shares), or in the case of any merger or consolidation of the Company with or into another corporation (other than a consolidation or merger in which the Company is the continuing corporation and that does not result in any reclassification or reorganization of outstanding Common Shares), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of the Company as an entirety or substantially as an entirety in connection with which the Company is dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the shares of its Common Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Common Shares in such a transaction is payable in the form of Common Shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty&#160;days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of the warrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The warrants will be issued in registered form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company, as warrant agent, and the Company. You should review a copy of the warrant agreement, which is filed as an exhibit to the registration statement of which this prospectus is a part, for a complete description of the terms and conditions applicable to the warrants. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 50% of the then outstanding Public Warrants to make any change that adversely affects the interests of the registered holders of Public Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of Common Shares and any voting rights until they exercise their warrants and receive Common Shares. After the issuance of Common Shares upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round down to the nearest whole number of Common Shares to be issued to the warrant holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Private Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Private Warrants were assumed by the Company upon the consummation of the Business Combination, and after the Business Combination, each warrant is exercisable for Common Shares. The Private Warrants may be exercised on a cashless basis and will not be redeemable by the Company so long as they are held by the initial holders thereof or their permitted transferees. Otherwise, the Private Warrants have terms and provisions that are identical to those of the Public Warrants. If the Private Warrants are held by holders other than the initial holders thereof or their permitted transferees, the Private Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. If holders of the Private Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants for that number of Common Shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Common Shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market value&#8221; (defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported last sale price of the Common Shares for the 10 trading&#160;days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_11b94e5c_589a_42aa_8ca0_303ec9027c36"></a><a id="CERTAINMATERIALUSFEDERALINCOMETAXCONSIDE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CERTAIN MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a discussion of certain material United States federal income tax considerations relating to the acquisition, ownership, and disposition of our Common Shares by a U.S. Holder, as defined below, that acquires our Common Shares in this offering and holds our Common Shares as &#8220;capital assets&#8221; (generally, property held for investment) under the Code. This discussion is based on existing United States federal income tax law, which is subject to differing interpretations or change, possibly with retroactive effect. No ruling has been sought from the Internal Revenue Service (the &#8220;IRS&#8221;) with respect to any United States federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position. This discussion does not address all aspects of United States federal income taxation that may be important to particular investors in light of their individual circumstances, including investors subject to special tax rules&#160;(such as, for example, certain financial institutions, insurance companies, regulated investment companies, real estate investment trusts, broker-dealers, traders in securities that elect mark-to-market treatment, partnerships (or other entities treated as partnerships for United States federal income tax purposes) and their partners, tax-exempt organizations (including private foundations)), investors who are not U.S. Holders, investors that own (directly, indirectly, or constructively) 5% or more of our voting shares, investors that hold their Common Shares as part of a straddle, hedge, conversion, constructive sale or other integrated transaction), investors that are subject to the applicable financial statement accounting rules&#160;under Section&#160;451 of the Code, or investors that have a functional currency other than the U.S. dollar, all of whom may be subject to tax rules&#160;that differ significantly from those summarized below. In addition, this discussion does not address any tax laws other than the United States federal income tax laws, including any state, local, alternative minimum tax or non-United States tax considerations, or the Medicare tax on unearned income. Each potential investor is urged to consult its tax advisor regarding the United States federal, state, local and non-United States income and other tax considerations of an investment in our Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is a beneficial owner of our Common Shares that is, for United States federal income tax purposes, (i)&#160;an individual who is a citizen or resident of the United States, (ii)&#160;a corporation (or other entity treated as a corporation for United States federal income tax purposes) created in, or organized under the laws of, the United States or any state thereof or the District of Columbia, (iii)&#160;an estate the income of which is includible in gross income for United States federal income tax purposes regardless of its source, or (iv)&#160;a trust (A)&#160;the administration of which is subject to the primary supervision of a United States court and which has one or more United States persons who have the authority to control all substantial decisions of the trust or (B)&#160;that has otherwise elected to be treated as a United States person under the Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a partnership (or other entity treated as a partnership for United States federal income tax purposes) is a beneficial owner of our Common Shares, the tax treatment of a partner in the partnership will depend upon the status of the partner and the activities of the partnership. Partnerships and partners of a partnership holding our Common Shares are urged to consult their tax advisors regarding an investment in our Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The discussion set forth below is addressed only to U.S. Holders that purchase Common Shares in this offering. Prospective purchasers are urged to consult their own tax advisors about the application of U.S. federal income tax law to their particular circumstances as well as the state, local, foreign and other tax consequences to them of the purchase, ownership and disposition of our Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Taxation of Dividends and Other Distributions on our Common Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the passive foreign investment company rules&#160;discussed below, distributions of cash or other property made by us to you with respect to the Common Shares (including the amount of any taxes withheld therefrom) will generally be includable in your gross income as dividend income on the date of receipt by you, but only to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). With respect to corporate U.S. Holders, the dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">With respect to non-corporate U.S. Holders, including individual U.S. Holders, dividends will be taxed at the lower capital gains rate applicable to qualified dividend income, provided that (1)&#160;the Common Shares are readily tradable on an established securities market in the United States, or we are eligible for the benefits of an approved qualifying income tax treaty with the United States that includes an exchange of information program, (2)&#160;we are not a passive foreign investment company (as discussed below) for either our taxable&#160;year in which the dividend is paid or the preceding taxable&#160;year, and (3)&#160;certain holding period requirements are met. You are </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">urged to consult your tax advisors regarding the availability of the lower rate for dividends paid with respect to our Common Shares, including the effects of any change in law after the date of this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">To the extent that the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), it will be treated first as a tax-free return of your tax basis in your Common Shares, and to the extent the amount of the distribution exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that a distribution will be treated as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules&#160;described above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Taxation of Dispositions of Common Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Subject to the passive foreign investment company rules&#160;discussed below, you will recognize taxable gain or loss on any sale, exchange or other taxable disposition of a share equal to the difference between the amount realized (in U.S. dollars) for the share and your tax basis (in U.S. dollars) in the Common Shares. The gain or loss will be capital gain or loss. If you are a non-corporate U.S. Holder, including an individual U.S. Holder, who has held the Common Shares for more than one&#160;year, you may be eligible for reduced tax rates on any such capital gains. The deductibility of capital losses is subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Passive Foreign Investment Company</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A non-U.S. corporation is considered a PFIC for any taxable&#160;year if either:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least 75% of its gross income for such taxable year is passive income; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income (the &#8220;asset test&#8221;).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, at least 25% (by value) of the shares. In determining the value and composition of our assets for purposes of the PFIC asset test, the value of our assets must be determined based on the market value of our Common Shares from time to time, which could cause the value of our non-passive assets to be less than 50% of the value of all of our assets on any particular quarterly testing date for purposes of the asset test.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We must make a separate determination each&#160;year as to whether we are a PFIC. Depending on the amount of our cash and other assets held for the production of passive income, it is possible that, for our current taxable&#160;year or for any subsequent taxable&#160;year, more than 50% of our assets may be assets held for the production of passive income. We will make this determination following the end of any particular tax&#160;year. Although the law in this regard is unclear, we treat our consolidated affiliated entities as being owned by us for United States federal income tax purposes, not only because we exercise effective control over the operation of such entities but also because we are entitled to substantially all of their economic benefits, and, as a result, we consolidate their operating results in our consolidated financial statements. In particular, because the value of our assets for purposes of the asset test will generally be determined based on the market price of our Common Shares and because cash is generally considered to be an asset held for the production of passive income, our PFIC status will depend in large part on the market price of our Common Shares and the amount of our cash and other assets held for the production of passive income. Accordingly, fluctuations in the market price of the Common Shares may cause us to become a PFIC. In addition, the application of the PFIC rules&#160;is subject to uncertainty in several respects. We are under no obligation to take steps to reduce the risk of our being classified as a PFIC. As stated above, the determination of the value of our assets will depend upon material facts (including the market price of our Common Shares from time to time) that may not be within our control, and no opinion of counsel has or will be provided regarding our classification as a PFIC. If we are a PFIC for any&#160;year during which you hold Common Shares, we will continue to be treated as a PFIC for all succeeding&#160;years during which you hold Common Shares. However, if we cease to be a PFIC and you did not previously make a timely &#8220;mark-to-market&#8221; election as described below, you may avoid some of the adverse effects of the PFIC regime by making a &#8220;purging election&#8221; (as described below) with respect to the Common Shares.</p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are a PFIC for your taxable&#160;year(s)&#160;during which you hold Common Shares, you will be subject to special tax rules&#160;with respect to any &#8220;excess distribution&#8221; that you receive and any gain you realize from a sale or other disposition (including a pledge) of the Common Shares, unless you make a &#8220;mark-to-market&#8221; election as discussed below. Distributions you receive in a taxable&#160;year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable&#160;years or your holding period for the Common Shares will be treated as an excess distribution. Under these special tax rules:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the excess distribution or gain will be allocated ratably over your holding period for the Common Shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount allocated to your current taxable year, and any amount allocated to any of your taxable year(s) prior to the first taxable year in which we were a PFIC, will be treated as ordinary income, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amount allocated to each of your other taxable year(s) will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The tax liability for amounts allocated to&#160;years prior to the&#160;year of disposition or &#8220;excess distribution&#8221; cannot be offset by any net operating losses for such&#160;years, and gains (but not losses) realized on the sale of the Common Shares cannot be treated as capital, even if you hold the Common Shares as capital assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A U.S. Holder of &#8220;marketable stock&#8221; (as defined below) in a PFIC may make a mark-to-market election for such stock to elect out of the tax treatment discussed above. If you make a mark-to-market election for the first taxable&#160;year during which you hold (or are deemed to hold) Common Shares and for which we are determined to be a PFIC, you will include in your income each&#160;year an amount equal to the excess, if any, of the fair market value of the Common Shares as of the close of such taxable&#160;year over your adjusted basis in such Common Shares, which excess will be treated as ordinary income and not capital gain. You are allowed an ordinary loss for the excess, if any, of the adjusted basis of the Common Shares over their fair market value as of the close of the taxable&#160;year. However, such ordinary loss is allowable only to the extent of any net mark-to-market gains on the Common Shares included in your income for prior taxable&#160;years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of the Common Shares, are treated as ordinary income. Ordinary loss treatment also applies to any loss realized on the actual sale or disposition of the Common Shares, to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such Common Shares. Your basis in the Common Shares will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market election, the tax rules&#160;that apply to distributions by corporations which are not PFICs would apply to distributions by us, except that the lower applicable capital gains rate for qualified dividend income discussed above under &#8220;&#8212; Taxation of Dividends and Other Distributions on our Common Shares&#8221; generally would not apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The mark-to-market election is available only for &#8220;marketable stock&#8221;, which is stock that is traded in other than de minimis quantities on at least 15&#160;days during each calendar quarter (&#8220;regularly traded&#8221;) on a qualified exchange or other market (as defined in applicable U.S. Treasury regulations), including Nasdaq. U.S. holders should consult their own tax advisors regarding the availability and tax consequences of a mark-to-market election in respect to our Common Shares under their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alternatively, a U.S. Holder of stock in a PFIC may make a &#8220;qualified electing fund&#8221; election with respect to such PFIC to elect out of the tax treatment discussed above. A U.S. Holder who makes a valid qualified electing fund election with respect to a PFIC will generally include in gross income for a taxable&#160;year such holder&#8217;s pro rata share of the corporation&#8217;s earnings and profits for the taxable&#160;year. However, the qualified electing fund election is available only if such PFIC provides such U.S. Holder with certain information regarding its earnings and profits as required under applicable U.S. Treasury regulations. We do not currently intend to prepare or provide the information that would enable you to make a qualified electing fund election. If you hold Common Shares in any taxable&#160;year in which we are a PFIC, you will be required to file IRS Form&#160;8621 in each such&#160;year and provide certain annual information regarding such Common Shares, including regarding distributions received on the Common Shares and any gain realized on the disposition of the Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">If you do not make a timely &#8220;mark-to-market&#8221; election (as described above), and if we were a PFIC at any time during the period you hold our Common Shares, then such Common Shares will continue to be treated as stock of a PFIC with respect to you even if we cease to be a PFIC in a future&#160;year, unless you make a &#8220;purging election&#8221; for the&#160;year we cease to be a PFIC. A &#8220;purging election&#8221; creates a deemed sale of such Common Shares at their fair market value on the last day of the last&#160;year in which we are treated as a PFIC. The gain recognized by the purging election will be subject to the special tax and interest charge rules&#160;treating the gain as an excess distribution, as described above. As a result of the purging election, you will have a new basis (equal to the fair market value of </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the Common Shares on the last day of the last&#160;year in which we are treated as a PFIC) and holding period (which new holding period will begin the day after such last day) in your Common Shares for tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You are urged to consult your tax advisors regarding the application of the PFIC rules&#160;to your investment in our Common Shares and the elections discussed above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;">Information Reporting and Backup Withholding</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividend payments with respect to our Common Shares and proceeds from the sale, exchange or redemption of our Common Shares may be subject to information reporting to the IRS and possible U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes any other required certification on IRS Form&#160;W-9 or who is otherwise exempt from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification on IRS Form&#160;W-9. U.S. Holders are urged to consult their tax advisors regarding the application of the U.S. information reporting and backup withholding rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules&#160;by filing the appropriate claim for refund with the IRS and furnishing any required information. We do not intend to withhold taxes for individual shareholders. However, transactions effected through certain brokers or other intermediaries may be subject to withholding taxes (including backup withholding), and such brokers or intermediaries may be required by law to withhold such taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Hiring Incentives to Restore Employment Act of 2010, certain U.S. Holders are required to report information relating to our Common Shares, subject to certain exceptions (including an exception for Common Shares held in accounts maintained by certain financial institutions), by attaching a complete IRS Form&#160;8938, Statement of Specified Foreign Financial Assets, with their tax return for each&#160;year in which they hold Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dc7c5568_8467_41db_998b_6fa2dc573537"></a><a id="MATERIALCANADIANTAXCONSIDERATIONS_127128"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">MATERIAL CANADIAN TAX CONSIDERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following summary describes the principal Canadian federal income tax considerations under the <i style="font-style:italic;">Income Tax Act </i>(Canada) and the regulations thereunder (collectively, the &#8220;<b style="font-weight:bold;">Tax Act</b>&#8221;), as of the date hereof, that are generally applicable to an investor who acquires, as beneficial owner, Common Shares from a Selling Shareholder pursuant to this statement and who, at all relevant times, for the purposes of the Tax Act and any applicable tax treaty or convention: (i)&#160;is not, and is not deemed to be, resident in Canada; (ii)&#160;deals at arm&#8217;s length with each of the Company and the Selling Shareholder&#894; (iii)&#160;is not affiliated with either of the Company or the Selling Shareholder&#894; (iv)&#160;has not entered into, with respect to the Common Shares, a &#8220;derivative forward agreement&#8221; or &#8220;dividend rental arrangement&#8221; each as defined in the Tax Act; (v)&#160;does not have a &#8220;permanent establishment&#8221; or &#8220;fixed base&#8221; in Canada; and (vi)&#160;does not use or hold, and is not deemed to use or hold, the Common Shares in connection with, or in the course of carrying on, a business in Canada (each a &#8220;<b style="font-weight:bold;">Non-Canadian Holder</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Special rules, which are not discussed in this summary, may apply to a Non-Canadian Holder that is an insurer carrying on business in Canada and elsewhere. Such Non-Canadian Holders should consult their own tax advisors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary does not address any income tax considerations relevant to the acquisition, holding, disposition or conversion of First Tranche Notes&#160;into Common Shares or the payment of any amount of principal or interest on First Tranche Notes. This summary also does not address any income tax considerations that may arise as a result of a Non-Canadian Holder being an employee of the Company or its affiliates. All such persons should consult their own tax advisors with respect to the Canadian federal income tax consequences to them, which may differ materially from the discussion provided in this summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This summary is based upon the current provisions of the Tax Act and the <i style="font-style:italic;">Canada-United States Tax Convention </i>(1980) in force as of the date hereof and an understanding of the current administrative policies and assessing practices published in writing by the Canada Revenue Agency (&#8220;<b style="font-weight:bold;">CRA</b>&#8221;) prior to the date hereof. This summary also takes into account all specific proposals to amend the Tax Act and the <i style="font-style:italic;">Canada-United States Tax Convention </i>(1980) publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the &#8220;<b style="font-weight:bold;">Proposed Amendments</b>&#8221;) and assumes that all Proposed Amendments will be enacted in the form proposed. However, no assurances can be given that the Proposed Amendments will be enacted as proposed, or at all. Except for the Proposed Amendments, this summary does not take into account or anticipate any changes in law or administrative policies, whether by legislative, regulatory, administrative or judicial action or decision, nor does it take into account other federal or any provincial, territorial or foreign tax legislation or considerations, which may be different from those discussed in this summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice to any particular Non-Canadian Holder. Accordingly, Non-Canadian Holders should consult their own tax advisors with respect to their particular circumstances.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Currency</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, for purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of Common Shares must be expressed in Canadian dollars. Amounts denominated in another currency must be converted into Canadian dollars using the exchange rate quoted by the Bank of Canada on the date such amounts first arose, or such other rate of exchange as is acceptable to the CRA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Adjusted cost base of Common Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The adjusted cost base of a Common Share to a Non-Canadian Holder will generally include all amounts paid by the Non-Canadian Holder for the Common Share. When Common Shares are acquired by a Non-Canadian Holder who already owns Common Shares, the cost of newly acquired Common Shares will generally be averaged with the adjusted cost base of all Common Shares held by the Non-Canadian Holder as capital property immediately prior to the acquisition for the purpose of determining the Non-Canadian Holder&#8217;s adjusted cost base of each Common Share held by such Non-Canadian Holder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Dividends paid or credited, or deemed to be paid or credited, on Common Shares to a Non-Canadian Holder generally will be subject to Canadian withholding tax. Under the Tax Act, the rate of withholding tax is 25% of the gross amount of such dividends, which rate may be subject to reduction under the provisions of an applicable income tax treaty. For example, a Non-Canadian Holder who is resident in the United States for the purposes of the <i style="font-style:italic;">Canada-United States Tax Convention </i>(1980), fully entitled to the benefits </p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of such convention and the beneficial owner of the dividends, will generally be subject to Canadian withholding tax at a rate of 15% of the amount of such dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Disposition of Common Shares</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A Non-Canadian Holder who disposes or is deemed to dispose of a Common Share in a taxation&#160;year will not be subject to tax in Canada, unless the Common Share is, or is deemed to be, &#8220;taxable Canadian property&#8221; to the Non-Canadian Holder at the time of disposition and the Non-Canadian Holder is not entitled to relief under an applicable income tax treaty between Canada and the country in which the Non-Canadian Holder is resident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provided the Common Shares are listed on a &#8220;designated stock exchange&#8221;, as defined in the Tax Act (which currently includes the Nasdaq), at the time of disposition, the Common Shares generally will not constitute taxable Canadian property of a Non-Canadian Holder at that time, unless at any time during the 60-month period immediately preceding the disposition the following two conditions are met concurrently: (i)&#160;one or any combination of (a)&#160;the Non-Canadian Holder, (b)&#160;persons with whom the Non-Canadian Holder did not deal at arm&#8217;s length, and (c)&#160;partnerships in which the Non-Canadian Holder or a person described in (b)&#160;holds a membership interest directly or indirectly through one or more partnerships owned 25% or more of the issued shares of any class or series of shares of the Company&#894; and (ii)&#160;more than 50% of the fair market value of the Common Shares was derived directly or indirectly from one or any combination of (a)&#160;real or immovable property situated in Canada, (b)&#160;&#8220;Canadian resource property&#8221;(as defined in the Tax Act), (c)&#160;&#8220;timber resource property&#8221;(as defined in the Tax Act), or (d)&#160;an option in respect of, an interest in, or for civil law rights in, property described in any of (a)&#160;through (c), whether or not such property exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-Resident Holders who dispose of Common Shares that are taxable Canadian property should consult their own tax advisors with respect to the requirement to file a Canadian income tax return in respect of the disposition in their particular circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e0065d6e_95af_4942_bcb5_51c7bb55e19e"></a><a id="EXPENSESRELATINGTOTHISOFFERING_33177"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXPENSES RELATING TO THIS OFFERING</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Set forth below is an itemization of the total expenses, excluding underwriting discounts and commissions, that we expect to incur in connection with this offering. With the exception of the SEC registration fee, all amounts are estimates.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">SEC registration fee</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,807.09</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Legal fees and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounting fees and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Printing fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">20,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Miscellaneous expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">48,807.09</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_fedfbd24_9d69_4444_ba1e_46ea7a6bc87c"></a><a id="LEGALMATTERS_548671"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">LEGAL MATTERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The validity of the Common Shares offered by this prospectus and certain other Canadian legal matters will be passed upon by WeirFoulds LLP.</p><a id="_bdca33fa_8832_4ba4_9cfb_d95d63d6dd54"></a><a id="EXPERTS_102440"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXPERTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carve-out consolidated financial statements of Psyence Biomed Corp. as of March&#160;31, 2024 and 2023 and for each of the&#160;years in the two-year period ended March&#160;31, 2023 included in this prospectus have been audited by MNP LLP, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</p><a id="_b814eb6a_dc1c_4523_b950_cde924b2bca9"></a><a id="WHEREYOUCANFINDADDITIONALINFORMATION_564"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">WHERE YOU CAN FIND ADDITIONAL INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence has filed with the SEC a registration statement on Form&#160;F-1&#160;under the Securities Act with respect to the securities being sold by the Selling Securityholders. This prospectus does not contain all of the information included in the registration statement. For further information about us and our securities, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are materially complete but may not include a description of all aspects of such contracts, agreements or other documents, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also file periodic reports and other information with the SEC. These reports and other information will be available at the website of the SEC <i style="font-style:italic;">at www.sec.gov</i>. We also maintain a website at <i style="font-style:italic;">www.psyencebiomed.com</i>, by which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information that is contained on, or that may be accessed through, our website is not a part of this prospectus. We have included our website in this prospectus solely as an inactive textual reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_29cc75a2_bcb2_4d23_abfc_73ba4b1c3d1e"></a><a id="INDEXTOFINANCIALSTATEMENTS_783580"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">INDEX TO FINANCIAL STATEMENTS</b>&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements for Psyence Biomedical Ltd. as of and for the Years ended March 31, 2024 and 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:90.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:90.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:3.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page </b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:90.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#FinancialReporting_728338"><span style="font-style:normal;font-weight:normal;">Independent Auditor&#8217;s Report</span></a><span style="color:#242424;"> (PCAOB ID: 1930)</span></p></td><td style="vertical-align:bottom;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:90.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#FinancialPosition_396068"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Financial Position as at March 31, 2024 and March 31, 2023</span></a></p></td><td style="vertical-align:bottom;width:3.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:90.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ComprehensiveLoss_394370"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Loss and Comprehensive Loss for the fiscal years ended March 31, 2024 and March 31, 2023</span></a></p></td><td style="vertical-align:bottom;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:90.37%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ShareholderEquity_89940"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Shareholder Equity (Deficit) for the fiscal years ended March 31, 2024 and March 31, 2023</span></a></p></td><td style="vertical-align:bottom;width:3.13%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:90.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#CashFlows_785885"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the fiscal years ended March 31, 2024 and March 31, 2023</span></a></p></td><td style="vertical-align:bottom;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:90.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#FinancialStatements_920054"><span style="font-style:normal;font-weight:normal;">Notes to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt;">8</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:112.5pt;"><a id="_5b6dcc01_bfe2_4ecf_9b8e_0a0b021b726d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="pbm-20240331xf1024.jpg" alt="Graphic" style="display:inline-block;height:111.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:341.25pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Psyence Biomedical&#160;Ltd.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Formerly the carve-out of Psyence Biomed Corp.)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended March&#160;31, 2024 and 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">Expressed in United States Dollars</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(USD $)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><a id="_857613c2_21dd_4e83_9470_b27eb6ebadc8"></a><a id="_4796a845_5520_4e3f_81b5_81727b64ecc6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2c8edd7a_9f4b_4a1c_9b66_8ba54bee66a8"></a><a id="FinancialReporting_728338"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Management&#8217;s Responsibility for Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements of the Company have been prepared by management in accordance with International Financial Reporting Standards. These financial statements contain estimates based on management&#8217;s judgment. Management maintains an appropriate system of internal controls to provide reasonable assurance that transactions are authorized, assets safeguarded, and proper records maintained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Audit Committee of the Board of Directors reviews the results of the annual audit and the consolidated financial statements prior to submitting the consolidated financial statements to the Board for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s auditors, MNP LLP, are appointed by the audit committee to conduct an audit and their report follows.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.9%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#8220;Dr.&#160;Neil Maresky&#8221;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">/s/ Dr. Neil Maresky</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Toronto, Canada</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">July&#160;25, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><a id="_b86a4a56_1c89_4708_9d5a_c8bd5a8f9b63"></a><a id="_72e67f96_cf15_4cd8_921f_857e39f1207d"></a><a id="_e215dbc0_cf46_4f7d_a01f_5b9d2fe6ba52"></a><a id="_77d53b82_f04a_4f04_9cf5_5b4f0f466372"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">2</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:21.6pt;"><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:bottom;width:75.17%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p></td><td style="vertical-align:top;width:24.82%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;"><img src="pbm-20240331xf1026.jpg" alt="Graphic" style="display:inline-block;height:21.6pt;width:57.18pt;"/></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9.5pt;">To the Board of Directors and Shareholders of Psyence Biomedical Ltd.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">Opinion on the Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9.5pt;">We have audited the accompanying consolidated statements of financial position of Psyence Biomedical Ltd. (the </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8220;</span><span style="font-size:9.5pt;">Company</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8221;</span><span style="font-size:9.5pt;">) as at March 31, 2024 and 2023, and the related consolidated statements of net loss and comprehensive loss, changes in shareholder equity (deficit), and cash flows for each of the years in the two-year period ended March 31, 2024, and the related notes (collectively referred to as the </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8220;</span><span style="font-size:9.5pt;">consolidated financial statements</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8221;</span><span style="font-size:9.5pt;">).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9.5pt;">In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as at March 31, 2024 and 2023, and the results of its consolidated operations and its consolidated cash flows for each of the years in the two-year period ended March 31, 2024, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">Change in Accounting Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9.5pt;">As discussed in Note 3 to the consolidated financial statements, the Company has changed its presentation currency from Canadian dollars to U.S. dollars. The change in presentation currency is as of January 25, 2024, and this change has been retrospectively applied in the consolidated financial statements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">Material Uncertainty Related to Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9.5pt;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses and has not generated any revenue to date, which raises significant doubt about its ability to continue as a going concern. Management</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8217;</span><span style="font-size:9.5pt;">s plans in regard to these matters are described in Note 4. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><b style="font-size:9.5pt;font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9.5pt;">These consolidated financial statements are the responsibility of the Company</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8217;</span><span style="font-size:9.5pt;">s management. Our responsibility is to express an opinion on the Company</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8217;</span><span style="font-size:9.5pt;">s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8220;</span><span style="font-size:9.5pt;">PCAOB</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8221;</span><span style="font-size:9.5pt;">) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9.5pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8217;</span><span style="font-size:9.5pt;">s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 21.6pt 0pt 0pt;"><span style="font-size:11pt;"><img src="pbm-20240331xf1027.jpg" alt="Graphic" style="display:inline-block;height:14.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:60.51pt;"/></span></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Burlington, Ontario</p></td><td style="vertical-align:bottom;width:39.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 18pt 0pt 0pt;">Chartered Professional Accountants</p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:39.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 18pt 0pt 0pt;"><span style="font-size:6pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">July 25, 2024</p></td><td style="vertical-align:bottom;width:39.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 18pt 0pt 0pt;">Licensed Public Accountants</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">We have served as the Company</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;">&#8217;</span><span style="font-size:9.5pt;">s auditor since 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td style="vertical-align:top;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">MNP LLP</b></p></td><td style="vertical-align:top;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:60%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 3pt 0pt;">1122 International Blvd, 6th floor, Burlington ON,<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;</span>L7L 6Z8</p></td><td style="vertical-align:top;width:40%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 3pt 0pt;">T: 905.333.9888<span style="font-family:'Arial','Helvetica','sans-serif';">&#160;&#160;&#160;</span>F: 905.333.9583</p></td></tr><tr><td style="vertical-align:top;width:60%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><img src="pbm-20240331xf1028.jpg" alt="Graphic" style="display:inline-block;height:17pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:57.75pt;"/></p></td><td style="vertical-align:middle;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">MNP.ca</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">3</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_39cbac76_9d4f_45a7_a1db_ff6e0fb9e814"></a><a id="FinancialPosition_396068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consolidated Statements of Financial Position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As at March&#160;31, 2024 and March&#160;31, 2023</p><a id="_29f13210_470d_4c74_b49a_eb7ec2afe2e4"></a><a id="Tc_sHUsdJ6sNkKO0QIlthv_nw_1_4"></a><a id="Tc_Ov2J9IZ4z0mfSBmN18V9fw_1_6"></a><a id="Tc_xFfO1ZSgx0eF7RYIpQAK0Q_2_2"></a><a id="Tc_Lfyeklr7r0qjrf6eI1xINw_2_4"></a><a id="Tc_Pqko59b0KUS89CPaZjERmg_2_6"></a><a id="Tc_htGZVwaJpU6LlB3GaH_m8g_3_0"></a><a id="Tc_FyYg7NvRlkK4AHYLtxfYWg_3_2"></a><a id="Tc_8y0NnbTKHEGyWmh-G3D_mw_3_4"></a><a id="Tc_Em_cE0eBFEa3X0_LYgpqtQ_3_6"></a><a id="Tc_uTY47srT2ESY8kCbmpAVVA_4_6"></a><a id="Tc_9K-Mo3iBUEesfT67ZlSGoA_6_0"></a><a id="Tc_fi4CLMCv-kutplthkY50nw_7_0"></a><a id="Tc_rrTT1_27l0OsKRk7tQPzIg_8_0"></a><a id="Tc_3Wpttr9rxku2Hu6jAXLzwA_8_2"></a><a id="Tc_zwjTelGGqkCKtWSlCQYmjQ_9_0"></a><a id="Tc_LSbWxltNM0mleYC3qJMISw_9_2"></a><a id="Tc_t-gTmLUC9Eas7JZeqgIy2Q_10_0"></a><a id="Tc_TM3gmqQyqEGsSgbhVEdKAA_11_0"></a><a id="Tc_bb9z1UJhrkK5wSjGjlLoJw_12_0"></a><a id="Tc_mOxH9BL5t0epMa_yl7E3kA_13_0"></a><a id="Tc_s4Des093Z0eBdvYs0goDlA_14_0"></a><a id="Tc_fHEpr8WzOUCS9UpQPlp4VA_14_2"></a><a id="Tc_Dn2mgdByMk6Tuy-jjDWdog_14_6"></a><a id="Tc_4QQ8TGwT70KQU9jvaEGdRg_15_0"></a><a id="Tc_IRNkgVAmX0abjiKOCb72tQ_16_0"></a><a id="Tc_hJAvSjLizkaSb9vjXuOuRw_17_0"></a><a id="Tc_5K2p6L092EK_OqgrkWRJlg_18_0"></a><a id="Tc_VQLfBdCWJ0Cgdg0mV3a4mg_18_2"></a><a id="Tc_mUkBj6_7a0SVax80STEhPg_19_0"></a><a id="Tc_1QfCs_kZckapqmwfZDQuMw_19_2"></a><a id="Tc_KbHZ61t8HUu_etZIMzIdPA_19_6"></a><a id="Tc_bA-AE2QO90WxS7u-HcxpIA_20_0"></a><a id="Tc_5ZBmJk4NHkCZwbXd3dEfpA_20_2"></a><a id="Tc_PnJwzbBYvEGLYRkcgIjn7A_20_6"></a><a id="Tc_vmtTW_1C-kKvbqvephBSEA_21_0"></a><a id="Tc_t5m3MnD4SE-ZtIVvZ-22uw_21_2"></a><a id="Tc_N2uHcR7rekCGRee_BleQKg_21_6"></a><a id="Tc_wLM83b3D7UemM4DcbfTtsA_22_0"></a><a id="Tc_p58ptOkQKUi8nbEbQ4CmSQ_22_2"></a><a id="Tc_oigdLXtxykSVm8tCvq95Xg_22_6"></a><a id="Tc_ElNLaE0xxkSwTjDjDQQApw_23_0"></a><a id="Tc_owICYL1Mb0aIWI0KoiEJBg_24_0"></a><a id="Tc_JsnA3Ykm606xwKuPQxytEw_25_0"></a><a id="Tc_WehP194Vlku8-ss_s3oLoA_25_2"></a><a id="Tc_PH0ZyUjmqEOPumrLHtllow_26_0"></a><a id="Tc_QoxKl8fPRkadjfXUfHWztA_27_0"></a><a id="Tc_7UFhqWFHSEuGSlNmIx16zg_28_0"></a><a id="Tc_npFw1crnpU-KP9TUboiSxA_29_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;at&#160;March&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;at&#160;March</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">31,&#160;2024&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USD$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Consolidated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;(Carve-out)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Restated Note 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_x1Qqh41E9EySCcsjAdCnHQ_8_4">733,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_cBQGQakoJEGBp-shHNeB0Q_8_6">1,334,280</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="0" id="Tc_I2I4XH94rEKkz-msI5eaeg_9_4">29,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="0" id="Tc_5TVU4BHinkuP-Dq66iUt6w_9_6">29,556</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="0" id="Tc_vEhB1tfjdEevpaGpg1t_pg_10_4">41,747</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="0" id="Tc_OEe7XPRpZ0-mSl207ldEIw_10_6">149,369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepayments" scale="0" id="Tc_K0phNwiZvE2iFSGQILUA0g_11_4">322,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepayments" scale="0" id="Tc_WollwDf_J0eucPQvbjGY5g_11_6">77,050</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="0" id="Tc_KYT_vcT9aUe-iGuhDd43YA_12_4">1,126,672</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="0" id="Tc_mTjigcqlKky1754_XE6ydg_12_6">1,590,255</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="Tc_UozzWbkWzUu-ghyVoe8TDA_14_4">5,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="0" id="Tc_rkj0VOxzJEiO1VzQ5m3prA_15_4">1,132,159</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="0" id="Tc_RdarLxAC0ECNHBqQHJpoJA_15_6">1,590,255</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_yiugqf9410Km0b70lXrSbw_18_4">755,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_0MMbr6MISESwpAvwGvitZw_18_6">1,790,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible note liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsConvertibleDebtCurrent" scale="0" id="Tc_iQvdW3uYTEu1kP9ra2PP6w_19_4">7,657,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Derivative warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentWarrantLiability" scale="0" id="Tc_15a9ouhNv0uGp9QxmohdUw_20_4">901,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due to NCAC Sponsor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_sCiZc0LkzEif6BGm_OtlfA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDebtInstrumentsIssued" scale="0" id="Tc_cny4Y5hJQkSli0uNGxSqgQ_21_4">1,474,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due to Psyence Group Inc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_gwAintdcuUyQ_JwYJbceZQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDebtInstrumentsIssued" scale="0" id="Tc_zqr0RMAjPkKkJn5SUKovyg_22_4">1,316,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="0" id="Tc_xLvSlovEpU2nSvS5B9LONA_23_4">12,104,699</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="0" id="Tc_ZUycRYiCxEGEk5FKuQNloQ_23_6">1,790,700</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share Capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="0" id="Tc_jM6P7uzdHEm-AZY7wGlHvA_25_4">46,125,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="0" id="Tc_i4mBk0MQREKCg-rDqP5gRw_25_6">5,934,141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated Deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="0" id="Tc_Yvs2uZlXnEqhkAC44HsmDw_26_4">57,458,994</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="0" id="Tc_DETrI6rbeEqaRxIdERL9mg_26_6">6,299,946</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherReserves" scale="0" id="Tc_CpOVcLYHykSq0s1ZCxzpxg_27_4">361,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherReserves" scale="0" id="Tc_pydrKyEZHkqNB1Uval3M5Q_27_6">165,360</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_kz5QRndsEkCXfUMoSMftZQ_28_4">10,972,540</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_Wac-HDGemkeGVsWzoifqIQ_28_6">200,445</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="0" id="Tc_daLrV5cDBkWxydAJ61ysww_29_4">1,132,159</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="0" id="Tc_G7CX-pLhrUqAqVC4nyUt1A_29_6">1,590,255</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Nature of operations (note 1)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Subsequent events (note 19)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Approved on behalf of Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8220;Dr. Neil Maresky&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#8220;Jody Aufrichtig&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.08%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:top;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Executive Chairman and Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">4</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7d940c9d_eb60_4d63_8cd1_acd461fdf065"></a><a id="ComprehensiveLoss_394370"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consolidated Statements of Net Loss and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended March&#160;31, 2024 and 2023</p><a id="_39e1ee3c_d848_4b1f_ad8e_039cec1e67b4"></a><a id="_1cd7f666_1a7d_48cc_a26e_15bd43043c21"></a><a id="Tc__zx8usLBc02vvxwRUGM1YA_2_2"></a><a id="Tc_9vrrp9O-00eHalgqQAr9DA_2_4"></a><a id="Tc_DJEDBCBUPU-Wlbkqm1vMpA_2_6"></a><a id="Tc_22iQ4eXfGkGxzXhaHFpdXw_3_0"></a><a id="Tc_ZV6G7TXUYEe1_WTojrHFjA_3_2"></a><a id="Tc_Q7vbGMsuhkiRhNwwPHjGRg_3_4"></a><a id="Tc_BEzsY5YhYkWErCntrDdMgw_3_6"></a><a id="Tc_-YZZvHiEGU-Eq6hFKj3OKw_4_6"></a><a id="Tc_WQJyQO9S7U68FZKhqppWVw_5_0"></a><a id="Tc_Uez383WLEkCJhyphUNgYMQ_6_0"></a><a id="Tc_w9YEEBtob0e67gnioq0KxA_7_0"></a><a id="Tc_2lM9BIN9QEm3ipkql8YgIQ_8_0"></a><a id="Tc_WApVUIQbiEKJyIdY_flbOw_8_2"></a><a id="Tc_o23RJGzVRUe_5n-xGzTRkw_9_0"></a><a id="Tc_LV2WG71Diki-TSQwXr9uzQ_9_2"></a><a id="Tc_HnhvEyUhgEar_7EPZN-u5g_10_0"></a><a id="Tc_t6Wjzi5JyEKNHLYNjmIOAA_11_0"></a><a id="Tc_7J9UDkVhxEyrWoQbvtmRvA_12_0"></a><a id="Tc_zvLRlDuEdkSn8xXy_3tSZQ_12_2"></a><a id="Tc_At2phpC8g0GIHBnXlzGEPw_12_6"></a><a id="Tc_rqSYkdO5nEKbBu7zPp4cwA_13_0"></a><a id="Tc_1xvyoJnt-0-iBkBq-LiBsw_13_2"></a><a id="Tc_ZXwAlee4G0W9WPts1aL5-g_13_6"></a><a id="Tc__djkQTLz1061EZ_Udx4mNQ_14_0"></a><a id="Tc_r2UFGMEfcUqKK6Ya7uZrGg_15_0"></a><a id="Tc_SNnovgZmLUG6xNOgKx1S0g_15_2"></a><a id="Tc_Ev1yZfE4DUexecjIDDNTmQ_15_6"></a><a id="Tc_8QwKAdrRIU-Qe6Q-qpr6Lg_16_0"></a><a id="Tc_Cv6Kw4_BKU6do_QslIZ1Wg_17_0"></a><a id="Tc_fDu5hUDlL0-Stb57f4MP4g_17_2"></a><a id="Tc_wLz6DHZsME6KRCpoOhDcFg_17_6"></a><a id="Tc_XjbHEV2Qak-NiKYioHJYWA_18_0"></a><a id="Tc_JMHAPjFlake4Qjtt0ZQfdg_18_2"></a><a id="Tc_Q8sAHtfA_0Sz8TeX8wg64Q_18_6"></a><a id="Tc_pxFRz8e1t0KHCYEMPBENtQ_19_0"></a><a id="Tc_JjQZzaZktUqtVKUR_ubHwg_19_2"></a><a id="Tc_KyVN212WX0uvMc0fnWAi4w_19_6"></a><a id="Tc_0qnLQjhvyEyMXiuE94w0fw_20_0"></a><a id="Tc_8AyPYrin70i6YwSSFBpOMw_20_2"></a><a id="Tc_SJFTQCbGpkGjj5I-LfIdtg_20_6"></a><a id="Tc_E7xC0J2Z2Uag6U-sttSGJA_21_0"></a><a id="Tc_FNcPVotYR0qreiXJ3CW8UA_21_2"></a><a id="Tc_gNTHa8_NuUOK-oATbwZeRA_21_6"></a><a id="Tc_zEGd5u25rEq-zc_i_NLdLA_22_0"></a><a id="Tc_qpiAZWz1v0q6rQq7_yZSZQ_22_2"></a><a id="Tc_W1su1QOaQUaYthVJece15g_22_6"></a><a id="Tc_KHnINiLrd0ahyVQOSKGf7g_23_0"></a><a id="Tc_RTrygvyheEKWqN1_2Vhv4g_24_0"></a><a id="Tc_WTdzZWukzEi4euC7AuX1Ig_25_0"></a><a id="Tc_thm65u5lf0mrX9xlO40X8Q_26_0"></a><a id="Tc_Hiw9CQj7dEyzg9KOq5iv8Q_26_6"></a><a id="Tc_w805htidY0my2L09e4Tryg_27_0"></a><a id="Tc_kAGKnQKEqEW4kkWWnZ2hXQ_28_0"></a><a id="Tc_YnwBGjUAAEmzt8j1iFOSzw_29_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USD $</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Consolidated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Carve-out)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Restated Note 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" id="Tc_-GwANUxouUu4mzcBt-4b8A_6_4">80,603</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" id="Tc_dp-BnDU-sUCVyKaAkld6hA_6_6">7,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="Tc_ariiDjc7hESj0vw6ZLzijg_7_4">954,593</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="Tc_myuQM4DO2kKv0GvKdmxdiw_7_6">1,608,895</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" id="Tc_VqYnTSwGz0qEc4J1UvaSQg_8_4">557,904</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" id="Tc_RjzuJl9eyUW38RBdNhmfxA_8_6">366,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="0" id="Tc_MZTxMt71MUSWhi9kRoNgmw_9_4">1,158,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="0" id="Tc_HzaXmUkRZE2ifIgU3_5sbw_9_6">1,252,510</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsOperatingIncomeLoss" sign="-" scale="0" id="Tc_CrRVNtlMkU-eLMMjykkMRw_10_4">2,751,584</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsOperatingIncomeLoss" sign="-" scale="0" id="Tc_m3aVq5U3nkeQl8U8tIvktw_10_6">3,234,869</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherIncome" scale="0" id="Tc_5BudOsPnC06C937i6wfbvA_12_4">879,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationExpense" scale="0" id="Tc_wssUoKDrFU6qHY_S56scBQ_13_4">240</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="0" id="Tc_mmNADUFe0kmk6r8x__8HFQ_14_4">2,134</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="0" id="Tc_LIHz6KqAFEGFDCkQcrksHA_14_6">1,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="0" id="Tc_4jNnV1F5RUybbsHD5LktEQ_15_4">52,941</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" sign="-" scale="0" id="Tc_kUwtxIgdsEqwAuNBbe7N4g_16_4">2,695</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" id="Tc_WCuqShgJJ0av-2KejZUOZQ_16_6">26,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Listing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:ListingExpense" scale="0" id="Tc_czD3PX8SBk27g06icrhgMg_17_4">41,481,605</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transaction expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:TransactionExpense" scale="0" id="Tc_eyWMNnhYUkG8VHtIzmGGgg_18_4">2,461,025</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on debt settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsGainLossOnExtinguishmentOfDebt" scale="0" id="Tc_ZgzYRvaYJ0-a1LshWuEjbQ_19_4">281,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value loss on convertible note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:FairValueAdjustmentOnConvertibleNote" scale="0" id="Tc_IxgOy1ONGkqOXkkfRWCbPw_20_4">5,157,397</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value loss on warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsFairValueAdjustmentOfWarrants" scale="0" id="Tc_r_3bQOL5i0ap86vTa2Zb1Q_21_4">306,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value loss on promissory notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:FairValueAdjustmentOnPromissoryNote" scale="0" id="Tc_tnqyqWeX202v1DqosvLnWQ_22_4">108,288</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_Scq2r8kJOkmhVNiba8d1pg_23_4">51,159,048</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_sbceRfRN9Eq0L9h5CwGD2g_23_6">3,206,403</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other comprehensive income/(loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain/(loss) on translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" scale="0" id="Tc_GRhJt7qTj0WM7-aQ-5MoYQ_25_4">3,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="0" id="Tc_RQS_6iigDkaxFSwCm_ADrA_25_6">89,828</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:OtherComprehensiveIncomeLoss" scale="0" id="Tc_g6BP2kqc6UKoYVD4uo0nAg_26_4">191,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL COMPREHENSIVE LOSS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:ComprehensiveIncomeLoss" sign="-" scale="0" id="Tc_ypEFobEqtkeO0rhxx1UAMg_27_4">50,963,351</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:ComprehensiveIncomeLoss" sign="-" scale="0" id="Tc_Xi4BOgkNGUSv9jkQrz4EXw_27_6">3,296,231</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss per share - basic and diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_-pB7pOv7_kuUDtOUmaid8g_28_4"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_-pB7pOv7_kuUDtOUmaid8g_28_4_2">7.82</ix:nonFraction></ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_MJX0vlDD4EOszXJ8RDUCVw_28_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_MJX0vlDD4EOszXJ8RDUCVw_28_6_2">0.66</ix:nonFraction></ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average number of outstanding shares - basic and diluted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_-MMMbjvTMES-QJ-k2bLZEQ_29_4"><ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_-MMMbjvTMES-QJ-k2bLZEQ_29_4_2">6,517,215</ix:nonFraction></ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Tc_eiS64Hjb8kCZx78FUvvSpQ_29_6"><ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustedWeightedAverageShares" scale="0" id="Tc_eiS64Hjb8kCZx78FUvvSpQ_29_6_2">5,000,000</ix:nonFraction></ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">5</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d0342cc1_7f21_4dd9_9d66_7adae920069b"></a><a id="ShareholderEquity_89940"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consolidated Statements of Changes in Shareholder Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended March&#160;31, 2024 and 2023</p><a id="_537e382e_1981_4b38_8214_527ce1f34416"></a><a id="Tc_8MLS44oJc06kEL4fEMem0Q_1_12"></a><a id="Tc_ziYfBs1zEkGriysNyBKEYQ_2_4"></a><a id="Tc_JoxUR8R46Uit7D66rLifMQ_2_12"></a><a id="Tc_nn2VbLG6x0mPgKusuy-2rg_3_0"></a><a id="Tc_fZckmd7SqkWUTln__ij_Yw_3_2"></a><a id="Tc_0TG6Q3Llq060KWY4ju0YLw_3_4"></a><a id="Tc_NKLvZhhkpk2opbL4e8sRBQ_3_6"></a><a id="Tc_33evic_joked4LMAZilNCw_3_8"></a><a id="Tc_dJEdPWtPAUGxYxjGKEDPzw_3_10"></a><a id="Tc_kPR5cw3lxEeSK-TV15Bk_A_3_12"></a><a id="Tc_4rGNGpSHT0mRdFSZpsxelg_5_0"></a><a id="Tc_iJ97M8b3QkqCex61rmWjqg_5_4"></a><a id="Tc_nZyaBBiozUmk_lbmkVBfBQ_6_0"></a><a id="Tc_wEexiMxcd0G00VjzQBV7ug_6_4"></a><a id="Tc_kcvf91YhiUGix3Z4MhTqoQ_6_8"></a><a id="Tc_i1cfDgrfXU250QXsct5WrA_6_10"></a><a id="Tc_SqAPsWQYokSViAAyzyp86A_7_0"></a><a id="Tc_RM0OQlMAKUuK5t5ejCn-Gg_7_4"></a><a id="Tc_rxkORt-YaUGfi_WgpE5exQ_7_6"></a><a id="Tc_IpgBhy9wL06zyMfZnm-o2g_7_8"></a><a id="Tc_JUSAfU-GOUCmdhtxwF1iHA_8_0"></a><a id="Tc_98-mIH0thECw3wX8QsdC0A_8_4"></a><a id="Tc_jq3R1ySlkE-fXCynINYhVg_8_6"></a><a id="Tc_YVH8SJ3ahUu0V6cv9IOuxw_8_10"></a><a id="Tc_VXOwlL0eXkiK4ijvLWy1pw_9_0"></a><a id="Tc_9wSSruCYqUuxBqoKrV1qvw_9_4"></a><a id="Tc_p4EKAzoNDUOvVvmHdKHMeg_11_0"></a><a id="Tc_DBXaaqZzbU6PrZbPsYnibQ_11_4"></a><a id="Tc_3rZEDXQ690iC6D6TRpSWnw_12_0"></a><a id="Tc_86eqc56dX0eG-Klcs27kAQ_12_2"></a><a id="Tc_s6kCn8ZsNEi8mAK_8-JuXQ_12_6"></a><a id="Tc_aGE0MftOrUeZ7XVi6WKfMg_12_8"></a><a id="Tc_9QLstOOA7EezVqaQJimjhQ_12_10"></a><a id="Tc_Gn6hA4yxuE-Oh2zM3av-Mg_12_12"></a><a id="Tc_vUiU7Bf7j06yH8GEeA0e8A_13_0"></a><a id="Tc_i9larANiGECA_NQTbjLBqA_13_2"></a><a id="Tc_xj7SshZZNEyx-96QmAwJrw_13_8"></a><a id="Tc_e0ZQx34yPUST5Q9W8c3mTg_13_10"></a><a id="Tc_BXmCZsWzS0uma3U-W_8dHA_14_0"></a><a id="Tc_QuDo5FklYkySqDQblCiciA_14_2"></a><a id="Tc_R7_n1njUek60ph-JrM4M7g_14_8"></a><a id="Tc_F5udjH5U80OMHdiQnXR5xg_14_10"></a><a id="Tc_hvv5cDNW40elC-5DuK_GSg_15_0"></a><a id="Tc_KqvNIYDmIk-nmcn09Bcrag_15_2"></a><a id="Tc_o8YON4HrWkKH22UBkwsytQ_15_8"></a><a id="Tc_eAtGKjpIrEO0h7CFzKr3dg_15_10"></a><a id="Tc_AYwWBtIeoUSSh3UhVPSduQ_16_0"></a><a id="Tc_4A2caRhahEGuvnomeqr9NQ_16_4"></a><a id="Tc_cKR-0TtXT0SgmBlD44dvpA_16_6"></a><a id="Tc_sloQ700ITUqM7Mtv41YFYg_16_8"></a><a id="Tc_GE50euBtTUOAidMzaWMl6w_17_0"></a><a id="Tc_p82doIrSK0OyfRgoL7sfDw_17_4"></a><a id="Tc_p8QPu8tZWEGT_nM51A7Hwg_17_6"></a><a id="Tc_OwwFE268zkCpIq_LmbkKVg_17_8"></a><a id="Tc_J5qcIopPq0Kl00EA8T6y8A_17_10"></a><a id="Tc_0j4paJvbV0aibx7h_Aft4g_17_12"></a><a id="Tc_xY43_SRzYEuhWYoIDneADw_18_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shareholders&#8217;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">USD $</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Share&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reserves</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity&#160;(deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Opening balance as at April 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_-XClE6sYLESe4Ac51L39fw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_Sp7ozIRsBUqIPKd4mzYEUQ_5_6">4,537,055</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_Dw3sdk3PW0qHioYev-uYqQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_CsFrENtTiUWdjMuWJyRHXw_5_8">255,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_5KKmfXcG5UWbCL--sLIg7A" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_vHTiQyNH0E6ThJuwGl3V8Q_5_10">3,093,543</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_95xhTU7Cu0K8ydaXh1K7bw_5_12">1,698,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Psyence Group Inc contribution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3QvCsKmuG0iNZ278OZUdsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" scale="0" id="Tc_Ub3E3nYZx0qwYQ4l6pBhkQ_6_6">1,397,086</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners" scale="0" id="Tc_H2gxdyFu6kGZ-aUMyPG2ug_6_12">1,397,086</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Y8ha6ksYVkK1MvnJV2HJKw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_pVC85iJrXkWVLKvd12FgNA_7_10">3,206,403</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_qzB66dVrv0uk5Tyu0doUdA_7_12">3,206,403</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_G3Bu9s5MGkyw9paFYnaXQw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="0" id="Tc_5p1LunLl4EG4L3EHFzwA5A_8_8">89,828</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="0" id="Tc_x28UOzLG7ku41sGz_N5wug_8_12">89,828</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, March 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_c2lWJEMjh0WThzeAGu23wg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_CiV6iQ7NXE2wyOc5ePVWMA_9_6">5,934,141</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_I2azYclQNUyISbz7ooT7Zw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_Y0AjnR-9aUKhNQuP5pzqqg_9_8">165,360</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_tuvfzSbZYUSwJW82QolpRg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_nZ4U7ozTLkWemiLqsYyDzQ_9_10">6,299,946</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_tW2NeXKnHUGEHts6g3lugw_9_12">200,445</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Opening balance as at April 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_c2lWJEMjh0WThzeAGu23wg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_NIDw4N1MqUuQB4b9xdpIKA_11_6">5,934,141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_I2azYclQNUyISbz7ooT7Zw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_g0G8QoUY4UmQnbxgXo54sA_11_8">165,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_tuvfzSbZYUSwJW82QolpRg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_ML7vBaGMdUa05QSRHKeK8g_11_10">6,299,946</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_FRAukmpN80255D7csUL27A_11_12">200,445</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of shares to Psyence Group Inc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_bvPGj60BfUSrD5EMG-60sg" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" scale="0" id="Tc_ev2Pzg6XsUiKotQN_LvjCQ_12_4">5,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of shares to NCAC shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MgMsfnVGck2AmUnYInyYOg" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" scale="0" id="Tc_u0sKKoj_wEydXTi_4qli7Q_13_4">7,794,659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MgMsfnVGck2AmUnYInyYOg" decimals="0" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" scale="0" id="Tc_UXL0xskJdU6kGEptx37FoA_13_6">37,336,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_EDSUwdQ36UKTQvA2QAr00A" decimals="0" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" scale="0" id="Tc_iGxCJKTVWESneNXQHpMrOw_13_12">37,336,416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of shares for debt settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Hjb5c9ngrEaYgdmgugFj6g" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement" scale="0" id="Tc_0QGOa1iJcUiK0hUhfdp7eQ_14_4">150,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Hjb5c9ngrEaYgdmgugFj6g" decimals="0" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodValueIssuedForDebtSettlement" scale="0" id="Tc_2L4uwagbuU-PQ_klIwbMeA_14_6">718,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodValueIssuedForDebtSettlement" scale="0" id="Tc_b0AykaJ3cEWZikUlQAdwPQ_14_12">718,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of shares to third party advisors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_Q5QpV3tf5Ea3fIz2QATK7w" decimals="INF" format="ixt:numdotdecimal" name="pbm:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_lbi6nFaGS0ODvtBpLGzIww_15_4">446,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_Q5QpV3tf5Ea3fIz2QATK7w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="Tc_C8nmBzRWrkSd2Cj55DZ9XQ_15_6">2,136,340</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_hsBM3S00RUmiCZS-VgNMhA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="0" id="Tc_-DB9nxVPYUKWQ5QIWZUGYA_15_12">2,136,340</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_BDylPQLgv0aDtOticTwZeQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc__-9jr2M77EOj1VG5t7N4ww_16_10">51,159,048</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_U5UBfmrtYE63RyDuttVbyQ_16_12">51,159,048</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 195,697</p></td></tr><tr><td style="vertical-align:bottom;width:31.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4Ep3QBgg9E-C5EIM6WXlUw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Tc_g_qi3VQNDkK8jwFMuSBKgw_18_4">13,390,659</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4Ep3QBgg9E-C5EIM6WXlUw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_hPvKUfjf_Ui9DtwCgXIFyA_18_6">46,125,397</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_fDdHxo-EdE-nSoM7ApAHWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_D6_TbtSfWUKiechjvm4Ulw_18_8">361,057</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Pj4XiiixQkW2C1vuJhevIg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_PLXCpOjZz0SUfTdtBUUALg_18_10">57,458,994</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_94IEf8UzGU2agk7Zxo5fqg_18_12">10,972,540</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">6</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_89ea904e_54b6_4fe9_8adb_86e8732ccb03"></a><a id="CashFlows_785885"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">For the&#160;years ended March&#160;31, 2024 and March&#160;31, 2023</p><a id="_c87589da_8130_46d9_bd0b_648ae116c6b4"></a><a id="Tc_QBHeYM2oP0aY36eKoJyJ5Q_1_4"></a><a id="Tc_v-E5eMgGwkKVEZLqa8tkxQ_1_6"></a><a id="Tc_DBusFk-K_EW5sEEPLT8TrQ_2_2"></a><a id="Tc_4cUVPQjeP0CVNe98UWO8og_2_4"></a><a id="Tc_BxN5KJ_AdE6ZTJ0yketK_w_2_6"></a><a id="Tc_5e2UYOqj-EmpWXAtrfHJWw_3_2"></a><a id="Tc_y87RMqX4_kmpcelepp_poA_3_4"></a><a id="Tc_TvIUhsqN_06IKPoEH24tPg_3_6"></a><a id="Tc_-mL5ghXgS062dRpNV3nbvg_4_6"></a><a id="Tc_ot6e1s2zC0Cn7f7S_x4eEQ_6_0"></a><a id="Tc_TOaWT2Zfd0a3A-tHdcrCVQ_7_0"></a><a id="Tc_X8n7CC_E80aflsv25nwcYg_8_0"></a><a id="Tc_HK37TnIgTEGq0YWNWHYYxQ_8_2"></a><a id="Tc_wyIJIPvkh0eeLBHa7Wh--w_8_6"></a><a id="Tc_xaj1HKG29kyza1kVd46ChQ_9_0"></a><a id="Tc_l8wDjICy3kehfKCnDeyrFw_9_2"></a><a id="Tc_xLSfm3bgfEe4b0UnWOtGuw_9_6"></a><a id="Tc_m6o8JLmBgkGxZWfUgk3hFQ_10_0"></a><a id="Tc_tuZ8Ro4pMUSqPTBAB8iGDQ_10_2"></a><a id="Tc_C8ihwVTPjEOKdJTnD592KQ_10_6"></a><a id="Tc_sFQY9S3UL0uUowf-BcK3Vw_11_0"></a><a id="Tc_fyNKEnT0ZEuVNIs1vyo5nw_11_2"></a><a id="Tc_FvIzZjzxQEyVBM7JyjIqRA_11_6"></a><a id="Tc_kU1_VKt2K0GXlYsbdcOe8w_12_0"></a><a id="Tc_WWEP37LKikGl5sfeNI9ysg_12_2"></a><a id="Tc_a8BQZcBPOUCoKufYe6fdYA_13_0"></a><a id="Tc_txmMH9VE5EmOliaWw4rYHA_13_2"></a><a id="Tc_KEfALJ4yqUCO43JKxKbSXw_13_6"></a><a id="Tc_c1T33P7u90aNKiHmrNBuvg_14_0"></a><a id="Tc_mRY2769rYUaiblaAgp2ToA_15_0"></a><a id="Tc_C1Tp_lt8yU20YZQJZHiaxA_15_2"></a><a id="Tc_iJjmo8G-60-FNAoL2e5i9w_15_6"></a><a id="Tc_NLoOLIz27Uab-DzwJuecqw_16_0"></a><a id="Tc_YzP-HgeegUOcAG5qy8tIFQ_16_2"></a><a id="Tc_mdlbpBfeS0GBSRAN645Ltg_16_6"></a><a id="Tc_2VYm81OUgUij8o-mjMzHaQ_18_0"></a><a id="Tc_9itAB5DRu0CRHOxI8BZPRw_19_0"></a><a id="Tc_cHXapaKdUUO9y1DWZNQoCw_20_0"></a><a id="Tc_meZdUHKyWUimoiBEjTkY2Q_21_0"></a><a id="Tc_UdjzNaDROU2KzR-tlo0JSA_21_2"></a><a id="Tc_8NMHjJrRlEywbhsfMm73Vg_22_0"></a><a id="Tc_9soBDzJwNkO63tge85NvKQ_24_0"></a><a id="Tc_ZkGAKPrMuUaAA55oeT-Wmg_24_2"></a><a id="Tc_GOBJ-wP48EGRMVSETenwIg_24_6"></a><a id="Tc_KK956W5vs0iYkFUYJoaRbw_25_0"></a><a id="Tc_RMVwVMhdtEyyhfEQkBjJTQ_25_6"></a><a id="Tc_BTjVwK_5TUSJI4VtUYa5nA_27_0"></a><a id="Tc_QN6f05wGxUG_9Fm9YUN0Ww_27_2"></a><a id="Tc_oZSbqMcnp0eUGML3nPt0wQ_27_6"></a><a id="Tc_tzLVPLOuFUO7ZrBy4Q-fZQ_28_0"></a><a id="Tc_idIVwY2QgU-WQGgMQA46Aw_28_2"></a><a id="Tc_C3f03f9a_U-_SFKlK-8c0Q_28_6"></a><a id="Tc_6_Ui5L7SWECgQAMBh5o45g_29_0"></a><a id="Tc_y208aGY0-0eaJVL7GqRLcQ_29_4"></a><a id="Tc_hQyL8blhkk2LqOOZ30aUHQ_30_0"></a><a id="Tc_CxUTv-eqSkqEeToCgi68HA_32_0"></a><a id="Tc_LAJVn9DyzEiwKZ4jPD8DYA_33_0"></a><a id="Tc_5nF07CcJUU2sfT2fqK_2pg_34_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;March&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Consolidated)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Carve-out)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Restated Note 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_9rIwSR9HEUaajH_tS7iz_A_6_4">51,159,048</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_MZ7DaHxzOkG-ABCFw7GtOQ_6_6">3,206,403</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-cash adjustment:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value loss on convertible note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:FairValueAdjustmentOnConvertibleNote" scale="0" id="Tc_qNUvAmryOEOrT0UM5K1rnw_8_4">5,157,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value loss on derivative warrant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsFairValueAdjustmentOfWarrants" scale="0" id="Tc_ISxQsm09dUy93CYPJTET8Q_9_4">306,250</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value loss on promissory notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:FairValueAdjustmentsOnPromissoryNote" scale="0" id="Tc_duFuPaOYLEO4DJy-tPUevQ_10_4">300,270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gain on debt settlement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsGainLossOnExtinguishmentOfDebt" scale="0" id="Tc_eNJ33QMqi0K44e282bZ2hA_11_4">281,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" id="Tc_3ARRTokHjUa03XrM5Fs54w_12_4">317,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" id="Tc_gpcs3HqT0kWxue27ci0wjQ_12_6">221,287</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="0" id="Tc_j_2wF71uDkyXyiXA0jOu6g_13_4">240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="0" id="Tc_1OYfnIXNjUmntuzViu4-6w_14_4">3,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" sign="-" scale="0" id="Tc_waSx_0oBK0mKN_d343MpWg_14_6">84,499</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Listing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:AdjustmentsForListingExpense" scale="0" id="Tc_D4NKY364FUy4805od_SYvQ_15_4">41,481,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Transaction expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:AdjustmentsForTransactionExpenses" scale="0" id="Tc_tgDPoRmLOESCr7NCQVtp9w_16_4">2,100,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes in working capital:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="0" id="Tc_p08izjJ860aG_AcKe-bimQ_19_4">107,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" sign="-" scale="0" id="Tc_7jjLGhxfDU2dhF0fYt10fQ_19_6">109,858</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" sign="-" scale="0" id="Tc_aIFywVCNdEmV4jzLjzlJRg_20_4">245,075</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" sign="-" scale="0" id="Tc_aJ3VHK9QskCYyNIwnMwWEA_20_6">71,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_1beH3rPyuUS1H5cPgYda7Q_21_4">1,035,498</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_H4OkgX252kaSRfZt4hTjTw_21_6">1,659,058</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="0" id="Tc_MmzGa86g3U2mzIgFwooEmw_22_4">2,945,367</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="0" id="Tc_szJjnhbJ00ODKdG8hORI9g_22_6">1,592,080</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Additions to equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" id="Tc_glBp8BCymUCSH34R7ADMAg_24_4">5,727</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash used for investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="0" id="Tc_zjTJ6O8J80qy1LdQhBhMJA_25_4">5,727</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds received from convertible note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromCurrentBorrowings" scale="0" id="Tc_icnTyGNyEkOwrTjH1MzZlg_27_4">2,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment of promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="0" id="Tc_pvbErN5f3kqMnz1T4ddwog_28_4">150,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds received from Psyence Group Inc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:ProceedsFromContributionsOfParent" scale="0" id="Tc_P3nERFCapUCuA6N1E31NpA_29_6">1,172,923</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash provided from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" id="Tc_Doi3rODe4kK6Mpbid9YWHg_30_4">2,350,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" id="Tc_G6OvkXgPkEOF8ndQnekG3A_30_6">1,172,923</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" sign="-" scale="0" id="Tc_EASUPucocUK4Dpx_UDepLQ_32_4">601,092</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" sign="-" scale="0" id="Tc_G3wwFZOeI06QIJQbThPIow_32_6">419,157</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents, beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_rpw0qex-AkK3RWsEuq-h-g_33_4">1,334,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_YDWTsPAVwEW7TUEo4DCmgQ_33_6">1,753,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_qO0jaYrqike0QZcrri-aUA_34_4">733,188</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_E_mJN5w6Q0azMMxy5mJ2nQ_34_6">1,334,280</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of the Consolidated Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6dd897e5_7d23_41ce_9888_2b4a9c60b8ec"></a><a id="FinancialStatements_920054"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notes&#160;to the Consolidated Financial Statements</b></p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="Tb_2TPafptSuEaAfUFv9m8wmA" continuedAt="Tb_2TPafptSuEaAfUFv9m8wmA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of operations and going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence Biomedical&#160;Ltd. (the <b style="font-weight:bold;">&#8220;Company&#8221;</b> or <b style="font-weight:bold;">&#8220;PBM&#8221;</b>), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The Company is working towards developing safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. The Company is initially focused on mental health disorders in the context of Palliative Care. The Company is currently conducting research through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context (the &#8220;<b style="font-weight:bold;">Clinical Trials</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s registered office is at 121 Richmond Street West, PH Suite&#160;1300, Toronto, Ontario M5H 2K1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company listed on the NASDAQ exchange on January&#160;25, 2024. (&#8220;<b style="font-weight:bold;">Carve-out Financial Statements</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;15, 2023, Psyence Australia (Pty) Ltd was incorporated and registered in Victoria, Australia. It is a wholly owned subsidiary of the Company. It was incorporated as a wholly owned subsidiary of Psyence Group&#160;Inc. and was transferred to the Company concurrently upon completion of the RTO Transaction as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Business Combination Agreement and NASDAQ listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;9, 2023, Psyence Group&#160;Inc. (&#8220;<b style="font-weight:bold;">Psyence Group</b>&#8221; or &#8220;<b style="font-weight:bold;">PGI</b>&#8221;) entered into a definitive business combination agreement (the &#8220;<b style="font-weight:bold;">Business Combination Agreement</b>&#8221;) with Newcourt Acquisition Corp. (NASDAQ: NCAC), a special purpose acquisition company (&#8220;<b style="font-weight:bold;">SPAC</b>&#8221;). The agreement aimed to create a public company leveraging natural psilocybin for palliative care treatment. PGI is a listed Canadian company that contributed its clinical trial activities to the Company as described below. After the Business Combination Agreement closed the Company became an associate of PGI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transaction concluded on January&#160;25, 2024, with PBM&#8217;s listing on NASDAQ. This transaction involved PBM acquiring the SPAC through a merger, thereby making the SPAC a wholly-owned subsidiary of PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Transaction Overview:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024 (the &#8220;<b style="font-weight:bold;">Closing Date</b>&#8221;), the Company, a corporation organized under the laws of Ontario, Canada, completed the previously announced business combination (the &#8220;<b style="font-weight:bold;">RTO Transaction</b>&#8221;) as per the Amended and Restated Business Combination Agreement (the &#8220;<b style="font-weight:bold;">BCA</b>&#8221;), dated July&#160;31, 2023. The parties involved in the BCA included:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Psyence Group&#160;Inc.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Newcourt Acquisition Corp., a Cayman Islands exempted company.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Newcourt SPAC Sponsor LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">NCAC Sponsor</b>&#8221;).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of Psyence Group.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada (&#8220;<b style="font-weight:bold;">Original Target</b>&#8221;).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (&#8220;<b style="font-weight:bold;">Psyence Biomed II</b>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Key Transactions (collectively, the &#8220;<span style="font-weight:bold;">Business Combination</span>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Formation of Subsidiaries</i>: Prior to the execution of the BCA, Psyence Group formed two wholly owned subsidiaries: Psyence Biomed II and PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amalgamation</i>: Prior to the Closing Date, Psyence Group amalgamated with the Original Target. Consequently, Psyence Group transferred shares of Psyence Australia Pty&#160;Ltd. and related business assets previously owned by the Original Target to Psyence Biomed II.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">8</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2TPafptSuEaAfUFv9m8wmA_cont1" continuedAt="Tb_2TPafptSuEaAfUFv9m8wmA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Share Exchange</i>: Psyence Group contributed Psyence Biomed II to PBM in a share-for-share exchange (the &#8220;<b style="font-weight:bold;">Company Exchange</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Merger</i>: Following the Company Exchange, Psyence (Cayman) Merger Sub merged with Newcourt Acquisition Corp., with Newcourt Acquisition Corp. being the surviving entity. Each outstanding ordinary share of Newcourt Acquisition Corp. was converted into the right to receive one common share of PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Conversion</i>: Each outstanding warrant to purchase Newcourt Acquisition Corp. Class&#160;A ordinary shares was converted into warrants to acquire <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_1_25_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_H47wk_lCv0mLLYxNgeLpyA" decimals="INF" format="ixt-sec:numwordsen" name="pbm:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_tnMIQ5SRGUyby41JQx5nDQ">one</ix:nonFraction> common share of PBM on substantially the same terms as the original warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;15, 2024 and January&#160;23, 2024, the parties to the Business Combination Agreement entered into letter agreements (the &#8220;<b style="font-weight:bold;">Closing Letter Agreements</b>&#8221;) pursuant to which, among other things, PBM, Psyence Group, Original Target and Merger Sub (collectively, the &#8220;<b style="font-weight:bold;">Psyence Parties</b>&#8221;) agreed, on a conditional basis, to waive the closing conditions contained in the BCA that, at or prior to the closing of the Business Combination (the &#8220;<b style="font-weight:bold;">Closing</b>&#8221;), (i)&#160;Newcourt SPAC shall have no less than $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_23_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_1M028Mwq5kytRxpB_bSdUw" decimals="0" format="ixt:numdotdecimal" name="pbm:ThresholdAmountForMinimumCashCondition" scale="0" id="Narr_28Sr7G0qrU6Y9NfOQehTNg">20,000,000</ix:nonFraction>, net of liabilities, as of the Closing (the &#8220;<b style="font-weight:bold;">Minimum Cash Condition</b>&#8221;) and (ii)&#160;the PIPE (Private Investment in Public Equity) Investment in the PIPE Investment Amount shall have occurred or shall be ready to occur substantially concurrently with the Closing (the &#8220;<b style="font-weight:bold;">PIPE Investment Condition</b>&#8221;) and (iii)&#160;to waive certain deliverables of the Business Combination Agreement (the &#8220;<b style="font-weight:bold;">Closing Deliverables</b>&#8221;). Upon the Closing, the Psyence Parties waived in full the Minimum Cash Condition, the PIPE Investment Condition and the Closing Deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Convertible Note&#160;Financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;15, 2024, in connection with the Business Combination, the Company entered into a securities purchase agreement (the &#8220;<b style="font-weight:bold;">Securities Purchase Agreement</b>&#8221;) by and among (i)&#160;the Company, (ii)&#160;Psyence Biomed II, (iii)&#160;Sponsor and (iv)&#160;certain investors (the &#8220;<b style="font-weight:bold;">Investors</b>&#8221;) relating to up to <ix:nonFraction unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A" contextRef="As_Of_1_15_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_AFjT0Vhi0UeLxeHCocK_EA" decimals="INF" format="ixt-sec:numwordsen" name="pbm:NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" scale="0" id="Narr_HHWMQfNP502w0Ih76MkX1A">four</ix:nonFraction> senior secured convertible notes (collectively, the &#8220;<b style="font-weight:bold;">Notes</b>&#8221; and the transactions pursuant to the Securities Purchase Agreement, the &#8220;<b style="font-weight:bold;">Financing</b>&#8221;), obligations under which will be guaranteed by certain assets of the Company and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_T9W7od1CnEWSc0EL6UeLCA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsDebtInstrumentFaceAmount" scale="0" id="Narr_o315IfNpPkCePw3iWZ38Xg">12,500,000</ix:nonFraction> in exchange for up to $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_T9W7od1CnEWSc0EL6UeLCA" decimals="0" format="ixt:numdotdecimal" name="pbm:SubscriptionAmount" scale="0" id="Narr_ttNWWx6hnkaar3MKeImtEw">10,000,000</ix:nonFraction> in cash subscription amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Note&#160;for the first tranche of the Financing (the &#8220;<b style="font-weight:bold;">First Tranche Note</b>&#8221;), for a total of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_p40vy71k1EO-ouLsmL1rWg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_5IPCxpwz1kCHSLmT5yc6UA">3,125,000</ix:nonFraction> of principal in exchange for a total of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_1_15_2024_To_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_TVvUizpQt0O2JuSrfGUeqw" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsProceedsFromConvertibleDebt" scale="0" id="Narr_Hif-uL_rP0CnHy9nYlxefw">2,500,000</ix:nonFraction> in subscription amounts and was issued to the Investors substantially concurrently with, and contingent upon, the Closing. The Financing closed immediately prior to the Business Combination (Refer to Note&#160;9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Merger Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As consideration for all the issued and outstanding Psyence Biomed II common shares that the Company received in the Company Exchange, the Company issued to Psyence Group, <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_TE-tT_L3DE-Ydn-lI9Eu5Q" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" scale="0" id="Narr_FNyu3nbPxUKCWA1mIF-2GQ">5,000,000</ix:nonFraction> Common Shares. As a result, Psyence Group is the largest shareholder of the Company as at March&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Consolidated Financial Statements (the &#8220;<b style="font-weight:bold;">Financial Statements</b>&#8221;) provide historical financial information of PBM, reflecting PBM as if it had been historically operating the Clinical Trials conducted by Psyence Group prior to the listing of PBM. The Financial Statements are carve out statements up to the date of listing of PBM.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2TPafptSuEaAfUFv9m8wmA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Going concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements are prepared on a going concern basis, which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the&#160;year ended March&#160;31, 2024, the Company incurred a net loss and comprehensive loss of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:ComprehensiveIncomeLoss" sign="-" scale="0" id="Narr_AN_2ltFwpUyWzjtIfeaPAw">50,963,351</ix:nonFraction> (Year ended March&#160;31, 2023: $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:ComprehensiveIncomeLoss" sign="-" scale="0" id="Narr_XyZK5Lj0UEqw5xzQJzX15Q">3,296,231</ix:nonFraction>) and the Company has not yet generated any revenue. The Company&#8217;s ability to continue operations depends on its ability to secure additional financing. There is uncertainty regarding the availability of financing at acceptable terms, which could impact the Company&#8217;s ability to continue operating. These conditions indicate a material uncertainty that cast significant doubt on the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements do not reflect the adjustments to the carrying values and classifications of assets and liabilities that would be necessary if the Company were unable to realize its assets and settle its liabilities as a in the normal course of operations. Such adjustments could be significant.</p></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Tb_a3n4H1gnzkC7vTiZrbcbCw" continuedAt="Tb_a3n4H1gnzkC7vTiZrbcbCw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Statement of compliance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements of the Company have been prepared using accounting policies in compliance with International Financial Reporting Standards (&#8220;<b style="font-weight:bold;">IFRS</b>&#8221;) issued by the International Accounting Standards Board (&#8220;<b style="font-weight:bold;">IASB</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements were authorized for issue on July&#160;25, 2024 by the directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Financial Position</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Consolidated Statements of Financial Position include the assets and liabilities that are the Clinical Trial related assets and liabilities, which have been determined in the following manner:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash is comprised of cash and cash equivalents which the Company utilizes for working capital purposes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restricted cash comprises a guaranteed investment certificate which is held as collateral for a credit lending agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other receivables are comprised of sales tax receivable from the Canadian Revenue Agency and the Australian Taxation Office.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prepaids consists of D&amp;O insurance fees prepaid.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accounts payable and accrued liabilities consist of audit, consulting fees and legal fees related to the Company and its Clinical Trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Net Loss and Comprehensive Loss</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Consolidated Statements of Net Loss and Comprehensive Loss include operating expenses that are related to the Company and its Clinical Trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Financial Statements up until January 25, 2024 were presented on a carve out basis (&#8220;</span><b style="font-style:normal;font-weight:bold;">Carve-out Financial Statements</b><span style="font-style:normal;font-weight:normal;">&#8221;).</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">10</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_kUMtbinAAkKgPWsm0RiD6Q_1_0"></a><a id="Tc_wMEq_C2Bbku5xerlTdSm_w_1_2"></a><a id="Tc_26eCOItW_UmVhkMXOTCWPQ_1_4"></a><a id="Tc_DrStlHRUYU6G2eNF3Ds5KA_1_6"></a><a id="Tc_ctgttEAYeUCm4N2oTUJr8g_2_0"></a><a id="Tc_v1wnz28RGkC8l2ad-osx8Q_2_2"></a><a id="Tc_ft8dUUvbakWKybEWIzE69Q_2_5"></a><a id="Tc_oLf91N31PU2PSFgA3iQstA_2_6"></a><a id="Tc_rO6-nvPWcEqtNLbKSUC_ug_3_0"></a><a id="Tc_CwYbxQKDV02itNMm-aclLQ_3_2"></a><a id="Tc_cbGF-k30gEGQsrH-YYgydA_3_5"></a><a id="Tc_5ZiXH2sOfE-gJXZtXlYI_Q_3_6"></a><a id="Tc_Pvglog9CXkay6UDvPNSQCg_4_0"></a><a id="Tc__w8dgtBs70-EOrJlmJgXEw_4_2"></a><a id="Tc_bZRSktZtNEWAMFuuTmkDNQ_4_5"></a><a id="Tc_PN8SH9BzyU29khZ-hOpHMQ_4_6"></a><ix:continuation id="Tb_a3n4H1gnzkC7vTiZrbcbCw_cont1" continuedAt="Tb_a3n4H1gnzkC7vTiZrbcbCw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements have been prepared on a carve-out basis from the PGI consolidated financial statements for the purpose of presenting the historical financial position, financial performance and cash flows of the Company on a stand-alone basis. The accounting policies applied in the Carve-out Financial Statements are, to the extent applicable, consistent with accounting policies applied in the PGI consolidated financial statements, and as a result, reflect the carrying amounts that are included in PGI&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining the perimeter of the Carve-out Financial Statements, the activities related to the Company&#8217;s clinical trials were considered to include the operations of Psyence Biomed Corp. and Psyence Australia (Pty) Ltd carried out through PGI directly as well as through legal entities of PGI as detailed above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the Carve-out Financial Statements of PBM, all intercompany balances and have been eliminated. The transactions and balances with the remaining PGI operations that are not part of these Carve-out Financial Statements have not been eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carve-out Financial Statements present the assets, liabilities, expenses and cash flows attributable to the clinical trial activities for the year ended March 31, 2023 and from April 1, 2023 to the Closing Date, and include allocations of certain transactions and balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company believes the allocation assumptions applied in the Carve-out Financial Statements to be a reasonable reflection of the utilization of services provided by PGI. However, different allocation assumptions could have resulted in different outcomes. The allocations are therefore not necessarily representative of the financial position, financial performance or cash flows that would have been reported if PBM operated on its own or as an entity independent from PGI during the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company believes the basis of preparation described above results in the Carve-out Financial Statements reflecting the assets and liabilities associated with PBM and reflects costs associated with the functions that would be necessary to operate independently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of consolidation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statement incorporate the accounts of PBM and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Control exists when an investor is exposed, or has the rights, to variable returns from the involvement with the investee and has liability to affect those returns through its power over the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The subsidiaries of PBM have been consolidated commencing the Closing Date and on March 31, 2024 for the purpose of these Financial Statements are as follows:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory" id="Tb_wGXAwa7k7kKAJkNJGQ3frw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Place&#160;of&#160;incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounting&#160;method</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Psyence Australia Pty Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PsyenceAustraliaPtyLtd.Member_6XWCmWdVH0epdAirb_PHmQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Tc_fuUxTkh1eUGoJaoiOKWOJw_2_4">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pysence Biomed II Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PysenceBiomedIICorpMember_G26BZFrZI02CLYH9Vu0ViA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Tc_s9xhNLKKZUuBgqqvetIUXg_3_4">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Newcourt Acquisition Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cayman Islands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_NewcourtAcquistionCorpMember_RS2hbyZeVE21RshMW0SvfQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInSubsidiary" scale="-2" id="Tc_m-oa5JvCxkuv0UuiNCWBkg_4_4">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inter-company balances and transactions are eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial results of subsidiaries in financial&#160;year ended March&#160;31, 2023 and up to January 25, 2024 were presented on a carve out basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements have been prepared on an accrual basis, are based on historical costs, unless otherwise noted.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">11</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_a3n4H1gnzkC7vTiZrbcbCw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Functional and presentation currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements are presented in United States Dollars (<b style="font-weight:bold;">&#8220;USD $&#8221;</b>)<b style="font-weight:bold;">,</b> which is also PBM&#8217;s functional currency. The Company&#8217;s functional currency before the Closing Date of the BCA was Canadian Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This changed upon consummation of the BCA at which time the USD $ represents the currency of the Company&#8217;s funding and is the currency of the primary economic environment in which the Company operates in, except for the Company&#8217;s Australian subsidiary which has an Australian Dollar functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See change in accounting policy in note 3 for further details on the change in the Company&#8217;s presentation currency.</p></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="Tb_fcMOFmZi8UKkW_jQRkrtLw" continuedAt="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Material accounting policies</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" id="Tb_dSYkwhi5SEqi3by8h2oc-w" continuedAt="Tb_dSYkwhi5SEqi3by8h2oc-w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets and financial liabilities, including derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument or derivative contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Summary of the Company&#8217;s classification and measurements of financial assets and liabilities:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:4.8pt;"><td style="vertical-align:bottom;width:50.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Financial Assets and Liabilities</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:22.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Measurement </b></p></td></tr><tr style="height:5.75pt;"><td style="vertical-align:bottom;width:50.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr style="height:5.75pt;"><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Restricted cash</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivative warrant liability</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">NCAC promissory note</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PGI promissory note</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Classification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its financial assets and financial liabilities in the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (&#8220;FVTPL&#8221;); ii) those to be measured subsequently at fair value through other comprehensive income (&#8220;FVOCI&#8221;); and iii) those to be measured at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair value, gains and losses are either recorded in net loss or other comprehensive income (loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company reclassifies financial assets only when its business model for managing those assets changes. Financial liabilities are not reclassified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Amortized cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This category includes financial assets that are held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments of principal and interest (&#8220;SPPI&#8221;) criterion. Financial assets classified in this category are measured at amortized cost using the effective interest method.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">12</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont1" continuedAt="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont2"><ix:continuation id="Tb_dSYkwhi5SEqi3by8h2oc-w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair value through profit or loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This category includes derivative instruments as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL. This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest (&#8220;SPPI&#8221;) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Financial assets at fair value through other comprehensive income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Equity instruments that are not held-for-trading can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable transaction costs are included in the carrying value of the instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets at fair value through other comprehensive income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Compound financial instrument and derivative liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the warrants, including public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized in net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each embedded derivative is measured and presented separately unless the whole hybrid financial instrument is designated as at FVTPL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All financial instruments are required to be measured at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payments of principal and interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value are attributable to changes in own credit risk which is recorded in other comprehensive income.</p></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" id="Tb_YE50mDVzX0ePav8tg3_rhA" continuedAt="Tb_YE50mDVzX0ePav8tg3_rhA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash on hand and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three&#160;months at the date of their acquisition.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">13</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont2" continuedAt="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont3"><ix:continuation id="Tb_YE50mDVzX0ePav8tg3_rhA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" id="Tb_abw6gUgbJESXKOHDc33s8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted cash comprises a collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment certificate with the bank.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory" id="Tb_WnQykXTwKkGXsiIZvf6k4w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Related party transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be a related party transaction when there is transfer of resources or obligations between related parties.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:DescriptionOfChangeInAccountingPolicyPolicyTextBlock" id="Tb_Q1PZdTY2VESz2FNZjWwBGQ" continuedAt="Tb_Q1PZdTY2VESz2FNZjWwBGQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Change in accounting policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to completion of the Business Combination Agreement and NASDAQ listing as explained in Note 1 to the audited consolidated financial statements, on January 25, 2024, the Corporation decided to change the presentation currency of its consolidated financial statements from Canadian Dollars to United States Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors believe that US Dollar financial reporting provides more relevant presentation of the Corporation&#8217;s financial position, funding and treasury functions, financial performance and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in presentation currency represents a change in accounting policy in terms of IAS 8 &#8211; <i style="font-style:italic;">Accounting Policies, Changes in Accounting Estimates and Errors</i>, requiring the restatement of comparative information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with IAS 21 &#8211; <i style="font-style:italic;">The Effects of Changes in Foreign Exchange Rates</i>, the methodology followed in restating historical financial information from CDN$ to US$.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The average and closing rates used in translating the historical financial information from CDN$ to US$ for the various periods were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing rate used as at March 31, 2024 was $<ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="Narr_sXvkkmMUnUSr30Zs70-JhA">0.738</ix:nonFraction> and as at March 31, 2023 was $<ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ClosingForeignExchangeRate" scale="0" id="Narr_IhiczHR5bkWIWCRXodMxug">0.7389</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The average rate used for the year ended March 31, 2024 was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="Narr_BYV1ua7PEEq0BzHyYWZHqg">0.7415</ix:nonFraction>, for the year ended March 31, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="Narr_vt1YLxO6PEqraStpzQOdDA">0.7559</ix:nonFraction> and for the year ended March 31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2021_To_3_31_2022_JQf3C7gGZUeF0m5KrvQUIg" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:AverageForeignExchangeRate" scale="0" id="Narr_Y7GXQnasd0-kR1Gp4Xt1Kw">0.8003</ix:nonFraction>.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">14</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b2392aae_ea60_42c7_8623_f72250796d37"></a><a id="Tc_pT3UFxLl7kuuB3Lotw7-3A_1_2"></a><a id="Tc_g10XS1E8KkqpZuXEu8eb1A_1_6"></a><a id="Tc_MnosbMZPPEmYFMmZtm-1Bg_2_2"></a><a id="Tc_zgiKTlyenkuHyrk1CMFiYQ_2_4"></a><a id="Tc_JGEydjKvy06EJCPRc1KM8Q_2_6"></a><a id="Tc_xqC5UjPhMk2WIU2ZFueL4Q_3_2"></a><a id="Tc_bG9tS0R_R0qFlmkvOJc2lQ_3_4"></a><a id="Tc_ntr2k069zUCUI0OYKmPvsA_3_6"></a><a id="Tc__p8RMyaU_EG0dnsPcJce5A_4_0"></a><a id="Tc_qR1XTbhDuE6k8Dlfce6xCg_4_2"></a><a id="Tc_pVBMfS7Eo0S5hDBWEkqidg_4_4"></a><a id="Tc_l7hk1s54L0yGSbEQHqCzTA_4_6"></a><a id="Tc_qsZDzvgiR0uF9pdGA9CLZA_5_0"></a><a id="Tc_L_OQWYSb8UOUMmmvjR-FIw_6_0"></a><a id="Tc_lpd2Op9mqUC8w2DeFJr8OQ_7_0"></a><a id="Tc_Wy_MXZAOvEiQ_xUKOgy26g_8_0"></a><a id="Tc_xbxKF59_80iz_iB3M6-pLQ_9_0"></a><a id="Tc_M-s9Bbg0FkmKKa8cr8vfRQ_10_0"></a><a id="Tc_8yKxeLnkEUeSJ-ZtopdBOA_11_0"></a><a id="Tc_urtCAKJsOUiO8QBQFNBiEQ_12_0"></a><a id="Tc_zyxBvXuv30CAt7dfRtajKQ_13_0"></a><a id="Tc_OcI6PuFm0UWO3O_uDWYb7A_14_0"></a><a id="Tc_WmJvyDMeJ06CL5U27RV0mQ_15_0"></a><a id="Tc_Kw7av9IfJ0mtMFV2w1kI6A_16_0"></a><a id="Tc_UHuD_yB_nkGQ2OSZLA-utA_17_0"></a><a id="Tc_C8x35XCPTEuodQsJCvbo8A_18_0"></a><a id="Tc_hQYboJjO20qjFYT24ZsCsg_19_0"></a><a id="Tc_B9ItGr0FQEiFH5o1qKdsAg_20_0"></a><a id="_e84af48a_e548_4fa2_91b1_c7b3e74d5553"></a><a id="Tc__ALdPh1l-k-g5hzWQtRatA_1_2"></a><a id="Tc_hZVCkfLwOUey-0dYs945AQ_1_6"></a><a id="Tc_BGpFzxBvPE-T-ET5GD39xQ_2_2"></a><a id="Tc_3yUc81mc_Em0am-4p0OyRA_2_4"></a><a id="Tc_Xvpay8XBV0K1hTbLQ-NKfw_2_6"></a><a id="Tc__-Z2R9C6EEmJgYVIdt79hw_3_2"></a><a id="Tc_yX6EMhXM2UGQxTD_uT0e4g_3_4"></a><a id="Tc_be9iLbvwfUO2PXp-ZEP5rA_3_6"></a><a id="Tc__afukXHLj0mgxkAeFLlHeA_4_0"></a><a id="Tc_wZYnH5AVzkyY2Bn8Aa_O9Q_4_2"></a><a id="Tc_VyrA3ZSclEO1_s0MW0KrVg_4_4"></a><a id="Tc_PFr8QAUbfE6h_mcji3PnNA_4_6"></a><a id="Tc_HhnFzzZygkGVR909NF1wAg_5_0"></a><a id="Tc_RegtU5DPFEGlQMFTlqFQWg_6_0"></a><a id="Tc_OYrEW2996U6vzM_yz_DOZg_7_0"></a><a id="Tc_ORRUMa_x6EeHPQKtSl6i7g_8_0"></a><a id="Tc_hnBb1aqnakS6kEUewk0ELQ_9_0"></a><a id="Tc_gYwxgWz8TkSrL_TKfxFPPg_10_0"></a><a id="Tc_-3_Is35CkUOPCFc2qziZxw_11_0"></a><a id="Tc_Nz4PvbvRZ0avGa-aHzjVBw_12_0"></a><a id="Tc_73ClIBgaakuS6iOj8y6Wkw_13_0"></a><a id="Tc_GPKqS6TOX0OXvTqLXLMVxA_14_0"></a><a id="Tc_CY3fR6pHoEuVee-9hHNzJA_15_0"></a><a id="Tc_jD84gW8vCEC4HqL1JGWbCw_16_0"></a><a id="Tc_Q4E8I5F2sUWNu1k7sfCMpQ_17_0"></a><a id="Tc_dGkkjEpEP0egqSw48ZB-nw_18_0"></a><a id="Tc_FPYUraNjJk-O1vaiEvevFg_19_0"></a><a id="Tc_bwZ6tPuiaUqgsjutZ8kTRQ_20_0"></a><ix:continuation id="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont3" continuedAt="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont4"><ix:continuation id="Tb_Q1PZdTY2VESz2FNZjWwBGQ_cont1" continuedAt="Tb_Q1PZdTY2VESz2FNZjWwBGQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The change in presentation currency is a voluntary change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated to United States dollars which is disclosed in the tables below:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" id="Tb_kMe6bp-krkeeVp_UXNU6BQ" continuedAt="Tb_kMe6bp-krkeeVp_UXNU6BQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_FjOeHoSo3UK_2gVgXNMksQ_7_2">1,805,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" sign="-" scale="0" id="Tc_Y8mye1y9xEmyTC35aY1e3Q_7_4">471,485</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_U6dlW_OCyEmc8pKMfik6AA_7_6">1,334,280</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="0" id="Tc_wybS7hCqAE-cVBbJqaF_0g_8_2">40,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" sign="-" scale="0" id="Tc_ZA6YaTktr0aB2q520KC54w_8_4">10,444</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="0" id="Tc_LsTlHHbON0eKN5Yd0I6uBg_8_6">29,556</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="0" id="Tc_qvS6DRXdh0qFEBszgJyEyw_9_2">202,150</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" sign="-" scale="0" id="Tc_TsnO1fWH4EmdvjnUKRZiCQ_9_4">52,782</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="0" id="Tc_7GoXqDxtWkGQWBwphxoGcw_9_6">149,369</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepayments" scale="0" id="Tc_m87rTGjyN0mgv1ms8D3-gw_10_2">104,276</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepayments" sign="-" scale="0" id="Tc_Dwhb1J1qhU-vyQ6RIKnrfA_10_4">27,226</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepayments" scale="0" id="Tc_5rOCM_l9WEuIse0bq4I7rQ_10_6">77,050</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="0" id="Tc_KuWECQC8-UmbtTFFXMxEfQ_11_2">2,152,192</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" sign="-" scale="0" id="Tc_X2Nm0x1Z2kWMN7uY0Ic8HA_11_4">561,937</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="0" id="Tc_l8Zz6F3twk-Iicyeo5WCEA_11_6">1,590,255</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="0" id="Tc_rrRhLWL6_kqs7Ti8ERPECw_12_2">2,152,192</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" sign="-" scale="0" id="Tc_IMp7r_rU3kq4JOS28zhNzw_12_4">561,937</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="0" id="Tc_QU3iqN-EO0eGAJby96I6hg_12_6">1,590,255</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_47gZbSlWH0OgQ0siDmK0jA_15_2">2,423,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" sign="-" scale="0" id="Tc_UxQIrOTvsE2pfwBk9ebDPw_15_4">632,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_SkxV3ZMu60uT0dQOhM_qDA_15_6">1,790,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="0" id="Tc_myY2kNmZQUCWuKC1SEmX8Q_16_2">2,423,467</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" sign="-" scale="0" id="Tc_Mp-fbAoZdUe2xLB7PF0zbw_16_4">632,767</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="0" id="Tc_9tq2E3K6vkKrVD5vvjrnlw_16_6">1,790,700</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAttributableToOwnersOfParent" sign="-" scale="0" id="Tc_Wbbzer8UWE-ZKh9dUybeEw_18_2">271,275</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" id="Tc__TO72iCTT0qOazWiVBKtvg_18_4">70,830</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAttributableToOwnersOfParent" sign="-" scale="0" id="Tc_bU80ATKWQ0uhK-fkCcLCOg_18_6">200,445</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_q2y963a4P0SgasGGjzngmw_19_2">271,275</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_B7VaVRVfQ0KGGSPNmI5R6A_19_4">70,830</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_Gb_BKiwaFkKGzdFfg_FWmg_19_6">200,445</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="0" id="Tc_I6krmRJHrUuhvm8LJo5GtA_20_2">2,152,192</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" sign="-" scale="0" id="Tc_7IHG10dYPkeZhyAxLpTMLw_20_4">561,937</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="0" id="Tc_5gXTAeZEeEiyQSyWkHRMIg_20_6">1,590,255</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022&#160;Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> $</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_X1MnZeLvd0yY0PeyjodYJA_7_2">2,191,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" sign="-" scale="0" id="Tc_5hX1XKjQ50ye1RPLyHZHEw_7_4">437,658</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_nQ0cWMOIh0C3SwTJhK6l4g_7_6">1,753,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="0" id="Tc_Px8gMGgs10m3_6Ct-YpSJw_8_2">40,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" sign="-" scale="0" id="Tc_vw0I8gekOUeOsVF1yd6SHQ_8_4">7,990</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="0" id="Tc_QNDDB1G4MkWESfJEQJK5CA_8_6">32,010</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="0" id="Tc_5_M-0yWjeUqb-u1veOmEyA_9_2">49,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" sign="-" scale="0" id="Tc_j91Rl9zGAkaAZxycsp-9Gw_9_4">9,862</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentReceivables" scale="0" id="Tc_LdVg54mzkEeuHral4T8xDg_9_6">39,510</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepayments" scale="0" id="Tc_7nkK4ielHEKWT9Gdq8QDhg_10_2">6,729</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepayments" sign="-" scale="0" id="Tc_23H2T4pCbEGhoI-1ebEjAA_10_4">1,344</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepayments" scale="0" id="Tc_N8u094Wrik6GqrQPcppRRA_10_6">5,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="0" id="Tc_XgCaHxXSzEKAUXWoUpPw-g_11_2">2,287,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" sign="-" scale="0" id="Tc_Iz3re_IfqkCrjY-olgN16g_11_4">456,854</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="0" id="Tc_x-TKCMXdl0KI_DFMk3cB_w_11_6">1,830,342</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="0" id="Tc_9nFVYo4AjESW2-QWlNqGTg_12_2">2,287,196</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" sign="-" scale="0" id="Tc_C62lemubyUiXFLptkE7_DA_12_4">456,854</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="0" id="Tc_p9VncCi5_0CIS_pjsSNiNw_12_6">1,830,342</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_iz6hDW51s02wyyfmfZCsvA_15_2">164,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" sign="-" scale="0" id="Tc_BTGfT6jTHEOukgAKOXjRUQ_15_4">32,858</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_BAS801EX_kKEKDHzqiEA6g_15_6">131,642</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="0" id="Tc_9h7lBd6b20O5Dv0oTTeeRA_16_2">164,500</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" sign="-" scale="0" id="Tc_KB5L0D0cIUC68N7LXfMrDQ_16_4">32,858</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="0" id="Tc_KmFY4ivQyUK4fLMj2rmYfg_16_6">131,642</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" id="Tc_7RvoJcfyOEi0-qMr6WhlVg_18_2">2,122,696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAttributableToOwnersOfParent" sign="-" scale="0" id="Tc_6pcbFsUlVU29GMlJZwDLzg_18_4">423,996</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" id="Tc_FoGKgkGHp0aWEudjDpZAQQ_18_6">1,698,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_OcfUzFnQAUCyThwBmJKNFw_19_2">2,122,696</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="0" id="Tc_TgjzwyE930ul5qlsDjrM_A_19_4">423,996</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="0" id="Tc_3x37JFi6PkeIC4C72NPilw_19_6">1,698,700</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="0" id="Tc_09TIiTvkVkSeRGvEzlqifg_20_2">2,287,196</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" sign="-" scale="0" id="Tc_sG2i93B4XkmhpX03g7X8KQ_20_4">456,854</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="0" id="Tc_Os-ee_9mZkO4KMwZAYYzbg_20_6">1,830,342</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">15</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0a181489_4650_490c_bc8e_610ce9aa58b1"></a><a id="Tc_ng3Iutm1a0GX1cMyaqxVWw_1_2"></a><a id="Tc_loCVxbsYs0-a8-jU329gVQ_1_6"></a><a id="Tc_t3PxH7PTGESP52Y-Khgppw_2_2"></a><a id="Tc_bRRm6xZSTkO1GvGnA4ogIA_2_4"></a><a id="Tc_ValIvXkBdEifB1dHjnPKUQ_2_6"></a><a id="Tc_mv269dd1y0G173oWHOIbZQ_3_2"></a><a id="Tc_Ubz6kPIfR0erIH_yaJ99_Q_3_4"></a><a id="Tc_iRlfO67me0KTOovDECN9Ng_3_6"></a><a id="Tc_Ftd4p0__ak2jD3X3wiTTqQ_4_0"></a><a id="Tc_ZvfSlFjtzEyn3cfXFtyNWg_4_2"></a><a id="Tc_gCWMNnZtEU-mTdNpySxFIQ_4_4"></a><a id="Tc_WtwgQ0n19k-5KD5k3YPJvQ_4_6"></a><a id="Tc_dqlDvQFXrUi7zCfq7dpxzA_5_0"></a><a id="Tc_o14JlZvB8k2oEVEiI9e7KQ_6_0"></a><a id="Tc_seLZ5PJuJES7xUeGePekbw_7_0"></a><a id="Tc_FXSL7cUdE0q_LcLNtK9YUQ_8_0"></a><a id="Tc_tXBYxGiKska1iO_XfLhB3g_9_0"></a><a id="Tc_AZA9MrLaU0-2iO3g0IHITg_10_0"></a><a id="Tc_TP8SVrrmGESse6k8acntrQ_11_0"></a><a id="Tc_lG5mEPq4q0K4sqdouFaa5g_12_0"></a><a id="Tc_btk2vccKekyXiyxPy3NRTQ_13_0"></a><a id="Tc_AmNq93sXD0uLiL18PANuYg_14_0"></a><a id="_5e24958a_0a0b_4dfa_916b_f734bd38c037"></a><a id="Tc_c-fkUXm5VEWgrW9cJ51iXA_1_2"></a><a id="Tc_uDn9AZFutU-qTyOCPYGT2Q_1_6"></a><a id="Tc_IVUpQ-azIUqklH83GDNv_Q_2_2"></a><a id="Tc_bdPd2mO3ZkWtaYbBhi5mdA_2_4"></a><a id="Tc_mMAQ4xL-rUGGK-YLFijabg_2_6"></a><a id="Tc_dCsLSqyPsEutBK028RcCQQ_3_2"></a><a id="Tc_y2ODldk330O7QcvtihyJbQ_3_4"></a><a id="Tc_Sgqs2M8iNk2Inc5wStOj8A_3_6"></a><a id="Tc_erjjvE-dkUe18BwJ7WzVUw_4_0"></a><a id="Tc_BDbvyda9g0Op7HraLtms9w_4_2"></a><a id="Tc_gH7mzKbrbUyAZym746GENg_4_4"></a><a id="Tc_I7cCSJSBDEGEk5kNXHJ7Tw_4_6"></a><a id="Tc_t_iI8FZOgUaNdb-H5LxZ-g_5_0"></a><a id="Tc_pygclqqaM0eYDKlEqSSTCQ_5_2"></a><a id="Tc_nYI_rrNLpkamZE6ha1XZSw_5_4"></a><a id="Tc_G8WEo59KxUWgp5eKeqd-rw_5_6"></a><a id="Tc_F2liwT6gCEq_XDTKwgx3kw_6_0"></a><a id="Tc_vCE91QG6aEuHLe1X-oaIaA_7_0"></a><a id="Tc_SSl-DMw4_ES6UCyil6vDaw_8_0"></a><a id="Tc_HKBgP0W3P0qYgABVaCw1cQ_8_2"></a><a id="Tc_OADKdwyetEqbDnH9ROXO3A_10_0"></a><a id="Tc_6A7RPa4EWkqj2T9iQlFX3w_11_0"></a><a id="Tc_zdk0hjIFK0C9q1KTGAr-og_12_0"></a><a id="Tc_VqaFf3aBN0OIdO3Tp4LEUw_13_0"></a><a id="Tc_MGQrKPEuHEGPK-nYfHzmmA_14_0"></a><a id="Tc_W9OP0vo_RU69LunUNcSC3w_16_0"></a><a id="Tc_mj8x7svD50yda52n1JGBtA_17_0"></a><a id="Tc_8qU0NGaANUyujWkZQVsutw_19_0"></a><a id="Tc_d3BYdEFO30aR6S_sCwJ_ig_20_0"></a><a id="Tc_PiSY2J5pLEiTAyB3qT8diQ_21_0"></a><a id="Tc_3ZriZFEDik2Mjr_woiL4xA_21_2"></a><a id="Tc_B6eR2ZDjzkST5DkaX28Idg_21_4"></a><a id="Tc_u5PVmNKfvUGTNfkY1AiRwA_21_6"></a><ix:continuation id="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont4" continuedAt="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont5"><ix:continuation id="Tb_Q1PZdTY2VESz2FNZjWwBGQ_cont2"><ix:continuation id="Tb_kMe6bp-krkeeVp_UXNU6BQ_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" id="Tc_r_xC98wlwkecN8vlp1B7sw_6_2">9,292</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" sign="-" scale="0" id="Tc_j1Zd0Vr_F0iZ4H0W8ZRIOA_6_4">2,263</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" id="Tc_d_0uaflwqEG1Mwkk4iEG3g_6_6">7,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="Tc_eQZdyNBEG0GiLFJqB0aSYw_7_2">2,126,762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" sign="-" scale="0" id="Tc_g0QaVPiaEEyVksb3cc7Bsg_7_4">517,867</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" id="Tc_j10Sev3fkEeEY8qgC_O2Ow_7_6">1,608,895</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" id="Tc__iBEZ89EMkWuDQbBfYKPFA_8_2">484,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" sign="-" scale="0" id="Tc_L2J0Be06NEOCGm5SSZjipQ_8_4">117,947</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" id="Tc_q7Piv3KmgkeYanXdD2ZvQg_8_6">366,435</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="0" id="Tc_3f5IfTdMcUOGd6Hxzct5_A_9_2">1,655,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" sign="-" scale="0" id="Tc__WZo_BLqtUOk-R0LPkMG4A_9_4">403,153</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="0" id="Tc_64WA_lfrQU2nVDilEbR3CA_9_6">1,252,510</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsOperatingIncomeLoss" sign="-" scale="0" id="Tc_xEcsYGR02kmAGIoElLU--A_10_2">4,276,099</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsOperatingIncomeLoss" sign="-" scale="0" id="Tc_WPlgpsKX50eCTxQvu8o6MA_10_4">1,041,230</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsOperatingIncomeLoss" sign="-" scale="0" id="Tc_lW2wWpsXFEWkT2SNxmp-_A_10_6">3,234,869</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="0" id="Tc_YCgQtolG-0KXXXUGrNuZ0Q_12_2">2,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" sign="-" scale="0" id="Tc_VdBM3JE7l0ynqRXm0VrATw_12_4">500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="0" id="Tc_Rt88LYw_Rkm5lH40EtZjKw_12_6">1,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" id="Tc_M5NdwuLPEUaBgeAW4WtkjA_13_2">35,574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" sign="-" scale="0" id="Tc_uMIBRwe6NEGTdhxNkhMxBg_13_4">8,662</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" id="Tc_1Ed1Gs8LlUWIzh0Odko1zg_13_6">26,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_Bw3jO0ecN0mMSIeQ1Nzlqw_14_2">4,238,471</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_Eu-HxIPJfEeKX1e_SJshnA_14_4">1,050,392</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="0" id="Tc_WME3iaiZoU6izXosf2onOA_14_6">3,206,403</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,238,471)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,206,403)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-cash adjustment:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" id="Tc_IKzBO4tWz0KVoh6SjYVOhg_7_2">292,756</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" sign="-" scale="0" id="Tc_CeQduK7jJkamdaiWMIwfMg_7_4">71,469</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="0" id="Tc_jvVDoCoPCUesLfxsG_5J8g_7_6">221,287</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" sign="-" scale="0" id="Tc_IQ48OgQpgUCxVF3IIhQ6aA_8_4">84,499</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" sign="-" scale="0" id="Tc_Bq0GW5_SR0aqtnNUMAuKfA_8_6">84,499</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Changes in working capital:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" sign="-" scale="0" id="Tc_aqF-leFBCkKzl2WaLegmoQ_11_2">152,778</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="0" id="Tc_4iPfgOx9KUyTOA8NlEaBog_11_4">42,920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" sign="-" scale="0" id="Tc_0UH41OOrtkuk_EHlK6YGKA_11_6">109,858</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" sign="-" scale="0" id="Tc_LCWESRcysE2DIoVFMS2sog_12_2">97,547</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="0" id="Tc_JSGiq8Cy7Eu1URBWxPLzSg_12_4">25,882</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" sign="-" scale="0" id="Tc_nQ5Y0Rw_sUC-jKL7mewDcw_12_6">71,665</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_6Vy8K8UFUEi0yTkpRiuf-Q_13_2">2,258,967</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_ZISC8yBH6k2QNtRJawlrJA_13_4">599,909</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_27A0iePANkSqk80_xz-52Q_13_6">1,659,058</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="0" id="Tc_FkW6NW5Uuk6sIto-FR7IWQ_14_2">1,937,073</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" id="Tc_PcbqzFcbbEa7J4KUYZh6lA_14_4">344,993</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="0" id="Tc_pgMYZa3ZFUevmB-Nqvtc5g_14_6">1,592,080</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Proceeds received from Psyence Group Inc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="pbm:ProceedsFromContributionsOfParent" scale="0" id="Tc_GXjPfQ5PqEu_O67UnI5FUQ_16_2">1,551,744</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="pbm:ProceedsFromContributionsOfParent" sign="-" scale="0" id="Tc_KMYK2hDABU6CIm1kEUziKg_16_4">378,821</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:ProceedsFromContributionsOfParent" scale="0" id="Tc_bv-yNKIbykCb_xt0Qw4SGw_16_6">1,172,923</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash provided from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" id="Tc_k7g-eRg950WwTlxa3iHWtw_17_2">1,551,744</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="0" id="Tc_QnZimVmsmkqK5Wb_oyQ9nw_17_4">378,821</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" id="Tc_aAzdOBkoNUyTdk9uJQVzCA_17_6">1,172,923</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" sign="-" scale="0" id="Tc_roWbW0tChEmw0bg8EFRK-A_19_2">385,329</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" sign="-" scale="0" id="Tc_ck-Kkr2_X0ijXPKF7O4ZcA_19_4">33,828</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" sign="-" scale="0" id="Tc_qEF8gBwdHU2_C4v8R7aD4Q_19_6">419,157</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents, start of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_rG-SfbmN7USJOxAcrFF7Hg_20_2">2,191,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" sign="-" scale="0" id="Tc_imSgiZN0qE2Oc1_-Lx2dtA_20_4">437,658</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_Vhud2QPOr0Oh2gyckKwFBQ_20_6">1,753,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,805,765</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (471,486)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,334,280</b></p></td></tr></table></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="Tb_3qBYtWxRgkiCFbTzd8u9uw" continuedAt="Tb_3qBYtWxRgkiCFbTzd8u9uw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and comprehensive loss as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">16</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont5" continuedAt="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont6"><ix:continuation id="Tb_3qBYtWxRgkiCFbTzd8u9uw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory" id="Tb_jAACk6tMBEONYqcTeN_39A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="Tb_Z5FfFs4FL0e3LHGXlmpsaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign currency translation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements are presented in USD $ which is PBM&#8217;s functional currency. The functional currency of its subsidiary consolidated within these Financial Statements is AUD $.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In each individual entity, a foreign currency transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency and the foreign currency at the date of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the end of the reporting period, monetary assets and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The resulting exchange gains or losses arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition, are included in statement of net loss and comprehensive loss in the period in which they arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purpose of presenting these Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries is recorded in reserves.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="Tb_CIzduc5RvUiJJoAZo_UNpg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company presents basic and diluted loss per share data for its common shares. Basic loss per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting the loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="Tb_Z-EBavxaL0GR6oDAya-vzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the options and RSUs granted by the Company shall be recognized as an expense in the Consolidated Financial Statements of the Company. The expense shall be recognized over the vesting period of the options. The fair value options shall be determined using the Black-Scholes model.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory" id="Tb_vxsMY9t8_0CDj_6DiSnFiQ" continuedAt="Tb_vxsMY9t8_0CDj_6DiSnFiQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Income tax comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders&#8217; equity, in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also recognized directly in equity or other comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current tax is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect of previous&#160;years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the amounts and the Company.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">17</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fcMOFmZi8UKkW_jQRkrtLw_cont6"><ix:continuation id="Tb_vxsMY9t8_0CDj_6DiSnFiQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax is recognized in respect of all qualifying temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Financial Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.</p></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="Tb_vrm3OVcKVUaEcZTTozUKbQ" continuedAt="Tb_vrm3OVcKVUaEcZTTozUKbQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Critical accounting estimates and judgements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results may differ from these estimates. The Company&#8217;s management reviews these estimates, judgments, and assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical accounting policies as these require a high level of subjectivity and judgement and could have a material impact on PBM&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Going concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management routinely plans future activities including forecasting future cash flows and forming judgements collectively with directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Judgement is required in determining if the Company&#8217;s has sufficient cash reserves, together with all other available information, to continue as a going concern for a period of at least twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As at March&#160;31, 2024 the Company has concluded that a material uncertainty exists that casts significant doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Reverse takeover transaction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The determination of fair values of consideration paid and net assets acquired is subject to significant estimation. The Company treated the RTO Transaction as a capital transaction equivalent to the issue of shares of the Company in exchange for the net monetary assets of NCAC. The Company determined that the original shareholders of PGI became the single largest shareholder of the Company after the RTO Transaction, therefore the Company was the acquiror and NCAC was the acquiree.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has determined the RTO Transaction did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was estimated by the closing trading price ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2024_ZZfEBp5vhECip57BNE-wtg" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsSharePrice" scale="0" id="Narr_lwYGRlcR40CBnCJenyw5cw">4.79</ix:nonFraction>/share) of the Company&#8217;s common shares listed on the NASDAQ on January&#160;25, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Convertible instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The valuation of convertible debt instruments is subject to significant management estimation. Convertible notes are compound financial instruments which have been designated as a FVTPL classification.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">18</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vrm3OVcKVUaEcZTTozUKbQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The identification of convertible debenture components is based on interpretations of the substance of the contractual arrangement and therefore requires judgment from management. The separation of the components affects the initial recognition of the convertible debenture at issuance and the subsequent remeasurement. As the Company has designated the entire convertible financial instrument as FVTPL given the embedded derivate liability that was contained by the convertible financial instrument, the debentures have not been separated into debt and derivative components. The determination of the fair value of the instrument used a combined discount cash flow approach and a Monte Carlo simulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company is named as a party to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome of these matters may not be estimable at the reporting date, the Company makes provisions, where possible, for the estimated outcome of such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the difference will be accounted for as a charge to profit or loss in that period. The actual results may vary and may cause significant adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rebate over the tax claim is subject to inherent uncertainty and could be subject to being denied and clawed back by the Australian Tax office at a future date. The Company expects that a claw back of the rebate is highly unlikely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Deferred taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant estimates are required in determining the Company&#8217;s income tax provision. Some estimates are based on interpretations of existing tax laws or regulations. Various internal and external factors may have favourable or unfavourable effects on the Company&#8217;s future effective tax rate. These include, but are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, and results of tax audits by tax authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Inputs when using Black-Scholes valuation model</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimates used in determining the private warrant fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes valuation model. Inputs subject to estimates include volatility, estimated lives and market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Government grants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government grants are recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the government grants will be received. Grants are recognized as income when they are received. The Company has recognized the government grant received during the period as research and development grants as other income in the consolidated statements of loss and comprehensive loss.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">19</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_SP4-7RP80kK7HlAXFfrnbQ_1_2"></a><a id="Tc_Ss2mHqA-IUyDrY6XDG2JXA_2_2"></a><a id="Tc_E2JzhEw1L0ihNlQFLbiQeA_3_0"></a><a id="Tc_ebnTAyakEUOcwRedVfOpcw_4_0"></a><a id="Tc_dh7bxnD7Rka8hNcg9pDiVw_5_0"></a><a id="Tc_qjO8y0sD9EGLC0lFHQ-Qiw_6_0"></a><a id="Tc_9xwf7xggUkSbjBu-FmVlsQ_6_2"></a><a id="Tc_Ei1tNS9nW0uUSyxdS7HJIA_7_0"></a><a id="Tc_Gx4qsCyX0U2rcSDIqqT2eA_7_2"></a><a id="Tc_YptroTkQGECPsxklLr3j-g_9_0"></a><a id="Tc_MPWqFk4Qp0WsAJ8__2mOlA_10_0"></a><a id="Tc_iLES9uOR7UioDF2RUxOh8A_10_2"></a><a id="Tc_-3gp0DKedEmHVOz-pM4eeQ_11_0"></a><a id="Tc_jWltbkq7pkauew8OvyerqQ_11_2"></a><a id="Tc_bfJ9rn7fHEu0vbb-iE_9Pw_12_0"></a><a id="Tc_Wp97DOIkGE2OSqTrdtb20w_12_2"></a><a id="Tc_mEUMW224LESG9oLMADR95A_13_0"></a><a id="Tc_oW9Gy33Ej0mmyG17bAes_A_13_2"></a><a id="Tc_uiWFdP9Wf0C3keIGa1u1pQ_14_0"></a><a id="Tc_qPKEKPUF7E2IBY3ygCjLHQ_14_2"></a><a id="Tc_5EHTG2XL0U6rsU13otfqlw_16_0"></a><a id="Tc_7J0TAcTIe0iXAh7YkSJZVA_16_2"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:ReverseTakeoverTransactionWithNcacTextBlock" id="Tb_BWyn9IlEAkeX3rrF1M96Yg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Reverse takeover transaction with NCAC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024 the Company completed the RTO Transaction (See Note&#160;1). As disclosed in Note 4, the RTO Transaction did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was determined by the closing trading price ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_LZT5nK0-7UestTgckCLkuA" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsSharePrice" scale="0" id="Narr_0WEuh-iRiUCIzILyr-AnXQ">4.79</ix:nonFraction>/share) of the NCAC&#8217;s common shares listed on the NASDAQ on January 25, 2024. This was initially estimated by the Company as the opening trading price ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_26_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_lrZq_P2lj0W1n0ER5UZe2A" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsSharePrice" scale="0" id="Narr_eX4tBak_J0-18MCcisHPLA">3.55</ix:nonFraction>/share) of the Company&#8217;s common shares listed on the NASDAQ on January&#160;26, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, upon consummation of the BCA the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g" decimals="INF" format="ixt:numdotdecimal" name="pbm:ReverseTakeoverTransactionSharesIssued" scale="0" id="Narr_JwnLb-89PUSS8y9HhXs8xQ">7,794,659</ix:nonFraction> common shares in exchange for the outstanding ordinary shares held by NCAC stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of listing expenses is as follows:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:ScheduleOfListingExpensesTableTextBlock" id="Tb_iKjR4PRojk-oWnKzq5VQzw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Listing</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;Expense</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consideration paid:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Shares issued to NCAC shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" scale="0" id="Tc_-BjWvLiSA0uAa1dNIk1dYA_4_3">7,794,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total consideration shares issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g" decimals="INF" format="ixt:numdotdecimal" name="pbm:ReverseTakeoverTransactionSharesIssued" scale="0" id="Tc_TXp785p3IEqmDUyD2al-oQ_5_3">7,794,659</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value of the common shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsSharePrice" scale="0" id="Tc_pqohAcBV5EyVjPvWrf8lzg_6_3">4.79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Deemed consideration amount for the common shares issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A" decimals="0" format="ixt:numdotdecimal" name="pbm:ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" scale="0" id="Tc_69yGwjEhOEuumPS7cILh9w_7_3">37,336,416</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net identifiable liabilities acquired:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="0" id="Tc_rNlmj__gsUGj_kUuzOlk2g_10_3">203</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_NDLwPDdV50m_ECSmk7Hdfg_11_3">2,136,505</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">NCAC promissory note (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Borrowings" scale="0" id="Tc_nop5FXgbrkmzjRpvy2soTw_12_3">1,413,529</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Derivative warrant liabilities (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentWarrantLiability" scale="0" id="Tc_ICafjLWRGk2I_CefezI0AQ_13_3">595,358</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net liabilities acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NetAssetsLiabilities" scale="0" id="Tc_dHa-M3NepUmjH5DeZS897w_14_3">4,145,189</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Listing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g" decimals="0" format="ixt:numdotdecimal" name="pbm:ListingExpense" scale="0" id="Tc_5wEbPcPEv0-y3tJmQF3jaA_16_3">41,481,605</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The listing expense has been included in the consolidated statements of net loss and comprehensive loss. Transaction expenses included in the consolidated statements of net loss and comprehensive loss are others costs of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:TransactionExpense" scale="0" id="Narr_kTin9rQpbUGB4fEQ7MoTbQ">2,461,025</ix:nonFraction> in connection with the RTO Transaction composed of legal, banking, professional fees and costs related to the settlement of carved-out assets and liabilities from Psyence Group. Some payments to brokers and advisors were in the Company&#8217;s shares upon RTO at the closing trading price on January 25, 2024 (Refer Note 12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The change in the estimate of the share price used to determine the fair value of consideration paid resulted in an increase to listing expense by $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice" scale="0" id="Narr_gyCs3x1VnEKed-WDjR67mg">9,483,945</ix:nonFraction> from the amount previously reported.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">20</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_PvCfQ016RkWs2xQOZJa6YQ_1_2"></a><a id="Tc_-C3xdIlHx0u3MIqehWwD2Q_1_4"></a><a id="Tc_p4QX5Wb-HkaC9BVKoCl4TA_2_2"></a><a id="Tc_LDesDquX0EKJmB8J-fd6dQ_2_4"></a><a id="Tc_DzshXs9I80Oae9v64t-I-g_3_0"></a><a id="Tc_qJypxKcgIk6TkdV_cT6wiQ_4_0"></a><a id="Tc_ZAyzt-Gb30yTFdvlZHGFtA_5_0"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:CashRestrictedCashAndCashEquivalentsTextBlock" id="Tb_r3rP_ietpEulc4gw7LJC9w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Cash, restricted cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include the following amounts:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory" id="Tb_inq7zBjgF0WXHm4mwqHzlg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unrestricted cash held with chartered banks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:BalancesWithBanks" scale="0" id="Tc_z1mzuvkeoU666LaXIiwa2Q_3_2">733,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:BalancesWithBanks" scale="0" id="Tc_zRND7SJdFEGuRcvqYyTtDw_3_4">1,334,280</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="0" id="Tc_jAMPZdck00W2iXXfuHrkFQ_4_2">29,611</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="0" id="Tc_Xix5mS_MWUqGnjBZARimyA_4_4">29,556</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="pbm:CashRestrictedCashAndCashEquivalents" scale="0" id="Tc_IpCtr2u9R02-QsyRtx5LPQ_5_2">762,799</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="pbm:CashRestrictedCashAndCashEquivalents" scale="0" id="Tc_2VQ0UQDZ-0qONC_9DfTSjA_5_4">1,363,836</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.9pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unrestricted cash held with chartered banks and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $40,000 in a guaranteed investment certificate with the bank. Amounts are presented as restricted cash on the statements of financial position.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><a id="Tc_vV7zScKQZUWo8FE5NxzlRw_1_2"></a><a id="Tc_aDm2xaX4jEKAc7xYOg3ZUA_2_2"></a><a id="Tc_VVHgrf6r8kKmg4DAcr4dkg_3_0"></a><a id="Tc_6R9JSLY5A0ykRHI2VIlq3A_4_0"></a><a id="Tc_7WynCEDbO0W5PmMqpNHIsg_4_2"></a><a id="Tc_vKB9xFjOzk-hM7SsCjJ7tA_5_0"></a><a id="Tc_ijqZmoi-L0CLaWh7s26ETg_6_0"></a><a id="Tc_CLjhIiBCf0GiiREVTNrkAA_8_0"></a><a id="Tc_qg2ZtXTmak-qfPGpS6MeTw_9_0"></a><a id="Tc_qL_c3qowSEWD4Jp7VNdQxw_9_2"></a><a id="Tc_y0Ey8olne0Wg0YXvHB6hJA_10_0"></a><a id="Tc_ebTq9HMzJ0m2m5axbgvohw_11_0"></a><a id="Tc_0bUpZ_tLXUWG9sq1w1nN0w_13_0"></a><a id="Tc_M0NdQ12ZyEeEUOS4L-IxyA_14_0"></a><a id="Tc_Dxq_pxxEIkuw3NUoLFl4KQ_14_2"></a><a id="Tc_zwjE1NFDt0e4BBYaca1IRg_15_0"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="Tb_3lU0F8ptSkiJRa7vNXJTmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Equipment</b></p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="Tb_9Io86Wf7rEyehjRGbwdG2g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Computer </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_ZRqYyGoYrU2C6-I2Wd8ynA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="0" id="Tc_CJJbGSr0VkK9fJtOR3H1pg_5_2">5,727</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_1QeYdHjl3EWi94YMiSvNOA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="Tc_6jJS-agAw0eZx-gxQicuNA_6_2">5,727</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accumulated Depreciation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Charge for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_1-dfoVe4v0uYJUHIYSGRgQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" id="Tc_Y5Egrd_v8k27jp2leAOZMA_10_2">240</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_ipePrLsiFUeta9xYIvy-Ng" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" sign="-" scale="0" id="Tc_FlR8Xkt9bU-lYyj9Tx-tGg_11_2">240</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_xjrxvVhFRE2AUu-5qZqFxg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" id="Tc_aWkNjH0TvESlsi4DbZDiNA_15_2">5,487</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_0bUP_SoBpEi8hzyrN3aXJQ_1_2"></a><a id="Tc_Am-XVm_z3ky0mxWLzdsQfw_1_4"></a><a id="Tc_s5leqGHhVk-afk2QVGllAA_2_2"></a><a id="Tc_harp1qo1002q_M2gJigzpg_2_4"></a><a id="Tc_whvgTfBKXkybJTzCCd9QmA_3_0"></a><a id="Tc_y9c4XDv6U0WnFHQcebAoMw_4_0"></a><a id="Tc_gcko-AfLrEWs9BcDDRtdpQ_5_0"></a><a id="Tc_utB9Rr25Z0ub1_ki1ztoJQ_5_4"></a><a id="Tc_lCekM1Km40uXWZoqokS6Hw_6_0"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:AccountsPayableAndAccruedLiabilitiesTextBlock" id="Tb_0_x6xjXoUUm6gBXH31vmnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Accounts payable and accrued liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued liabilities include the following amounts:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock" id="Tb_ghm-zAIfPk-am8mTInAclA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="0" id="Tc_HpPd2Cq8KEmvwA_CFfrw7A_3_2">562,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" scale="0" id="Tc_Idov-lG6xEySJMIRjlLNBQ_3_4">1,628,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="0" id="Tc_T7NOixjv-UyuNos4oDidXw_4_2">125,951</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AccrualsClassifiedAsCurrent" scale="0" id="Tc_NJGGPWj-BEuXSzu1_PAvVg_4_4">162,557</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:OtherShorttermProvisions" scale="0" id="Tc_XjsviK0HEUOHwu89amMXrw_5_2">66,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_PWduBNAEBUqk318cKOCjVw_6_2">755,202</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" id="Tc_-rfnC6A61k2exnk5AID4dg_6_4">1,790,700</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">21</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_bMAqfC6P9EqqXVQ7W5oTwA_1_2"></a><a id="Tc_TV4XiPClU0yd__fF4yxwsA_2_0"></a><a id="Tc_s_gQeOayTkOz196zh3-qZA_3_0"></a><a id="Tc_HcQk_U5h8EWbWMrYb8cXPA_4_0"></a><a id="Tc_JMGJ6NO7rkeVf72XmmamkQ_4_3"></a><a id="Tc_dRz3Ba-DP0OXTdOZoWofbg_5_0"></a><a id="Tc_erhJStvwcUSkrnJG-ZCsJA_5_3"></a><a id="Tc_pXwZK6IbFUKn7xDgmW6vsA_6_0"></a><a id="Tc_2k9u95uGGU-P98HnvPFEjw_6_3"></a><a id="Tc_wr00cHyyskWIRDaasQQJVA_7_0"></a><a id="Tc_Kx5y1sDaWUG_ESqWw4YUCA_7_3"></a><a id="Tc_H_bJpqjNE061IiR1TDSk9g_8_0"></a><a id="Tc_229iU6zx70qQYisvlT4HnQ_8_3"></a><a id="Tc_0YpeRWa1nEOEDL0Lq7WvfQ_9_0"></a><a id="Tc_mTNS-xvZBE2m1__piX44HA_9_3"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:DisclosureOfConvertibleNoteLiabilityTextBlock" id="Tb_3t-spL67a0Srimx3b33_cg" continuedAt="Tb_3t-spL67a0Srimx3b33_cg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Convertible note liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;15, 2024, in connection with the RTO Transaction (Note&#160;5), the Company and Psyence Biomed II entered into the Securities Purchase Agreement with the Investors and the NCAC Sponsor, relating to up to <ix:nonFraction unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A" contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_RC1H4ZLwU0apeImJQBE_dA" decimals="INF" format="ixt-sec:numwordsen" name="pbm:NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" scale="0" id="Narr_e_cWzvqSGE2O7TBFGdoH5g">four</ix:nonFraction> senior secured convertible notes obligations under which are guaranteed by certain assets of the Company and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_snyZUpSh_k-8or2abjhYpw" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsDebtInstrumentFaceAmount" scale="0" id="Narr_9QWx06s0m0eX2j2ysk_2Mg">12,500,000</ix:nonFraction> in exchange for up to $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_snyZUpSh_k-8or2abjhYpw" decimals="0" format="ixt:numdotdecimal" name="pbm:SubscriptionAmount" scale="0" id="Narr_UKwzcE3Fo0ij3_NdzonpUQ">10,000,000</ix:nonFraction> in cash subscription amounts (the &#8220;<b style="font-weight:bold;">Convertible Note&#160;Financing</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The First Tranche Notes, for an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_dXrtFPMS3U-OLj3sZ1COaA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_FZN3RKKtDU6DeSfAXl2l6w">3,125,000</ix:nonFraction> principal, were delivered by the Company to the Investors on January&#160;25, 2024, in exchange for an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_EyC98DIUWkSnV6ZsDXjDuA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsProceedsFromConvertibleDebt" scale="0" id="Narr_gCqLi0zS2UOaxRlA1H-dHA">2,500,000</ix:nonFraction> in financing, which occurred substantially concurrently with the consummation of the RTO Transaction. On the original issuance date of the First Tranche Notes, interest began accruing at <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_Ov4A1NkLkEa1t15pEcI7Fw" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_VqUH2Wwa_UW4wu2-nk2zbA">8.0</ix:nonFraction>% per annum based on the outstanding principal amount of the First Tranche Notes&#160;and is payable&#160;monthly in arrears in cash or in common shares of the Company at the Conversion Price (as defined below). The maturity date of the First Tranche Note&#160;is January&#160;25, 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The price at which the Investors can convert the outstanding principal and interest to the common shares (the &#8220;Conversion Price&#8221;) is determined as follows: The initial Conversion Price of the First Tranche Notes&#160;was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_Ov4A1NkLkEa1t15pEcI7Fw" decimals="2" format="ixt:numdotdecimal" name="pbm:DebtInstrumentConvertibleInitialConversionPrice" scale="0" id="Narr_Qn_DZuCtbUucUHeQxvZz5g">10.00</ix:nonFraction>; provided, however, that such Conversion Price is subject to certain adjustments according to the terms and reset dates included in the First Tranche Notes&#160;and may be reduced to a Conversion&#160;Floor of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_srt_StatementScenarioAxis_pbm_UntilFirstResetDateMember_xUD9ygGdy0ikpiUdFa3HuA" decimals="2" format="ixt:numdotdecimal" name="pbm:DebtInstrumentConvertibleFloorPrice" scale="0" id="Narr_L8dpvR_ys06KHyZOTWglZQ">1.00</ix:nonFraction>, until the First Reset Date (<ix:nonNumeric contextRef="Duration_1_25_2024_To_1_25_2024_eZQ4RlMJqUmySF9gmBlrAA" format="ixt-sec:durday" name="pbm:NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" id="Narr_WCzkzFWlH0usR5SODD2B2A">5</ix:nonNumeric>&#160;days prior the initial Registration Statement is effective), then to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_srt_StatementScenarioAxis_pbm_OnSecondResetDateMember_xTV-TVOmlEOSuiCCH637yg" decimals="2" format="ixt:numdotdecimal" name="pbm:DebtInstrumentConvertibleFloorPrice" scale="0" id="Narr_coy_2Wo1lEqQlvmXd-HNVQ">0.50</ix:nonFraction> on the Second Reset Date (<ix:nonNumeric contextRef="Duration_1_25_2024_To_1_25_2024_eZQ4RlMJqUmySF9gmBlrAA" format="ixt-sec:durmonth" name="pbm:PeriodOfClosingDateConsideredForSecondResetDate" id="Narr_duyFQZ5KI0aaguvecSFPxw">3</ix:nonNumeric>-month anniversary of Closing Date) and <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2023_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_wL0j3sQ_P02l4cmD5Xha0Q" decimals="2" format="ixt-sec:numwordsen" name="pbm:DebtInstrumentConvertibleFloorPrice" scale="0" id="Narr_QnCbSR4AK0uE4dcBboeuDw">no</ix:nonFraction> floor thereafter. The Conversion Price is the lowest volume-weighted average price (&#8220;<b style="font-weight:bold;">VWAP</b>&#8221;) of the shares up until conversion date subject to the conversion floor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is obligated to make a Make Whole Payment to Investors within <span style="-sec-ix-hidden:Hidden_8zLKxnneHEOziY32s6_j8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-five</span></span> (35) Trading Days following a Conversion Date if the <span style="-sec-ix-hidden:Hidden_bgTt3-yaZkufZ6GsyM4Hmw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty</span></span> (30) Day VWAP, starting from the first Trading Date after the conversion, is lower than the Conversion Price. The Make Whole Payment can be made in either cash or Common Shares, at the Company&#8217;s discretion, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company elects to settle the Make Whole Payment in Common Shares, it will transfer to the Holder the number of Common Shares (the &#8220;Make Whole Shares&#8221;) calculated as the difference between (A)&#160;the principal amount converted on the Conversion Date divided by the <ix:nonNumeric contextRef="Duration_1_15_2024_To_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_t2bpJrv-CEWvzpwrJA9aDA" format="ixt-sec:durday" name="pbm:ThresholdPeriodForVolumeWeightedAveragePrice" id="Narr_oek72jkfq0CVDPYMjc6VQQ">30</ix:nonNumeric> Day VWAP, and (B)&#160;the principal amount converted divided by the Conversion Price on the Conversion Date. Alternatively, if the Company chooses to pay in cash, the payment will equal the number of Make Whole Shares multiplied by the 30 Day VWAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Total proceeds received were $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_w3jAzl07ZUOTF5NYOWIMug" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsProceedsFromConvertibleDebt" scale="0" id="Narr__Mh6FK_RKUqOTh05wuF7Mg">2,500,000</ix:nonFraction>. The Company has designated the entire instrument as FVTPL instrument. The fair value of the convertible notes was estimated using a combined discounted cash flow approach and Monte Carlo simulation with the following assumptions as of March&#160;31, 2024.</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_XpSCtJGVFEW3JU9sTAbAHQ" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" id="Tb_XKycgw6Ickm8w9oikyfuPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_FIOBwMXOW0G4Rh9Kg-g5zw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_XD9o7XbreUWZro5fK31-iw_2_2">1.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Note principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_DrXtvzbxdUuHFqH8Mzx6Eg" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsDebtInstrumentFaceAmount" scale="0" id="Tc_AHtYULc9yE6wv6NV8VXnHA_3_2">3,125,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepayment Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_ifrs-full_ConstantPrepaymentRateMeasurementInputMember_OOYtrkOvCkOAIWIIs2K24g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_cyvgatNCXUyNemm0Y-F7lQ_4_2">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_DiscountRateSharesMeasurementInputMember_T-qLZ5GLyUqYuqKzU6A99Q" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc__Tgn55z2vUSxXDF7axX1XA_5_2">4.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_DiscountRateCashMeasurementInputMember_9zeIuNj3jkeNuHkmFUSZww" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_jqZgM7QLf0yshQFgV4kUDw_6_2">20.83</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility annual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_0n6lL7b98kK_7fXZv3ARAw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_LR0N_YSBHke73UtzhX3OOA_7_2">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility daily</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_8aaTSxqRuk2-CUB0EpgfuA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_GxejfoDEIUqG8cRxlkdH0g_8_2">6.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free annual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_AnnualInterestRateMeasurementInputMember_rlp9Ay7neEuAWClA72ZtUg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_k1XKzxD2lke1x8JL5XyerA_9_2">4.43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value was calculated to be $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_DrXtvzbxdUuHFqH8Mzx6Eg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_lHEkhRARLUWt-Vpf9IhXKQ">7,657,397</ix:nonFraction> as of March&#160;31, 2024. A fair value loss was recognized of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_XpSCtJGVFEW3JU9sTAbAHQ" decimals="0" format="ixt:numdotdecimal" name="pbm:FairValueAdjustmentOnConvertibleNote" sign="-" scale="0" id="Narr_ZCtbfiQFv0WTn-qtsmQEFA">5,157,397</ix:nonFraction> during the&#160;year end March&#160;31, 2024 ($<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_SZy8rGHGj06aGJODffVKug" decimals="0" format="ixt-sec:numwordsen" name="pbm:FairValueAdjustmentOnConvertibleNote" scale="0" id="Narr_k4SLVqeU8UieX7Uvc1FQUA">nil</ix:nonFraction>, March&#160;31, 2023).</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">22</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_3t-spL67a0Srimx3b33_cg_cont1"></ix:continuation><a id="Tc_P5ebF4oCZUSNlHyCdUlPZA_1_2"></a><a id="Tc_fOYDhSSMx0y2kaSZM_X5Sw_1_4"></a><a id="Tc_b0myDtscD0isHhulUud99w_2_2"></a><a id="Tc_m6H5acdU1UWkPON6xTUvSw_2_4"></a><a id="Tc_kn0ZC1q_qUGROll8Lful_w_3_0"></a><a id="Tc_nxvXrsKSwEqyT0MPad7zyw_4_0"></a><a id="Tc_f7k9rEY0XkKEPmSxypUFAQ_5_0"></a><a id="Tc_-Z_VkpesvE6RQOeL-1cFNA_6_0"></a><a id="Tc_gmyaXuu0PEeMryiTTKGIxg_6_3"></a><a id="Tc_sHmn0DqZp0W_kK69sp3Ksw_6_5"></a><a id="Tc_8n1hMYVqUU2Nv9__-3YawQ_7_0"></a><a id="Tc_3MM7oeCHjUqvdlQNhgq-MQ_8_0"></a><a id="Tc_CQlHzAz__E6zoM8mwXt7NQ_8_3"></a><a id="Tc_7DoqV5wTG069qKqUZxpLrA_8_5"></a><a id="Tc_G6liB3JqW0SIHAVJRFIXWA_9_0"></a><a id="Tc_Ee072CTtw0K8AfhpYVM0Qg_9_2"></a><a id="Tc_nuxqTIT1nEmqLPPptKoTBg_9_4"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory" id="Tb_HWhe3C4AzEW4KsHMyWTSlw" continuedAt="Tb_HWhe3C4AzEW4KsHMyWTSlw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Derivative warrant liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the RTO Transaction, NCAC had <ix:nonFraction unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="INF" format="ixt-sec:numwordsen" name="pbm:NumberOfClassesOfWarrantsOutstanding" scale="0" id="Narr_LFIh6KbWcE-yhpBb4LEesg">two</ix:nonFraction> classes of warrants outstanding, which were assumed by the Company upon completion of the RTO Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Public Warrants: which had resulted from NCAC&#8217;s initial public offering (the &#8220;<b style="font-weight:bold;">NCAC IPO</b>&#8221;) and entitled to registration on the Form&#160;F-4 filed in connection with the RTO Transaction. These warrants were listed on Nasdaq Capital Market under the symbol &#8220;PBMWW&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Private Warrants: which had resulted from NCAC&#8217;s private placement prior to the NCAC IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As at the Closing Date and March&#160;31, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsIssued" scale="0" id="Narr_3h4UB6ZRzE6sXz8ItRJqWw">13,070,000</ix:nonFraction> warrants <span style="-sec-ix-hidden:Hidden_x8bw_yf0B0-hUxug_gXzGw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_s2yDhvbquUGMuaS1WGntNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, comprised of <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsOutstanding" scale="0" id="Narr_RLicSE_z3EaM_7ZCm8QSTg">12,500,000</ix:nonFraction> Public Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsIssued" scale="0" id="Narr__b_D9jet80GTen9MsMMIMg">570,000</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_zlOG_EIIqEixGctRvHNJ-A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Private Warrants</span></span>. Each warrant is exercisable to purchase <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="INF" format="ixt-sec:numwordsen" name="pbm:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_IXYPE_1mkk6TSkVplYffEQ">one</ix:nonFraction> common share at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Narr_xzxcF3QISkuIqHVit09KEw">11.50</ix:nonFraction> per share. As a result of the potential cashless exercise feature included within the indenture of the warrants, the Company has classified the warrants as a liability measured at fair value through profit or loss as they failed to meet the &#8220;fixed-for-fixed&#8221; requirements prescribed by <i style="font-style:italic;">IAS 32&#160;&#8211; Financial Instruments: presentation.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since the Public Warrants are traded on Nasdaq, their price is observable. The Company valued the Public Warrants using the closing price of PBMWW to measure their fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes a Black-Scholes options valuation model to value the private warrants at each reporting period, with changes in fair value recognized in the statement of net loss and comprehensive loss. The estimated fair value of the warrant liability is determined using Level 2 inputs. Inherent in a Black-Scholes pricing model are assumptions related to expected volatility of the Public Warrants, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on industry historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="2" format="ixt-sec:numwordsen" name="pbm:DividendYield" scale="-2" id="Narr_xlrDw4OJc0WL5OcdEftiig">zero</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table provides quantitative information regarding Level 2 fair value measurements at March&#160;31, 2024:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" id="Tb_GyYh-yIlLUqkWocMNDUSDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Inputs at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Inputs at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 25, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_mklxx0Juv0KNIx9Swl1rqg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_dCg2NBabD0yJHkVJ9Hl-jQ_3_2">4.79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_kXEDmraaCEyS6VFHtQQhVw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_1LyCJw3eyEum68rmXyFI5g_3_4">1.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A" contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedDividendYieldMeasurementInputMember_VFv-YHMmsUK_zTq5IChJuw" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_WFoATKG2Pkq4aSzJHZrgbQ_4_2">Nil</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedDividendYieldMeasurementInputMember_SJAHRg26zES9xeoq_XHY8g" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_TuLLiwFJbkePF0_Jl0NLzg_4_4">Nil</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExercisePriceMeasurementInputMember_xlkc7XKVtk2Kga0Muvve7g" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_VN3H6746aUmL6nuCxnneqw_5_2">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExercisePriceMeasurementInputMember_MsEFN7RVDUWdk_1PcKNO4w" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_woYxZ4c54UCFeq-VpOuGag_5_4">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_nDnNEVpGr0yCKCdSdpxUUA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_vLkR2LPHJEq8gqOPLa2-Ng_6_2">4.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Z65vDr3AykS8Ay5XjpdTIQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc__mvscMt2SEelatO-lzmyfQ_6_4">4.21</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_GuMP1MngLk2rtbNTk6zhew" contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedLifeMeasurementInputMember_4vaXn8GAh0W1rO5og87law" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_HRCC_5g7yU26vN34UP_eeQ_7_2">5.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_GuMP1MngLk2rtbNTk6zhew" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedLifeMeasurementInputMember_VCLVBTHMYEOISLzWk8xClg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_KZXvvzSwvEKsW_kSuXjHgg_7_4">5.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_C7czhwq_XUix_v98K7IvfA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_snvfJRzASU62xCjmkFwpsg_8_2">17.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_iwqqB_9GUE6i4oPg6dByJQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Tc_WwJL61LvEkGErBfu3Txp1w_8_4">59.98</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiry date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 25, 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 25, 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At March&#160;31, 2024 the fair value of the Public and Private Warrants was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_fFupLa2PC06B5iGPl35ang">875,000</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA" decimals="2" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesFairValuePerShare" scale="0" id="Narr_ElJocgTGukyjVcGTodDAKw">0.07</ix:nonFraction>/warrant) (January 25, 2024 - $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_fZwi28Ln9kCZ-qKFXmRfrQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_4iP9aAX5-UScVQP77qgG-A">568,750</ix:nonFraction>) and $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_dDODhbs5CUGud6lN8O8Rxw">26,608</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_569tQMQIbUuCRwNdZsHxOA" decimals="4" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesFairValuePerShare" scale="0" id="Narr_EW7R_brMo0yVxAE_jFaskw">0.4668</ix:nonFraction>/warrant) (January 25, 2024 - $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Am2J6wS5NU2pK_QwXcD3tg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_Hvp80zY4UkWHHMhnRww6gw">26,608</ix:nonFraction>), respectively. A fair value loss of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="0" id="Narr_egH_qKN1Dka-VcCIYfHKvA">306,250</ix:nonFraction> was recognized on the statement of net loss and comprehensive loss.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">23</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_33u53rjcK0CbpgZDTMUpKg_1_2"></a><a id="Tc_lwKjhRyl_UKAI6SmOlhhDQ_1_7"></a><a id="Tc__REutwhIFEGvOP1HQ8UMBg_2_5"></a><a id="Tc_jJ2Nwpkt3UO51lRmOseROQ_2_10"></a><a id="Tc_AM2roSlMnUe7dyfQnW9PKg_3_5"></a><a id="Tc_ijUilQTeKEuv-ClSSg3qiA_3_10"></a><a id="Tc_OiY3prDcuUmjF7V-d7UhyA_4_2"></a><a id="Tc_8iij9PUy0km0-nqVAumRZQ_4_5"></a><a id="Tc_SiVf5sJnJka-P9OsSoi7DA_4_7"></a><a id="Tc_KGC28tsXvEO0MXN6kmXLoA_4_10"></a><a id="Tc_11p079rvwUCBb-MaUk2adQ_5_2"></a><a id="Tc_dJ3yU9A_GU-MIYqnNQ4ppQ_5_5"></a><a id="Tc_O2Hce9q5Tkqai1PZsaXLBg_5_7"></a><a id="Tc_U4BQu1N_Ikuzcvc_YjMxSg_5_10"></a><a id="Tc_l1KZsvR4rEe2yQ0mQZGILw_6_0"></a><a id="Tc_JMWH_KWFWU6ImNGlBX7S1w_6_2"></a><a id="Tc_p021IbE2tUCVX0qiJVHx2A_6_4"></a><a id="Tc_gu3cM0lR0U667V57VPoPVQ_6_5"></a><a id="Tc_qclKy0W7z0Sc7d2X90TwnA_6_7"></a><a id="Tc_yRa_Vkt43k-V07cc19Lqvw_6_9"></a><a id="Tc_6gsDiXJK00We2PX_0kHzTA_6_10"></a><a id="Tc_d9fqT7VMN0ifxU3sijpBXQ_7_0"></a><a id="Tc_gD4udstVXUG3jOIz9foPjg_8_0"></a><a id="Tc_UQl_ht_FHUC297erV-V8XQ_8_4"></a><a id="Tc_KfxNz_L8x0ySxI8UBQleUw_8_9"></a><a id="Tc_ZKFAQTsAXk-AAeOxF7IquA_1_7"></a><a id="Tc_fsFfqCeY4kmQeVYrXmLQTg_1_9"></a><a id="Tc_6O6VGj-lDUqlUYzHvn5Gzg_2_5"></a><a id="Tc_y8I6zURdEEe1oXKzsv0oFw_2_7"></a><a id="Tc_rkLk7SzZUUWovPG7cs0jrg_2_9"></a><a id="Tc_2A27MxAIqkG0hfln_R1DNg_3_0"></a><a id="Tc_47Idmuf_3kWHWGEm261jJQ_3_2"></a><a id="Tc_wWyUBCAly0a_CfJPp9WmqQ_3_5"></a><a id="Tc_9gjUHHBEkkaXWCanYo2ibA_3_7"></a><a id="Tc_UZ2pdn7a70O4T9SV5n-Jdw_3_9"></a><a id="Tc_OeGAhK4NLE6LNQKznzeJQQ_4_0"></a><a id="Tc_R2RQo75ThEud6ABDpoXWbA_4_2"></a><a id="Tc_WO07jj6wqkCaNSV2irIUtQ_4_4"></a><a id="Tc_v481pWdQYkKMYsqGcPvWWw_5_0"></a><a id="Tc_11FtFBFWUUCoH-bg_6YZXw_5_4"></a><ix:continuation id="Tb_HWhe3C4AzEW4KsHMyWTSlw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Warrant transactions and the number of warrants outstanding are summarized as follows:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock" id="Tb_e0i7vYsd30iW4X96TO9Gkw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Public Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Private Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Weighted  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Weighted   </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA" decimals="INF" format="ixt:numdotdecimal" name="pbm:WarrantsIssuedNumber" scale="0" id="Tc_Hk_GY1nHr0Obrt3jOJqhow_7_2">12,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA" decimals="2" format="ixt:numdotdecimal" name="pbm:WarrantsIssuedWeightedAverageExercisePrice" scale="0" id="Tc_TMX19-j8akOhGHQsz0N5NQ_7_5">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_569tQMQIbUuCRwNdZsHxOA" decimals="INF" format="ixt:numdotdecimal" name="pbm:WarrantsIssuedNumber" scale="0" id="Tc_j-KQdoHmdkqPWux7l8V6tA_7_7">570,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_569tQMQIbUuCRwNdZsHxOA" decimals="2" format="ixt:numdotdecimal" name="pbm:WarrantsIssuedWeightedAverageExercisePrice" scale="0" id="Tc_9RZ_aoWFaUKMG-yx1IpRAA_7_10">11.50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsOutstanding" scale="0" id="Tc_tcVgqDgPmUWsALZS2I4fOA_8_2">12,500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Tc_ktaFz38LL0iZp6K6spvckA_8_5">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsOutstanding" scale="0" id="Tc_TtQfaNn8Fk6PLbHOdW3uug_8_7">570,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Tc_OzV3jZ4jeUKNyi20q47bKQ_8_10">11.50</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following warrants were outstanding and exercisable at March&#160;31, 2024:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" id="Tb_Z6aoDVz1tkmDMoj-hSj50A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">January 25, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January 25, 2029 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_WarrantsIssuedOnJanuary252024Member_Ge_kREe1AE-p07ojtGFkCw" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Tc_3pwsGfnLjkSZgffBShi4zw_4_5">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_WarrantsIssuedOnJanuary252024Member_Ge_kREe1AE-p07ojtGFkCw" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsOutstanding" scale="0" id="Tc_nnuU_ZaU40S2zUQHbgPT3w_4_7">13,070,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_WarrantsIssuedOnJanuary252024Member_Ge_kREe1AE-p07ojtGFkCw" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsExercisable" scale="0" id="Tc_eUKevFAI0k6uRL_CkWLyPw_4_9">13,070,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="2" format="ixt:numdotdecimal" name="pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Tc_3xSVeqQ3Nk-ROl2Nh-Hq5A_5_5">11.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsOutstanding" scale="0" id="Tc_GFQBI6kN9UKT5kSZa1wYFA_5_7">13,070,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="INF" format="ixt:numdotdecimal" name="pbm:NumberOfWarrantsExercisable" scale="0" id="Tc_aVST9ijzJEO7JPvymmFvew_5_9">13,070,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:PromissoryNotesTextBlock" id="Tb_Jr1avuuqeEm9_ECxbFH9PA" continuedAt="Tb_Jr1avuuqeEm9_ECxbFH9PA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Promissory Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, the Company issued an unsecured convertible promissory note to Psyence Group&#160;Inc. (the &#8220;<b style="font-weight:bold;">PGI Note</b>&#8221;), in the principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_-fS2Ulmor0yJbZC9hB8gyA">1,610,657</ix:nonFraction>, which is equal to the total amount owed to PGI in connection with loans the PGI had previously made to the Company. The PGI Note&#160;bears <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ" decimals="2" format="ixt-sec:numwordsen" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_sF4JSFQmwUC46-vUtMA9HA">no</ix:nonFraction> interest, and (i)&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_Rt33JWhG7ku7cESAe2Q9TA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfCurrentBorrowings" scale="0" id="Narr_uxRhJY9rSUSKBybFkLJSQA">150,000</ix:nonFraction> of the principal balance of the PGI Note&#160;was paid on the date of the Closing and (ii)&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_srt_StatementScenarioAxis_pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_5hN9t5cHDkWZRJOTiq9-ZQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDebtInstrumentsIssued" scale="0" id="Narr_R7EkraA580OUPkN4VST8hg">1,460,657</ix:nonFraction> of the principal balance of the PGI Note&#160;will be payable on the date that is the one-year anniversary after the Business Combination, or January&#160;25, 2025. The proceeds from this loan were already received by the Company prior to the acquisition date. This note is convertible into shares at the option of PGI. The conversion price will be mutually agreed upon and such conversion terms will not be less favourable than the below NCAC convertible promissory note. Given that the conversion price is not fixed, the conversion feature has been determined to be an embedded derivative and thus the entire instrument has been designated as FVTPL. The PGI Note upon initial recognition at fair value was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_SxklkCSwtEOOA-C1-coX_A">1,418,675</ix:nonFraction>. At year end the fair value of the PGI Note was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_0gDwTd2QTkau6NL_MH7NiA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_xfc1thKO0U2QhEET7eI-7Q">1,316,236</ix:nonFraction>. A fair value loss of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_Rt33JWhG7ku7cESAe2Q9TA" decimals="0" format="ixt:numdotdecimal" name="pbm:FairValueAdjustmentOnPromissoryNote" scale="0" id="Narr_DqXzZ7xYu0SdK31jban7_Q">47,561</ix:nonFraction>, after factoring in the repayment of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_Rt33JWhG7ku7cESAe2Q9TA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfCurrentBorrowings" scale="0" id="Narr_Rhqhs6V8S0ycNrRzT4WUKA">150,000</ix:nonFraction>, was included in the consolidated statements of net loss and comprehensive loss relating to the PGI Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the notes was calculated using a credit adjusted market borrowing rate to determine fair value. Since the PGI Note is from a related party the difference between fair value and the face value of the PGI Note on initial measurement was recognized in other comprehensive loss. Subsequent change in fair value movements is recognized in consolidated statements of net loss and comprehensive loss.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, NCAC issued an unsecured convertible promissory note, prior to the closing of the RTO, to the NCAC Sponsor (the &#8220;<b style="font-weight:bold;">NCAC Replacement Note</b>&#8221;), in the principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_nXcMNI1ydUezo0_dxGEwgQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_grp58mLg3kGfdbI_c4XnOA">1,615,501</ix:nonFraction>, which is equal to the total amount owed to Sponsor under certain existing promissory notes previously issued by NCAC to the Sponsor (the &#8220;<b style="font-weight:bold;">Existing Notes</b>&#8221;). The NCAC Replacement Note&#160;bears <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_nXcMNI1ydUezo0_dxGEwgQ" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_ytYqbyxkOU-sCC59nwc7DA">no</ix:nonFraction> interest, and (i)&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_-EfQBvs7Lka4G6nGPl75Bw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfCurrentBorrowings" scale="0" id="Narr_cWv8oJ1w3kmN7VVWIh89Og">100,000</ix:nonFraction> of the principal balance of the NCAC Replacement Note&#160;became owing on the date of the Closing and (ii)&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_srt_StatementScenarioAxis_pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_miXMAYbfxkOSULYF69B0Hw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDebtInstrumentsIssued" scale="0" id="Narr_GkhLFY6Qg0SVkHtnRv7JUQ">1,515,501</ix:nonFraction> of the principal balance of the NCAC Replacement Note&#160;will be payable on the date that is the one-year anniversary after the Business Combination, or January&#160;25, 2025. As at March 31, 2024 the Company had not made payment of the $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_tIiRp3n8-02l_21JjlykGA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:CurrentDebtInstrumentsIssued" scale="0" id="Narr_DwO74JaS3kqGAEvVK_ZnwA">100,000</ix:nonFraction> owing to the NCAC Sponsor. This note is convertible into shares at the option of NCAC Sponsor. The conversion price will be mutually agreed upon and such conversion terms will not be less favourable than the above PGI convertible promissory note. Given that the conversion price is not fixed, the conversion feature has been determined to be an embedded derivative and thus the entire instrument has been designated as FVTPL. The NCAC Replacement Note upon initial recognition at fair value was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_nXcMNI1ydUezo0_dxGEwgQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_RTL-lWz84UaLfrmqRNC_kA">1,413,529</ix:nonFraction>. At year end the fair value of the NCAC Replacement Note was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_tIiRp3n8-02l_21JjlykGA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Narr_xPpIlpbJf0egkNxe-tCVtQ">1,474,255</ix:nonFraction>. A fair value loss of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_-EfQBvs7Lka4G6nGPl75Bw" decimals="0" format="ixt:numdotdecimal" name="pbm:FairValueAdjustmentOnPromissoryNote" scale="0" id="Narr_Sj0n-FPaT06Stg0opc3rDw">60,727</ix:nonFraction> was included in the consolidated statements of net loss and comprehensive loss relating to the NCAC Replacement Note.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">24</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Jr1avuuqeEm9_ECxbFH9PA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the notes was calculated using a credit adjusted market borrowing rate.</p></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfIssuedCapitalExplanatory" id="Tb_xKncB5O7XUWGz00o3vFefQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Share capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">a) Authorized</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue an unlimited number of Common Shares, each without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">b) Issued and outstanding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As at March&#160;31, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_TaJIUzhq4kWCHqW0pJNhrA">13,390,659</ix:nonFraction> (March 31, 2023 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfSharesOutstanding" scale="0" id="Narr_Um3_ydiilkmD8SnGymuTuA"><ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_6NH2QaU5RkuqTD28a7mc5Q">nil</ix:nonFraction></ix:nonFraction>) issued and <span style="-sec-ix-hidden:Hidden_t5Q4ViJtT0a_n3x8PTtDQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, because of the completion of the RTO Transaction, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_0wYG8t1HXE-O2rRhbaBJaw" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" scale="0" id="Narr_BDxcY74D8UK_DqcupXCpmA">5,000,000</ix:nonFraction> Common Shares to PGI, <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_KTMtplbPx0WC_t5qQhav6w" decimals="INF" format="ixt:numdotdecimal" name="pbm:ReverseTakeoverTransactionSharesIssued" scale="0" id="Narr_kqNbPCj6i0yLZqxoArc1-A">7,794,659</ix:nonFraction> to the previous shareholders of NCAC and <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_ThirdPartyAdvisorsMember_mC8mvXWyOki084m60qbTKQ" decimals="INF" format="ixt:numdotdecimal" name="pbm:ReverseTakeoverTransactionSharesIssued" scale="0" id="Narr_DjTSbSzLKUKlhjm7dYt7Cg">596,000</ix:nonFraction> to third party advisors (see Note&#160;5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments to advisors of NCAC was settled in the Company&#8217;s shares upon RTO at the closing price. Accounts payable of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_DRqwp1PzKECgohUZ8NbYwA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherPayables" scale="0" id="Narr_Z80Rv8zOa0OpKec-6AFOMQ">2,136,340</ix:nonFraction> acquired from NCAC as part of the RTO transaction was settled through the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_KTMtplbPx0WC_t5qQhav6w" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" scale="0" id="Narr_nS6IhhZ04UWPXyy0H0suKg">446,000</ix:nonFraction> shares at a fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_DRqwp1PzKECgohUZ8NbYwA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_VA1ZTw3bqEWVJRP0h7HzFg">4.79</ix:nonFraction> per share on January 25, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An amount of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ServicesExpense" scale="0" id="Narr_mSxw3Vb3OkqHvgNoClLwQg">1,000,000</ix:nonFraction> owing by the Company for services provided in relation to the RTO transaction was settled through the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" scale="0" id="Narr_YSmQMG_t8k-npx-9L4UYaQ">150,000</ix:nonFraction> common shares at a fair value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_2SQoqYWg3Equ3pwQaDuhMQ">4.79</ix:nonFraction>. A gain on settlement of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsGainLossOnExtinguishmentOfDebt" scale="0" id="Narr_KbvQmOV-hkqiYz4mGXtVVg">281,500</ix:nonFraction> was included in the consolidated statements of net loss and comprehensive loss relating to this advisor settlement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The prior year equity is the net parent investment which represents the net financings that the Company received from Psyence Group to fund it&#8217;s operations through contributions to the clinical trials, cash extended to the Company&#8217;s subsidiaries and the net effect of cost allocations from transactions with Psyence Group, all of which did not require repayments.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">c) Loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of basic and diluted loss per share is based on the loss for the&#160;year divided by the weighted average number of shares in circulation during the&#160;year. In calculating the diluted loss per share, potentially dilutive shares such as options, convertible debt and warrants have not been included as they would have the effect of decreasing the loss per share, and they would therefore be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="Tb_tYvmM4zT7kqIK-hpO9LvqQ" continuedAt="Tb_tYvmM4zT7kqIK-hpO9LvqQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Other income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company received a research and development rebate of AUD $<ix:nonFraction unitRef="Unit_Standard_AUD_jW69VxHF6ECitQL_0ZsRRw" contextRef="Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="0" id="Narr_8CHaM1nCTEWI0gPCd1NU7Q">1,336,622</ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromGovernmentGrants" scale="0" id="Narr_lRB0hHrEI0GMfJQfAy3ENg">879,344</ix:nonFraction>) from the Australian Taxation office. The Company benefits from the Australian Federal Government&#8217;s Research&#160;&amp; Development tax incentive program, which provides up to a <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw" decimals="3" format="ixt:numdotdecimal" name="pbm:MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" scale="-2" id="Narr_h12y_8jr-Um6zhPPyo3W_Q">43.5</ix:nonFraction>% rebate on research and development expenses in Australia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This rebate represents a government grant aimed at supporting research and development activities. Therefore, in accordance with International Financial Reporting Standards (IFRS), the grant is recognized as income when there is a reasonable assurance that the grant will be received and that the Company will comply with the conditions attached to it. These conditions were satisfied when the Company received the rebate on October&#160;5, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;21, 2023 the Company entered into a loan agreement via its Australian subsidiary Psyence Australia (Pty) Ltd (the &#8220;<b style="font-weight:bold;">Borrower</b>&#8221;), to borrow up to AUD $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_ieM9jWT5V0m51QaeqASX4w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_8IgELxvGNEK7rN-Kal_Rqw">1,100,000</ix:nonFraction> by way of a secured loan from RH Capital Finance Co.,&#160;LLC. The Loan is secured by way of a General Security Agreement and company guarantee against the assets of the Borrower and the Company.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">25</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_tYvmM4zT7kqIK-hpO9LvqQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The loan was granted to the Borrower after it successfully registered its research and development activities with the Australian Federal Government. The Borrower benefits from the Australian Federal Government&#8217;s Research&#160;&amp; Development tax incentive program, which provides up to a <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="Duration_8_21_2023_To_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_4lNLIUCIGkWdqrARdGf_Vw" decimals="3" format="ixt:numdotdecimal" name="pbm:MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" scale="-2" id="Narr_Ji-LpXlBLk65BJswQaZhZQ">43.5</ix:nonFraction>% rebate on research and development expenses in Australia. The Loan bears interest at <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_ieM9jWT5V0m51QaeqASX4w" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_tkSAuSjgbUCKNWWEsUwkkQ">16</ix:nonFraction>% per annum subject to a minimum interest chargeable period of <ix:nonNumeric contextRef="Duration_8_21_2023_To_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_4lNLIUCIGkWdqrARdGf_Vw" format="ixt-sec:durwordsen" name="pbm:BorrowingsMinimumInterestChargeablePeriod" id="Narr_6A9MBUvLuEq_WE3MTYWANQ">91&#160;days</ix:nonNumeric> and is repayable at the earlier of: (a)&#160;<ix:nonNumeric contextRef="Duration_8_21_2023_To_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_4lNLIUCIGkWdqrARdGf_Vw" format="ixt-sec:durday" name="pbm:BorrowingsPeriodToRepayAfterNoticeOfAssessment" id="Narr_FOHRsQAquEKcZo1PsgsIcQ">21</ix:nonNumeric> business&#160;days after the notice of assessment (in respect of R&amp;D refunds) is issued by the Australian Taxation Office to the Borrower for the financial&#160;year ended June&#160;30, 2023 (b)&#160;an event of default and (c)&#160;30 November&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The loan with RH Capital Finance Co., LLC was repaid in full on October&#160;5, 2023 when the Company received the research and development rebate from the Australian Taxation office, which was utilized to settle the loan payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_3f-lrQXd4E6JrxjlD7INuQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnBorrowings" scale="0" id="Narr_WJnFB5YgPUetVdEohHnh5w">29,697</ix:nonFraction> (March&#160;31, 2023&#160;- $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_qlM5Q3rZkUqmLNL6sPVskw" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:InterestExpenseOnBorrowings" scale="0" id="Narr_qZsxVk22uUazyzwF69RsYQ">nil</ix:nonFraction>) in interest expense was incurred during the&#160;year ended March&#160;31, 2024, on this loan. The loan and all outstanding interest was repaid.</p></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:CapitalManagementDisclosureTextBlock" id="Tb_7gX-S4-Hg0irHiZ7RLI2eg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Capital management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern to pursue the development of natural health business, to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company manages its capital structure and adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust the amount of cash and cash equivalents on hand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company&#8217;s approach to capital management during the period.</p></ix:nonNumeric><a id="Tc_D4yIGsZWZkyb4swUmjd4rw_1_0"></a><a id="Tc_2u7sTgqs70a86lV1SYmr4A_1_2"></a><a id="Tc_ZJXkaDwTrkeame9as7JhOg_1_4"></a><a id="Tc_9UeRJvQODkGbtaRBzTuR8g_2_0"></a><a id="Tc_-qeGX4X4EEilFpBz4moGkQ_3_0"></a><a id="Tc_67S0GVnq90acadQUm-zNrQ_4_0"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="Tb_h-iJYccXpkW6hVyfGHvLaw" continuedAt="Tb_h-iJYccXpkW6hVyfGHvLaw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Transactions with related parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. The Company incurred the following transactions with related parties during the&#160;years ended March&#160;31, 2024 and March&#160;31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Compensation to key management personnel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key management personnel are those people who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company&#8217;s executive officers and Board of Directors.</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" id="Tb_9TujsyO-FEuRALAGP8aW9A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Key Management Personnel</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short term benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" id="Tc_h6CYSEgHeE-rjv9vhAKjIw_2_2">465,702</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" scale="0" id="Tc_ruWF0B5UQ0iZ7eE0Jam4Iw_2_4">593,729</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" id="Tc_1NBh9nOPrE-kcQaee-BoHw_3_2">233,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" scale="0" id="Tc_kKR39HHap0GvBLZNYjgSCw_3_4">174,782</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" id="Tc_TTGziQSk8Ey2vHBpig-fuA_4_2">698,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:KeyManagementPersonnelCompensation" scale="0" id="Tc_HPpzIjye-UaIQXSqlqCVjg_4_4">768,511</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Short term benefits consist of consulting fees, director&#8217;s fees, payroll and other benefits paid to key management personnel. Share based compensation is options granted to key management personnel.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">26</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_h-iJYccXpkW6hVyfGHvLaw_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="Tb_wot1bC_4ZkGBnnQcst3VEA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">16. Share based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the&#160;year ended March&#160;31, 2024, $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" id="Narr_k23fy62TT02TcaVMbSib1g">317,882</ix:nonFraction> (Year ended March&#160;31, 2023&#160;- $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" id="Narr_qve3RMyOfEqZg44EuuOVXw">221,287</ix:nonFraction>) was recognized for options and restricted stock units (&#8220;RSU&#8217;s&#8221;) granted by Psyence Group under professional and consulting fees expenses and general and administrative expenses on the consolidated statements of net loss and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This share-based compensation relates only to the historic carve out pre-combination period and does not relate to options or RSUs in the Company. <ix:nonFraction unitRef="Unit_Standard_Options_7uzaMjMwKkiCpqW1np5Gkw" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_cS3c1YLOpEGPY5zqKrE9sQ">No</ix:nonFraction> share options or <span style="-sec-ix-hidden:Hidden_XxB_F4KMEE25cXOfcM4pEQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">RSUs</span></span> have been issued by the Company post transaction and listing date.</p></ix:nonNumeric><a id="Tc_vXQxQFOV3EmSMOWDXefBKg_1_2"></a><a id="Tc_ql51knJ08UubL4tuZtQTjQ_1_4"></a><a id="Tc_OafV1faLZ0SYpgVHOzkqYg_2_0"></a><a id="Tc_g3E0ScnF-k29bA3vb8mmOA_3_0"></a><a id="Tc_bEWFb5uhS0y_TawfKkR5LA_4_0"></a><a id="Tc_UP-n_OVoykKV8VwpdFEJGQ_4_4"></a><a id="Tc_zVoFpxlaS0G9jgLY5RdudA_5_0"></a><a id="Tc_MdhXvp0eeUaMLxrphXjiIg_5_4"></a><a id="Tc_AWSzvhl_8USdFCdT-hkdaQ_6_0"></a><a id="Tc_WMRjxIgdcEWW0TFrN2ZSPw_6_4"></a><a id="Tc_SD8u3o0Y1UOLzb6mUua55Q_7_0"></a><a id="Tc_olmz8zP_3EmPkWobE74Fhg_8_0"></a><a id="Tc_n4pR8DsnAEughjMnlm950g_8_2"></a><a id="Tc_5fjHP7u0b0aRih-uELCgVA_8_4"></a><a id="Tc_-iuthMvugEam_YkZ4jw5GA_1_0"></a><a id="Tc_cSP8Z9fuWUqxacXsJSzVsg_1_2"></a><a id="Tc_T9uicyhqC0Wkqg5f3aMgNQ_1_4"></a><a id="Tc_-29ebqjaHEiIQvGAAeVRwA_2_0"></a><a id="Tc_AJsiWE_rmUiU2xX0w_Goag_2_4"></a><a id="Tc_SWe5lsup80uLdEMrv57ouw_3_0"></a><a id="Tc_0-7JRvjLPEazAKLdzNoc1g_4_0"></a><a id="Tc_oDqIj3MbCUGaZlUe0fm9-Q_4_4"></a><a id="Tc_jLKy9fyn0U64Kw_gX-roPw_5_0"></a><a id="Tc_knarj-v2wUGfckyo1L6fVA_1_0"></a><a id="Tc_HSJnsedbG0O4x0hMYzFaMg_1_2"></a><a id="Tc_A_FBrrje1USMfss63QvVhA_1_4"></a><a id="Tc_fF05g1-fhk-zEBWBajIyuA_2_0"></a><a id="Tc_NdfXtWz8Sk-CAo1jlyycqw_2_4"></a><a id="Tc_r1uOQFGGdEO8iUUqkOpepA_3_0"></a><a id="Tc_Fo_EaXsEWUyQJnpFdU2V3g_3_2"></a><a id="Tc_PuBA-Y_fTECPqYKkNyji9w_4_0"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="Tb_6RHmZCAQKEG1spBFvgbCOw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. Income tax note</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of the combined Canadian federal and provincial statutory income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA__NbCY8cPYUCtxWf2hnkGgw" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:ApplicableTaxRate" scale="-2" id="Narr_r3UmBuDbjEy4FsIyCpP5Jg">26.5</ix:nonFraction>% (2023&#160;&#8211; <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_GeographicalAreasAxis_country_CA_ipl1RTFCVU6OA2u7sgwd-g" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:ApplicableTaxRate" scale="-2" id="Narr_i7zNbyVzbUeRiFDoxEkCwg">26.5</ix:nonFraction>%) to the effective tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_DmIzE4iLS0CIS_a_zFxsPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Income/(Loss) before recovery of income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AccountingProfit" sign="-" scale="0" id="Tc_lbzVtJnSCUKqTta8n9Ydow_2_2">51,159,048</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:AccountingProfit" sign="-" scale="0" id="Tc_OWGnjgJuX0SvghqmWnJmeA_2_4">3,206,403</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax (recovery)/expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" sign="-" scale="0" id="Tc_Vc8H6LHXNE2TFEAYZuVdGQ_3_2">13,557,148</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" sign="-" scale="0" id="Tc_evdkFlrxpUiKMYi7wEnJXw_3_4">849,679</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Difference in foreign tax rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:TaxEffectOfForeignTaxRates" scale="0" id="Tc_YeFXCGYX6kKEoRpi6DY-BQ_4_2">966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Listing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:TaxEffectOflistingExpense" scale="0" id="Tc_Lgy2DU9JAEezR28PGOEcSQ_5_2">10,992,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other permanent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:TaxEffectOfotherPermanentExpenses" scale="0" id="Tc_KBabWDCviUOxjfg0-d2X3w_6_2">2,061,001</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in tax benefits not recognized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:TaxEffectFromChangeInTaxBenefitsNotRecognized" scale="0" id="Tc_OgFzGuQGyUm9aPa8JlE9MQ_7_2">502,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA" decimals="0" format="ixt:numdotdecimal" name="pbm:TaxEffectFromChangeInTaxBenefitsNotRecognized" scale="0" id="Tc_1XM2wKwNaEqm0TD_PIvGGg_7_4">849,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax (recovery)/expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Unrecognized deferred tax asset</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amounts of assets and liabilities. Deferred tax assets have not been recognized in respect of the following deductible temporary differences:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="Tb_iV4aqMeHE0-r6AG7bhYwJg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Unrecognized deductible temporary differences</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_ComputerEquipmentMember_7jZCSqZ_9UaOraMsvT_DUg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="Tc_zqjpnTabjUCbJGoTWGi5lg_2_2">240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_pbm_LoanLiabilityMember_Bfg_MzgGgE248VkLkaHv1A" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="Tc_aZ74Q6NyhEyIj0EZ5i0fdg_3_2">124,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_pbm_LoanLiabilityMember_IYWYvzYJfU2ryBzR65Zllg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="Tc_XC05k7wybkib7tu6qEAgzg_3_4">22,035</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward-Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_ebbDbrQcZkK0zv4fy_SFHg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="Tc_fPa5mQkVu0mlJuMJUBSOWw_4_2">1,357,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward-Australia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_nAJQDxrBpkSuuvZsO96n0Q" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="Tc_stkYiZEbFUqXPo6FZO0iKw_5_2">164,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_ifrs-full_GeographicalAreasAxis_country_AU_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_oXkJbW1flU65sYmCYJGLPg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="Tc_Q03xLiiDfkadmAdf4w8HDA_5_4">1,699,257</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="Tc_fgvqbQXSV021CEhM14FOAA_6_2">1,646,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="0" id="Tc_9V7Q5B9BB0KGIukNcesh7A_6_4">1,721,292</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-capital loss carry forwards will expire as noted in the table below:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock" id="Tb_zpBF2twU_Uy6eQQIXOFxKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year of expiry</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Canada</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Australia</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_pbm_IfrsTaxPeriodAxis_pbm_TaxYear2044Member_WwE4lXg6VE6ETeoIPfEQ6w" decimals="0" format="ixt:numdotdecimal" name="pbm:NonCapitalLossCarryForwards" scale="0" id="Tc_IQ2zSQOh6UCZjbQdwsepKw_2_2">1,357,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Indefinite</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_pbm_IfrsTaxPeriodAxis_pbm_IndefinitePeriodMember_X0xZ3jp2mkq_3uYS8sNVww" decimals="0" format="ixt:numdotdecimal" name="pbm:NonCapitalLossCarryForwards" scale="0" id="Tc_g9GUgzeeuE6xiVXutrMWTA_3_4">164,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_RIjV61siK0uleVe4MSXSMg" decimals="0" format="ixt:numdotdecimal" name="pbm:NonCapitalLossCarryForwards" scale="0" id="Tc_Y68susX21EOhwKR2lF4Qvw_4_2">1,357,347</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ay66gT7zZ0uREQ7yRI0cAw" decimals="0" format="ixt:numdotdecimal" name="pbm:NonCapitalLossCarryForwards" scale="0" id="Tc_PR7PGfO7SEWwSZ6VRq2xGQ_4_4">164,861</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">27</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_PEEEofU9ikObkY4wA2XIng_1_2"></a><a id="Tc_txlT2PnN4kqCJ7xQZ46w0g_1_4"></a><a id="Tc_wtvC24Cx7USamYy-2yaBYg_1_6"></a><a id="Tc_CBcUba3bf022ivv_MRpI1w_1_8"></a><a id="Tc_DyXkhREL80isxePHVs_rhw_2_0"></a><a id="Tc_IO21Nx70TEGvz6susUmTcg_2_2"></a><a id="Tc_KmH0Z2QDh0WjC6o4VWMflg_2_6"></a><a id="Tc_VeEDAbpHcEq-xQrbRZ3hyA_3_0"></a><a id="Tc_2XFAmmULFE6Sn0oLV5Zc7Q_3_4"></a><a id="Tc_qsfBdNGYR0mH31XzK9ZXNg_3_6"></a><a id="Tc_K1WsswoClUyp6Ct56Qx4Rg_4_0"></a><a id="Tc_pbPz0bF1bku2y1RBoQbWSQ_4_2"></a><a id="Tc_OM1Znv_0NE-Sv91VSkbNZQ_4_4"></a><a id="Tc_oOWXRU3P0E2U5471_nIUvQ_5_0"></a><a id="Tc_pgG9eMxW70qS89qBi0W-UQ_5_2"></a><a id="Tc_RWQrjZsixUe_A9aQF6k5iw_5_4"></a><a id="Tc_mCt4LGgTH02fyrCNYEsG0g_6_0"></a><a id="Tc_4ZjLrFu4vkyxVajsOAsaaw_6_2"></a><a id="Tc_9viDcZTBDUmzs1DaGFeOzw_6_4"></a><a id="Tc_-VhBJ3oFtUus8gM9JwA_Xg_7_0"></a><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="Tb_fZ3wPvk57UGE6UumSG_1hg" continuedAt="Tb_fZ3wPvk57UGE6UumSG_1hg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18. Financial instruments and financial risk management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">a) Financial instrument classification and fair value measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that are recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of hierarchy has the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8211; quoted prices in active markets for identical financial instruments.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8211; quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in the markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8211; valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below presents the carrying value of the Company&#8217;s financial instruments:</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory" id="Tb_lO79mJUvmEeawG0ugUOuBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities &#8211; private warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_H4W4G8XGKUi_LOkR72lsQA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_Tfre897-2EufnmDU5aelWw_2_4">26,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_0tIdiQ7fUEKkoN3p-hLo-Q" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_xdXzQD0_3kuQitIrU8dpcA_2_8">26,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities &#8211; public warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PublicWarrantsMember_dwZDj5CY_kWj6NkZwas54g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_0oybAn8usU6SpwQFUtEDgQ_3_2">875,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PublicWarrantsMember_ZIGv0avMc0GYY8eOD0yDqw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_R19rfPXjTU2OXD243RmOjg_3_8">875,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_5wmoOjA370-BDjmpcYZTtw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_Ift6JbVhw0O_eU0uoNej-g_4_6">7,657,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_HzIBP-BDS0iBcUlFJmYxvQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_6-RRM5H3H0WUDkM76p9KIg_4_8">7,657,397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NCAC Sponsor promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_a6DRGR0kP0CtkXqAEpTHbw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_HC9Yr-OGxUulSd5oRLa3Qg_5_6">1,474,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_sCiZc0LkzEif6BGm_OtlfA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_23ucUCAiCkStVvHsHCd8Jw_5_8">1,474,256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PGI promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsPromissoryNoteMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1MqeGaZQTkmZ9uo64ysG4Q" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_zjADtPutRECW_B_uErTmSA_6_6">1,316,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsPromissoryNoteMember_9ScKY7OBvU6qJkoGTvZzKw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_wS4VIrY81ke3gU58Jx7USQ_6_8">1,316,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_gpUJ9iKr40yfgmBdIh8i8Q" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_U3Lz1u_MG0GDD3k43Ckw_w_7_2">875,000</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_GVpNsIbN90GJv-LofUYMOg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_KBilO7-pukevaskWemvctg_7_4">26,608</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_9W7HSkN-ZEWhSSTlLJLMYw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_yj-JyL0LCke2Enxy9lMVRA_7_6">10,447,889</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilitiesAtFairValue" scale="0" id="Tc_B02ceIRr2UC2Li6i-xp2MQ_7_8">11,349,497</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The face value of the other financial instruments approximates the fair value due to the short-term maturity nature of the financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There were no transfers in and out of level 3 during the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">b) Risk management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company&#8217;s Board of Directors has overall responsibility for the establishment and oversight of the Company&#8217;s risk management framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Credit risk arises from cash and cash equivalents held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Liquidity risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">28</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_X16GBiU4EEeOKkSZPLT8iQ_1_2"></a><a id="Tc_wV0vL2PAM0C8vZANcX7LWA_1_4"></a><a id="Tc_m8Bitzno80aRtcoam4i-qA_1_6"></a><a id="Tc_9X9HtTuvbE-E_RK-W7ksQg_1_8"></a><a id="Tc_IRSa3bSos0y15iyXUTGLsA_2_2"></a><a id="Tc_BDlNYzT62UaFVLhfE1oi0A_2_4"></a><a id="Tc_CL5bqEPbA0mXkZgf2umFFw_2_6"></a><a id="Tc_FnlI40BN1EWuAWWAe9Ih_w_2_8"></a><a id="Tc_G3olChjbSk22OBrGaTB08Q_3_0"></a><a id="Tc_Tw3PaK8CSkeqvQQqlALSEw_3_8"></a><a id="Tc_oDYofSM31UGJs2t3Lv3pQg_4_0"></a><a id="Tc_skQbIaP8okiFrB1FgLJrDg_5_0"></a><a id="Tc_nm8T54FbzE6xoYxIqWLOzA_5_8"></a><a id="Tc_qTg6lU0Ss0elKIkIhhdqAw_6_0"></a><a id="Tc_TI4BLUQOWkW8ZhSgLjFWzw_6_8"></a><a id="Tc_ezeJY-xo7UKvMqx8_3QSWg_7_0"></a><ix:continuation id="Tb_fZ3wPvk57UGE6UumSG_1hg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company&#8217;s main source of funding has been through investments from its parent. The Company&#8217;s access to financing is uncertain. There can be no assurance of continued access to significant equity or debt funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table set forth the maturity of the contractual obligations as at March&#160;31, 2024 and after</p><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="pbm:ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock" id="Tb_b1lSi6mWy0iSW4LxBedeFQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between 1 </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and 3 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable &amp; accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_AmT7G0GxkU2kHfFmvoXWyg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="0" id="Tc_4TovZc-9TUm3gDm_WDLLUw_3_2">714,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_AmT7G0GxkU2kHfFmvoXWyg" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_YBE6XTNZfkmcou8qY9Btog_3_4">714,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_0Qw1JPRffk-sFJICGMRYNg" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_ONjfTP7d2EyOyc8b1Fkyaw_3_6">714,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible note liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_HzIBP-BDS0iBcUlFJmYxvQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="0" id="Tc_byXQSjIYHkyjHe6wFUEfJw_4_2">7,657,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_HzIBP-BDS0iBcUlFJmYxvQ" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_GjNbjL4Pi0uME7FT6AXUZA_4_4">3,875,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_cEdgQ5bJd06uTqKWAeXLww" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_1wsW8QGVbUSPAFSrp4f42g_4_6">250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_CBu0LGH96Uq1bwkLGIZIlw" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_HBrd8r7vrEqgm3iY77uNpg_4_8">3,625,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due to NCAC sponsor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_h3aSU-K3ukq60Id9Kf0N4w" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="0" id="Tc_7Ue94PVWZ0GYQ5ZgShzctA_5_2">1,615,501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_h3aSU-K3ukq60Id9Kf0N4w" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_BRAHNF_ou0O2OJKa05SeNw_5_4">1,615,501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_fldBCEgE6kSkrzCFgPayzg" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_IYDkLDcrP0OYOn44J8WIvQ_5_6">1,615,501</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due to Psyence Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_aKXOxKCzikiefTsqg-KknQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="0" id="Tc_0ICYLiIGdUu8XrJV7JoGZw_6_2">1,460,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_aKXOxKCzikiefTsqg-KknQ" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_UrPqlRU3U06ksaUAXeOYhA_6_4">1,460,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o-z_ZS_GkkqdhTX8BnXnaQ" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_AXaMaramB0i-s0duI0t4Bw_6_6">1,460,657</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total contractual obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:FinancialLiabilities" scale="0" id="Tc_6ru2r3WaDkeRNluTPaMf9Q_7_2">11,447,737</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_PmKF-qH0fUy_eNo1LsGKIQ_7_4">7,665,340</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_-EyNTF-GgkaIrUlPa35XIg" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_6LcU-R1oaEqTkQ58gNt-XA_7_6">4,040,340</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_Se9-CIpcRkaZzb8oP9NClQ" decimals="0" format="ixt:numdotdecimal" name="pbm:FinancialLiabilitiesUndiscountedCashFlows" scale="0" id="Tc_2Oy9JEaweEevqLeFBkHV2A_7_8">3,625,000</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Foreign exchange risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As at March&#160;31, 2024, a <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw" decimals="2" format="ixt:numdotdecimal" name="pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption" scale="-2" id="Narr_ayDNJG7jeU6AIzvfXnr2Uw">10</ix:nonFraction>% fluctuation in foreign exchange rates would result in a $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="0" format="ixt:numdotdecimal" name="pbm:IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent" scale="0" id="Narr_NIPG85VJkUGEqIPBAGzwtg">4,139</ix:nonFraction> impact to net loss and comprehensive loss.</p></ix:continuation><ix:nonNumeric contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="Tb_-8wbqtV5ZkC80XdpNqlxdw" continuedAt="Tb_-8wbqtV5ZkC80XdpNqlxdw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has received additional financing of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_WCUD7D3O30eL671BNA5zOQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_LJ9pdFvQdEypOet19sw5DA">1,000,000</ix:nonFraction> related to the Second Tranche of convertible notes:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On May&#160;31, 2024, the Company received proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_5_31_2024_To_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_n_9pkBhIOEaocJLzvCa1KQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="0" id="Narr_si0jORV7_EeHmZMmXnVz4w">250,000</ix:nonFraction> related to the issuance of the Second Tranche Notes. The principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_xbkoUUMcMU-zQH04gc1B7Q" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_KXaYmdQII0evGHRvEggxpw">312,250</ix:nonFraction> was issued under the same terms as the First Tranche Notes, with interest accruing at <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_xbkoUUMcMU-zQH04gc1B7Q" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_J5jsS-KbRUWwKjXTkHMFgQ">8.0</ix:nonFraction>% per annum from the issuance date. The Conversion Price remains subject to adjustment as per the terms outlined in the original Securities Purchase Agreement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On June&#160;17, 2024, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_6_17_2024_To_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_TakD6semK0yRl952XvE8qg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="0" id="Narr_BYUIGXDRlkSd7TVTX1jgrA">250,000</ix:nonFraction> in proceeds was received by the Company for the issuance of the Second Tranche Notes. The principal amount issued was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_BJrV3lqLKEyRyjAj25AV4Q" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_o3MVvcO-okWeXbcpCERDng">312,250</ix:nonFraction>, also under the terms consistent with the First Tranche Notes. Interest accrues at <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_PM6a_iQxqU-pxFt4cy2t8A" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_QrG-qNIC0kasRW2y2-qbUQ">8.0</ix:nonFraction>% per annum from the date of issuance, with the Conversion Price subject to the same adjustment mechanisms detailed in the initial agreement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On July 15, 2024, an additional $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_zZkoynDJMUmruO9PlmDnHQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities" scale="0" id="Narr_bhpFkTUWpUuBAgOLvQr_uw">500,000</ix:nonFraction> in proceeds was received by the Company for the issuance of the Second Tranche Notes. The principal amount issued was $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RxOFqjiYkk-14gPIVMGVgg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:NotionalAmount" scale="0" id="Narr_-v568Oc-Zki7nbgVhScmBA">625,000</ix:nonFraction>, also under the terms consistent with the First Tranche Notes. Interest accrues at <ix:nonFraction unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ" contextRef="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_nExNeJnlAkCUbDgmBzFjag" decimals="3" format="ixt:numdotdecimal" name="ifrs-full:BorrowingsInterestRate" scale="-2" id="Narr_bsPzsLA-UUyHaxeVlTPDCA">8.0</ix:nonFraction>% per annum from the date of issuance, with the Conversion Price subject to the same adjustment mechanisms detailed in the initial agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These subsequent financings are part of the Convertible Note&#160;Financing arrangement entered into in connection with the RTO Transaction.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">29</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 16pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Consolidated Financial Statements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-8wbqtV5ZkC80XdpNqlxdw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has received <ix:nonFraction unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A" contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA" decimals="INF" format="ixt-sec:numwordsen" name="pbm:NumberOfConversionNotices" scale="0" id="Narr_zSc7fozTTUeGkVT4CZJmaQ">two</ix:nonFraction> conversion notices related to the First Tranche of convertible notes:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On May&#160;15, 2024, a conversion notice was received for a principal amount of $<ix:nonFraction unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA" contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_w55DsmyS8EihPG7FoizvZw" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsDebtConversionOriginalDebtAmount1" scale="0" id="Narr_uixnfqiS-UWbiCLQeqbFHA">70,000</ix:nonFraction>. This amount converted at a VWAP of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_w55DsmyS8EihPG7FoizvZw" decimals="4" format="ixt:numdotdecimal" name="pbm:DebtConversionVolumeWeightedAveragePricePerShare" scale="0" id="Narr_xcWbYWHGvUif72YjaqsepQ">0.5361</ix:nonFraction> per share, resulting in the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_w55DsmyS8EihPG7FoizvZw" decimals="INF" format="ixt:numdotdecimal" name="pbm:IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_ROzZ-vlgn0G4fF_TN7kipA">130,572</ix:nonFraction> shares.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On June&#160;20, 2024, a second conversion notice was received for a principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA" contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RzTFDy0njUmWjdXWuxBKzA" decimals="0" format="ixt:numdotdecimal" name="pbm:IfrsDebtConversionOriginalDebtAmount1" scale="0" id="Narr_svcPapFZu02aWOKVS5o8yQ">1,072,200</ix:nonFraction>. This converted at a VWAP of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RzTFDy0njUmWjdXWuxBKzA" decimals="4" format="ixt:numdotdecimal" name="pbm:DebtConversionVolumeWeightedAveragePricePerShare" scale="0" id="Narr_djF9R-cDMEKsi2LUYIVdMA">0.5361</ix:nonFraction> per share, leading to the issuance of <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RzTFDy0njUmWjdXWuxBKzA" decimals="INF" format="ixt:numdotdecimal" name="pbm:IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_-TWtzskQWEySvRMslHPJsw">2,000,000</ix:nonFraction> shares.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_GWT3zleBVUqWPPvqxVkOFg" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement" scale="0" id="Narr_rzaoLx6jS0Oprd9hsAOsGA">86,790</ix:nonFraction> shares on May&#160;15, 2024, and <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_dOTID6jPYEuNrAYNswuBQA" decimals="INF" format="ixt:numdotdecimal" name="pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement" scale="0" id="Narr_TiqbQHXjt0KQd6jrvyRSHA">78,522</ix:nonFraction> shares on June&#160;20, 2024, to cover outstanding interest on the outstanding principal at a VWAP of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_GWT3zleBVUqWPPvqxVkOFg" decimals="4" format="ixt:numdotdecimal" name="pbm:DebtConversionVolumeWeightedAveragePricePerShare" scale="0" id="Narr_dBtpyPWlrUSl6b50dv8M7A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_dOTID6jPYEuNrAYNswuBQA" decimals="4" format="ixt:numdotdecimal" name="pbm:DebtConversionVolumeWeightedAveragePricePerShare" scale="0" id="Narr_oP7aQd-HnEikFYNX2dh9EA">0.5361</ix:nonFraction></ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These conversions and interest issuances are in accordance with the terms outlined in the Securities Purchase Agreement and are related to the Convertible Note&#160;Financing arrangement initiated in connection with the RTO Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July, 2024, the Company completed a warrant exchange agreement with an unaffiliated third-party investor of warrants to purchase the Company&#8217;s common shares, <ix:nonFraction unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg" contextRef="As_Of_7_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember_P86XfCLzD0iMCh0cmIVomA" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_cPMZz7p2rEGh5uy3HFkGbA">no</ix:nonFraction> par value per share, which warrants are currently trading on Nasdaq. Pursuant to the Warrant Exchange Agreement, the Company issued to the Holder <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_7_1_2024_To_7_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember__hvPDjzjLUyCCDf5J2hfyw" decimals="INF" format="ixt:numdotdecimal" name="pbm:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_slXEQVypRkqjsKJH6599lQ">660,000</ix:nonFraction> Common Shares in exchange for the surrender and cancellation of <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_7_1_2024_To_7_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember_T_SrbOBOBUmz9DO4DYwbFg" decimals="INF" format="ixt:numdotdecimal" name="pbm:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Q2Qx-4KzMkuSV6LbdbgSYA">660,000</ix:nonFraction> Public Warrants held by the Holder.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May&#160;16, 2024, the Company issued an additional <ix:nonFraction unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw" contextRef="Duration_6_16_2024_To_6_16_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_Kkk9C124KESJe8OR92o3TA" decimals="INF" format="ixt:numdotdecimal" name="pbm:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_7jQVZ5GJrE2PaYTw5nou8A">178,000</ix:nonFraction> shares to third-party consultants and legal advisors.</p></ix:continuation><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xf1025.jpg" alt="Graphic" style="display:inline-block;height:28.5pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:87.75pt;"/></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">30</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d9bd9a77_4eff_45c5_8861_0c587f5e1a6e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;6. Indemnification of Directors and Officers</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Ontario Business Corporations Act (&#8220;OBCA&#8221;), we may indemnify our current or former directors or officers or another individual who acts or acted at our request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of his or her association with us or another entity. The OBCA also provides that we may also advance moneys to a director, officer or other individual for costs, charges and expenses incurred in connection with such a proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, indemnification is prohibited under the OBCA unless the individual:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acted honestly and in good faith with a view to our best interests, or the best interests of the other entity for which the individual acted as director or officer or in a similar capacity at our request; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the case of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual had reasonable grounds for believing that his or her conduct was lawful.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our bylaws require us to indemnify each of our current or former directors or officers and each individual who acts or acted at our request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including an amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of his or her association with us or another entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the OBCA, we are permitted to purchase and maintain insurance for the benefit of each of our current or former directors or officers and each person who acts or acted at our request as a director or officer, or an individual acting in a similar capacity, of another entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the completion of the transaction we intend to enter into indemnity agreements with our directors and certain officers which provide, among other things, that we will indemnify, including but not limited to the indemnity permitted under the OBCA, him or her for losses reasonably incurred by reason of being or having been a director or officer; provided that, we shall not indemnify such individual if, among other things, he or she did not act honestly and in good faith with a view to our best interests and, in the case</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">of a criminal or administrative action or proceeding that is enforced by a monetary penalty, the individual did not have reasonable grounds for believing that his or her conduct was lawful, and in so acting was in breach of the obligations under the indemnity agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At present, we are not aware of any pending or threatened litigation or proceeding involving any of our directors, officers, employees or agents in which indemnification would be required or permitted.</p><a id="_93986f9f_da4f_4ef8_8822_37cb3f0564bc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;7. Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to and in connection with consummating the Business Combination, the registrant issued securities to, among other parties, to the Sponsor, to certain vendors in respect of transaction expenses, as consideration for services or pursuant to advisory agreements, and as otherwise described above in relevant sections of this prospectus (such securities, collectively, the &#8220;Closing Issuances&#8221;). The securities issued in such Closing Issuances were not registered under the Securities Act in reliance on the exemption from registration provided by Section&#160;4(a)(2)&#160;of the Securities Act and/or Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering without any form of general solicitation or general advertising.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On May 29, 2024, the Company issued 3,000 Common Shares issued to Donohoe Advisory Associates LLC in full and final settlement of accrued service and advisory fees. On May 29, 2024, the Company issued 25,000 Common Shares issued to Outside The </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Box Capital Inc. in respect of past service delivery. On August 12, 2024, the Company issued an additional 172,028 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August 15, 2024, the Company entered into a first addendum (the &#8220;Addendum&#8221;) to the Securities Purchase Agreement, dated January 15, 2024, and related agreements, with the holders of the Company&#8217;s senior convertible notes. In consideration for the waiver and abandonment of the holders&#8217; claims and entitlements as contemplated in the Addendum, the Company shall pay the holders a fee in connection with future offerings as follows: </p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#8226;</span>a cash fee equal to 50% of the aggregate gross proceeds raised at each closing of any future offering until $655,625.00 has been paid to the Holders; provided, however, that 50% of such fee may be paid in the form of common shares, in lieu of cash, at a price of $0.50 per share, in the event that within two months from the effective date of the Addendum the aggregate gross amount raised in any future offerings is less than $5,000,000;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#8226;</span>the Company shall issue to the holders or their respective designees 1,000,000 common shares; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#8226;</span>the Company shall issue to the holders or their respective designees warrants to purchase 500,000 common shares, with an exercise price of $0.50 per share.</div><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may issue up to $25.0 million of Common Shares to White Lion pursuant to the White Lion Purchase Agreement after the date of this prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Such issuances were not registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering without any form of general solicitation or general advertising.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6813a3a9_5b09_4be3_bf02_134f6385a0f3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;8. Exhibits and Financial Statement Schedules</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.1#</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923116850/tm2320950-12_f4a.htm#tANNA1"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Business Combination Agreement, dated as of July&#160;31, 2023, by and among Newcourt Acquisition Corp, Newcourt SPAC Sponsor LLC, Psyence Group&#160;Inc., Psyence Biomedical&#160;Ltd., Psyence (Cayman) Merger Sub, Psyence Biomed Corp. and Psyence Biomed II Corp. (incorporated by reference to Exhibit&#160;2.2 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923116850/tm2320950-12_f4a.htm#tANNAA1"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the Amended and Restated Business Combination Agreement, dated as of November&#160;9, 2023, by and among Newcourt Acquisition Corp, Newcourt SPAC Sponsor LLC, Psyence Group&#160;Inc., Psyence Biomedical&#160;Ltd., Psyence (Cayman) Merger Sub, Psyence Biomed Corp. and Psyence Biomed II Corp. (incorporated by reference to Exhibit&#160;2.3 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.3</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1849475/000110465924003826/tm243297d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Securities Purchase Agreement, dated as of January&#160;15, 2024, by and among Psyence Biomedical&#160;Ltd., Psyence Biomed II Corp. and the investors party thereto (incorporated by reference to Exhibit&#160;10.1 to Newcourt Acquisition Corp&#8217;s Form&#160;8-K (File No.&#160;001-40929) filed with the SEC on January&#160;16, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923116850/tm2320950-12_f4a.htm#tANNB1"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of Psyence Biomedical&#160;Ltd. (incorporated by reference to Exhibit&#160;3.2 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923116850/tm2320950-12_f4a.htm#tANNXC"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of Psyence Biomedical&#160;Ltd. (incorporated by reference to Exhibit&#160;3.3 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923114379/tm2320950d10_ex3-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Share Certificate of Psyence Biomedical&#160;Ltd. (incorporated by reference to Exhibit&#160;3.4 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-268525) (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923114379/tm2320950d10_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Warrant Certificate of Psyence Biomedical&#160;Ltd. (incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-268525) (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pbm-20240331xex5d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Opinion of WeirFoulds LLP*</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Guaranty (incorporated by reference to Exhibit&#160;4.4 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.2</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923114379/tm2320950d10_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Lock-Up Agreement (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.3</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923114379/tm2320950d10_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sponsor Support Agreement (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.4</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923114379/tm2320950d10_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Parent Support Agreement (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.5&#8224;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000141057824001112/pbm-20240331xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Psyence Biomedical&#160;Ltd. 2023 Equity Incentive Plan (incorporated by reference to Exhibit&#160;4.8 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on July 29, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.6&#8224;</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit&#160;4.9 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.7</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923114379/tm2320950d10_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Research IP Agreement, by and between Psyence and Filament (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.8</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465923114379/tm2320950d10_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Commercial IP Term Sheet, by and between Psyence and Filament (incorporated by reference to Exhibit&#160;10.6 to the Company&#8217;s Registration Statement on Form&#160;F-4 (File No.&#160;333-273553) filed with the SEC on November&#160;13, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.9</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Engagement Letter, dated as of January&#160;25, 2024, by and between J.V.B. Financial Group, LLC, acting through its Cohen&#160;&amp; Company Capital Markets division and Newcourt </span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Acquisition Corp. (incorporated by reference to Exhibit&#160;4.12 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.10</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fee Modification Agreement, dated as of January&#160;25, 2024, by and between Cantor Fitzgerald&#160;&amp; Co. and Newcourt Acquisition Corp. (incorporated by reference to Exhibit&#160;4.13 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.11</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Engagement Letter, dated as of January&#160;25, 2024, by and between Maxim Group LLC and Psyence Group&#160;Inc. (incorporated by reference to Exhibit&#160;4.14 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.12</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Registration Rights Agreement, dated as of January&#160;25, 2024, by and among Psyence Biomedical&#160;Ltd. and the investors party thereto (incorporated by reference to Exhibit&#160;4.15 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.13</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of General Security Agreement, executed by Psyence Biomedical&#160;Ltd. and Psyence Biomed II Corp. (incorporated by reference to Exhibit&#160;4.16 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.14</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Lock-Up Agreement, dated as of January&#160;25, 2024, by and among Psyence Biomedical, Newcourt Acquisition Corp. and the other parties thereto (incorporated by reference to Exhibit&#160;4.17 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.15</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924008872/tm244512d1_ex4-18.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Senior Secured Convertible Note, dated as of January&#160;25, 2024, issued by Psyence Biomedical&#160;Ltd. to the Investors (incorporated by reference to Exhibit&#160;4.18 to the Company&#8217;s Annual Report on Form&#160;20-F (File No.&#160;001-41937) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.16</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1849475/000110465924008879/tm244743d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Promissory Note, dated January&#160;25, 2024, issued by Newcourt Acquisition Corp to Newcourt SPAC Sponsor LLC (incorporated by reference to Exhibit&#160;10.3 to Newcourt Acquisition Corp&#8217;s Form&#160;8-K (File No.&#160;001-40929) filed with the SEC on January&#160;31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.17</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000141057824000510/pbm-20240131xex10d17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Call Option Agreement (</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">incorporated by reference to Exhibit 10.17 to the Company&#8217;s Amendment No.3 to Registration Statement on Form F-1/A filed on May 10, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.18</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000141057824001112/pbm-20240331xex4d26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant Exchange Agreement (incorporated by reference to Exhibit 4.26 to the Company&#8217;s Annual Report on Form 20-F (File No. 001-41937) filed with the SEC on July 29, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.19</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924082356/tm2419189d2_ex99-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Addendum to the License Agreement and Commercial Term Sheet, dated as of July 22, 2024, by and among the Company, Psyence Group Inc. and Filament Health Corp (incorporated by reference to Exhibit 99.3 to the Company&#8217;s Current Report on Form 6-K filed with the SEC on July 24, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.20</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924084349/tm2420559d1_ex99-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Common Stock Purchase Agreement, dated July 25, 2024, by and between the Company and White Lion (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 6-K filed with the SEC on July 31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.21</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924084349/tm2420559d1_ex99-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement, dated July 25, 2024, by and between the Company and White Lion (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Current Report on Form 6-K filed with the SEC on July 31, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">10.22</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pbm-20240331xex10d22.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Addendum to the Securities Purchase Agreement and Senior Secured Convertible Notes *</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">21.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1985062/000110465924012923/tm245382d1_ex21-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries of Psyence (incorporated by reference to Exhibit 21.1 to the Company&#8217;s Registration Statement on Form F - 1 (File No. 333 - 276973) filed with the SEC on February 9, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">23.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pbm-20240331xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of MNP LLP</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">*</sup></a></p></td></tr><tr style="height:5.4pt;"><td style="vertical-align:top;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">24.1</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Signatures"><span style="font-style:normal;font-weight:normal;">Power of Attorney</span><sup style="font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">*</sup></a></p></td></tr><tr><td style="vertical-align:top;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">107</p></td><td style="vertical-align:top;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pbm-20240331xexfees.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Filing Fee Table</span><b style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:bold;">*</b></a></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">#</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The exhibits and schedules to this Exhibit&#160;have been omitted in accordance with Item&#160;601(b)(2)&#160;of Regulation&#160;S-K.&#160;The Registrant agrees to furnish supplementally to the SEC a copy of all omitted exhibits and schedules upon its request.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Indicates a management contract or compensation plan.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Filed herewith.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f0477cc7_b6de_4644_b438_e31ab06b4358"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;9. Undertakings</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The undersigned registrant hereby undertakes:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To include any prospectus required by section 10(a)(3)&#160;of the Securities Act&#160;of&#160;1933;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">That, for the purpose of determining any liability under the Securities Act&#160;of&#160;1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(4)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">To file a post-effective amendment to the registration statement to include any financial statements required by Item&#160;8.A of Form&#160;20-F at the start of any delayed offering or throughout a continuous offering.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(5)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">That, for the purpose of determining liability of the Registrant under the Securities Act&#160;of&#160;1933 to any purchaser in the initial distribution of the securities, in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(6)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">That, for the purpose of determining any liability under the Securities Act&#160;of&#160;1933 to any purchaser, each filing of the registrant&#8217;s annual report pursuant to section 13(a)&#160;or section 15(d)&#160;of the Securities Exchange&#160;Act&#160;of&#160;1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d)&#160;of the Securities Exchange&#160;Act&#160;of&#160;1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Insofar as indemnification for liabilities arising under the Securities Act&#160;of&#160;1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(f)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">The undersigned registrant hereby undertakes that:</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7d39945e_a7fd_4f06_b1ef_c03d3107e2e5"></a><a id="Signatures"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Toronto, Ontario, Canada on the 19th day of August, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Psyence Biomedical&#160;Ltd.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Neil Maresky</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Neil Maresky</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Neil Maresky and Warwick Corden-Lloyd, each acting alone, as his true and lawful attorneys-in-fact and agents, each with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitutes, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Pursuant to the requirements of the Securities Act&#160;of&#160;1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:28.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:42.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:19.89%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Neil Maresky</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 19, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Neil Maresky</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Warwick Corden-Lloyd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 19, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Warwick Corden-Lloyd</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Jody Aufrichtig</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board and Strategic Business Development Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 19, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Jody Aufrichtig</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Marc Balkin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 19, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Marc Balkin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Christopher (Chris) Bull</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 19, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Christopher (Chris) Bull</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Seth Feuerstein</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Director</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">August 19, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Seth Feuerstein</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">AUTHORIZED U.S.&#160;REPRESENTATIVE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Psyence Biomedical Ltd. has signed this registration statement in the city of Newark, Delaware on the 19th day of August, 2024.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Puglisi&#160;&amp; Associates</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Donald J. Puglisi</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Donald J. Puglisi</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Authorized Representative</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">II-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>pbm-20240331xex5d1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/19/2024 07:07:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 5.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr style="height:31.55pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Barristers &amp; Solicitors</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="pbm-20240331xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:170.22pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">August 19, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Psyence Biomedical Ltd.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">121 Richmond Street West</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Penthouse Suite 1300</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Toronto, Ontario, M5H 2K1</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Dear Mesdames/Messrs:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Re:</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:11pt;font-weight:bold;">Registration Statement on Form F-1</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">We have acted as Canadian corporate counsel to Psyence Biomedical Ltd. (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Corporation</b><font style="font-size:11pt;">&#8221;), a corporation incorporated under the laws of Ontario, Canada, in connection with the registration by the Corporation for resale by certain selling shareholders and warrant holders, as detailed in the prospectus constituting part of the Corporation&#8217;s registration statement (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Registration Statement</b><font style="font-size:11pt;">&#8221;) on Form F-1 filed today by the Corporation with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Securities Act</b><font style="font-size:11pt;">&#8221;), of an aggregate of 50,575,028 common shares of the Corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Common Shares</b><font style="font-size:11pt;">&#8221;) consisting of:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">an aggregate of up to 50,375,000 Common Shares (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">White Lion Shares</b><font style="font-size:11pt;">&#8221;) issuable pursuant to a share purchase agreement with White Lion Capital LLC (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">White Lion Purchase Agreement</b><font style="font-size:11pt;">&#8221;) dated July 25, 2024;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(ii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">3,000 Common Shares (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Donohoe Shares</b><font style="font-size:11pt;">&#8221;) that were issued on May 29, 2024 in payment of accrued service and advisory fees;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(iii)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">25,000 Common Shares (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Outside The Box Group 1 Shares</b><font style="font-size:11pt;">&#8221;) that were issued on May 29, 2024 as payment to Outside The Box Capital Inc. for past services rendered; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(iv)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">An additional 172,028 Common Shares (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Outside The Box Group 2 Shares</b><font style="font-size:11pt;">&#8221; and, together with the Donohoe Shares, the Outside the Box Group 1 Shares, the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Services Fee Shares</b><font style="font-size:11pt;">&#8221;) that were issued on August 12, 2024 as payment to Outside The Box Capital Inc. for past services rendered.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Examination of Documents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">In giving the opinions expressed below we have examined:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr style="height:17.9pt;"><td rowspan="2" style="vertical-align:middle;width:71.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">4100 - 66 Wellington Street West, PO Box 35, TD Bank Tower, Toronto, Ontario, Canada. M5K 1B7</p></td><td style="vertical-align:middle;width:28.26%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">T: 416-365-1110&#160;&#160;&#160;F: 416-365-1876</b></p></td></tr><tr style="height:16.65pt;"><td style="display:none;vertical-align:top;width:71.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:middle;width:28.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">www.weirfoulds.com</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr style="height:31.55pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Barristers &amp; Solicitors</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="pbm-20240331xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:170.22pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">a Certificate of Status issued under the </font><i style="font-size:11pt;font-style:italic;">Business Corporations Act</i><font style="font-size:11pt;"> (Ontario) dated August 16, 2024;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the certificate of incorporation, articles and by-laws of the Corporation (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Articles</b><font style="font-size:11pt;">&#8221;); and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">certain resolutions of the Corporation&#8217;s directors.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Assumptions and Reliances</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">As to certain matters of fact, we have relied on a certificate of an officer of the Corporation of even date (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Officer&#39;s Certificate</b><font style="font-size:11pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">In preparation for the delivery of this opinion, we have examined the above-mentioned documents and we have examined all such other documents and made such other investigations as we consider relevant and necessary in order to give this opinion. In particular, we have not reviewed, and express no opinion on, any document that is referred to or incorporated by reference into the documents reviewed by us. As to various questions of fact material to this opinion which we have not independently established, we have examined and relied upon, without independent verification, certificates of public officials and officers of the Corporation including, without limitation, the Officer&#8217;s Certificate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For purposes of this opinion letter, we have also assumed that:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the legal capacity of all individuals;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the genuineness of all signatures on, and the authenticity and completeness of all documents submitted to us as originals and the conformity to authentic or original documents of all documents submitted to us as certified, conformed, telecopied, photostatic, electronically transmitted copies (including commercial reproductions);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the identity and capacity of any person acting or purporting to act as a corporate or public official;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the accuracy and completeness of all information provided to us by public officials or offices of public record;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr style="height:31.55pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Barristers &amp; Solicitors</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="pbm-20240331xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:170.22pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(e)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the accuracy and completeness of all representations and statements of fact contained in all documents, instruments and certificates (including the Officer&#8217;s Certificate);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(f)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the accuracy and completeness of the minute books and all other corporate records of the Corporation reviewed by us;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(g)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the facts stated in the Certificate of Status continue to be true as of the date hereof;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(h)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">all securities referred to herein have been offered, issued and sold in compliance with applicable United States federal and state securities laws, and in the manner stated in the Registration Statement; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">(i)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">that the facts stated in the Certificate of Status and the Officer&#8217;s Certificate shall continue to be true and correct as at the date of completion of the share issuances contemplated hereby.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">We have not undertaken any independent investigation to verify the accuracy of any of the foregoing assumptions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">When our opinion refers to White Lion Shares to be issued or Services Fee Shares having been issued as being &#8220;fully paid and non-assessable&#8221;, such opinion indicates that the holder of such Common Shares cannot be required to contribute any further amounts to the Corporation by virtue of his, her or its status as holder of such Common Shares, either in order to complete payment for the Common Shares, to satisfy claims of creditors or otherwise. No opinion is expressed as to the adequacy of any consideration received for such Common Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">We are qualified to practice law only in the Province of Ontario. Our opinion below is limited to the existing laws of the Province of Ontario and the federal laws of Canada applicable therein as of the date of this opinion and should not be relied upon, nor are they given, in respect of the laws of any other jurisdiction. In particular, we express no opinion as to United States federal or state securities laws or any other laws, rule or regulation, federal or state, applicable to the Corporation. We disclaim any obligation or duty to update this opinion to reflect any changes in such laws or other circumstances after the date hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The opinions given below are given as of the date off this letter and are not prospective.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:99.9%;"><tr style="height:31.55pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Barristers &amp; Solicitors</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="pbm-20240331xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:22.49pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:170.22pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Opinions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Based upon and subject to the foregoing, we are of the opinion that:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the White Lion Shares have been duly authorized for issuance by all necessary corporate action by the Corporation, and upon their issuance pursuant to the terms of the White Lion Purchase Agreement, the White Lion Shares will be validly issued, fully paid and non-assessable common shares in the capital of the Corporation; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the Services Fee Shares have been validly issued as fully paid and non-assessable common shares in the capital of the Corporation.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This opinion letter is rendered as of the date hereof, and is opining upon and is limited to the laws of the Province of Ontario and the federal laws of Canada applicable therein, as such laws presently exist as of the date hereof. We express no opinion with respect to the effect or applicability of the laws of any other jurisdiction. We assume no obligation to revise or supplement this opinion letter should applicable laws be changed after the date hereof by legislative action, judicial decision or otherwise, or if we become aware of any facts that might change the opinions expressed herein after the date hereof. The opinions expressed in this letter are limited to the matters set forth herein and no other opinions should be inferred beyond the matters expressly stated.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">We consent to the filing of this opinion as an exhibit to the Registration Statement and to the reference to our firm under the caption &#8220;Legal Matters&#8221; in the prospectus constituting part of the Registration Statement. In giving this consent, we do not thereby imply or admit that we are an &#8220;expert&#8221; within the meaning of Section 11 of the Securities Act or the rules and regulations promulgated thereunder or that we come within the categories of persons whose consent is required by Section 7 of the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Yours truly,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#8220;</font><i style="font-size:11pt;font-style:italic;">WeirFoulds LLP</i><font style="font-size:11pt;">&#8221;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>3
<FILENAME>pbm-20240331xex10d22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/19/2024 07:07:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.22</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FIRST ADDENDUM TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE NOTES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Between</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b>, a corporation existing under the laws of Ontario, Canada (the &quot;<b style="font-weight:bold;">Company</b>&quot;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PSYENCE BIOMED II CORP.</b>, a corporation existing under the laws of Ontario, Canada (&quot;<b style="font-weight:bold;">Biomed II</b>&quot;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HARRADEN CIRCLE INVESTORS, LP</b>, a fund, account, and/other investment vehicle managed by Harraden Circle Investments, LLC (&quot;<b style="font-weight:bold;">HCI</b>&quot;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">HARRADEN CIRCLE SPECIAL OPPORTUNITIES, LP</b>, a fund, account, and/other investment vehicle managed by Harraden Circle Investments, LLC (&quot;<b style="font-weight:bold;">HCSO</b>&quot;, and together with HCI the &quot;<b style="font-weight:bold;">Holders</b>&quot;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Newcourt SPAC Sponsor LLC (&quot;<b style="font-weight:bold;">Sponsor</b>&quot;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(collectively, the &quot;<b style="font-weight:bold;">Parties</b>&quot;)</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">RECITALS</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">On January<font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font>15, 2024, the Company and Biomed II entered into (i) the Securities Purchase Agreement (&quot;<b style="font-weight:bold;">Harraden SPA</b>&quot;) with the Holders and the Sponsor, relating to up to four senior secured convertible notes (each a &quot;<b style="font-weight:bold;">Note</b>&quot; and collectively the &quot;<b style="font-weight:bold;">Notes</b>&quot;) obligations under which are guaranteed by certain assets of the Company and Biomed II, issuable to the Holders for the aggregate principal amount of up to $12,500,000 in exchange for up to $10,000,000 in subscription amounts, and (ii) the Lock-Up Agreement (&quot;<b style="font-weight:bold;">Lock-Up Agreement</b>&quot;) with Psyence Group Inc. (&quot;<b style="font-weight:bold;">PSYG</b>&quot;) restricting certain transactions by PSYG.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The two first tranche notes, for an aggregate of $3,125,000, were delivered by the Company to the Holders on January<font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font>25, 2024, in exchange for an aggregate of $2,500,000 in financing (&quot;<b style="font-weight:bold;">First Tranche Notes</b>&quot;). &#160;On May<font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font>31, 2024, the Notes (the &quot;<b style="font-weight:bold;">May Second Tranche Notes</b>&quot;) for the initial portion of the second tranche of the financing (the &quot;<b style="font-weight:bold;">Second Tranche</b>&quot;), for a total of $312,500 of principal in exchange for a total of $250,000 in subscription amounts, were issued to the Holders. &#160;On June<font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font>14, 2024, the Company issued two additional Notes (the &quot;<b style="font-weight:bold;">June Second Tranche Notes</b>&quot;) for an additional portion of the Second Tranche, for an aggregate total of $312,500 principal in exchange for $250,000 provided by the Holders. &#160;In July 2024, the Company issued two additional Notes (the &quot;<b style="font-weight:bold;">July Second Tranche Notes</b>&quot;) for an additional portion of the Second Tranche, for an aggregate total of $625,000 principal in exchange for $500,000 provided by the Holders. &#160;The May, June and July Second Tranche Notes shall be collectively referred to as the &quot;<b style="font-weight:bold;">Second Tranche Notes</b>&quot;.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Pursuant to Section 4.8 of the Harraden SPA, the Company and its subsidiaries are restricted from issuing shares pursuant to certain transactions enumerated therein.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Pursuant to Section 2(i) of the Registration Rights Agreement (&quot;<b style="font-weight:bold;">RRA</b>&quot; and collectively with the Harraden SPA and the Notes, the &quot;<b style="font-weight:bold;">Transaction Documents</b>&quot;), dated January 15, 2024, entered into by and between the Company and the Holders, the Company is restricted from</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 42.55pt;">registering certain issuances of shares as set forth therein.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Pursuant to Section 1 of the Lock-Up Agreement, PSYG may not transfer its shares of Common Stock for a period of time.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">On July 25, 2024, the Company entered into a Common Stock Purchase Agreement (the &quot;<b style="font-weight:bold;">WLC SPA</b>&quot;) with White Lion Capital, LLC (&quot;<b style="font-weight:bold;">WLC</b>&quot;) and a related registration rights agreement whereby the Company has the right, but not the obligation, to require WLC to purchase, from time to time, up to $25,000,000 in aggregate gross purchase price of newly issued shares of the Company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s common shares, no par value (the &quot;<b style="font-weight:bold;">Common Stock</b>&quot;), subject to certain limitations and conditions set forth in the WLC SPA.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Furthermore, pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder, and/or Rule 506 of Regulation D promulgated thereunder, the Company desires to issue and sell to investors securities of the Company and to register the resale of such securities (&quot;<b style="font-weight:bold;">Offering</b>&quot;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In addition, the Company may desire to issue or register securities pursuant to other transactions in the future, whether in connection with a financing transaction, creditor settlement, acquisition, share employment plan or otherwise (&quot;<b style="font-weight:bold;">Future Issuances</b>&quot;).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.9</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Following the Effective Date, PSYG wishes to transfer some of the shares of Common Stock that it holds.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.10</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In addition to the terms defined elsewhere in this first addendum to the Harraden SPA and the Notes (&quot;<b style="font-weight:bold;">Addendum</b>&quot;) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Harraden SPA and the Notes (as the case may be) or in the annexures thereto.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.11</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Parties wish to create additional obligations and make certain amendments to the Harraden SPA and the Notes and include additional clauses thereto.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.12</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Parties wish to record these additional obligations and amendments in writing.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">EFFECTIVE DATE AND CONDITIONS PRECEDENT</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Addendum shall be effective upon on the date that all of the conditions specified in clause 2.2 are satisfied (the &quot;<b style="font-weight:bold;">Effective Date</b>&quot;), subject to the fulfilment or waiver (as the case may be) of the suspensive conditions (&quot;<b style="font-weight:bold;">Conditions Precedent</b>&quot;) contained in clause 2.2.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Addendum shall become effective upon the following:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">by not later than 17h00 on <b style="font-weight:bold;">August 27, 2024</b>, the board of directors of PBM approves and ratifies the entering into of the WLC SPA, the Offering and this Addendum and all other agreements and transactions contemplated therein; &#160;and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Holder Warrants being issued no later than <b style="font-weight:bold;">August 27, 2024</b>.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Holder Shares being issued no later than <b style="font-weight:bold;">August 27, 2024</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In the event that the provisions of clause 2.2 are not satisfied, this Addendum shall be void and of no further force or effect.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Unless all the Conditions Precedent have been fulfilled or waived by not later than the relevant</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 42.55pt;">dates for fulfilment thereof set out in clause 2.2 (or such later date or dates as may be agreed in writing between the Parties) the provisions of this Addendum, save for clauses 1, 2, 7 and 8, which will remain of full force and effect, will never become of any force or effect and the <i style="font-style:italic;">status quo ante</i> will be restored as near as may be and neither of the Parties will have any claim against the other in terms hereof or arising from the failure of the Conditions Precedent.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">SETTLEMENT OF THE FIRST TRANCHE AND SECOND TRANCHE NOTES</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Extinguishing the First and Second Tranche Notes</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Within five (5) days after the effectiveness of the post-effective amendment to the registration statement on Form F-1 to be filed in connection with the resale by the Holders of the Company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s common shares (the &quot;<b style="font-weight:bold;">Conversion Date</b>&quot;), and in accordance with Section 5(e) of the First and Second Tranche Notes, the Holders shall convert the maximum amount permitted under Section 2.1(e) of the Harraden SPA as of the Effective Date of the First Tranche and Second Tranche Notes (&quot;<b style="font-weight:bold;">Outstanding Note Amount</b>&quot;) at the Conversion Price applicable on the Effective Date, .</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Subject to the limitation specified in Section 2.1(e) of the Harraden SPA, in accordance with Section 5(e)(ii) of the First and Second Tranche Notes, the Holders shall, by the Conversion Date, complete, manually sign and deliver an irrevocable Notice of Conversion and state in writing therein the Outstanding Note Amount to be converted, the numbers of Conversion Shares and the name or names (with addresses) in which the Holder wishes the Common Shares to be delivered upon settlement of the conversion to be registered, and, if required, pay all transfer or similar taxes, if any.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Full and Final Settlement</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Due performance of clause 3.1 by the Parties shall result in the extinguishment of the portion of the First and/or Second Tranche Notes converted as of the Effective Date and constitute full and final settlement of all and any claims which the Parties may have against each other or any of their respective shareholders, directors, employees and agents, of whatsoever nature and howsoever arising with respect to the portion of the First and Second Tranche Notes extinguished. &#160;For avoidance of doubt Holders will retain all rights under the Transaction Documents pertaining to the unextinguished portion of the First and Second Tranche Notes outstanding as of the Effective Date until such time as the full value of the outstanding principal amount of the First and Second Tranche Notes outstanding as of the Effective Date has been converted.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">For purposes of this Addendum, claims includes without limitation thereto any action, application, arbitration, cause of action, complaint, cost, debt due, demand, determination, enquiry, judgment, cost order and verdict at common law; constituting a delict; in equity; arising under contract; and arising under any statute, regulation or otherwise howsoever.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Without limitation to the generality of clause 3.2.2 -</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:70.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.2.3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the Holders waive their respective rights to call an &quot;Event of Default&quot; under the Transaction Documents with respect to the Company<font style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</font>s failure to cause the Registration Statement to become effective within (3) months following the First Tranche Closing, and any deficiency notice received from Nasdaq prior to the Effective Date. &#160;Furthermore, Holders agree to abandon their respective rights to invoke the provisions of section 6(a) read with sub-section (b) (<i style="font-style:italic;">Remedies Upon Event of Default</i>) of the Notes in connection therewith, and additionally, the Holders undertake not to pursue any rights</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 70.9pt;">and remedies provided to them under the Security Agreement in connection therewith; and</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:70.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">3.2.3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">the Holders waive all penalties or liquidated damages payable under the Transaction Documents with respect to the Events of Default that were waived pursuant to clause 3.2.3.1 (the <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Waived Defaults<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>) which are due as at the Effective Date (if any) and undertake not to pursue any rights and remedies provided to them under the Transaction Documents with respect to any penalties or liquidated damages payable under the Transaction Documents with respect to the Waived Defaults which are due as at the Effective Date (if any).</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">AMENDMENTS TO THE HARRADEN SPA AND RRA</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 28.35pt;">Pursuant to Section 5.4 of the Harraden SPA and Section 10 of the RRA, respectively, the Harraden SPA and RRA are hereby amended as follows:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The addition of the following provision at the end of Section 2.1(b) of the Harraden SPA (<i style="font-style:italic;">Sale of Note</i>):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 42.55pt;">&quot;<i style="font-style:italic;">The Conversion Price (as defined in the Notes) of the portion of the Second Tranche Note not draw down prior to August 13, 2024, Third Tranche Note and Fourth Tranche Note shall, at all times, be subject to a conversion floor of $0.50 (&quot;</i><font style="font-style:italic;font-weight:bold;">Conversion Floor</font><i style="font-style:italic;">&quot;), and accordingly, the Conversion Price and Conversion Reset of these Notes shall in no event be lower than the Conversion Floor.</i>&quot;</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Section 4.8 of the Harraden SPA (<i style="font-style:italic;">Subsequent Equity Sales</i>) shall not apply with respect to the WLC SPA or with respect to any Future Issuance at no less than $0.50 per share.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The last sentence of Section 2(i) of the RRA (<i style="font-style:italic;">No Inclusion of Other Securities</i>) shall not apply with respect to the registration of shares issued pursuant to the WLC SPA or pursuant to any Future Issuance at no less than $0.50 per share.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">CONSENT &amp; CONSIDERATION</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Holders hereby consent to the Company entering into the WLC SPA, the Offering and any Future Issuance at no less than $0.50 per share, and to register the sale or resale of any securities issued thereto, and consent to all transactions contemplated therein.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">In consideration for the waiver and abandonment of the Holder&#39;s claims and entitlements as contemplated in clause 3 and the consent set out in clause 5.1, the Company agrees to pay the Holders a fee in connection with an Offering as follows:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company shall pay to the Holders a cash fee (&quot;<b style="font-weight:bold;">Cash Fee</b>&quot;) equal to 50% of the aggregate gross proceeds raised at each closing of any future Offering (each, a &quot;<b style="font-weight:bold;">Closing</b>&quot;) until $655,625.00 has been paid to the Holders; provided, however, that 50% of the Cash Fee may be paid in shares of Common Stock, in lieu of cash, at a price of $0.50 per share (<font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Fee Shares<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>), in the event that within 2 months from the Effective Date the aggregate gross amount raised in any future Offerings is less than $5,000,000. &#160;The relevant portion of the Cash Fee shall only become payable within 5 (five) business days of receipt of such proceeds by the Company.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Promptly after the signing hereof, the Company shall issue to the Holders or their respective designees 1,000,000 Common Shares (<font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Holder Shares<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>). &#160;The Holder Shares represent additional Common Shares that should have been issued to the Holder pursuant</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 56.7pt;">to prior conversions of the First Tranche Notes.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Promptly after the signing hereof, the Company shall issue to the Holders or their respective designees warrants (the &quot;<b style="font-weight:bold;">Holder Warrants</b>&quot;) to purchase 500,000 (five hundred thousand) Common Shares, on the following terms:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:70.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Holder Warrants shall have an exercise price of $0.50 (fifty US cents); and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:70.9pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Holder Warrants shall be in the form attached to this agreement as Exhibit A.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:56.7pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.2.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Fee Shares, Holder Shares and shares underlying the Holder Warrants shall be deemed to be <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Underlying Shares<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> and <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Registrable Securities<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> under the terms of the RRA<font style="font-size:11pt;">.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:42.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">5.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Pursuant to Section 2(h) of the Lock-Up Agreement, effective as of the Effective Date the Holders hereby consent to the release from lock-up of 500,000 shares of Common Stock held by PSYG (<font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Immediate Released Shares<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>) and hereby waive any restrictions set forth in the Lock-Up Agreement with respect to the Immediate Released Shares. &#160;Additionally pursuant to Section 2(h) of the Lock-Up Agreement effective as of (5) days following the Holders performance of clause 3.1, the Holders hereby consent to the release from lock-up of 500,000 shares of Common Stock held by PSYG (the &quot;Additional <b style="font-weight:bold;">Released Shares</b>&quot;), and hereby waive any restrictions set forth in the Lock-Up Agreement with respect to the Additional Released Shares.</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">SAVINGS CLAUSE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 28.35pt;">Save to the extent specifically or by necessary implication modified in or inconsistent with the provisions of this Addendum, all the terms and conditions of the Transaction Documents shall <i style="font-style:italic;">mutatis mutandis </i>continue in full force and effect. If there is any discrepancy between this Addendum and any of the Transaction Documents, this Addendum shall prevail.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">7</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">COSTS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 28.35pt;">Each Party will bear and pay its own legal costs and expenses of and incidental to the negotiation, drafting, preparation and implementation of this Addendum.</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">8</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">SIGNATURE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 28.35pt;">Signed on behalf of the parties, each signatory hereto warranting that he/she has due authority to do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.5pt 0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF THE PARTIES HAVE EXECUTED THIS ADDENDUM AS OF THE DATE FIRST WRITTEN ABOVE.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMEDICAL LTD.</b></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jody Aufrichtig</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jody Aufrichtig</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Director</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ </p></div></div></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PSYENCE BIOMED II CORP.</b></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jody Aufrichtig</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Jody Aufrichtig</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Director</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HARRADEN CIRCLE INVESTORS, LP, as Purchaser</b></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ </b>Frederick V. Fortmiller</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Frederick V. Fortmiller</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">HARRADEN CIRCLE SPECIAL OPPORTUNITIES, LP, as Purchaser</b></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ </b>Frederick V. Fortmiller</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Frederick V. Fortmiller</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Authorized Signatory</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEWCOURT SPAC SPONSOR LLC</b></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ </b>Marc Balkin</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Marc Balkin</p></td></tr><tr><td style="vertical-align:top;width:49.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.38%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Manager</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Form of Warrant</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>pbm-20240331xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/19/2024 07:07:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;"><img src="pbm-20240331xex23d1002.jpg" alt="Graphic" style="display:inline-block;height:44.24pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:112.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">We consent to the inclusion in this Registration Statement on Form F-1 (the &#8220;Form F-1&#8221;), of our auditor&#8217;s report dated July 25, 2024 relating to the consolidated financial statements of Psyence Biomedical Ltd. as at March 31, 2024 and 2023, and for each of the years in the two-year period ended March 31, 2024, as included in the Annual Report on Form 20-F of Psyence Biomedical Ltd. for the year ended March 31, 2024, as filed with the United States Securities and Exchange Commission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">We also consent to the reference to our firm under the heading &#8220;Experts&#8221; in the Form F-1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;"><font style="font-size:11pt;"><img src="pbm-20240331xex23d1003.jpg" alt="Graphic" style="display:inline-block;height:21.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:92.98pt;"></font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chartered Professional Accountants </font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Licensed Public Accountants</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Burlington, Canada </font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">August 19, 2024</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><img src="pbm-20240331xex23d1001.jpg" alt="Graphic" style="display:inline-block;height:61.5pt;width:540pt;"></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>pbm-20240331xexfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/19/2024 07:07:53 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:3.45%;padding-right:3.45%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 107</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Calculation of Filing Fee Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Form F-1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Form Type)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Psyence Biomedical Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Exact Name of Registrant as Specified in its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Table 1: Newly Registered and Carry Forward Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Security&#160;Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Security</b><br><b style="font-weight:bold;">Class&#160;Title</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fee&#160;Calculation</b><br><b style="font-weight:bold;">or&#160;Carry&#160;Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Rule</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount&#160;Registered&#160;</b><sup style="font-size:5.25pt;font-weight:bold;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Proposed&#160;Maximum</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Offering</b><br><b style="font-weight:bold;">Price&#160;Per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Maximum&#160;Aggregate</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Offering&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fee&#160;Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount&#160;of</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Registration</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Fee</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry&#160;Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Form&#160;Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry&#160;Forward&#160;File</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carry&#160;Forward</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Initial&#160;effective&#160;date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing&#160;Fee</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Previously&#160;Paid</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">In&#160;Connection</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">with&#160;Unsold</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Securities&#160;to&#160;be</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Carried</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">Forward</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="28" style="vertical-align:bottom;width:99.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Newly Registered Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Fees to Be</b> <b style="font-weight:bold;">Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Common Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">(c)&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">50,575,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-size:5.25pt;vertical-align:top;">(2)&#160;&#160;&#160;</sup><font style="vertical-align:top;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">0.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-size:5.25pt;vertical-align:top;">(3)&#160;&#160;</sup><font style="vertical-align:top;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">25,793,264.28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00014760</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3,807.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-size:5.25pt;vertical-align:top;">(4)&#160;&#160;</sup><font style="vertical-align:top;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Fees</b> <b style="font-weight:bold;">Previously Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Carry Forward Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Carry</b> <b style="font-weight:bold;">Forward Securities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;"><font style="font-size:7pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:40.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Total Offering Amounts</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.9pt 0pt 0pt;">3,807.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:40.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Total Fees Previously Paid</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:40.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Total Fee Offsets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="10" style="vertical-align:bottom;white-space:nowrap;width:40.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Net Fee Due</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:0.48%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.53%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,807.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.3%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.06%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.71%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.23%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Represents the sum of (i) up to an aggregate of up to 50,375,000 common shares, no par value (the &#8220;Common Shares&#8221;) of Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada  (the &#8220;Company&#8221;), issuable by the Company to White Lion Capital, LLC (&#8220;White Lion&#8221;), (ii) 3,000 Common Shares issued to Donohoe Advisory Associates LLC in full and final settlement of accrued service  and advisory fees, (iii) 25,000 Common Shares issued to Outside The Box Capital Inc. in respect of past service delivery and (iv) an additional 172,028 Common Shares issued to Outside The Box Capital Inc.  in respect of past service delivery.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the common stock on The Nasdaq Stock Market LLC on August 15, 2024 ($0.51 per share),  in accordance with Rule 457(c) of the Securities Act.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Calculated pursuant to Rule 457 of the Securities Act by multiplying the proposed maximum aggregate offering price of securities to be registered by 0.00014760.</font></td></tr></table><div style="margin-top:12pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:3.45%;margin-right:3.45%;margin-top:30pt;page-break-after:avoid;width:93.09%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>pbm-20240331xf1009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )R O8# 2(  A$! Q$!_\0
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M4,3_ "_BO\P_MK ?\_/PE_D?3=%?,G_#:7_4G?\ E4_^TT?\-I?]2=_Y5/\
M[31]0Q/\OXK_ ##^VL!_S\_"7^1]-T5\R?\ #:7_ %)W_E4_^TT?\-I?]2=_
MY5/_ +31]0Q/\OXK_,/[:P'_ #\_"7^1]-T5\R?\-I?]2=_Y5/\ [31_PVE_
MU)W_ )5/_M-'U#$_R_BO\P_MK ?\_/PE_D?3=%?,G_#:7_4G?^53_P"TT?\
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M4 %%%% !1110!\R?MI?\R=_V^?\ M"OF2OIO]M+_ )D[_M\_]H5\R5]=@/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %>Z?L>_\E,U/_L$2_\ HZ&O"Z]T_8]_Y*9J?_8(E_\
M1T-<F,_@3]#U,K_WVEZGV%1117QI^KA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S)^VE
M_P R=_V^?^T*^9*^F_VTO^9._P"WS_VA7S)7UV _W:/S_-GY?G7^_P!3Y?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'S)^VE_P R=_V^?^T*^9*^F_VTO^9._P"WS_VA7S)7UV _
MW:/S_-GY?G7^_P!3Y?\ I*"BBBN\\0**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KW3]CW_ )*9J?\ V")?_1T->%U[I^Q[_P E,U/_ +!$O_HZ&N3&?P)^AZF5
M_P"^TO4^PJ***^-/U<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^9/VTO^9._[?/_ &A7
MS)7TW^VE_P R=_V^?^T*^9*^NP'^[1^?YL_+\Z_W^I\O_24%%%%=YX@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7NG['O_)3-3_[!$O\ Z.AKPNO=/V/?^2F:
MG_V")?\ T=#7)C/X$_0]3*_]]I>I]A4445\:?JX4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\[_M<>%]9\2?\(I_9&D7^J^3]K\W[%;/-Y>?)QNV@XS@XSZ&OGC_A5_C/
M_H4M=_\ !;-_\37Z'T5ZE''RHTU34;V/G,7DM/%UI5I3:;M^"L?GA_PJ_P 9
M_P#0I:[_ ."V;_XFC_A5_C/_ *%+7?\ P6S?_$U^A]%;_P!J3_E1Q_ZN4O\
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M ,31_P *O\9_]"EKO_@MF_\ B:_0^BC^U)_RH/\ 5RE_S\?W(_/#_A5_C/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKP#]L/1++Q-H?PRT?4H?
MM.G:AX[TRTN8=[)YD4BS*Z[E((RI(R"#Z5T4*2K5%3;M<RJ3]G!R2N>_T5X=
M_P ,3?!?_H3/_*I>_P#QZC_AB;X+_P#0F?\ E4O?_CU:\F%_GE_X"O\ Y,CF
MK?RK[W_\B>XT5X=_PQ-\%_\ H3/_ "J7O_QZC_AB;X+_ /0F?^52]_\ CU')
MA?YY?^ K_P"3#FK?RK[W_P#(GN-%>'?\,3?!?_H3/_*I>_\ QZC_ (8F^"__
M $)G_E4O?_CU')A?YY?^ K_Y,.:M_*OO?_R)[C17AW_#$WP7_P"A,_\ *I>_
M_'J/^&)O@O\ ]"9_Y5+W_P"/4<F%_GE_X"O_ ),.:M_*OO?_ ,B>XT5X=_PQ
M-\%_^A,_\JE[_P#'J/\ AB;X+_\ 0F?^52]_^/4<F%_GE_X"O_DPYJW\J^]_
M_(GN-%>'?\,3?!?_ *$S_P JE[_\>H_X8F^"_P#T)G_E4O?_ (]1R87^>7_@
M*_\ DPYJW\J^]_\ R)[C17AW_#$WP7_Z$S_RJ7O_ ,>H_P"&)O@O_P!"9_Y5
M+W_X]1R87^>7_@*_^3#FK?RK[W_\B>XT5X=_PQ-\%_\ H3/_ "J7O_QZC_AB
M;X+_ /0F?^52]_\ CU')A?YY?^ K_P"3#FK?RK[W_P#(GN-%>'?\,3?!?_H3
M/_*I>_\ QZC_ (8F^"__ $)G_E4O?_CU')A?YY?^ K_Y,.:M_*OO?_R)[C17
MAW_#$WP7_P"A,_\ *I>__'J/^&)O@O\ ]"9_Y5+W_P"/4<F%_GE_X"O_ ),.
M:M_*OO?_ ,B>XT5X=_PQ-\%_^A,_\JE[_P#'J/\ AB;X+_\ 0F?^52]_^/4<
MF%_GE_X"O_DPYJW\J^]__(GN-%>'?\,3?!?_ *$S_P JE[_\>H_X8F^"_P#T
M)G_E4O?_ (]1R87^>7_@*_\ DPYJW\J^]_\ R)[C7$?''CX*?$#M_P 4]J'_
M *325PO_  Q-\%_^A,_\JE[_ /'J/^&)O@O_ -"9_P"52]_^/5I!86$E+GEI
M_=7_ ,F3+VTDURK[W_\ (A^Q-_R;'X,_[??_ $MGKW&O#O\ AB;X+_\ 0F?^
M52]_^/4?\,3?!?\ Z$S_ ,JE[_\ 'JNO+"UJLZO/)<S;^%=7_C)IJM3A&'*M
M%;=__(GN-%>'?\,3?!?_ *$S_P JE[_\>H_X8F^"_P#T)G_E4O?_ (]6')A?
MYY?^ K_Y,TYJW\J^]_\ R)[C17AW_#$WP7_Z$S_RJ7O_ ,>H_P"&)O@O_P!"
M9_Y5+W_X]1R87^>7_@*_^3#FK?RK[W_\B>XT5X=_PQ-\%_\ H3/_ "J7O_QZ
MC_AB;X+_ /0F?^52]_\ CU')A?YY?^ K_P"3#FK?RK[W_P#(GN-%>'?\,3?!
M?_H3/_*I>_\ QZC_ (8F^"__ $)G_E4O?_CU')A?YY?^ K_Y,.:M_*OO?_R)
M[C17AW_#$WP7_P"A,_\ *I>__'J/^&)O@O\ ]"9_Y5+W_P"/4<F%_GE_X"O_
M ),.:M_*OO?_ ,B>XT5X=_PQ-\%_^A,_\JE[_P#'J/\ AB;X+_\ 0F?^52]_
M^/4<F%_GE_X"O_DPYJW\J^]__(GN-%>'?\,3?!?_ *$S_P JE[_\>H_X8F^"
M_P#T)G_E4O?_ (]1R87^>7_@*_\ DPYJW\J^]_\ R)[C17AW_#$WP7_Z$S_R
MJ7O_ ,>H_P"&)O@O_P!"9_Y5+W_X]1R87^>7_@*_^3#FK?RK[W_\B>XT5X=_
MPQ-\%_\ H3/_ "J7O_QZC_AB;X+_ /0F?^52]_\ CU')A?YY?^ K_P"3#FK?
MRK[W_P#(GN-%>'?\,3?!?_H3/_*I>_\ QZC_ (8F^"__ $)G_E4O?_CU')A?
MYY?^ K_Y,.:M_*OO?_R)[C17AW_#$WP7_P"A,_\ *I>__'J\Q_:7_98^&'P_
M^!_BCQ!X?\,#3]7LHX6@N3?W4NS=/&K?*\I4Y5F'(/6M:5##5:D:<:DKMI?"
MNO\ V^1.I6A%R<5IYO\ ^1/K^BJFD\:59_\ 7%/_ $$5;KSF=84444@"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\._:F_P":0_\ 91-(
M_P#:U>XUX=^U-_S2'_LHFD?^UJ[<%_'C\_R9SXC^&SW&BBBN(Z HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^ \W_P >KT88"M.*DK69X53.L)2G*G)NZ=MNQ]A45\>_\-A>,_\ H&:%_P"
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MS?\ QZC^SJ_9?>']O8+N_N/L*BOCW_AL+QG_ - S0O\ P'F_^/4?\-A>,_\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]A?L>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,7'GQE2-[7D_S9S]%?2'QS\&^!?A+>^&C!X/@O;*_:?[4KWUT)0J>7CRV\W
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M[-I73OKH%%%%68A1110 5]A?L>_\DSU/_L+R_P#HF&OCVOL+]CW_ ))GJ?\
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M"O&I&,H*]_P]3HK8*I0G.G5:3BK]=5MII_D>>4445TGGA1110 4444 %%%%
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MZM;0\1KZU_:H_P"2->'?^PA;_P#I/-7RMI,>GRWJ+J=Q<VMG@[I+2W6:0'L
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MYI,&EW2YBO[V)]SWBA0YSA05X1\<G!<\UZ#XCURY\.?M">&O">D%=.\.1I#
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M-\WFNO\ PQY1\7O#5KX0^).O:38Y%I!.&B4_P*ZAPOT&['X56^%W_)3/"/\
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M-_%3:7JFVOS/GJBBBNP\D**** "OL+]CW_DF>I_]A>7_ -$PU\>U]A?L>_\
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MIO\ YLI_S_T$J;X"NX7\!>";G0[>[\)Q6NJ0)?ZC(0D>JR,2CQIM)>4LW'S
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M_P!')7,5T_PN_P"2F>$?^PO:?^CDJ*GP/T-Z'\6'JOS/T/HHHKX4_9 HHHH
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MVE?^2U^(_P#MV_\ 2:*O,:^VP_\ !AZ+\C\BQW^]5?\ %+\V%%%%;G"%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5]A?L>_P#),]3_ .PO+_Z)AKX]K["_8]_Y
M)GJ?_87E_P#1,->9F/\  ?JCZ+(?]]7HSW2BBBOE3])"BBB@ HHHH *YCXH_
M\DS\7?\ 8(N__1+UT]<Q\4?^29^+O^P1=_\ HEZTI_''U,*_\*?H_P C\\**
M**^Y/QL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X
MK^QIS^S9X/QR/],P<YR/MD_>O:J\6_8US_PS;X0SG/\ IAY[?Z9/7M-=V/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&?\ T#-"_P# >;_X]1_9U?LOO#^WL%W?W'V%17Q[_P -A>,_^@9H7_@/-_\
M'J/^&PO&?_0,T+_P'F_^/4?V=7[+[P_M[!=W]Q]A45\>_P##87C/_H&:%_X#
MS?\ QZC_ (;"\9_] S0O_ >;_P"/4?V=7[+[P_M[!=W]Q]A45\>_\-A>,_\
MH&:%_P" \W_QZC_AL+QG_P! S0O_  'F_P#CU']G5^R^\/[>P7=_<?85%?'O
M_#87C/\ Z!FA?^ \W_QZC_AL+QG_ - S0O\ P'F_^/4?V=7[+[P_M[!=W]Q]
MA45\>_\ #87C/_H&:%_X#S?_ !ZC_AL+QG_T#-"_\!YO_CU']G5^R^\/[>P7
M=_<?85%?'O\ PV%XS_Z!FA?^ \W_ ,>H_P"&PO&?_0,T+_P'F_\ CU']G5^R
M^\/[>P7=_<?85%?'O_#87C/_ *!FA?\ @/-_\>H_X;"\9_\ 0,T+_P !YO\
MX]1_9U?LOO#^WL%W?W'V%17Q[_PV%XS_ .@9H7_@/-_\>H_X;"\9_P#0,T+_
M ,!YO_CU']G5^R^\/[>P7=_<?85%?'O_  V%XS_Z!FA?^ \W_P >H_X;"\9_
M] S0O_ >;_X]1_9U?LOO#^WL%W?W'V%17Q[_ ,-A>,_^@9H7_@/-_P#'J/\
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MYNH(!%)QPMM)2^Y?_)#3K=4OO?\ D?'GQ1_Y*9XN_P"PO=_^CGKF*Z?XH_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3;G+#(QCCI@XKNM4T&/5OV<]:CUN[3Q#?Z9]J*7[NTK1RQR-@+(P#,%.5S@
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?GA\4?\ DIGB[_L+W?\
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M"[8 4#HJ@<*!Z 8I?5TE&$?A3N/Z_.4JE:>LYKE^6EWZVT,NBBBNP\D****
M"BBB@ HHHH **** "BBB@ KZ;_8M_P"9Q_[<_P#VO7S)7TW^Q;_S./\ VY_^
MUZX,?_NTOE^:/;R7_?Z?S_\ 26?3=%%%?(GZ@%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YX?%'_DIG
MB[_L+W?_ *.>N8KI_BC_ ,E,\7?]A>[_ /1SUS%?<T_@CZ'XW7_BS]7^8444
M5H8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]-_L6_\SC_ -N?
M_M>OF2OIO]BW_F<?^W/_ -KUP8__ ':7R_-'MY+_ +_3^?\ Z2SZ;HHHKY$_
M4 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _/#XH_P#)3/%W_87N_P#T<]<Q73_%'_DIGB[_ +"]W_Z.
M>N8K[FG\$?0_&Z_\6?J_S"BBBM# **** "BBB@ HHHH **** "BBB@ HHHH
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MNBBC^TZW9?C_ )A_J[A?YI?>O\CX7_X9J^(__0N?^3UM_P#'*/\ AFKXC_\
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>pbm-20240331xf1011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '/ E@# 2(  A$! Q$!_\0
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M '/*DYQS7OFX9 R,GG%<AX!N));WQ7N=Y0FL2HO]U1M3@?3//\J .PHI"P!
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M=]& TA8A2V -PYQZC./44 2T444 %%%% !1110 4444 %%%% !1110 4444
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M444 %%%% !1110 4444 %%%% !1110 4444 %(1D=2/I2TV0$J,9SD=/K]:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.U5MP7?_ *VX<?WV/ ] />@"[\-/!S^$-&D:^F2\U[4I&N]3NU/^LF/&U?\
M80811V"BNPJ-5V,, D<\@^IR<C\O?FI* "BBB@ HHHH **** "BBB@ HHHH
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M84$0:0O\TBE0/F&:W[GX$>*OAHS7WPL\83)&H_Y &MR>?;R#CY5<\J3D?Y-
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MC) Q^'3UJI\;?'>B_&Y=$\!>"Y?^$BO+G48;JYN[5"\-G''R6=^!G&>N3ZT
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M^E=?X2T_0-=^)&O0>*S;S75OI]DFF6NHM^[^R>4"TB*V 3NW MUXZ#%>S?\
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M3CJ*]WW'S&R2#\O"\]S_ )Z?CZ 'EOPN^!<7@C5[SQ-KVJ3>*/&-TFV74[I
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M0''/:O:=.U"UU"RM[NUF$EO-&LL3(00Z$97 'M^/% 'SUXM^%^N_L_6C^*_
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MBPN=1 WKCDAXQR!^73C/MQ]3L_RG&0<''RD]/\_C7RU^VR0VH?#W!!_XF)'
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MM>$88$$P(6P.<'GU_'DG-<#JOA+QOIOQAT'P+%\4];F.H6,E]+<F)5>%4P
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M&SCS+5Y)-SP@9SY>3D''<#KU]HH **** "BBB@ HHHH **** "BBB@ HHHH
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M<_;-J+EI8"NV=,8YRI!X'517<:;J,&K6MK>VSK-;W,7G12 CE" 1COR"#[4
M7:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1F"@DD
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ME0W3)QZ4 ?6Y;#8P>>A[4ZL+P:UP?"^C&YF:YG:SA,L[#EWV9;(_A.?\*W:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 444C,%!)( '))[4 +148ERX7:P;J1QP/?^5"S!QE%9ATSC&.GK_G@T
M 2444P2@X/\ ">CY&#TQ_.@!]%1^<",JK..1P.X[?SI1*"<#DYP,$<^I_"@!
M]%%% !1110 44UV"*2?R]?:F^:#T!)^;@$<X./7_ #WH DHI@E!?;WSCJ/3.
M?U'YT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIK
M,%QW). * '44Q) Y& <$9#=0?Q_SUI] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4U^$;DCCJ!DTZB@#S3QSXIU^[\7Z?X.\,W%KI=[<6DE_=Z
MA/ 9_(A#,GR*" 6+COZ'O4O@/Q3KDOB[7?"7B*2UO-3TR.*[BOK=?+2Z@DW;
M<Q\[&5A@X)Z"K7C;P%J-_P"(-+\2>'=1AT[6M.MWM0EW"TL$\+$$HP4AAC!P
M1GKTXKC8-*UOPGXJU&YN;F"Z\:ZS'$UO.T 6RFBAW;;.,\F,_P 6YAU/O0![
M6S Y4@Y/& <$CC)'/O7+?$GQHW@7P;J&M0VYNYH]D4$8/#.Y"IG. !N89/IZ
M]*T].UVTN8H4FEM[2[=-[VWGH[0N>HSGK\WIZUR_C2)/B++J7@Q;*Z%J80]U
MJH8*EI-\KQ!><NP(#$#CW!H Y^YU[QWX#O=%NO$E_I^NZ?JEY'936EO;?9S9
M32?ZORWY\Q=RX.>1N]!7I>@SZE=Z<DFJ6$=C=>8RFWCN/.4*#\K;BHYP.@[G
MJ>M<'%\-_%?B#4]!_P"$LUVPO=+T>Y6\6"PMFC:\F4,$:7<2  2&P.I_7T[8
M3R0C'Y<\8Z'K_A0!)1110 4444 -D;:A.2!ZC''OS7E7QK\<^(O!]CIRZ+I,
MTRW%[;QO>Q3QA,M* 8=I(.6R1G';G'!KU8YQP0#[BH+FU2ZC"S@2*&#!=@(!
M!X/(/3C\OK0!2T6_N=0T^VN+FRETV:7+/:,RNT)R.&(&,^N">OXB\+D';A22
M5W;006Z@#@'OZ]*^99O$5]X+\3_$K6KV\,GA34[^?3[MRY_T"86^(IE/7:V=
MA*XQ@''&:F^&6M^)-)\4:<-*TB7Q'*_A+3_,234$B"MO8LY#'EFZYXS\O)Q0
M!]+"=6QCDDX(!'!].O7_  J6O"OA5\0X/"/@>2;78;R&:ZUB_DE"$SBU59>0
M[G@ ':@ )Z\<#CV^*Y658V'*R<HP/48SG_/^. ":BBB@ HHHH **** $)P.A
M/TKD_%WQ.T7P7=6]I?FYEOIU\Q;2SMWGE$8^\Y5 < <_4C ZC/4S@F([=I;C
M&X$C.>.E>4:E>3^!OBKJ?B"ZTB_U'2-7L;>VAN]/C-PT$D1;,;*IXW$CGH2
M* /1?#GB?3O%FE0:EI=P+JRGSY<J@\XZA@1E2#D8.#Q6I)((QDY.> !W->1?
M"O68_#JSKJEK+IC:_K%S<P0,NY+-V V02X_U4K*I<ACU)&>@KUKS=PX(CVX9
MMXZ#G/?VZ]/K0!S/BWXEZ+X-NK:TOGGEO9T,HM;2!IY5C )9V5 2% !Y^GK5
MS1?'FA:_;:=-9ZC$XU",RVT;';)(%SN 0\Y7'(QQ7GLNK)X:^*&I>)5L[O6=
M&U:RALH;W3(VN##/#(P:%E!R-P(.[IE3D]JU_@[X:GM=)O-3U/2%TVZU'5+C
M4H+6=%,MHC\!2><-QGAL?-QWR >D;@3@<\X..W&>?\]Z=30I!&23@8SGKZY'
M2G4 %(3@="?I2TR5"Z$+P>W)'\J $,P!Y!7&<[L# '?Z=/SK@/C!\3;GX<Z'
M%<VFEW5]<2.J[T16BCRR@JYSD'#9& >E4]2^,&G>'O''B+1-5N;338;&T@N+
M1I&*M*70G# =LKC\#5_P;XRB\=_#C3=8U"&U-Q>VK7JVHD\Q6VEMC*.,CY<X
M&>H^M '6Z'JIU?3K6[%G=6(FC#?9;J((\?/?G ^F?I[Z.\\?(WZ>OU_&O#_#
M7QYOO$'A72KJ?3+>T\02:K;Z??Z=+*2J0S%MDR-@Y5U3.!QD$9'4]]<^-]0N
M;B:+1_#&IWTD;;?M%P$MX6.2,!F.2!].ASS0!V0?) (8$]L=/QZ=J=6!X;E\
M0W$L[ZU9V-A#G,,-K.TCC@9WG:!USTSZUOT %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%(QP"0"2.P[U@Z5XQM-8\4ZSH4,4RW.E"(S2.N$;>N5VGOW
M!]Q0!NN=J,<A<#J>@JNUO%<,ADB5WB<.H**?+;.<C/0X/.#_ #K@)?CMHK:'
MI=[8V=]J=[JKRI8:7:1;KB<1OL=\= @/\?W?>BV\67'Q0L9+#P_=7/AZZMK@
M0:M%>(8[VT7&0$4Y&6_O<CKSQ0!Y++X#NO'&J?$2*S\'6&L7DVL7%M'K]W>+
M#);,$500N"WR$#&.3M%>\>"=:LM3TBU@M]636+JQC6UN9%<"03(,-N0]"<$9
M_P#KFMK3M!LM(>X:RMH[=[B;[1/(!EI9",,S>Y'?_)SM2\":5JFKP:L]N+?5
M82"MW;G9(><E6(QN7A>"/X10!NF;.0BEB#CTY]_3_P"OQFG[\Y( 9>F0>^<'
M\J\6TG2M4^+=]XJU.?Q3J>APV.H3:9I]KITFU(!'M!DE4CYR6YP<<<>M=C\'
MO%-[XR\ Z9J.HNAO]\L,LL8PL[1R-'O';D(21^(P,4 =U1110 44A.!T)^E,
M$H)XPP.,%3G@]": )*:X)1@.21ZX_6H9KZ"V#&::*%5SN,D@7'I7(Z[\6_#>
MEVDXAU2"\OMK+#;6;>?(\F#A<+GG<"* */A_1M%\52^.].&DQ'1[V]>"]D+[
MA>S%%$I/I@87@\;?:M[P]\/=%\+WR7>F6BVD\=C'IB.K,V+>/)1?F)Y!/7G.
M.:C^'&C3:'X1TZ"ZB9+]E\^ZR03YLGSNI)Y^7('.#\HKJ6&X$'.#QP<4 >8^
M+_A3=7NC2:)H#V-EI=[-)<W<=RKEUG9]_GHR_>;<0=C<''I7HME:26UO%').
MTTB(JM*?O.0 "Q[9.!],GFK5% !1110 4444 %%%(3@="?I0 ,,@@$@GN.U0
MO&Q.XD G ( )/IC(QZ]^G7Z9]MXITZZU#4+!+A6O=.6-KN%#N,.\9&3].?I7
M.ZE\9O!]AINGW4VJADU&$7%O#%$TDTD//S^6 6VX!YQ0!-XGT6VT33_$?B&R
MB6VU)[)Y&9AE&EC0O'(R\ NIX#<GWZUY3\./%>O>);_PY%_;&IZ]8ZC8DZS'
MJ-A]FM[53$,"*957EF!XW,<9]L>H/?OX_CM8M*>VF\)W]LZS:C'+EI496'E1
M!?NGKDG&-O>MO_A$=//A:#0+F'[3IT4*0JDLK!OE "Y88.<_Q#!SCO0!;T[2
M[?1K2*QLHDL[2/")!"F J\CH.1GKN)ZU>1M[*P)&>0"0<C Z8/KCGZ^M>:>)
M;W4?AGX;BM[*\?7;O5=0@L=*CU+!6U,AQAV3!=5&3_>.<<T[0?$'BCP[\0--
M\.>)+ZTUNWU6VEN+2]MK9K5XI(PI>-T+$,N#D'MT('% 'IU%%% !39%WIM(#
M XR"<<4I."."<_I3!(2,J W?Y3U'.,'I0!R</@)$\5^(-<GF2=]4MHK81>4,
M1[%*YR<D?>[''M7F-O\ #>YT[Q!X>\//I=U<6^G0XE\2)$NZ:0B0(@^?]V@#
MDN .>,YYKWF295'+B,=-S?+CKTR.>E<7\2/%T%GH%WIEAJ$/]O:BGV2SMXW#
MOO=MF\*.>,Y/IC\: .*TCX1:5XPT3P-J%AJ5Q#+H,B*;KRMOVZ*)C\CIT&&P
M5/4=L5[48SDX9E'J#GU['Z_YQ5#0-+AT+2K+38%VI:0+'UZ]L^AR03_^NM.@
M!NTAR1M /)XY/X_E^5.HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2#"DCH6(AXX7YCQVSBM#XD> &\>>(/"ANK6VN](TZXGGO8IB=Q5HRJ;0/?\
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+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>pbm-20240331xf1017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $\ B,# 2(  A$! Q$!_\0
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M*D*Y"*[_ #Q;LJW]R@#W36_VKOAGH7PRT3QZ_B1+SP_KDBP:6+"%Y[F\E/\
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MLT[0-+MOV;[GP+\88KZV>_\ ']H8K/3XFC?][.C1-\^[[VRN]_;4TGQ5K_Q
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MXOOC1\2]<?POXWMM+\2^ )](T_4_&MVMQ>SW/]R5E;]Q_LK02?2G[)?Q]?\
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MF_[5.U7X(^.9_A%^U]8)X2U!]5\6>(;B?1H<+OU&+<FQXO\ 9^]0!],?$_\
M:N^'GPENM'LM6U*[U._U:T^WVMGHEC+?W#VO_/PR1*=L7^T:]%\"^.]"^)/A
M73_$?AO48=6T34(_-MKN#[K+7P;XR^#?C_X?_%#PUXZAT7QW?:3J'@;3]&N%
M\ W446IV%Y;QK^XE67=^Z;_9_CKZ@_9!^'$WPM^"6FZ7=Z#?>&;NXN9[^;2-
M1U);^:U:5]VUI415_P!K:!\NZ@"I\0/VVOA+\,_&%[X;UC6KM[[3F1-3GL-.
MGNK72V;[OVB5%*QUY'^U=^UYJGA7XA_#KP;X'\2MH5KK@^V7WB&WT!M7_P!'
M9-T'V=/NR[_XMOW:Y.+PM\3/@9IWQN^'MK\)M5^(*>.]4O[W2/$>GM$UJZWB
M;-EXSONB\JND\/\ [._C3P!XQ_9+TPV,VL6O@RUOXM:U*U&ZWM7EM_[W]W<V
MU?\ <H ]A_:[^*?B?X(_LR:]XM\/WT)\1::EF$O+BV5T=GFC1V\K_:W-Q7B%
M[\>?C5\&?&7PKF\8>,?"/C[0/&VHP::VFZ5I_P!EOK7S50^:FU_FV[_\[J]I
M_;S\#^(/B'^R[XOT'PKI-QK>O71M?(L;4?/+MN(G;_QU33O@S^QS\)_AI)X?
M\2Z?X$MK+Q=!:1-]KNY)9Y8)=GS[=[LJMRW2@!_B_P#;B^%'@?Q9J6@ZGJFH
MLVDW*6>IZI::5<3Z?83MTBEN$7:K5SOB3X]^*[3]ISQAX.L+ZT?POI_P]E\2
M6BFV5G^U;L(^_P#B7_9KYR^/'@3XX?%#0?BYX>UKPIXXU;5I=2:71+71Y[>U
M\./8+*C([JNUKJ?:OW7W_-L_NUZ[;?"SQA-^T+X@\0+X;OTT>Z^$RZ1!<,J[
M&O=J_P"C_P"_0!=^%O[1WBGQ;X%_9OU;7/&&GZ5JGCBXN4U"R_L9Y?[6V?P1
M,GRV^W'WFKT7Q;^W%\)/!'C"]\.ZGKMT)M.N5L]1U*WTZ>73["=O^64]PJ[$
M:OGSX?\ P1\?:5X1_8WMKOPG?Q3^$K^^?7D=5_XERO\ <:7YJG\#:;\6?V>-
M)^('PSL/@Q/\0;S6_$MQJNE:[/Y3:+=03RHV^]=GW*R;?N4 ?5^@?'SP9XDU
MSQSI-MJ3PWG@Q4EU=+B!HA%"\32K,C?\M(V12P9,UX%XW_;=L[#XF?!O5=)U
M9XOA=XLT[4;JZ^T:3*UU<M%\L/E)M\WYF^ZJK\]>9_MQ>$?$WAWXJ^%G\*&S
MMM:^+.BKX'UBTM9#\K*\;"XB7[VU4W+N[*M>A_&3X7>)O 7QM^ VL^!? EYX
MO\,^!-$O;2XM[-XD9(_*1%V%V"^;M^95_B-!1W/C+]J_PSXP_9Z\;>-O WB^
M+PS=Z#)#!>7>L:1/-+IDK2HNVXL\;_F5MOX_[-=%XE_:U\ _#>^L/#_B'5;V
M]\33:+!JR0:;I,\SW:/_ ,\D56^;AFV?PK7RWXG^#/Q'^)7PR_:;\9'P)JF@
M:AX_?3H=&\*2[?MKQVTJ[I94W[59_P#XJO:/!'PQ\467[97A_P 4WOA^YAT"
MW^'<&EOJ;!1%%>;U+1?[U!)[W\(OB_X6^.7@NV\4>$=1_M+2)Y'AWO$T3QRK
M]^-T;YE=?2O(/#G[15]I7[0_QPT3Q?K%E8>!/!.FV%_!*T&Q[=98M\K._P!Y
MJ=^PMX!\1?#SX>^-++Q+HUSH5W=^,M4O[>"Y7:TL$CILE7_9:O.O&'@#XK:+
M\7/VG/$_@GPZW]J:QH^EIX?N[J.)K>\EBB19=BM\K,J[OO\ \5 'M?PK_:]^
M'7Q?\5P^&M%N=5M-8N+1K^S@U?29[+[;;KUF@\Q1O6IH_P!K/X<O\&[GXH+J
M%Y_PB5O??V<]S]AE\WSO-$6/*QN^^U?,WP>^'WCV^_:=^%?CC4O#/Q"_LNTT
M>_L-3U7QM<Q2RQ7319.RW7_40;OE78J;JX&Y^&OQ<L_V5_$OP2B^%.O3ZK:>
M(C?G6$>+[%/:_;5E5X'W[I6_V/[HH*/M'Q[^U_\ #;X;>*=2\-:Q>ZBVOV-I
M%?MIUCIEQ<RS0R?-NB")\VU?F;^Z*MS_ +6/PQM_@[9_$YO$JGPE?2_9[6=+
M>5IYKC<5\A8=N_S-RL-FVN#^'_PZ\1Z?^V]XP\77F@W$/AVZ\%V&GVVK.%\I
MKA'7?$E?._A?]G?XF:!\ ?AIK$7@JZN]>\"^/KSQ#<^%9G2*XO;5I?O1?P[\
M?=H)/>_B;^V?HVO?LZ?$SQ3\,]3>V\7^%;>)Y=/UJP:*XLV>555I8)1]UEW5
MU?P>_; \"?$G6/#GA%]6N/\ A+M2TV.YB:?3Y8+2_D6/=-]EE=0DNUMWW?[M
M>2_%F;XF_M!? [XV;/@[)X3BU.PM;71;>]C1=>U.998]_GHK[=J[?E^>NA\;
M?"OQ5>_%C]E74;/PY<MIWABTGBUF5%798;K2)$5O^!*RT ?7M%%% &9J&M6&
ME&WCOKZVLVN9/*@$\JH97_NKN/S-3%U_3#>75FNH6ANK-/-N(!.N^%/[SKGY
M5]Z\._;H\ W'C7]GC6K[3(MVN^%Y8/$FFNB_.LMJ_FL5_P" !Z^ ->\<^+/+
MUOXR:9;7?G?'A-4\)V=I_P ^OSV\5H__ 'PDM 'Z9ZA\93;?$71]%MM,AO\
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MS5S1M%T_P_IMM8:786^EV%NNR&TLX%BAB7T15^5:TZ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNES6NG1>'--ETR[WOJ>J->6]OON(GW?P>;_=;?Y4NYEKXU_X>0>./[4EU/\
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M_@1_S^Z__P"">6@#[!HKX^_X>I_ C_G]U_\ \$\M'_#U/X$?\_NO_P#@GEH
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MM'_#U/X$?\_NO_\ @GEH ^P:*^/O^'J?P(_Y_=?_ /!/+1_P]3^!'_/[K_\
MX)Y: /L&BOC[_AZG\"/^?W7_ /P3RT?\/4_@1_S^Z_\ ^">6@#[!HKX^_P"'
MJ?P(_P"?W7__  3RT?\ #U/X$?\ /[K_ /X)Y: /L&BOC[_AZG\"/^?W7_\
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MS\<Z5X%T36]>MO FJ:EIUHN@2Z?#J-_!>Q1;WTM_F_T>*7Y?O>;][^"O+O\
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M,?'WC^"^GU"%(-,MV1]/U&XM7_UK_?>)TW5^DW_"B_#O_00\3?\ A27_ /\
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M[:M=/:?%BUU#X5P>.K32-6NK*>U6\BTV*WS=ONYV;=VW_@6[;0 O_"*>/?\
MH?H/_!%%_P#':/\ A%/'O_0_0?\ @BB_^.UR^M?M):?IVC:3J5EH&K:M'=:
MOB>[2U\K?8Z<P_UK;G^9O]A-WW&K=D^-6C/\4M&\#VL-Y>7=_:/>&_B13:P?
M*DB1.^>)'1M^W^[S_$M %O\ X13Q[_T/T'_@BB_^.TRX\*^._(EW>/H/NM_S
M HO_ ([61XG^/-CX;^(R^%6TJ^N62:TM;F\A:)1%+=/M@*QLX>5<_>9%;;_P
M%L>IW'_'M+_N-0!PWP5#?\*A\&;I-S?V1:Y/K^Z6BK'P._Y(_P"#O^P7!_Z
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M;JWN9=<U2:XM6WP3/>2N\3_WT??\M1)K>IPRO+%J=ZDSR_:&=+IM[R_\]?\
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M;J.H7%Q]KGU2R25);RX91YLLV]O]T*J_*B*J_P -?,G_  ]W^%W_ $*OBO\
M[\6__P =H_X>[_"[_H5?%?\ WXM__CM 'U5\0O\ DH'PS_["MS_Z07%=I?\
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M=>#/B==:KIGB.?7;"[@LY]0;5K%HDT_2X(HM_FW&[YFWM\FSY?OT$GW5:?\
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M8+OV1.[HB?ZU/G1*\LH _6+7O^"I/P*\3Z<^GZOX7\0:I82\-;7NDV\L3_\
M 'EK$G_X*+_L[W.I->3>#?$%S_Q+O[(6VETRW:VCM=^[REB\W:JLVS=\O\*_
MW:^$OAU\/?!WC#X5>-=8OI=;TW6_#]B]ZVINT7]F>;OVV]KL^\TLO_LE=!\>
M/@#X>^%WPYT?7M*N=4FENKJ"WBN+MD>*]B:U25Y=BINM61GV>5+\S?>H ^UK
MG_@I'^SI>:=8:?/X"U.;3].;=96LN@6KQ6K?],DWX7_@%6KG_@IW\ [K7(-;
MN/!VM3ZW FR+47T:![B)?[JR[]RU\*ZQ\&?#5G\*O#GBBQ76]8\];!]:U'3M
M1LI;?37G?8\3V_\ K8F_N._R[GKHM>_9X\*Z/X\\&:8MCX@FBU[3);IM)?6+
M!/*E67;_ ,?_ /J&79\SHFYE^[0,^P4_X*6?L]PWNGWL?@?6%OK!66SN5T.V
M\VU5OF98FW_+]YN%KH/^'M?P?_Z _BO_ , 8O_CM?G3;?!G0W_:=E^&DNJZ@
MFA)JTMDM\]KLNV14WI\G\.]OEW_=_BK,^/WPWTSX7>,K+2M,6^A^T:9;WL]I
M?2I<?996W_NDN(OEG7[GSI_NT")?VGOB=I?QF^._BWQGHD=S%I>K3Q2P+=)L
ME7;$B?,G_ *\RAF\F>*555V1D?8Z[T?_ 'Z;106>RWG[6_CV_P!<TK4_(\-V
MTNG:=+I"V]OH$$5O/82IL>UEBV?O8O\ 8_AJDG[4OQ$A\3/XA74-/36'U&+4
MEN_[,M]\7E6_D);I\GRP>5\OE?=J7P?^S'XA\8?#NW\40:SI-G<7]G?W^CZ)
M<2O]KU2WL?\ C[>+Y-J[/[CO\VRLKX&_ 37OC]J^I6>BWECIMOIUK]HGOM39
MDBW_ #^5$FW[TK['V)_L/02.UC]HKQ?K$_F?\2O34BT>70K&+3-.BM8M+M97
MWRI:HO\ JFEWNKO][8[UE?$+XQ^*/B=I>B:?KUS!-:Z2C>0EO:I%O9DBB>67
M;]Z5UBB7?_L5VL/[)WB;^P?"FM3ZOI%GI.LVJW]Y=S-*D6D6K6Z77VB5]FUE
M\IT_U6[YG1?OO7BK[?-?RI?.BW?*^W9O3^_0 ROW/_X)_?\ )GGPS_Z\9?\
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MF_=W-]VOB$HR6VW[GR_<H*/Z$?V=/^2 _#G_ +%ZP_\ 1"44?LZ?\D!^'/\
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M6_\ !=+_ /$4?\(?X@_Z%[5O_!=+_P#$5_1U@48% <Q_.+_PA_B#_H7M6_\
M!=+_ /$4?\(?X@_Z%[5O_!=+_P#$5_1U@48% <Q_.+_PA_B#_H7M6_\ !=+_
M /$4/X/\1OLW:#K+[/D7?8R_)_XY7]'6!1@4!S'\XO\ PA_B#_H7M6_\%TO_
M ,11_P (?X@_Z%[5O_!=+_\ $5_1U@48% <Q_.+_ ,(9X@_Z%_5O_!=+_P#$
M4R;P?XA\I_\ BGM7^[_T#I?_ (BOZ/<"C H#F///V> ]O\!?AU'+%)%(GA^Q
M5D=""I\A."**]$HH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_19C^#_>_P" UZBDBR(K+\RMWH DHHHH **** "BBB@ HHHH **** "BBB@
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MLB;JP+[X:>$M4_X_/"^C77_76PB;_P!EH ELOB!X8U ?Z'XCTFZ_ZXWT3_\
MLU;-O?6]RFZ&>.4?[#;J\]N_V</A=?MOE\!:%O\ [R6:)_Z#5+_AESX69WIX
M0MH3_P!,9I4_]!>@#UBBO+1^S/\ #Q!^ZT6YA_ZY:M>+_P"U:3_AFOP'_P ^
M6J_^#V^_^/4 >IU%+<10+NDD5%]6->9?\,U?#YDVOI5[-_UUUB\;_P!JU&/V
M8/AA(,R>$X)?^NUS._\ Z$] '=77C7P_IZ_Z9KNFVO\ UVO(T_\ 9JY75/V@
M_AKHAVWGCG0T;T6\1V_\=J"U_9L^%ML=Z>!-%+>LMJ'_ /0JZ"P^%'@K2Q_H
MGA+1;;_KGIT0_P#9: //;_\ ;(^%]LVRSUB[UN7^YIFG7$O_ +)60_[5>HZO
MA?"WPH\9:V&'RRW-K]D3\VW5[S::7::>FVVM8;9?[L,2K5V@#YJF\:_M&^+E
M*Z1X'T+PE;O]V;5+OS94_P" [O\ V6J,W[.OQ;\=L?\ A-?BM+#;.,O9Z-$R
M)_[*M?4=% '@'A+]B[X=>'R)+ZVOO$$_\1U"?:K?\ BV?^/9KV;P[X6T;PI8
MK::+I5EI-HO2*Q@6)?R6MFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **X_PI\5?!OCK5M1TSP]XHTG6]1T\_Z7;Z?>)*
MT/S;?FV_[0VUV% !1110 445R/C#XE^&/ +.OB#6;?2BMC/J3>=N_P"/>';Y
MLGT7>OYT ==17&CXJ^%!I'B;5?[<MOL'AIW35[@[MEFRQ+*V_CC]TZ-_P*NE
MT^^M]6L;:\M95FM;B-9HI%Z,C#<K4 7:*** "BBB@ HHKFO&OQ \-_#C2?[3
M\3ZW8:%I^[RUN=0G6)&;^[DT =+17G>I_'OX<:)J%A9:CXVT.SN[^**XMH9K
MY 9XI?\ 5.G/S*W\/K6BOQ8\'S6VJ7$7B739(M+NTL+QDN5807#/L6)O1F;Y
M<4 =G117*Q_$30)O'<W@Z/44?Q)#9K?S:>B,SQ0,VU79A\J\T =515&RO[;5
M(O,M+B*YBWLI>)@R[E^5EH_M"V-\]F+F+[4D?FM!O^=5Z;MO]V@"]17/ZQXO
MT70=;T;2M1U"*SU+6YI;?3H)#\T[(F]U3_@*[JL^)?$NF>#_  _?ZYK-Y%8:
M7I\#W%S=3<+%&HRS&@#7HJI97\&HV<%U;RK+;SQK+&Z]&5N5-6Z "BL3Q'XF
MTGP?80WFKWL5A:2W$5JLDO :65PB+_P)FK;H **X_P 3_%+PKX.U*73]:UNU
MTZ]BL_[1>&8MN6W\U8O-_P!WS'5?QKL* "BBB@ HHK&B\4:7-XHG\/I=Q-K,
M5JE[):9^=8&=D5O^^D:@#9HHHH **XG6_BWX1\.^(7T34M>M[75%:SC:T?=O
MW7,K16__ 'VZ,O\ P&MSPSXGTKQ=I2ZCHUY%?V+N\:SP_=+([(W_ (\K4 ;5
M%<WJ7C;0=*N;*"XU2VCEOK[^S855]Q>YV%O*^7[K;5KI* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N<\?:)=^(_ _B'2-/N?L>H7^GW%K;W'_/*1XF57_,UT=% 'QCIVD>
M-++X Z)X-M/@O?Z/K.A66GZ3J%RMS$D4\:NJW#V_V6X26=?E\W8[Q;]WS5RP
M^#'QFUOX;00ZJ?%4.M:3X-U3[!%;:TT3-JB:@[:>C[)?G=(-NW>[+_?9J^]M
MM&V@#XT\5>!OBS?7OQ6:STWQ+_PFE_ PT#Q!#JJIID5AY5O_ *(L7FIMGW+/
M\VS[[[]]-\&_"'QOK=QX!T[4G\7V?A2/Q#J-UJ%JUR^G?8[;[$OV>'Y+J65X
M&N$W?,[_ #N_\-?9U)MH ^5/VE_AU\5?$WQ!CC^'^HZC9:'X@TI8M1OK>]V_
MV;=6,KW$&U=W_+Q_J&V?\"K@_$_PR^,7C#P'>2ZCI.K?VGXE\-^);K4M$DU)
M98K.\N9;065E]_;\D43;?X5^:ON?;2T ?+L7PK\6+\+OVB=-_L>5-0\2W5T^
MD0AT_P!*1],MXDV_-_?5E^;^[7DUK\+_ (NVG@K5[71]&\5:7X>74-&^U:#J
MVJ_;;NZ2.WE74&B*W2-Y3RM;_(DJ[O*;;_=K[#3XE6#_ !8N/ 7V6Y34XM%7
M6VNOE\KRFF,6W_>W+65:?M"_#6_TK5M2B\<:,+#2I(XKZZ:Z54MVD?9&7+=%
M9C\K?=/X4 >9:OX;\;:;^RMH6BQ:?K'BS7Q+!#>1:C</;WJVWVCYW9(KC=+L
MBV_NO/\ G7[SU\\:IX>^*?V70/!6I6?C/4O&!\(:H]C9:7KOV=[.Z_M5TT^Z
MN'^T?/%$K1?QMM7^]7VO9_M ?#G4-<M=&MO&6DS:G>0K<P6R7'SO$T7FAO\
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M6K?B?X_>!O".K>!M/U'6HE?QF^S1Y8U+Q3_)O1MV?E5OD5?]IU'>@#Y6\/\
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M+\_^U77:S\,-?\3^-+K7-0O--MWF\(3Z#'':B4_Z1.R/*[;O^6:LB[?XOF-
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M^S5KTGP>3P=IOB^36W;3[?2Y+;Q%%'+IZ1*B)*T"+%OB?8K*C;FV;Z .CO\
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MI7;S95^Z_P LK*O]W:M $]M^RK\(M"T;4YVTS9I5Y8O9M+=:K<-%!:M*LZI
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M9, ?W695:MNOG+X:? _Q-X%\5>%GO(=&CTW3-1\0:GYNC[HEB2^E1XK54?\
MVG;_ &?W25]&T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!E/JR#7AIQADW>1]H6;^!OFV
C[?\ QZM6LZ71[4ZFNJ%&-XD1C#>8V-O7IG%:- !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>pbm-20240331xf1018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $G C\# 2(  A$! Q$!_\0
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M9+G3YX+?48E7<SV\KH%DP-W_ 'R:RD_;G^$S>+4T1=3U+RI=2_LA-;_LJ?\
MLIKS=L\G[5LV;MWRUQ_C'X5>*KSXY_LS:M9>'IVTKPOIMW;ZI<+LV6#-9*B*
M_P#P(;?EKYR\9?#;XY_$CPU9Q>*?!_C?5?%ND^+8-0NT2]M8/#\=JEQ\GV*U
MB=/-;9_&_P R_-\] 'U]\%_B[XG\9_M+?&SP?JES!-H'A5M.33(HH%1XO.B9
MWW/_ !=JXW]H[XK?%'3OVF? ?PS\ ^*=&\)VNO:)=:A/?ZQIBW:K+$S?[:_P
MI70? KX?^)?#?[5/Q\\1:KHUQ8Z%KSZ6VFWTNW9=>5"ZOM_W:Y3]H;]G27XU
M_MA_#6\\0^$YM?\ AU:^'KRWU.X\TI#'/N9XE9E=7^]MH P? W[8WBWP&/C;
MI'Q.N=%\7W7PZL(=2BUOPTGE17GF_*MNZ?,J/O95_P"^JMZ3JG[6][X-T+XE
M6E_X4UW^T1!>M\/(;#[/LLY=CJB73/\ ZU5;^*O3?&G['/@:7]GSQO\ #3P+
MH=AX0C\16N&F@1F#7"X:)Y68EF4,BUY+IWQ)_:;7X>>'OAIHGPFE\.>-+!+7
M39_&EW<P7&CI!%M5KA%_BW*OW* /L35_$EOX;\*7FO:O&]G!8VCWMVB_O6B5
M$WO]W[VWFO!;/_@H#\&+R;2LZ_?Q66J6_P!HL]2GTJX2UE;;EH%EV8:4=-B_
MQ?+FO6_B=HNI:Q\&_%NDP*VHZS=Z#=6JB%=AN)VMW7Y5_AW,:^1=&^!?C>+X
M4_L@Z5/X3NOMGA#78KK7;?Y?] 5=_P [_-_>Q0!]$^$_VN_AGXN\$^+/%4.L
MSZ7IOA-]FMQ:Q9RVMQ9?W"\3KN^;^&F_#G]K[X>_%#6[K1],EU?3]6@T]M46
MQUC29[.6>U7K-$'7YTKPG7_AY\8/#GBS]JKQ#X&T"2+6M>DTM_#]S<+$Z7J1
M)MN/*5OEWJF[9O\ XJYWX:_##Q]??M"Z1XROO"/CL:-/X.U'2I-1\;:A%=78
MO&7=M\I'_<1-]U53[U '>?%?]OGPUK_P/\:ZS\)=5N[KQ%I&D1ZK!?7>D2_9
M(_\ 2HHF1V9-GF_/]S_:KV3P%^T;X7\3:];>$?MTU_XJL]%@U77'M[9OLNG;
MHE?]_+]R)O\ 8/S5\YZ/\#?'5C_P3 O/A^/"EW%XXDM7']A[4\UG^W[_ .]M
M^Y\]+\*_V<O''P?/C#X9Z=:ZG>^!?B)X6\TZ[<LK2Z/K+6ODRI<,HW['_P"!
M;: />O O[9WPN^(WC&T\.:)JU\;G47EATN^N].G@LM4>/[ZVL[KLE8>QKE_V
M9?VO(/VA?B/\0_#IT^73ETB^9-*!L)UW6J;59[AW^1)6=_\ 5?*VVO ?@A\"
M/&KZI\)_"/BKP'X_2;P=J,5U>:AJ'B*W30;!X/N2V2*CM+O_ +GR_>^_7N'[
M+_A_QA\//CS\;]%UWPAJEOI'B/Q%/XAL/$OR?8I8WV*L7WMV_'_H- 'U=111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '%_$OX5>%/C#X8DT#QCH=KXBTEG646]VI^5U^ZZL
MIW*W^TM97PK_ &>_ 'P1:_?P3X=AT:XO]GVNY\Z6>>?;]U7EE9WV^V:])HH
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M*[S_ ,'"_P#QJC_A\=:?]$KO/_!PO_QJOS2HH#E/TM_X?'6G_1*[S_P<+_\
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M7>T3URB?LE_%*Y\2V^AV>@VU_=SV+ZE%<6FIVLMHUJLOE/+]HW[=J-\K_/\
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MKIH/-E??^Z5-NZ@1]=_\/CK/_HE=W_X.$_\ C5'_  ^.L_\ HE=W_P"#A/\
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M3_HE=Y_X.%_^-4?\/CK3_HE=Y_X.%_\ C5?FE10'*?I;_P /CK/_ *)7=_\
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M !='_#NNZ_Z'^V_\%C__ !='*',?'E%?8?\ P[KNO^A_MO\ P6/_ /%U6?\
MX)]7,.I6]G_PG5M^_BE??_9C_)MV?[?^W1RAS'R+17V'_P .Z[K_ *'^V_\
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M ,70'N'-:_\ MS77BN[LY-9\$:;JEK!/HT\ME=S[XI_L/F^;N39_RU:X9O\
M9;^_5+XA_MEOXXT75-+C\+2V]O=>'+SPS%+>:CYLJ13W23^:VR)%^39MVKM7
M;79?\.Z[K_H?[;_P6/\ _%T?\.Z[K_H?[;_P6/\ _%T![AQ=S^VGJE[H'A#2
M[CPO:3)X.BTF7P\\MQN^QWEG_K9?N_,MPORM%_N?/6GXA_;1L_$?B9YKOPA?
MS>&[K1]4TJ\TR76M\NZ^V^:T3^4BQ;/*5?N[F7[U=#_P[KNO^A_MO_!8_P#\
M751_^"?5RFK16/\ PG5M^]@>XW_V8_\ "Z)_?_VZ ]P\;^&GQ'L?#_PD\<>&
MI[E;#4O[2TSQ)HK/$[I+=6<K+]G?_>BEW?\  :[3QW^U9HGB33_$;:)\-[/2
M]5\7:O9ZSXG?4-0:_M;^2!O-\J*!D7RXW=WW+O;[]=W_ ,.Z[K_H?[;_ ,%C
M_P#Q='_#NNZ_Z'^V_P#!8_\ \70'N&'8?MMZ?X5/AVW\*^ [G3=*T[7XO$-U
MIFH>(I;V)94B9$M[+<G^BQ?O7_O5YA\2_C?I/B?P/%X*\'>"XO!/AM]5?7+Z
M)]1EO[B\O-NU6:5D38BJS;4V?Q5[7_P[KNO^A_MO_!8__P 71_P[KNO^A_MO
M_!8__P 70'N'%^&_VU-3\-^!H_#$'ABW>)-'TG2_M#73;U^QSO*\J_)\OFJ_
ME5%_PV+.GC'0O$'_  B<&_2=8\0:JEO]N;][_:J.CIOV?+Y6[[_\5=S_ ,.Z
M[K_H?[;_ ,%C_P#Q=5G_ .">]RFI16?_  GMM^]@:7?_ &8_\+HO]_\ VZ ]
MT\-^+7C/2M8\*?#/POHUS]OM?#&A^5=7>UTW7D]P\]PB;OX4WJO_  "O-Z^P
M_P#AW7=?]#_;?^"Q_P#XNC_AW7=?]#_;?^"Q_P#XNCE#F/CRBOL/_AW7=?\
M0_VW_@L?_P"+H_X=UW7_ $/]M_X+'_\ BZ.4.8^/**^P_P#AW7=?]#_;?^"Q
M_P#XNJ?_  [ZN1JZ6/\ PG5M\]JUUO\ [.;^^J[/O_[5'*',?)%%?8?_  [K
MNO\ H?[;_P %C_\ Q='_  [KNO\ H?[;_P %C_\ Q='*',?'E%?8?_#NNZ_Z
M'^V_\%C_ /Q='_#NNZ_Z'^V_\%C_ /Q='*',?'E%?8?_  [KNO\ H?[;_P %
MC_\ Q=5G_P"">]S_ &HEG_PGMM\\#7&_^SG_ +Z+_?\ ]JCE#F/D6BOL/_AW
M7=?]#_;?^"Q__BZ/^'==U_T/]M_X+'_^+HY0YCX\HK[#_P"'==U_T/\ ;?\
M@L?_ .+H_P"'==U_T/\ ;?\ @L?_ .+HY0YCX\HK[#_X=UW7_0_VW_@L?_XN
MJG_#OJY_MD:?_P )U;?\>WVK?_9C?WMNS[]'*',?(]%?8?\ P[KNO^A_MO\
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M!_IEM'.-N[;\R;N,U1U+_D>]"_Z\[W_T.WH Y?\ X9Y\$?\ /E?_ /@VNO\
MX[1_PSSX(_Y\K_\ \&UU_P#':],KPV#XW:A8Z?X^EO;:WNKK18)[RPLK5DE1
MXDDE1"\J2M\_[K<Z-M9: .F_X9Y\$?\ /E?_ /@VNO\ X[1_PSSX(_Y\K_\
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MWXO^FM>SPRK-$DB<JR[EKFM0_P"2DZ-_V#+K_P!&V] '._\ #//@C_GRO_\
MP;77_P =H_X9Y\$?\^5__P"#:Z_^.UZ97@.D?M ZK<^%/&FM7&GVSSZ7!]JL
MK&+[^SS98MDK;V^?]UNV_*_^S0!V7_#//@C_ )\K_P#\&UU_\=H_X9Y\$?\
M/E?_ /@VNO\ X[7E=Y^TSXBTZ1R]EIFH+96TZW/E+L\RZ3[1LV?O6^3]TGS+
MO7[_ ,ZULZY^T#K&E> M&OXK:QEU::]N;:[E*8MXE@65_E'F[6+>5M7;*V[Y
MMFZ@#N_^&>?!'_/E?_\ @VNO_CM8EQ\ /!*^,=/@%C?[6L;AO^0M=?WXO^FM
M>MZ?=)>6<%PO"RQK(/EV_>K)N?\ D?+#_L'3_P#HV*@#E/\ AG;P1_SY7_\
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MW_T.WJG_ ,*ZF_Z&[Q-_X&)_\:KG;_P#*/'FBP?\)3XC.^PNVW?;$W+\]O\
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MKF9_^2DV/_8*G_\ 1L54/^%=3?\ 0W>)O_ Q/_C584_@"3_A.K2#_A*_$?\
MR#)VW?;%W?ZV+_8H ]2K$D\,:2\[R_V;:[G=I7/D+\S,NQV;^]N7Y:Q?^%=3
M?]#=XF_\#$_^-4?\*ZF_Z&[Q-_X&)_\ &J .E_LBR6V6T^PV_P!E6/REB\I=
MBI_=VX^[[5 WA[3'M887TZS:&+9Y<?D)M79]S;QQM_A]*P?^%=3?]#=XF_\
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MODS6:JTGE+YOWF5?^^?FWT <+_8.K_\ 0WZA_P" =K_\:H_L'5_^AOU#_P
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MX#L=?709WO;W49M-33O,?&^-979R_E;U79"[?-&&]J .K_X0?Q'_ -%!U?\
M\ [/_P"-5AW_ (-\0)XQT6-O'FK.[6UUM;['9_+_ *K_ *95Z'H^IQ:OI5E?
M0,K0W4*3H5;=\K+N'S5FZE_R/>A?]>=[_P"AV] &5_P@_B/_ **#J_\ X!V?
M_P :H_X0?Q'_ -%!U?\ \ [/_P"-5W->9O\ %2[LV\8+=>&IMV@6WVS997"S
MF9?GVQ-L^Y+M1'V?-\KK0!I_\(/XC_Z*#J__ (!V?_QJC_A!_$?_ $4'5_\
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MKU.V>62"-I8_)E9?F3=NVFN<U#_DI.C?]@RZ_P#1MO0!0_X0?Q'_ -%!U?\
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M [G3=2AU?3K2]MFWP7<231-ZHR[E-8>I?\E(T'_L'WO_ *';UT%M;1V=O'!
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M[U ';P3K<PI+'RCKN6N7?_DJMO\ ]@:7_P!'I75(HC7:J[$6N5?_ )*K;_\
M8&E_]'I0!UU>>:'\3Y=?@\3+!X>O4U31)U@;36EBW3;T5T^;=M7Y6&[=]VO0
MFZ5YS=_!G0)[>_L_-U1+34D:*\5=0FW31;?DB\S=O5%W/M53_$U '-K^TC8R
M:6]^OA[4Y+-()098FB??=+$TOV==K_-O1"RRK\M:NJ?'"TTOPUX<U@Z?YZZQ
M.T3!;E?)L]OWVFEV_+M^[6G!\&/#=O,+M%U"2Y\CR!+_ &A/O'R[/,^__K57
MY0_WMORU+)\(/#L^EIIICOFLM[M+$-0G7S]_^M\[YOWOF;B7W?>H [U3N&:Y
M5O\ DJ%O_P!@B7_T>E=.D81=JC8HKF&_Y*A;_P#8(E_]'I0!U=>7?\+EMQH?
MC&\N-!U&&Z\-,JRZ?\LLLN]5>+;L+?-\R\?PUZC7 0_";1K4W!M[C584NAMG
M":A+O=/^62B7=O58B69 K#;N- ')2_M*Z;;B4RZ9+LBT_P"VNZW*;'E_Y]XF
M_B9?X_[OS?W:O:S^T'I&B^#O#WB.?3KDV6JQRSMF6)!!%$/WK;F;YV_NHOS-
M6R_P.\)SQ0QR6UXZ0C=&C:C.56X^]]J7YO\ 7_\ 37[U3W?P=\-7^E6>F3VU
MS-I]K+YJVSW<I1V^;?O^;Y]S.S-N^]F@#NHY%D1&7[K5SH_Y*/+_ -@I/_1K
M5TU<R/\ DH\O_8*3_P!&M0!TU>4^-OCS9^"?$][X?DT/5+N_@LH+J#:B1Q7<
ML\Z016\3LW+;Y4W-]U1^5>K5Q7B[X7^'O&]U+<:O8O-=26GV+SUF>-UB\U)5
M*LK#:RR(C*X^;*T <3KG[3>A:%H'@75QI>HW5MXNF\J!%V*]N=R(P?<WW@S?
M=7^ZU;?PV^-=C\2=1>TM]+O=*N%21I(M1VQ.NV5D157[S;E5W_V:2]_9[\#7
M=KIMG<:1)+::=M6UM_M<VR*+;$C0[0W^K;RHF=/NLR;FS6JOP?\ #!\9V_BH
MVLCZ[;S3RI=/,S'=*NQO^^5^5?[M '>5S(_Y*0__ &"D_P#1K5TU<R/^2D/_
M -@I/_1K4 ?./Q/377^)GB?^SY=)2#[2G_'W%*[_ /'O%_<:N8V>*O\ GOX?
M_P"_%Q_\57=?$+_DHGB;_K\7_P!)XJH6>CRW]E<745U;(D&W=$[/O^;[FQ-G
M\=:D'*;/%7_/?P__ -^+C_XJC9XJ_P">_A__ +\7'_Q5=@_AC545V;3YT_>I
M;['7Y][)O^Y52_TVYTU+?[2ODO*KNJ/]]=K[/GH YK9XJ_Y[^'_^_%Q_\51L
M\5?\]_#_ /WXN/\ XJMVB@#"V>*O^>_A_P#[\7'_ ,51L\5?\]_#_P#WXN/_
M (JMVB@#"V>*O^>_A_\ [\7'_P 51L\5?\]_#_\ WXN/_BJW:* ,+9XJ_P">
M_A__ +\7'_Q5=1\*8?&/_"Q[+[-<^'?M'V"ZV[H+C9]Z+_;JI77?!S_DJ6G_
M /8.O/\ T.WJ0/5OL_Q(_P"?SPO_ . MU_\ ':=]G^(__/[X6_\  6Y_^.UU
ME[?0:99SW=RP2""-I9'Q]U5YKS;1/C_X:\2W_@^WLX-5$/BM96TVYEL72-FC
M\W<K?Q*VV%VZ?*-N[;N7,%F[]G^(_P#S^^%O_ 6Y_P#CM'V?XC_\_OA;_P !
M;G_X[7%>(/VJ_!?AZZUNUG74IKO2=1ATN2&&U3?+/*SH@3<RC[T3_>V_=W?=
MYKJ/!_QF\.>-=2\2V>F27##P])LOKB6$^4&4MO53S]QE=?\ @/R[J +OV?XC
M_P#/[X6_\!;G_P".U@W\'Q!_X2_1M]YX9^T?9;K;_HMUM^]%_P!-:ZWX?>.=
M*^)'A&Q\1Z+]H_LV\\SROM4#0R_*[(VY&^9?F1JEU+_D>]"_Z\[W_P!#MZ ,
MO[/\1_\ G]\+?^ MS_\ ':/L_P 1_P#G]\+?^ MS_P#':ZR_OH=-LI[JY;R[
M>!&ED?\ NJO->6>&/VDO"GC'Q'X9T72DU*YN_$5G+?VI>W6+RH%E>+?('963
MYHV^7:6H Z?[/\1_^?WPM_X"W/\ \=H^S_$?_G]\+?\ @+<__':Q-8_:#\(:
M)JNLZ?<SWOVC2=2LM+FVV4NQI[I]L2HV/F7/WG^ZM.MOCGH@D\:KJ.F:UHR>
M$T274)[VTVI*&W[/)VLV_=LW;?\ ;3^]0!L_9_B/_P _OA;_ ,!;G_X[7.7T
M/C[_ (3S1=UWX:\_[#=[1]FN-NW?;_[==MX&\86'C[PY#J^GQW$,+2RV\EO=
MQ>7-;RQ2-%+$Z_PLKHRU'J7_ "4C0?\ L'WO_H=O0!0^S_$?_G]\+?\ @+<_
M_':/L_Q'_P"?WPM_X"W/_P =KJ=3U.WT?3[B]NY/)M;>-I97QG:J]:\T\*_M
M$^$/&VO>'=)TI[Z:]UNP_M&!)+8H8H?GV>:K?,N[RG^FSYMM '1?9_B/_P _
MOA;_ ,!;G_X[1]G^(_\ S^^%O_ 6Y_\ CM<=?_M3>#=-OM>@EBU.<:-J#Z;.
M]O;++YLT:.\Q1%;?LB6*5F9U7[OR[ZWO#OQGL/$M_P"*K&QT+7OM'AV-)9E>
MT4?:U=':+[/\WS[D3=_#]]/[U &C]G^)'_/YX7_\!;K_ ..USUY#X^_X3S2M
MUWX:^T?V?=;?]&N-NW?%_MUU'PT^(UA\3_"D&OZ=9:CI]I-++"D6IP>3*?*=
MD9MNYOEW*WS59U#_ )*3HW_8,NO_ $;;T 9_V?XD?\_GA?\ \!;K_P".T[[/
M\1_^?WPM_P" MS_\=KIM8U2WT33+G4;N0PVMK&TLC[6;:J]?E7[U><:#^T5X
M2\2>(_"FCVKZ@;OQ)IRZE8K):[5,+*S)O_NM^Z?C^'^+;N7(!T/V?XC_ //[
MX6_\!;G_ ..T?9_B/_S^^%O_  %N?_CM<M>_M->!M-TK7=1N;F_BM=)NHK8E
MK9\WAEG:W1[<?\M4\V*5=W_3)_X>:V'^./AV"7QHEVM_IS>$5674/M=HZ;HV
M#['B_OA]C;<?[/\ >6@#1^S_ !'_ .?WPM_X"W/_ ,=K%N(/B!_PF%ENO/"_
MVC[#<;?]%NON[XO^FM=;X(\9V/COP]#K%C'<6T;RR6\MO>Q>5/!+$[))%*G\
M+*RM3[G_ )'RP_[!T_\ Z-BH R?L_P 1_P#G]\+?^ MS_P#':/L_Q'_Y_?"W
M_@+<_P#QVNFU?5K;1M+NK^ZE,-K;1-+*X1FV*O4[5^8UYSX4_:.\&^,=?T32
M=.DO5N=:M8;JVEN+5D3=)$\J0N?X9?+B=MO^S0!T'V?XC_\ /[X6_P# 6Y_^
M.T?9_B/_ ,_OA;_P%N?_ ([7*W_[2NAZ3<Z\E_X>\2V*:)>06E[<RZ?^Z02_
M<DW[ON]./O?.OR_-5[1OVAO!NL:9XJOH[JYBM_#47VJ[>>W9/,M]TJ++$O\
M$C/#*J_[M &Y]G^(_P#S^^%O_ 6Y_P#CM8$T7Q _X3FR/VOPS]H_LR?_ )=;
MC;M\V+_IK78>!?&ECX]\/1:Q8I<6T3RRV\MO>Q>5<02QNR2Q2I_"RLK4L_\
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MQMIFOWFC0ZG>C1PCM!#8NTUU$V[RI8$_C5V1]O\ NT :_P!G^(__ #^^%O\
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M%9/_  HOQO\ \]?#W_@3/_\ &JH@Q4\87B-%_HUCY43;XHO*^2+[_P!SY_\
M;>JFL:W<Z]<)/>>5O3?_ *E=GWGWUTO_  HOQO\ \]?#W_@3/_\ &J/^%%^-
M_P#GKX>_\"9__C55= <517:_\*+\;_\ /7P]_P"!,_\ \:H_X47XW_YZ^'O_
M  )G_P#C5%T!Q5%=K_PHOQO_ ,]?#W_@3/\ _&J/^%%^-_\ GKX>_P# F?\
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M79*O[KS=_E?-*S_+_%7:^;XT_P"?'0O_  .G_P#C5'F^-/\ GQT+_P #I_\
MXU0!)X'\'V_@#PEIWA^SNKF[L[&+RH);KRM^W^%?D1%_\=HG_P"2DV/_ &"I
M_P#T;%4?F^-/^?'0O_ Z?_XU68]AXR?Q)#JGV/0LQ6;VNS[9/_$Z-_SR_P!F
M@#=\9>&8_&WA/5=">^O=+CU"![=KO39?*N(E;[VQ_P"%J\]A_9ZL=-DTB:P\
M3Z[#>:-:_9=+>:6)HK4[=GFK$L2KO\K<FW[G\6W?\U=QYOC3_GQT+_P.G_\
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M8HWEE>XNWWRSRRRM++*[=V9W9JB;_DI]O_V")?\ T>E+YOC3_GQT+_P.G_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#8?.VU-D"_W-G]W^XVW_ '35.&W\(VWAU-*72;"'1[D;6TM+-/)_O8:)5VT
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M:-S-]]F>*5O]G[O^T?9JSK32+&PGNIK6U@MKBZ?S)Y(HE5IFQMW/C[WXUHT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?
M=Z1;7TZ32J6=%VJP:M"B@#!F\,VKHXBW0S-]V7=NV_YVTZ+PO90VZQ!9/D_Y
M:>9\_P##\V?^ BMRB@##B\,6,,WF*L@?=N_UK>_R_P"[\U">$]/1(EVR;8DV
M)^\_AK<HH R)/#5C*^YHF_W?-;#5!%X7M4\W=NW/)NW(VWY=FS;_ -\UO44
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ML'_A)KC_ * FI?\ ?I/_ (NC_A(9O^@-J'_?M?\ &@#>HK$_MZ7_ *!.H?\
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J\0%7J** "N7\.>#5T'4M>N_M)GEU6[-RW[E$V+_"N!PV.?F/-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>pbm-20240331xf1019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #X D$# 2(  A$! Q$!_\0
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M,GBK]K3QA\-?!/CS0/!ND:'HEGJBOK.DK=;WDV[UW;U_O5=^ /[:&_X9>/\
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MN=3U'!5!/*^W;$^UMS)\WW*^IKFQ3Q-X7FL[^!K1-1M&AG@)^:/S$VLO_CU
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M_P %-K_\17S110!]+_\ #R']H'_H=8/_  4VO_Q%'_#R']H'_H=8/_!3:_\
MQ%?-%% 'TO\ \/(?V@?^AU@_\%-K_P#$4?\ #R']H'_H=8/_  4VO_Q%?-%%
M 'TO_P /(?V@?^AU@_\ !3:__$4?\/(?V@?^AU@_\%-K_P#$5\T44 ?2_P#P
M\A_:!_Z'6#_P4VO_ ,11_P /(?V@?^AU@_\ !3:__$5\T44 ?2__  \A_:!_
MZ'6#_P %-K_\11_P\A_:!_Z'6#_P4VO_ ,17S110!]+_ /#R']H'_H=8/_!3
M:_\ Q%'_  \A_:!_Z'6#_P %-K_\17SAI5A_:NJ65CYZVWVJ>*W\Y_N1;GV;
MZ^O_ !_\%O"KI\7?!/A?X;Z>)? -LZQ^(W\0^5K<LL$2RRW4MO*^V6!UW?*B
M?+\M!)Q__#R']H'_ *'6#_P4VO\ \11_P\A_:!_Z'6#_ ,%-K_\ $5O?$;]E
MCPC!X]OI9/$'_"">';_5=+\-Z%;6UC+?O+J4^GV]P[2_/^ZBWR_?^9OG^5?D
MJOXA_94\/S>#_!^C1:RN@_$W^P-9O[K3TM7N+?5);&ZN%E=[C?\ NOW46Q-B
M?P?/0!D_\/(?V@?^AU@_\%-K_P#$4?\ #R']H'_H=8/_  4VO_Q%='X$_8VT
MJSU'X7ZYJ^IW.L:5J_B'2]*U;1M1TY[+S5NHGE_=?/YNWY-N]U3?]Y*YK]F#
MX9>%_%GB'XQ-K&@Z+K?_  CNGO/IEOXCU)["QB?[;Y7[VX1TV)LH =_P\A_:
M!_Z'6#_P4VO_ ,11_P /(?V@?^AU@_\ !3:__$5T;_LN^!?C!\9-3TKP/KW]
MCZ);P:=;W7]@Q-JNGVNJ3[_-1+J5T3R$;_;9F_A1J>G[/?A/1_ NW4-(@O-;
ML_ NO:A/?)++LEO[754M8KC9O_N?P4 <S_P\B_:"_P"AU@_\%-K_ /$4?\/(
MOV@O^AU@_P#!3:__ !%=3JO[$D'BKXA_$#3['55\-OI-Y+:V-O8Z9*^F;XK)
M)WWW$\N[Y_N[$\UOXONUEZK^SYX#T_PK!=Z;?^=$_P /=.\2:G?:G!+NL)9[
MV*)KB!%?;]QF^1OEVK_M4![IE?\ #R+]H+_H=8/_  4VO_Q%'_#R+]H+_H=8
M/_!3:_\ Q%36?[#&K_\ "51:#J'B:"SN);[5/*\JUWO<:78Q(SWL7SIN\UY4
M1$_W_G^2N3F_9NMM(_:4\$?#>\\0+>Z1XBGL634H]L<L4$_WT=59U2=?G3;N
M?YJ ]TZ;_AY#^T#_ -#K!_X*;7_XBC_AY#^T#_T.L'_@IM?_ (BL_P 5:'X1
M^)VL7'A?PU\*[WP-=:=XI70HM>TS[5J$7D,[)Y5[$VYFNODWKY6W^.NB\0?L
M3:1X9N)M0U7XARZ7X5M]!?Q#<W=QH_FW<445TMJ\7E12LN[<R,GS?[+[* ,W
M_AY%^T%_T.L'_@IM?_B*/^'D7[07_0ZP?^"FU_\ B*S_ (B?L@W/@'X1/XQ/
MB:*ZU""QL]4GTR6!(D:UN?\ 5>0_F[I945E9TV_Q?*[;*]0^%?[-/@/Q_P#
MWX5:]/I7DZK!/+K7BN[2=_\ 2M&BEN%E_C^79Y42;D_OT![IY_\ \/(OV@O^
MAU@_\%-K_P#$4?\ #R+]H+_H=8/_  4VO_Q%=KKG[%NB>/\ XP?$+3O#>HW'
MA/2[#4/LFE6J6#SVB[;))]LL[RK_ +NQ-[_[.VLCX0?LH^&M;FTK3[S7(O$?
MBKQ/X'NO$.G:)- UK;Z<S1?Z/++=;]OR2_P_W: ]TP?^'D7[07_0ZP?^"FU_
M^(H_X>1?M!?]#K!_X*;7_P"(J]X2_8;_ .$DU?Q7:MXS:VLM#UK_ (1B*^FT
MSRDEO_*WRO*C2IY5JGW=_P SMOW;*\^_: ^$OAKX8^%?A<VAZA<WFNZ[HSWF
MII+'^Y\WSY8M\3[ON[U=-G^QO_CH#W3L_P#AY#^T#_T.L'_@IM?_ (BC_AY#
M^T#_ -#K!_X*;7_XBKWQE^"W@[P'\,_B]#8Z2O\ ;7@F]\/Z0NJ/*V^666W9
MKV7^[\[?^.HM=V_PE^$?A7XE^+M*OM#T"SG6UT'^R(O&-Y>6^B,\]DDMTGVJ
M+[MR[-N7=\M CS;_ (>0_M _]#K!_P""FU_^(H_X>0_M _\ 0ZP?^"FU_P#B
M*ZGQ#X \!?!3P=K.H^(_A%'K%^WQ E\/)I>IZQ/]HL[/[*DJ+%+ ^V5OG^1M
MO\:5@>$/@;X-\,_MPZU\/-=M)/$'@O1VOYFM[B5UE:**U>=$9T_B3_V2@95_
MX>1?M!?]#K!_X*;7_P"(H_X>1?M!?]#K!_X*;7_XBO7M9_8M\'6OPZOM$BBC
ML_&NK>+;5=.UAV>7['I-Y=-%:_+OV-O6)VKRKPM^S-X5'BWP?IZ^(V\5:/XQ
M.M^'8[M[!K*73M4LT^25%WONBW*OW_X7?Y: ]TK?\/(?V@?^AU@_\%-K_P#$
M4?\ #R']H'_H=8/_  4VO_Q%?-!1HR4;[Z?(U%!1]+_\/(?V@?\ H=8/_!3:
M_P#Q%'_#R']H'_H=8/\ P4VO_P 17S110!]+_P##R']H'_H=8/\ P4VO_P 1
M1_P\A_:!_P"AU@_\%-K_ /$5\T44 ?2__#R']H'_ *'6#_P4VO\ \11_P\A_
M:!_Z'6#_ ,%-K_\ $5\T44 ?2_\ P\A_:!_Z'6#_ ,%-K_\ $4?\/(?V@?\
MH=8/_!3:_P#Q%?-%% 'TO_P\A_:!_P"AU@_\%-K_ /$4?\/(?V@?^AU@_P#!
M3:__ !%?-%% 'TO_ ,/(?V@?^AU@_P#!3:__ !%'_#R']H'_ *'6#_P4VO\
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MT>V\!Q/%;^?<S_:'B>78GE?O=OF_)%_WQ]]_E^>GS>$M*V10+?+O_BEW+O\
M];]S[^W=_#7G7_";:*C*R^(]/WI%Y2_Z<OW?[GW_ +M1?\);X>_Z#FE_^!D5
M6!Z5IO@S3GV2WES*B>?L^S^?%O?_ &-Z_P 6ZHD\'V-RD3?V@L.]8MVS;LB=
MD3Y'^?[S[W_[XKSK_A*?#W_0<TO_ ,#(J/\ A+?#W_0<TO\ \#(J .GUZPMM
M-NHDLYVN8I8M_P"^V[U^=T_A_P!RL^L?_A+-!_Z#FE_^!D5/_P"$LT'_ *#^
MF_\ @9%_\70!JT5E?\)9H/\ T']-_P# R+_XNC_A+-!_Z#^F_P#@9%_\70!J
MUC^)/NZ1_P!A:U_]#>G_ /"6:#_T']-_\#(O_BZRO$/BK0YET=5UK3W_ .)M
M:O\ )=)_?>@#JJNZ+9_;]6M;98(YO-;[DLOE)_P)JYW_ (2G1?\ H+V/_?\
M6C_A)M%_Z"]C_P!_UH ]*D\-Z9*FVVM5\UKG:J7=SM^;?_JG^?[NSYZI:]HE
MG9Z1>SQ6+0[+KRH'\_>^S^/>F_Y5_N_Q5P7_  DFA_\ 05T__O\ K2?\)/H?
M_05T_P#[_I0!K5E>)/\ 5:;_ -A.U_\ 0Z?_ ,)3HO\ T%['_O\ K63XA\3Z
M0\6F;=5L7_XF=K_RW3^_0!U%7=%M&OM6M;98(YO-;;LEE\I?^!-7._\ "4Z+
M_P!!>Q_[_K1_PD^AO_S%]/\ ^_ZT >FS>&],?:MM:KYK76Q4N[G;\V]]Z/\
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MGW=O_CU<+_PE.B_]!>Q_[_K1_P )3HO_ $%['_O^M2!I5B^+?^0,G_7Y:_\
MI0E6/^$IT7_H+V/_ '_6L?Q;XDTA](3;JMD_^F6O_+=?^?A*H#JW^^U7-"M/
MMVL6MMY4<WF-]R63RD_X$U8#^*M%WO\ \3>Q_P"_Z4S_ (2;1?\ H+V/_?\
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MV/WO^>Z5%_PD^C?]!?3_ /O^E 'I$V@Z4D3M!9[W^U;%BN+K8[?._P"Z^_\
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MZTB?\?#Q;OF16^3:J_[?E4 >[?V?;?\ /O'_ -\USOCJTMT\.[E@C_X_+/\
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M_P"?>'_OD5\P:\_Q+OK_ %J:UEU]-/NKQVDEM(KC]U:[Y?LOV=5?Y]Z^5O\
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M?$?X=>$[?P7J$L?AK2$=6B^9+"+/^M3_ &: /0?[4L?^?RW_ ._JT?VI8_\
M/Y;_ /?U:Q?^%9>$O^A7T;_P B_^)H_X5CX1_P"A6T7_ , (O_B: -K^U+'_
M )_+?_OZM']J6/\ S^6__?U:Q?\ A6/A'_H5M%_\ (O_ (FC_A6/A'_H5M%_
M\ (O_B: -K^U+'_G\M_^_JURWQ/U&SE\#ZFJWD#M^Z_Y:K_SU2K_ /PK'PC_
M -"MHO\ X 1?_$US'Q)^'?A6S\$ZE+#X:TB%U\KYDL(O^>J?[- 'H(U2QP/]
M,M_^_JT?VI8_\_EO_P!_5K%'PR\)8'_%+Z-_X 1?_$T?\*Q\(_\ 0K:+_P"
M$7_Q- &U_:EC_P _EO\ ]_5H_M2Q_P"?RW_[^K6+_P *Q\(_]"MHO_@!%_\
M$T?\*Q\(_P#0K:+_ . $7_Q- &U_:EC_ ,_EO_W]6N8^)FI6C^!=85;R!V\G
M_GJO]Y:N_P#"L?"/_0K:+_X 1?\ Q-<O\2?AQX3M_ VKRQ^&M(C=(OE9+"+^
M]_NT >A#5+' _P!,M_\ OZM']J6/_/Y;_P#?U:Q!\,O"6!_Q2^C_ /@!%_\
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M&4NHW'@;2)M7O5U/4)8R\MP!][YV*#[B;BJ[5W[5W;=U6O'?_'AI?_86LO\
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M7X^U.'Q;K=[!JNKWOAB6Q3R?[%LV9[5=J?.FZ+;*\K[X]V[Y/^ M3/AWXO\
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M@WA__H&1_P#?V7_XNMVB@#"_X0;P_P#] R/_ +^R_P#Q='_"#>'_ /H&1_\
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M+:F**+>Z>;*ZW#_=^;Y/E2@#Z _X5!X0_P"@.O\ W_E_^*H_X5!X0_Z Z_\
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M58?[-<7CR*RUX>-O[8\SS8-G]L.K-]JV?Z5Y'_3#?MV?P_W:])^('_(%MO\
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MO_03UO\ \&L__P 70!O16\4&XQHJ;FW/M'WFK"\>_P#(MG_K\L__ $HBI/\
MA!+7_H)ZW_X-9_\ XNJ]S\.-/O(_+GOM8FCW*^U]5N/O*VY?XZ .NJBFEVD4
MLLB6<*/+]]EC7YO][UK'_P"$$M?^@GK?_@UG_P#BZ/\ A!+7_H)ZW_X-9_\
MXN@#4M-&LM-=VM[6&)GE>X9D0<RO]]_]YJM_9X_)\KRH]G]S;\M8'_""6O\
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MKN]UBYMW'SQ/J<^UO_'Z .N'050BTBQ@_P!7:6Z?-YOR1*OS?WJR?^$#M?\
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M\:?M;>'M$ET]=#M+C5XIX/M5Q?O%*EE:HVGRWT2O*J,/->)$?9][:V:WKO\
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M&OA274!X;\-ZE=7L^J16L\6C:&8GO7EO7LWN%^5?-1+A75G_ +W^]70_$_\
M:!G^'7C"\TH>%7U;2M+TJTUC5=12^6.2U@GN)8,I"Z_O=GDL[?.ORUJ77[.W
M@&]@>)]%>$D$++!=RH\6;W[=N5E;Y6^T-O\ T^[Q6CXN^"'@WQMXLM?$6MZ2
MU_J<$$5N-]W*L,J12M+$DL2OLEVN[-\ZM0!P>E?M#?#Z*U>TO[:&W?1X[K4S
M#96+RV]JD5W+:JR?(O[UW1U^1?O/_M#=J/\ M4^!HX,W/]KV\D-M/<7,$VER
MJ]F8I?*:*7^Y+YFU%7^-F3;FM74/V:?A_JS*EWHTMQ!'%=116TM].8HOM,K2
MW#JN_P"5G9V^:GVW[.W@*WTJ^T\Z.]Q%?VTEK>2W%Y-+-.KR^>S/*S[C)YOS
M[_O4 <GX:_:\\*W=Q;V6O0WOA_4KW4[JSMK2YMG\V.**X\A))U_Y9,S_ "[?
M[U=7!^T!X9N_AUIGC.WM]8ETW5YTM]*M4TV7[7J+-EE\B#&Y]R*[[O[JENE)
MI'[.7@;0;ZQO[+3[NWOK7SLW"ZE<.\XE<RRI*S/^]5G9F.ZM;4?@YX6U+P+H
M?A)K&6WT;1A --2TNI89;/REV1-%,K!U8+\N=W>@#D6_:7^'6M6YU.!;_6K2
MPC@N(+VWTF65%NI]B16L3;?^/I_-7]U][YZT+_\ :4\$:-;7UQ>SZC:/8O.M
MU!-I\JRQ/%:Q74JLN/O+%*G_ *#3C^S)\.Q;W5M!H<EE:7,-O UO:7T\42-!
ML\J555_EG3RD_>_?^4?-1<_LR_#V\U.]U*[T:>[N;JU:TG>6_N&W*UNL#OMW
M_P"L>)41G^\VQ: &1_%#P5\4+3Q+;2Z$VIMX8@2\NK;7],\M;>4Q>:J[)5W*
M^W_9I_@']HCPKXW\0V'AVV:XAUJ>#?@6DOV5Y5MXIWABG9%5V6*XB?\ W6KH
MQ\)O#2^*-=\0M92S:KK=C_9MW<2W,KYMO^>*+N^1>_RXJOH/P1\&>%]4L=2T
MS2OLUY8RR3VTOGR/L=K6*U9N6_YY01)_P&@#RR?]KU=4\2ZOHGAOPPVM7D5Y
M%:Z1(^IQ00ZHC1732SA]K^4B_8IMN?O_ "=-U3^&OVO-/\1ZQI]BWAV?28-6
M-G-IE]JMRMO#<02HK/*S.O\ #O3;LW;V=5^6NSU/]F?X;:M=ZE<KX5MM.N[]
MH&GN=(9[*3=%YNW:\179_K95;;][?\V:N:I\ _ NMQPV]WH8>&(6RQ(L\J>5
M% C110+M;Y8@K.-GW6WMF@"OX[_:&\+> M?NM#NEO[S4H(LLMK:.\*SM$\L5
MLTOW5EE5&V+6%8_M,Z3H'PR\&>)_&5C?:9>^(=.EU+[#86,]T;6")%EE=\)N
M5$B9&9FKK?$7P2\'^)_%S>)M1TM[C5"JJY^TRK%(R(T:2O$K[&D17=5?;N7=
MQ63XX_9V\,>/9/!]MJ"W<>@^&K6>RBTBWN)8DN()8DB,<KJV]TV1_<_BS\U
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M(NV5'W(K[5KL-=_9T\+>,?B5J7B_Q EQJSW5M;6JZ:\K);1>4LZ[F56^=O\
M2'^]]W^&H;?]E;X:VFCIIL>B3_8]LZ/_ *?/ND2>!;>5';?\RM%%$NW_ &%H
M K#]K#P M[JMBMW>7E[IKQ0R1:?8RW'GRO*D6R+:OS[9'5:S8/VP?!<TVI2&
MRUS[#96UA<1WW]G/Y-PUX[I%$O\ =D5E=6#[?NM79V/P#\&:;J-S<6NFR0I/
M?0ZDUHEW+]G2ZBE6595BW[5;<JLW'S5G7'[,_@*XT^_L!I-S;V%[:)87=O;:
MA/$L]NLKNJOM?YO];*/]U]M 'JL$_G0K)M9-R[L-4]4K#3[?3+*"TM8EAM[>
M-(HXTZ*J_=6KM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%> :W^VS\*?#^N:AI5_J.LI>Z?<26LZ)H%^Z;T;:_S+%M:
MJO\ PWM\(?\ H(Z[_P"$Y?\ _P :H ^B:*^=O^&]OA#_ -!'7?\ PG+_ /\
MC5'_  WM\(?^@CKO_A.7_P#\:H ^B:*^=O\ AO;X0_\ 01UW_P )R_\ _C5'
M_#>WPA_Z".N_^$Y?_P#QJ@#Z)HKYV_X;V^$/_01UW_PG+_\ ^-4?\-[?"'_H
M(Z[_ .$Y?_\ QJ@#Z)HKYV_X;V^$/_01UW_PG+__ .-4?\-[?"'_ *".N_\
MA.7_ /\ &J /HFBOG;_AO;X0_P#01UW_ ,)R_P#_ (U1_P -[?"'_H(Z[_X3
ME_\ _&J /HFBOG;_ (;V^$/_ $$==_\ "<O_ /XU1_PWM\(?^@CKO_A.7_\
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M?^%W>$_^?B^_\%T__P 13/\ A>/A/_GXOO\ P73_ /Q% 'H-%>??\+Q\)_\
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MW_@NG_\ B*/^%Z>$_P#GXOO_  73_P#Q% 'H-%<!_P +Q\)_\_%]_P""Z?\
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M:>)GD2TBNUGA=HIH[BU:-X)5QE)/[C;65N?O*V5S74T %%%% !1110 4444
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M10J>=*SON;V7Y5SU:NZHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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9WTL\0+,WD1M_!\WXM_P*BB@#J**** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pbm-20240331xf1020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %2 E@# 2(  A$! Q$!_\0
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M)./>O-_&.B>"?$?A#]JJ_P!#\.Z?9Z?X>6QL=&-JA01^6YCFD&#@EV#'Z$4
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M5>*;_4K,7$T95+-2\A!1>=Q7Y57/0 T ?,?F('V;UW_W<\_E0SJI 9@#V4L
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M1=V;@ESTSGM5>_\ A#\*O!\_A[P#JB^%SI&H>&EO;N\DMKJ;Q%/</'D7<,B
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M.W+MCC<>E<R_Q6\7M<>$[B+7KBWNO"EO]ET6XMPL;V4?4*&4?,.WS?2N4HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[:S-]"<-<7+0QQ!LA&0GS"/;!3'XUS_&T>HXZ?K4DEQ+,D2/*S)$,(AZ(/\
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MBB/_ %J?6B@!9O\ 6M_O4VG3?ZUO]ZFT %%%% !1110 4444 %%%% !1110
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MT;>A%??/VOT8@^M<7\0OAEX?^(L0DOX!::FB[8]2MAB13V#?WQZYJ1GQS_\
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M\T=<\]*;&CQO6=+DT74Y[*0[C"<*W]Y>QJGC%=_\2-.$]K!J" >9$=DF.X.
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M110 L?\ K4^M%$?^M3ZT4 +-_K6_WJ;3IO\ 6M_O4V@ HHHH **** "BBB@
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M/,-'F&DP+?G$ \]N*X?Q,@77+DCHV&S^%=;YF0:Y'Q$X?5Y<'. !2 S:***
M"BBB@ HHHH **** "BBB@ HHHH 6/_6I]:*(_P#6I]:* %F_UK?[U-ITW^M;
M_>IM !1110 4444 %%%% !1110 #J*ZKPM<9T^2,]8VR!7*UJZ!=>5/)'G <
M9'O0!UGG>]'G>]9XFSWI?-H T!,,\GBOJ;]ESPJ-+\%W.O3)BZU:7:I8<B&,
ME5 ^K;C7R+-<[(F;...M?H/X)T9?#W@W0M,CP!;V4*M[G8"Q_$FJ(-NBBD)
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M5#YM24: FR>M9WB&YV:1+@\N0OZTHF-8_B&ZS'!"#G)W$4 8@&,#L!BEHHH
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M110 4444 %%%% "Q_P"M3ZT41_ZU/K10 LW^M;_>IM.F_P!:W^]3: "BBB@
MHHHH **** "BBB@ HHHH **/H"3Z"@X4\LH&<9SQ]?I0 448.,E2._(Q01@
M]CT(Z&@ HI!R0!SD CW%!8#'(YZ<]?I0 [('&/D_ND9_S^%$$KVDA>V>2UDS
MNWV[F)L_52/UIH(.<$'''!HSD9 )YQ@=<T :B^*=;10!K>J?A?2\?^/5GW<\
MNHD-=SS73YSNGE:0_P#CQ-1;U+%0RD@9(!Z"E!#GY2''JO(/XT *< !1]T=
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M0!ZKH:Z3:?$O4CXTTK04TZ/39BEM82+]GP75870H<>8JMN7G/RG(KHX_A_\
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MJOB71=&TC0;F/3YXKB[D\@Y>8.8VWD.%;^[WKBRBG&,# P/E'3_.?SH$:#H
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M(N-1DG^<2 R%B=P&$8'/#*.,^G%3MKFN/+)(VLW3-*ZR2EIG)=@,!CSU'8T
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M:K/]GD7SY$.-JKC,?(;[YP<<5DCQ18FSGM)(=4E@N)4FF5[[/F.G*L3C/!Y
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M?]A ?X4?VKX*[>'-5'_<0'^% ',;:3'TKJ/[5\%_]"[JW_@Q'_Q-']J^"_\
MH7-6_P#!B/\ XF@#E\>X_.@\=Q^==1_:W@O_ *%S5O\ P8C_  I1JW@O_H7-
M6_#41_A0!RN?<?F*/U_$5U?]K>"_^A<U<?\ <1'^%(=6\%'_ )ES5C_W$A_\
M30!RO3_]8HS_ )R*ZD:KX)[^&]7/_<2'_P 33TU7P/G_ )%K5_\ P9C_  H
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MWO 'B<_]S"/_ (F@#SC:1U!% &:](_X23X0_]$]\4'Z>(A_\33D\2_!X??\
MAYXJ_#Q&!_[)0!YK^.*,>^:]-_X27X,_]$Z\5GZ^)!_\13E\3?!@=?AQXK/T
M\2#_ .(H \PQ0>/_ -5>HKXH^"HZ_#?Q;_X4H_\ B*7_ (2CX)]_AOXN_P#"
MF'_Q% 'EF?K^5&?8_E7JG_"4?!+_ *)KXN/_ ',P_P#B*#XH^"0_YIGXN_\
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M%)G_ #FC/^<T +129_SFC/\ G- "T4F?\YHS_G- "T4F?\YHS_G- "T4F?\
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M_.: %!Q28P3AF"D8(!.#^'2C/^<T9_SF@!22S$GJ>3]:*3/^<T9_SF@!T?\
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0B@!T<:;U^5>OI1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pbm-20240331xf1021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $\ E@# 2(  A$! Q$!_\0
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M&X1,>=PXQFO"O%7[-_Q:UW]GL_#:729+J[^'7B6&]\.7,%U' -;TQ'+(BO\
M\LYD4XR0.0.E;GA3X">*_&>E?%[6F\$:[X<U;6O##Z!IEQXMU_[;?WI(+;)$
M&41%;A26)YH ^D/V8?C$WQX^#F@>++FUDM-1N(PEY&UL\,?G#[WE!OO1\\-W
M%?*VG_'3XY>-9OB[K&E_$[P;X9TOP;K-W96VFZYIJJ]Q'$N\?/N!&?NYQS7T
MS^Q\/$FG_ +PIHGBOPI>>$M8T.U33'MKV1',OE*%\U2I^ZW:O$?@9^Q/X?U[
MQ?\ %76?BU\/;;4+N^\53W>C7%Y*7$EFP!4A4;;C=GAJ .[\!_MM>'C^SUX"
M\?\ C>&;3=;\3J8;;1M,MGN+B]G4E6,$2Y8H<9R>V*I_%C]NKPQH_P"SQX@^
M(/@=)]:U2PN5TW^R[ZTEBDLKMCPMU&1NCP,D9X/:HOCY\)/%'A+XO?"OXF_#
MOPA#XHL/!UE<Z3-X7M)$MG6"4?+);[OEW+TQ7EOB#]G3XG?$?X6_M%>*+GPU
M%H/B7XB?9?[,\)_:$,J16[J0\KCY?-8 ]* />Y?VR?!6A^ _!NL:G'K-WJ_B
M*U,]OHNGZ3-)?S!!B67[.!N$0(.&/![5KZQ^V!\+]%\$>%?%]SKTC>'?$EV;
M"RO(+:1R)P"6CD4#<C C;CKFOFWQY\)OB1K7C'X>?%@>!_%*>5X9_L#5/#FA
M:Q':ZO82HP\N59-VUT< [@.1D9JPG[,7B^Q\!?!N"Q\$-I=S:^/AXDUG2VU4
M7QLX6!R[R/MW,>&95SS04>OZ_P#MS>#C\,_B'X@\/6FJ7&O>$80\^BZGI\MM
M.&?B&1D(R(BW5ST )K%\&?M1W_Q T+X$ZL-8B\-S^*]0DLM1TRYT:4K?S+%N
M:*!S_JT!R1(>&'2LWXA_ 7QIXE^,G[16HV6CA=.\5>"[;3-(O'D15N+I8R&3
MU'.!DUS_ (4^&WQ%\4Z3^RT=1\"W^AOX#U22VU>.[N8G9(([41+< @\JS#IU
MXH)/9=0_;C^&&E^*Y=%N)]9%M#J(TB77?[)F_LQ+PD*(6N-NW=D@58^%OQ;\
M1>*OVH?B[X*U"YMY?#OARUTV;38D@VNIFC+.6D_CR<8]*^2/B9\%_CK\2=$U
MRQ\1^%/$.N>([7Q.FH1W::M##HIL%N-R"VM59=\NP=6!(YY[5]3?!_X;^)O#
M_P"U1\8/%FHZ6]KH.MV&D1:?>>8I$[10E9!MSD%2<'/IQ0!Y_P#M'?M/>)=
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M..@![YH \8M/CU\7_A1\6/A7I'BOQKX2^(>C^.;U+)['1[(6][8%U!$N%8Y
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M+L?^&J?"?_"$W5W;>-Q<ZGHNLP7,?D7#&,(D&W.Y7.>IX^6NT^'/P6\8Z/\
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M^T>5]@,&,B3;SN^]0!^G/:N4^)'Q%T#X4>#K_P 4^*;[^S-#L0K7%SL9P@)
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MH!\--%_X3O4O'*+X1OI4GUB=)[FV#$$CS%'*M]X9Z XH ^Q_&?Q2\,^!-?\
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M6VGZ/HLWE!_W[R'=<LW]P#V%=/X'\27_ (R_:R_9VU[5)5N-3U/X92WEW*H
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MQ+M[(BDMGUKVRB@!@P#QCWQ3Z** "BBB@ HHHH **** "BBB@ HHHH ****
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M@C_??_XF@#V:BO&?^&Q/@MC/_"QM(QZ^8_\ \31_PV)\%L _\+%TC!Z?._\
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M#.%"H@/W<#N3[5?*!H>-O&_B3XE7@G\5ZO+J$:G<FG1 Q6<0[8C!^8^[9K(
M"JH5=BJ,*, *!]!3&D1>K*.O>I)X)+8Q&=#'YJAXQV93T-40-ZTM30Z=>3I
M\=I<2+.6$9"'#XZ[?7'M4,D+PHK.ACWJ&!8XR.F1GM[T )GC/;UHJ5;*9[%K
M\1.;17\LSY 7=Z8[GD5$: /H']E+CP9\5><?,>?^W6OECX=6\)\ ^'B;> DV
MHSF)23R>2<5]3_LHY_X0[XJXZ[__ &VKXZ\ _$/PQ9^"=$MKC6(HYXK8"13'
M(64[F]L5*&>@>1%_SPA_[]+_ (4>1%_SP@_[]+_A7._\+)\* X.NP9_W)/\
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MX4[:[ ?^ 2?_ !-<]\0_B'X9N_ 7B""'6;=YI+5E1<.,DG@9*T >@0V\/D0
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M'XB?$/PU>:/I:0:U;NRZO:2-\C@(N\]<K75W'Q+\*--(W]NPX+<C8_!_[YH
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MDFLY/B_\.X-2T:_@^(2I<Z5;Q6]L?[$F(*H"/F'H<D?0T :*_#C4'D+JNE/
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M7#G:+C:' ^3'&P8JK#K/PYM;J9E\36\EO-$(I[9X2WG$1^5N61D+(=H7IZ4
M=IH'BVW\2:[?VEM9F*V@M8+A6FM!&S>86P0".1A5Y]S5?XKJJ_#+Q052,,+*
M3!$8!Z_2L'0/&_@K0;J:XD\<?VI,]K!8JUTCC;#%N*;<)_M<_2J?Q/\ BCX/
MU#X=>)(+?Q#9O-+:.B)MD!8D\#.V@#U"VC06MOB*/(C3Y5B4Y^4<DXJ;8O\
MSQC_ ._2_P"%<;#\7/!44,43>(K16"*"CI)E"%&1D+4G_"W_  3_ -#)9_\
M?N3_ .)H Z[8O_/&/_OTO^%&Q?\ GC'_ -^E_P *Y'_A;_@G_H9+/_OW)_\
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M?\*-B_\ /&/_ +]+_A7(_P#"W_!/_0R6?_?N3_XFC_A;_@G_ *&2S_[]R?\
MQ- '7;%_YXQ_]^E_PHV+_P \8_\ OTO^%<C_ ,+?\$_]#)9_]^Y/_B:/^%O^
M"?\ H9+/_OW)_P#$T ==L7_GC'_WZ7_"C8O_ #QC_P"_2_X5R/\ PM_P3_T,
MEG_W[D_^)H_X6_X)X_XJ2SYZ?))S_P".T ==L7_GC'_WZ7_"C8O_ #QC_P"_
M2_X5R)^+_@D=?$EG_P!^Y/\ XFC_ (6_X)_Z&2S_ ._<G_Q- '7;%_YXQ_\
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M$&:&.2"*,R)"0P"'KGR_X^-_J!Q0!JI\0))AH!;3=-LHM1B:5[F^#"W#+)L
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M_>445G+<H_0BDR#QD4M>7?&7Q9J-M#8>$?#D_D^*/$C-#!,!DV5NN//NR/\
M84X'JQ6I YKQ'<GXW^*[G0H7/_"OM"N NI3(Q U>]4Y^S CK#'_'_>;"^M>D
M !0JJ%C 4*J(H&T#[JJ!P *SO#GAS3_"&@6&BZ7#Y-A91>2BDY<\?,['^)F/
M)/K6C0 44458!1110!%>W*Z?I]Y=L-PMH&G(!P2%4DC]*\T\$?M":%X\T/PK
MJ-OI]Y8?V_/<6\UM>A0^G/%!Y[>=Z@H 01UW UZ-J]F=2TG4;16"M=6LT 8]
M 60J"?SKQG3/V<KS2_$W@G4(M;@2VTW1#IVM6HB)6\N!:-;17,7]TA796!ZK
MM]* /4[OQ]X9L+#^T+G7M/@M/L*ZC]IDFP@M20!,QZ>620,^I%4-'^,'@;7M
M3L-/L?%FFW5[?3&&WA20AGD'\&"ORMZ!OO#D9KRNV_9^\67^@W&D:MJVA&.#
MP[!X<L?LT,GSI'<QR+),2?XE3!0< ]ZZW4O@U->>(=:U."ZLX%U#Q/IVOIB(
MATAM556B)!X8[3@CUJ -/X<?&CP[\1;62/[?:6&M0BY^T:4\P8PQ0S/&6)(
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M?[2TM0JN?^FT/W7^O6O4J/\ /% 'P]XW^%WC#X52BXUG3!J6C1R;EUG2D:2
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MA""?ES6IM_V8_P#O@5P>B?$;P/H&D6VGP>($DB@!57>*3<022"?D]S^E7?\
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M4^&VJ7%GG[=I!CU:T=?O+);L'('U3>/QKMJ3[+%?(]I,NZ"X1H'7U#@J?YT
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MX/J*Z*"^M[B&&XCEC:*95:*3/#!AD8^HH 7[#;#_ )=XO^^!_A0;*V R;>$
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M.YN,LAPP [\U/>:S8:>D;75[;VZR2K C2RJH:1ONH,G[Q["@!_V&W_Y]XO\
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MWP+\>ZCX7O[@:;8Z7+=QW%I<6=_<RO-J"M>O(LSJX*QR)& $SN&&KZ^ZT=*
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MAQ]W?QWKZ6HH ^<9/@IXML-2AUG1=.TG26B:W9-#BO9/)5%@DB9#*%R2"X8
M#''7-85C^S/XTBN]*6:]L6OK6*,Q>)3=RFYL\6DD)ACCQ@@2/YFXG)YS@U]5
MT4 ?)T/[-7BM/!":9+;P:A(TLXNM-U#4V^RRR/;B)+I"D8VL&!<JP.=YR0>O
MT?X#T"Y\,^#M"TFZ>.6>PLX[>1H_NEE4#(R!Q^%=%10 4444 %%%% !1110
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M).5/K6C_ ,,]_#OMX<B.!G_CXG_^+KXN^%<6HZW\7OAM=77CS5/#.J^(?A;
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M:M>>+XO"/PL\2+?W'BGQ5?-/?0I>($6%_LK;E10/3D*>I% 'NX_9Z^'9&?\
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M;Q/XV@\/@&TC*:=:"[FB(1-OSL5 )9N.!Z4 ?71_9Z^'@!)\.1 #G_CXG_\
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M1W6DP[FC%G)&H5"H4\[5  KL:* ',Y>1F/)<Y)IM%% !1110 444<8)/(Z$
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M!#IEE)'<JUM 4N<>>K1+B7C W_WN..:9;:+8VT4$,5C:P6]N0T,2PJJQ$=U
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MV.D65K%:2&6"..$ 1,?O,N.C$=ZWJ* .>O/ ^@ZEIXL+K0K":S65I5MY(%9
MYZL!C@GO4S>$=&E^PM)I-D[6 Q:9@7]P,8PG''!/3UK;HH P;KP;HFHV5K97
M6C6<]E;-O@@D@4I&WJH[4LG@_1I/L1.D6;&QR;3= O[G/7;QQU/ ]:W:* .=
MO? F@:E:6EM=Z'874%D=UM#+;J4A/^R"..>:MS^'-.N&G,NFVLC7$*V\SM$#
MYD0_@/L.PK7HH R=0\-Z;JMG;VE[IUM=VMO(DT,,\:LD;H<HR@]"O4>E4_\
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M ,55G_A /#'_ $+FD_\ @%'_ /$T?\(!X8_Z%S2?_ */_P")H K?\+2\&?\
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M ,&</_Q56?\ A /#'_0N:3_X!1__ !-'_" >&/\ H7-)_P# */\ ^)H K?\
M"TO!G_0W:#_X,X?_ (JC_A:7@S_H;M!_\&</_P 55G_A /#'_0N:3_X!1_\
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M"JQQQ1:C %15X4 !N !QBM3_ (0#PQ_T+FD_^ 4?_P 31_P@'AC_ *%S2?\
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M /#'_0N:3_X!1_\ Q-'_  @'AC_H7-)_\ H__B: *W_"TO!G_0W:#_X,X?\
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M;% 'KFK:58Z]8RV6H6<%]:2C$EO<QAT<>X(YKS.;X$MX=D>?P'XBO?"')/\
M99Q=::Y]X'^Y_P  (-.\0_%J\TSQ!IEG;Q:;9V\NFOJLS7TVYIE5U4PVY5@K
MO@DYY'3BL76_VG;"TTZYFTG19=0D2!Y(-]S''%-(L<4AB##)Z2\D\#:W.>*
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MB@#@?^$>^(/_ $-VG_\ @K'_ ,52_P#"/>/_ /H;=/\ _!8/_BJ[VB@#@O\
MA'O'_P#T-NG_ /@L'_Q5'_"/?$#_ *&W3_\ P6#_ .*KO:* .!_X1[X@_P#0
MW:?_ ."L?_%4?\(]\0?^ANT__P %8_\ BJ[ZB@#S_P#X1SXA?]#?IW_@K'_Q
M5'_".?$+_H;]._\ !6/_ (JO0** //\ _A'/B%_T-^G?^"L?_%4?\(Y\0O\
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M'/B)_P!#AIW_ (*Q_P#%5Z#10!Y\/#GQ$[^,-._\%8_^*IP\.?$+/_(WZ?\
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MAX^T_P 9W%U%817(-J=LKS1X7=Z @X)^E=34%K;QPQ_NT6,$Y(0!<GUXJ>@
MIKDA3CKCC-.I&Z4 <AXRU#Q':W6G_P!AP07,;%Q-%,ZJ7/\ ".2..IXYX Z&
ML&+7?B/)/)&?#&FJ%(!E>\(4^ON>.?;ISUKHO%O@33/&MW9/J)N0]JLHB:WF
M,94G;\W'?C]37/VWP7TS$+'6_$#(H'[HZDVP].HQ0!I>#M5\;WFM2+XBT6PT
M[3#%N26VNM[[^ %(].O-=P'!.,\^E>26'P8TN)Q,NL:\'^6'/]H-]WD8Z>]>
ME:#HL/A[3+6P@EGGC@!59+F0R2$>['K0!ITUNG7%.I&&1C.* .>\/^+K77];
MUG3(8Y8[C2IEBE,F!OW+G(]NU=%52"V@AO)WC@CCDDP7D5<,Y]SWJW0 4444
# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pbm-20240331xf1024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #@ JL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**0D $
MDX [T +7GGQ>^/W@+X%:2;[QEXBM=*+*6AM-V^YG_P"N<0^8_7IZFOD#]L3_
M (*66O@:ZOO!_P +)H-2UN+,5SKV!);VS="L0Z.P]?N_6OR^\4^*]9\;Z]=Z
MWK^IW6L:M=OOGO+R4R22'W)_0=!7LX;+I55SU-%^(KGZ._%#_@KY!%));^ /
M!S3J.%OM:EVY]Q&G]37SIXD_X*7_ !YU]W-OXDL]$5B2%T[3XN!Z?O ]?+%%
M>Y#!4*>T?OU%<]_7]OCX_+<></B3J&_T-M;%?^^?+Q^E=AX5_P""G/QU\/21
MF\UO3]?C4_,NHZ?&"P^L>S%?*%%:O#49:."^X#]0OA9_P5YT>_FBMO'WA&;2
MP<!K[2)/.0'N3&V#^1K[C^&'QC\&?&70UU;P;XALM=M<#S%MY!YL)/:2,_,A
M_P!X"OYVJZ'P'\0?$?PQ\26VO^%=9N]#U:W/R7-I(4)'=6'1E/=3D'N*\ZME
ME.:O3T?X!<_HWHKXB_8U_P""BVE?&26R\(>/?(T3QD_[NWO5PEKJ#<8 S]R0
M\_+T/;TK[=KYRK1G1ERS6I04445B 4444 >;_M)2/#^S[\2'C9D=?#U\593@
M@^0_(-?@!_PDFK_]!2]_\"'_ ,:_?W]I;_DWGXE?]B[?_P#HAZ_GQKZ7*E[D
MO43-'_A)-7_Z"E[_ .!#_P"-'_"2:O\ ]!2]_P# A_\ &LZBO=LB31_X235_
M^@I>_P#@0_\ C1_PDFK_ /04O?\ P(?_ !K.HHL@-(>)=74@C5;T$="+A_\
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MK!$3[%SDC\*=.A4K?!&X'VW17YM_\/BK3[0/^+<S>1GD_;QNQ_WSBNU\&_\
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MXF>%+$6FB:O<&+5+6$8CM[ILD2*O\*O@Y'3<#ZUZF$QWUA^QK+<+'WO^RO\
MM/Z#^T]X!&LZ<@L-8M-L6IZ6S9:WD(Z@]T/8U[57X1_L1_'6Y^ _Q_\ #VH2
M79@\/ZI,FF:O&Q^0P2,%$A]/+8J^>N P[FOW;!# $'(/0UY6-PWU>I:.SV!"
MU\E?MJ_MT:;^SC8G0/#HMM7\=W"96"0[HK)3T>4 \GT7\Z]:_:A^/FG_ +.7
MPBU7Q7<A)]0 ^SZ;:.?]?<L#L!_V1U/L*_-']B+]FJ^_:V^*VK>/?B";C5/#
MEM=-=7TDS$?VC=LV[RB?[G.6 QQ@<56%H0<77K?"OQ8%3X4_LL_&/]N7Q(_C
M;QEK-U9Z/='/]MZH"=ZY^[;P\#:.V,+7VQ\/_P#@EW\$_"5DBZWIVH>,+W W
MSZA>R0IG_92%DP/8EJ^M;*RM]-LX;2T@BM;6!!'%!"@1(U P%51P !Q@5/2J
MXZK4T@^5=D%CP2[_ &#O@'>V7V63X::6L7]Z&6>*3_OM9 WZUXC\7?\ @D[\
M.O$UO/<>!-1O?!U_M/EVLTK7=H6[ [R9%^NYOI7W316$,57@[J;&?B;8ZY\<
MO^"=?Q#6TG\VWTNYD+&SE<RZ9J: X++S@-C^(889].OZM_LX_M'>%_VE/ <.
MO^'Y_*NX@L>H:9*1YUG+CE6'=3SAAP1^-;'QO^"?AGX^> ;[PKXFM%FMYU+0
M7*@>;:RX^62,]B#V[C@U^0OPJ\8^*?V _P!J>ZTO6U<6=O.+'585)\N[LW(*
M3+Z\%7'XCK7I>YF$&[6J+\1;'[<U\V? 3G]BV_[_ .B^(/\ TKO*^B].OX-5
ML+:]MI!+;7$:RQR*<AE89!'X&EBLK>"V-O%!%';G(,2( G.2>.G.3GZUX\9\
MJMYK\+C/@'07U[X4>#_#_AOPW#.;'XO>'].6U>!?EL=3$,<-W)[;[?;)GNT9
MKX6_:I\,67@S]H/QKH.GPB&QTZ\6UA1>@5(T _E7[S"PM0L"BVA M_\ 4@(/
MW?&/E]...*IW/A71;V=Y[C1[">9SEY);9&9CZDD<UZ-''>RDY.._]?D(_G$U
M*[.H:C=73'+3RO*2?<D_UJM117UI(4444P"BBB@ HHHH **** "BBB@#MO@A
M<M9_&+P5,GWDU>U(_P"_JU_1%7\Z_P '/^2L>#O^PM:_^C5K^BBOF\V^*'S*
M04445X SS7]I;_DWGXE?]B[?_P#HAZ_GQK^@[]I;_DWGXE?]B[?_ /HAZ_GQ
MKZ7*?@GZB85TWPT^(6J_"CQYHOB[0Q =6TB<7-L+J,O'O (^901D<^M<S17N
MM)JS)/LG_AZ[\;_^>?AC_P %C_\ QVC_ (>N_&__ )Y^&/\ P6/_ /':^-J*
MY?JE#^1#N?6>J_\ !4/X]ZB#]GUO2=+S_P ^FDPMC_OX'KQ?XG_M*?$_XR*T
M?C#QKJFL6I;=]C,@AML^ODQA4_\ ':\THK2%"E!WC%+Y %%%=9\-?A3XK^+W
MB.#1/">BW6L7TK!2($)2($_>=NBCW-:MJ*NQ#OA/\+]<^,GC_2/"7AZW-QJ.
MH3! <?+$G\4C'LJC)-?O(? -E\,?V?[OPEX=C,5KI'A^:SM<?>9E@8;SZLS?
M,?<FO+?V,_V,-'_9@\/27MY+'J_C;48E%[?A?W<"]?)AR,[<]2>21V%?2LL:
MS1O&ZAT<%64]"#U%?*8[%JO-*'PK\2D?S5O]]OK25[%^U?\  34/V>?C-KGA
MV:VE31I9Y+G1[ER6$UHS$Q_-W900K>X/J*\=KZJ$E.*E'9DGTM^P)^T)HW[/
M7QL_M'Q$6AT+5K4Z?=72KN^SY8,KD8R0"!G%?M?X=\2Z3XNTBWU71-1MM5TZ
MX4-%=6DHDC8?4?RK^;JNM\ _%SQK\+;X7?A+Q3JOA^;(+?8;IXT?'9DSM8>Q
M!%>9B\ L1+GB[,=S^BNN&^.'PRA^,?PH\2^#II(X/[6M&@2>5=PB?JKX]B*_
M*GP#_P %5?C/X6,<>O'1O&-N/O&^LQ;S$>SP;%'U*&OHCP'_ ,%?O"FIRQ0^
M+?!>HZ(6X>XT^=;J-/?!"M^0->-+ 8FD^:*O;L.YYY_PYX\3_P#10-)_\!9:
M/^'/'B?_ **!I/\ X"RU]R_#?]L#X0_%5XH="\;:<;V4@+9WK_9YLGH-KXY^
ME>R A@"#D'H13ECL7!VD[?(+'AO['G[/VK?LT_">;P=JVM6VNL-2FO()[9&1
M4C=(_D(;ON5S_P "K\K_ /@H5\(?^%2?M+Z\MO#Y6E:Z!K%GM7:H$A(D4=OE
MD5Q],>M?N'7P_P#\%7/@_P#\)K\$]-\9V=OOU+PK=$RLHY-G-A9.W.UUB;V&
M_P!:>"Q#6)YI_:W!GY#UT_PP\:W/PX^(GAOQ1:-MN-)OX;Q3C/W'!/Z9KF**
M^L:35F2?TC>&]=M?%'A_3=8LGWVE_;1W,3?[+J&'\ZTJ^4?^":?Q3_X6-^S/
MI=A/-YFH>&YGTN8$\A!\T1_[X8#\#7U:S!%+,0 !DD]J^"JTW2J2@^A9^:7_
M  6 ^)^\^"?A];3<(7UF\0'^+!BA!^@,I_X$*_-6O;OVS_B<?BQ^TAXRUE)?
M-LX;HV-J0V1Y4/R#'Y&O$:^RPE/V5&,26365G-J-[!:VZ-+//(L4:*,EF)P
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M(Y'S?9H\J@^A.\_C7L/[=DT\'[)'Q+:W&9#IJJ?]PS1A_P#QTFO7/ GA&S\
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MY^S?_P E\^'_ /V&[7_T8*]C_P""G/\ R=_XG_Z\[#_TFCKQS]F__DOGP_\
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M\G('3BON2BBN"M5E7FYRW&%%%%8@?S3T445^AD!1110 4444 %%%% !1110
M4444 =A\'/\ DK'@[_L+6O\ Z-6OZ**_G7^#G_)6/!W_ &%K7_T:M?T45\WF
MWQ0^92"BBBO &>:_M+?\F\_$K_L7;_\ ]$/7\^-?T'?M+?\ )O/Q*_[%V_\
M_1#U_/C7TN4_!/U$PKW']A__ ).R^&/_ &%E_P#0&KPZO<?V'_\ D[+X8_\
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M2QL,,K ]00:_'[]L[_@G[K?P0U.Y\2^";6ZUWP+,Q<Q1J99]-_V),9+)Z/\
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M'[3_ /R2"_\ ^OVQ_P#2J*O5ZU?\->K_ $ ****R \U_:6_Y-Y^)7_8NW_\
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M-^&]+\(:)9Z/HUC#INF6D8B@MK= J(H[ "M.BO-K8BI7=ZC&%%%%<X!1110
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MPG_)3/ 7_8+G_P#1HK@P$(SKJ,E=:@SR?_AYQ\?/^ACT_P#\%4'_ ,33HO\
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M>ODSQ7^U%\6/&LSR:MX^UR??_!'=M$H]@$Q7EU &3@<FOIJ>&HTE:,1'0_\
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MN5Y'^R3\O[-?P[B)!,&DQ6YQZQY0_P#H->N5K5_B2]6 4445D 4444 %%%%
M!1110 4444 >4?M/_P#)(+__ *_;'_TJBKU>O*?VFQO^%$\6<&74M/B'U:[B
M%>K5J_X:]7^@!11160'FO[2W_)O/Q*_[%V__ /1#U_/C7]!W[2W_ ";S\2O^
MQ=O_ /T0]?SXU]+E/P3]1,* Q4Y!(/J**M:7I-]KE]'9Z=9W%_>29*6]K$TD
MC8&3A5!)P 3^%>Z20>=)_P ]&_.CSI/^>C?G72_\*K\:?]"CKO\ X+9O_B:/
M^%5^-/\ H4==_P#!;-_\34\T>X',M([C#,2/<TVNH_X57XT_Z%'7?_!;-_\
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MH='4Y#*1D$&N7^+'Q"L/A1\-?$GB_4F"VFCV,MT5)QO8+\B#W9MJCW(KR_\
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MN^('[1NIZJ,/H_@?3SI-LP.0^H76R6Y(_P"N<*0)]97':O8*UGHE'^M?^!8
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MV'B+2;/5-+O(-0TZ\B6>WNK:0/'+&PRK*PX((.<U<K$ HHHH **** "BBB@
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M=&1O56&01Z&OV=_9N_;P^''QZTBSMKG5[3PQXN("3:-J<PB,CXZP.V%D!.<
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M_C4/Q'\#Z?\ $OP%X@\*ZH@>PUBQELY>,E0ZD!A[J<,#V(%>#2J*E64ULG^
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M/_Q5'_#M;X]_]"I;?^#&'_XJO:^LT/YU]XCY>HKZA_X=K?'O_H5+;_P8P_\
MQ5'_  [6^/?_ $*EM_X,8?\ XJCZS0_G7W@?+U%?4/\ P[6^/?\ T*EM_P"#
M&'_XJK=C_P $Q_CQ>.%?0M.M >\^HI@?]\YI?6:'\Z^\#Y3HK[S\&?\ !(KX
M@ZH8G\2>*-&T2,X+QVP>Y<#T!PHS7UE\&O\ @FI\)OA9=VNI:E:S^,M6@(=9
M-6(,"N.XA'RGG^]FN:IF%"FM'=^06/@S]C;]A#Q!^T)J=KX@\0P7.A^ 8V#F
MZ="DE^ >4ASU7C!?H.W-?LOH.A6'AC1+#2-*M8['3;&!+>VMH1A(XU "J![
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MMT&&PT>.PN8&F2\CD(=P-HPI)[5ZV)Q%&5&:4U>W<1^F%%%%?'E!7\V&J?\
M(3N_^NS_ /H1K^D^OQ/O_P#@FW\>9K^YD3PM;,CR,RG^T8>02?\ :KW,LJPI
M\_.TMOU$SY7K[I_X)&_\EU\1_P#8&/\ Z,6O-_\ AVM\>_\ H5+;_P &,/\
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2H<DD]QHV:***\$84444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pbm-20240331xf1025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Y + # 2(  A$! Q$!_\0
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MCLI_"VG:>+%+N9G1D65PS,RGH5! (:OKBRLH--LX+2UA2WMH$$<448PJ*!@
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M (?RKNG*$J7UIQU?2^@BE_P4W_9UUOQ3\-?"/B_1['[?>^&[;[)J4%C#C$1
M)D1!_"'SD#H#7,?LY?\ !3[PYX%^#.B^&O%^D7UQK6A6:6-O+:8*W,<:[8\Y
MZ$*%!^E?H_KW_($OO^N+_P J_%R;_D['_N)?^SUCA7'$4G2JJ_+J@.>7QEK?
MQ#_;4T+Q/K^GR:5J&K^(K*]%G*I#11.Z-$,'G[A6OW3KX.\>_P#)SFG?]?6G
2_P#HN*OO&N?&U%45.RMH!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pbm-20240331xf1026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L ',# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4BP'6O-_
MB!^T;\-_A7KB:/XK\5V6BZF\*W"VTX<L8R2 WRJ>I4_E7HLAP:_%_P#;M\5+
MXL_:>\7RQRF6*S>.P0D\+Y: $#_@6ZFCRLQQCP=)3BKMNQ^G5M^V=\%KRYBM
MX/'^FR32N(T0"3+,3@#[OK7LZRJZ@@\&OYYK&0PWMO(IVE9%8'TP:_H&T&[^
MV:%I]UNWB:WCDW#OE0<T,Y\LS">-YN=)6ML4O'?Q#\._#/P]+KGB?58-'TJ)
MUC:YN"=H9CA1@9))/H*\S_X;7^"7_10M,_[YE_\ B*^(?^"E_P =E\8>/[3P
M!I<[-IWA\^9?$<![MA]WW"(1^+-Z5\4&A(X<9G,J-9TZ44TOS/W=M?VB/AY>
M^ ;SQM!XGM)/"MG,+>?5,.(DD+*H7D9)RZC@=ZY?_AM?X)#_ )J%IG_?,O\
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M$%C7Z;N3[ U^<7[=>C_V-^U'XUCV[1/+%<CWWQ(V?SS6?\:OC])\0/AA\-/
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-!Z4CZ(4=!12T4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pbm-20240331xf1027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  = 'H# 2(  A$! Q$!_\0
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M?%=[O+RK*QAC=_\ 6/'$3M1FYR1ZGUH ].\$^%K;P-X/T;0;1BUMIEG%:(Q
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@Z9IEKHVGVUA8V\=I9VT:Q0P1*%2- ,!0!T %6J /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pbm-20240331xf1028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xf1028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  > &4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4ZA>]@C,
MH::-3$ 9 6'R#U/I7C_[47QMT#X.> @-5\27?A[4M8<VFG?V59"\U"9^-PMH
MCP7 (PS?*I(X/ KXS\$?L]V?BGQTUUX7U'XL?#KX@2C[3_:NN:U8WUP2PR&N
M[1)!*B-_=<<CL: /TN@N(KJ%)89%EB<95T8,"/8BGU\5+\2?&GP&UC0M9\6V
MD.GW"ZY;>'O%]EIX/]FZE'=9%IK-FG2)RZE9$&,G<",A361^U'!8^(OVS-!T
M/Q3XXU[P=X(@\%SZI?7&DZU)IZ1M'*^)'93M[@$D>E 'W9FC-?DGXA^)OBK4
M_A'XVT71/'GB7Q!X"T_Q]I>F^'O%4M[*EY/;RB031"X&&D4#:<GCH<#.*]O^
M"&N-HG[7ND>%?A-XZ\8^/_ D5K=P^+4\0W,UY:Z?<1[@FR:10 V]5'R]?4@G
M !]^T9K\Y8OC%XCTK]L:U^*%QK]ZOPNU?Q?<^ X[26ZD^QJT5NB"X"$[ #-G
M# ?P-7=_M;>,_&?[)WQ<MOBAX:GNM>\.^+;1]%N_#MU>,T-OJ03-M/$C$A02
M 6"@9VMG&X&@#[?S1FO@/XB^&/%7P6\'?LVZ?J'B[5M2\2:UXZMKO7[X:C*R
MW,LP#/"/FP85X4)]WC..:I?&SX!P>'OVJ_A7X0LO'OQ BT;QH^I7.I(/$LX9
M&C7>HA(X103C&#QQ0!^A-&17Q]\7]!U+]F'XD?"+QOI>N:UJ'@>QMIO#?B.+
M5-0DN,V_E23174F3AI!L8%\ G:H[UM_L?^#=:^(?PHU3Q[XSU'51JGCK5IM<
MMX!>2+]@M,LEM'$"<(-I+X &=RYZ4 ?4]%5M-L5TS3[:T1Y)4@C6,/,^]V &
M,L3U/O10!\[_ +;-A%X-^'.I_%ZTMEN_%'@S2;J/1O-C#I:3W4D,1N@#_%&N
MXCZFL?X">,O"?P)N]:\$ZK>I:&WMM+U*XUJZ;/VQKNWS)>W$IY.^X$B;V^5<
MQJ2,BOIW6-'L?$&E7>F:E:0W^GW<30W%K<('CEC88964\$$'I7BGCS]D;P_X
MKO\ PEJ6CZYJWA35O#5L^G6MY9,DYFL&ZV<ZS*RRPCH%<'CCF@!?CIH>D?&/
M6O 'AIM3TY]%_MF#6+PQW"22WHMB9(;:)%)9@7P[M]U40\Y(JKXM^!<?BG]K
M31_B!>ZCH]UH]AX9ETF[T*[7S)I/,D9ED*$%=F>.>XKO?AQ\ / 'PHU&YU3P
MSX5TO2=8NXA%=7]I:K$\H')  X0$\E4 '3C@5J>)_A/X8\9:F]]K&FK?3NL:
M-O=@I\LOLX!QD>8_YT >:_M/?L_O\9OAKH7A;PQ=:5X>73M=M-4"O'LAV0L2
MR*J#@G<.V*PM-_9\\0?"[XR^-/%7P^U_2=*\,>,+&0WV@WV]4@U;8PBNH=H(
M +$%EX)W-C^''I-O^SGX&BLWMI=.GND?S=[37<NYO,(+9(8?W0!]*M1? /P1
M")PNC[A.$$@DN)7!VA .K'&1&N?7G.<F@#Y/N/\ @GE8Z=^SD_@G_A,(1\1]
M6NX+W^UKR]E:S-U%*\A-O">4)CD;<5&XGDUZMXJ_9KUGXO?$;2M5^(OB/3[K
M1M'\-R:9IFF:8S!DU&>$17-\VX8W#<?+'./E)YKU6V_9_P#!\$9C>TFN(UO9
M;^!99V_T=Y(%@8(1@[=B  $DCGFI8?@)X+BD\QM-DFD\Q9=TUU*YWJH4-RW7
M"CGKD9H \ C_ &4O'VJ^ /@UX>U_QAHVIW?P\\21:BNH 2[KNPB'[J,Y'$H7
MY<],*.>M>A?$GX8)\0_C]\+?B7I_B72$T;P=%>F[A:;<\HG78I1A\H *MG)[
M&O0=$^!G@_P]=6D]CI\T;VH C#W<SC C>/D,QW?+(P.<YX]!BM-^SUX'N+98
M)-*D>-0Z\W4N2&SG)W<_>- &1^U+\.#\;?@IXA^']EK.GZ1J^NQQQ6D]ZV5#
M)+&[8 ^8_*,<?WAZUZ%X#T$^%O!'A_16>.1M-T^WLR\(PC&.)4RH]#MXKDI?
MV>?!+P7B)I\T+W,/D-*EU)O0; @*DL<' '/KS7HMK;1V5M%;PH(X8D"(HZ!0
*, 4 2T444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pbm-20240331xex23d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xex23d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ![!#@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]1M9UFQ\.
MZ1>ZIJ=U%8Z=90O<7-S.VU(HT!9G8]@ "2:K^&/%6C^-/#]AKFA:E:ZOH]_$
M)[6]LY1)%,AZ,K#K7'_M&?\ ) ?B/_V+NH?^D[U\*_!;X9?&KP?\&?!^B?"Z
M\NKCPC\4- L)I]2EG_Y%.\= ;VXCSR%EC+%,=)#ZXR ?>U]\<O &F^%]4\27
M7C#1X=!TS4&TJ]U)[M?(M[M6"-"[] X9@,>IK:\8>/?#O@#PM<^)/$6M66C:
M#;!#-J-Y,$@0.P5"6Z<LR@>N17YN>)?"&G^#_P!AKXK>%;3S9=*TSXK2:7$)
MW+2/"E];Q_,>Y*CD^]1?M.R^+_V>?@%\0_@QXMNKK7/!VI"VN/ OB.Y<R2%(
M[N"233ICSM>- S+G (4XX("@['W[XS_:2^%WP[U2RT[Q-X]T#0;Z]MX[NW@U
M"^2)I87)".N>JG!P?:O0K*_MM2M(;JTN(KJVG02130N'21",AE8<$$'@BOS[
M\:2Z@G[7&@IIOP[3XG7,OPIMXAHTLMM&D>9T_?,;CY< X4[?F^?CC-?4_P"R
M7\*]:^"_P%\+>$O$-RD^KV:2RSQPR>9%;&65I!!&W=(PP08X^7CB@#T/P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&$1,J& R3U!QQ6[\._@OJ_PQU&TTS2M<TF7P/8S-)9V%UHH;4;:(Y*VZW0D
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M5WGQ1\&^(/$M[X7U'PUJFFZ9JNB7LEVC:K9274$JO;RP,I6.2,@XER#N[=*
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MM&EO[ZUU.]>SA:>]LB#!<2&-=TD9'5&.2/8BMFL#P#X,T_X=^"="\+Z3YO\
M9FCV45A;>>^^0QQH%4LW<D#)-;] !1110 4444 %%%% !1110 4444 %%%%
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M]#_\&4/_ ,51_P +0\'?]#7H?_@RA_\ BJ .GHKF/^%H>#O^AKT/_P &4/\
M\51_PM#P=_T->A_^#*'_ .*H Z>BN8_X6AX._P"AKT/_ ,&4/_Q5'_"T/!W_
M $->A_\ @RA_^*H Z>BN8_X6AX._Z&O0_P#P90__ !5'_"T/!W_0UZ'_ .#*
M'_XJ@#IZ*YC_ (6AX._Z&O0__!E#_P#%4?\ "T/!W_0UZ'_X,H?_ (J@#IZ*
MYC_A:'@[_H:]#_\ !E#_ /%4?\+0\'?]#7H?_@RA_P#BJ .GHKF/^%H>#O\
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M#O\ H:]#_P#!E#_\51_PM#P=_P!#7H?_ (,H?_BJ .GHKF/^%H>#O^AKT/\
M\&4/_P 51_PM#P=_T->A_P#@RA_^*H Z>BN8_P"%H>#O^AKT/_P90_\ Q5'_
M  M#P=_T->A_^#*'_P"*H Z>BN8_X6AX._Z&O0__  90_P#Q5'_"T/!W_0UZ
M'_X,H?\ XJ@#IZ*YC_A:'@[_ *&O0_\ P90__%4?\+0\'?\ 0UZ'_P"#*'_X
MJ@#IZ*YC_A:'@[_H:]#_ /!E#_\ %4?\+0\'?]#7H?\ X,H?_BJ .GHKF/\
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MT/\ \&4/_P 51_PM#P=_T->A_P#@RA_^*H Z>BN8_P"%H>#O^AKT/_P90_\
MQ5'_  M#P=_T->A_^#*'_P"*H Z>BN8_X6AX._Z&O0__  90_P#Q5'_"T/!W
M_0UZ'_X,H?\ XJ@#IZ*YC_A:'@[_ *&O0_\ P90__%4?\+0\'?\ 0UZ'_P"#
M*'_XJ@#IZ*YC_A:'@[_H:]#_ /!E#_\ %4?\+0\'?]#7H?\ X,H?_BJ .GHK
MF/\ A:'@[_H:]#_\&4/_ ,51_P +0\'?]#7H?_@RA_\ BJ .GHKF/^%H>#O^
MAKT/_P &4/\ \51_PM#P=_T->A_^#*'_ .*H Z>DKF?^%H>#O^AKT/\ \&4/
M_P 51_PM#P=_T->A_P#@RA_^*H Z>BN8_P"%H>#O^AKT/_P90_\ Q5'_  M#
MP=_T->A_^#*'_P"*H Z>BN8_X6AX._Z&O0__  90_P#Q5'_"T/!W_0UZ'_X,
MH?\ XJ@#IZ*YC_A:'@[_ *&O0_\ P90__%4?\+0\'?\ 0UZ'_P"#*'_XJ@#I
MZ*YC_A:'@[_H:]#_ /!E#_\ %4?\+0\'?]#7H?\ X,H?_BJ .GHKF/\ A:'@
M[_H:]#_\&4/_ ,51_P +0\'?]#7H?_@RA_\ BJ .GHKF/^%H>#O^AKT/_P &
M4/\ \51_PM#P=_T->A_^#*'_ .*H Z>BN8_X6AX._P"AKT/_ ,&4/_Q5'_"T
M/!W_ $->A_\ @RA_^*H Z>BN8_X6AX._Z&O0_P#P90__ !5'_"T/!W_0UZ'_
M .#*'_XJ@#IZ*YC_ (6AX._Z&O0__!E#_P#%4?\ "T/!W_0UZ'_X,H?_ (J@
M#IZ*YC_A:'@[_H:]#_\ !E#_ /%4?\+0\'?]#7H?_@RA_P#BJ .GHKF/^%H>
M#O\ H:]#_P#!E#_\51_PM#P=_P!#7H?_ (,H?_BJ .GHKF/^%H>#O^AKT/\
M\&4/_P 51_PM#P=_T->A_P#@RA_^*H Z>BN8_P"%H>#O^AKT/_P90_\ Q5'_
M  M#P=_T->B?^#*'_P"*H Z>BJNFZG9ZQ9QW=A=07MK(,I/;R"1&YQPP)!Y%
M% %#Q;X-T+Q[H4^B^)-(LM=TB<J9;'4(%FAD*L&7*,"#@@$?2N _X9-^"_\
MT2KP?_X)8/\ XFO6** /)_\ ADWX+?\ 1*O!_P#X)8/_ (FC_ADWX+?]$J\'
M_P#@E@_^)KUBB@#R?_ADWX+?]$J\'_\ @E@_^)H_X9-^"W_1*O!__@E@_P#B
M:]8HH \G_P"&3?@M_P!$J\'_ /@E@_\ B:/^&3?@M_T2KP?_ ."6#_XFO6**
M /)_^&3?@M_T2KP?_P""6#_XFC_ADWX+?]$J\'_^"6#_ .)KUBB@#R?_ (9-
M^"W_ $2KP?\ ^"6#_P")H_X9-^"W_1*O!_\ X)8/_B:]8HH \G_X9-^"W_1*
MO!__ ()8/_B:/^&3?@M_T2KP?_X)8/\ XFO6** /)_\ ADWX+?\ 1*O!_P#X
M)8/_ (FC_ADWX+?]$J\'_P#@E@_^)KUBB@#R?_ADWX+?]$J\'_\ @E@_^)H_
MX9-^"W_1*O!__@E@_P#B:]8HH \G_P"&3?@M_P!$J\'_ /@E@_\ B:/^&3?@
MM_T2KP?_ ."6#_XFO6** /)_^&3?@M_T2KP?_P""6#_XFC_ADWX+?]$J\'_^
M"6#_ .)KUBB@#R?_ (9-^"W_ $2KP?\ ^"6#_P")H_X9-^"W_1*O!_\ X)8/
M_B:]8HH \G_X9-^"W_1*O!__ ()8/_B:/^&3?@M_T2KP?_X)8/\ XFO6** /
M)_\ ADWX+?\ 1*O!_P#X)8/_ (FC_ADWX+?]$J\'_P#@E@_^)KUBB@#R?_AD
MWX+?]$J\'_\ @E@_^)H_X9-^"W_1*O!__@E@_P#B:]8HH \G_P"&3?@M_P!$
MJ\'_ /@E@_\ B:/^&3?@M_T2KP?_ ."6#_XFO6** /)_^&3?@M_T2KP?_P""
M6#_XFC_ADWX+?]$J\'_^"6#_ .)KUBB@#R?_ (9-^"W_ $2KP?\ ^"6#_P")
MH_X9-^"W_1*O!_\ X)8/_B:]8HH \G_X9-^"W_1*O!__ ()8/_B:/^&3?@M_
MT2KP?_X)8/\ XFO6** /)_\ ADWX+?\ 1*O!_P#X)8/_ (FC_ADWX+?]$J\'
M_P#@E@_^)KUBB@#R?_ADWX+?]$J\'_\ @E@_^)H_X9-^"W_1*O!__@E@_P#B
M:]8HH \G_P"&3?@M_P!$J\'_ /@E@_\ B:/^&3?@M_T2KP?_ ."6#_XFO6**
M /)_^&3?@M_T2KP?_P""6#_XFC_ADWX+?]$J\'_^"6#_ .)KUBB@#R?_ (9-
M^"W_ $2KP?\ ^"6#_P")H_X9-^"W_1*O!_\ X)8/_B:]8HH \G_X9-^"W_1*
MO!__ ()8/_B:/^&3?@M_T2KP?_X)8/\ XFO6** /)_\ ADWX+?\ 1*O!_P#X
M)8/_ (FC_ADWX+?]$J\'_P#@E@_^)KUBB@#R?_ADWX+?]$J\'_\ @E@_^)H_
MX9-^"W_1*O!__@E@_P#B:]8HH \G_P"&3?@M_P!$J\'_ /@E@_\ B:/^&3?@
MM_T2KP?_ ."6#_XFO6** /)_^&3?@M_T2KP?_P""6#_XFC_ADWX+?]$J\'_^
M"6#_ .)KUBB@#R?_ (9-^"W_ $2KP?\ ^"6#_P")H_X9-^"W_1*O!_\ X)8/
M_B:]8HH \G_X9-^"W_1*O!__ ()8/_B:/^&3?@M_T2KP?_X)8/\ XFO6** /
M)_\ ADWX+?\ 1*O!_P#X)8/_ (FC_ADWX+?]$J\'_P#@E@_^)KUBB@#R?_AD
MWX+?]$J\'_\ @E@_^)H_X9-^"W_1*O!__@E@_P#B:]8HH \G_P"&3?@M_P!$
MJ\'_ /@E@_\ B:/^&3?@M_T2KP?_ ."6#_XFO6** /)_^&3?@M_T2KP?_P""
M6#_XFC_ADWX+?]$J\'_^"6#_ .)KUBB@#R?_ (9-^"W_ $2KP?\ ^"6#_P")
MH_X9-^"W_1*O!_\ X)8/_B:]8HH \G_X9-^"W_1*O!__ ()8/_B:/^&3?@M_
MT2KP?_X)8/\ XFO6** /)_\ ADWX+?\ 1*O!_P#X)8/_ (FC_ADWX+?]$J\'
M_P#@E@_^)KUBB@#R?_ADWX+?]$J\'_\ @E@_^)H_X9-^"W_1*O!__@E@_P#B
M:]8HH \G_P"&3?@M_P!$J\'_ /@E@_\ B:/^&3?@M_T2KP?_ ."6#_XFO6**
M /)_^&3?@M_T2KP?_P""6#_XFC_ADWX+?]$J\'_^"6#_ .)KUBB@#R?_ (9-
M^"W_ $2KP?\ ^"6#_P")H_X9-^"W_1*O!_\ X)8/_B:]8HH \G_X9-^"W_1*
MO!__ ()8/_B:/^&3?@M_T2KP?_X)8/\ XFO6** /)_\ ADWX+?\ 1*O!_P#X
M)8/_ (FC_ADWX+?]$J\'_P#@E@_^)KUBB@#R?_ADWX+?]$J\'_\ @E@_^)H_
MX9-^"W_1*O!__@E@_P#B:]8HH \G_P"&3?@M_P!$J\'_ /@E@_\ B:/^&3?@
MM_T2KP?_ ."6#_XFO6** /)_^&3?@M_T2KP?_P""6#_XFC_ADWX+?]$J\'_^
M"6#_ .)KUBB@#R?_ (9-^"W_ $2KP?\ ^"6#_P")H_X9-^"W_1*O!_\ X)8/
M_B:]8HH \G_X9-^"W_1*O!__ ()8/_B:/^&3?@M_T2KP?_X)8/\ XFO6** /
M)_\ ADWX+?\ 1*O!_P#X)8/_ (FC_ADWX+?]$J\'_P#@E@_^)KUBB@#R?_AD
MWX+?]$J\'_\ @E@_^)H_X9-^"W_1*O!__@E@_P#B:]8HH \G_P"&3?@M_P!$
MJ\'_ /@E@_\ B:/^&3?@M_T2KP?_ ."6#_XFO6** /)_^&3?@M_T2KP?_P""
M6#_XFC_ADWX+?]$J\'_^"6#_ .)KUBB@#R?_ (9-^"W_ $2KP?\ ^"6#_P")
MH_X9-^"W_1*O!_\ X)8/_B:]8HH \G_X9-^"W_1*O!__ ()8/_B:/^&3?@M_
MT2KP?_X)8/\ XFO6** /)_\ ADWX+?\ 1*O!_P#X)8/_ (FC_ADWX+?]$J\'
M_P#@E@_^)KUBB@#R?_ADWX+?]$J\'_\ @E@_^)H_X9-^"W_1*O!__@E@_P#B
M:]8HH \G_P"&3?@M_P!$J\'_ /@E@_\ B:/^&3?@M_T2KP?_ ."6#_XFO6**
M /)_^&3?@M_T2KP?_P""6#_XFC_ADWX+?]$J\'_^"6#_ .)KUBB@#R?_ (9-
M^"W_ $2KP?\ ^"6#_P")H_X9-^"W_1*O!_\ X)8/_B:]8HH \G_X9-^"W_1*
MO!__ ()8/_B:/^&3?@M_T2KP?_X)8/\ XFO6** /)_\ ADWX+?\ 1*O!_P#X
M)8/_ (FC_ADWX+?]$J\'_P#@E@_^)KUBB@#R?_ADWX+?]$J\'_\ @E@_^)H_
MX9-^"W_1*O!__@E@_P#B:]8HH \G_P"&3?@M_P!$J\'_ /@E@_\ B:/^&3?@
MM_T2KP?_ ."6#_XFO6** /)_^&3?@M_T2KP?_P""6#_XFC_ADWX+?]$J\'_^
M"6#_ .)KUBB@#R?_ (9-^"W_ $2KP?\ ^"6#_P")H_X9-^"W_1*O!_\ X)8/
M_B:]8HH \G_X9-^"W_1*O!__ ()8/_B:/^&3?@O_ -$J\'_^"6#_ .)KUBB@
M#)\+^%-&\$Z':Z-X?TNTT72+52L%C8PK##$"2Q"HH &22?QHK6HH *\N^-/[
M2GP\^ 6G1W'C/Q%#IUQ,K/;Z?$K37=P!P2D298C/&XX'O7>>*?$>G^$O#^H:
MSJU_!I>F6,#W%S>W+;8X449+,?0?K7YE1?$;X*_%[XI:RV@_!OQ?^T/XMO6\
MV\UK5)A%&4SA3'$2%@A7@*"J<>IYH ^QOAU^W'\)OBQ'!!X<\4VHUVX.R+0]
M8?\ L^ZD;LB>8-K,>P#<YZUZ;X<^+>A:WX@3P[<F[T/Q,\#W*:+K$!@N9(D.
M&>/JDJ@D9,;,!D9Q7PK=_L9?#WXSWMQIEM\-M:^#'B:, QRZ3KMEJ]K!)V\^
MVCG>2/G'(5/]X5M>+-"^)NO?#?7?AIXZNI;;XK_#NU_X2_P?XZL'.W58(,JP
MW$;A*%/ENIY.Y"P/)8 _0.69(8VD=MJ*"Q)[ =:\/;]N+X$JY4_$W0PP.T@R
MOP?^^:9^RU\>V_:/_9[LO%]Q:BSU/RIK'4(5QL^TQ+AV3_9;*L!VW8[5\,_\
M$]/AM\*?&/@CXF:Q\4=)\/W=K8:O;V\-]K[+&D(>-B4#LR@9(SCJ30.Q^E'A
MOXU>!?&/A+4?$^A>*]*UC0=.1Y+R^LKE94M@B%W\S;DJ0H+8(SBN!A_;A^!,
M[JJ?$_0<MTW3,H_,KBO@;X OI>C_ !6_:AT?X<74MY\,#X.U:2.0,SQ92,B
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>pbm-20240331xex23d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xex23d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ )8# 2(  A$! Q$!_\0
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MT:P\V0B>[C5OG)^7.3^@-.QY:Q_,TE'\3[>>:./&]U7/3<<4W[5!_P ]H_\
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M,FYR5&)SMU:R6;JDJ['9%D"GKAAD?I7I7[.FD_VC\28)RN4LK>28GT)&T?\
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# ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>pbm-20240331xex23d1003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xex23d1003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  = 'P# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>pbm-20240331xex5d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pbm-20240331xex5d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  > .,# 2(  A$! Q$!_\0
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M)8,Q&6"HW3O2:=X)_P"%J? #XAWDB;KKQM->ZE;$C)"+\EE]0$@A8?6O*O\
M@FGXR,FB^,/"4SL'M;B/4(4;T<>7)@>Q2/\ [ZK>I)U<#.*>M-J_H]'^-SEH
M0CA\VIU&O=K1=O)IW5NWNV/7_&WPR\-^*?CKH&D1::5VV]SKVN.EQ*OGJ3Y4
M$;8;&&D9WP!_RQKVK0M!L/#.E0:;IEN+6R@!$<08MMR23R23U)KYWUWXRV/P
MN\(_$'XM74(O;G6=5_LC0[9FP)XK8-#%SU"EUN)3CL?7%;?PD\">(/BC\.-.
M\5>,_&/B&/6];A%[##H]\]C!81OS&L<:8#';@DONZX^OG5:<W34JDK16G>[W
M>GEL>UAZ])5Y0HPO.5Y:65H[+7^]:]OFSWVOG7Q=\-?B_J'[3VD>)-+\2F#P
M!%Y1EM/M16-(E4"6)H,X=G(8AL'&X<C:*Y3X(?'3Q!?_ !1\5?!3QMK$]SJ5
MN]S;:9XAMML5TX3/!.,;]GSJV.Q!SQ7/ZSX[\8^!?VRO#7@*W\9ZWJ7AR:2W
M:6#4IDD:3?&2P)"+QFMZ.%JT:DXIJ_*WJKIKNO,Y<5F&'Q5&E-J5O:):.S4D
M]GKMWL?:M%>*?M16FK:#\-O$?C'1O%6N:+J&EV2M#:V5PBVS,) -S(4))(;'
M4=!7DO[,?C+QO^T#\,[FTU#Q/J]M!ITLYO\ 5;)UCO;F5@##;Q2%3L55!=B!
MD[T (&:XX81SHNOS*R=F>G5S*-+%+!N#<FKK:S_R_P CW3]H'P/HFN_#WQ+K
M5[9F75-.T>Z:TN5GDC:(K&S*1M8#(;GFOF']@CPGIOQ1T7QC-XKCGUR6SN+9
M(&NKJ4F,,LFX###K@?E6S\ /''CWQ5^S_P#&"Q\:-J5U%IFGW$=I=ZJI\\,8
M)?,B+$9;;M4\Y(W?2N0_8"^*.@?#O0O&B:T]^K7%Q;-']CTVXNAA5DSDQ(VW
MJ.N*]F-&K1PM>DG=Q<;6_0^7GB</BLPPF(E'EC.,K\UNEUK^A]/>,/V5? GB
M;3;FUL!J/A_43&?*O-.U.X#1,0<$QM(589[$<XZBJ'[&UEJ>C_">^TC6+J6[
MU/2M<OK">29V<[HW /)YQZ5G? +XL:=\8?CC\2]7TB.YCTRUL=-L8C=1F-W*
M-<%F*'E>6(P><#G'2N7U[XGWOC;]HJ;X1^ +S_A%=,6>:^\1:SIZ+]IGF"@R
MB-B"$.0B%L9W$^G/$X5Y1EAJCV2DV^FE_7KL>JJN#ISIXZC%+F<H)1^UK9=E
MTO?L?5]%?/'QQ\+>(?@[X O/&O@CQ9KAO=%"W%UI^LW[W]M>P[@'#+*258 Y
MRA7H1Z$8WBSXHS_%3]FJ]^*GAOQ%K/AK4].T]Q)IUA<H($N48;PX9"6Z\'(^
M4BN..$=11G&7NMVOV?F>G4S&-&4Z52-IQCS6NM8]6GY=G8^H**^?_P!BGQQK
M_P 2/@G)JGB35KC5-1;4IX!=3$;U0*F ,#MDG\:\?_:E\6>,_@A\0/!.E^'_
M ![XCGM-6^>Y74+B.4\2JN!B-<#!JX8&4\1+#<RYE?\  RJYM"E@X8[D;A*W
M:ZOHNI]7?%'P3HOBWPW>3ZM9"[EL;6>2W?S70QMLSD;2/[HZ^E?,_P#P3<UG
M4-8\.^.&O[ZYO62ZM0IN)6DVC;)TR>*^M/%W_(J:U_UY3_\ HMJ^,_\ @G%J
MMMH7@3XD:E>/Y=I9R07$S_W42.5F/Y UOA[RP-9><;?><>,489OA9;74[_*/
M4^XJ^%?V^_"^G_#;1?"=YX82?1;F^O+@7,EM=2@R@*A&<MZD_G70_ CQ/XP_
M:W\9>)=?U;Q/K'AKP;I4RPV6D:%=&U9V;<5#R+\S84 MSR6&,#BN%_X*!:+K
MGA;2O!^E7FJ7.O:(UQ<365]J#!KJ%MJ!X9' 'F#E65B-W+ DX!KJP.'>'QL*
M4I:]5\MO,X,VQL<;E53$0IOE^S+2_P 25^Z3_P"'/N7P [2>!/#CNS.[:;;%
MF8Y)/E+R36]7E'BOXB-\*/V;H_%4<"W,^GZ):M#"^=K2LB(F[';<P)]@:XSX
M6^![GXQ?#+2?%LOQ0\4/X@U.W\^2YTO41%;6<QY,(MU&S"'Y2&&3@\C->3[#
MFBZLG:-[?,^C^M\DHX>$>:?+S6NEIMU_KO8^BJ*\ \'^*_'>G_LZ^,[[Q!J\
MC^+_  V^I1+J!MHQYIM@Q1BI7:RMMZXR0>N>:],^#FM:CXG^%7A36M6O#>:E
MJ>F6][/+Y:1C?)&KD*J@  $\=_4FN>I3=.3BW>QW4*RKTXU$FKJ]GNO4[.BO
M(?@GXQU_Q1XT^)=AJ^JO?6GA_6?[-LHS!%'^[\M7W,44$MDD>F.U0?$3QEK^
ME?'KP%X6L]=DTW1=>LM0FNE6"!F1X$0IL9T.,EN<Y]L5G8VN>RT5\60_MH_$
M'29K[3D\ R^,([&^NK--=L(W2&]6*=XUD4*"HX49P<9!QCI13Y63S(^T9(UF
MC:-U#HP*LI&00>HK\Q?!L^I? 7]H?Q_X%T])3+K<5QH-@L8/RM.R_99#_NAE
M.?<U^GE?-_B_X2Z?J7[:G@_Q,Y7/]BSWDD6/OS0$1(Q_"9#_ -LQ7JY?7C3]
MI">J<7]ZU1\YG6$G7]A5I.THS2OY2T?Z'T!X>T2V\-:#IND6:[;2PMH[6(?[
M"*%'Z"OS=TW4]0_9X_:S\:Z/I4,IFU076GZ?$@_CN0'M>/0.T7X U^F5?-_C
M+X2V&M?MI^#_ !'*5_=:)+?/%C[\L#^6C?AYR'_MF*,OKQ@ZBJ:J47]ZU#.<
M)*K&A*B[2C-6\D]'^AY'^W[X3_X0KX0?"_1+/<=.TR1[1G'1I!$@5C[G$A_$
MU[3\(/@AI/B'X5>#]23Q7XQB%SI%K(8[;Q#<)$A,2Y55!PJ@Y  Z5Z+\</A!
MIOQO^'M]X9U&0V[2$36MVJ[FMYUSM<#N.2".X8]*^5O G[4MQ^RM;2_##QYI
MKZ\^ADQVFHZ+(#F(L2$99 G3G!'; QQD]5.I4Q.$4*3]^+;?FGU^\X*U&A@<
MRE5Q*_=U(I+K9QTM9:[=3W_P[^RGX \)>/K/QG$VJS^(XIS*EY?ZD\SRR%2I
MW;OO$J37SU\4/^4BWA7_ 'K/_P!%&O>]$\6W?CW1H_BMJEM'#X=T6SGO='T.
M&4O*\GED-/.Y4 /LW(JJ"%WL=Q)&/EKQ7XX?Q+^TQI'Q5BL%ATRP: O8//F9
MO+3:<';CFM,&JTJDW4=VH->CZ+^M##,Y8:G1I*A%13J1EHMTMY?UJ?7?[6O_
M ";EXZ_Z\1_Z,2N!_P"">EM%#^SZLB(%>75;AG8#EB @&?P K"^/'[05MX^^
M$UYX<M=%EMKGQ'I^Z*::X&R'$Q7YL+D_ZL]/6JO[$_CO_A#M%T[X;W=CYU[/
M=7%T+Z&7,8!3=C:5!S\A'XUBJ-2.7RBUKS7^5CJEB:,\ZIU(O3DMUW;T/HWX
MU?\ )'O&_P#V!;S_ -$O7RW_ ,$RO^1>\>_]?=K_ .@RU[+^TW\6X/".@ZAX
M3;39+JYU[2;B**X$P1(BZM&-PP20"<\5\U_LD>.Y_@"-7TN_TV/56UR[M]DM
MM<E!%MW*<@IS]\?E3PU*<L!5BEJVK?>3CL32AG&'G)Z14D]]+K0^PO#'@.XT
M/XV>-?$J6<4&FZUIVGH)D9<RW$1G$A91SD*T?)Z_A7Q[^R'%<6O[9_CB+4 P
MO1'J8<2?>W_:4S_6OT'KY?\ C3\,)/A%\4T^.WAMK=EMT8:[H\[%/M2%-C/$
MP4X<C!P0!E0<\FL,'7Y_:4I;SC9>JV7S.O,\)[)T<3#X:<W*7I)W;^7;<]1_
M:=('[/GC_/\ T")P/KMX_6OCSX 07<?[#_QADE#"TDFD\G/0D11;R/\ QW\J
M]+\7_M#1_M7Z5_PK+P/9W&AW6M1H][J.M;56*W#!F6-8RY9C@#G:,9]<CW*V
M_9^T?2/@#>?"_3)FAM)]/EM3>R+\[S."3,P'??SCT&.U;4Y_5*"IU=Y23^2M
MJ<U>E_:6,E7P[O&%.4>UY2OIKY:W/./^">'_ ";ZW_87N?\ T&.O+/\ @H-(
MI^+OPRC# NL98KGD SK@_H?RKG_@%^T?)^S VM_#/7]&_MN>'5#]GNM/GVH)
M7"H58NH.W*@[L9Y/!JW^UA\/O$.J^._!_BW5KRREU2YA^T2VL,K^1;PI(#%#
M$2N6P"Q+D#+.> ,"O1IT90S&566SO;SNCQ:V*A6R2.'IZRCRJ7E9K[]>Q]W>
M+O\ D5-:_P"O*?\ ]%M7Y^_LGP7%S^S/\>([4,T[:?\ *%ZG]Q-G],U]#Z[^
MUEI^H^!Y[A?#URHOFGL%4W*_*WEJ=Q.WI^\'Y5X9^R-XJ3X-1:OX:UK34U=/
M$MU;P!K>;"(IW1L&#*,@^9V]ZXL+2J4L-5NM;Q?W/4]3,,10Q&/P[C+3EFF[
M/3FC9'H7_!-)E_X5?XK7_EH-9R1[>1'C^1JE_P %,64>#?!*DC>=0G(]<>6N
M?YBL"RU>3]@#XE:M9W*GQ#X(\2#S[>"V?%W;%"VPD, I(#%3\W/!XQBL_P#:
MP.L_'WPAX*\86LD&F:+.\Z:?ITTC%PA"EY)2%P') &T9 "]23QUPIN68QQ*^
M"6J?R/.JUU#))X%_Q8:->DM[[;'U?JEAX:U[X'Z%H'BN;R=*UVPLM+&,AFFE
M1!$%(!PV[!!/&0,U\?\ B?\ 9$^,'P&O;K6OAKXAN=3L(R9-FG3&&Z*C^_"3
MMDP.P+9_NUZUK?BC4_C=\ I-/\-Q1:+K/A*?3+A;B]F+1N\/.Y=J$]8\C(Y]
MJ9I/_!0G1)M*6VO?"^H?\)*DBVCQ02)]C:<\9$A.\(3_ +!('K7)06)P\6Z:
M33;3B[6Z6^\]'%_4,;**KMQ:BG&2NGUO]S75==!_P3^.'B3]I#X#^/\ P[J&
MG+=>,[2QET_]SMA%QY\3I&[!B A# AL<="!VKT[P_%XZ\+_!SPAX8TSPQ<)K
MUE::?875R]W;K# D?EK.ZG>2_P JO@ <Y%)^S9\%)?A?I^OZ[JES;77B/Q5=
M_P!HWGV)2+>!6+.L4>X D R,<D#J..,GVBO)QCI^WE[)6C_5_P 3Z/+%7^IT
M_K+O.V_E?2_G:QXC\+=!\3^!?%7Q-U2\\+WD\7B#6CJ-BD%Q;DM'Y2H V9!M
M)*U@/X \:>,?B3\+O$7BWPM%<1:5:ZFFKPR3V\\<+7+#R54%OW@10 2!VXS7
ET;17'<]2Q7L-/M=*LXK2RMH;.UB&V."WC"(@] HX%%6**0S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>22
<FILENAME>pbm-20240331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/19/2024 7:08:12 PM-->
<!--Modified on: 8/19/2024 7:08:12 PM-->
<xsd:schema targetNamespace="http://www.psyence.com/20240331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:fact-explanatoryFact="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:attributeFormDefault="unqualified" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:pbm="http://www.psyence.com/20240331">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition" id="StatementConsolidatedStatementsOfFinancialPosition">
        <link:definition>00100 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" id="StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss">
        <link:definition>00200 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails" id="DisclosureCashRestrictedCashAndCashEquivalentsDetails">
        <link:definition>40601 - Disclosure - Cash, restricted cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" id="DisclosureAccountsPayableAndAccruedLiabilitiesDetails">
        <link:definition>40801 - Disclosure - Accounts payable and accrued liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails" id="DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails">
        <link:definition>41501 - Disclosure - Transactions with related parties - Key Management Personnel (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails" id="DisclosureIncomeTaxNoteDetails">
        <link:definition>41701 - Disclosure - Income tax note (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity" id="StatementConsolidatedStatementsOfChangesInShareholderEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Changes in Shareholder Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables" id="DisclosureConvertibleNoteLiabilityTables">
        <link:definition>30903 - Disclosure - Convertible note liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails" id="DisclosureNatureOfOperationsAndGoingConcernDetails">
        <link:definition>40101 - Disclosure - Nature of operations and going concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
        <link:definition>40201 - Disclosure - Basis of presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails" id="DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails">
        <link:definition>40301 - Disclosure - Material accounting policies - historical financial information has been translated to United States dollars (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails" id="DisclosureReverseTakeoverTransactionWithNcacDetails">
        <link:definition>40501 - Disclosure - Reverse takeover transaction with NCAC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails" id="DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails">
        <link:definition>40502 - Disclosure - Reverse takeover transaction with NCAC - listing expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureEquipmentDetails" id="DisclosureEquipmentDetails">
        <link:definition>40701 - Disclosure - Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails" id="DisclosureConvertibleNoteLiabilityDetails">
        <link:definition>40901 - Disclosure - Convertible note liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails" id="DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails">
        <link:definition>40902 - Disclosure - Convertible note liability -fair value of the convertible notes combined discounted cash flow approach (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails" id="DisclosureDerivativeWarrantLiabilitiesDetails">
        <link:definition>41001 - Disclosure - Derivative warrant liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails" id="DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails">
        <link:definition>41002 - Disclosure - Derivative warrant liabilities - Fair value measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails" id="DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails">
        <link:definition>41003 - Disclosure - Derivative warrant liabilities - Warrant transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails" id="DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails">
        <link:definition>41004 - Disclosure - Derivative warrant liabilities - Outstanding and exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosurePromissoryNotesDetails" id="DisclosurePromissoryNotesDetails">
        <link:definition>41101 - Disclosure - Promissory Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureShareCapitalDetails" id="DisclosureShareCapitalDetails">
        <link:definition>41201 - Disclosure - Share capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureOtherIncomeDetails" id="DisclosureOtherIncomeDetails">
        <link:definition>41301 - Disclosure - Other income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails" id="DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails">
        <link:definition>41702 - Disclosure - Income tax note - Unrecognized deductible temporary differences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails" id="DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails">
        <link:definition>41703 - Disclosure - Income tax note - Non-capital loss carry forwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails" id="DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails">
        <link:definition>41801 - Disclosure - Financial instruments and financial risk management - Carrying Value of the Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails" id="DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails">
        <link:definition>41802 - Disclosure - Financial instruments and financial risk management - Maturity of the Contractual Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41901 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcern" id="DisclosureNatureOfOperationsAndGoingConcern">
        <link:definition>10101 - Disclosure - Nature of operations and going concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - Basis of presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPolicies" id="DisclosureMaterialAccountingPolicies">
        <link:definition>10301 - Disclosure - Material accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgements" id="DisclosureCriticalAccountingEstimatesAndJudgements">
        <link:definition>10401 - Disclosure - Critical accounting estimates and judgements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcac" id="DisclosureReverseTakeoverTransactionWithNcac">
        <link:definition>10501 - Disclosure - Reverse takeover transaction with NCAC</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalents" id="DisclosureCashRestrictedCashAndCashEquivalents">
        <link:definition>10601 - Disclosure - Cash, restricted cash and cash equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureEquipment" id="DisclosureEquipment">
        <link:definition>10701 - Disclosure - Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilities" id="DisclosureAccountsPayableAndAccruedLiabilities">
        <link:definition>10801 - Disclosure - Accounts payable and accrued liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiability" id="DisclosureConvertibleNoteLiability">
        <link:definition>10901 - Disclosure - Convertible note liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilities" id="DisclosureDerivativeWarrantLiabilities">
        <link:definition>11001 - Disclosure - Derivative warrant liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosurePromissoryNotes" id="DisclosurePromissoryNotes">
        <link:definition>11101 - Disclosure - Promissory Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureShareCapital" id="DisclosureShareCapital">
        <link:definition>11201 - Disclosure - Share capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureOtherIncome" id="DisclosureOtherIncome">
        <link:definition>11301 - Disclosure - Other income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureCapitalManagement" id="DisclosureCapitalManagement">
        <link:definition>11401 - Disclosure - Capital management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureTransactionsWithRelatedParties" id="DisclosureTransactionsWithRelatedParties">
        <link:definition>11501 - Disclosure - Transactions with related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>11601 - Disclosure - Share based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNote" id="DisclosureIncomeTaxNote">
        <link:definition>11701 - Disclosure - Income tax note</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagement" id="DisclosureFinancialInstrumentsAndFinancialRiskManagement">
        <link:definition>11801 - Disclosure - Financial instruments and financial risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11901 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies" id="DisclosureMaterialAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Material accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureBasisOfPresentationTables" id="DisclosureBasisOfPresentationTables">
        <link:definition>30203 - Disclosure - Basis of presentation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesTables" id="DisclosureMaterialAccountingPoliciesTables">
        <link:definition>30303 - Disclosure - Material accounting policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacTables" id="DisclosureReverseTakeoverTransactionWithNcacTables">
        <link:definition>30503 - Disclosure - Reverse takeover transaction with NCAC (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsTables" id="DisclosureCashRestrictedCashAndCashEquivalentsTables">
        <link:definition>30603 - Disclosure - Cash, restricted cash and cash equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureEquipmentTables" id="DisclosureEquipmentTables">
        <link:definition>30703 - Disclosure - Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" id="DisclosureAccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>30803 - Disclosure - Accounts payable and accrued liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables" id="DisclosureDerivativeWarrantLiabilitiesTables">
        <link:definition>31003 - Disclosure - Derivative warrant liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesTables" id="DisclosureTransactionsWithRelatedPartiesTables">
        <link:definition>31503 - Disclosure - Transactions with related parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteTables" id="DisclosureIncomeTaxNoteTables">
        <link:definition>31703 - Disclosure - Income tax note (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementTables" id="DisclosureFinancialInstrumentsAndFinancialRiskManagementTables">
        <link:definition>31803 - Disclosure - Financial instruments and financial risk management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesAdditionalInformationDetails" id="DisclosureMaterialAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - Material accounting policies - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails" id="DisclosureCriticalAccountingEstimatesAndJudgementsDetails">
        <link:definition>40401 - Disclosure - Critical accounting estimates and judgements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails" id="DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails">
        <link:definition>40503 - Disclosure - Reverse takeover transaction with NCAC - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>41601 - Disclosure - Share based compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails" id="DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails">
        <link:definition>41803 - Disclosure - Financial instruments and financial risk management (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="pbm-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pbm-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pbm-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pbm-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.psyence.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd" />
  <xsd:element name="IncreaseDecreaseInWorkingCapitalAbstract" id="pbm_IncreaseDecreaseInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" id="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NatureOfOperationsAndGoingConcernAbstract" id="pbm_NatureOfOperationsAndGoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BasisOfPresentationAbstract" id="pbm_BasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CriticalAccountingEstimatesAndJudgementsAbstract" id="pbm_CriticalAccountingEstimatesAndJudgementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CashRestrictedCashAndCashEquivalentsAbstract" id="pbm_CashRestrictedCashAndCashEquivalentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CashRestrictedCashAndCashEquivalentsTextBlock" id="pbm_CashRestrictedCashAndCashEquivalentsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CapitalManagementAbstract" id="pbm_CapitalManagementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CapitalManagementDisclosureTextBlock" id="pbm_CapitalManagementDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PsyenceAustraliaPtyLtd.Member" id="pbm_PsyenceAustraliaPtyLtd.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CashRestrictedCashAndCashEquivalents" id="pbm_CashRestrictedCashAndCashEquivalents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PercentageOfReasonablyPossibleChangeInRiskAssumption" id="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent" id="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" id="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesTextBlock" id="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock" id="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PysenceBiomedIICorpMember" id="pbm_PysenceBiomedIICorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewcourtAcquistionCorpMember" id="pbm_NewcourtAcquistionCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaterialAccountingPoliciesAbstract" id="pbm_MaterialAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsConvertibleDebtCurrent" id="pbm_IfrsConvertibleDebtCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsStatementTable" id="pbm_IfrsStatementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsStatementLineItems" id="pbm_IfrsStatementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NcacSponsorMember" id="pbm_NcacSponsorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsOperatingIncomeLoss" id="pbm_IfrsOperatingIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsNonoperatingIncomeExpenseAbstract" id="pbm_IfrsNonoperatingIncomeExpenseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ListingExpense" id="pbm_ListingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TransactionExpense" id="pbm_TransactionExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsFairValueAdjustmentOfWarrants" id="pbm_IfrsFairValueAdjustmentOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsAccountsPayableAndAccruedLiabilitiesMember" id="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsConvertibleDebtMember" id="pbm_IfrsConvertibleDebtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FinancialLiabilitiesUndiscountedCashFlows" id="pbm_FinancialLiabilitiesUndiscountedCashFlows" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="WarrantLiabilitiesMember" id="pbm_WarrantLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock" id="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsClassOfWarrantOrRightAxis" id="pbm_IfrsClassOfWarrantOrRightAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsClassOfWarrantOrRightDomain" id="pbm_IfrsClassOfWarrantOrRightDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrivateWarrantsMember" id="pbm_PrivateWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PublicWarrantsMember" id="pbm_PublicWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThirdPartyAdvisorsMember" id="pbm_ThirdPartyAdvisorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsStockIssuedDuringPeriodSharesNewIssues" id="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuedForDebtSettlement" id="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesIssuedForDebtSettlement" id="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AdjustmentsForListingExpense" id="pbm_AdjustmentsForListingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdjustmentsForTransactionExpenses" id="pbm_AdjustmentsForTransactionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsProceedsFromConvertibleDebt" id="pbm_IfrsProceedsFromConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromContributionsOfParent" id="pbm_ProceedsFromContributionsOfParent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" id="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" id="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsSharePrice" id="pbm_IfrsSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ThresholdAmountForMinimumCashCondition" id="pbm_ThresholdAmountForMinimumCashCondition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" id="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsDebtInstrumentFaceAmount" id="pbm_IfrsDebtInstrumentFaceAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SubscriptionAmount" id="pbm_SubscriptionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" id="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InvestorsMember" id="pbm_InvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsDebtInstrumentAxis" id="pbm_IfrsDebtInstrumentAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsDebtInstrumentNameDomain" id="pbm_IfrsDebtInstrumentNameDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FirstTrancheNoteMember" id="pbm_FirstTrancheNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsOtherIncomeAbstract" id="pbm_IfrsOtherIncomeAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" id="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BorrowingsMinimumInterestChargeablePeriod" id="pbm_BorrowingsMinimumInterestChargeablePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BorrowingsPeriodToRepayAfterNoticeOfAssessment" id="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DisclosureOfDetailedInformationAboutOtherIncomeTable" id="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfDetailedInformationAboutOtherIncomeLineItems" id="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LoanFromRhCapitalFinanceCo.LlcMember" id="pbm_LoanFromRhCapitalFinanceCo.LlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PromissoryNotesAbstract" id="pbm_PromissoryNotesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PromissoryNotesTextBlock" id="pbm_PromissoryNotesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="UnsecuredConvertiblePromissoryNotesMember" id="pbm_UnsecuredConvertiblePromissoryNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" id="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtIssuedMember" id="pbm_DebtIssuedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConvertibleNoteLiabilityAbstract" id="pbm_ConvertibleNoteLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfConvertibleNoteLiabilityTextBlock" id="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="UntilFirstResetDateMember" id="pbm_UntilFirstResetDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OnSecondResetDateMember" id="pbm_OnSecondResetDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentConvertibleInitialConversionPrice" id="pbm_DebtInstrumentConvertibleInitialConversionPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DebtInstrumentConvertibleFloorPrice" id="pbm_DebtInstrumentConvertibleFloorPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" id="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PeriodOfClosingDateConsideredForSecondResetDate" id="pbm_PeriodOfClosingDateConsideredForSecondResetDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" id="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThresholdPeriodForVolumeWeightedAveragePrice" id="pbm_ThresholdPeriodForVolumeWeightedAveragePrice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReverseTakeoverTransactionWithNcacTextBlock" id="pbm_ReverseTakeoverTransactionWithNcacTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReverseTakeoverTransactionAbstract" id="pbm_ReverseTakeoverTransactionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfListingExpensesTableTextBlock" id="pbm_ScheduleOfListingExpensesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" id="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" id="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReverseTakeoverTransactionWithNcacAxis" id="pbm_ReverseTakeoverTransactionWithNcacAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReverseTakeoverTransactionWithNcacDomain" id="pbm_ReverseTakeoverTransactionWithNcacDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NcacMember" id="pbm_NcacMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReverseTakeoverTransactionSharesIssued" id="pbm_ReverseTakeoverTransactionSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReverseTakeoverTransactionConsiderationPaidAbstract" id="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" id="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" id="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DerivativeWarrantLiabilitiesAbstract" id="pbm_DerivativeWarrantLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock" id="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" id="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfClassesOfWarrantsOutstanding" id="pbm_NumberOfClassesOfWarrantsOutstanding" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfWarrantsIssued" id="pbm_NumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfWarrantsOutstanding" id="pbm_NumberOfWarrantsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" id="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DividendYield" id="pbm_DividendYield" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="SharePriceMeasurementInputMember" id="pbm_SharePriceMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpectedDividendYieldMeasurementInputMember" id="pbm_ExpectedDividendYieldMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExercisePriceMeasurementInputMember" id="pbm_ExercisePriceMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpectedLifeMeasurementInputMember" id="pbm_ExpectedLifeMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FinancialLiabilitiesFairValuePerShare" id="pbm_FinancialLiabilitiesFairValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MovementsOfNumberOfWarrantsRollForward" id="pbm_MovementsOfNumberOfWarrantsRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsIssuedNumber" id="pbm_WarrantsIssuedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" id="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsIssuedWeightedAverageExercisePrice" id="pbm_WarrantsIssuedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantsIssuedOnJanuary252024Member" id="pbm_WarrantsIssuedOnJanuary252024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfWarrantsExercisable" id="pbm_NumberOfWarrantsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsGainLossOnExtinguishmentOfDebt" id="pbm_IfrsGainLossOnExtinguishmentOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueAdjustmentOnConvertibleNote" id="pbm_FairValueAdjustmentOnConvertibleNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FairValueAdjustmentOnPromissoryNote" id="pbm_FairValueAdjustmentOnPromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SecondTrancheNoteMember" id="pbm_SecondTrancheNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" id="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfConversionNotices" id="pbm_NumberOfConversionNotices" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsDebtConversionOriginalDebtAmount1" id="pbm_IfrsDebtConversionOriginalDebtAmount1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtConversionVolumeWeightedAveragePricePerShare" id="pbm_DebtConversionVolumeWeightedAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" id="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" id="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="IfrsPromissoryNoteMember" id="pbm_IfrsPromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock" id="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TaxEffectOflistingExpense" id="pbm_TaxEffectOflistingExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TaxEffectOfotherPermanentExpenses" id="pbm_TaxEffectOfotherPermanentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TaxEffectFromChangeInTaxBenefitsNotRecognized" id="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LoanLiabilityMember" id="pbm_LoanLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NonCapitalLossCarryForwards" id="pbm_NonCapitalLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsTaxPeriodAxis" id="pbm_IfrsTaxPeriodAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsTaxPeriodDomain" id="pbm_IfrsTaxPeriodDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TaxYear2044Member" id="pbm_TaxYear2044Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IndefinitePeriodMember" id="pbm_IndefinitePeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DiscountRateSharesMeasurementInputMember" id="pbm_DiscountRateSharesMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DiscountRateCashMeasurementInputMember" id="pbm_DiscountRateCashMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HistoricalAnnualVolatilityForSharesMeasurementInputMember" id="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HistoricalDailyVolatilityForSharesMeasurementInputMember" id="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AnnualInterestRateMeasurementInputMember" id="pbm_AnnualInterestRateMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice" id="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisclosureOfChangeInPresentationCurrencyTable" id="pbm_DisclosureOfChangeInPresentationCurrencyTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleDisclosingChangeInPresentationCurrencyLineItems" id="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="UnaffiliatedThirdPartyInvestorMember" id="pbm_UnaffiliatedThirdPartyInvestorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DescriptionOfChangeInAccountingPolicyPolicyTextBlock" id="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FairValueAdjustmentsOnPromissoryNote" id="pbm_FairValueAdjustmentsOnPromissoryNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" id="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherComprehensiveIncomeLoss" id="pbm_OtherComprehensiveIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ComprehensiveIncomeLoss" id="pbm_ComprehensiveIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>23
<FILENAME>pbm-20240331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/19/2024 7:08:12 PM-->
<!--Modified on: 8/19/2024 7:08:12 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfFinancialPosition" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureCashRestrictedCashAndCashEquivalentsDetails" roleURI="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails" roleURI="http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNoteDetails" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638596912911940096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_PropertyPlantAndEquipment_638596912911940096" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638596912911940096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets_638596912911940096" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments_638596912911950095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638596912911940096" xlink:to="ifrs-full_CurrentPrepayments_638596912911950095" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables_638596912911950095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638596912911940096" xlink:to="ifrs-full_OtherCurrentReceivables_638596912911950095" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912911950095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638596912911940096" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912911950095" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638596912911950095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638596912911940096" xlink:to="ifrs-full_CashAndCashEquivalents_638596912911950095" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638596912911950095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity_638596912911950095" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638596912911950095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638596912911950095" xlink:to="ifrs-full_IssuedCapital_638596912911950095" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638596912911950095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638596912911950095" xlink:to="ifrs-full_RetainedEarnings_638596912911950095" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves_638596912911950095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638596912911950095" xlink:to="ifrs-full_OtherReserves_638596912911950095" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638596912911960095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_638596912911960095" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638596912911960095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638596912911960095" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638596912911960095" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued_638596912911960095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638596912911960095" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued_638596912911960095" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtCurrent" xlink:label="pbm_IfrsConvertibleDebtCurrent_638596912911960095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638596912911960095" xlink:to="pbm_IfrsConvertibleDebtCurrent_638596912911960095" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="ifrs-full_CurrentWarrantLiability_638596912911960095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638596912911960095" xlink:to="ifrs-full_CurrentWarrantLiability_638596912911960095" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ComprehensiveIncomeLoss" xlink:label="pbm_ComprehensiveIncomeLoss" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" xlink:label="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation_638596912911960095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_ComprehensiveIncomeLoss" xlink:to="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation_638596912911960095" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OtherComprehensiveIncomeLoss" xlink:label="pbm_OtherComprehensiveIncomeLoss_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_ComprehensiveIncomeLoss" xlink:to="pbm_OtherComprehensiveIncomeLoss_638596912911970097" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_ComprehensiveIncomeLoss" xlink:to="ifrs-full_ProfitLoss_638596912911970097" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_638596912911970097" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="ifrs-full_FinanceIncome_638596912911970097" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense" xlink:label="ifrs-full_DepreciationExpense_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="ifrs-full_DepreciationExpense_638596912911970097" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="ifrs-full_OtherIncome_638596912911970097" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="ifrs-full_FinanceCosts_638596912911970097" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ListingExpense" xlink:label="pbm_ListingExpense_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="pbm_ListingExpense_638596912911970097" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TransactionExpense" xlink:label="pbm_TransactionExpense_638596912911970097" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="pbm_TransactionExpense_638596912911970097" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnPromissoryNote" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote_638596912911980098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="pbm_FairValueAdjustmentOnPromissoryNote_638596912911980098" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnConvertibleNote" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_638596912911980098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="pbm_FairValueAdjustmentOnConvertibleNote_638596912911980098" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsGainLossOnExtinguishmentOfDebt" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912911980098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912911980098" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsFairValueAdjustmentOfWarrants" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants_638596912911980098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="pbm_IfrsFairValueAdjustmentOfWarrants_638596912911980098" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsOperatingIncomeLoss" xlink:label="pbm_IfrsOperatingIncomeLoss_638596912911980098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638596912911970097" xlink:to="pbm_IfrsOperatingIncomeLoss_638596912911980098" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638596912911980098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_IfrsOperatingIncomeLoss_638596912911980098" xlink:to="ifrs-full_ProfessionalFeesExpense_638596912911980098" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638596912911980098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_IfrsOperatingIncomeLoss_638596912911980098" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638596912911980098" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638596912911980098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_IfrsOperatingIncomeLoss_638596912911980098" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638596912911980098" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638596912911990098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_IfrsOperatingIncomeLoss_638596912911980098" xlink:to="ifrs-full_SalesAndMarketingExpense_638596912911990098" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912911990098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912911990098" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ProceedsFromContributionsOfParent" xlink:label="pbm_ProceedsFromContributionsOfParent_638596912911990098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912911990098" xlink:to="pbm_ProceedsFromContributionsOfParent_638596912911990098" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromCurrentBorrowings" xlink:label="ifrs-full_ProceedsFromCurrentBorrowings_638596912911990098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912911990098" xlink:to="ifrs-full_ProceedsFromCurrentBorrowings_638596912911990098" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638596912911990098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912911990098" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638596912911990098" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638596912911990098" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638596912911990098" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638596912912000099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638596912911990098" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638596912912000099" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638596912912000099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638596912912000099" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_638596912912000099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_638596912912000099" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638596912912000099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638596912912000099" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638596912912000099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="ifrs-full_ProfitLoss_638596912912000099" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638596912912000099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638596912912000099" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsFairValueAdjustmentOfWarrants" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants_638596912912000099" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="pbm_IfrsFairValueAdjustmentOfWarrants_638596912912000099" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForListingExpense" xlink:label="pbm_AdjustmentsForListingExpense_638596912912010094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="pbm_AdjustmentsForListingExpense_638596912912010094" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForTransactionExpenses" xlink:label="pbm_AdjustmentsForTransactionExpenses_638596912912010094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="pbm_AdjustmentsForTransactionExpenses_638596912912010094" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnConvertibleNote" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_638596912912010094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="pbm_FairValueAdjustmentOnConvertibleNote_638596912912010094" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentsOnPromissoryNote" xlink:label="pbm_FairValueAdjustmentsOnPromissoryNote_638596912912010094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="pbm_FairValueAdjustmentsOnPromissoryNote_638596912912010094" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsGainLossOnExtinguishmentOfDebt" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912912010094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912912010094" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_638596912912010094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_638596912912010094" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638596912912010094" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912000099" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638596912912010094" order="13" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Cash, restricted cash and cash equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalents" xlink:label="pbm_CashRestrictedCashAndCashEquivalents_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks_638596912912020100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_CashRestrictedCashAndCashEquivalents_1" xlink:to="ifrs-full_BalancesWithBanks_638596912912020100" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912912020100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pbm_CashRestrictedCashAndCashEquivalents_1" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912912020100" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accounts payable and accrued liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_638596912912020100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables_1" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_638596912912020100" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="ifrs-full_OtherShorttermProvisions_638596912912020100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables_1" xlink:to="ifrs-full_OtherShorttermProvisions_638596912912020100" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638596912912020100" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables_1" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638596912912020100" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Transactions with related parties - Key Management Personnel (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_638596912912030104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation_1" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_638596912912030104" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_638596912912030104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation_1" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_638596912912030104" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Income tax note (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_638596912912030104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations_1" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_638596912912030104" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_638596912912030104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations_1" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_638596912912030104" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectOflistingExpense" xlink:label="pbm_TaxEffectOflistingExpense_638596912912030104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations_1" xlink:to="pbm_TaxEffectOflistingExpense_638596912912030104" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectOfotherPermanentExpenses" xlink:label="pbm_TaxEffectOfotherPermanentExpenses_638596912912030104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations_1" xlink:to="pbm_TaxEffectOfotherPermanentExpenses_638596912912030104" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" xlink:label="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized_638596912912030104" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations_1" xlink:to="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized_638596912912030104" order="5" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>24
<FILENAME>pbm-20240331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/19/2024 7:08:12 PM-->
<!--Modified on: 8/19/2024 7:08:12 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfFinancialPosition" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfChangesInShareholderEquity" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureConvertibleNoteLiabilityTables" roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureNatureOfOperationsAndGoingConcernDetails" roleURI="http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.psyence.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails" roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureReverseTakeoverTransactionWithNcacDetails" roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails" roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureEquipmentDetails" roleURI="http://www.psyence.com/role/DisclosureEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureConvertibleNoteLiabilityDetails" roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails" roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesDetails" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosurePromissoryNotesDetails" roleURI="http://www.psyence.com/role/DisclosurePromissoryNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureShareCapitalDetails" roleURI="http://www.psyence.com/role/DisclosureShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureOtherIncomeDetails" roleURI="http://www.psyence.com/role/DisclosureOtherIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNoteDetails" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails" roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails" roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.psyence.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.psyence.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="pbm-20240331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://www.psyence.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_1" xlink:title="ifrs-full_EntitysTotalForSubsidiariesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1 To ifrs-full_EntitysTotalForSubsidiariesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1 To ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_1" xlink:title="ifrs-full_GeographicalAreasAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_1" xlink:title="ifrs-full_GeographicalAreasMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_GeographicalAreasAxis_1" xlink:to="ifrs-full_GeographicalAreasMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_GeographicalAreasAxis_1 To ifrs-full_GeographicalAreasMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_1" xlink:title="ifrs-full_MaturityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_1" xlink:title="ifrs-full_AggregatedTimeBandsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_MaturityAxis_1" xlink:to="ifrs-full_AggregatedTimeBandsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_MaturityAxis_1 To ifrs-full_AggregatedTimeBandsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_1" xlink:title="ifrs-full_RangesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="ifrs-full_RangesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To ifrs-full_RangesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:title="ifrs-full_CategoriesOfRelatedPartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_1" xlink:title="ifrs-full_EntitysTotalForRelatedPartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfRelatedPartiesAxis_1 To ifrs-full_EntitysTotalForRelatedPartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_1" xlink:title="ifrs-full_FinancialLiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" xlink:to="ifrs-full_FinancialLiabilitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfFinancialLiabilitiesAxis_1 To ifrs-full_FinancialLiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:title="ifrs-full_LevelsOfFairValueHierarchyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" xlink:title="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_LevelsOfFairValueHierarchyAxis_1 To ifrs-full_AllLevelsOfFairValueHierarchyMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightAxis" xlink:label="pbm_IfrsClassOfWarrantOrRightAxis_1" xlink:title="pbm_IfrsClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightDomain" xlink:label="pbm_IfrsClassOfWarrantOrRightDomain_1" xlink:title="pbm_IfrsClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="pbm_IfrsClassOfWarrantOrRightAxis_1" xlink:to="pbm_IfrsClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:pbm_IfrsClassOfWarrantOrRightAxis_1 To pbm_IfrsClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_1" xlink:title="ifrs-full_ComponentsOfEquityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_1" xlink:title="ifrs-full_EquityMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ComponentsOfEquityAxis_1" xlink:to="ifrs-full_EquityMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ComponentsOfEquityAxis_1 To ifrs-full_EquityMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_1" xlink:title="ifrs-full_BusinessCombinationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_1" xlink:title="ifrs-full_EntitysTotalForBusinessCombinationsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_BusinessCombinationsAxis_1" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_BusinessCombinationsAxis_1 To ifrs-full_EntitysTotalForBusinessCombinationsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_1" xlink:title="ifrs-full_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_2" xlink:title="ifrs-full_RangesMember_2" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_RangeAxis_1" xlink:to="ifrs-full_RangesMember_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_RangeAxis_1 To ifrs-full_RangesMember_2" order="1" />
    <link:loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentAxis" xlink:label="pbm_IfrsDebtInstrumentAxis_1" xlink:title="pbm_IfrsDebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentNameDomain" xlink:label="pbm_IfrsDebtInstrumentNameDomain_1" xlink:title="pbm_IfrsDebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="pbm_IfrsDebtInstrumentAxis_1" xlink:to="pbm_IfrsDebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:pbm_IfrsDebtInstrumentAxis_1 To pbm_IfrsDebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_1" xlink:title="ifrs-full_BorrowingsByNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_1" xlink:title="ifrs-full_BorrowingsByNameMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_BorrowingsByNameAxis_1" xlink:to="ifrs-full_BorrowingsByNameMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_BorrowingsByNameAxis_1 To ifrs-full_BorrowingsByNameMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis_1" xlink:title="pbm_ReverseTakeoverTransactionWithNcacAxis_1" />
    <link:loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain_1" xlink:title="pbm_ReverseTakeoverTransactionWithNcacDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="pbm_ReverseTakeoverTransactionWithNcacAxis_1" xlink:to="pbm_ReverseTakeoverTransactionWithNcacDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:pbm_ReverseTakeoverTransactionWithNcacAxis_1 To pbm_ReverseTakeoverTransactionWithNcacDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:title="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_1" xlink:title="ifrs-full_ClassesOfFinancialInstrumentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfFinancialInstrumentsAxis_1 To ifrs-full_ClassesOfFinancialInstrumentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis_1" xlink:title="ifrs-full_UnobservableInputsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember_1" xlink:title="ifrs-full_UnobservableInputsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_UnobservableInputsAxis_1" xlink:to="ifrs-full_UnobservableInputsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_UnobservableInputsAxis_1 To ifrs-full_UnobservableInputsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:title="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_1" xlink:title="ifrs-full_NonadjustingEventsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:to="ifrs-full_NonadjustingEventsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1 To ifrs-full_NonadjustingEventsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:title="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_1" xlink:title="ifrs-full_PropertyPlantAndEquipmentMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1 To ifrs-full_PropertyPlantAndEquipmentMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:title="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_1" xlink:title="ifrs-full_CarryingAmountMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="ifrs-full_CarryingAmountMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1 To ifrs-full_CarryingAmountMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsTaxPeriodAxis" xlink:label="pbm_IfrsTaxPeriodAxis_1" xlink:title="pbm_IfrsTaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsTaxPeriodDomain" xlink:label="pbm_IfrsTaxPeriodDomain_1" xlink:title="pbm_IfrsTaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="pbm_IfrsTaxPeriodAxis_1" xlink:to="pbm_IfrsTaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:pbm_IfrsTaxPeriodAxis_1 To pbm_IfrsTaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_1" xlink:title="ifrs-full_ClassesOfShareCapitalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_1" xlink:title="ifrs-full_ClassesOfShareCapitalMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="ifrs-full_ClassesOfShareCapitalMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfShareCapitalAxis_1 To ifrs-full_ClassesOfShareCapitalMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_1" xlink:title="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_1" xlink:title="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_1" xlink:to="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_1 To ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStatementTable" xlink:label="pbm_IfrsStatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pbm_IfrsStatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_NcacSponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_ParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStatementLineItems" xlink:label="pbm_IfrsStatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pbm_IfrsStatementLineItems" xlink:to="pbm_IfrsStatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_IfrsStatementLineItems" xlink:to="ifrs-full_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pbm_IfrsStatementLineItems" xlink:to="ifrs-full_LiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtCurrent" xlink:label="pbm_IfrsConvertibleDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="pbm_IfrsConvertibleDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="ifrs-full_CurrentWarrantLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pbm_IfrsStatementLineItems" xlink:to="ifrs-full_EquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pbm_IfrsStatementLineItems" xlink:to="ifrs-full_EquityAndLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Changes in Shareholder Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember" xlink:label="ifrs-full_OtherReservesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherReservesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_ParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_NcacSponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThirdPartyAdvisorsMember" xlink:label="pbm_ThirdPartyAdvisorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="pbm_ThirdPartyAdvisorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Convertible note liability (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="pbm_IfrsConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of operations and going concern (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" xlink:label="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="pbm_IfrsConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FirstTrancheNoteMember" xlink:label="pbm_FirstTrancheNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_IfrsConvertibleDebtMember" xlink:to="pbm_FirstTrancheNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_InvestorsMember" xlink:label="pbm_InvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_InvestorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_ParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdAmountForMinimumCashCondition" xlink:label="pbm_ThresholdAmountForMinimumCashCondition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="pbm_ThresholdAmountForMinimumCashCondition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" xlink:label="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentFaceAmount" xlink:label="pbm_IfrsDebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="pbm_IfrsDebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SubscriptionAmount" xlink:label="pbm_SubscriptionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="pbm_SubscriptionAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsProceedsFromConvertibleDebt" xlink:label="pbm_IfrsProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="pbm_IfrsProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ComprehensiveIncomeLoss" xlink:label="pbm_ComprehensiveIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="pbm_ComprehensiveIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PsyenceAustraliaPtyLtd.Member" xlink:label="pbm_PsyenceAustraliaPtyLtd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="pbm_PsyenceAustraliaPtyLtd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PysenceBiomedIICorpMember" xlink:label="pbm_PysenceBiomedIICorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="pbm_PysenceBiomedIICorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NewcourtAcquistionCorpMember" xlink:label="pbm_NewcourtAcquistionCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="pbm_NewcourtAcquistionCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Material accounting policies - historical financial information has been translated to United States dollars (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfChangeInPresentationCurrencyTable" xlink:label="pbm_DisclosureOfChangeInPresentationCurrencyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pbm_DisclosureOfChangeInPresentationCurrencyTable" xlink:to="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:label="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="pbm_DisclosureOfChangeInPresentationCurrencyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_LiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_EquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAndLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="ifrs-full_ExpenseByNatureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_ExpenseByNatureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ProfessionalFeesExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsOperatingIncomeLoss" xlink:label="pbm_IfrsOperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="pbm_IfrsOperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsNonoperatingIncomeExpenseAbstract" xlink:label="pbm_IfrsNonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="pbm_IfrsNonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract" xlink:to="ifrs-full_FinanceIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IncreaseDecreaseInWorkingCapitalAbstract" xlink:label="pbm_IncreaseDecreaseInWorkingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="pbm_IncreaseDecreaseInWorkingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract" xlink:to="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ProceedsFromContributionsOfParent" xlink:label="pbm_ProceedsFromContributionsOfParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="pbm_ProceedsFromContributionsOfParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Reverse takeover transaction with NCAC (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xlink:to="pbm_ReverseTakeoverTransactionWithNcacAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:to="pbm_ReverseTakeoverTransactionWithNcacDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacMember" xlink:label="pbm_NcacMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:to="pbm_NcacMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:to="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsSharePrice" xlink:label="pbm_IfrsSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:to="pbm_IfrsSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:to="pbm_ReverseTakeoverTransactionSharesIssued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Reverse takeover transaction with NCAC - listing expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xlink:to="pbm_ReverseTakeoverTransactionWithNcacAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:to="pbm_ReverseTakeoverTransactionWithNcacDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacMember" xlink:label="pbm_NcacMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:to="pbm_NcacMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:to="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xlink:label="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:to="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xlink:to="pbm_ReverseTakeoverTransactionSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsSharePrice" xlink:label="pbm_IfrsSharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xlink:to="pbm_IfrsSharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xlink:to="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:label="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:to="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:to="ifrs-full_Borrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="ifrs-full_CurrentWarrantLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:to="ifrs-full_CurrentWarrantLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="ifrs-full_NetAssetsLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:to="ifrs-full_NetAssetsLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ListingExpense" xlink:label="pbm_ListingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:to="pbm_ListingExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Convertible note liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="pbm_IfrsConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FirstTrancheNoteMember" xlink:label="pbm_FirstTrancheNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_IfrsConvertibleDebtMember" xlink:to="pbm_FirstTrancheNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_InvestorsMember" xlink:label="pbm_InvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_InvestorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UntilFirstResetDateMember" xlink:label="pbm_UntilFirstResetDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pbm_UntilFirstResetDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OnSecondResetDateMember" xlink:label="pbm_OnSecondResetDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pbm_OnSecondResetDateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" xlink:label="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentFaceAmount" xlink:label="pbm_IfrsDebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_IfrsDebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SubscriptionAmount" xlink:label="pbm_SubscriptionAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_SubscriptionAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsProceedsFromConvertibleDebt" xlink:label="pbm_IfrsProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_IfrsProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtInstrumentConvertibleInitialConversionPrice" xlink:label="pbm_DebtInstrumentConvertibleInitialConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_DebtInstrumentConvertibleInitialConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtInstrumentConvertibleFloorPrice" xlink:label="pbm_DebtInstrumentConvertibleFloorPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_DebtInstrumentConvertibleFloorPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" xlink:label="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PeriodOfClosingDateConsideredForSecondResetDate" xlink:label="pbm_PeriodOfClosingDateConsideredForSecondResetDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_PeriodOfClosingDateConsideredForSecondResetDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" xlink:label="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdPeriodForVolumeWeightedAveragePrice" xlink:label="pbm_ThresholdPeriodForVolumeWeightedAveragePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_ThresholdPeriodForVolumeWeightedAveragePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Convertible note liability -fair value of the convertible notes combined discounted cash flow approach (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="pbm_IfrsConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_UnobservableInputsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SharePriceMeasurementInputMember" xlink:label="pbm_SharePriceMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_SharePriceMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstantPrepaymentRateMeasurementInputMember" xlink:label="ifrs-full_ConstantPrepaymentRateMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_ConstantPrepaymentRateMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DiscountRateSharesMeasurementInputMember" xlink:label="pbm_DiscountRateSharesMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_DiscountRateSharesMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DiscountRateCashMeasurementInputMember" xlink:label="pbm_DiscountRateCashMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_DiscountRateCashMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember" xlink:label="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember" xlink:label="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AnnualInterestRateMeasurementInputMember" xlink:label="pbm_AnnualInterestRateMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_AnnualInterestRateMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentFaceAmount" xlink:label="pbm_IfrsDebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_IfrsDebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnConvertibleNote" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_FairValueAdjustmentOnConvertibleNote" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Derivative warrant liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="pbm_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="pbm_PrivateWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfClassesOfWarrantsOutstanding" xlink:label="pbm_NumberOfClassesOfWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_NumberOfClassesOfWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsIssued" xlink:label="pbm_NumberOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_NumberOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsOutstanding" xlink:label="pbm_NumberOfWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_NumberOfWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DividendYield" xlink:label="pbm_DividendYield" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_DividendYield" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Derivative warrant liabilities - Fair value measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_UnobservableInputsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SharePriceMeasurementInputMember" xlink:label="pbm_SharePriceMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_SharePriceMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExpectedDividendYieldMeasurementInputMember" xlink:label="pbm_ExpectedDividendYieldMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_ExpectedDividendYieldMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExercisePriceMeasurementInputMember" xlink:label="pbm_ExercisePriceMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_ExercisePriceMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="ifrs-full_InterestRateMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_InterestRateMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExpectedLifeMeasurementInputMember" xlink:label="pbm_ExpectedLifeMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="pbm_ExpectedLifeMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="pbm_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="pbm_PrivateWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FinancialLiabilitiesFairValuePerShare" xlink:label="pbm_FinancialLiabilitiesFairValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:to="pbm_FinancialLiabilitiesFairValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Derivative warrant liabilities - Warrant transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="pbm_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="pbm_PrivateWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MovementsOfNumberOfWarrantsRollForward" xlink:label="pbm_MovementsOfNumberOfWarrantsRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_MovementsOfNumberOfWarrantsRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsOutstanding" xlink:label="pbm_NumberOfWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_MovementsOfNumberOfWarrantsRollForward" xlink:to="pbm_NumberOfWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedNumber" xlink:label="pbm_WarrantsIssuedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_MovementsOfNumberOfWarrantsRollForward" xlink:to="pbm_WarrantsIssuedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" xlink:label="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" xlink:to="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedWeightedAverageExercisePrice" xlink:label="pbm_WarrantsIssuedWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" xlink:to="pbm_WarrantsIssuedWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Derivative warrant liabilities - Outstanding and exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedOnJanuary252024Member" xlink:label="pbm_WarrantsIssuedOnJanuary252024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="pbm_WarrantsIssuedOnJanuary252024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsOutstanding" xlink:label="pbm_NumberOfWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_NumberOfWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsExercisable" xlink:label="pbm_NumberOfWarrantsExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="pbm_NumberOfWarrantsExercisable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosurePromissoryNotesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Promissory Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UnsecuredConvertiblePromissoryNotesMember" xlink:label="pbm_UnsecuredConvertiblePromissoryNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="pbm_UnsecuredConvertiblePromissoryNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_ParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_NcacSponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" xlink:label="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="ifrs-full_RepaymentsOfCurrentBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_RepaymentsOfCurrentBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnPromissoryNote" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="pbm_FairValueAdjustmentOnPromissoryNote" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureShareCapitalDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_ParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacMember" xlink:label="pbm_NcacMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_NcacMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThirdPartyAdvisorsMember" xlink:label="pbm_ThirdPartyAdvisorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_ThirdPartyAdvisorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="pbm_ReverseTakeoverTransactionSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_TradeAndOtherPayables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsGainLossOnExtinguishmentOfDebt" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="pbm_IfrsGainLossOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense" xlink:label="ifrs-full_ServicesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ServicesExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureOtherIncomeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Other income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_LoanFromRhCapitalFinanceCo.LlcMember" xlink:label="pbm_LoanFromRhCapitalFinanceCo.LlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="pbm_LoanFromRhCapitalFinanceCo.LlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="ifrs-full_RevenueFromGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="ifrs-full_InterestExpenseOnBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" xlink:label="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BorrowingsMinimumInterestChargeablePeriod" xlink:label="pbm_BorrowingsMinimumInterestChargeablePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="pbm_BorrowingsMinimumInterestChargeablePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment" xlink:label="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Income tax note (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="ifrs-full_DisclosureOfGeographicalAreasTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CA" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="ifrs-full_DisclosureOfGeographicalAreasLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="ifrs-full_ApplicableTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_AccountingProfit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectOflistingExpense" xlink:label="pbm_TaxEffectOflistingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="pbm_TaxEffectOflistingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectOfotherPermanentExpenses" xlink:label="pbm_TaxEffectOfotherPermanentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="pbm_TaxEffectOfotherPermanentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" xlink:label="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Income tax note - Unrecognized deductible temporary differences (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CA" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="country_AU" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_AU" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_LoanLiabilityMember" xlink:label="pbm_LoanLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="pbm_LoanLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxLossesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Income tax note - Non-capital loss carry forwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="ifrs-full_DisclosureOfGeographicalAreasTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="country_AU" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_AU" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CA" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsTaxPeriodAxis" xlink:label="pbm_IfrsTaxPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="pbm_IfrsTaxPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsTaxPeriodDomain" xlink:label="pbm_IfrsTaxPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="pbm_IfrsTaxPeriodAxis" xlink:to="pbm_IfrsTaxPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxYear2044Member" xlink:label="pbm_TaxYear2044Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_IfrsTaxPeriodDomain" xlink:to="pbm_TaxYear2044Member" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IndefinitePeriodMember" xlink:label="pbm_IndefinitePeriodMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_IfrsTaxPeriodDomain" xlink:to="pbm_IndefinitePeriodMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="ifrs-full_DisclosureOfGeographicalAreasLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NonCapitalLossCarryForwards" xlink:label="pbm_NonCapitalLossCarryForwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="pbm_NonCapitalLossCarryForwards" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Financial instruments and financial risk management - Carrying Value of the Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantLiabilitiesMember" xlink:label="pbm_WarrantLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="pbm_WarrantLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="pbm_IfrsConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsPromissoryNoteMember" xlink:label="pbm_IfrsPromissoryNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="pbm_IfrsPromissoryNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightAxis" xlink:label="pbm_IfrsClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="pbm_IfrsClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightDomain" xlink:label="pbm_IfrsClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="pbm_IfrsClassOfWarrantOrRightAxis" xlink:to="pbm_IfrsClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_IfrsClassOfWarrantOrRightDomain" xlink:to="pbm_PrivateWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_IfrsClassOfWarrantOrRightDomain" xlink:to="pbm_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_NcacSponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Financial instruments and financial risk management - Maturity of the Contractual Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="pbm_IfrsConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtIssuedMember" xlink:label="pbm_DebtIssuedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="pbm_DebtIssuedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="pbm_NcacSponsorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_ParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_FinancialLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FinancialLiabilitiesUndiscountedCashFlows" xlink:label="pbm_FinancialLiabilitiesUndiscountedCashFlows" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="pbm_FinancialLiabilitiesUndiscountedCashFlows" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.psyence.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="pbm_IfrsConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FirstTrancheNoteMember" xlink:label="pbm_FirstTrancheNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="pbm_IfrsConvertibleDebtMember" xlink:to="pbm_FirstTrancheNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SecondTrancheNoteMember" xlink:label="pbm_SecondTrancheNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pbm_IfrsConvertibleDebtMember" xlink:to="pbm_SecondTrancheNoteMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" xlink:label="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UnaffiliatedThirdPartyInvestorMember" xlink:label="pbm_UnaffiliatedThirdPartyInvestorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="pbm_UnaffiliatedThirdPartyInvestorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="pbm_PublicWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfConversionNotices" xlink:label="pbm_NumberOfConversionNotices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="pbm_NumberOfConversionNotices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtConversionOriginalDebtAmount1" xlink:label="pbm_IfrsDebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="pbm_IfrsDebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtConversionVolumeWeightedAveragePricePerShare" xlink:label="pbm_DebtConversionVolumeWeightedAveragePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="pbm_DebtConversionVolumeWeightedAveragePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>25
<FILENAME>pbm-20240331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/19/2024 7:08:12 PM-->
<!--Modified on: 8/19/2024 7:08:12 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStatementTable" xlink:label="pbm_IfrsStatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsStatementTable" xlink:to="pbm_IfrsStatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsStatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsStatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStatementLineItems" xlink:label="pbm_IfrsStatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsStatementLineItems" xlink:to="pbm_IfrsStatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsStatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsStatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Financial Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NcacSponsorMember" xlink:to="pbm_NcacSponsorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NcacSponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Newcourt Acquisition Corp (NCAC) Sponsor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NcacSponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NCAC Sponsor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NcacSponsorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NCAC Sponsor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Parent [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Psyence Group Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current restricted cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtCurrent" xlink:label="pbm_IfrsConvertibleDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsConvertibleDebtCurrent" xlink:to="pbm_IfrsConvertibleDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsConvertibleDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsConvertibleDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_IfrsConvertibleDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible note liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="ifrs-full_CurrentWarrantLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentWarrantLiability" xlink:to="ifrs-full_CurrentWarrantLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CurrentWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liabilities (Note 10)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDebtInstrumentsIssued" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current debt instruments issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory notes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Opening balance as at beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET DEFICIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES AND NET DEFICIT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES AND NET DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Net Loss and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="ifrs-full_ExpenseByNatureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNatureAbstract" xlink:to="ifrs-full_ExpenseByNatureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNatureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses by nature [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseByNatureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional and consulting fees</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsOperatingIncomeLoss" xlink:label="pbm_IfrsOperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsOperatingIncomeLoss" xlink:to="pbm_IfrsOperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsOperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The net result for the period of deducting operating expenses from operating revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsOperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsOperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before other items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pbm_IfrsOperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before other items</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsNonoperatingIncomeExpenseAbstract" xlink:label="pbm_IfrsNonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract" xlink:to="pbm_IfrsNonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense" xlink:label="ifrs-full_DepreciationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ListingExpense" xlink:label="pbm_ListingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ListingExpense" xlink:to="pbm_ListingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ListingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of listing expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ListingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Listing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pbm_ListingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Listing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pbm_ListingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Listing Expense</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TransactionExpense" xlink:label="pbm_TransactionExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_TransactionExpense" xlink:to="pbm_TransactionExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_TransactionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of transaction expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_TransactionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pbm_TransactionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_TransactionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction expenses included other costs</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsGainLossOnExtinguishmentOfDebt" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsGainLossOnExtinguishmentOfDebt" xlink:to="pbm_IfrsGainLossOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on debt settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on debt settlement</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnConvertibleNote" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_FairValueAdjustmentOnConvertibleNote" xlink:to="pbm_FairValueAdjustmentOnConvertibleNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of convertible note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment on Convertible Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value loss on convertible note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value loss on convertible note</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsFairValueAdjustmentOfWarrants" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsFairValueAdjustmentOfWarrants" xlink:to="pbm_IfrsFairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value loss on warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value loss on derivative warrant</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnPromissoryNote" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_FairValueAdjustmentOnPromissoryNote" xlink:to="pbm_FairValueAdjustmentOnPromissoryNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment on Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value loss on promissory notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value loss on promissory notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income/(loss)</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" xlink:label="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" xlink:to="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income Loss Net Of Tax Exchange Differences On Translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain/(loss) on translation</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OtherComprehensiveIncomeLoss" xlink:label="pbm_OtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_OtherComprehensiveIncomeLoss" xlink:to="pbm_OtherComprehensiveIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_OtherComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_OtherComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_OtherComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ComprehensiveIncomeLoss" xlink:label="pbm_ComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ComprehensiveIncomeLoss" xlink:to="pbm_ComprehensiveIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pbm_ComprehensiveIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share - basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share - diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of outstanding shares - basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares used in calculating diluted earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of outstanding shares - diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Changes in Shareholder Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember" xlink:label="ifrs-full_OtherReservesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReservesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other reserves [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReservesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThirdPartyAdvisorsMember" xlink:label="pbm_ThirdPartyAdvisorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ThirdPartyAdvisorsMember" xlink:to="pbm_ThirdPartyAdvisorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ThirdPartyAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for third party advisors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ThirdPartyAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Party Advisors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ThirdPartyAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third party advisors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Carve out Consolidated Interim Statements of Change in Shareholder Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Opening balance as at beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase through other contributions by owners, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Psyence Group contribution</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" xlink:to="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued for reverse takeover transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Reverse Takeover Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares, reverse takeover transaction</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock issued during the period for reverse takeover transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Reverse Takeover Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares, reverse takeover transaction (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued to NCAC shareholders</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement" xlink:to="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued for settlement of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Debt Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares for debt settlement</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock issued for debt settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Debt Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares for debt settlement (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued to settle NCAC liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:to="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued for services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash adjustment:</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentsOnPromissoryNote" xlink:label="pbm_FairValueAdjustmentsOnPromissoryNote" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_FairValueAdjustmentsOnPromissoryNote" xlink:to="pbm_FairValueAdjustmentsOnPromissoryNote_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_FairValueAdjustmentsOnPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair
 value of promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_FairValueAdjustmentsOnPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustments On Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_FairValueAdjustmentsOnPromissoryNote_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value loss on promissory notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for unrealised foreign exchange losses (gains)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForListingExpense" xlink:label="pbm_AdjustmentsForListingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_AdjustmentsForListingExpense" xlink:to="pbm_AdjustmentsForListingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_AdjustmentsForListingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for listing expense to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_AdjustmentsForListingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Listing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_AdjustmentsForListingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Listing expense</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForTransactionExpenses" xlink:label="pbm_AdjustmentsForTransactionExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_AdjustmentsForTransactionExpenses" xlink:to="pbm_AdjustmentsForTransactionExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_AdjustmentsForTransactionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for transaction expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_AdjustmentsForTransactionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Transaction Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_AdjustmentsForTransactionExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction expenses</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IncreaseDecreaseInWorkingCapitalAbstract" xlink:label="pbm_IncreaseDecreaseInWorkingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract" xlink:to="pbm_IncreaseDecreaseInWorkingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IncreaseDecreaseInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IncreaseDecreaseInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Working Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IncreaseDecreaseInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in working capital:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in other operating receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in accounts payable and accrued liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions to equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash used for investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromCurrentBorrowings" xlink:label="ifrs-full_ProceedsFromCurrentBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromCurrentBorrowings" xlink:to="ifrs-full_ProceedsFromCurrentBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromCurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from current borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromCurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds received from convertible note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of promissory note</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ProceedsFromContributionsOfParent" xlink:label="pbm_ProceedsFromContributionsOfParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ProceedsFromContributionsOfParent" xlink:to="pbm_ProceedsFromContributionsOfParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ProceedsFromContributionsOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of proceeds from contributions of parent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ProceedsFromContributionsOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Contributions of Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ProceedsFromContributionsOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds received from Psyence Group Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash provided from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash provided from financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NatureOfOperationsAndGoingConcernAbstract" xlink:label="pbm_NatureOfOperationsAndGoingConcernAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NatureOfOperationsAndGoingConcernAbstract" xlink:to="pbm_NatureOfOperationsAndGoingConcernAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NatureOfOperationsAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NatureOfOperationsAndGoingConcernAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of operations and going concern</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of general information about financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of operations and going concern</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BasisOfPresentationAbstract" xlink:label="pbm_BasisOfPresentationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_BasisOfPresentationAbstract" xlink:to="pbm_BasisOfPresentationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaterialAccountingPoliciesAbstract" xlink:label="pbm_MaterialAccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_MaterialAccountingPoliciesAbstract" xlink:to="pbm_MaterialAccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_MaterialAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_MaterialAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material accounting policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of material accounting policy information [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Material accounting policies</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:label="pbm_CriticalAccountingEstimatesAndJudgementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:to="pbm_CriticalAccountingEstimatesAndJudgementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_CriticalAccountingEstimatesAndJudgementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_CriticalAccountingEstimatesAndJudgementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Critical accounting estimates and judgements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting judgements and estimates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Critical accounting estimates and judgements</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionAbstract" xlink:label="pbm_ReverseTakeoverTransactionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ReverseTakeoverTransactionAbstract" xlink:to="pbm_ReverseTakeoverTransactionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ReverseTakeoverTransactionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ReverseTakeoverTransactionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse takeover transaction with NCAC</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacTextBlock" xlink:label="pbm_ReverseTakeoverTransactionWithNcacTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ReverseTakeoverTransactionWithNcacTextBlock" xlink:to="pbm_ReverseTakeoverTransactionWithNcacTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ReverseTakeoverTransactionWithNcacTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse takeover transaction with NCAC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ReverseTakeoverTransactionWithNcacTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction with NCAC [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ReverseTakeoverTransactionWithNcacTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse takeover transaction with NCAC</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalentsAbstract" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_CashRestrictedCashAndCashEquivalentsAbstract" xlink:to="pbm_CashRestrictedCashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, restricted cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalentsTextBlock" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_CashRestrictedCashAndCashEquivalentsTextBlock" xlink:to="pbm_CashRestrictedCashAndCashEquivalentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on cash, restricted cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Restricted Cash and Cash Equivalents [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, restricted cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:to="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:to="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on accounts payable and accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ConvertibleNoteLiabilityAbstract" xlink:label="pbm_ConvertibleNoteLiabilityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ConvertibleNoteLiabilityAbstract" xlink:to="pbm_ConvertibleNoteLiabilityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ConvertibleNoteLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ConvertibleNoteLiabilityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible note liability</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfConvertibleNoteLiabilityTextBlock" xlink:label="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock" xlink:to="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of Convertible note liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Convertible Note Liability [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible note liability</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DerivativeWarrantLiabilitiesAbstract" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract" xlink:to="pbm_DerivativeWarrantLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of derivative financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PromissoryNotesAbstract" xlink:label="pbm_PromissoryNotesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_PromissoryNotesAbstract" xlink:to="pbm_PromissoryNotesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_PromissoryNotesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_PromissoryNotesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Notes</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PromissoryNotesTextBlock" xlink:label="pbm_PromissoryNotesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_PromissoryNotesTextBlock" xlink:to="pbm_PromissoryNotesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_PromissoryNotesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_PromissoryNotesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Notes [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_PromissoryNotesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalAbstract" xlink:label="ifrs-full_IssuedCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_IssuedCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of issued capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsOtherIncomeAbstract" xlink:label="pbm_IfrsOtherIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsOtherIncomeAbstract" xlink:to="pbm_IfrsOtherIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsOtherIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsOtherIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CapitalManagementAbstract" xlink:label="pbm_CapitalManagementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_CapitalManagementAbstract" xlink:to="pbm_CapitalManagementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_CapitalManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_CapitalManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital management</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CapitalManagementDisclosureTextBlock" xlink:label="pbm_CapitalManagementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_CapitalManagementDisclosureTextBlock" xlink:to="pbm_CapitalManagementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_CapitalManagementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on capital management.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_CapitalManagementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Management Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_CapitalManagementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments and financial risk management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial risk management [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments and financial risk management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for determining components of cash and cash equivalents [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for restricted cash and cash equivalents [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for transactions with related parties [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party transactions</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock" xlink:label="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock" xlink:to="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of change in accounting policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description Of Change In Accounting Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in accounting policy</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for provisions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for foreign currency translation [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for share-based payment transactions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:to="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of interests in subsidiaries [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xlink:to="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of nature of change in accounting estimate [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of change in accounting policy</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfListingExpensesTableTextBlock" xlink:label="pbm_ScheduleOfListingExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ScheduleOfListingExpensesTableTextBlock" xlink:to="pbm_ScheduleOfListingExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ScheduleOfListingExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of calculation of listing expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ScheduleOfListingExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Listing Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ScheduleOfListingExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of calculation of listing expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of cash and cash equivalents [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information about equipment</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:to="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accounts payable and accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts Payable and Accrued Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="ifrs-full_BorrowingsByNameMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsConvertibleDebtMember" xlink:to="pbm_IfrsConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible note liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible note liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of quantitative information regarding Level 2 fair value measurements of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of convertible notes combined discounted cash flow</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock" xlink:label="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock" xlink:to="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of warrant transactions and number of warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Warrant Transactions and Number of Warrants Outstanding [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of warrant transactions and the number of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of warrants outstanding and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Warrants Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of warrants outstanding and exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about key management personnel [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of compensation to key management personnel</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of reconciliation of the combined Canadian federal and provincial statutory income tax rate to the effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of unrecognized deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock" xlink:label="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock" xlink:to="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carry forwards, including an assessment of the likelihood of utilization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Summary of Operating Loss Carry Forwards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of non-capital loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value of financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of carrying value of the financial instruments</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock" xlink:label="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock" xlink:to="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thee tabular disclosure of maturity analysis for financial instruments (including derivative and non-derivative instruments) that shows the remaining contractual maturities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Maturity Analysis Of Financial Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturities of contractual obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for business combinations [member]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" xlink:label="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" xlink:to="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Business Combination Agreement with Newcourt Acquisition Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Agreement With Newcourt Acquisition Corp. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination agreement</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FirstTrancheNoteMember" xlink:label="pbm_FirstTrancheNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_FirstTrancheNoteMember" xlink:to="pbm_FirstTrancheNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_FirstTrancheNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for First tranche note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_FirstTrancheNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Tranche Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_FirstTrancheNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Tranche Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Top of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_InvestorsMember" xlink:label="pbm_InvestorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_InvestorsMember" xlink:to="pbm_InvestorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_InvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_InvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_InvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of operations and going concern</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares to acquire</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdAmountForMinimumCashCondition" xlink:label="pbm_ThresholdAmountForMinimumCashCondition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ThresholdAmountForMinimumCashCondition" xlink:to="pbm_ThresholdAmountForMinimumCashCondition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ThresholdAmountForMinimumCashCondition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold amount for minimum cash condition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ThresholdAmountForMinimumCashCondition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Amount For Minimum Cash Condition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ThresholdAmountForMinimumCashCondition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount for minimum cash condition</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" xlink:label="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" xlink:to="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of senior secured convertible notes collectively called as notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Senior Secured Convertible Notes Collectively as Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior secured convertible notes</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentFaceAmount" xlink:label="pbm_IfrsDebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsDebtInstrumentFaceAmount" xlink:to="pbm_IfrsDebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face (par) amount of debt instrument at time of issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_IfrsDebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Note principal amount</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SubscriptionAmount" xlink:label="pbm_SubscriptionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_SubscriptionAmount" xlink:to="pbm_SubscriptionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_SubscriptionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the subscription amounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_SubscriptionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_SubscriptionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount of debt issued</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsProceedsFromConvertibleDebt" xlink:label="pbm_IfrsProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsProceedsFromConvertibleDebt" xlink:to="pbm_IfrsProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds received from convertible note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_IfrsProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total subscription amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of subsidiaries [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiaries [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for subsidiaries [member]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PsyenceAustraliaPtyLtd.Member" xlink:label="pbm_PsyenceAustraliaPtyLtd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_PsyenceAustraliaPtyLtd.Member" xlink:to="pbm_PsyenceAustraliaPtyLtd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_PsyenceAustraliaPtyLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Psyence Australia Pty Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_PsyenceAustraliaPtyLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Psyence Australia Pty Ltd.[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_PsyenceAustraliaPtyLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Psyence Australia Pty Ltd.</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PysenceBiomedIICorpMember" xlink:label="pbm_PysenceBiomedIICorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_PysenceBiomedIICorpMember" xlink:to="pbm_PysenceBiomedIICorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_PysenceBiomedIICorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Pysence Biomed II Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_PysenceBiomedIICorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pysence Biomed II Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_PysenceBiomedIICorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pysence Biomed II Corp.</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NewcourtAcquistionCorpMember" xlink:label="pbm_NewcourtAcquistionCorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NewcourtAcquistionCorpMember" xlink:to="pbm_NewcourtAcquistionCorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NewcourtAcquistionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Newcourt Acquistion Corp.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NewcourtAcquistionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Newcourt Acquistion Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NewcourtAcquistionCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Newcourt Acquistion Corp.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of subsidiaries [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment in subsidiaries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">% ownership</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfChangeInPresentationCurrencyTable" xlink:label="pbm_DisclosureOfChangeInPresentationCurrencyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DisclosureOfChangeInPresentationCurrencyTable" xlink:to="pbm_DisclosureOfChangeInPresentationCurrencyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DisclosureOfChangeInPresentationCurrencyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to presentation currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DisclosureOfChangeInPresentationCurrencyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Change In Presentation Currency [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:to="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative effect at date of initial application [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Opening balance before adjustment, cumulative effect at date of initial application [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reported</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:to="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Opening balance after adjustment, cumulative effect at date of initial application [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Translation</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:label="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:to="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information presentation currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Disclosing Change In Presentation Currency [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity attributable to owners of parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClosingForeignExchangeRate" xlink:to="ifrs-full_ClosingForeignExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing foreign exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average foreign exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average rate</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsSharePrice" xlink:label="pbm_IfrsSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsSharePrice" xlink:to="pbm_IfrsSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of a single share of a number of saleable stocks of a company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing trading price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_IfrsSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the common shares</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xlink:to="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to reverse takeover transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Detailed Information About Reverse Takeover Transaction with NCAC [Table]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:to="pbm_ReverseTakeoverTransactionWithNcacAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction with NCAC [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction with NCAC [Axis]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:to="pbm_ReverseTakeoverTransactionWithNcacDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for reverse takeover transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction with NCAC [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction with NCAC [Domain]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacMember" xlink:label="pbm_NcacMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NcacMember" xlink:to="pbm_NcacMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NcacMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Newcourt Acquisition Corp (NCAC).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NcacMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NCAC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NcacMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NCAC</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:to="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Detailed Information About Reverse Takeover Transaction with NCAC [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse takeover transaction with NCAC</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ReverseTakeoverTransactionSharesIssued" xlink:to="pbm_ReverseTakeoverTransactionSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares issued as consideration to shareholders in reverse takeover transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration shares issued to NCAC shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration shares issued</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xlink:label="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xlink:to="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction, Consideration Paid [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration paid:</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" xlink:to="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed consideration amount for the common shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction, Deemed Consideration Amount for Common Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed consideration amount for the common shares issued</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:label="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:to="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse Takeover Transaction, Net Identifiable Liability Acquired [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net identifiable liabilities acquired:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NCAC promissory note (Note 11)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="ifrs-full_NetAssetsLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetAssetsLiabilities" xlink:to="ifrs-full_NetAssetsLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetAssetsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets (liabilities)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NetAssetsLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net liabilities acquired</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice" xlink:label="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice" xlink:to="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in listing expense from change in estimate of share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Listing Expense From Change in Estimate of Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in listing expense from change in estimate of share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BalancesWithBanks" xlink:to="ifrs-full_BalancesWithBanks_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BalancesWithBanks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balances with banks</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BalancesWithBanks_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrestricted cash held with chartered banks</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalents" xlink:label="pbm_CashRestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_CashRestrictedCashAndCashEquivalents" xlink:to="pbm_CashRestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_CashRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash, restricted cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_CashRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Restricted Cash and Cash Equivalents, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pbm_CashRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross carrying amount [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation, amortisation and impairment [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Charge for the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals classified as current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="ifrs-full_OtherShorttermProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherShorttermProvisions" xlink:to="ifrs-full_OtherShorttermProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherShorttermProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherShorttermProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UntilFirstResetDateMember" xlink:label="pbm_UntilFirstResetDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_UntilFirstResetDateMember" xlink:to="pbm_UntilFirstResetDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_UntilFirstResetDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for until the First Reset Date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_UntilFirstResetDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Until the First Reset Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_UntilFirstResetDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Until the First Reset Date</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OnSecondResetDateMember" xlink:label="pbm_OnSecondResetDateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_OnSecondResetDateMember" xlink:to="pbm_OnSecondResetDateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_OnSecondResetDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands on the second reset date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_OnSecondResetDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">On the Second Reset Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_OnSecondResetDateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">On the Second Reset Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtInstrumentConvertibleInitialConversionPrice" xlink:label="pbm_DebtInstrumentConvertibleInitialConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DebtInstrumentConvertibleInitialConversionPrice" xlink:to="pbm_DebtInstrumentConvertibleInitialConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DebtInstrumentConvertibleInitialConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The price per share of the conversion feature embedded in the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DebtInstrumentConvertibleInitialConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Initial Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DebtInstrumentConvertibleInitialConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Conversion Price</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtInstrumentConvertibleFloorPrice" xlink:label="pbm_DebtInstrumentConvertibleFloorPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DebtInstrumentConvertibleFloorPrice" xlink:to="pbm_DebtInstrumentConvertibleFloorPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DebtInstrumentConvertibleFloorPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The floor price per share of the conversion feature embedded in the debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DebtInstrumentConvertibleFloorPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible Floor Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DebtInstrumentConvertibleFloorPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion floor price</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" xlink:label="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" xlink:to="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of days prior to effective initial registration statement for first reset date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Days Prior to Effective Initial Registration Statement for First Reset Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of days prior to effective initial registration statement for first reset date</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PeriodOfClosingDateConsideredForSecondResetDate" xlink:label="pbm_PeriodOfClosingDateConsideredForSecondResetDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_PeriodOfClosingDateConsideredForSecondResetDate" xlink:to="pbm_PeriodOfClosingDateConsideredForSecondResetDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_PeriodOfClosingDateConsideredForSecondResetDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period of closing date considered for second reset date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_PeriodOfClosingDateConsideredForSecondResetDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of Closing Date Considered for Second Reset Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_PeriodOfClosingDateConsideredForSecondResetDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of closing date considered for second reset date</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" xlink:label="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" xlink:to="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold period for payment of price difference between VWAP and conversion price in cash or in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period for Payment of Price Difference Between VWAP and Conversion Price in Cash or in Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period for payment of price difference between VWAP and conversion price in cash or in shares</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdPeriodForVolumeWeightedAveragePrice" xlink:label="pbm_ThresholdPeriodForVolumeWeightedAveragePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ThresholdPeriodForVolumeWeightedAveragePrice" xlink:to="pbm_ThresholdPeriodForVolumeWeightedAveragePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ThresholdPeriodForVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold period for volume-weighted average price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ThresholdPeriodForVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Period for Volume-weighted Average Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ThresholdPeriodForVolumeWeightedAveragePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period for volume-weighted average price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnobservableInputsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unobservable inputs [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UnobservableInputsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unobservable inputs [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_UnobservableInputsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnobservableInputsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unobservable inputs [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UnobservableInputsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unobservable inputs [member]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SharePriceMeasurementInputMember" xlink:label="pbm_SharePriceMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_SharePriceMeasurementInputMember" xlink:to="pbm_SharePriceMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_SharePriceMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for share price used as a measurement input.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_SharePriceMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price, Measurement Input [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_SharePriceMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstantPrepaymentRateMeasurementInputMember" xlink:label="ifrs-full_ConstantPrepaymentRateMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConstantPrepaymentRateMeasurementInputMember" xlink:to="ifrs-full_ConstantPrepaymentRateMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConstantPrepaymentRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Constant prepayment rate, measurement input [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ConstantPrepaymentRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayment Amount</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DiscountRateSharesMeasurementInputMember" xlink:label="pbm_DiscountRateSharesMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DiscountRateSharesMeasurementInputMember" xlink:to="pbm_DiscountRateSharesMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DiscountRateSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for a discount rate, shares used as a measurement input used in valuation techniques based on a present value calculation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DiscountRateSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount Rate, Shares, Measurement Input [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DiscountRateSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate shares</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DiscountRateCashMeasurementInputMember" xlink:label="pbm_DiscountRateCashMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DiscountRateCashMeasurementInputMember" xlink:to="pbm_DiscountRateCashMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DiscountRateCashMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for a discount rate, cash used as a measurement input used in valuation techniques based on a present value calculation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DiscountRateCashMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount Rate, Cash, Measurement Input [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DiscountRateCashMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discount rate cash</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember" xlink:label="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember" xlink:to="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the historical annual volatility for shares used as a measurement input.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Historical Annual Volatility for Shares, Measurement Input [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility annual</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember" xlink:label="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember" xlink:to="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the historical daily volatility for shares used as a measurement input.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Historical Daily Volatility for Shares, Measurement Input [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility daily</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AnnualInterestRateMeasurementInputMember" xlink:label="pbm_AnnualInterestRateMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_AnnualInterestRateMeasurementInputMember" xlink:to="pbm_AnnualInterestRateMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_AnnualInterestRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for an annual interest rate used as a measurement input.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_AnnualInterestRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Interest Rate, Measurement Input [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_AnnualInterestRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free annual</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantUnobservableInputLiabilities" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant unobservable input, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Measurement input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible note, Measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial instruments [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial instruments [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments, class [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments, class [member]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_PublicWarrantsMember" xlink:to="pbm_PublicWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for public warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_PublicWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public warrants</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_PrivateWarrantsMember" xlink:to="pbm_PrivateWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_PrivateWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for private warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_PrivateWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_PrivateWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfClassesOfWarrantsOutstanding" xlink:label="pbm_NumberOfClassesOfWarrantsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NumberOfClassesOfWarrantsOutstanding" xlink:to="pbm_NumberOfClassesOfWarrantsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NumberOfClassesOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of classes of warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NumberOfClassesOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Classes of Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NumberOfClassesOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of classes of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsIssued" xlink:label="pbm_NumberOfWarrantsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NumberOfWarrantsIssued" xlink:to="pbm_NumberOfWarrantsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NumberOfWarrantsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsOutstanding" xlink:label="pbm_NumberOfWarrantsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NumberOfWarrantsOutstanding" xlink:to="pbm_NumberOfWarrantsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="pbm_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants outstanding, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="pbm_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants outstanding, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per share, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price per share, Beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants per share</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DividendYield" xlink:label="pbm_DividendYield" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DividendYield" xlink:to="pbm_DividendYield_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DividendYield_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DividendYield_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DividendYield_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExpectedDividendYieldMeasurementInputMember" xlink:label="pbm_ExpectedDividendYieldMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ExpectedDividendYieldMeasurementInputMember" xlink:to="pbm_ExpectedDividendYieldMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ExpectedDividendYieldMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for expected dividend yield used as a measurement input.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ExpectedDividendYieldMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Dividend Yield, Measurement Input [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ExpectedDividendYieldMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExercisePriceMeasurementInputMember" xlink:label="pbm_ExercisePriceMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ExercisePriceMeasurementInputMember" xlink:to="pbm_ExercisePriceMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ExercisePriceMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for exercise price used as a measurement input.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ExercisePriceMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Price, Measurement Input [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ExercisePriceMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="ifrs-full_InterestRateMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateMeasurementInputMember" xlink:to="ifrs-full_InterestRateMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate, measurement input [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExpectedLifeMeasurementInputMember" xlink:label="pbm_ExpectedLifeMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_ExpectedLifeMeasurementInputMember" xlink:to="pbm_ExpectedLifeMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_ExpectedLifeMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for expected life used as a measurement input.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_ExpectedLifeMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Life, Measurement Input [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_ExpectedLifeMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Historical volatility for shares, measurement input [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Levels of fair value hierarchy [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Levels of fair value hierarchy [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All levels of fair value hierarchy [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All levels of fair value hierarchy [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2 of fair value hierarchy [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quantitative information regarding Level 2 fair value measurements</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FinancialLiabilitiesFairValuePerShare" xlink:label="pbm_FinancialLiabilitiesFairValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_FinancialLiabilitiesFairValuePerShare" xlink:to="pbm_FinancialLiabilitiesFairValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_FinancialLiabilitiesFairValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value per share of financial liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_FinancialLiabilitiesFairValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities, Fair Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_FinancialLiabilitiesFairValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value per warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains (losses) on change in fair value of derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value loss</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MovementsOfNumberOfWarrantsRollForward" xlink:label="pbm_MovementsOfNumberOfWarrantsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_MovementsOfNumberOfWarrantsRollForward" xlink:to="pbm_MovementsOfNumberOfWarrantsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_MovementsOfNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_MovementsOfNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movements of Number of Warrants [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_MovementsOfNumberOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedNumber" xlink:label="pbm_WarrantsIssuedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_WarrantsIssuedNumber" xlink:to="pbm_WarrantsIssuedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_WarrantsIssuedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_WarrantsIssuedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_WarrantsIssuedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" xlink:label="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" xlink:to="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movements of Weighted Average Exercise Price of Warrants [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedWeightedAverageExercisePrice" xlink:label="pbm_WarrantsIssuedWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_WarrantsIssuedWeightedAverageExercisePrice" xlink:to="pbm_WarrantsIssuedWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_WarrantsIssuedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price per share or per unit of warrants or rights issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_WarrantsIssuedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_WarrantsIssuedWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued, Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedOnJanuary252024Member" xlink:label="pbm_WarrantsIssuedOnJanuary252024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_WarrantsIssuedOnJanuary252024Member" xlink:to="pbm_WarrantsIssuedOnJanuary252024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_WarrantsIssuedOnJanuary252024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for warrants issued on January 25, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_WarrantsIssuedOnJanuary252024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued on January 25, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_WarrantsIssuedOnJanuary252024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued on January 25, 2024</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsExercisable" xlink:label="pbm_NumberOfWarrantsExercisable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NumberOfWarrantsExercisable" xlink:to="pbm_NumberOfWarrantsExercisable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NumberOfWarrantsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NumberOfWarrantsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NumberOfWarrantsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants Exercisable</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UnsecuredConvertiblePromissoryNotesMember" xlink:label="pbm_UnsecuredConvertiblePromissoryNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_UnsecuredConvertiblePromissoryNotesMember" xlink:to="pbm_UnsecuredConvertiblePromissoryNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_UnsecuredConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to unsecured convertible promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_UnsecuredConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unsecured Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_UnsecuredConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unsecured convertible promissory note</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" xlink:label="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" xlink:to="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the scenario where notes be payable on the date that is the one-year anniversary after the Business Combination, or January 25, 2025.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable On The Date Of That Is The One-Year Anniversary After The Business Combination Or January 25, 2025 Closing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes payable on the date that is the one-year anniversary after the Business Combination, or January 25, 2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="ifrs-full_RepaymentsOfCurrentBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfCurrentBorrowings" xlink:to="ifrs-full_RepaymentsOfCurrentBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfCurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of current borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RepaymentsOfCurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense" xlink:label="ifrs-full_ServicesExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesExpense" xlink:to="ifrs-full_ServicesExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ServicesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Services expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ServicesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Services rendered</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" xlink:to="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to the other income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Detailed Information About Other Income [Table]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_LoanFromRhCapitalFinanceCo.LlcMember" xlink:label="pbm_LoanFromRhCapitalFinanceCo.LlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_LoanFromRhCapitalFinanceCo.LlcMember" xlink:to="pbm_LoanFromRhCapitalFinanceCo.LlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_LoanFromRhCapitalFinanceCo.LlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Loan from RH Capital Finance Co., LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_LoanFromRhCapitalFinanceCo.LlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan From RH Capital Finance Co., LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_LoanFromRhCapitalFinanceCo.LlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan From RH Capital Finance Co., LLC</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:to="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Detailed Information About Other Income [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rebate amount of research and development expenses received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnBorrowings" xlink:to="ifrs-full_InterestExpenseOnBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" xlink:label="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" xlink:to="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum percentage of rebate for the research &amp; development expenses under the research &amp; development tax incentive program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Percentage Of Rebate On Research &amp; Development Tax Incentive Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of rebate on eligible research and development expenses</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BorrowingsMinimumInterestChargeablePeriod" xlink:label="pbm_BorrowingsMinimumInterestChargeablePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_BorrowingsMinimumInterestChargeablePeriod" xlink:to="pbm_BorrowingsMinimumInterestChargeablePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_BorrowingsMinimumInterestChargeablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum interest chargeable period of borrowings in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_BorrowingsMinimumInterestChargeablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, Minimum Interest Chargeable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_BorrowingsMinimumInterestChargeablePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum interest chargeable period</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment" xlink:label="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment" xlink:to="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period to repay the borrowings after the notice assessment received related to the research and development refunds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, Period To Repay After Notice Of Assessment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment period after notice of assessment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel compensation, short-term employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel compensation, share-based payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of options and restricted stock units granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="ifrs-full_DisclosureOfGeographicalAreasTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="ifrs-full_DisclosureOfGeographicalAreasTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeographicalAreasTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of geographical areas [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeographicalAreasTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of geographical areas [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CA_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CANADA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CA_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canada</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="ifrs-full_DisclosureOfGeographicalAreasLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeographicalAreasLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of geographical areas [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeographicalAreasLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of statutory income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of accounting profit multiplied by applicable tax rates [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of the statutory income tax rate to the effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccountingProfit" xlink:to="ifrs-full_AccountingProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccountingProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccountingProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income/(Loss) before recovery of income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income) at applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected income tax (recovery)/expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax effect of foreign tax rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Difference in foreign tax rates</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectOflistingExpense" xlink:label="pbm_TaxEffectOflistingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_TaxEffectOflistingExpense" xlink:to="pbm_TaxEffectOflistingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_TaxEffectOflistingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to listing expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_TaxEffectOflistingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect of Listing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_TaxEffectOflistingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Listing expense</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectOfotherPermanentExpenses" xlink:label="pbm_TaxEffectOfotherPermanentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_TaxEffectOfotherPermanentExpenses" xlink:to="pbm_TaxEffectOfotherPermanentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_TaxEffectOfotherPermanentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to other permanent expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_TaxEffectOfotherPermanentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect of Other Permanent Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_TaxEffectOfotherPermanentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other permanent expenses</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" xlink:label="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" xlink:to="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to change in tax benefits not recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect From Change in Tax Benefits Not Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in tax benefits not recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (recovery)/expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of geographical areas [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="country_AU" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AUSTRALIA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_AU_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Australia</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_LoanLiabilityMember" xlink:label="pbm_LoanLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_LoanLiabilityMember" xlink:to="pbm_LoanLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_LoanLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for loan liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_LoanLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pbm_LoanLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesMember" xlink:to="ifrs-full_UnusedTaxLossesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unused tax losses [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UnusedTaxLossesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-capital losses carried forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deductible temporary differences for which no deferred tax asset is recognised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsTaxPeriodAxis" xlink:label="pbm_IfrsTaxPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsTaxPeriodAxis" xlink:to="pbm_IfrsTaxPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsTaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsTaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Tax Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsTaxPeriodDomain" xlink:label="pbm_IfrsTaxPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsTaxPeriodDomain" xlink:to="pbm_IfrsTaxPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsTaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsTaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Tax Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxYear2044Member" xlink:label="pbm_TaxYear2044Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_TaxYear2044Member" xlink:to="pbm_TaxYear2044Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_TaxYear2044Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Identified as tax year 2044.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_TaxYear2044Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Year 2044 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_TaxYear2044Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2044</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IndefinitePeriodMember" xlink:label="pbm_IndefinitePeriodMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IndefinitePeriodMember" xlink:to="pbm_IndefinitePeriodMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IndefinitePeriodMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the indefinite period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IndefinitePeriodMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite Period [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IndefinitePeriodMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indefinite</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NonCapitalLossCarryForwards" xlink:label="pbm_NonCapitalLossCarryForwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NonCapitalLossCarryForwards" xlink:to="pbm_NonCapitalLossCarryForwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NonCapitalLossCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-capital loss carry forwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NonCapitalLossCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-capital Loss Carry Forwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NonCapitalLossCarryForwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-capital loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of liabilities [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1 of fair value hierarchy [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 of fair value hierarchy [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, class [member]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantLiabilitiesMember" xlink:label="pbm_WarrantLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_WarrantLiabilitiesMember" xlink:to="pbm_WarrantLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_WarrantLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsPromissoryNoteMember" xlink:label="pbm_IfrsPromissoryNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsPromissoryNoteMember" xlink:to="pbm_IfrsPromissoryNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsPromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsPromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Promissory Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsPromissoryNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Note</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightAxis" xlink:label="pbm_IfrsClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsClassOfWarrantOrRightAxis" xlink:to="pbm_IfrsClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by type of warrant or right issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightDomain" xlink:label="pbm_IfrsClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsClassOfWarrantOrRightDomain" xlink:to="pbm_IfrsClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments and financial risk management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial liabilities [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated time bands [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Not later than one year [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less than 1 year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Later than one year and not later than three years [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Between 1 and 3 year</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember" xlink:to="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing accounts payable and accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Accounts Payable and Accrued Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtIssuedMember" xlink:label="pbm_DebtIssuedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DebtIssuedMember" xlink:to="pbm_DebtIssuedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DebtIssuedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to debt issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DebtIssuedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issued [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DebtIssuedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments and financial risk management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FinancialLiabilitiesUndiscountedCashFlows" xlink:label="pbm_FinancialLiabilitiesUndiscountedCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_FinancialLiabilitiesUndiscountedCashFlows" xlink:to="pbm_FinancialLiabilitiesUndiscountedCashFlows_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_FinancialLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contractual undiscounted cash flows in relation to financial liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_FinancialLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Undiscounted Cash Flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_FinancialLiabilitiesUndiscountedCashFlows_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Cash Flows</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption" xlink:label="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption" xlink:to="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The reasonably possible percentage of the change in the designated risk component used to determine the value of the financial instrument.  Excludes defined benefit plan obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Reasonably Possible Change in Risk Assumption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fluctuation in foreign exchange rates (as a percent)</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent" xlink:label="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent" xlink:to="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in profit and loss as a result of an change in a designated risk component that was reasonably possible at the end of the reporting period.  Excludes defined benefit plan obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Profit or Loss Due To Reasonably Possible Change In Designated Risk Component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impact to profit or loss from fluctuation in foreign exchange rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-adjusting events after reporting period [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [member]</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SecondTrancheNoteMember" xlink:label="pbm_SecondTrancheNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_SecondTrancheNoteMember" xlink:to="pbm_SecondTrancheNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_SecondTrancheNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Second tranche note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_SecondTrancheNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Tranche Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_SecondTrancheNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Tranche Note</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UnaffiliatedThirdPartyInvestorMember" xlink:label="pbm_UnaffiliatedThirdPartyInvestorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_UnaffiliatedThirdPartyInvestorMember" xlink:to="pbm_UnaffiliatedThirdPartyInvestorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_UnaffiliatedThirdPartyInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for information pertaining to shares issued to the third party consultants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_UnaffiliatedThirdPartyInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaffiliated Third Party Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_UnaffiliatedThirdPartyInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unaffiliated third-party investor</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" xlink:label="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" xlink:to="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for information pertaining to shares issued to the third party consultants and legal advisors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued to Third Party Consultants And Legal Advisors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued to third-party consultants and legal advisors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-adjusting events after reporting period [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds received from convertible note</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfConversionNotices" xlink:label="pbm_NumberOfConversionNotices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_NumberOfConversionNotices" xlink:to="pbm_NumberOfConversionNotices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_NumberOfConversionNotices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of conversion notices received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_NumberOfConversionNotices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Conversion Notices</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_NumberOfConversionNotices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of conversion notices</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtConversionOriginalDebtAmount1" xlink:label="pbm_IfrsDebtConversionOriginalDebtAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsDebtConversionOriginalDebtAmount1" xlink:to="pbm_IfrsDebtConversionOriginalDebtAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsDebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsDebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Debt Conversion Original Debt Amount1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsDebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount of debt converted</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtConversionVolumeWeightedAveragePricePerShare" xlink:label="pbm_DebtConversionVolumeWeightedAveragePricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_DebtConversionVolumeWeightedAveragePricePerShare" xlink:to="pbm_DebtConversionVolumeWeightedAveragePricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_DebtConversionVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the volume weighted average price per share in the event of debt conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_DebtConversionVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Volume Weighted Average Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_DebtConversionVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volume weighted average price per share</label>
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period as a result of the conversion of convertible securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock issued upon conversion of debt</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>26
<FILENAME>pbm-20240331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/19/2024 7:08:12 PM-->
<!--Modified on: 8/19/2024 7:08:12 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.psyence.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfFinancialPosition" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfChangesInShareholderEquity" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureNatureOfOperationsAndGoingConcern" roleURI="http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcern" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureBasisOfPresentation" roleURI="http://www.psyence.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureMaterialAccountingPolicies" roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureCriticalAccountingEstimatesAndJudgements" roleURI="http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureReverseTakeoverTransactionWithNcac" roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcac" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureCashRestrictedCashAndCashEquivalents" roleURI="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureEquipment" roleURI="http://www.psyence.com/role/DisclosureEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureAccountsPayableAndAccruedLiabilities" roleURI="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureConvertibleNoteLiability" roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilities" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosurePromissoryNotes" roleURI="http://www.psyence.com/role/DisclosurePromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureShareCapital" roleURI="http://www.psyence.com/role/DisclosureShareCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureOtherIncome" roleURI="http://www.psyence.com/role/DisclosureOtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureCapitalManagement" roleURI="http://www.psyence.com/role/DisclosureCapitalManagement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureTransactionsWithRelatedParties" roleURI="http://www.psyence.com/role/DisclosureTransactionsWithRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureShareBasedCompensation" roleURI="http://www.psyence.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNote" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNote" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureFinancialInstrumentsAndFinancialRiskManagement" roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureSubsequentEvents" roleURI="http://www.psyence.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureMaterialAccountingPoliciesPolicies" roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureBasisOfPresentationTables" roleURI="http://www.psyence.com/role/DisclosureBasisOfPresentationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureMaterialAccountingPoliciesTables" roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureReverseTakeoverTransactionWithNcacTables" roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureCashRestrictedCashAndCashEquivalentsTables" roleURI="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureEquipmentTables" roleURI="http://www.psyence.com/role/DisclosureEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesTables" roleURI="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureConvertibleNoteLiabilityTables" roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesTables" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureTransactionsWithRelatedPartiesTables" roleURI="http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNoteTables" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureFinancialInstrumentsAndFinancialRiskManagementTables" roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureNatureOfOperationsAndGoingConcernDetails" roleURI="http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.psyence.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails" roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureMaterialAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureCriticalAccountingEstimatesAndJudgementsDetails" roleURI="http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureReverseTakeoverTransactionWithNcacDetails" roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails" roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails" roleURI="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureCashRestrictedCashAndCashEquivalentsDetails" roleURI="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureEquipmentDetails" roleURI="http://www.psyence.com/role/DisclosureEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureAccountsPayableAndAccruedLiabilitiesDetails" roleURI="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureConvertibleNoteLiabilityDetails" roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails" roleURI="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesDetails" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails" roleURI="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosurePromissoryNotesDetails" roleURI="http://www.psyence.com/role/DisclosurePromissoryNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureShareCapitalDetails" roleURI="http://www.psyence.com/role/DisclosureShareCapitalDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureOtherIncomeDetails" roleURI="http://www.psyence.com/role/DisclosureOtherIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails" roleURI="http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.psyence.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNoteDetails" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails" roleURI="http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails" roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails" roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails" roleURI="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pbm-20240331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.psyence.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.psyence.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638596912912840111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638596912912840111" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638596912912840111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638596912912840111" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638596912912840111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638596912912840111" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638596912912840111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638596912912840111" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638596912912840111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638596912912840111" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638596912912850115" order="6" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStatementTable" xlink:label="pbm_IfrsStatementTable_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="pbm_IfrsStatementTable_638596912912850115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsStatementTable_638596912912850115" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912912850115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912912850115" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912912850115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912912850115" xlink:to="pbm_NcacSponsorMember_638596912912850115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912912850115" xlink:to="ifrs-full_ParentMember_638596912912850115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStatementLineItems" xlink:label="pbm_IfrsStatementLineItems_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsStatementTable_638596912912850115" xlink:to="pbm_IfrsStatementLineItems_638596912912850115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsStatementLineItems_638596912912850115" xlink:to="ifrs-full_AssetsAbstract_638596912912850115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638596912912850115" xlink:to="ifrs-full_CurrentAssetsAbstract_638596912912850115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638596912912850115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912912850115" xlink:to="ifrs-full_CashAndCashEquivalents_638596912912850115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912912850115" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912912860114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912912850115" xlink:to="ifrs-full_OtherCurrentReceivables_638596912912860114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912912850115" xlink:to="ifrs-full_CurrentPrepayments_638596912912860114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912912850115" xlink:to="ifrs-full_CurrentAssets_638596912912860114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638596912912850115" xlink:to="ifrs-full_NoncurrentAssetsAbstract_638596912912860114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638596912912860114" xlink:to="ifrs-full_PropertyPlantAndEquipment_638596912912860114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638596912912850115" xlink:to="ifrs-full_Assets_638596912912860114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsStatementLineItems_638596912912850115" xlink:to="ifrs-full_LiabilitiesAbstract_638596912912860114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638596912912860114" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_638596912912860114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638596912912860114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638596912912860114" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638596912912860114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtCurrent" xlink:label="pbm_IfrsConvertibleDebtCurrent_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638596912912860114" xlink:to="pbm_IfrsConvertibleDebtCurrent_638596912912870124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="ifrs-full_CurrentWarrantLiability_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638596912912860114" xlink:to="ifrs-full_CurrentWarrantLiability_638596912912870124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638596912912860114" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued_638596912912870124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638596912912860114" xlink:to="ifrs-full_Liabilities_638596912912870124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsStatementLineItems_638596912912850115" xlink:to="ifrs-full_EquityAbstract_638596912912870124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638596912912870124" xlink:to="ifrs-full_IssuedCapital_638596912912870124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638596912912870124" xlink:to="ifrs-full_RetainedEarnings_638596912912870124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638596912912870124" xlink:to="ifrs-full_OtherReserves_638596912912870124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638596912912870124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638596912912870124" xlink:to="ifrs-full_Equity_638596912912870124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsStatementLineItems_638596912912850115" xlink:to="ifrs-full_EquityAndLiabilities_638596912912880116" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="ifrs-full_ExpenseByNatureAbstract_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ExpenseByNatureAbstract_638596912912880116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract_638596912912880116" xlink:to="ifrs-full_SalesAndMarketingExpense_638596912912880116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract_638596912912880116" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638596912912880116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract_638596912912880116" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638596912912880116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract_638596912912880116" xlink:to="ifrs-full_ProfessionalFeesExpense_638596912912880116" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsOperatingIncomeLoss" xlink:label="pbm_IfrsOperatingIncomeLoss_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="pbm_IfrsOperatingIncomeLoss_638596912912880116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsNonoperatingIncomeExpenseAbstract" xlink:label="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome_638596912912880116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="ifrs-full_OtherIncome_638596912912880116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense" xlink:label="ifrs-full_DepreciationExpense_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="ifrs-full_DepreciationExpense_638596912912890157" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="ifrs-full_FinanceIncome_638596912912890157" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="ifrs-full_FinanceCosts_638596912912890157" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_638596912912890157" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ListingExpense" xlink:label="pbm_ListingExpense_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="pbm_ListingExpense_638596912912890157" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TransactionExpense" xlink:label="pbm_TransactionExpense_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="pbm_TransactionExpense_638596912912890157" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsGainLossOnExtinguishmentOfDebt" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912912890157" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnConvertibleNote" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="pbm_FairValueAdjustmentOnConvertibleNote_638596912912890157" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsFairValueAdjustmentOfWarrants" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="pbm_IfrsFairValueAdjustmentOfWarrants_638596912912890157" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnPromissoryNote" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912912880116" xlink:to="pbm_FairValueAdjustmentOnPromissoryNote_638596912912890157" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638596912912890157" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_638596912912890157" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_638596912912900115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_638596912912900115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation" xlink:label="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation_638596912912900115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_638596912912900115" xlink:to="pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation_638596912912900115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OtherComprehensiveIncomeLoss" xlink:label="pbm_OtherComprehensiveIncomeLoss_638596912912900115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_638596912912900115" xlink:to="pbm_OtherComprehensiveIncomeLoss_638596912912900115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ComprehensiveIncomeLoss" xlink:label="pbm_ComprehensiveIncomeLoss_638596912912900115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="pbm_ComprehensiveIncomeLoss_638596912912900115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638596912912900115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638596912912900115" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_638596912912900115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare_638596912912900115" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_638596912912900115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares_638596912912900115" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares_638596912912900115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares_638596912912900115" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Changes in Shareholder Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_638596912912910118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638596912912910118" xlink:to="ifrs-full_ComponentsOfEquityAxis_638596912912910118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638596912912910118" xlink:to="ifrs-full_IssuedCapitalMember_638596912912910118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReservesMember" xlink:label="ifrs-full_OtherReservesMember_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638596912912910118" xlink:to="ifrs-full_OtherReservesMember_638596912912910118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638596912912910118" xlink:to="ifrs-full_RetainedEarningsMember_638596912912910118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638596912912910118" xlink:to="ifrs-full_EquityMember_638596912912910118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638596912912910118" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912912910118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912912910118" xlink:to="ifrs-full_ParentMember_638596912912910118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912912910118" xlink:to="pbm_NcacSponsorMember_638596912912910118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912912910118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912912910118" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912912910118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638596912912910118" xlink:to="srt_CounterpartyNameAxis_638596912912920115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThirdPartyAdvisorsMember" xlink:label="pbm_ThirdPartyAdvisorsMember_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638596912912920115" xlink:to="pbm_ThirdPartyAdvisorsMember_638596912912920115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638596912912920115" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638596912912920115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638596912912910118" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="ifrs-full_Equity_638596912912920115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="ifrs-full_NumberOfSharesOutstanding_638596912912920115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners_638596912912920115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction_638596912912920115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_638596912912920115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement" xlink:label="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement_638596912912920115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement_638596912912920115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_638596912912930116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_638596912912930116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_638596912912930116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="ifrs-full_IssueOfEquity_638596912912930116" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_638596912912930116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_638596912912930116" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638596912912930116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="ifrs-full_ProfitLoss_638596912912930116" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_638596912912930116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="ifrs-full_OtherComprehensiveIncome_638596912912930116" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638596912912930116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="ifrs-full_Equity_638596912912930116" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638596912912930116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638596912912920115" xlink:to="ifrs-full_NumberOfSharesOutstanding_638596912912930116" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProfitLoss_638596912912940117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnConvertibleNote" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="pbm_FairValueAdjustmentOnConvertibleNote_638596912912940117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsFairValueAdjustmentOfWarrants" xlink:label="pbm_IfrsFairValueAdjustmentOfWarrants_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="pbm_IfrsFairValueAdjustmentOfWarrants_638596912912940117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentsOnPromissoryNote" xlink:label="pbm_FairValueAdjustmentsOnPromissoryNote_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="pbm_FairValueAdjustmentsOnPromissoryNote_638596912912940117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsGainLossOnExtinguishmentOfDebt" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912912940117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638596912912940117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_638596912912940117" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638596912912940117" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForListingExpense" xlink:label="pbm_AdjustmentsForListingExpense_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="pbm_AdjustmentsForListingExpense_638596912912940117" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForTransactionExpenses" xlink:label="pbm_AdjustmentsForTransactionExpenses_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="pbm_AdjustmentsForTransactionExpenses_638596912912940117" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IncreaseDecreaseInWorkingCapitalAbstract" xlink:label="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912912940117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912912940117" xlink:to="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912912940117" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912912940117" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638596912912950116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912912940117" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_638596912912950116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912912940117" xlink:to="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638596912912950116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912912950116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638596912912950116" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638596912912950116" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromCurrentBorrowings" xlink:label="ifrs-full_ProceedsFromCurrentBorrowings_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_ProceedsFromCurrentBorrowings_638596912912950116" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638596912912950116" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ProceedsFromContributionsOfParent" xlink:label="pbm_ProceedsFromContributionsOfParent_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="pbm_ProceedsFromContributionsOfParent_638596912912950116" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912912950116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912912950116" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_638596912912960121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_638596912912960121" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638596912912960121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_638596912912960121" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6385969129129601211" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_6385969129129601211" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcern" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of operations and going concern" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NatureOfOperationsAndGoingConcernAbstract" xlink:label="pbm_NatureOfOperationsAndGoingConcernAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_638596912912960121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_NatureOfOperationsAndGoingConcernAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_638596912912960121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BasisOfPresentationAbstract" xlink:label="pbm_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638596912912960121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_BasisOfPresentationAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638596912912960121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureMaterialAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Material accounting policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaterialAccountingPoliciesAbstract" xlink:label="pbm_MaterialAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:label="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_638596912912970119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_638596912912970119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgements" xlink:type="extended" xlink:title="10401 - Disclosure - Critical accounting estimates and judgements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:label="pbm_CriticalAccountingEstimatesAndJudgementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_638596912912970119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_638596912912970119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcac" xlink:type="extended" xlink:title="10501 - Disclosure - Reverse takeover transaction with NCAC" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionAbstract" xlink:label="pbm_ReverseTakeoverTransactionAbstract_1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacTextBlock" xlink:label="pbm_ReverseTakeoverTransactionWithNcacTextBlock_638596912912970119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionAbstract_1" xlink:to="pbm_ReverseTakeoverTransactionWithNcacTextBlock_638596912912970119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalents" xlink:type="extended" xlink:title="10601 - Disclosure - Cash, restricted cash and cash equivalents" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalentsAbstract" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsAbstract" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalentsTextBlock" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsTextBlock_638596912912970119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_CashRestrictedCashAndCashEquivalentsAbstract" xlink:to="pbm_CashRestrictedCashAndCashEquivalentsTextBlock_638596912912970119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureEquipment" xlink:type="extended" xlink:title="10701 - Disclosure - Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_638596912912980118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_638596912912980118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilities" xlink:type="extended" xlink:title="10801 - Disclosure - Accounts payable and accrued liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock_638596912912980118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:to="pbm_AccountsPayableAndAccruedLiabilitiesTextBlock_638596912912980118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureConvertibleNoteLiability" xlink:type="extended" xlink:title="10901 - Disclosure - Convertible note liability" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ConvertibleNoteLiabilityAbstract" xlink:label="pbm_ConvertibleNoteLiabilityAbstract" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfConvertibleNoteLiabilityTextBlock" xlink:label="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock_638596912912980118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ConvertibleNoteLiabilityAbstract" xlink:to="pbm_DisclosureOfConvertibleNoteLiabilityTextBlock_638596912912980118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilities" xlink:type="extended" xlink:title="11001 - Disclosure - Derivative warrant liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DerivativeWarrantLiabilitiesAbstract" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_638596912912980118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory_638596912912980118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosurePromissoryNotes" xlink:type="extended" xlink:title="11101 - Disclosure - Promissory Notes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PromissoryNotesAbstract" xlink:label="pbm_PromissoryNotesAbstract" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PromissoryNotesTextBlock" xlink:label="pbm_PromissoryNotesTextBlock_638596912912990118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_PromissoryNotesAbstract" xlink:to="pbm_PromissoryNotesTextBlock_638596912912990118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureShareCapital" xlink:type="extended" xlink:title="11201 - Disclosure - Share capital" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalAbstract" xlink:label="ifrs-full_IssuedCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory_638596912912990118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract" xlink:to="ifrs-full_DisclosureOfIssuedCapitalExplanatory_638596912912990118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureOtherIncome" xlink:type="extended" xlink:title="11301 - Disclosure - Other income" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsOtherIncomeAbstract" xlink:label="pbm_IfrsOtherIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638596912912990118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsOtherIncomeAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638596912912990118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureCapitalManagement" xlink:type="extended" xlink:title="11401 - Disclosure - Capital management" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CapitalManagementAbstract" xlink:label="pbm_CapitalManagementAbstract" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CapitalManagementDisclosureTextBlock" xlink:label="pbm_CapitalManagementDisclosureTextBlock_638596912912990118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_CapitalManagementAbstract" xlink:to="pbm_CapitalManagementDisclosureTextBlock_638596912912990118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureTransactionsWithRelatedParties" xlink:type="extended" xlink:title="11501 - Disclosure - Transactions with related parties" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_638596912913000116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_638596912913000116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="11601 - Disclosure - Share based compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638596912913000116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638596912913000116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNote" xlink:type="extended" xlink:title="11701 - Disclosure - Income tax note" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_638596912913000116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_638596912913000116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagement" xlink:type="extended" xlink:title="11801 - Disclosure - Financial instruments and financial risk management" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_638596912913000116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_638596912913000116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11901 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638596912913010124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Material accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaterialAccountingPoliciesAbstract" xlink:label="pbm_MaterialAccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_638596912913010124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents" xlink:label="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents_638596912913010124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_638596912913010124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory_638596912913010124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock" xlink:label="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock_638596912913010124" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory_638596912913010124" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_638596912913010124" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_638596912913010124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_638596912913010124" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_638596912913020119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_638596912913020119" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_638596912913020119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_638596912913020119" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_638596912913020119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_1" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_638596912913020119" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureBasisOfPresentationTables" xlink:type="extended" xlink:title="30203 - Disclosure - Basis of presentation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BasisOfPresentationAbstract" xlink:label="pbm_BasisOfPresentationAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory" xlink:label="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_638596912913020119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_BasisOfPresentationAbstract_1" xlink:to="ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory_638596912913020119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Material accounting policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaterialAccountingPoliciesAbstract" xlink:label="pbm_MaterialAccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate" xlink:label="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_638596912913020119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_2" xlink:to="ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate_638596912913020119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacTables" xlink:type="extended" xlink:title="30503 - Disclosure - Reverse takeover transaction with NCAC (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionAbstract" xlink:label="pbm_ReverseTakeoverTransactionAbstract" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfListingExpensesTableTextBlock" xlink:label="pbm_ScheduleOfListingExpensesTableTextBlock_638596912913030119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionAbstract" xlink:to="pbm_ScheduleOfListingExpensesTableTextBlock_638596912913030119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Cash, restricted cash and cash equivalents (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalentsAbstract" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_638596912913030119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_CashRestrictedCashAndCashEquivalentsAbstract_1" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_638596912913030119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureEquipmentTables" xlink:type="extended" xlink:title="30703 - Disclosure - Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_638596912913030119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_1" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_638596912913030119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Accounts payable and accrued liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock_638596912913030119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_1" xlink:to="pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock_638596912913030119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables" xlink:type="extended" xlink:title="30903 - Disclosure - Convertible note liability (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ConvertibleNoteLiabilityAbstract" xlink:label="pbm_ConvertibleNoteLiabilityAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ConvertibleNoteLiabilityAbstract_2" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913040118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913040118" xlink:to="ifrs-full_BorrowingsByNameAxis_638596912913040118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638596912913040118" xlink:to="ifrs-full_BorrowingsByNameMember_638596912913040118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638596912913040118" xlink:to="pbm_IfrsConvertibleDebtMember_638596912913040118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913040118" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913040118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913040118" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_638596912913040118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Derivative warrant liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DerivativeWarrantLiabilitiesAbstract" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract_1" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_638596912913040118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock" xlink:label="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract_1" xlink:to="pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock_638596912913040118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_638596912913040118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract_1" xlink:to="pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_638596912913040118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesTables" xlink:type="extended" xlink:title="31503 - Disclosure - Transactions with related parties (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_638596912913050119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_1" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_638596912913050119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNoteTables" xlink:type="extended" xlink:title="31703 - Disclosure - Income tax note (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638596912913050119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1" xlink:to="pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638596912913050119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_638596912913050119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_638596912913050119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock" xlink:label="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock_638596912913050119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_1" xlink:to="pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock_638596912913050119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementTables" xlink:type="extended" xlink:title="31803 - Disclosure - Financial instruments and financial risk management (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory_638596912913060125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock" xlink:label="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:to="pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock_638596912913060125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of operations and going concern (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NatureOfOperationsAndGoingConcernAbstract" xlink:label="pbm_NatureOfOperationsAndGoingConcernAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_NatureOfOperationsAndGoingConcernAbstract_1" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638596912913060125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638596912913060125" xlink:to="ifrs-full_BusinessCombinationsAxis_638596912913060125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638596912913060125" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638596912913060125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member" xlink:label="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638596912913060125" xlink:to="pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_638596912913060125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638596912913060125" xlink:to="ifrs-full_BorrowingsByNameAxis_638596912913060125" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638596912913060125" xlink:to="ifrs-full_BorrowingsByNameMember_638596912913060125" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638596912913060125" xlink:to="pbm_IfrsConvertibleDebtMember_638596912913060125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FirstTrancheNoteMember" xlink:label="pbm_FirstTrancheNoteMember_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsConvertibleDebtMember_638596912913060125" xlink:to="pbm_FirstTrancheNoteMember_638596912913060125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638596912913060125" xlink:to="ifrs-full_RangeAxis_638596912913060125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638596912913060125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638596912913060125" xlink:to="ifrs-full_RangesMember_638596912913060125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638596912913060125" xlink:to="ifrs-full_TopOfRangeMember_638596912913070121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638596912913060125" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913070121" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913070121" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913070121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_InvestorsMember" xlink:label="pbm_InvestorsMember_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913070121" xlink:to="pbm_InvestorsMember_638596912913070121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913070121" xlink:to="ifrs-full_ParentMember_638596912913070121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638596912913060125" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_638596912913070121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdAmountForMinimumCashCondition" xlink:label="pbm_ThresholdAmountForMinimumCashCondition_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="pbm_ThresholdAmountForMinimumCashCondition_638596912913070121" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" xlink:label="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes_638596912913070121" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentFaceAmount" xlink:label="pbm_IfrsDebtInstrumentFaceAmount_638596912913070121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="pbm_IfrsDebtInstrumentFaceAmount_638596912913070121" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SubscriptionAmount" xlink:label="pbm_SubscriptionAmount_638596912913080119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="pbm_SubscriptionAmount_638596912913080119" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638596912913080119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="ifrs-full_NotionalAmount_638596912913080119" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsProceedsFromConvertibleDebt" xlink:label="pbm_IfrsProceedsFromConvertibleDebt_638596912913080119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="pbm_IfrsProceedsFromConvertibleDebt_638596912913080119" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_638596912913080119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_638596912913080119" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ComprehensiveIncomeLoss" xlink:label="pbm_ComprehensiveIncomeLoss_638596912913080119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638596912913070121" xlink:to="pbm_ComprehensiveIncomeLoss_638596912913080119" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BasisOfPresentationAbstract" xlink:label="pbm_BasisOfPresentationAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638596912913080119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_BasisOfPresentationAbstract_2" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638596912913080119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638596912913080119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638596912913080119" xlink:to="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638596912913080119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_638596912913090119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_638596912913080119" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_638596912913090119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PsyenceAustraliaPtyLtd.Member" xlink:label="pbm_PsyenceAustraliaPtyLtd.Member_638596912913090119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_638596912913090119" xlink:to="pbm_PsyenceAustraliaPtyLtd.Member_638596912913090119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PysenceBiomedIICorpMember" xlink:label="pbm_PysenceBiomedIICorpMember_638596912913090119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_638596912913090119" xlink:to="pbm_PysenceBiomedIICorpMember_638596912913090119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NewcourtAcquistionCorpMember" xlink:label="pbm_NewcourtAcquistionCorpMember_638596912913090119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForSubsidiariesMember_638596912913090119" xlink:to="pbm_NewcourtAcquistionCorpMember_638596912913090119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638596912913090119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable_638596912913080119" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638596912913090119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638596912913090119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems_638596912913090119" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638596912913090119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Material accounting policies - historical financial information has been translated to United States dollars (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaterialAccountingPoliciesAbstract" xlink:label="pbm_MaterialAccountingPoliciesAbstract_3" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfChangeInPresentationCurrencyTable" xlink:label="pbm_DisclosureOfChangeInPresentationCurrencyTable_638596912913090119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_3" xlink:to="pbm_DisclosureOfChangeInPresentationCurrencyTable_638596912913090119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis" xlink:label="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_638596912913120119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfChangeInPresentationCurrencyTable_638596912913090119" xlink:to="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_638596912913120119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_638596912913120119" xlink:to="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_638596912913130119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_638596912913130119" xlink:to="ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_638596912913130119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember" xlink:label="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_638596912913130119" xlink:to="ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_638596912913130119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems" xlink:label="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfChangeInPresentationCurrencyTable_638596912913090119" xlink:to="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_AssetsAbstract_638596912913130119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638596912913130119" xlink:to="ifrs-full_CurrentAssetsAbstract_638596912913130119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912913130119" xlink:to="ifrs-full_CashAndCashEquivalents_638596912913130119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912913130119" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912913130119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912913130119" xlink:to="ifrs-full_OtherCurrentReceivables_638596912913130119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912913130119" xlink:to="ifrs-full_CurrentPrepayments_638596912913130119" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638596912913130119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638596912913130119" xlink:to="ifrs-full_CurrentAssets_638596912913130119" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638596912913130119" xlink:to="ifrs-full_Assets_638596912913140122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_LiabilitiesAbstract_638596912913140122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638596912913140122" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_638596912913140122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638596912913140122" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638596912913140122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638596912913140122" xlink:to="ifrs-full_Liabilities_638596912913140122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_EquityAbstract_638596912913140122" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638596912913140122" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_638596912913140122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638596912913140122" xlink:to="ifrs-full_Equity_638596912913140122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638596912913140122" xlink:to="ifrs-full_EquityAndLiabilities_638596912913140122" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract" xlink:label="ifrs-full_ExpenseByNatureAbstract_638596912913140122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_ExpenseByNatureAbstract_638596912913140122" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638596912913150120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract_638596912913140122" xlink:to="ifrs-full_SalesAndMarketingExpense_638596912913150120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638596912913150120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract_638596912913140122" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638596912913150120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638596912913150120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract_638596912913140122" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638596912913150120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638596912913150120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExpenseByNatureAbstract_638596912913140122" xlink:to="ifrs-full_ProfessionalFeesExpense_638596912913150120" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsOperatingIncomeLoss" xlink:label="pbm_IfrsOperatingIncomeLoss_638596912913150120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="pbm_IfrsOperatingIncomeLoss_638596912913150120" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsNonoperatingIncomeExpenseAbstract" xlink:label="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912913150120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912913150120" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638596912913150120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912913150120" xlink:to="ifrs-full_FinanceIncome_638596912913150120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_638596912913150120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsNonoperatingIncomeExpenseAbstract_638596912913150120" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_638596912913150120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638596912913160128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_ProfitLoss_638596912913160128" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912913160128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912913160128" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638596912913160128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912913160128" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638596912913160128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638596912913160128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912913160128" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_638596912913160128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IncreaseDecreaseInWorkingCapitalAbstract" xlink:label="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912913160128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638596912913160128" xlink:to="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912913160128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638596912913160128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912913160128" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638596912913160128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_638596912913160128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912913160128" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_638596912913160128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638596912913170126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IncreaseDecreaseInWorkingCapitalAbstract_638596912913160128" xlink:to="pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638596912913170126" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912913170126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638596912913170126" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ProceedsFromContributionsOfParent" xlink:label="pbm_ProceedsFromContributionsOfParent_638596912913170126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="pbm_ProceedsFromContributionsOfParent_638596912913170126" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912913170126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638596912913170126" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_638596912913170126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_638596912913170126" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638596912913170126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_CashAndCashEquivalents_638596912913170126" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6385969129131701261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems_638596912913130119" xlink:to="ifrs-full_CashAndCashEquivalents_6385969129131701261" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Material accounting policies - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaterialAccountingPoliciesAbstract" xlink:label="pbm_MaterialAccountingPoliciesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate_638596912913180123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_4" xlink:to="ifrs-full_ClosingForeignExchangeRate_638596912913180123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate_638596912913180123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MaterialAccountingPoliciesAbstract_4" xlink:to="ifrs-full_AverageForeignExchangeRate_638596912913180123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Critical accounting estimates and judgements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CriticalAccountingEstimatesAndJudgementsAbstract" xlink:label="pbm_CriticalAccountingEstimatesAndJudgementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsSharePrice" xlink:label="pbm_IfrsSharePrice_638596912913180123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_CriticalAccountingEstimatesAndJudgementsAbstract_1" xlink:to="pbm_IfrsSharePrice_638596912913180123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Reverse takeover transaction with NCAC (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionAbstract" xlink:label="pbm_ReverseTakeoverTransactionAbstract_2" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionAbstract_2" xlink:to="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_638596912913190122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_638596912913190122" xlink:to="pbm_ReverseTakeoverTransactionWithNcacAxis_638596912913190122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionWithNcacAxis_638596912913190122" xlink:to="pbm_ReverseTakeoverTransactionWithNcacDomain_638596912913190122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacMember" xlink:label="pbm_NcacMember_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionWithNcacDomain_638596912913190122" xlink:to="pbm_NcacMember_638596912913190122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_638596912913190122" xlink:to="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913190122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsSharePrice" xlink:label="pbm_IfrsSharePrice_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913190122" xlink:to="pbm_IfrsSharePrice_638596912913190122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913190122" xlink:to="pbm_ReverseTakeoverTransactionSharesIssued_638596912913190122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Reverse takeover transaction with NCAC - listing expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionAbstract" xlink:label="pbm_ReverseTakeoverTransactionAbstract_3" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionAbstract_3" xlink:to="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_638596912913190122" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacAxis" xlink:label="pbm_ReverseTakeoverTransactionWithNcacAxis_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_638596912913190122" xlink:to="pbm_ReverseTakeoverTransactionWithNcacAxis_638596912913190122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionWithNcacDomain" xlink:label="pbm_ReverseTakeoverTransactionWithNcacDomain_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionWithNcacAxis_638596912913190122" xlink:to="pbm_ReverseTakeoverTransactionWithNcacDomain_638596912913190122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacMember" xlink:label="pbm_NcacMember_638596912913190122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionWithNcacDomain_638596912913190122" xlink:to="pbm_NcacMember_638596912913190122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems" xlink:label="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable_638596912913190122" xlink:to="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913200124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionConsiderationPaidAbstract" xlink:label="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913200124" xlink:to="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_638596912913200124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_638596912913200124" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_638596912913200124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_638596912913200124" xlink:to="pbm_ReverseTakeoverTransactionSharesIssued_638596912913200124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsSharePrice" xlink:label="pbm_IfrsSharePrice_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_638596912913200124" xlink:to="pbm_IfrsSharePrice_638596912913200124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionConsiderationPaidAbstract_638596912913200124" xlink:to="pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued_638596912913200124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract" xlink:label="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913200124" xlink:to="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_638596912913200124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_638596912913200124" xlink:to="ifrs-full_CashAndCashEquivalents_638596912913200124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_638596912913200124" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638596912913200124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_638596912913200124" xlink:to="ifrs-full_Borrowings_638596912913200124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentWarrantLiability" xlink:label="ifrs-full_CurrentWarrantLiability_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_638596912913200124" xlink:to="ifrs-full_CurrentWarrantLiability_638596912913200124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NetAssetsLiabilities" xlink:label="ifrs-full_NetAssetsLiabilities_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract_638596912913200124" xlink:to="ifrs-full_NetAssetsLiabilities_638596912913200124" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ListingExpense" xlink:label="pbm_ListingExpense_638596912913200124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems_638596912913200124" xlink:to="pbm_ListingExpense_638596912913200124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Reverse takeover transaction with NCAC - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionAbstract" xlink:label="pbm_ReverseTakeoverTransactionAbstract_4" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TransactionExpense" xlink:label="pbm_TransactionExpense_638596912913210124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionAbstract_4" xlink:to="pbm_TransactionExpense_638596912913210124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice" xlink:label="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice_638596912913210124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ReverseTakeoverTransactionAbstract_4" xlink:to="pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice_638596912913210124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Cash, restricted cash and cash equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalentsAbstract" xlink:label="pbm_CashRestrictedCashAndCashEquivalentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks_638596912913210124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_CashRestrictedCashAndCashEquivalentsAbstract_2" xlink:to="ifrs-full_BalancesWithBanks_638596912913210124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912913210124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_CashRestrictedCashAndCashEquivalentsAbstract_2" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638596912913210124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_CashRestrictedCashAndCashEquivalents" xlink:label="pbm_CashRestrictedCashAndCashEquivalents_638596912913210124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_CashRestrictedCashAndCashEquivalentsAbstract_2" xlink:to="pbm_CashRestrictedCashAndCashEquivalents_638596912913210124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureEquipmentDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_2" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638596912913220117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638596912913220117" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638596912913220117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638596912913220117" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638596912913220117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638596912913220117" xlink:to="ifrs-full_ComputerEquipmentMember_638596912913220117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638596912913220117" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638596912913220117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_638596912913220117" xlink:to="ifrs-full_CarryingAmountMember_638596912913220117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638596912913220117" xlink:to="ifrs-full_GrossCarryingAmountMember_638596912913220117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountMember_638596912913220117" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_638596912913220117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638596912913220117" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638596912913220117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638596912913220117" xlink:to="ifrs-full_PropertyPlantAndEquipment_638596912913220117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638596912913220117" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_638596912913220117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_638596912913220117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638596912913220117" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_638596912913220117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638596912913230126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638596912913220117" xlink:to="ifrs-full_PropertyPlantAndEquipment_638596912913230126" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Accounts payable and accrued liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638596912913230126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_2" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638596912913230126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent_638596912913230126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_2" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent_638596912913230126" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherShorttermProvisions" xlink:label="ifrs-full_OtherShorttermProvisions_638596912913230126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_2" xlink:to="ifrs-full_OtherShorttermProvisions_638596912913230126" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638596912913230126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock_2" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638596912913230126" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Convertible note liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ConvertibleNoteLiabilityAbstract" xlink:label="pbm_ConvertibleNoteLiabilityAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913230126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ConvertibleNoteLiabilityAbstract_1" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913230126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638596912913230126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913230126" xlink:to="ifrs-full_BorrowingsByNameAxis_638596912913230126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638596912913230126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638596912913230126" xlink:to="ifrs-full_BorrowingsByNameMember_638596912913230126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638596912913230126" xlink:to="pbm_IfrsConvertibleDebtMember_638596912913240105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FirstTrancheNoteMember" xlink:label="pbm_FirstTrancheNoteMember_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsConvertibleDebtMember_638596912913240105" xlink:to="pbm_FirstTrancheNoteMember_638596912913240105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913230126" xlink:to="srt_RangeAxis_638596912913240105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638596912913240105" xlink:to="ifrs-full_RangesMember_638596912913240105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638596912913240105" xlink:to="ifrs-full_TopOfRangeMember_638596912913240105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913230126" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913240105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913240105" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913240105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_InvestorsMember" xlink:label="pbm_InvestorsMember_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913240105" xlink:to="pbm_InvestorsMember_638596912913240105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913230126" xlink:to="srt_StatementScenarioAxis_638596912913240105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638596912913240105" xlink:to="srt_ScenarioUnspecifiedDomain_638596912913240105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UntilFirstResetDateMember" xlink:label="pbm_UntilFirstResetDateMember_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638596912913240105" xlink:to="pbm_UntilFirstResetDateMember_638596912913240105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_OnSecondResetDateMember" xlink:label="pbm_OnSecondResetDateMember_638596912913240105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638596912913240105" xlink:to="pbm_OnSecondResetDateMember_638596912913240105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913230126" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes" xlink:label="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes_638596912913250174" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentFaceAmount" xlink:label="pbm_IfrsDebtInstrumentFaceAmount_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_IfrsDebtInstrumentFaceAmount_638596912913250174" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SubscriptionAmount" xlink:label="pbm_SubscriptionAmount_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_SubscriptionAmount_638596912913250174" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="ifrs-full_NotionalAmount_638596912913250174" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsProceedsFromConvertibleDebt" xlink:label="pbm_IfrsProceedsFromConvertibleDebt_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_IfrsProceedsFromConvertibleDebt_638596912913250174" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="ifrs-full_BorrowingsInterestRate_638596912913250174" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtInstrumentConvertibleInitialConversionPrice" xlink:label="pbm_DebtInstrumentConvertibleInitialConversionPrice_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_DebtInstrumentConvertibleInitialConversionPrice_638596912913250174" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtInstrumentConvertibleFloorPrice" xlink:label="pbm_DebtInstrumentConvertibleFloorPrice_638596912913250174" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_DebtInstrumentConvertibleFloorPrice_638596912913250174" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate" xlink:label="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate_638596912913260137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate_638596912913260137" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PeriodOfClosingDateConsideredForSecondResetDate" xlink:label="pbm_PeriodOfClosingDateConsideredForSecondResetDate_638596912913260137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_PeriodOfClosingDateConsideredForSecondResetDate_638596912913260137" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares" xlink:label="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares_638596912913260137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares_638596912913260137" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThresholdPeriodForVolumeWeightedAveragePrice" xlink:label="pbm_ThresholdPeriodForVolumeWeightedAveragePrice_638596912913260137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913250174" xlink:to="pbm_ThresholdPeriodForVolumeWeightedAveragePrice_638596912913260137" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Convertible note liability -fair value of the convertible notes combined discounted cash flow approach (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ConvertibleNoteLiabilityAbstract" xlink:label="pbm_ConvertibleNoteLiabilityAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913260137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_ConvertibleNoteLiabilityAbstract_3" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913260137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638596912913260137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913260137" xlink:to="ifrs-full_BorrowingsByNameAxis_638596912913260137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638596912913260137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638596912913260137" xlink:to="ifrs-full_BorrowingsByNameMember_638596912913260137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember_638596912913260137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638596912913260137" xlink:to="pbm_IfrsConvertibleDebtMember_638596912913260137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913260137" xlink:to="ifrs-full_UnobservableInputsAxis_638596912913270128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsAxis_638596912913270128" xlink:to="ifrs-full_UnobservableInputsMember_638596912913270128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SharePriceMeasurementInputMember" xlink:label="pbm_SharePriceMeasurementInputMember_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913270128" xlink:to="pbm_SharePriceMeasurementInputMember_638596912913270128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ConstantPrepaymentRateMeasurementInputMember" xlink:label="ifrs-full_ConstantPrepaymentRateMeasurementInputMember_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913270128" xlink:to="ifrs-full_ConstantPrepaymentRateMeasurementInputMember_638596912913270128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DiscountRateSharesMeasurementInputMember" xlink:label="pbm_DiscountRateSharesMeasurementInputMember_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913270128" xlink:to="pbm_DiscountRateSharesMeasurementInputMember_638596912913270128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DiscountRateCashMeasurementInputMember" xlink:label="pbm_DiscountRateCashMeasurementInputMember_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913270128" xlink:to="pbm_DiscountRateCashMeasurementInputMember_638596912913270128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember" xlink:label="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913270128" xlink:to="pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_638596912913270128" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember" xlink:label="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913270128" xlink:to="pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_638596912913270128" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_AnnualInterestRateMeasurementInputMember" xlink:label="pbm_AnnualInterestRateMeasurementInputMember_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913270128" xlink:to="pbm_AnnualInterestRateMeasurementInputMember_638596912913270128" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913260137" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913270128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913270128" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities_638596912913270128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtInstrumentFaceAmount" xlink:label="pbm_IfrsDebtInstrumentFaceAmount_638596912913270128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913270128" xlink:to="pbm_IfrsDebtInstrumentFaceAmount_638596912913270128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913270128" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_638596912913280120" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnConvertibleNote" xlink:label="pbm_FairValueAdjustmentOnConvertibleNote_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913270128" xlink:to="pbm_FairValueAdjustmentOnConvertibleNote_638596912913280120" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Derivative warrant liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DerivativeWarrantLiabilitiesAbstract" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract_2" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913280120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913280120" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913280120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913280120" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913280120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913280120" xlink:to="pbm_PublicWarrantsMember_638596912913280120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913280120" xlink:to="pbm_PrivateWarrantsMember_638596912913280120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913280120" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913280120" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfClassesOfWarrantsOutstanding" xlink:label="pbm_NumberOfClassesOfWarrantsOutstanding_638596912913280120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913280120" xlink:to="pbm_NumberOfClassesOfWarrantsOutstanding_638596912913280120" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsIssued" xlink:label="pbm_NumberOfWarrantsIssued_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913280120" xlink:to="pbm_NumberOfWarrantsIssued_638596912913290118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsOutstanding" xlink:label="pbm_NumberOfWarrantsOutstanding_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913280120" xlink:to="pbm_NumberOfWarrantsOutstanding_638596912913290118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913280120" xlink:to="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638596912913290118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913280120" xlink:to="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638596912913290118" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DividendYield" xlink:label="pbm_DividendYield_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913280120" xlink:to="pbm_DividendYield_638596912913290118" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Derivative warrant liabilities - Fair value measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DerivativeWarrantLiabilitiesAbstract" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract_3" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_638596912913290118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_638596912913290118" xlink:to="ifrs-full_UnobservableInputsAxis_638596912913290118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsAxis_638596912913290118" xlink:to="ifrs-full_UnobservableInputsMember_638596912913290118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SharePriceMeasurementInputMember" xlink:label="pbm_SharePriceMeasurementInputMember_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913290118" xlink:to="pbm_SharePriceMeasurementInputMember_638596912913290118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExpectedDividendYieldMeasurementInputMember" xlink:label="pbm_ExpectedDividendYieldMeasurementInputMember_638596912913290118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913290118" xlink:to="pbm_ExpectedDividendYieldMeasurementInputMember_638596912913290118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExercisePriceMeasurementInputMember" xlink:label="pbm_ExercisePriceMeasurementInputMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913290118" xlink:to="pbm_ExercisePriceMeasurementInputMember_638596912913300117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="ifrs-full_InterestRateMeasurementInputMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913290118" xlink:to="ifrs-full_InterestRateMeasurementInputMember_638596912913300117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ExpectedLifeMeasurementInputMember" xlink:label="pbm_ExpectedLifeMeasurementInputMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913290118" xlink:to="pbm_ExpectedLifeMeasurementInputMember_638596912913300117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638596912913290118" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_638596912913300117" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_638596912913290118" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_638596912913300117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_638596912913300117" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_638596912913300117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_638596912913300117" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_638596912913300117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_638596912913290118" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913300117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913300117" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913300117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913300117" xlink:to="pbm_PublicWarrantsMember_638596912913300117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913300117" xlink:to="pbm_PrivateWarrantsMember_638596912913300117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_638596912913300117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable_638596912913290118" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_638596912913300117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_638596912913310117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_638596912913300117" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities_638596912913310117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_638596912913310117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_638596912913300117" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_638596912913310117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FinancialLiabilitiesFairValuePerShare" xlink:label="pbm_FinancialLiabilitiesFairValuePerShare_638596912913310117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_638596912913300117" xlink:to="pbm_FinancialLiabilitiesFairValuePerShare_638596912913310117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_638596912913310117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems_638596912913300117" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_638596912913310117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Derivative warrant liabilities - Warrant transactions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DerivativeWarrantLiabilitiesAbstract" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913310117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract_4" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913310117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913310117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913310117" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913310117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913310117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913310117" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913310117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember_638596912913310117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913310117" xlink:to="pbm_PublicWarrantsMember_638596912913310117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember_638596912913320119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913310117" xlink:to="pbm_PrivateWarrantsMember_638596912913320119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913320119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913310117" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913320119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MovementsOfNumberOfWarrantsRollForward" xlink:label="pbm_MovementsOfNumberOfWarrantsRollForward_638596912913320119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913320119" xlink:to="pbm_MovementsOfNumberOfWarrantsRollForward_638596912913320119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsOutstanding" xlink:label="pbm_NumberOfWarrantsOutstanding_638596912913320119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MovementsOfNumberOfWarrantsRollForward_638596912913320119" xlink:to="pbm_NumberOfWarrantsOutstanding_638596912913320119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedNumber" xlink:label="pbm_WarrantsIssuedNumber_638596912913320119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MovementsOfNumberOfWarrantsRollForward_638596912913320119" xlink:to="pbm_WarrantsIssuedNumber_638596912913320119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsOutstanding" xlink:label="pbm_NumberOfWarrantsOutstanding_6385969129133201191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MovementsOfNumberOfWarrantsRollForward_638596912913320119" xlink:to="pbm_NumberOfWarrantsOutstanding_6385969129133201191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward" xlink:label="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_638596912913320119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913320119" xlink:to="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_638596912913320119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638596912913320119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_638596912913320119" xlink:to="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638596912913320119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedWeightedAverageExercisePrice" xlink:label="pbm_WarrantsIssuedWeightedAverageExercisePrice_638596912913320119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_638596912913320119" xlink:to="pbm_WarrantsIssuedWeightedAverageExercisePrice_638596912913320119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_6385969129133201191" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward_638596912913320119" xlink:to="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_6385969129133201191" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Derivative warrant liabilities - Outstanding and exercisable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DerivativeWarrantLiabilitiesAbstract" xlink:label="pbm_DerivativeWarrantLiabilitiesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DerivativeWarrantLiabilitiesAbstract_5" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913330124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913330124" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913330124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913330124" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913330124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantsIssuedOnJanuary252024Member" xlink:label="pbm_WarrantsIssuedOnJanuary252024Member_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913330124" xlink:to="pbm_WarrantsIssuedOnJanuary252024Member_638596912913330124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638596912913330124" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913330124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913330124" xlink:to="pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638596912913330124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsOutstanding" xlink:label="pbm_NumberOfWarrantsOutstanding_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913330124" xlink:to="pbm_NumberOfWarrantsOutstanding_638596912913330124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfWarrantsExercisable" xlink:label="pbm_NumberOfWarrantsExercisable_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638596912913330124" xlink:to="pbm_NumberOfWarrantsExercisable_638596912913330124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosurePromissoryNotesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Promissory Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PromissoryNotesAbstract" xlink:label="pbm_PromissoryNotesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_PromissoryNotesAbstract_1" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913330124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913330124" xlink:to="ifrs-full_BorrowingsByNameAxis_638596912913330124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638596912913330124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638596912913330124" xlink:to="ifrs-full_BorrowingsByNameMember_638596912913330124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UnsecuredConvertiblePromissoryNotesMember" xlink:label="pbm_UnsecuredConvertiblePromissoryNotesMember_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638596912913330124" xlink:to="pbm_UnsecuredConvertiblePromissoryNotesMember_638596912913340127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913330124" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913340127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913340127" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913340127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913340127" xlink:to="ifrs-full_ParentMember_638596912913340127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913340127" xlink:to="pbm_NcacSponsorMember_638596912913340127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913330124" xlink:to="srt_StatementScenarioAxis_638596912913340127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638596912913340127" xlink:to="srt_ScenarioUnspecifiedDomain_638596912913340127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember" xlink:label="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638596912913340127" xlink:to="pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_638596912913340127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_638596912913330124" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913340127" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913340127" xlink:to="ifrs-full_NotionalAmount_638596912913340127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate_638596912913340127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913340127" xlink:to="ifrs-full_BorrowingsInterestRate_638596912913340127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfCurrentBorrowings" xlink:label="ifrs-full_RepaymentsOfCurrentBorrowings_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913340127" xlink:to="ifrs-full_RepaymentsOfCurrentBorrowings_638596912913350118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913340127" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued_638596912913350118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913340127" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_638596912913350118" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FairValueAdjustmentOnPromissoryNote" xlink:label="pbm_FairValueAdjustmentOnPromissoryNote_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_638596912913340127" xlink:to="pbm_FairValueAdjustmentOnPromissoryNote_638596912913350118" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureShareCapitalDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Share capital (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalAbstract" xlink:label="ifrs-full_IssuedCapitalAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalAbstract_1" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638596912913350118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638596912913350118" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913350118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913350118" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913350118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913350118" xlink:to="ifrs-full_ParentMember_638596912913350118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacMember" xlink:label="pbm_NcacMember_638596912913350118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913350118" xlink:to="pbm_NcacMember_638596912913350118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ThirdPartyAdvisorsMember" xlink:label="pbm_ThirdPartyAdvisorsMember_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913350118" xlink:to="pbm_ThirdPartyAdvisorsMember_638596912913360117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638596912913350118" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" xlink:to="ifrs-full_NumberOfSharesIssued_638596912913360117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" xlink:to="ifrs-full_NumberOfSharesOutstanding_638596912913360117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction_638596912913360117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_ReverseTakeoverTransactionSharesIssued" xlink:label="pbm_ReverseTakeoverTransactionSharesIssued_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" xlink:to="pbm_ReverseTakeoverTransactionSharesIssued_638596912913360117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" xlink:to="ifrs-full_TradeAndOtherPayables_638596912913360117" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" xlink:to="ifrs-full_ParValuePerShare_638596912913360117" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsGainLossOnExtinguishmentOfDebt" xlink:label="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" xlink:to="pbm_IfrsGainLossOnExtinguishmentOfDebt_638596912913360117" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ServicesExpense" xlink:label="ifrs-full_ServicesExpense_638596912913360117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638596912913360117" xlink:to="ifrs-full_ServicesExpense_638596912913360117" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureOtherIncomeDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Other income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsOtherIncomeAbstract" xlink:label="pbm_IfrsOtherIncomeAbstract_2" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsOtherIncomeAbstract_2" xlink:to="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable_638596912913370128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable_638596912913370128" xlink:to="ifrs-full_BorrowingsByNameAxis_638596912913370128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_638596912913370128" xlink:to="ifrs-full_BorrowingsByNameMember_638596912913370128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_LoanFromRhCapitalFinanceCo.LlcMember" xlink:label="pbm_LoanFromRhCapitalFinanceCo.LlcMember_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_638596912913370128" xlink:to="pbm_LoanFromRhCapitalFinanceCo.LlcMember_638596912913370128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems" xlink:label="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable_638596912913370128" xlink:to="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" xlink:to="ifrs-full_RevenueFromGovernmentGrants_638596912913370128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" xlink:to="ifrs-full_InterestExpenseOnBorrowings_638596912913370128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" xlink:to="ifrs-full_NotionalAmount_638596912913370128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram" xlink:label="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" xlink:to="pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram_638596912913370128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" xlink:to="ifrs-full_BorrowingsInterestRate_638596912913370128" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BorrowingsMinimumInterestChargeablePeriod" xlink:label="pbm_BorrowingsMinimumInterestChargeablePeriod_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" xlink:to="pbm_BorrowingsMinimumInterestChargeablePeriod_638596912913370128" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment" xlink:label="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment_638596912913370128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems_638596912913370128" xlink:to="pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment_638596912913370128" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Transactions with related parties - Key Management Personnel (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_638596912913380127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_2" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_638596912913380127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_638596912913380127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_2" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_638596912913380127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_638596912913380127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_2" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_638596912913380127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Share based compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638596912913380127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638596912913380127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638596912913380127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638596912913380127" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638596912913380127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_2" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638596912913380127" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Income tax note (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_2" xlink:to="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913390123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913390123" xlink:to="ifrs-full_GeographicalAreasAxis_638596912913390123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_638596912913390123" xlink:to="ifrs-full_GeographicalAreasMember_638596912913390123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638596912913390123" xlink:to="country_CA_638596912913390123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="ifrs-full_DisclosureOfGeographicalAreasLineItems_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913390123" xlink:to="ifrs-full_DisclosureOfGeographicalAreasLineItems_638596912913390123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems_638596912913390123" xlink:to="ifrs-full_ApplicableTaxRate_638596912913390123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract" xlink:label="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems_638596912913390123" xlink:to="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" xlink:to="ifrs-full_AccountingProfit_638596912913390123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_638596912913390123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates" xlink:label="ifrs-full_TaxEffectOfForeignTaxRates_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" xlink:to="ifrs-full_TaxEffectOfForeignTaxRates_638596912913390123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectOflistingExpense" xlink:label="pbm_TaxEffectOflistingExpense_638596912913390123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" xlink:to="pbm_TaxEffectOflistingExpense_638596912913390123" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectOfotherPermanentExpenses" xlink:label="pbm_TaxEffectOfotherPermanentExpenses_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" xlink:to="pbm_TaxEffectOfotherPermanentExpenses_638596912913400122" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized" xlink:label="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" xlink:to="pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized_638596912913400122" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract_638596912913390123" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638596912913400122" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Income tax note - Unrecognized deductible temporary differences (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_3" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638596912913400122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638596912913400122" xlink:to="ifrs-full_GeographicalAreasAxis_638596912913400122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_638596912913400122" xlink:to="ifrs-full_GeographicalAreasMember_638596912913400122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638596912913400122" xlink:to="country_CA_638596912913400122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="country_AU_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638596912913400122" xlink:to="country_AU_638596912913400122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638596912913400122" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_638596912913400122" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638596912913400122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_638596912913400122" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638596912913400122" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638596912913400122" xlink:to="ifrs-full_ComputerEquipmentMember_638596912913410125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_LoanLiabilityMember" xlink:label="pbm_LoanLiabilityMember_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638596912913400122" xlink:to="pbm_LoanLiabilityMember_638596912913410125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_638596912913400122" xlink:to="ifrs-full_UnusedTaxLossesMember_638596912913410125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_638596912913400122" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638596912913410125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_638596912913410125" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_638596912913410125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails" xlink:type="extended" xlink:title="41703 - Disclosure - Income tax note - Non-capital loss carry forwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasTable" xlink:label="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_4" xlink:to="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913410125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913410125" xlink:to="ifrs-full_GeographicalAreasAxis_638596912913410125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_638596912913410125" xlink:to="ifrs-full_GeographicalAreasMember_638596912913410125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU" xlink:label="country_AU_638596912913410125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638596912913410125" xlink:to="country_AU_638596912913410125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA" xlink:label="country_CA_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638596912913410125" xlink:to="country_CA_638596912913420125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsTaxPeriodAxis" xlink:label="pbm_IfrsTaxPeriodAxis_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913410125" xlink:to="pbm_IfrsTaxPeriodAxis_638596912913420125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsTaxPeriodDomain" xlink:label="pbm_IfrsTaxPeriodDomain_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsTaxPeriodAxis_638596912913420125" xlink:to="pbm_IfrsTaxPeriodDomain_638596912913420125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_TaxYear2044Member" xlink:label="pbm_TaxYear2044Member_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsTaxPeriodDomain_638596912913420125" xlink:to="pbm_TaxYear2044Member_638596912913420125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IndefinitePeriodMember" xlink:label="pbm_IndefinitePeriodMember_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsTaxPeriodDomain_638596912913420125" xlink:to="pbm_IndefinitePeriodMember_638596912913420125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:label="ifrs-full_DisclosureOfGeographicalAreasLineItems_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasTable_638596912913410125" xlink:to="ifrs-full_DisclosureOfGeographicalAreasLineItems_638596912913420125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NonCapitalLossCarryForwards" xlink:label="pbm_NonCapitalLossCarryForwards_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasLineItems_638596912913420125" xlink:to="pbm_NonCapitalLossCarryForwards_638596912913420125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Financial instruments and financial risk management - Carrying Value of the Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_1" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_638596912913420125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_638596912913420125" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_638596912913420125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_638596912913420125" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_638596912913420125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_638596912913420125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_638596912913420125" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_638596912913420125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_638596912913420125" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_638596912913430124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_638596912913420125" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_638596912913430124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_638596912913420125" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638596912913430124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638596912913430124" xlink:to="ifrs-full_FinancialLiabilitiesMember_638596912913430124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_WarrantLiabilitiesMember" xlink:label="pbm_WarrantLiabilitiesMember_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638596912913430124" xlink:to="pbm_WarrantLiabilitiesMember_638596912913430124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638596912913430124" xlink:to="pbm_IfrsConvertibleDebtMember_638596912913430124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsPromissoryNoteMember" xlink:label="pbm_IfrsPromissoryNoteMember_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638596912913430124" xlink:to="pbm_IfrsPromissoryNoteMember_638596912913430124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightAxis" xlink:label="pbm_IfrsClassOfWarrantOrRightAxis_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_638596912913420125" xlink:to="pbm_IfrsClassOfWarrantOrRightAxis_638596912913430124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightDomain" xlink:label="pbm_IfrsClassOfWarrantOrRightDomain_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsClassOfWarrantOrRightAxis_638596912913430124" xlink:to="pbm_IfrsClassOfWarrantOrRightDomain_638596912913430124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PrivateWarrantsMember" xlink:label="pbm_PrivateWarrantsMember_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsClassOfWarrantOrRightDomain_638596912913430124" xlink:to="pbm_PrivateWarrantsMember_638596912913430124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsClassOfWarrantOrRightDomain_638596912913430124" xlink:to="pbm_PublicWarrantsMember_638596912913430124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913430124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_638596912913420125" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913430124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913440126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913430124" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913440126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember_638596912913440126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913440126" xlink:to="pbm_NcacSponsorMember_638596912913440126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_638596912913440126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_638596912913420125" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_638596912913440126" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_638596912913440126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_638596912913440126" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_638596912913440126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Financial instruments and financial risk management - Maturity of the Contractual Obligations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesTable_638596912913440126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_2" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesTable_638596912913440126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_638596912913440126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable_638596912913440126" xlink:to="ifrs-full_MaturityAxis_638596912913440126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638596912913440126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_638596912913440126" xlink:to="ifrs-full_AggregatedTimeBandsMember_638596912913440126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember_638596912913440126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638596912913440126" xlink:to="ifrs-full_NotLaterThanOneYearMember_638596912913440126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638596912913440126" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_638596912913450123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable_638596912913440126" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638596912913450123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_638596912913450123" xlink:to="ifrs-full_FinancialLiabilitiesMember_638596912913450123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember" xlink:label="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638596912913450123" xlink:to="pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_638596912913450123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638596912913450123" xlink:to="pbm_IfrsConvertibleDebtMember_638596912913450123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtIssuedMember" xlink:label="pbm_DebtIssuedMember_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember_638596912913450123" xlink:to="pbm_DebtIssuedMember_638596912913450123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable_638596912913440126" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913450123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638596912913450123" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913450123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NcacSponsorMember" xlink:label="pbm_NcacSponsorMember_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913450123" xlink:to="pbm_NcacSponsorMember_638596912913450123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638596912913450123" xlink:to="ifrs-full_ParentMember_638596912913450123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_638596912913450123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesTable_638596912913440126" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_638596912913450123" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities_638596912913460128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_638596912913450123" xlink:to="ifrs-full_FinancialLiabilities_638596912913460128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FinancialLiabilitiesUndiscountedCashFlows" xlink:label="pbm_FinancialLiabilitiesUndiscountedCashFlows_638596912913460128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesLineItems_638596912913450123" xlink:to="pbm_FinancialLiabilitiesUndiscountedCashFlows_638596912913460128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Financial instruments and financial risk management (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption" xlink:label="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption_638596912913460128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_1" xlink:to="pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption_638596912913460128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent" xlink:label="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent_638596912913460128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract_1" xlink:to="pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent_638596912913460128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.psyence.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638596912913460128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_1" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638596912913460128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638596912913460128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638596912913460128" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638596912913460128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638596912913460128" xlink:to="ifrs-full_NonadjustingEventsMember_638596912913470132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsConvertibleDebtMember" xlink:label="pbm_IfrsConvertibleDebtMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638596912913470132" xlink:to="pbm_IfrsConvertibleDebtMember_638596912913470132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_FirstTrancheNoteMember" xlink:label="pbm_FirstTrancheNoteMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsConvertibleDebtMember_638596912913470132" xlink:to="pbm_FirstTrancheNoteMember_638596912913470132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SecondTrancheNoteMember" xlink:label="pbm_SecondTrancheNoteMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pbm_IfrsConvertibleDebtMember_638596912913470132" xlink:to="pbm_SecondTrancheNoteMember_638596912913470132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_UnaffiliatedThirdPartyInvestorMember" xlink:label="pbm_UnaffiliatedThirdPartyInvestorMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638596912913470132" xlink:to="pbm_UnaffiliatedThirdPartyInvestorMember_638596912913470132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember" xlink:label="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638596912913470132" xlink:to="pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_638596912913470132" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638596912913460128" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913470132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_638596912913470132" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913470132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_PublicWarrantsMember" xlink:label="pbm_PublicWarrantsMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638596912913470132" xlink:to="pbm_PublicWarrantsMember_638596912913470132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638596912913460128" xlink:to="ifrs-full_ComponentsOfEquityAxis_638596912913470132" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638596912913470132" xlink:to="ifrs-full_EquityMember_638596912913470132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638596912913470132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_638596912913470132" xlink:to="ifrs-full_IssuedCapitalMember_638596912913470132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638596912913460128" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="ifrs-full_NotionalAmount_638596912913480125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_638596912913480125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="ifrs-full_BorrowingsInterestRate_638596912913480125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_NumberOfConversionNotices" xlink:label="pbm_NumberOfConversionNotices_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="pbm_NumberOfConversionNotices_638596912913480125" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsDebtConversionOriginalDebtAmount1" xlink:label="pbm_IfrsDebtConversionOriginalDebtAmount1_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="pbm_IfrsDebtConversionOriginalDebtAmount1_638596912913480125" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_DebtConversionVolumeWeightedAveragePricePerShare" xlink:label="pbm_DebtConversionVolumeWeightedAveragePricePerShare_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="pbm_DebtConversionVolumeWeightedAveragePricePerShare_638596912913480125" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638596912913480125" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement" xlink:label="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_638596912913480125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement_638596912913480125" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_638596912913490132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="pbm_IfrsStockIssuedDuringPeriodSharesNewIssues_638596912913490132" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638596912913490132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="ifrs-full_ParValuePerShare_638596912913490132" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pbm-20240331.xsd#pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638596912913490132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638596912913480125" xlink:to="pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638596912913490132" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426583984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">F-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Psyence Biomedical&#160;Ltd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001985062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425471392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 733,188<span></span>
</td>
<td class="nump">$ 1,334,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">29,611<span></span>
</td>
<td class="nump">29,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">41,747<span></span>
</td>
<td class="nump">149,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaids</a></td>
<td class="nump">322,126<span></span>
</td>
<td class="nump">77,050<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">1,126,672<span></span>
</td>
<td class="nump">1,590,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Equipment</a></td>
<td class="nump">5,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,132,159<span></span>
</td>
<td class="nump">1,590,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">755,202<span></span>
</td>
<td class="nump">1,790,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsConvertibleDebtCurrent', window );">Convertible note liability</a></td>
<td class="nump">7,657,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Derivative warrant liabilities</a></td>
<td class="nump">901,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">12,104,699<span></span>
</td>
<td class="nump">1,790,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share Capital</a></td>
<td class="nump">46,125,397<span></span>
</td>
<td class="nump">5,934,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated Deficit</a></td>
<td class="num">(57,458,994)<span></span>
</td>
<td class="num">(6,299,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Reserves</a></td>
<td class="nump">361,057<span></span>
</td>
<td class="nump">165,360<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">NET DEFICIT</a></td>
<td class="num">(10,972,540)<span></span>
</td>
<td class="num">(200,445)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND NET DEFICIT</a></td>
<td class="nump">1,132,159<span></span>
</td>
<td class="nump">$ 1,590,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember', window );">NCAC Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDebtInstrumentsIssued', window );">Due to related party</a></td>
<td class="nump">1,474,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDebtInstrumentsIssued', window );">Due to related party</a></td>
<td class="nump">$ 1,316,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current debt instruments issued. [Refer: Debt instruments issued]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392427772352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Net Loss and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">$ 80,603<span></span>
</td>
<td class="nump">$ 7,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">954,593<span></span>
</td>
<td class="nump">1,608,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">557,904<span></span>
</td>
<td class="nump">366,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees</a></td>
<td class="nump">1,158,484<span></span>
</td>
<td class="nump">1,252,510<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsOperatingIncomeLoss', window );">Loss before other items</a></td>
<td class="num">(2,751,584)<span></span>
</td>
<td class="num">(3,234,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsNonoperatingIncomeExpenseAbstract', window );"><strong>Other items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">879,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation</a></td>
<td class="num">(240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Interest income</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Interest expense</a></td>
<td class="num">(52,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain</a></td>
<td class="num">(2,695)<span></span>
</td>
<td class="nump">26,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ListingExpense', window );">Listing expense</a></td>
<td class="num">(41,481,605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_TransactionExpense', window );">Transaction expense</a></td>
<td class="num">(2,461,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsGainLossOnExtinguishmentOfDebt', window );">Gain on debt settlement</a></td>
<td class="nump">281,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentOnConvertibleNote', window );">Fair value loss on convertible note</a></td>
<td class="num">(5,157,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsFairValueAdjustmentOfWarrants', window );">Fair value loss on warrant liability</a></td>
<td class="num">(306,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentOnPromissoryNote', window );">Fair value loss on promissory notes</a></td>
<td class="num">(108,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(51,159,048)<span></span>
</td>
<td class="num">(3,206,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income/(loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign exchange gain/(loss) on translation</a></td>
<td class="nump">3,715<span></span>
</td>
<td class="num">(89,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_OtherComprehensiveIncomeLoss', window );">Other comprehensive income</a></td>
<td class="nump">191,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ComprehensiveIncomeLoss', window );">TOTAL COMPREHENSIVE LOSS</a></td>
<td class="num">$ (50,963,351)<span></span>
</td>
<td class="num">$ (3,296,231)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (7.82)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (7.82)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of outstanding shares - basic (in shares)</a></td>
<td class="nump">6,517,215<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of outstanding shares - diluted (in shares)</a></td>
<td class="nump">6,517,215<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_FairValueAdjustmentOnConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_FairValueAdjustmentOnConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_FairValueAdjustmentOnPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_FairValueAdjustmentOnPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsFairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsFairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsGainLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsGainLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_OtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_OtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_TransactionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transaction expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_TransactionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392423655040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Shareholder Equity<br></strong></div></th>
<th class="th">
<div>Share Capital </div>
<div>Psyence Group Inc </div>
<div>shares</div>
</th>
<th class="th">
<div>Share Capital </div>
<div>NCAC Sponsor </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Share Capital </div>
<div>Third party advisors </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Share Capital </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Reserve </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Deficit </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Psyence Group Inc </div>
<div>shares</div>
</th>
<th class="th">
<div>NCAC Sponsor </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Third party advisors </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Opening balance as at beginning at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,537,055<span></span>
</td>
<td class="nump">$ 255,188<span></span>
</td>
<td class="num">$ (3,093,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,698,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners', window );">Psyence Group contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,397,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,397,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,206,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,206,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,934,141<span></span>
</td>
<td class="nump">165,360<span></span>
</td>
<td class="num">(6,299,946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200,445)<span></span>
</td>
<td class="num">$ (200,445)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance at end (in shares) at Mar. 31, 2023 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction', window );">Issuance of shares, reverse takeover transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,336,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,336,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction', window );">Issuance of shares, reverse takeover transaction (in shares) | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">7,794,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement', window );">Issuance of shares for debt settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement', window );">Issuance of shares for debt settlement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,136,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,136,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,159,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,159,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,125,397<span></span>
</td>
<td class="nump">$ 361,057<span></span>
</td>
<td class="num">$ (57,458,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,972,540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance at end (in shares) at Mar. 31, 2024 | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,390,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,390,659<span></span>
</td>
<td class="nump">13,390,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued for debt settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period for reverse takeover transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for settlement of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for reverse takeover transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392427783136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>Consolidated Statements of Cash Flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">$ (51,159,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Non-cash adjustment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentOnConvertibleNote', window );">Fair value loss on convertible note</a></td>
<td class="nump">5,157,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsFairValueAdjustmentOfWarrants', window );">Fair value loss on derivative warrant</a></td>
<td class="nump">306,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentsOnPromissoryNote', window );">Fair value loss on promissory notes</a></td>
<td class="nump">300,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsGainLossOnExtinguishmentOfDebt', window );">Gain on debt settlement</a></td>
<td class="num">(281,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based compensation</a></td>
<td class="nump">317,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange</a></td>
<td class="nump">3,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_AdjustmentsForListingExpense', window );">Listing expense</a></td>
<td class="nump">41,481,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_AdjustmentsForTransactionExpenses', window );">Transaction expenses</a></td>
<td class="nump">2,100,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IncreaseDecreaseInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="nump">107,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaids</a></td>
<td class="num">(245,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,035,498)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(2,945,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Additions to equipment</a></td>
<td class="num">(5,727)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash used for investing activities</a></td>
<td class="num">(5,727)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromCurrentBorrowings', window );">Proceeds received from convertible note</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Payment of promissory note</a></td>
<td class="num">(150,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided from financing activities</a></td>
<td class="nump">2,350,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Change in cash and cash equivalents</a></td>
<td class="num">(601,092)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">1,334,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 733,188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from current borrowings obtained. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in accounts payable and accrued liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_AdjustmentsForListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for listing expense to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_AdjustmentsForListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_AdjustmentsForTransactionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for transaction expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_AdjustmentsForTransactionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_FairValueAdjustmentOnConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_FairValueAdjustmentOnConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_FairValueAdjustmentsOnPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair
 value of promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_FairValueAdjustmentsOnPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsFairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsFairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsGainLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsGainLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IncreaseDecreaseInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IncreaseDecreaseInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392428085600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of operations and going concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NatureOfOperationsAndGoingConcernAbstract', window );"><strong>Nature of operations and going concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Nature of operations and going concern</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of operations and going concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Psyence Biomedical&#160;Ltd. (the <b style="font-weight:bold;">&#8220;Company&#8221;</b> or <b style="font-weight:bold;">&#8220;PBM&#8221;</b>), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The Company is working towards developing safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. The Company is initially focused on mental health disorders in the context of Palliative Care. The Company is currently conducting research through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context (the &#8220;<b style="font-weight:bold;">Clinical Trials</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s registered office is at 121 Richmond Street West, PH Suite&#160;1300, Toronto, Ontario M5H 2K1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company listed on the NASDAQ exchange on January&#160;25, 2024. (&#8220;<b style="font-weight:bold;">Carve-out Financial Statements</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February&#160;15, 2023, Psyence Australia (Pty) Ltd was incorporated and registered in Victoria, Australia. It is a wholly owned subsidiary of the Company. It was incorporated as a wholly owned subsidiary of Psyence Group&#160;Inc. and was transferred to the Company concurrently upon completion of the RTO Transaction as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Business Combination Agreement and NASDAQ listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;9, 2023, Psyence Group&#160;Inc. (&#8220;<b style="font-weight:bold;">Psyence Group</b>&#8221; or &#8220;<b style="font-weight:bold;">PGI</b>&#8221;) entered into a definitive business combination agreement (the &#8220;<b style="font-weight:bold;">Business Combination Agreement</b>&#8221;) with Newcourt Acquisition Corp. (NASDAQ: NCAC), a special purpose acquisition company (&#8220;<b style="font-weight:bold;">SPAC</b>&#8221;). The agreement aimed to create a public company leveraging natural psilocybin for palliative care treatment. PGI is a listed Canadian company that contributed its clinical trial activities to the Company as described below. After the Business Combination Agreement closed the Company became an associate of PGI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The transaction concluded on January&#160;25, 2024, with PBM&#8217;s listing on NASDAQ. This transaction involved PBM acquiring the SPAC through a merger, thereby making the SPAC a wholly-owned subsidiary of PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Transaction Overview:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024 (the &#8220;<b style="font-weight:bold;">Closing Date</b>&#8221;), the Company, a corporation organized under the laws of Ontario, Canada, completed the previously announced business combination (the &#8220;<b style="font-weight:bold;">RTO Transaction</b>&#8221;) as per the Amended and Restated Business Combination Agreement (the &#8220;<b style="font-weight:bold;">BCA</b>&#8221;), dated July&#160;31, 2023. The parties involved in the BCA included:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Psyence Group&#160;Inc.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Newcourt Acquisition Corp., a Cayman Islands exempted company.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Newcourt SPAC Sponsor LLC, a Delaware limited liability company (&#8220;<b style="font-weight:bold;">NCAC Sponsor</b>&#8221;).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of Psyence Group.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada (&#8220;<b style="font-weight:bold;">Original Target</b>&#8221;).</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (&#8220;<b style="font-weight:bold;">Psyence Biomed II</b>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Key Transactions (collectively, the &#8220;<span style="font-weight:bold;">Business Combination</span>&#8221;):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Formation of Subsidiaries</i>: Prior to the execution of the BCA, Psyence Group formed two wholly owned subsidiaries: Psyence Biomed II and PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Amalgamation</i>: Prior to the Closing Date, Psyence Group amalgamated with the Original Target. Consequently, Psyence Group transferred shares of Psyence Australia Pty&#160;Ltd. and related business assets previously owned by the Original Target to Psyence Biomed II.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Share Exchange</i>: Psyence Group contributed Psyence Biomed II to PBM in a share-for-share exchange (the &#8220;<b style="font-weight:bold;">Company Exchange</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Merger</i>: Following the Company Exchange, Psyence (Cayman) Merger Sub merged with Newcourt Acquisition Corp., with Newcourt Acquisition Corp. being the surviving entity. Each outstanding ordinary share of Newcourt Acquisition Corp. was converted into the right to receive one common share of PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Warrant Conversion</i>: Each outstanding warrant to purchase Newcourt Acquisition Corp. Class&#160;A ordinary shares was converted into warrants to acquire one common share of PBM on substantially the same terms as the original warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;15, 2024 and January&#160;23, 2024, the parties to the Business Combination Agreement entered into letter agreements (the &#8220;<b style="font-weight:bold;">Closing Letter Agreements</b>&#8221;) pursuant to which, among other things, PBM, Psyence Group, Original Target and Merger Sub (collectively, the &#8220;<b style="font-weight:bold;">Psyence Parties</b>&#8221;) agreed, on a conditional basis, to waive the closing conditions contained in the BCA that, at or prior to the closing of the Business Combination (the &#8220;<b style="font-weight:bold;">Closing</b>&#8221;), (i)&#160;Newcourt SPAC shall have no less than $20,000,000, net of liabilities, as of the Closing (the &#8220;<b style="font-weight:bold;">Minimum Cash Condition</b>&#8221;) and (ii)&#160;the PIPE (Private Investment in Public Equity) Investment in the PIPE Investment Amount shall have occurred or shall be ready to occur substantially concurrently with the Closing (the &#8220;<b style="font-weight:bold;">PIPE Investment Condition</b>&#8221;) and (iii)&#160;to waive certain deliverables of the Business Combination Agreement (the &#8220;<b style="font-weight:bold;">Closing Deliverables</b>&#8221;). Upon the Closing, the Psyence Parties waived in full the Minimum Cash Condition, the PIPE Investment Condition and the Closing Deliverables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Convertible Note&#160;Financing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;15, 2024, in connection with the Business Combination, the Company entered into a securities purchase agreement (the &#8220;<b style="font-weight:bold;">Securities Purchase Agreement</b>&#8221;) by and among (i)&#160;the Company, (ii)&#160;Psyence Biomed II, (iii)&#160;Sponsor and (iv)&#160;certain investors (the &#8220;<b style="font-weight:bold;">Investors</b>&#8221;) relating to up to four senior secured convertible notes (collectively, the &#8220;<b style="font-weight:bold;">Notes</b>&#8221; and the transactions pursuant to the Securities Purchase Agreement, the &#8220;<b style="font-weight:bold;">Financing</b>&#8221;), obligations under which will be guaranteed by certain assets of the Company and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up to $12,500,000 in exchange for up to $10,000,000 in cash subscription amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Note&#160;for the first tranche of the Financing (the &#8220;<b style="font-weight:bold;">First Tranche Note</b>&#8221;), for a total of $3,125,000 of principal in exchange for a total of $2,500,000 in subscription amounts and was issued to the Investors substantially concurrently with, and contingent upon, the Closing. The Financing closed immediately prior to the Business Combination (Refer to Note&#160;9).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Merger Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As consideration for all the issued and outstanding Psyence Biomed II common shares that the Company received in the Company Exchange, the Company issued to Psyence Group, 5,000,000 Common Shares. As a result, Psyence Group is the largest shareholder of the Company as at March&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Consolidated Financial Statements (the &#8220;<b style="font-weight:bold;">Financial Statements</b>&#8221;) provide historical financial information of PBM, reflecting PBM as if it had been historically operating the Clinical Trials conducted by Psyence Group prior to the listing of PBM. The Financial Statements are carve out statements up to the date of listing of PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Going concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements are prepared on a going concern basis, which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the&#160;year ended March&#160;31, 2024, the Company incurred a net loss and comprehensive loss of $50,963,351 (Year ended March&#160;31, 2023: $3,296,231) and the Company has not yet generated any revenue. The Company&#8217;s ability to continue operations depends on its ability to secure additional financing. There is uncertainty regarding the availability of financing at acceptable terms, which could impact the Company&#8217;s ability to continue operating. These conditions indicate a material uncertainty that cast significant doubt on the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements do not reflect the adjustments to the carrying values and classifications of assets and liabilities that would be necessary if the Company were unable to realize its assets and settle its liabilities as a in the normal course of operations. Such adjustments could be significant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NatureOfOperationsAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NatureOfOperationsAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426950048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_BasisOfPresentationAbstract', window );"><strong>Basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Statement of compliance</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements of the Company have been prepared using accounting policies in compliance with International Financial Reporting Standards (&#8220;<b style="font-weight:bold;">IFRS</b>&#8221;) issued by the International Accounting Standards Board (&#8220;<b style="font-weight:bold;">IASB</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements were authorized for issue on July&#160;25, 2024 by the directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Financial Position</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Consolidated Statements of Financial Position include the assets and liabilities that are the Clinical Trial related assets and liabilities, which have been determined in the following manner:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cash is comprised of cash and cash equivalents which the Company utilizes for working capital purposes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restricted cash comprises a guaranteed investment certificate which is held as collateral for a credit lending agreement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Other receivables are comprised of sales tax receivable from the Canadian Revenue Agency and the Australian Taxation Office.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prepaids consists of D&amp;O insurance fees prepaid.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Accounts payable and accrued liabilities consist of audit, consulting fees and legal fees related to the Company and its Clinical Trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Consolidated Statements of Net Loss and Comprehensive Loss</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Consolidated Statements of Net Loss and Comprehensive Loss include operating expenses that are related to the Company and its Clinical Trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Financial Statements up until January 25, 2024 were presented on a carve out basis (&#8220;</span><b style="font-style:normal;font-weight:bold;">Carve-out Financial Statements</b><span style="font-style:normal;font-weight:normal;">&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements have been prepared on a carve-out basis from the PGI consolidated financial statements for the purpose of presenting the historical financial position, financial performance and cash flows of the Company on a stand-alone basis. The accounting policies applied in the Carve-out Financial Statements are, to the extent applicable, consistent with accounting policies applied in the PGI consolidated financial statements, and as a result, reflect the carrying amounts that are included in PGI&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In determining the perimeter of the Carve-out Financial Statements, the activities related to the Company&#8217;s clinical trials were considered to include the operations of Psyence Biomed Corp. and Psyence Australia (Pty) Ltd carried out through PGI directly as well as through legal entities of PGI as detailed above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the Carve-out Financial Statements of PBM, all intercompany balances and have been eliminated. The transactions and balances with the remaining PGI operations that are not part of these Carve-out Financial Statements have not been eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Carve-out Financial Statements present the assets, liabilities, expenses and cash flows attributable to the clinical trial activities for the year ended March 31, 2023 and from April 1, 2023 to the Closing Date, and include allocations of certain transactions and balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company believes the allocation assumptions applied in the Carve-out Financial Statements to be a reasonable reflection of the utilization of services provided by PGI. However, different allocation assumptions could have resulted in different outcomes. The allocations are therefore not necessarily representative of the financial position, financial performance or cash flows that would have been reported if PBM operated on its own or as an entity independent from PGI during the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company believes the basis of preparation described above results in the Carve-out Financial Statements reflecting the assets and liabilities associated with PBM and reflects costs associated with the functions that would be necessary to operate independently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of consolidation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statement incorporate the accounts of PBM and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Control exists when an investor is exposed, or has the rights, to variable returns from the involvement with the investee and has liability to affect those returns through its power over the investee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The subsidiaries of PBM have been consolidated commencing the Closing Date and on March 31, 2024 for the purpose of these Financial Statements are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Place&#160;of&#160;incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounting&#160;method</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Psyence Australia Pty Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pysence Biomed II Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Newcourt Acquisition Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cayman Islands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inter-company balances and transactions are eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial results of subsidiaries in financial&#160;year ended March&#160;31, 2023 and up to January 25, 2024 were presented on a carve out basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Basis of measurement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements have been prepared on an accrual basis, are based on historical costs, unless otherwise noted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Functional and presentation currency</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements are presented in United States Dollars (<b style="font-weight:bold;">&#8220;USD $&#8221;</b>)<b style="font-weight:bold;">,</b> which is also PBM&#8217;s functional currency. The Company&#8217;s functional currency before the Closing Date of the BCA was Canadian Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This changed upon consummation of the BCA at which time the USD $ represents the currency of the Company&#8217;s funding and is the currency of the primary economic environment in which the Company operates in, except for the Company&#8217;s Australian subsidiary which has an Australian Dollar functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See change in accounting policy in note 3 for further details on the change in the Company&#8217;s presentation currency.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392427985360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MaterialAccountingPoliciesAbstract', window );"><strong>Material accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Material accounting policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Material accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets and financial liabilities, including derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument or derivative contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Summary of the Company&#8217;s classification and measurements of financial assets and liabilities:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:4.8pt;"><td style="vertical-align:bottom;width:50.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Financial Assets and Liabilities</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:22.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Measurement </b></p></td></tr><tr style="height:5.75pt;"><td style="vertical-align:bottom;width:50.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr style="height:5.75pt;"><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Restricted cash</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivative warrant liability</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">NCAC promissory note</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PGI promissory note</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Classification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its financial assets and financial liabilities in the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (&#8220;FVTPL&#8221;); ii) those to be measured subsequently at fair value through other comprehensive income (&#8220;FVOCI&#8221;); and iii) those to be measured at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair value, gains and losses are either recorded in net loss or other comprehensive income (loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company reclassifies financial assets only when its business model for managing those assets changes. Financial liabilities are not reclassified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Amortized cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This category includes financial assets that are held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments of principal and interest (&#8220;SPPI&#8221;) criterion. Financial assets classified in this category are measured at amortized cost using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair value through profit or loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This category includes derivative instruments as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL. This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest (&#8220;SPPI&#8221;) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Financial assets at fair value through other comprehensive income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Equity instruments that are not held-for-trading can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable transaction costs are included in the carrying value of the instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets at fair value through other comprehensive income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Compound financial instrument and derivative liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the warrants, including public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized in net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each embedded derivative is measured and presented separately unless the whole hybrid financial instrument is designated as at FVTPL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All financial instruments are required to be measured at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payments of principal and interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value are attributable to changes in own credit risk which is recorded in other comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash on hand and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three&#160;months at the date of their acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted cash comprises a collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment certificate with the bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Related party transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be a related party transaction when there is transfer of resources or obligations between related parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Change in accounting policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to completion of the Business Combination Agreement and NASDAQ listing as explained in Note 1 to the audited consolidated financial statements, on January 25, 2024, the Corporation decided to change the presentation currency of its consolidated financial statements from Canadian Dollars to United States Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors believe that US Dollar financial reporting provides more relevant presentation of the Corporation&#8217;s financial position, funding and treasury functions, financial performance and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in presentation currency represents a change in accounting policy in terms of IAS 8 &#8211; <i style="font-style:italic;">Accounting Policies, Changes in Accounting Estimates and Errors</i>, requiring the restatement of comparative information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with IAS 21 &#8211; <i style="font-style:italic;">The Effects of Changes in Foreign Exchange Rates</i>, the methodology followed in restating historical financial information from CDN$ to US$.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The average and closing rates used in translating the historical financial information from CDN$ to US$ for the various periods were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing rate used as at March 31, 2024 was $0.738 and as at March 31, 2023 was $0.7389.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The average rate used for the year ended March 31, 2024 was $0.7415, for the year ended March 31, 2023 was $0.7559 and for the year ended March 31, 2022 was $0.8003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The change in presentation currency is a voluntary change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated to United States dollars which is disclosed in the tables below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,805,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (471,485)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,334,280</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,556</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 202,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,782)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149,369</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,050</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,152,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (561,937)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,590,255</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,152,192</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (561,937)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,590,255</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,423,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (632,767)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,700</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,423,467</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (632,767)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,790,700</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (271,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200,445)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (271,275)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 70,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (200,445)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,152,192</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (561,937)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,590,255</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022&#160;Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> $</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,191,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (437,658)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,753,437</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,990)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,010</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,862)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,510</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,385</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,287,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (456,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,830,342</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,287,196</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (456,854)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,830,342</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,642</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 164,500</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (32,858)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 131,642</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,122,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (423,996)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,698,700</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,122,696</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (423,996)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,698,700</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,287,196</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (456,854)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,830,342</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,029</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,126,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (517,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,608,895</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 484,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (117,947)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 366,435</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,655,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (403,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,252,510</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (4,276,099)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,041,230)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,234,869)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,554</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,662)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,912</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (4,238,471)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,050,392)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,206,403)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,238,471)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,206,403)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-cash adjustment:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 292,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,469)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,287</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84,499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(84,499)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Changes in working capital:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (152,778)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(109,858)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (97,547)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(71,665)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,258,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (599,909)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,659,058</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,937,073)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 344,993</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(1,592,080)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Proceeds received from Psyence Group Inc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,551,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (378,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,172,923</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash provided from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,551,744</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (378,821)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,172,923</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (385,329)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,828)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(419,157)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents, start of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,191,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (437,658)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,753,437</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,805,765</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (471,486)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,334,280</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and comprehensive loss as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign currency translation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements are presented in USD $ which is PBM&#8217;s functional currency. The functional currency of its subsidiary consolidated within these Financial Statements is AUD $.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In each individual entity, a foreign currency transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency and the foreign currency at the date of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the end of the reporting period, monetary assets and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The resulting exchange gains or losses arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition, are included in statement of net loss and comprehensive loss in the period in which they arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purpose of presenting these Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries is recorded in reserves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company presents basic and diluted loss per share data for its common shares. Basic loss per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting the loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the options and RSUs granted by the Company shall be recognized as an expense in the Consolidated Financial Statements of the Company. The expense shall be recognized over the vesting period of the options. The fair value options shall be determined using the Black-Scholes model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Income tax comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders&#8217; equity, in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also recognized directly in equity or other comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current tax is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect of previous&#160;years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the amounts and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax is recognized in respect of all qualifying temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Financial Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_MaterialAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_MaterialAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425863824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical accounting estimates and judgements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CriticalAccountingEstimatesAndJudgementsAbstract', window );"><strong>Critical accounting estimates and judgements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Critical accounting estimates and judgements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Critical accounting estimates and judgements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results may differ from these estimates. The Company&#8217;s management reviews these estimates, judgments, and assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical accounting policies as these require a high level of subjectivity and judgement and could have a material impact on PBM&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Going concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These Financial Statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management routinely plans future activities including forecasting future cash flows and forming judgements collectively with directors of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Judgement is required in determining if the Company&#8217;s has sufficient cash reserves, together with all other available information, to continue as a going concern for a period of at least twelve&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As at March&#160;31, 2024 the Company has concluded that a material uncertainty exists that casts significant doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Reverse takeover transaction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The determination of fair values of consideration paid and net assets acquired is subject to significant estimation. The Company treated the RTO Transaction as a capital transaction equivalent to the issue of shares of the Company in exchange for the net monetary assets of NCAC. The Company determined that the original shareholders of PGI became the single largest shareholder of the Company after the RTO Transaction, therefore the Company was the acquiror and NCAC was the acquiree.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has determined the RTO Transaction did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was estimated by the closing trading price ($4.79/share) of the Company&#8217;s common shares listed on the NASDAQ on January&#160;25, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Convertible instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The valuation of convertible debt instruments is subject to significant management estimation. Convertible notes are compound financial instruments which have been designated as a FVTPL classification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The identification of convertible debenture components is based on interpretations of the substance of the contractual arrangement and therefore requires judgment from management. The separation of the components affects the initial recognition of the convertible debenture at issuance and the subsequent remeasurement. As the Company has designated the entire convertible financial instrument as FVTPL given the embedded derivate liability that was contained by the convertible financial instrument, the debentures have not been separated into debt and derivative components. The determination of the fair value of the instrument used a combined discount cash flow approach and a Monte Carlo simulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Contingencies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, the Company is named as a party to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome of these matters may not be estimable at the reporting date, the Company makes provisions, where possible, for the estimated outcome of such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the difference will be accounted for as a charge to profit or loss in that period. The actual results may vary and may cause significant adjustments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The rebate over the tax claim is subject to inherent uncertainty and could be subject to being denied and clawed back by the Australian Tax office at a future date. The Company expects that a claw back of the rebate is highly unlikely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Deferred taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant estimates are required in determining the Company&#8217;s income tax provision. Some estimates are based on interpretations of existing tax laws or regulations. Various internal and external factors may have favourable or unfavourable effects on the Company&#8217;s future effective tax rate. These include, but are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, and results of tax audits by tax authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Inputs when using Black-Scholes valuation model</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The estimates used in determining the private warrant fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes valuation model. Inputs subject to estimates include volatility, estimated lives and market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Government grants</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Government grants are recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the government grants will be received. Grants are recognized as income when they are received. The Company has recognized the government grant received during the period as research and development grants as other income in the consolidated statements of loss and comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CriticalAccountingEstimatesAndJudgementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CriticalAccountingEstimatesAndJudgementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392428088080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse takeover transaction with NCAC<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionAbstract', window );"><strong>Reverse takeover transaction with NCAC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionWithNcacTextBlock', window );">Reverse takeover transaction with NCAC</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Reverse takeover transaction with NCAC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024 the Company completed the RTO Transaction (See Note&#160;1). As disclosed in Note 4, the RTO Transaction did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was determined by the closing trading price ($4.79/share) of the NCAC&#8217;s common shares listed on the NASDAQ on January 25, 2024. This was initially estimated by the Company as the opening trading price ($3.55/share) of the Company&#8217;s common shares listed on the NASDAQ on January&#160;26, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, upon consummation of the BCA the Company issued 7,794,659 common shares in exchange for the outstanding ordinary shares held by NCAC stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of listing expenses is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Listing</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;Expense</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consideration paid:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Shares issued to NCAC shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,794,659</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total consideration shares issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,794,659</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value of the common shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.79</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Deemed consideration amount for the common shares issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,336,416</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net identifiable liabilities acquired:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,136,505)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">NCAC promissory note (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,413,529)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Derivative warrant liabilities (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (595,358)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net liabilities acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,145,189</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Listing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,481,605</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The listing expense has been included in the consolidated statements of net loss and comprehensive loss. Transaction expenses included in the consolidated statements of net loss and comprehensive loss are others costs of $2,461,025 in connection with the RTO Transaction composed of legal, banking, professional fees and costs related to the settlement of carved-out assets and liabilities from Psyence Group. Some payments to brokers and advisors were in the Company&#8217;s shares upon RTO at the closing trading price on January 25, 2024 (Refer Note 12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The change in the estimate of the share price used to determine the fair value of consideration paid resulted in an increase to listing expense by $9,483,945 from the amount previously reported.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionWithNcacTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse takeover transaction with NCAC</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionWithNcacTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426969632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, restricted cash and cash equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CashRestrictedCashAndCashEquivalentsAbstract', window );"><strong>Cash, restricted cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CashRestrictedCashAndCashEquivalentsTextBlock', window );">Cash, restricted cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Cash, restricted cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include the following amounts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unrestricted cash held with chartered banks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,334,280</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,556</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 762,799</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,363,836</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.9pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unrestricted cash held with chartered banks and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $40,000 in a guaranteed investment certificate with the bank. Amounts are presented as restricted cash on the statements of financial position.</span></td></tr></table><div style="margin-top:12pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CashRestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CashRestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CashRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on cash, restricted cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CashRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392428104992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Equipment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Computer </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,727</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,727</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accumulated Depreciation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Charge for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (240)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (240)</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,487</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425855648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock', window );"><strong>Accounts payable and accrued liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_AccountsPayableAndAccruedLiabilitiesTextBlock', window );">Accounts payable and accrued liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Accounts payable and accrued liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accounts payable and accrued liabilities include the following amounts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 562,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,628,143</p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162,557</p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 755,202</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,790,700</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_AccountsPayableAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_AccountsPayableAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425384832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible note liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ConvertibleNoteLiabilityAbstract', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DisclosureOfConvertibleNoteLiabilityTextBlock', window );">Convertible note liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Convertible note liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;15, 2024, in connection with the RTO Transaction (Note&#160;5), the Company and Psyence Biomed II entered into the Securities Purchase Agreement with the Investors and the NCAC Sponsor, relating to up to four senior secured convertible notes obligations under which are guaranteed by certain assets of the Company and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up to $12,500,000 in exchange for up to $10,000,000 in cash subscription amounts (the &#8220;<b style="font-weight:bold;">Convertible Note&#160;Financing</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The First Tranche Notes, for an aggregate of $3,125,000 principal, were delivered by the Company to the Investors on January&#160;25, 2024, in exchange for an aggregate of $2,500,000 in financing, which occurred substantially concurrently with the consummation of the RTO Transaction. On the original issuance date of the First Tranche Notes, interest began accruing at 8.0% per annum based on the outstanding principal amount of the First Tranche Notes&#160;and is payable&#160;monthly in arrears in cash or in common shares of the Company at the Conversion Price (as defined below). The maturity date of the First Tranche Note&#160;is January&#160;25, 2027.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The price at which the Investors can convert the outstanding principal and interest to the common shares (the &#8220;Conversion Price&#8221;) is determined as follows: The initial Conversion Price of the First Tranche Notes&#160;was $10.00; provided, however, that such Conversion Price is subject to certain adjustments according to the terms and reset dates included in the First Tranche Notes&#160;and may be reduced to a Conversion&#160;Floor of $1.00, until the First Reset Date (5&#160;days prior the initial Registration Statement is effective), then to $0.50 on the Second Reset Date (3-month anniversary of Closing Date) and no floor thereafter. The Conversion Price is the lowest volume-weighted average price (&#8220;<b style="font-weight:bold;">VWAP</b>&#8221;) of the shares up until conversion date subject to the conversion floor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is obligated to make a Make Whole Payment to Investors within <span style="-sec-ix-hidden:Hidden_8zLKxnneHEOziY32s6_j8Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty-five</span></span> (35) Trading Days following a Conversion Date if the <span style="-sec-ix-hidden:Hidden_bgTt3-yaZkufZ6GsyM4Hmw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thirty</span></span> (30) Day VWAP, starting from the first Trading Date after the conversion, is lower than the Conversion Price. The Make Whole Payment can be made in either cash or Common Shares, at the Company&#8217;s discretion, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If the Company elects to settle the Make Whole Payment in Common Shares, it will transfer to the Holder the number of Common Shares (the &#8220;Make Whole Shares&#8221;) calculated as the difference between (A)&#160;the principal amount converted on the Conversion Date divided by the 30 Day VWAP, and (B)&#160;the principal amount converted divided by the Conversion Price on the Conversion Date. Alternatively, if the Company chooses to pay in cash, the payment will equal the number of Make Whole Shares multiplied by the 30 Day VWAP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Total proceeds received were $2,500,000. The Company has designated the entire instrument as FVTPL instrument. The fair value of the convertible notes was estimated using a combined discounted cash flow approach and Monte Carlo simulation with the following assumptions as of March&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Note principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,125,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepayment Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility annual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility daily</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free annual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value was calculated to be $7,657,397 as of March&#160;31, 2024. A fair value loss was recognized of $5,157,397 during the&#160;year end March&#160;31, 2024 ($nil, March&#160;31, 2023).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ConvertibleNoteLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ConvertibleNoteLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DisclosureOfConvertibleNoteLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of Convertible note liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DisclosureOfConvertibleNoteLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426954144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative warrant liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DerivativeWarrantLiabilitiesAbstract', window );"><strong>Derivative warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Derivative warrant liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Derivative warrant liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to the RTO Transaction, NCAC had two classes of warrants outstanding, which were assumed by the Company upon completion of the RTO Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Public Warrants: which had resulted from NCAC&#8217;s initial public offering (the &#8220;<b style="font-weight:bold;">NCAC IPO</b>&#8221;) and entitled to registration on the Form&#160;F-4 filed in connection with the RTO Transaction. These warrants were listed on Nasdaq Capital Market under the symbol &#8220;PBMWW&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Private Warrants: which had resulted from NCAC&#8217;s private placement prior to the NCAC IPO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As at the Closing Date and March&#160;31, 2024, there were 13,070,000 warrants <span style="-sec-ix-hidden:Hidden_x8bw_yf0B0-hUxug_gXzGw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_s2yDhvbquUGMuaS1WGntNA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>, comprised of 12,500,000 Public Warrants and 570,000 <span style="-sec-ix-hidden:Hidden_zlOG_EIIqEixGctRvHNJ-A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Private Warrants</span></span>. Each warrant is exercisable to purchase one common share at a price of $11.50 per share. As a result of the potential cashless exercise feature included within the indenture of the warrants, the Company has classified the warrants as a liability measured at fair value through profit or loss as they failed to meet the &#8220;fixed-for-fixed&#8221; requirements prescribed by <i style="font-style:italic;">IAS 32&#160;&#8211; Financial Instruments: presentation.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since the Public Warrants are traded on Nasdaq, their price is observable. The Company valued the Public Warrants using the closing price of PBMWW to measure their fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes a Black-Scholes options valuation model to value the private warrants at each reporting period, with changes in fair value recognized in the statement of net loss and comprehensive loss. The estimated fair value of the warrant liability is determined using Level 2 inputs. Inherent in a Black-Scholes pricing model are assumptions related to expected volatility of the Public Warrants, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on industry historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table provides quantitative information regarding Level 2 fair value measurements at March&#160;31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Inputs at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Inputs at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 25, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiry date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 25, 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 25, 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At March&#160;31, 2024 the fair value of the Public and Private Warrants was $875,000 ($0.07/warrant) (January 25, 2024 - $568,750) and $26,608 ($0.4668/warrant) (January 25, 2024 - $26,608), respectively. A fair value loss of $306,250 was recognized on the statement of net loss and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Warrant transactions and the number of warrants outstanding are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Public Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Private Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Weighted  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Weighted   </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following warrants were outstanding and exercisable at March&#160;31, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">January 25, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January 25, 2029 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,070,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,070,000</p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,070,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,070,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DerivativeWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DerivativeWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392428069200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_PromissoryNotesAbstract', window );"><strong>Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_PromissoryNotesTextBlock', window );">Promissory Notes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Promissory Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, the Company issued an unsecured convertible promissory note to Psyence Group&#160;Inc. (the &#8220;<b style="font-weight:bold;">PGI Note</b>&#8221;), in the principal amount of $1,610,657, which is equal to the total amount owed to PGI in connection with loans the PGI had previously made to the Company. The PGI Note&#160;bears no interest, and (i)&#160;$150,000 of the principal balance of the PGI Note&#160;was paid on the date of the Closing and (ii)&#160;$1,460,657 of the principal balance of the PGI Note&#160;will be payable on the date that is the one-year anniversary after the Business Combination, or January&#160;25, 2025. The proceeds from this loan were already received by the Company prior to the acquisition date. This note is convertible into shares at the option of PGI. The conversion price will be mutually agreed upon and such conversion terms will not be less favourable than the below NCAC convertible promissory note. Given that the conversion price is not fixed, the conversion feature has been determined to be an embedded derivative and thus the entire instrument has been designated as FVTPL. The PGI Note upon initial recognition at fair value was $1,418,675. At year end the fair value of the PGI Note was $1,316,236. A fair value loss of $47,561, after factoring in the repayment of $150,000, was included in the consolidated statements of net loss and comprehensive loss relating to the PGI Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The fair value of the notes was calculated using a credit adjusted market borrowing rate to determine fair value. Since the PGI Note is from a related party the difference between fair value and the face value of the PGI Note on initial measurement was recognized in other comprehensive loss. Subsequent change in fair value movements is recognized in consolidated statements of net loss and comprehensive loss.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, NCAC issued an unsecured convertible promissory note, prior to the closing of the RTO, to the NCAC Sponsor (the &#8220;<b style="font-weight:bold;">NCAC Replacement Note</b>&#8221;), in the principal amount of $1,615,501, which is equal to the total amount owed to Sponsor under certain existing promissory notes previously issued by NCAC to the Sponsor (the &#8220;<b style="font-weight:bold;">Existing Notes</b>&#8221;). The NCAC Replacement Note&#160;bears no interest, and (i)&#160;$100,000 of the principal balance of the NCAC Replacement Note&#160;became owing on the date of the Closing and (ii)&#160;$1,515,501 of the principal balance of the NCAC Replacement Note&#160;will be payable on the date that is the one-year anniversary after the Business Combination, or January&#160;25, 2025. As at March 31, 2024 the Company had not made payment of the $100,000 owing to the NCAC Sponsor. This note is convertible into shares at the option of NCAC Sponsor. The conversion price will be mutually agreed upon and such conversion terms will not be less favourable than the above PGI convertible promissory note. Given that the conversion price is not fixed, the conversion feature has been determined to be an embedded derivative and thus the entire instrument has been designated as FVTPL. The NCAC Replacement Note upon initial recognition at fair value was $1,413,529. At year end the fair value of the NCAC Replacement Note was $1,474,255. A fair value loss of $60,727 was included in the consolidated statements of net loss and comprehensive loss relating to the NCAC Replacement Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the notes was calculated using a credit adjusted market borrowing rate.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_PromissoryNotesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_PromissoryNotesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_PromissoryNotesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on promissory notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_PromissoryNotesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426964688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapitalAbstract', window );"><strong>Share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Share capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">a) Authorized</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company is authorized to issue an unlimited number of Common Shares, each without par value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">b) Issued and outstanding</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As at March&#160;31, 2024, there were 13,390,659 (March 31, 2023 &#8211; nil) issued and <span style="-sec-ix-hidden:Hidden_t5Q4ViJtT0a_n3x8PTtDQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> Common Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January&#160;25, 2024, because of the completion of the RTO Transaction, the Company issued 5,000,000 Common Shares to PGI, 7,794,659 to the previous shareholders of NCAC and 596,000 to third party advisors (see Note&#160;5).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments to advisors of NCAC was settled in the Company&#8217;s shares upon RTO at the closing price. Accounts payable of $2,136,340 acquired from NCAC as part of the RTO transaction was settled through the issuance of 446,000 shares at a fair value of $4.79 per share on January 25, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An amount of $1,000,000 owing by the Company for services provided in relation to the RTO transaction was settled through the issuance of 150,000 common shares at a fair value of $4.79. A gain on settlement of $281,500 was included in the consolidated statements of net loss and comprehensive loss relating to this advisor settlement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The prior year equity is the net parent investment which represents the net financings that the Company received from Psyence Group to fund it&#8217;s operations through contributions to the clinical trials, cash extended to the Company&#8217;s subsidiaries and the net effect of cost allocations from transactions with Psyence Group, all of which did not require repayments.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">c) Loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculation of basic and diluted loss per share is based on the loss for the&#160;year divided by the weighted average number of shares in circulation during the&#160;year. In calculating the diluted loss per share, potentially dilutive shares such as options, convertible debt and warrants have not been included as they would have the effect of decreasing the loss per share, and they would therefore be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426763088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsOtherIncomeAbstract', window );"><strong>Other income.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Other income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Other income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company received a research and development rebate of AUD $1,336,622 ($879,344) from the Australian Taxation office. The Company benefits from the Australian Federal Government&#8217;s Research&#160;&amp; Development tax incentive program, which provides up to a 43.5% rebate on research and development expenses in Australia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This rebate represents a government grant aimed at supporting research and development activities. Therefore, in accordance with International Financial Reporting Standards (IFRS), the grant is recognized as income when there is a reasonable assurance that the grant will be received and that the Company will comply with the conditions attached to it. These conditions were satisfied when the Company received the rebate on October&#160;5, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On August&#160;21, 2023 the Company entered into a loan agreement via its Australian subsidiary Psyence Australia (Pty) Ltd (the &#8220;<b style="font-weight:bold;">Borrower</b>&#8221;), to borrow up to AUD $1,100,000 by way of a secured loan from RH Capital Finance Co.,&#160;LLC. The Loan is secured by way of a General Security Agreement and company guarantee against the assets of the Borrower and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The loan was granted to the Borrower after it successfully registered its research and development activities with the Australian Federal Government. The Borrower benefits from the Australian Federal Government&#8217;s Research&#160;&amp; Development tax incentive program, which provides up to a 43.5% rebate on research and development expenses in Australia. The Loan bears interest at 16% per annum subject to a minimum interest chargeable period of 91&#160;days and is repayable at the earlier of: (a)&#160;21 business&#160;days after the notice of assessment (in respect of R&amp;D refunds) is issued by the Australian Taxation Office to the Borrower for the financial&#160;year ended June&#160;30, 2023 (b)&#160;an event of default and (c)&#160;30 November&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The loan with RH Capital Finance Co., LLC was repaid in full on October&#160;5, 2023 when the Company received the research and development rebate from the Australian Taxation office, which was utilized to settle the loan payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">$29,697 (March&#160;31, 2023&#160;- $nil) in interest expense was incurred during the&#160;year ended March&#160;31, 2024, on this loan. The loan and all outstanding interest was repaid.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426841872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CapitalManagementAbstract', window );"><strong>Capital management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CapitalManagementDisclosureTextBlock', window );">Capital management</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Capital management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern to pursue the development of natural health business, to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company manages its capital structure and adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust the amount of cash and cash equivalents on hand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company&#8217;s approach to capital management during the period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CapitalManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CapitalManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CapitalManagementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on capital management.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CapitalManagementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392428073312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Transactions with related parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Transactions with related parties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Transactions with related parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. The Company incurred the following transactions with related parties during the&#160;years ended March&#160;31, 2024 and March&#160;31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Compensation to key management personnel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Key management personnel are those people who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company&#8217;s executive officers and Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Key Management Personnel</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short term benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 465,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 593,729</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 233,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,782</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 768,511</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Short term benefits consist of consulting fees, director&#8217;s fees, payroll and other benefits paid to key management personnel. Share based compensation is options granted to key management personnel.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425307360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">16. Share based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During the&#160;year ended March&#160;31, 2024, $317,882 (Year ended March&#160;31, 2023&#160;- $221,287) was recognized for options and restricted stock units (&#8220;RSU&#8217;s&#8221;) granted by Psyence Group under professional and consulting fees expenses and general and administrative expenses on the consolidated statements of net loss and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">This share-based compensation relates only to the historic carve out pre-combination period and does not relate to options or RSUs in the Company. No share options or <span style="-sec-ix-hidden:Hidden_XxB_F4KMEE25cXOfcM4pEQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">RSUs</span></span> have been issued by the Company post transaction and listing date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392428071520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax note<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax note</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17. Income tax note</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 26.5% (2023&#160;&#8211; 26.5%) to the effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Income/(Loss) before recovery of income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,159,048)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,206,403)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax (recovery)/expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,557,148)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (849,679)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Difference in foreign tax rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Listing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,992,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other permanent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,061,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in tax benefits not recognized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 502,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 849,679</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax (recovery)/expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Unrecognized deferred tax asset</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amounts of assets and liabilities. Deferred tax assets have not been recognized in respect of the following deductible temporary differences:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Unrecognized deductible temporary differences</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,035</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward-Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,357,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward-Australia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,699,257</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,646,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,721,292</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-capital loss carry forwards will expire as noted in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year of expiry</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Canada</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Australia</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,357,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Indefinite</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,861</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,357,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,861</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425854624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and financial risk management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial instruments and financial risk management</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">18. Financial instruments and financial risk management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">a) Financial instrument classification and fair value measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that are recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of hierarchy has the following levels:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1&#160;&#8211; quoted prices in active markets for identical financial instruments.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2&#160;&#8211; quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in the markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3&#160;&#8211; valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The table below presents the carrying value of the Company&#8217;s financial instruments:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities &#8211; private warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,608</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities &#8211; public warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 875,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 875,000</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,657,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,657,397</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NCAC Sponsor promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,474,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,474,256</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PGI promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316,236</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 875,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,608</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,447,889</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,349,497</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The face value of the other financial instruments approximates the fair value due to the short-term maturity nature of the financial instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There were no transfers in and out of level 3 during the year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">b) Risk management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company&#8217;s Board of Directors has overall responsibility for the establishment and oversight of the Company&#8217;s risk management framework.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Credit risk arises from cash and cash equivalents held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Liquidity risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company&#8217;s main source of funding has been through investments from its parent. The Company&#8217;s access to financing is uncertain. There can be no assurance of continued access to significant equity or debt funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table set forth the maturity of the contractual obligations as at March&#160;31, 2024 and after</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between 1 </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and 3 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable &amp; accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 714,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 714,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 714,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible note liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,657,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,875,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,625,000</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due to NCAC sponsor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,615,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,615,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,615,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due to Psyence Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,460,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,460,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,460,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total contractual obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,447,737</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,665,340</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,040,340</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,625,000</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Foreign exchange risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As at March&#160;31, 2024, a 10% fluctuation in foreign exchange rates would result in a $4,139 impact to net loss and comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426971856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19. Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has received additional financing of $1,000,000 related to the Second Tranche of convertible notes:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On May&#160;31, 2024, the Company received proceeds of $250,000 related to the issuance of the Second Tranche Notes. The principal amount of $312,250 was issued under the same terms as the First Tranche Notes, with interest accruing at 8.0% per annum from the issuance date. The Conversion Price remains subject to adjustment as per the terms outlined in the original Securities Purchase Agreement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On June&#160;17, 2024, an additional $250,000 in proceeds was received by the Company for the issuance of the Second Tranche Notes. The principal amount issued was $312,250, also under the terms consistent with the First Tranche Notes. Interest accrues at 8.0% per annum from the date of issuance, with the Conversion Price subject to the same adjustment mechanisms detailed in the initial agreement.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On July 15, 2024, an additional $500,000 in proceeds was received by the Company for the issuance of the Second Tranche Notes. The principal amount issued was $625,000, also under the terms consistent with the First Tranche Notes. Interest accrues at 8.0% per annum from the date of issuance, with the Conversion Price subject to the same adjustment mechanisms detailed in the initial agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These subsequent financings are part of the Convertible Note&#160;Financing arrangement entered into in connection with the RTO Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company has received two conversion notices related to the First Tranche of convertible notes:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">On May&#160;15, 2024, a conversion notice was received for a principal amount of $70,000. This amount converted at a VWAP of $0.5361 per share, resulting in the issuance of 130,572 shares.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">On June&#160;20, 2024, a second conversion notice was received for a principal amount of $1,072,200. This converted at a VWAP of $0.5361 per share, leading to the issuance of 2,000,000 shares.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Concurrently, the Company issued 86,790 shares on May&#160;15, 2024, and 78,522 shares on June&#160;20, 2024, to cover outstanding interest on the outstanding principal at a VWAP of $0.5361 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These conversions and interest issuances are in accordance with the terms outlined in the Securities Purchase Agreement and are related to the Convertible Note&#160;Financing arrangement initiated in connection with the RTO Transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In July, 2024, the Company completed a warrant exchange agreement with an unaffiliated third-party investor of warrants to purchase the Company&#8217;s common shares, no par value per share, which warrants are currently trading on Nasdaq. Pursuant to the Warrant Exchange Agreement, the Company issued to the Holder 660,000 Common Shares in exchange for the surrender and cancellation of 660,000 Public Warrants held by the Holder.<br/><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May&#160;16, 2024, the Company issued an additional 178,000 shares to third-party consultants and legal advisors.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392427535424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MaterialAccountingPoliciesAbstract', window );"><strong>Material accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financial instruments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets and financial liabilities, including derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument or derivative contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Summary of the Company&#8217;s classification and measurements of financial assets and liabilities:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:4.8pt;"><td style="vertical-align:bottom;width:50.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Financial Assets and Liabilities</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:22.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Measurement </b></p></td></tr><tr style="height:5.75pt;"><td style="vertical-align:bottom;width:50.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr style="height:5.75pt;"><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Restricted cash</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortized cost</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Derivative warrant liability</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Convertible notes</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">NCAC promissory note</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr><tr><td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PGI promissory note</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">FVTPL</p></td><td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Classification</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its financial assets and financial liabilities in the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (&#8220;FVTPL&#8221;); ii) those to be measured subsequently at fair value through other comprehensive income (&#8220;FVOCI&#8221;); and iii) those to be measured at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair value, gains and losses are either recorded in net loss or other comprehensive income (loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company reclassifies financial assets only when its business model for managing those assets changes. Financial liabilities are not reclassified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Amortized cost</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This category includes financial assets that are held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments of principal and interest (&#8220;SPPI&#8221;) criterion. Financial assets classified in this category are measured at amortized cost using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair value through profit or loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This category includes derivative instruments as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL. This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest (&#8220;SPPI&#8221;) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Financial assets at fair value through other comprehensive income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Equity instruments that are not held-for-trading can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable transaction costs are included in the carrying value of the instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets at fair value through other comprehensive income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Compound financial instrument and derivative liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company determined that the warrants, including public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized in net loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each embedded derivative is measured and presented separately unless the whole hybrid financial instrument is designated as at FVTPL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All financial instruments are required to be measured at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payments of principal and interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value are attributable to changes in own credit risk which is recorded in other comprehensive income.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Cash and cash equivalents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash on hand and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three&#160;months at the date of their acquisition.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory', window );">Restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Restricted cash</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Restricted cash comprises a collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment certificate with the bank.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory', window );">Related party transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Related party transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be a related party transaction when there is transfer of resources or obligations between related parties.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock', window );">Change in accounting policy</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Change in accounting policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to completion of the Business Combination Agreement and NASDAQ listing as explained in Note 1 to the audited consolidated financial statements, on January 25, 2024, the Corporation decided to change the presentation currency of its consolidated financial statements from Canadian Dollars to United States Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors believe that US Dollar financial reporting provides more relevant presentation of the Corporation&#8217;s financial position, funding and treasury functions, financial performance and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in presentation currency represents a change in accounting policy in terms of IAS 8 &#8211; <i style="font-style:italic;">Accounting Policies, Changes in Accounting Estimates and Errors</i>, requiring the restatement of comparative information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with IAS 21 &#8211; <i style="font-style:italic;">The Effects of Changes in Foreign Exchange Rates</i>, the methodology followed in restating historical financial information from CDN$ to US$.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The average and closing rates used in translating the historical financial information from CDN$ to US$ for the various periods were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The closing rate used as at March 31, 2024 was $0.738 and as at March 31, 2023 was $0.7389.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The average rate used for the year ended March 31, 2024 was $0.7415, for the year ended March 31, 2023 was $0.7559 and for the year ended March 31, 2022 was $0.8003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The change in presentation currency is a voluntary change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated to United States dollars which is disclosed in the tables below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,805,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (471,485)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,334,280</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,556</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 202,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,782)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149,369</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,050</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,152,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (561,937)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,590,255</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,152,192</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (561,937)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,590,255</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,423,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (632,767)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,700</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,423,467</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (632,767)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,790,700</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (271,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200,445)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (271,275)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 70,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (200,445)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,152,192</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (561,937)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,590,255</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022&#160;Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> $</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,191,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (437,658)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,753,437</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,990)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,010</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,862)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,510</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,385</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,287,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (456,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,830,342</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,287,196</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (456,854)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,830,342</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,642</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 164,500</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (32,858)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 131,642</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,122,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (423,996)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,698,700</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,122,696</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (423,996)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,698,700</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,287,196</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (456,854)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,830,342</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,029</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,126,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (517,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,608,895</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 484,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (117,947)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 366,435</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,655,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (403,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,252,510</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (4,276,099)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,041,230)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,234,869)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,554</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,662)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,912</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (4,238,471)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,050,392)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,206,403)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,238,471)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,206,403)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-cash adjustment:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 292,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,469)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,287</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84,499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(84,499)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Changes in working capital:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (152,778)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(109,858)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (97,547)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(71,665)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,258,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (599,909)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,659,058</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,937,073)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 344,993</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(1,592,080)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Proceeds received from Psyence Group Inc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,551,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (378,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,172,923</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash provided from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,551,744</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (378,821)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,172,923</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (385,329)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,828)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(419,157)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents, start of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,191,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (437,658)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,753,437</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,805,765</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (471,486)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,334,280</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Provisions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and comprehensive loss as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Foreign currency translation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Financial Statements are presented in USD $ which is PBM&#8217;s functional currency. The functional currency of its subsidiary consolidated within these Financial Statements is AUD $.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In each individual entity, a foreign currency transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency and the foreign currency at the date of the transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the end of the reporting period, monetary assets and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The resulting exchange gains or losses arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition, are included in statement of net loss and comprehensive loss in the period in which they arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the purpose of presenting these Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries is recorded in reserves.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Loss per share</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company presents basic and diluted loss per share data for its common shares. Basic loss per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting the loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Share based compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of the options and RSUs granted by the Company shall be recognized as an expense in the Consolidated Financial Statements of the Company. The expense shall be recognized over the vesting period of the options. The fair value options shall be determined using the Black-Scholes model.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Income taxes</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Income tax comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders&#8217; equity, in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also recognized directly in equity or other comprehensive income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Current tax is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect of previous&#160;years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the amounts and the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax is recognized in respect of all qualifying temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Financial Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions with related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 46<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_46&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of change in accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_MaterialAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_MaterialAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392428071520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_BasisOfPresentationAbstract', window );"><strong>Basis of presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory', window );">Summary of consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name of entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Place&#160;of&#160;incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%&#160;ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accounting&#160;method</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Psyence Australia Pty Ltd.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pysence Biomed II Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr><tr><td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Newcourt Acquisition Corp.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cayman Islands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consolidated</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 2<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_2_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425764224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material accounting policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MaterialAccountingPoliciesAbstract', window );"><strong>Material accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate', window );">Summary of change in accounting policy</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,805,765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (471,485)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,334,280</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,444)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,556</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 202,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,782)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 149,369</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104,276</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,226)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77,050</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,152,192</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (561,937)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,590,255</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,152,192</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (561,937)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,590,255</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,423,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (632,767)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,700</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,423,467</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (632,767)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,790,700</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (271,275)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,830</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (200,445)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (271,275)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 70,830</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (200,445)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,152,192</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (561,937)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,590,255</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022&#160;Restated</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> $</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,191,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (437,658)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,753,437</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,990)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 32,010</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 49,372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,862)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,510</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,729</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,344)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,385</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,287,196</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (456,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,830,342</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,287,196</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (456,854)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,830,342</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (32,858)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131,642</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 164,500</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (32,858)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 131,642</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,122,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (423,996)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,698,700</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,122,696</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (423,996)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,698,700</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND NET DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,287,196</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (456,854)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,830,342</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Sales and marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,292</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,263)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,029</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,126,762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (517,867)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,608,895</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 484,382</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (117,947)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 366,435</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Professional and consulting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,655,663</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (403,153)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,252,510</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (4,276,099)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,041,230)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,234,869)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,554</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,574</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,662)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,912</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (4,238,471)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (1,050,392)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (3,206,403)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Reported&#160;CAD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restated&#160;USD</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Change in presentation currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,238,471)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,206,403)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-cash adjustment:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 292,756</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,469)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 221,287</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Foreign exchange</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (84,499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(84,499)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Changes in working capital:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (152,778)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(109,858)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (97,547)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(71,665)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,258,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (599,909)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,659,058</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,937,073)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 344,993</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(1,592,080)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Proceeds received from Psyence Group Inc</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,551,744</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (378,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,172,923</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash provided from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,551,744</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (378,821)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,172,923</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Change in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (385,329)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (33,828)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(419,157)</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Cash and cash equivalents, start of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,191,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (437,658)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,753,437</p></td></tr><tr><td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,805,765</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (471,486)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,334,280</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the nature of changes in accounting estimates that have effects in the current period or are expected to have effects in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_MaterialAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_MaterialAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426771392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse takeover transaction with NCAC (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionAbstract', window );"><strong>Reverse takeover transaction with NCAC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ScheduleOfListingExpensesTableTextBlock', window );">Summary of calculation of listing expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Listing</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;Expense</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consideration paid:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Shares issued to NCAC shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,794,659</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Total consideration shares issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,794,659</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fair value of the common shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.79</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Deemed consideration amount for the common shares issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 37,336,416</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Net identifiable liabilities acquired:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 203</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,136,505)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">NCAC promissory note (Note 11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,413,529)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Derivative warrant liabilities (Note 10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (595,358)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net liabilities acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,145,189</b></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Listing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 41,481,605</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ScheduleOfListingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of calculation of listing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ScheduleOfListingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425757408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, restricted cash and cash equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CashRestrictedCashAndCashEquivalentsAbstract', window );"><strong>Cash, restricted cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Summary of cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Unrestricted cash held with chartered banks</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 733,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,334,280</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 29,556</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 762,799</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,363,836</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CashRestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CashRestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392424037408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of information about equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Computer </b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equipment</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,727</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,727</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Accumulated Depreciation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Charge for the year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (240)</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (240)</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">At March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,487</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425044368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts payable and accrued liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock', window );"><strong>Accounts payable and accrued liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock', window );">Summary of accounts payable and accrued liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Trade payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 562,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,628,143</p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 125,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 162,557</p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 755,202</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,790,700</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of accounts payable and accrued liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425767216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible note liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of fair value of convertible notes combined discounted cash flow</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Inputs at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Inputs at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 25, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiry date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 25, 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 25, 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of fair value of convertible notes combined discounted cash flow</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Note principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,125,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepayment Amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 130</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Discount rate cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility annual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility daily</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free annual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426734480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative warrant liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DerivativeWarrantLiabilitiesAbstract', window );"><strong>Derivative warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of quantitative information regarding Level 2 fair value measurements of warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Inputs at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrant Inputs at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">January 25, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Nil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59.98</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expiry date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 25, 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 25, 2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock', window );">Summary of warrant transactions and the number of warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Public Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Private Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Weighted  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Weighted   </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td></tr><tr><td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Balance, March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 570,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.50</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock', window );">Schedule of warrants outstanding and exercisable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants </b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issue Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiry Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">January 25, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January 25, 2029 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,070,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,070,000</p></td></tr><tr><td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance, March 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,070,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,070,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DerivativeWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DerivativeWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrant transactions and number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426748880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Transactions with related parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Summary of compensation to key management personnel</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Key Management Personnel</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short term benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 465,702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 593,729</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 233,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 174,782</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 698,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 768,511</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392424634416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax note (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of reconciliation of the combined Canadian federal and provincial statutory income tax rate to the effective tax rate</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net Income/(Loss) before recovery of income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (51,159,048)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,206,403)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax (recovery)/expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,557,148)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (849,679)</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Difference in foreign tax rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Listing expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,992,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other permanent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,061,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in tax benefits not recognized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 502,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 849,679</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax (recovery)/expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Summary of unrecognized deferred tax asset</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Unrecognized deductible temporary differences</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 124,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,035</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward-Canada</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,357,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-capital losses carried forward-Australia</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164,861</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,699,257</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,646,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,721,292</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock', window );">Summary of non-capital loss carry forwards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year of expiry</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Canada</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Australia</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,357,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Indefinite</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,861</p></td></tr><tr><td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,357,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164,861</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carry forwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425764752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and financial risk management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory', window );">Schedule of carrying value of the financial instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities &#8211; private warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,608</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,608</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Derivative warrant liabilities &#8211; public warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 875,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 875,000</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,657,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,657,397</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NCAC Sponsor promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,474,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,474,256</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PGI promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,316,236</p></td></tr><tr><td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, March 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 875,000</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 26,608</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 10,447,889</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,349,497</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock', window );">Schedule of maturities of contractual obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less than 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Between 1 </b></p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Flows</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">and 3 years</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable &amp; accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 714,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 714,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 714,182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Convertible note liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,657,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,875,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,625,000</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due to NCAC sponsor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,615,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,615,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,615,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Due to Psyence Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,460,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,460,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,460,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total contractual obligations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 11,447,737</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,665,340</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,040,340</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,625,000</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Thee tabular disclosure of maturity analysis for financial instruments (including derivative and non-derivative instruments) that shows the remaining contractual maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392427242848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of operations and going concern (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 25, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 15, 2024 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jan. 23, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Nature of operations and going concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction', window );">Shares issued to NCAC shareholders | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ComprehensiveIncomeLoss', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (50,963,351)<span></span>
</td>
<td class="num">$ (3,296,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Nature of operations and going concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction', window );">Shares issued to NCAC shareholders | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Nature of operations and going concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsDebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember', window );">First Tranche Note | Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Nature of operations and going concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount of debt issued</a></td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsProceedsFromConvertibleDebt', window );">Total subscription amount</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member', window );">Business combination agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Nature of operations and going concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares to acquire | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ThresholdAmountForMinimumCashCondition', window );">Amount for minimum cash condition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member', window );">Business combination agreement | Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Nature of operations and going concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes', window );">Senior secured convertible notes | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BusinessCombinationsAxis=pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member', window );">Business combination agreement | Convertible note liability | Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Nature of operations and going concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsDebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_SubscriptionAmount', window );">Subscription amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsDebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsDebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of senior secured convertible notes collectively called as notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period for reverse takeover transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_SubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the subscription amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_SubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ThresholdAmountForMinimumCashCondition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold amount for minimum cash condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ThresholdAmountForMinimumCashCondition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425072592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_PsyenceAustraliaPtyLtd.Member', window );">Psyence Australia Pty Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Investment in subsidiaries</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_PysenceBiomedIICorpMember', window );">Pysence Biomed II Corp.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Investment in subsidiaries</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_NewcourtAcquistionCorpMember', window );">Newcourt Acquistion Corp.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems', window );"><strong>Investment in subsidiaries</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary', window );">% ownership</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 19B<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_19B_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_PsyenceAustraliaPtyLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_PsyenceAustraliaPtyLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_PysenceBiomedIICorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_PysenceBiomedIICorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_NewcourtAcquistionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantInvestmentsInSubsidiariesAxis=pbm_NewcourtAcquistionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392420858592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material accounting policies - historical financial information has been translated to United States dollars (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 733,188<span></span>
</td>
<td class="nump">$ 1,334,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,334,280<span></span>
</td>
<td class="nump">$ 1,753,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">29,611<span></span>
</td>
<td class="nump">29,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,556<span></span>
</td>
<td class="nump">32,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">41,747<span></span>
</td>
<td class="nump">149,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,369<span></span>
</td>
<td class="nump">39,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaids</a></td>
<td class="nump">322,126<span></span>
</td>
<td class="nump">77,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,050<span></span>
</td>
<td class="nump">5,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">1,126,672<span></span>
</td>
<td class="nump">1,590,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,255<span></span>
</td>
<td class="nump">1,830,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,132,159<span></span>
</td>
<td class="nump">1,590,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,255<span></span>
</td>
<td class="nump">1,830,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">755,202<span></span>
</td>
<td class="nump">1,790,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,790,700<span></span>
</td>
<td class="nump">131,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">12,104,699<span></span>
</td>
<td class="nump">1,790,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,790,700<span></span>
</td>
<td class="nump">131,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Net equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,445)<span></span>
</td>
<td class="nump">1,698,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">NET DEFICIT</a></td>
<td class="num">(10,972,540)<span></span>
</td>
<td class="num">(200,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,445)<span></span>
</td>
<td class="nump">1,698,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND NET DEFICIT</a></td>
<td class="nump">1,132,159<span></span>
</td>
<td class="nump">1,590,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,590,255<span></span>
</td>
<td class="nump">$ 1,830,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">80,603<span></span>
</td>
<td class="nump">7,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">954,593<span></span>
</td>
<td class="nump">1,608,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">557,904<span></span>
</td>
<td class="nump">366,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees</a></td>
<td class="nump">1,158,484<span></span>
</td>
<td class="nump">1,252,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsOperatingIncomeLoss', window );">Loss before other items</a></td>
<td class="num">(2,751,584)<span></span>
</td>
<td class="num">(3,234,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsNonoperatingIncomeExpenseAbstract', window );"><strong>Other items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Interest income</a></td>
<td class="nump">2,134<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain</a></td>
<td class="num">(2,695)<span></span>
</td>
<td class="nump">26,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(51,159,048)<span></span>
</td>
<td class="num">(3,206,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Non-cash adjustment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based compensation</a></td>
<td class="nump">317,882<span></span>
</td>
<td class="nump">221,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange</a></td>
<td class="nump">3,658<span></span>
</td>
<td class="num">(84,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IncreaseDecreaseInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="nump">107,622<span></span>
</td>
<td class="num">(109,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaids</a></td>
<td class="num">(245,075)<span></span>
</td>
<td class="num">(71,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,035,498)<span></span>
</td>
<td class="nump">1,659,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(2,945,367)<span></span>
</td>
<td class="num">(1,592,080)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ProceedsFromContributionsOfParent', window );">Proceeds received from Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided from financing activities</a></td>
<td class="nump">2,350,000<span></span>
</td>
<td class="nump">1,172,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Change in cash and cash equivalents</a></td>
<td class="num">(601,092)<span></span>
</td>
<td class="num">(419,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">1,334,280<span></span>
</td>
<td class="nump">1,753,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">$ 733,188<span></span>
</td>
<td class="nump">$ 1,334,280<span></span>
</td>
<td class="nump">$ 1,334,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember', window );">Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,805,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,191,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaids</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,152,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,152,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,423,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,423,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Net equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(271,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,122,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">NET DEFICIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(271,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,122,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND NET DEFICIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,152,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,287,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,655,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsOperatingIncomeLoss', window );">Loss before other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,276,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsNonoperatingIncomeExpenseAbstract', window );"><strong>Other items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">NET LOSS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,238,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Non-cash adjustment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IncreaseDecreaseInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(152,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaids</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,258,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,937,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ProceedsFromContributionsOfParent', window );">Proceeds received from Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,551,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided from financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,551,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Change in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385,329)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,191,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,805,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(471,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(437,658)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaids</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(561,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(456,854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(561,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(456,854)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(632,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(632,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Net equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423,996)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">NET DEFICIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(423,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND NET DEFICIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (561,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (456,854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,263)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(517,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,947)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Professional and consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(403,153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsOperatingIncomeLoss', window );">Loss before other items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,041,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsNonoperatingIncomeExpenseAbstract', window );"><strong>Other items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">NET LOSS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,050,392)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Non-cash adjustment:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,469)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Foreign exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IncreaseDecreaseInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaids</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(599,909)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ProceedsFromContributionsOfParent', window );">Proceeds received from Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided from financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Change in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,828)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(437,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (471,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in accounts payable and accrued liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IncreaseDecreaseInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IncreaseDecreaseInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ProceedsFromContributionsOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from contributions of parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ProceedsFromContributionsOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis=ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392428116704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Material accounting policies - Additional information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MaterialAccountingPoliciesAbstract', window );"><strong>Material accounting policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing rate</a></td>
<td class="nump">0.738<span></span>
</td>
<td class="nump">0.7389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate</a></td>
<td class="nump">0.7415<span></span>
</td>
<td class="nump">0.7559<span></span>
</td>
<td class="nump">0.8003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_MaterialAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_MaterialAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425854624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Critical accounting estimates and judgements (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 25, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CriticalAccountingEstimatesAndJudgementsAbstract', window );"><strong>Critical accounting estimates and judgements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsSharePrice', window );">Closing trading price</a></td>
<td class="nump">$ 4.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CriticalAccountingEstimatesAndJudgementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CriticalAccountingEstimatesAndJudgementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392475821632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse takeover transaction with NCAC (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jan. 26, 2024</div></th>
<th class="th"><div>Jan. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems', window );"><strong>Reverse takeover transaction with NCAC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsSharePrice', window );">Closing trading price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionWithNcacAxis=pbm_NcacMember', window );">NCAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems', window );"><strong>Reverse takeover transaction with NCAC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsSharePrice', window );">Closing trading price</a></td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionSharesIssued', window );">Consideration shares issued to NCAC shareholders</a></td>
<td class="nump">7,794,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued as consideration to shareholders in reverse takeover transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionWithNcacAxis=pbm_NcacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionWithNcacAxis=pbm_NcacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425444848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse takeover transaction with NCAC - listing expenses (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 25, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionConsiderationPaidAbstract', window );"><strong>Consideration paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction', window );">Shares issued to NCAC shareholders | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsSharePrice', window );">Fair value of the common shares | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract', window );"><strong>Net identifiable liabilities acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 733,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,334,280<span></span>
</td>
<td class="nump">$ 1,334,280<span></span>
</td>
<td class="nump">$ 1,753,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(755,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,790,700)<span></span>
</td>
<td class="num">$ (1,790,700)<span></span>
</td>
<td class="num">$ (131,642)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Derivative warrant liabilities (Note 10)</a></td>
<td class="num">(901,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ListingExpense', window );">Listing Expense</a></td>
<td class="nump">$ 41,481,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionWithNcacAxis=pbm_NcacMember', window );">NCAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionConsiderationPaidAbstract', window );"><strong>Consideration paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction', window );">Shares issued to NCAC shareholders | shares</a></td>
<td class="nump">7,794,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionSharesIssued', window );">Total consideration shares issued | shares</a></td>
<td class="nump">7,794,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsSharePrice', window );">Fair value of the common shares | $ / shares</a></td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="nump">$ 3.55<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued', window );">Deemed consideration amount for the common shares issued</a></td>
<td class="nump">$ 37,336,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract', window );"><strong>Net identifiable liabilities acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(2,136,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">NCAC promissory note (Note 11)</a></td>
<td class="num">(1,413,529)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentWarrantLiability', window );">Derivative warrant liabilities (Note 10)</a></td>
<td class="num">(595,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetAssetsLiabilities', window );">Net liabilities acquired</a></td>
<td class="nump">4,145,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ListingExpense', window );">Listing Expense</a></td>
<td class="nump">$ 41,481,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current warrant liabilities. [Refer: Warrant liability]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets less the amount of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG63<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG63&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ListingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ListingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionConsiderationPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionConsiderationPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed consideration amount for the common shares issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued as consideration to shareholders in reverse takeover transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period for reverse takeover transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionWithNcacAxis=pbm_NcacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionWithNcacAxis=pbm_NcacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425323696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse takeover transaction with NCAC - Additional information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionAbstract', window );"><strong>Reverse takeover transaction with NCAC</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_TransactionExpense', window );">Transaction expenses included other costs</a></td>
<td class="nump">$ 2,461,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice', window );">Increase in listing expense from change in estimate of share price</a></td>
<td class="nump">$ 9,483,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in listing expense from change in estimate of share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_TransactionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transaction expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_TransactionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425050640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, restricted cash and cash equivalents (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CashRestrictedCashAndCashEquivalentsAbstract', window );"><strong>Cash, restricted cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Unrestricted cash held with chartered banks</a></td>
<td class="nump">$ 733,188<span></span>
</td>
<td class="nump">$ 1,334,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
<td class="nump">29,611<span></span>
</td>
<td class="nump">29,556<span></span>
</td>
<td class="nump">$ 29,556<span></span>
</td>
<td class="nump">$ 32,010<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_CashRestrictedCashAndCashEquivalents', window );">Total</a></td>
<td class="nump">$ 762,799<span></span>
</td>
<td class="nump">$ 1,363,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CashRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, restricted cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CashRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_CashRestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_CashRestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392419951824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">$ 5,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">5,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">5,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">5,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment | Accumulated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Charge for the year</a></td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="num">$ (240)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392497770976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts payable and accrued liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock', window );"><strong>Accounts payable and accrued liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 562,352<span></span>
</td>
<td class="nump">$ 1,628,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued liabilities</a></td>
<td class="nump">125,951<span></span>
</td>
<td class="nump">162,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermProvisions', window );">Provisions</a></td>
<td class="nump">66,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total</a></td>
<td class="nump">$ 755,202<span></span>
</td>
<td class="nump">$ 1,790,700<span></span>
</td>
<td class="nump">$ 1,790,700<span></span>
</td>
<td class="nump">$ 131,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392427601312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible note liability (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 15, 2024 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jan. 25, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate', window );">Number of days prior to effective initial registration statement for first reset date</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_PeriodOfClosingDateConsideredForSecondResetDate', window );">Period of closing date considered for second reset date</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsDebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ThresholdPeriodForVolumeWeightedAveragePrice', window );">Threshold period for volume-weighted average price</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares', window );">Threshold period for payment of price difference between VWAP and conversion price in cash or in shares</a></td>
<td class="text">35 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes', window );">Senior secured convertible notes | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Maximum | Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsDebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_SubscriptionAmount', window );">Subscription amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember', window );">First Tranche Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DebtInstrumentConvertibleInitialConversionPrice', window );">Initial Conversion Price | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember', window );">First Tranche Note | Until the First Reset Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DebtInstrumentConvertibleFloorPrice', window );">Conversion floor price | $ / shares</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember', window );">First Tranche Note | On the Second Reset Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DebtInstrumentConvertibleFloorPrice', window );">Conversion floor price | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember', window );">First Tranche Note | Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Convertible note liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsProceedsFromConvertibleDebt', window );">Proceeds received from convertible note</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DebtInstrumentConvertibleFloorPrice', window );">Conversion floor price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DebtInstrumentConvertibleFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DebtInstrumentConvertibleFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DebtInstrumentConvertibleInitialConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DebtInstrumentConvertibleInitialConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsDebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsDebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of days prior to effective initial registration statement for first reset date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of senior secured convertible notes collectively called as notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_PeriodOfClosingDateConsideredForSecondResetDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of closing date considered for second reset date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_PeriodOfClosingDateConsideredForSecondResetDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_SubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the subscription amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_SubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold period for payment of price difference between VWAP and conversion price in cash or in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ThresholdPeriodForVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold period for volume-weighted average price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ThresholdPeriodForVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=pbm_FirstTrancheNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pbm_UntilFirstResetDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pbm_UntilFirstResetDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pbm_OnSecondResetDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pbm_OnSecondResetDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392424471808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible note liability -fair value of the convertible notes combined discounted cash flow approach (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">$ 11,349,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentOnConvertibleNote', window );">Fair value loss on convertible note</a></td>
<td class="nump">5,157,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsDebtInstrumentFaceAmount', window );">Note principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">7,657,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentOnConvertibleNote', window );">Fair value loss on convertible note</a></td>
<td class="num">$ (5,157,397)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Convertible note, Measurement input | $ / shares</a></td>
<td class="nump">1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Prepayment Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Convertible note, Measurement input</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Discount rate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Convertible note, Measurement input</a></td>
<td class="nump">4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Discount rate cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Convertible note, Measurement input</a></td>
<td class="nump">20.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Volatility annual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Convertible note, Measurement input</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Volatility daily</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Convertible note, Measurement input</a></td>
<td class="nump">6.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability | Risk free annual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Convertible note, Measurement input</a></td>
<td class="nump">4.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_FairValueAdjustmentOnConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_FairValueAdjustmentOnConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsDebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsDebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=pbm_IfrsConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_ConstantPrepaymentRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_ConstantPrepaymentRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_DiscountRateSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_DiscountRateSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_DiscountRateCashMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_DiscountRateCashMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_AnnualInterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_AnnualInterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426042016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative warrant liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Derivative warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfClassesOfWarrantsOutstanding', window );">Number of classes of warrants outstanding | item</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsIssued', window );">Number of warrants issued</a></td>
<td class="nump">13,070,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsOutstanding', window );">Number of warrants outstanding</a></td>
<td class="nump">13,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares issued upon exercise of warrants</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants per share | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DividendYield', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember', window );">Public warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Derivative warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsIssued', window );">Number of warrants issued</a></td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsOutstanding', window );">Number of warrants outstanding</a></td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants per share | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember', window );">Private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Derivative warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsIssued', window );">Number of warrants issued</a></td>
<td class="nump">570,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsOutstanding', window );">Number of warrants outstanding</a></td>
<td class="nump">570,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants per share | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfClassesOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of classes of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfClassesOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425526640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative warrant liabilities - Fair value measurements (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>Y </div>
<div>$ / shares </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 25, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>Y </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">$ 11,349,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Fair value loss</a></td>
<td class="nump">306,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember', window );">Public warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">$ 875,000<span></span>
</td>
<td class="nump">$ 568,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesFairValuePerShare', window );">Fair value per warrant | $ / shares</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember', window );">Private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">$ 26,608<span></span>
</td>
<td class="nump">$ 26,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesFairValuePerShare', window );">Fair value per warrant | $ / shares</a></td>
<td class="nump">$ 0.4668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">$ 26,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=pbm_SharePriceMeasurementInputMember', window );">Share price | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Warrants, Measurement input | $ / shares</a></td>
<td class="nump">1.14<span></span>
</td>
<td class="nump">4.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=pbm_ExpectedDividendYieldMeasurementInputMember', window );">Expected dividend yield | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Warrants, Measurement input | item</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=pbm_ExercisePriceMeasurementInputMember', window );">Exercise price | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Warrants, Measurement input | $ / shares</a></td>
<td class="nump">11.50<span></span>
</td>
<td class="nump">11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Risk-free interest rate | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Warrants, Measurement input</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="nump">4.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=pbm_ExpectedLifeMeasurementInputMember', window );">Expected life | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Warrants, Measurement input | Y</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Expected volatility | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Quantitative information regarding Level 2 fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Warrants, Measurement input</a></td>
<td class="nump">59.98<span></span>
</td>
<td class="nump">17.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_FinancialLiabilitiesFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per share of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_FinancialLiabilitiesFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_ExpectedDividendYieldMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_ExpectedDividendYieldMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_ExercisePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_ExercisePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=pbm_ExpectedLifeMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=pbm_ExpectedLifeMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392427498288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative warrant liabilities - Warrant transactions (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MovementsOfNumberOfWarrantsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsOutstanding', window );">Number of warrants outstanding, Ending | shares</a></td>
<td class="nump">13,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Weighted Average Exercise Price per share, Ending | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember', window );">Public warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MovementsOfNumberOfWarrantsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_WarrantsIssuedNumber', window );">Issued | shares</a></td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsOutstanding', window );">Number of warrants outstanding, Ending | shares</a></td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_WarrantsIssuedWeightedAverageExercisePrice', window );">Issued, Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Weighted Average Exercise Price per share, Ending | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember', window );">Private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MovementsOfNumberOfWarrantsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_WarrantsIssuedNumber', window );">Issued | shares</a></td>
<td class="nump">570,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsOutstanding', window );">Number of warrants outstanding, Ending | shares</a></td>
<td class="nump">570,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_WarrantsIssuedWeightedAverageExercisePrice', window );">Issued, Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Weighted Average Exercise Price per share, Ending | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_MovementsOfNumberOfWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_MovementsOfNumberOfWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_WarrantsIssuedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_WarrantsIssuedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_WarrantsIssuedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share or per unit of warrants or rights issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_WarrantsIssuedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392424977840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative warrant liabilities - Outstanding and exercisable (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Derivative warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants per share | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsOutstanding', window );">Number of warrants outstanding</a></td>
<td class="nump">13,070,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsExercisable', window );">Number of warrants Exercisable</a></td>
<td class="nump">13,070,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_WarrantsIssuedOnJanuary252024Member', window );">Issued on January 25, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Derivative warrant liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants per share | $ / shares</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsOutstanding', window );">Number of warrants outstanding</a></td>
<td class="nump">13,070,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfWarrantsExercisable', window );">Number of warrants Exercisable</a></td>
<td class="nump">13,070,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_WarrantsIssuedOnJanuary252024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_WarrantsIssuedOnJanuary252024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425064784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,349,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentOnPromissoryNote', window );">Fair value loss on promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDebtInstrumentsIssued', window );">Promissory notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,316,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember', window );">NCAC Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDebtInstrumentsIssued', window );">Promissory notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_UnsecuredConvertiblePromissoryNotesMember', window );">Unsecured convertible promissory note | Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount of debt issued</a></td>
<td class="nump">$ 1,610,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfCurrentBorrowings', window );">Notes paid</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value</a></td>
<td class="nump">1,418,675<span></span>
</td>
<td class="nump">1,316,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentOnPromissoryNote', window );">Fair value loss on promissory notes</a></td>
<td class="nump">47,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_UnsecuredConvertiblePromissoryNotesMember', window );">Unsecured convertible promissory note | Psyence Group Inc | Notes payable on the date that is the one-year anniversary after the Business Combination, or January 25, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDebtInstrumentsIssued', window );">Promissory notes payable</a></td>
<td class="nump">1,460,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_UnsecuredConvertiblePromissoryNotesMember', window );">Unsecured convertible promissory note | NCAC Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount of debt issued</a></td>
<td class="nump">$ 1,615,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfCurrentBorrowings', window );">Notes paid</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDebtInstrumentsIssued', window );">Promissory notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value</a></td>
<td class="nump">1,413,529<span></span>
</td>
<td class="nump">$ 1,474,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FairValueAdjustmentOnPromissoryNote', window );">Fair value loss on promissory notes</a></td>
<td class="nump">60,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=pbm_UnsecuredConvertiblePromissoryNotesMember', window );">Unsecured convertible promissory note | NCAC Sponsor | Notes payable on the date that is the one-year anniversary after the Business Combination, or January 25, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Promissory Notes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDebtInstrumentsIssued', window );">Promissory notes payable</a></td>
<td class="nump">$ 1,515,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current debt instruments issued. [Refer: Debt instruments issued]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfCurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of current borrowings. [Refer: Current borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfCurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_FairValueAdjustmentOnPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_FairValueAdjustmentOnPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=pbm_UnsecuredConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=pbm_UnsecuredConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392427015472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share capital (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,390,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,390,659<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction', window );">Issuance of shares, reverse takeover transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsGainLossOnExtinguishmentOfDebt', window );">Gain on debt settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesExpense', window );">Services rendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction', window );">Issuance of shares, reverse takeover transaction (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacMember', window );">NCAC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction', window );">Issuance of shares, reverse takeover transaction (in shares)</a></td>
<td class="nump">446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionSharesIssued', window );">Consideration shares issued to NCAC shareholders</a></td>
<td class="nump">7,794,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Accounts payable</a></td>
<td class="nump">$ 2,136,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">share price</a></td>
<td class="nump">$ 4.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_ThirdPartyAdvisorsMember', window );">Third party advisors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Share capital</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_ReverseTakeoverTransactionSharesIssued', window );">Consideration shares issued to NCAC shareholders</a></td>
<td class="nump">596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsGainLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsGainLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_ReverseTakeoverTransactionSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued as consideration to shareholders in reverse takeover transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_ReverseTakeoverTransactionSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period for reverse takeover transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_ThirdPartyAdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_ThirdPartyAdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425644608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other income (Details) - Loan From RH Capital Finance Co., LLC<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 05, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 05, 2023 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Aug. 21, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Rebate amount of research and development expenses received</a></td>
<td class="nump">$ 879,344<span></span>
</td>
<td class="nump">$ 1,336,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,697<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram', window );">Maximum percentage of rebate on eligible research and development expenses</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_BorrowingsMinimumInterestChargeablePeriod', window );">Minimum interest chargeable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment', window );">Repayment period after notice of assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2023-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_BorrowingsMinimumInterestChargeablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum interest chargeable period of borrowings in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_BorrowingsMinimumInterestChargeablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period to repay the borrowings after the notice assessment received related to the research and development refunds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of rebate for the research &amp; development expenses under the research &amp; development tax incentive program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=pbm_LoanFromRhCapitalFinanceCo.LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=pbm_LoanFromRhCapitalFinanceCo.LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392429998736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with related parties - Key Management Personnel (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Transactions with related parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short term benefits</a></td>
<td class="nump">$ 465,702<span></span>
</td>
<td class="nump">$ 593,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share based compensation</a></td>
<td class="nump">233,295<span></span>
</td>
<td class="nump">174,782<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">$ 698,997<span></span>
</td>
<td class="nump">$ 768,511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392424141296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share based compensation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>Options </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Value of options and restricted stock units granted | $</a></td>
<td class="nump">$ 317,882<span></span>
</td>
<td class="nump">$ 221,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options granted | Options</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSUs granted | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425452144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax note (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract', window );"><strong>Reconciliation of the statutory income tax rate to the effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Net Income/(Loss) before recovery of income taxes</a></td>
<td class="num">$ (51,159,048)<span></span>
</td>
<td class="num">$ (3,206,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Expected income tax (recovery)/expense</a></td>
<td class="num">(13,557,148)<span></span>
</td>
<td class="num">(849,679)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Difference in foreign tax rates</a></td>
<td class="nump">966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_TaxEffectOflistingExpense', window );">Listing expense</a></td>
<td class="nump">10,992,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_TaxEffectOfotherPermanentExpenses', window );">Other permanent expenses</a></td>
<td class="nump">2,061,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized', window );">Change in tax benefits not recognized</a></td>
<td class="nump">$ 502,556<span></span>
</td>
<td class="nump">$ 849,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Percentage of statutory income tax rate</a></td>
<td class="nump">26.50%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to change in tax benefits not recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_TaxEffectOflistingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to listing expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_TaxEffectOflistingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_TaxEffectOfotherPermanentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to other permanent expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_TaxEffectOfotherPermanentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392426516176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income tax note - Unrecognized deductible temporary differences (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 1,646,580<span></span>
</td>
<td class="nump">$ 1,721,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_ComputerEquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=pbm_LoanLiabilityMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">124,132<span></span>
</td>
<td class="nump">22,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CA', window );">Canada | Non-capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">1,357,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AU', window );">Australia | Non-capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 164,861<span></span>
</td>
<td class="nump">$ 1,699,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=pbm_LoanLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=pbm_LoanLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392423905280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income tax note - Non-capital loss carry forwards (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NonCapitalLossCarryForwards', window );">Non-capital loss carry forwards</a></td>
<td class="nump">$ 164,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_AU', window );">Australia | Indefinite</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NonCapitalLossCarryForwards', window );">Non-capital loss carry forwards</a></td>
<td class="nump">164,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NonCapitalLossCarryForwards', window );">Non-capital loss carry forwards</a></td>
<td class="nump">1,357,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CA', window );">Canada | 2044</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Income tax note</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NonCapitalLossCarryForwards', window );">Non-capital loss carry forwards</a></td>
<td class="nump">$ 1,357,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NonCapitalLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-capital loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NonCapitalLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsTaxPeriodAxis=pbm_IndefinitePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsTaxPeriodAxis=pbm_IndefinitePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsTaxPeriodAxis=pbm_TaxYear2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsTaxPeriodAxis=pbm_TaxYear2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392420677536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and financial risk management - Carrying Value of the Financial Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">$ 11,349,497<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember', window );">NCAC Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">1,474,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_WarrantLiabilitiesMember', window );">Derivative warrant liabilities | Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">26,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_WarrantLiabilitiesMember', window );">Derivative warrant liabilities | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">875,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">7,657,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsPromissoryNoteMember', window );">Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">1,316,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">875,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember', window );">Level 1 | Derivative warrant liabilities | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">875,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">26,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2 | Derivative warrant liabilities | Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">26,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">10,447,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | NCAC Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">1,474,256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">7,657,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Financial instruments at fair value</a></td>
<td class="nump">$ 1,316,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_WarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_WarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsClassOfWarrantOrRightAxis=pbm_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsClassOfWarrantOrRightAxis=pbm_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsClassOfWarrantOrRightAxis=pbm_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsClassOfWarrantOrRightAxis=pbm_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392419913536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial instruments and financial risk management - Maturity of the Contractual Obligations (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Carrying Amount</a></td>
<td class="nump">$ 11,447,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">7,665,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Carrying Amount</a></td>
<td class="nump">714,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">714,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Carrying Amount</a></td>
<td class="nump">7,657,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">3,875,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_DebtIssuedMember', window );">Debt Issued | NCAC Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Carrying Amount</a></td>
<td class="nump">1,615,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">1,615,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_DebtIssuedMember', window );">Debt Issued | Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Carrying Amount</a></td>
<td class="nump">1,460,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">1,460,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">4,040,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year | Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">714,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year | Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year | Debt Issued | NCAC Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">1,615,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than 1 year | Debt Issued | Psyence Group Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">1,460,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Between 1 and 3 year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">3,625,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Between 1 and 3 year | Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_FinancialLiabilitiesUndiscountedCashFlows', window );">Contractual Cash Flows</a></td>
<td class="nump">$ 3,625,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_FinancialLiabilitiesUndiscountedCashFlows">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_FinancialLiabilitiesUndiscountedCashFlows</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_IfrsConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_DebtIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=pbm_DebtIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=pbm_NcacSponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392425307360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial instruments and financial risk management (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract', window );"><strong>Financial instruments and financial risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption', window );">Fluctuation in foreign exchange rates (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent', window );">Impact to profit or loss from fluctuation in foreign exchange rates</a></td>
<td class="nump">$ 4,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in profit and loss as a result of an change in a designated risk component that was reasonably possible at the end of the reporting period.  Excludes defined benefit plan obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The reasonably possible percentage of the change in the designated risk component used to determine the value of the financial instrument.  Excludes defined benefit plan obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140392422375504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 15, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 20, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 16, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 15, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 15, 2024 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_NumberOfConversionNotices', window );">Number of conversion notices | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares issued upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement', window );">Shares issued to settle NCAC liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_IfrsConvertibleDebtMember', window );">Convertible note liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DebtConversionVolumeWeightedAveragePricePerShare', window );">Volume weighted average price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement', window );">Shares issued to settle NCAC liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_FirstTrancheNoteMember', window );">First Tranche Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 312,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsDebtConversionOriginalDebtAmount1', window );">Principal amount of debt converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,072,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_DebtConversionVolumeWeightedAveragePricePerShare', window );">Volume weighted average price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon conversion of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_SecondTrancheNoteMember', window );">Second Tranche Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds received from convertible note | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_UnaffiliatedThirdPartyInvestorMember', window );">Unaffiliated third-party investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_UnaffiliatedThirdPartyInvestorMember', window );">Unaffiliated third-party investor | Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_UnaffiliatedThirdPartyInvestorMember', window );">Unaffiliated third-party investor | Public warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember', window );">Shares issued to third-party consultants and legal advisors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pbm_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Stock issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_DebtConversionVolumeWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the volume weighted average price per share in the event of debt conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_DebtConversionVolumeWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsDebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsDebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_NumberOfConversionNotices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of conversion notices received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_NumberOfConversionNotices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued for debt settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pbm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_IfrsConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_IfrsConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_FirstTrancheNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_FirstTrancheNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_SecondTrancheNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_SecondTrancheNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_UnaffiliatedThirdPartyInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_UnaffiliatedThirdPartyInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=pbm_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,N $UD'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #+@!-95ZNKX>\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M3L,P#(=?!>7>.NVF"J*N%Q"G(2$Q"<0M2KPMHOFCQ*C=VY.6K1."!^ 8^Y?/
MGR6W*@CE(SY''S"2P70SVMXEH<*&'8F" $CJB%:F,B=<;NY]M)+R,QX@2/4A
M#P@UYPU8)*DE29B 15B(K&NU$BJB)!_/>*T6?/B,_0S3"K!'BXX25&4%K)LF
MAM/8MW %3##":--W ?5"G*M_8N<.L'-R3&9)#<-0#JLYEW>HX.UI^S*O6QB7
M2#J%^5<R@DX!-^PR^75U_[![9%W-ZW7!;XOJ;E=SP1M1->^3ZP^_J[#UVNS-
M/S:^"'8M_+J+[@M02P,$%     @ RX 369E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@W6>2R6HWN%L6",#1!C&J1><8#7#_"@*_!ZH<0LU=D)]%'S!I-[&]WCGL(7
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M2%X8\/WK+&.GE>+[M?/GIK/_ 5!+ P04    " #+@!-9GNC@;K\$   Q$0
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M 8K=!%U)5E.>VY,.*3DA41PD8W.DYR1V@_(FR\3!; )J^F3ZC&B5P_XQDP<
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M]:M\<7KEKSPS[7"!\G^7N+&280'LSS6"7;VP@>T=^.9O4$L#!!0    ( ,N
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M2/-$!FIED0-"H2],6W+-?I% J5CA:MD6. U,N:O5!^- 'DK#(:S)4&VC-CN
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M-CUY%L/HA(.$PP0%"R'K&^PF@>""8+CA.-$U7L7P(H/^0.1K7B_CL\T:W@"
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M:WP12IF:V^]>&KIZD1GW<:C>K3^MG;DO2BMR]UT.H,\Y-'K!9L#J>^-A!Z[
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MF[U\D9\.+Y\!-]F!FSSG_?O@GC?/1WTX<@'J!&Z:5/I@_L4"/I8(=[ZJE=N
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MFXPZ+MW+_4MP7;H+"Q?H9DV/-'@HJVQ ^Y5SX?S" <8_1[M_ 5!+ P04
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MLV0936?+WNB.EP1;$?M"F-,UV,Z=)EA)',WGJ^CL[)PEV#P_C^:PNCV^ &(
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M9WAP>NN_.:ZU<[KRPT)PW(%I =[G&JC3/)""[B/TS?\ 4$L#!!0    ( ,N
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MFDT&S(0+97AQNO*7N*5V>"7TCP5V(S T <=7&HNB>2$#W:U^_C=02P,$%
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MQCZL@T@F0\]WA!$8+U#+B47JV!9"ZV)+Q0)?,<#.)[Y_&$P!%QK^81+-PAF
MU1_J>$.92XJG1 !0*CZW&#,; 4!XTPU@NOG(FVXXF0"ZC0%OBB676*_2,V(Q
MH,YHCTON&Q_@XCB<3)S(7HZB(3BVH4]C#'X.8>PS'D$L^!*3=U4^@V!_([VQ
M&(,!]LY?>42&T0BF&$;>LR%\'@$GX+UO+?/L_[TVAT2ZW\%Q.!J//.Y&4</S
MPG=&.[E)>['"ZM@U#L=3;X(9<,(+-D%Z\T%,1OKYV^UM8YO#60@!<G.;8S#-
M>=S<9@0"B3QF_I^U5V>9_7;[U1QU]7$;F(T>>3)KY?77(G]-3IVE?]:J-MZ=
M6MZNL3J+=V522HH!-)HD 1) U."A,>9%$T_#XWB D'VH:_Y2@]@M^1+L>-2P
MD?T'3_WK%7KP7I%J0=H*B".Z-]X=R[S$N'8ZG3EZ1G$XCQN)W5PYVH/ YN5\
M&HY]2(K'X<S'+.#>9 )Q]C-2E7@\"^=^BC&>S\-Y-&_ Z7@.ACA3<:*I7[DR
M/MVK:L[[DD+V,)IZ5@K1&#CPH?_.&-0@FD7/EQ%@<L)Y*C7+L3B#5;(;N>-8
MSONC+.HM(%W20# (6$<>0 VGX"SBAB$,IBB;H=JPKJ_JJ77AIGW;3YO]]Q03
M99 <#=Q?0O ;#F/?+H9#(,C3PY>CP1R<$ZA79QX08H6[K+#\204WSQMWI@5N
MOR8]Z)E>'^@W)N\LGTS\R77YI.?49&Y/3>:]!QTW*&?9=?CVV+&!]\^]=K:#
MZTUK:OG2T.X=#H5!QE?8K5%2C%&5M6HHH=?A;0@Z5+,1#+VGTB]$2GD5XMF8
MH.8HT-F%.MXW[6QFS0>19>HXS34_03)495QWFALB%';@>8)0/0^Z>MYL<USN
MC=(%X0W"4*-13)TG+C#@L#/IT=0IE(JJ+CO).N112U>*5W*E2GB(#1_X4>1X
M/*RP4;TIY$\5IM8Y'O!"_$)V+,&Q%OKLH[DO/*+<%^R]X ^V4<40PK$);I\2
M'8"BXS1MMTO7%*03P$[>4$*]K(D_WOE*C\H/(G?Y,SIV5M\:<+=>]WS>5"IK
M4/*E"SBE?=$B: B"2%$0V*!CC]FWNL2.S, 8$QF:\X= )@(/;I<BH>YPGJQS
M*JK_S(N'C*?ZV(5F--U.!Q<4=:F\>2?1M@2I\-YO<%&/J3\$Y95B[Z7;(O>W
MJ'HK*5+0=R&S'9JFSQ/59F=,R;0#:6/;A6;[:9U0V]X6_1P0@&9DMIOM#)D;
M7B:JUW8),PEJ3M'Z AO.BPTP:@&IT%+H)BL##Z;SS,$#MH[EJ?0.='F#;GP?
M84O6RZ4@,7@GW'V#X+M:4ML+MNBK\URLPISJF"GMXZ;M)6P(H%/AN$E333,/
M\$9W,.C^./W!Q3!VB*RWQG8]&5 4Z"VA3Y1(B(8@? 6#=\ ,N3:GIW@MOM*J
MNP55,VUNK3OJLVCO.O>@_X:OCIAMDE"YE*#5JI\_'3'!-4O>.EM22F:Z?($Q
MF,V\<$=6-Q^_4 !/!]#Z7-G6YY*=8F_+%^8<'OOF1"KHG,X_DM>MF2 YV4$9
M+'[^ V@YQ9-? FNO3Y_:0<#Z&)[QM6S;=8>X]G:_,Z[JIMKT]./TBQWUD>WL
M32>3W- !JFD,Z9K,F.P!B8?-83[5>&O@N,?<%("!R-:.2W_-6]1>?UO*$6=4
M/S:V'#:),ZT]WKFFIE8M_!J):K#AE#+.8^0<SJD.V=$4Z<B^P10+.N:,/%'!
M1G@PKP.9.V*3J?,T2AY^3SR#D )?T!VW*G11]]*7CJFJ(H.-0,WS_[T7[#92
M 9N@X(!R#WU=T>MEVZF->"SH:E??OQ-B'=]C_)Y6;1W,8$+L","=<W7^3>^H
MTV[5E$P H+6\PR!#7RH=VN99^Y[ *;)3V&+",%^))$7(#*9#.#ZJ_H@)5 MC
MI(W:([3KK=_S(&T[@ID'M<8(#SVC$I\G<;LETK9F?ZW^\8C^""]V_B#N!7"J
M+P)=@<2B3*L'>,H$C7LSMGMG 6%'HORPR&ID4]8<!?9'H*J[J*A7C[Z!P/HC
M#=X;0)?ULJ163 ?$))#VW+)_V_.@H]E; *_+0ARXCUPP(UTUH1]M0;%J>>;U
M9J$Z]QI4-CKGT[JTA&B!7[9OF^ZIV+M%B/N4!)C1CR;>8/YSR U=YF$OE[EV
M)A4: ?%H[-L"(Q0TT,9LH;9WT[C;N"Z8<@@M*50+FQ>C% >*K6IWQ+LI1T(<
M][,M@]Y?6OG055YL5>[G3:4"$.\6D$YT]6YP?]]O?\A@12W#J5$GHUVP=Y-F
MVXP#L_?<P(J!U L_>FD-6)IZJZ#%3-*V3''/=5L8EWX*VMS!Z<$&]<[LE)[>
MNCO9'S.6_'Q]F^ %+7WMI5>D[M=M!OV_2Z.!MV*_VG]ZYPG# _?!:S6W1[^4
M*P P4Y&!_3KU7Q?[E]OV<$9?L-#]J/P76HLJL>"%"6KDI2Q(N7%O*ML^+9J&
MK8-@?7 :.M=*%\JJM;V-JJFCUNB.>?7A:^]MEO_Y%4[M@;:>L%'%P&>F-EV8
M9K5?]%&3X3?VA4;S8)3RLSQGB>>$>T-9=7%CYQU8D&Q\$I2S-24&6TW#M65S
M(UZ DGB/]V-12O6+Y1)OVPFLT%$A#W\: +O\$DZKEHCAP!,A%47Z_<H6SN1^
M6H[%!J>RAVKJ;0*M]R_(9<12I1=\@QV_Y:X1CIAHU4\U<&+$0>45.L)M119=
MKM/7B0W%&L_:(,RCOJEK'L1@02_((>+'9D;=9XE!A?3 QZD!T<7,G3BZ-$=M
MDT8]L,H  18X0-6>^02]L;=MG<X6*EMS]5L?/]S52G>Y$ZA6"4"Z)SC#5M04
M)?3FQ8$^??$4I:F/^P)J)W/!,D:R5S!E,$PR)0Y=4ZTAQ2CI3F@7W?XE^@8,
MZH(3?@\>:.=7H2GU;"^,<KQ9=<A/LU9:)P<+&;RE2_2 RQ#LEWL%;Z\Z9> %
M3!J+,-(6P!GF!2;F8M@I3;93J.LK1CV4=,T-%-I:1Q1SYOT$WX:7*_JA08QU
M09G5K_'9I_;'#,_53_BYU]4O(7YAY0K3RXPO82AV/9\H)3 ?JF)+/^BW**JJ
MV- _UYR!0\$7X/ME 8&<_H +V)]X_/!?4$L#!!0    ( ,N $UE8'M"6>P(
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M$S3I?+J)F&EF2&,XK$+?KM#1% C;DL8N&!] YVM$=S!\@G:09W\ 4$L#!!0
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MT*$NJP6$:AL Q3YEV.=AJRYGX'.^H6X(ZH80V,;B;4J_#.?LMV_#\9\[K;B
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M:4[\9-3>1*5D09%)^O5*:1#.KNTW"$9#4$!!1FX2SD:4-T5B;.N%'5-46>;
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M>-]=&W>+1Y9:M*"LT(H86,WI17JVF'C_X/!#P-;NG8G/9*GU@[]\K^<T\8)
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MP7@'][[2&G<7'V"<WN5O4$L#!!0    ( ,N $UEB0Q42<0(  ! &   9
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M?IO3DXW:!9!_K93='5R![D\@^0102P,$%     @ RX 360$!(7%L @  [P4
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MX:^EW<BHG(.U;Z4T1\$EZ'=\]A=02P,$%     @ RX 36<VN*@]_ P  )0H
M !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULQ59MC]LV#/XKA(L6&]#Y
M+6]WUR3 O17K@!:'NZW],.R#8M.Q<++D27)R^?>C9,=)NB3;"FS[8DD4^9"4
M^,B<KI5^-B6BA9=*2#,+2FOKJR@R68D5,Z&J4=).H73%+"WU,C*U1I9[HTI$
M:1R/HXIQ&<RG7O:@YU/56,$E/F@P354QO;E!H=:S( FV@D>^+*T31/-IS9;X
MA/:7^D'3*NI1<EZA-%Q)T%C,@NODZF;B]+W"9XYKLS<'E\E"J6>W^)#/@M@%
MA (SZQ 8#2N\12$<$(7Q>X<9]"Z=X?Y\B_[>YTZY+)C!6R6^\-R6L^ B@!P+
MU@C[J-8_8I?/R.%E2AC_A76K.QD&D#7&JJHSI@@J+MN1O73GL&=P$9\P2#N#
MU,?=.O)1WC'+YE.MUJ"=-J&YB4_56U-P7+I+>;*:=CG9V?FMDBO4EB\$@E06
M07"VX(+;#7SW,R.I^7X:67+DU*.L [UI0=,3H$D*'Y6TI8%[F6-^"!!1A'V8
MZ3;,F_0LXD>F0Q@D;R&-T^$9O$&?]L#C#4[@W7&3"64:C: *ND7+N, <N&S+
MW-?+@FH8%DH3-)=+ [\Z$. 6*_/;L3-I/0Z/>W3DNC(URW 6$'L,ZA4&\S>O
MDG'\[DP^PSZ?X3GT^1.1-6^$SZ9@7,.*B<:OLJ\NV)"D6I!Y#CD=@FJDI6G&
M3 D%,?188N==OWEUD<:#=_"MXQ>F-9,6/LBZL0:8_1L[V_$G)AMZ2B =M971
M;U"]9&5?,+WXJ61TX[7F&<(PG%SV&TF8[+3N7VIZ,_P!K7B.,H<-1Y'#)RYZ
MG?WY_0OJC)LM<)*$HWB'?+!ZY.;YAT(CU1&=.]6!!<VL"R9.X#4-J1OZ  0O
M$$9AO ,X6/1Z*R6H:#UKDTDXGA#&Z#*\O&BQ.)U0[KR<.+;+O]PX4Z&COD)'
M9\OD]$-SK.3.8GTCE\9]I./__&T8_POY3/I\)O_?VW#>]3]]"SJF[]/T@)F?
M7.&07&:\9@)8Y4*$P=N$"C;>(\:#QIIMJ'>P<-WJ)(.8R'#79=62SC@WAD@W
M'/QISR>=QN&%V_J\HQ>3Q! !21P?RG,JD@V,0^_&L1P\RSOUUL6QNXSV?MT5
MZJ5O4-P]4"3M7[R7]CW0=?OKWZFW#12]>4LN#0@LR#0.)T0BW38E[<*JVC<"
M"V6IK?#3DOHXU$Z!]@M%Q]LMG(.^,YS_ 5!+ P04    " #+@!-9,6Z\?<L#
M   >#0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R]5VUOVS80_BN$
MVA4;X%DO?DM2VT#<9%B&M0N2;?U,2V>+"$6J)&4G_WY'2:;E1);3;-@7'<D[
M/G<\/D=2TZU4#SH%,.0QXT+/O-28_,+W=9Q"1G5?YB!0LY(JHP:[:NWK7 %-
MRDD9]Z,@&/L99<*;3\NQ6S6?RL)P)N!6$5UD&55/"^!R._-";S=PQ]:IL0/^
M?)K3-=R#^2N_5=CS'4K",A":24$4K&;>97BQ&%O[TN!O!EO=:!.[DJ64#[9S
MD\R\P 8$'&)C$2B*#7P"SBT0AO&MQO2<2SNQV=ZA_U*N'=>RI!H^2?Z5)2:=
M>6<>26!%"V[NY/97J-<SLGBQY+K\DFUM&W@D+K2163T9(\B8J"1]K//PF@E1
M/2$JXZX<E5%>44/G4R6W1%EK1+.-<JGE; R.";LI]T:AEN$\,[\"Q3;49H9L
MJ5)4&,(973+.# --?OR3+CGHGZ:^06=VBA_7P(L*.#H"'$;DLQ0FU>1:)) <
M O@8I0LUVH6ZB#H1/U/5)X.P1Z(@&G;@#=S2!R7>X$U+;UMQA3=LQ[/E<Z%S
M&L/,P_K0H#;@S3^\"\?!QXYHAR[:81?Z_![+,2DX$+DBWPH,EIDJ=B:JTJRJ
M9$U5PL2:_ X;X"0B*\H4V5!> ,F ZD(!5I31%J5>=.M*NV/Y\.XL"@8?R5OE
MUSK=-R(O,!9J7J'9R=^H*/#T(-&H(H)3(#WBU/'##=^G5 ')%8N!#/N3<Z<(
M^^'>ZOHQQV,"$I*P#4M ).2) 4_(%\:=3;-]_0@J9GH''(;]4;!'/NC=,?WP
M\TJ!W2D#2 Q#%#4VF" D/Z"(K' !<+8",NH'>X"#CK/;2(Y[CEQ](N&D/YX@
MQNB\?WY683',4&*]'$G;^4E%!V5'CK*C;LI6!WV#:\3@5]/R0,;=Q32;%(@H
MLB6H)B4)7A_:H!ZIW$;/;K__EI[?*V^+)6?QCKMZ/UZ>+_!2<;(^RKL$-_D_
M,]S)RPTHO&O?;/?%;=5SC:N(-YBV92YNR5LUO*"<BAAZAQ4_.' 31GMW[U^,
M'+>XT;IHI#.,>J,@Z 6- FPO\M&DRZH]XF&7F_<G'-3ZCBH=NRH=O_IB::N_
MLDRAVC+[&&BKQVX/_W<]GI(OF7F<J\?D:0Z[@9)3Y,J>!/7)?-4\F2M2_]%(
M^/4^V<>ONZ,'^G/FA(->\(P\C:%3U'PNOP^]XR[Q&V_6#-2Z?)EK$LM"F.KY
MZD;=X_^R>O/NS:L_!PQ]S? ^X;#"J4%_@M>#JE[C5<?(O'P!+Z7!]W393/$'
M!I0U0/U*2K/K6 ?NEVC^#U!+ P04    " #+@!-9&T'V,'D"  "F!0  &0
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ME[IK;O$5!<H:X'PI\4[J.G:!X5VV^@]02P,$%     @ RX 367SON,^G P
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M]X 52WR @30*N+\5^$/ZB7$P/.GF_P)02P,$%     @ RX 360OC&I<S!@
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MW,]N9^57;<G3F E)?A[_YMU9X5VU@X1Y)6Q2P$PAL9DZXX'^=]W?[*H"V6>
MA(4@6$,5XZTJQE95S'BFJ4M3*FT82;EL3;Z5T37Y2)A7PL8[R?]C/+B<#(=C
M9R__+2V'[N7$'>XU#)#C"T&P1FXGV]Q.K+E]D#^87@M(*/AZ13[D45MJK8BN
MJ47"/"3,1\(")"P$P1H*.=\JY/R-2HESI&R0, \)\Y&P  D+0;"&;"ZVLKEX
MRU+BXF#!+M;K_15[9AU$5UF<V*F/[#1 PD(0K)'QRVW&+U\I$_(-$RJ9IXSD
M7.E*(:'S)$W4C[8$6UE=)P<DS$/"?"0L0,)"$*PA%6=0.R2#-UI5*C!(.5":
M!Z7Y4%H I84H6E,^.P:;8YUK;A<+P1943S(KD>11LJ(IH1E?YZI5,E989\D@
M:1Z4YD-I047;O1\:.N[X8$$,4=TVU>#6:G"M:@@2(17Y+&@>+1FY-VO/3WTO
MLV%2<=%:7MB!G16!I'E0F@^E!5!:B*(U95-[I,Y;F:0.U"6%TCPHS8?2 B@M
M1-&:\JF]4L=NEC[LK3Q&2#&;J^J>IU4WH],FU-FI#3W[&#MG&VJ 0FDABM;,
M=NV!.G83]#-7.M-R/9>12%;E$]_C!<>AD>B.VVY?3VWHG=K0MU]&YQ1"C4X4
MK9G"VNIT[%[GW5KJ,U+JF3V;)SDMDZ@+29:Q(WF$.I]0F@>E^5!: *6%*%I3
M-K7_Z;R5 >I '5 HS8/2?"@M@-)"%*TIG]H'=>Q&Z/TZFS-AY%.ZG<8+I=&W
M=2*8U0%U#MU(9W_U@+J?4)H/I0506HBB-151^Z2.W2B]+<O%)R[,CX^2;)V1
MB,JEF4GBQ$POK7* &J90F@>E^5!: *6%%:U1A@WVGA$T?WY5.Z*NU3)[I3IY
MS="PP[O* TKSH#0?2@N@M!!%:TJH=D5=YXTJ%1?JD$)I'I3F0VD!E!:B:$WY
MU#:J:[=1'UF>Z#5)LDBK*#9R:3S/,P]LC_R"\\Y.[JP?]Z#T&>W=#T,[]*&T
M $H+4;2F*&J3U+6Z:*\O2\<?^^HW/]%\P5H% W50H30/2O.AM !*"U&TIK9J
M!]4=O=5ZA;069U":!Z7Y4%H I84H6E,^M27KVBW9;@^![;#.DCGT8YUVYQ;:
MKP^E!5!:B*(UY5#;NZ[=WGT\S9NW4SKK8'*H@_T;PDH'4+\62@N@M!!%*W70
MW]F'E3&Q*+;8F7)$Y[?<WK0]N]W&=UML7ML[[SE7?KD9K\:4>P,_4K%(]-*3
MLB>-')R=ZW2*<KM=>:#XJMCM->=*\:QXN60T9L(TT.\_<5WX5 >F@^VFQ^E_
M4$L#!!0    ( ,N $UG,4%NTEP(  +@(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;+56:VO;,!3]*\)C8X,1/_)LYQB2=F.!=826;9\5^R86E257
MNHF;?S])=MP,$C/Z^&+K=<X]]QZLZ[B2ZE[G $@>"R[TU,L1RTO?UVD.!=4]
M68(P.VNI"HIFJC:^+A70S($*[D=!,/(+RH27Q&YMJ9)8;I$S 4M%]+8HJ-K/
M@<MJZH7>8>&6;7*T"WX2EW0#=X"_RJ4R,[]ER5@!0C,IB(+UU)N%E_/0 =R)
MWPPJ?30F-I65E/=VLLBF7F 5 8<4+04UKQU< >>6R>AX:$B]-J8%'H\/[-]<
M\B:9%=5P)?D?EF$^]28>R6!-MQQO9?4=FH2&EB^57+LGJ>JS_<@CZ5:C+!JP
M45 P4;_I8U.((T X.@.(&D#D=->!G,IKBC2)E:R(LJ<-FQVX5!W:B&/"NG*'
MRNPR@\-D3C731*Z)\52#0.IJ]?$:D#*N/\4^FB#VJ)\VA/.:,#I#&$;D1@K,
M-?DJ,LC^)?"-NE9B=) XCSH9;ZCJD7[XF41!-.C@Z[<I]QW?X S?4N]!I$!F
MIKJ*<D;)$O?D!V:]4]EV<MEOYE*7-(6IYPJH=N E']Z%H^!+A])!JW3@V/MG
ME"[$#C2:;P )$^;#66F6,:H8Z%-*!V^@=-@J'7;6]#V1E0"E<U:>DE:#)PYL
M[XE=$L;^[D2\41MOU.WA7CL/YTP6D)'%@EQ)59XTL)/HF649MS+'KVC@^ V4
M3EJEDY<8./E? R_:>!>=\7Y"E<JM0C)+'[9,NUOGK(6=5,\L3!@\W9#!*YK8
MD+VRV*/K/'R)CPVZRTC_J)D4H#:N96IBW!)8]Y5VM6W+L[H9/1VO>[JYN3=,
M:,)A;:!!;VSN 56WR7J"LG2M:271-#HWS,VO!2A[P.ROI<3#Q 9H?U:2OU!+
M P04    " #+@!-96F6]=+,3  "#XP  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S.2YX;6RUG6]SV[AVA[\*Q^UT;F>NUP1(\$^:>"8Q"=0SV=TTSK;3EXQ,
MV^K*HB]))YMO7U*6#0&$#@GG=]_LV@KX',CG2"0? 4=OOS?MG]U=7??!7_>;
M;??NY*[O']Z<G76KN_J^ZGYI'NKM\"\W37M?]<.O[>U9]]#6U?7NH/O-&0_#
MY.R^6F]/SM_N'OO4GK]M'OO->EM_:H/N\?Z^:G]\J#?-]W<G[.3Y@<_KV[M^
M?.#L_.U#=5M?U?T?#Y_:X;>S%\KU^K[>=NMF&[3US;N3]^R-8BP>C]@-^>]U
M_;T[^#D8G\O7IOES_.7R^MU).$ZIWM2K?F14P_^^U1?U9C.BAHG\8T\]>0DZ
M'GCX\S-=[I[]\&R^5EU]T6S^9WW=W[T[R4Z"Z_JF>MSTGYOO_UGOGY$8>:MF
MT^W^&WS?CPU/@M5CUS?W^X.'&=ROMT__K_[:_R4.#N#\R %\?P!?>D"T/R!:
M>D"\/R!>>H#8'R"6'I#L#TB6'I#N#TAWR7KZZ^Y24U1]=?ZV;;X'[3AZH(T_
M[/*[.WK(R'H[UN)5WP[_NAZ.Z\]_K?JZ75>;H296S>.V7V]O@X=FLUZMZRXX
M#>[6PPS:]6H8<+/>5MO5.'2]?7H-C*5T5W7!U[K>!GU;;;O-0+L.^B;X8[L>
M?[KJAP>ZX+K9;*JV"_Y6U'VUWG3__O:L'^8^SN!LM9_GAZ=Y\B/S9#SXM=GV
M=UU0;J_K:Q-P-CSIEV?.GY_Y!TX2?ZW:7X*(_3W@(8^#/ZZ*X&__ZIK8Q7),
M1& *'\S%^V.8$H.1RS&<>%+*!^.<C9&ZZ*5HHQTW.L*]>&S;>ML'5=?5?><J
MIJ?C8_?QX_O[F^ZA6M7O3H8W\*YNO]4GY__V+RP)_\-5 $A8@8252)A$PA0(
M9I1'_%(>,44_OZBZNZ#:7@>K\8?Z'X_K;]5FJ!=GI3RAQ XUGKB_G:=1Q++L
M[=FWPQJ8#F-1%/,L-,<5Y,Q\T[LPJ'2,2T441ZDY3H$F9R1%O"1%D$GY7'?]
M<"(9SPIC6ERI> (D!T^#YPEC5B9<HX1(K#R0D_'-PZ*0<CHJXB&S<J5 $S-R
MD+SD("%S\'M_5[?#%>2J'EX17S>U\P613)Y&S-+8*J6+Z2@6YU&26VD@Y^.;
MAF4QY718E(M)'D S,_*0ON0A)?/PJ:T?JO6U\\^?.JJ(,VX5V\5T6)J&PGXW
M(J?A^^=?%%).1XDH$]8?'S0OXX^?O?SQ,_*/_Z7IAVO8U>PE1#:MMB$-2<JM
M3#C&B3SDPGK.!3DKWUPL#"H=X[(H',XA5D) DS,2DK\D)*<3\ON7]Q^#]U=7
MY9<K5R)R1R(B/CQ?*Q&.<<Y$D+/Q3<3"H-(QSID(T.2,1+!0WPR&BRZL-^OJ
MZWJS[M?N4\2> KJ\AM(***V$TB24IE TLU8.Q $C7[;OGX1!%SQ4/\:+B=T5
M=[5:M8_#)=Y< ;'IN42(X2[1>DD[QK$T#]/0/M'1<_7.^L*PTC4P8LGD58V:
MGIDJKE/%%[S#?KQ\_^'RX^67R]+Y-KMG&,^%LS!.<ON-UC72G15R6MY961A6
MN@8ZLP*:GID5+3$8;3'*__KC\LO_.E,!U1=06@&EE5":A-(4BF:6AY88C+88
MO]7]SEWT/YPE@A0-%U!: :65>]KAJ_F4AV$<VY=8CH$LR;/)^X-"S<],K!8A
MC#8AOY5?@J*4EQ>77YR9G7J$4Q;F*1=Q:+\1.X:Z_C0%/2/OC"P,*QT#CV3D
MGV%%F-8BC/8BD_-C\/ZW(IC+DT-'..]+7 .=-R;T++VSM#"LW \T]*'SW@0U
M/S-+6IJPE#Y?_O50;[LC%Y1(TW$!I1506@FE22A-H6AF@6BQPVBS<U5MZFYW
M&W)?M7_6XV>9SEJ92I$L3,+(?ME.AZ4AMP4G/27OY")I$DI3*)J97"V)&&V)
M/@_,JET]?;!S77^K-\W#?;WMG1F>VI9<Q"*?I-AA99(PR_+).S/4&4%I$DI3
M*)KYD;P64)R4%N>JWM;MN!IA= G7]^OMNNO;:ERMXLKS'F;(9C'<$L96GAWC
MHB2)(SO-].1\TPRE22A-H6AFFK4[XK0[^M0V-W4WKF?:YWK5;+O'S6[UR4WM
M/L5SAVMA(HNS2;8= [G@DX^ "GJ2WNE&TB24IE T,]W:/W':/WULNG&5T$W3
MUD&S^PQRW=?W[BQ/W<TI3\68:#O-CI$1C^)L\B$D/3OO/"-I$DI3*)J99VVT
M.&VT?I_)+51K06D%E%9":1)*4RB:62-::W%::UUN^WK@]L%ZNVKNW:?UJ<CA
M+)J\_AVZ1XC8?NU#7124)J$TA:*9>=56B]-62PYO[NO;;5#_M;JKMK=U<%NM
MM\[LNNQ18E]R7SB&#:,8M_,+-5M0FH32%(IFYE<[,DX[LM&&??S]ROG1$9^J
MIE/!1ML4V^OH7$,C'B:Q??]=T//QSBR2)J$TA:*9F=5>C=->[;=F>[I;*5E=
M_]]CUX\WU6^<688Z-BBM@-)**$U":0I%,XM%.S8^X]CNJN$B?MS\,=ZTW8]&
M=K<1P%DP4X,6L33+[$_Y'>/&)6]9:K\C0%T;E":A-(6BF4G6KHW3KLT^ESN3
M.W5G42(F;_?34:=9'-M+"@IZ0MZIA0HV*$VA:.;&"2W8HID57KN$=L/5]VZ/
MV"A<5M7#NJ\VSO?\"+K2"THKH+022I-0FD+1S)K1MBZB;=VB9>.1P[J%:<+M
M-WO'N/'C[<Q^ZRCH27FG%VKGH#2%HIGIU78NHNT<M1H]<NFX6(2I?;OF&IBR
M)+$5.ST7[ZQ"71R4IE T,ZL'6^1(C_-3RS/W:.LU&HDXM\_OCI$L&>[[IJ]F
M[+XW[,8W[,ZW?X9?B[1?BVB_MMO\]CA>G@^G^.:A'C\]&T[RNRW?QQ/N6F.5
MQR)*['T_KI'#C3X/)SOAZ'EZ9QQJWJ TA:*9&=?F+:+-VZ>V6=7U=;<_0P^9
MOVF;^^!3]Z/>KNI M<WC0W"Y73D3CU14%Y%CO1=+><YMMP,-6T)I$DI3*)I9
M&]K:1;2UV[T;/+3-M_7U<UWL]_'/OR=,31V/1!C:B_<N' ./9!UJ]* T":4I
M%,W,NC9Z$;V_\.DF;SP!K'RV0D?3O7NG23A<G$^NX1T#8Y8S81L;>I[>&8=J
M.2A-H6AFQK66BV@M=W3+^]^#K_7M>KL=7^_-3?"CKEIGZAT;!5U;S2]< UU[
MS0MZPMZIA\HZ*$VA:&;JM:R+:%E'I+X>'J62_@2>[7W@&.=N?K!T8$D_)>]T
M0@4=BF:VKM""+J97P'VN'YJVMSO</"6,/M3W:@U**Z"T$DJ34)I"T<P"T38N
M9K3!G=VY'B/MU 645D!I)90FH32%HIEEHJU>3%L]OR8X2/-U :454%H9._:&
M9J%(;5$IH6'5GG9X9N3#!7-XL.S%S+/V?#'M^3[/]]6A"=[9A:Z[@]+*>*HC
MX^D=JX0&5;-!S<P>=+&B3=ZBCUUHAG=ND;0"2BMCQZK D+-) QIH5.6(&N?1
M01,8,[E:VL5STN[XAR[TH=XY1=(***V,'<(PC'EJM]:"1E6.J$EZL+/+3*EV
M;?',+M*%C85HC'=ZD;0"2BMCAT)D8CCQ<3N_4/OF"LNSE.7)D11KL1;38FVN
M51%]N'=JH4ODH+0RGBK (ZF%:C976#*UVJ#%V:+;JIF/1F.D.KJ T@HHK832
M))2F4#2S5K1RBVGE]C.?K=-H[P)"T@HHK8RG:_]XS*/8_DQ90L,J1UB6Q.+8
M];C09D[09FY1%R6:X9M>**V TDHQW53K3B\TK'*$)=.KO9J@O=KQ=DP"ZM.@
MM )**Z$T":4I%,TL#^W3!.W3Z'9,],'>)0(5:%!:*9P;=!FW5P1*:%CE",L9
MY\FQ"S^A!9J@!=I,FQ_Z:._,0N49E%8*QZH_=V:A^LP1ELZL%FB"%FBO:NM$
M,[WS#15J4%HI'$+->0L'#:M<8:E;.''085[09W"B092 .C4HK8#22BA-0FD*
M13,+1!LZ01NZA0VB:(IWK4 %G9BZK9S;K]@2&E-":0I%,VM *SQ!*[S/]?(^
M4C3*NQ"@.D^X!!Q/TF12"]!5<U":0M',6M#.3]"KYORZ3=$P[VJ JC\Q7987
M9W%D;[4MH5$EE*90-+,8M-03M-1[34\J&NE=$E"9)UP>3(@DB>R:@"[&@](4
MBF9^78Y6?@FM_#P:5]$DWU* THIDZLQ.QT]90WL?=@F-*Z$TA:*9M:#]8$+[
MP9GF5@E4$D)I!9160FD22E,HFEDC6A(FM"1<T-R*)GC7"=04)@[)%MHMM4IH
M3 FE*13-S+]VB0GM$A<WP:(YWE4 M8K)5,A%0J23,H#NP872%(IFEH$6CPDM
M'JE>6?2AWIF'^L5DJN:&ZX0HBU-F)Q\95T)I"D4SDZ\M9$);R*7MM!*HD832
M"BBMA-(DE*90-+-8#KZ0<\9(>K33HE'>!0/5DHECR5W.4_L[4DMH5 FE*13-
M+ 4M)A.Z#9]G9Z8$ZB:AM )**Z$T":4I%,VL&2TP$UI@+OM"7ZBWA-**9.HM
M3YG@:9K9;QQ0<0FE*13-+ (M+I,Y<7E\*P%]J'?NH8(R<?0&S%-A?]5T"8TJ
MH32%HIE?(ZW]9$K[R9]9B$JC?4L#2BM2Q]I"+K+<7EM80L-**$VA:&9M:%^9
MTEW[7M4(BF9Z%P748J:NSH%YE(:I_8D&-*Z$TA2*9E:%-I3I7+._US>+HM'>
MQ0%5EZEC7Z\0+(UM;04-*Z$TA:*9M:'M94K;RY]H%D63O4L#ZC-31X]"=VE
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MLUD?^"?UC9M**$LDE X6+;:NI\S0ID. N@VM<=+H&BU,:_>RP?@$MU]JC9?
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M;JE*7> Z0*VO&)/[@=Z@*Y[37U!+ P04    " #+@!-9&[@?4C,&   <,0
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MKN]-^^L,J#,(2@M!:1$H+8:BZ?+H[$%L]@?_89)D*-$F%*%)QJB.8W_PA#I
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M"^C?ET+??LU.6<'^?QV8_@=02P,$%     @ RX 366C;GL>+!0  0"D  !D
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M<#=?TI+<K41'!PL:'(7[V0SJ/(Z$=,??6 KL74?[<SFN?A9#DIIO/-4-U$6
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M"5PO4.]7C,G=0 >H&]K@+U!+ P04    " #+@!-94_=_TI "  !Y"   &0
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M(C&7,I[26U8HPF&#IMXHQ(J2S3W7#+0H[=VR%AIO*MO-\-L I%F [S="Z,/
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M)_([V_Q)*D-AH3=GB2C_@TWUK.> >2XD2ZM@E4$:T^TO_EE5Q$X #%X)0%4
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MX[J@L=*+:<K+_^!0M0UDQGC'!<WJ8'F>D;SZ1-]K$$<!T#\3X-8![NN X$R
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M")J5AUN,)%W50'Z_IE2\G*@$S=ND\!]02P,$%     @ RX 36:B">K+W P
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M"(T9:(<YWE(@30%^7PFA]Q/S@_;>2W\!4$L#!!0    ( ,N $UFV#Z1JG@(
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MA@VW3K0^@/=K8V@W\01C,RY^ 5!+ P04    " #+@!-9)X*\@S@)  "/<
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M=^/[]G@?'>)]=./ZO1Y"146QY4NRW<CU//_.\T54\/+MMS#/PPL#(6T771,
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MG6Z;<WD)FY(8#[-";BHC(F[ J-.<!8]4C,B$"CY5'%@9S;E8N>$>#,P*4:A
MFY(TX;HP4OUV<-?UH%H;G9S+0MG8+H+[/6VF[P'K'ACD0K0&>\0-C(<EU9HI
M>6,Z=K(=? (%3?M^51J'<T57W=X5V1#LS029%BIEJ@W3)>NA\5"P#.PH/E_
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M;=-<T+Z/YD\KE_N/._<?II[_"U!+ P04    " #+@!-9M7%@?!8"  "J)@
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M_G=2/9[O+=?'7Y9?)R<OU 7G=%M1G_\"4$L#!!0    ( ,N $UG2-&04[ $
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ RX 369E<G",0!@  G"<  !,
M             ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" #+@!-9N?0=UY4"  "/!P  &               @($."   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ RX 361>-.!P%!0  <A<  !@
M             ("!V0H  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4
M Q0    ( ,N $UG5K>VIS 4   ,9   8              " @100  !X;"]W
M;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #+@!-9+VL5!9L&  !Z
M.@  &               @($6%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL
M4$L! A0#%     @ RX 369[HX&Z_!   ,1$  !@              ("!YQP
M 'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ,N $UG#QS0.
MRP<  !$4   8              " @=PA  !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6Q02P$"% ,4    " #+@!-9,,F9BEX)  !O&@  &
M@('=*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ RX 3
M6=JI:D9(%@  K4P  !@              ("!<3,  'AL+W=O<FMS:&5E=',O
M<VAE970X+GAM;%!+ 0(4 Q0    ( ,N $UF$#P!%1 L  -4=   8
M      " @>])  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M" #+@!-94V[!FND%   /#P  &0              @(%I50  >&PO=V]R:W-H
M965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,N $UGV&NC:(P,  +P'   9
M              " @8E;  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!
M A0#%     @ RX 364IV5FU: @  ]@4  !D              ("!XUX  'AL
M+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #+@!-9$99?L'<"
M  !/!@  &0              @(%T80  >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;%!+ 0(4 Q0    ( ,N $UE(K^#4+0<  ),1   9              "
M@2)D  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ RX 3
M6=^HG3&G!@  ?!0  !D              ("!AFL  'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6Q02P$"% ,4    " #+@!-9KG]F&T<#  # !P  &0
M        @(%D<@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0
M   ( ,N $UDWO7 ./@4  .T+   9              " @>)U  !X;"]W;W)K
M<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ RX 360B\9K(=!0  <PP
M !D              ("!5WL  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q0
M2P$"% ,4    " #+@!-9?B32!?H#   H"0  &0              @(&K@
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ,N $UD;K*(S
MYP,  'L)   9              " @=R$  !X;"]W;W)K<VAE971S+W-H965T
M,C N>&UL4$L! A0#%     @ RX 365K[7V8# P  NP8  !D
M ("!^H@  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #+
M@!-9X0UTXET$  !5"@  &0              @($TC   >&PO=V]R:W-H965T
M<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,N $UEW"<4"/0@  ) 6   9
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M970R-RYX;6Q02P$"% ,4    " #+@!-9BY,6+C$#  #(!P  &0
M    @(&BOP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (
M ,N $UELF5J-8@(  ,D%   9              " @0K#  !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL4$L! A0#%     @ RX 366)#%1)Q @  $ 8  !D
M             ("!H\4  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"
M% ,4    " #+@!-9 0$A<6P"  #O!0  &0              @(%+R   >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ,N $UG-KBH/?P,
M "4*   9              " @>[*  !X;"]W;W)K<VAE971S+W-H965T,S(N
M>&UL4$L! A0#%     @ RX 363%NO'W+ P  '@T  !D              ("!
MI,X  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #+@!-9
M&T'V,'D"  "F!0  &0              @(&FT@  >&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,N $UFP%+:US@,  *,)   9
M      " @5;5  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%
M  @ RX 367SON,^G P  W@D  !D              ("!6]D  'AL+W=O<FMS
M:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #+@!-9"^,:ES,&    .0
M&0              @($YW0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+
M 0(4 Q0    ( ,N $UG,4%NTEP(  +@(   9              " @:/C  !X
M;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ RX 365IEO72S
M$P  @^,  !D              ("!<>8  'AL+W=O<FMS:&5E=',O<VAE970S
M.2YX;6Q02P$"% ,4    " #+@!-957?5+8 "  "0!P  &0
M@(%;^@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ,N
M$UEUJX17^@$  #<$   9              " @1+]  !X;"]W;W)K<VAE971S
M+W-H965T-#$N>&UL4$L! A0#%     @ RX 36>'"+JO2 @  2 L  !D
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M=#0V+GAM;%!+ 0(4 Q0    ( ,N $UGF#X?IN0(  +8*   9
M  " @401 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @
MRX 36=@3O><"!P  @4   !D              ("!-!0! 'AL+W=O<FMS:&5E
M=',O<VAE970T."YX;6Q02P$"% ,4    " #+@!-9:-N>QXL%  ! *0  &0
M            @(%M&P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4
M Q0    ( ,N $UF HKAV1@,  ((-   9              " @2\A 0!X;"]W
M;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ RX 3688ZF!H^!0
M#R(  !D              ("!K"0! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX
M;6Q02P$"% ,4    " #+@!-9N^9V75P#  #<#@  &0              @($A
M*@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( ,N $UE3
M]W_2D (  'D(   9              " @;0M 0!X;"]W;W)K<VAE971S+W-H
M965T-3,N>&UL4$L! A0#%     @ RX 3653H]Q@-!0  R1\  !D
M     ("!>S ! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,N $UFB/.)4E ,  %(,   9              "
M@4%$ 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ RX 3
M67?'"H]% P  S \  !D              ("!#$@! 'AL+W=O<FMS:&5E=',O
M<VAE970V,"YX;6Q02P$"% ,4    " #+@!-9DK26VYD"   A"@  &0
M        @(&(2P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0
M   ( ,N $UF_D[*RA 0  .(>   9              " @5A. 0!X;"]W;W)K
M<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ RX 36080> RH!   XQP
M !D              ("!$U,! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q0
M2P$"% ,4    " #+@!-9X_!ID6$"  "8!0  &0              @('R5P$
M>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( ,N $UDG@KR#
M. D  (]P   9              " @8I: 0!X;"]W;W)K<VAE971S+W-H965T
M-C4N>&UL4$L! A0#%     @ RX 363@;57Y, P  MA0   T
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;72YX;6Q02P4&     $D 20#V$P  \7$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>163</ContextCount>
  <ElementCount>196</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Net Loss and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Changes in Shareholder Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity</Role>
      <ShortName>Consolidated Statements of Changes in Shareholder Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of operations and going concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcern</Role>
      <ShortName>Nature of operations and going concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Material accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureMaterialAccountingPolicies</Role>
      <ShortName>Material accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Critical accounting estimates and judgements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgements</Role>
      <ShortName>Critical accounting estimates and judgements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Reverse takeover transaction with NCAC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcac</Role>
      <ShortName>Reverse takeover transaction with NCAC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Cash, restricted cash and cash equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalents</Role>
      <ShortName>Cash, restricted cash and cash equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureEquipment</Role>
      <ShortName>Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Accounts payable and accrued liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts payable and accrued liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Convertible note liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureConvertibleNoteLiability</Role>
      <ShortName>Convertible note liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Derivative warrant liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilities</Role>
      <ShortName>Derivative warrant liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.psyence.com/role/DisclosurePromissoryNotes</Role>
      <ShortName>Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Share capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureShareCapital</Role>
      <ShortName>Share capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Other income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureOtherIncome</Role>
      <ShortName>Other income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Capital management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureCapitalManagement</Role>
      <ShortName>Capital management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Transactions with related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureTransactionsWithRelatedParties</Role>
      <ShortName>Transactions with related parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Share based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Income tax note</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureIncomeTaxNote</Role>
      <ShortName>Income tax note</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Financial instruments and financial risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagement</Role>
      <ShortName>Financial instruments and financial risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Material accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies</Role>
      <ShortName>Material accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Basis of presentation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureBasisOfPresentationTables</Role>
      <ShortName>Basis of presentation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Material accounting policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesTables</Role>
      <ShortName>Material accounting policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureMaterialAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Reverse takeover transaction with NCAC (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacTables</Role>
      <ShortName>Reverse takeover transaction with NCAC (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcac</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Cash, restricted cash and cash equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsTables</Role>
      <ShortName>Cash, restricted cash and cash equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalents</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureEquipmentTables</Role>
      <ShortName>Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Accounts payable and accrued liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts payable and accrued liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Convertible note liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables</Role>
      <ShortName>Convertible note liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureConvertibleNoteLiability</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Derivative warrant liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables</Role>
      <ShortName>Derivative warrant liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Transactions with related parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesTables</Role>
      <ShortName>Transactions with related parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureTransactionsWithRelatedParties</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Income tax note (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureIncomeTaxNoteTables</Role>
      <ShortName>Income tax note (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureIncomeTaxNote</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31803 - Disclosure - Financial instruments and financial risk management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementTables</Role>
      <ShortName>Financial instruments and financial risk management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagement</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of operations and going concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails</Role>
      <ShortName>Nature of operations and going concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcern</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureBasisOfPresentationDetails</Role>
      <ShortName>Basis of presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureBasisOfPresentationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Material accounting policies - historical financial information has been translated to United States dollars (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails</Role>
      <ShortName>Material accounting policies - historical financial information has been translated to United States dollars (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Material accounting policies - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Material accounting policies - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Critical accounting estimates and judgements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails</Role>
      <ShortName>Critical accounting estimates and judgements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Reverse takeover transaction with NCAC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails</Role>
      <ShortName>Reverse takeover transaction with NCAC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Reverse takeover transaction with NCAC - listing expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails</Role>
      <ShortName>Reverse takeover transaction with NCAC - listing expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Reverse takeover transaction with NCAC - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails</Role>
      <ShortName>Reverse takeover transaction with NCAC - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Cash, restricted cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails</Role>
      <ShortName>Cash, restricted cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureEquipmentDetails</Role>
      <ShortName>Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureEquipmentTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Accounts payable and accrued liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts payable and accrued liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Convertible note liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails</Role>
      <ShortName>Convertible note liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Convertible note liability -fair value of the convertible notes combined discounted cash flow approach (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails</Role>
      <ShortName>Convertible note liability -fair value of the convertible notes combined discounted cash flow approach (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Derivative warrant liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails</Role>
      <ShortName>Derivative warrant liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Derivative warrant liabilities - Fair value measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails</Role>
      <ShortName>Derivative warrant liabilities - Fair value measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Derivative warrant liabilities - Warrant transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails</Role>
      <ShortName>Derivative warrant liabilities - Warrant transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Derivative warrant liabilities - Outstanding and exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails</Role>
      <ShortName>Derivative warrant liabilities - Outstanding and exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Promissory Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.psyence.com/role/DisclosurePromissoryNotesDetails</Role>
      <ShortName>Promissory Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosurePromissoryNotes</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Share capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureShareCapitalDetails</Role>
      <ShortName>Share capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureShareCapital</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Other income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureOtherIncomeDetails</Role>
      <ShortName>Other income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureOtherIncome</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Transactions with related parties - Key Management Personnel (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails</Role>
      <ShortName>Transactions with related parties - Key Management Personnel (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Share based compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>Share based compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Income tax note (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails</Role>
      <ShortName>Income tax note (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureIncomeTaxNoteTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41702 - Disclosure - Income tax note - Unrecognized deductible temporary differences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails</Role>
      <ShortName>Income tax note - Unrecognized deductible temporary differences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41703 - Disclosure - Income tax note - Non-capital loss carry forwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails</Role>
      <ShortName>Income tax note - Non-capital loss carry forwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Financial instruments and financial risk management - Carrying Value of the Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Financial instruments and financial risk management - Carrying Value of the Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41802 - Disclosure - Financial instruments and financial risk management - Maturity of the Contractual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails</Role>
      <ShortName>Financial instruments and financial risk management - Maturity of the Contractual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41803 - Disclosure - Financial instruments and financial risk management (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails</Role>
      <ShortName>Financial instruments and financial risk management (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="pbm-20240331xf1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41901 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.psyence.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.psyence.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pbm-20240331.xsd</File>
    <File>pbm-20240331_cal.xml</File>
    <File>pbm-20240331_def.xml</File>
    <File>pbm-20240331_lab.xml</File>
    <File>pbm-20240331_pre.xml</File>
    <File doctype="F-1" isDefinitelyFs="true" isIfrs="true" original="pbm-20240331xf1.htm">pbm-20240331xf1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pbm-20240331xf1009.jpg</File>
    <File>pbm-20240331xf1011.jpg</File>
    <File>pbm-20240331xf1017.jpg</File>
    <File>pbm-20240331xf1018.jpg</File>
    <File>pbm-20240331xf1019.jpg</File>
    <File>pbm-20240331xf1020.jpg</File>
    <File>pbm-20240331xf1021.jpg</File>
    <File>pbm-20240331xf1024.jpg</File>
    <File>pbm-20240331xf1025.jpg</File>
    <File>pbm-20240331xf1026.jpg</File>
    <File>pbm-20240331xf1027.jpg</File>
    <File>pbm-20240331xf1028.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="6">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="389">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pbm-20240331xf1.htm": {
   "nsprefix": "pbm",
   "nsuri": "http://www.psyence.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "pbm-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pbm-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pbm-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pbm-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pbm-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "pbm-20240331xf1.htm"
     ]
    }
   },
   "keyStandard": 120,
   "keyCustom": 76,
   "axisStandard": 20,
   "axisCustom": 3,
   "memberStandard": 21,
   "memberCustom": 37,
   "hidden": {
    "total": 12,
    "http://www.psyence.com/20240331": 5,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 2,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 163,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 374,
   "unitCount": 9,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 389,
    "http://xbrl.sec.gov/dei/2023": 6
   },
   "report": {
    "R1": {
     "role": "http://www.psyence.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition",
     "longName": "00100 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "pbm:IfrsConvertibleDebtCurrent",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss",
     "longName": "00200 - Statement - Consolidated Statements of Net Loss and Comprehensive Loss",
     "shortName": "Consolidated Statements of Net Loss and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:SalesAndMarketingExpense",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:OtherIncome",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity",
     "longName": "00300 - Statement - Consolidated Statements of Changes in Shareholder Equity",
     "shortName": "Consolidated Statements of Changes in Shareholder Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_-XClE6sYLESe4Ac51L39fw",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_-XClE6sYLESe4Ac51L39fw",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:FairValueAdjustmentsOnPromissoryNote",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcern",
     "longName": "10101 - Disclosure - Nature of operations and going concern",
     "shortName": "Nature of operations and going concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.psyence.com/role/DisclosureBasisOfPresentation",
     "longName": "10201 - Disclosure - Basis of presentation",
     "shortName": "Basis of presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.psyence.com/role/DisclosureMaterialAccountingPolicies",
     "longName": "10301 - Disclosure - Material accounting policies",
     "shortName": "Material accounting policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgements",
     "longName": "10401 - Disclosure - Critical accounting estimates and judgements",
     "shortName": "Critical accounting estimates and judgements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcac",
     "longName": "10501 - Disclosure - Reverse takeover transaction with NCAC",
     "shortName": "Reverse takeover transaction with NCAC",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:ReverseTakeoverTransactionWithNcacTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:ReverseTakeoverTransactionWithNcacTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalents",
     "longName": "10601 - Disclosure - Cash, restricted cash and cash equivalents",
     "shortName": "Cash, restricted cash and cash equivalents",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:CashRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:CashRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.psyence.com/role/DisclosureEquipment",
     "longName": "10701 - Disclosure - Equipment",
     "shortName": "Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilities",
     "longName": "10801 - Disclosure - Accounts payable and accrued liabilities",
     "shortName": "Accounts payable and accrued liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:AccountsPayableAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:AccountsPayableAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.psyence.com/role/DisclosureConvertibleNoteLiability",
     "longName": "10901 - Disclosure - Convertible note liability",
     "shortName": "Convertible note liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilities",
     "longName": "11001 - Disclosure - Derivative warrant liabilities",
     "shortName": "Derivative warrant liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.psyence.com/role/DisclosurePromissoryNotes",
     "longName": "11101 - Disclosure - Promissory Notes",
     "shortName": "Promissory Notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:PromissoryNotesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:PromissoryNotesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.psyence.com/role/DisclosureShareCapital",
     "longName": "11201 - Disclosure - Share capital",
     "shortName": "Share capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.psyence.com/role/DisclosureOtherIncome",
     "longName": "11301 - Disclosure - Other income",
     "shortName": "Other income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.psyence.com/role/DisclosureCapitalManagement",
     "longName": "11401 - Disclosure - Capital management",
     "shortName": "Capital management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:CapitalManagementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:CapitalManagementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.psyence.com/role/DisclosureTransactionsWithRelatedParties",
     "longName": "11501 - Disclosure - Transactions with related parties",
     "shortName": "Transactions with related parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.psyence.com/role/DisclosureShareBasedCompensation",
     "longName": "11601 - Disclosure - Share based compensation",
     "shortName": "Share based compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.psyence.com/role/DisclosureIncomeTaxNote",
     "longName": "11701 - Disclosure - Income tax note",
     "shortName": "Income tax note",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagement",
     "longName": "11801 - Disclosure - Financial instruments and financial risk management",
     "shortName": "Financial instruments and financial risk management",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.psyence.com/role/DisclosureSubsequentEvents",
     "longName": "11901 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies",
     "longName": "20302 - Disclosure - Material accounting policies (Policies)",
     "shortName": "Material accounting policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.psyence.com/role/DisclosureBasisOfPresentationTables",
     "longName": "30203 - Disclosure - Basis of presentation (Tables)",
     "shortName": "Basis of presentation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesTables",
     "longName": "30303 - Disclosure - Material accounting policies (Tables)",
     "shortName": "Material accounting policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacTables",
     "longName": "30503 - Disclosure - Reverse takeover transaction with NCAC (Tables)",
     "shortName": "Reverse takeover transaction with NCAC (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:ScheduleOfListingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pbm:ReverseTakeoverTransactionWithNcacTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:ScheduleOfListingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pbm:ReverseTakeoverTransactionWithNcacTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsTables",
     "longName": "30603 - Disclosure - Cash, restricted cash and cash equivalents (Tables)",
     "shortName": "Cash, restricted cash and cash equivalents (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pbm:CashRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pbm:CashRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.psyence.com/role/DisclosureEquipmentTables",
     "longName": "30703 - Disclosure - Equipment (Tables)",
     "shortName": "Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables",
     "longName": "30803 - Disclosure - Accounts payable and accrued liabilities (Tables)",
     "shortName": "Accounts payable and accrued liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pbm:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pbm:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables",
     "longName": "30903 - Disclosure - Convertible note liability (Tables)",
     "shortName": "Convertible note liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_XpSCtJGVFEW3JU9sTAbAHQ",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables",
     "longName": "31003 - Disclosure - Derivative warrant liabilities (Tables)",
     "shortName": "Derivative warrant liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesTables",
     "longName": "31503 - Disclosure - Transactions with related parties (Tables)",
     "shortName": "Transactions with related parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.psyence.com/role/DisclosureIncomeTaxNoteTables",
     "longName": "31703 - Disclosure - Income tax note (Tables)",
     "shortName": "Income tax note (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementTables",
     "longName": "31803 - Disclosure - Financial instruments and financial risk management (Tables)",
     "shortName": "Financial instruments and financial risk management (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
     "longName": "40101 - Disclosure - Nature of operations and going concern (Details)",
     "shortName": "Nature of operations and going concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction",
      "unitRef": "Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_25_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_H47wk_lCv0mLLYxNgeLpyA",
      "name": "pbm:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
      "unitRef": "Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails",
     "longName": "40201 - Disclosure - Basis of presentation (Details)",
     "shortName": "Basis of presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PsyenceAustraliaPtyLtd.Member_6XWCmWdVH0epdAirb_PHmQ",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PsyenceAustraliaPtyLtd.Member_6XWCmWdVH0epdAirb_PHmQ",
      "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary",
      "unitRef": "Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
     "longName": "40301 - Disclosure - Material accounting policies - historical financial information has been translated to United States dollars (Details)",
     "shortName": "Material accounting policies - historical financial information has been translated to United States dollars (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w",
      "name": "ifrs-full:OtherCurrentReceivables",
      "unitRef": "Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesAdditionalInformationDetails",
     "longName": "40302 - Disclosure - Material accounting policies - Additional information (Details)",
     "shortName": "Material accounting policies - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "unitRef": "Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "pbm:DescriptionOfChangeInAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:ClosingForeignExchangeRate",
      "unitRef": "Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "pbm:DescriptionOfChangeInAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
     "longName": "40401 - Disclosure - Critical accounting estimates and judgements (Details)",
     "shortName": "Critical accounting estimates and judgements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_1_25_2024_ZZfEBp5vhECip57BNE-wtg",
      "name": "pbm:IfrsSharePrice",
      "unitRef": "Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails",
     "longName": "40501 - Disclosure - Reverse takeover transaction with NCAC (Details)",
     "shortName": "Reverse takeover transaction with NCAC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "As_Of_1_25_2024_ZZfEBp5vhECip57BNE-wtg",
      "name": "pbm:IfrsSharePrice",
      "unitRef": "Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails",
     "longName": "40502 - Disclosure - Reverse takeover transaction with NCAC - listing expenses (Details)",
     "shortName": "Reverse takeover transaction with NCAC - listing expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction",
      "unitRef": "Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g",
      "name": "pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction",
      "unitRef": "Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:ScheduleOfListingExpensesTableTextBlock",
       "pbm:ReverseTakeoverTransactionWithNcacTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails",
     "longName": "40503 - Disclosure - Reverse takeover transaction with NCAC - Additional information (Details)",
     "shortName": "Reverse takeover transaction with NCAC - Additional information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:TransactionExpense",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "pbm:ReverseTakeoverTransactionWithNcacTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails",
     "longName": "40601 - Disclosure - Cash, restricted cash and cash equivalents (Details)",
     "shortName": "Cash, restricted cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:BalancesWithBanks",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "pbm:CashRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:BalancesWithBanks",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "pbm:CashRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.psyence.com/role/DisclosureEquipmentDetails",
     "longName": "40701 - Disclosure - Equipment (Details)",
     "shortName": "Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_xjrxvVhFRE2AUu-5qZqFxg",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails",
     "longName": "40801 - Disclosure - Accounts payable and accrued liabilities (Details)",
     "shortName": "Accounts payable and accrued liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock",
       "pbm:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock",
       "pbm:AccountsPayableAndAccruedLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
     "longName": "40901 - Disclosure - Convertible note liability (Details)",
     "shortName": "Convertible note liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_25_2024_To_1_25_2024_eZQ4RlMJqUmySF9gmBlrAA",
      "name": "pbm:NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_25_2024_To_1_25_2024_eZQ4RlMJqUmySF9gmBlrAA",
      "name": "pbm:NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
     "longName": "40902 - Disclosure - Convertible note liability -fair value of the convertible notes combined discounted cash flow approach (Details)",
     "shortName": "Convertible note liability -fair value of the convertible notes combined discounted cash flow approach (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_DrXtvzbxdUuHFqH8Mzx6Eg",
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "pbm:DisclosureOfConvertibleNoteLiabilityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
     "longName": "41001 - Disclosure - Derivative warrant liabilities (Details)",
     "shortName": "Derivative warrant liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:NumberOfClassesOfWarrantsOutstanding",
      "unitRef": "Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:NumberOfClassesOfWarrantsOutstanding",
      "unitRef": "Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
     "longName": "41002 - Disclosure - Derivative warrant liabilities - Fair value measurements (Details)",
     "shortName": "Derivative warrant liabilities - Fair value measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails",
     "longName": "41003 - Disclosure - Derivative warrant liabilities - Warrant transactions (Details)",
     "shortName": "Derivative warrant liabilities - Warrant transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
      "unitRef": "Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA",
      "name": "pbm:WarrantsIssuedNumber",
      "unitRef": "Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails",
     "longName": "41004 - Disclosure - Derivative warrant liabilities - Outstanding and exercisable (Details)",
     "shortName": "Derivative warrant liabilities - Outstanding and exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
      "unitRef": "Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "pbm:NumberOfWarrantsExercisable",
      "unitRef": "Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
     "longName": "41101 - Disclosure - Promissory Notes (Details)",
     "shortName": "Promissory Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ",
      "name": "ifrs-full:NotionalAmount",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "pbm:PromissoryNotesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.psyence.com/role/DisclosureShareCapitalDetails",
     "longName": "41201 - Disclosure - Share capital (Details)",
     "shortName": "Share capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfIssuedCapitalExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.psyence.com/role/DisclosureOtherIncomeDetails",
     "longName": "41301 - Disclosure - Other income (Details)",
     "shortName": "Other income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw",
      "name": "ifrs-full:RevenueFromGovernmentGrants",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails",
     "longName": "41501 - Disclosure - Transactions with related parties - Key Management Personnel (Details)",
     "shortName": "Transactions with related parties - Key Management Personnel (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.psyence.com/role/DisclosureShareBasedCompensationDetails",
     "longName": "41601 - Disclosure - Share based compensation (Details)",
     "shortName": "Share based compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails",
     "longName": "41701 - Disclosure - Income tax note (Details)",
     "shortName": "Income tax note (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails",
     "longName": "41702 - Disclosure - Income tax note - Unrecognized deductible temporary differences (Details)",
     "shortName": "Income tax note - Unrecognized deductible temporary differences (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails",
     "longName": "41703 - Disclosure - Income tax note - Non-capital loss carry forwards (Details)",
     "shortName": "Income tax note - Non-capital loss carry forwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ay66gT7zZ0uREQ7yRI0cAw",
      "name": "pbm:NonCapitalLossCarryForwards",
      "unitRef": "Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ay66gT7zZ0uREQ7yRI0cAw",
      "name": "pbm:NonCapitalLossCarryForwards",
      "unitRef": "Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pbm:IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
     "longName": "41801 - Disclosure - Financial instruments and financial risk management - Carrying Value of the Financial Instruments (Details)",
     "shortName": "Financial instruments and financial risk management - Carrying Value of the Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_0tIdiQ7fUEKkoN3p-hLo-Q",
      "name": "ifrs-full:FinancialLiabilitiesAtFairValue",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails",
     "longName": "41802 - Disclosure - Financial instruments and financial risk management - Maturity of the Contractual Obligations (Details)",
     "shortName": "Financial instruments and financial risk management - Maturity of the Contractual Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "pbm:ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "ifrs-full:FinancialLiabilities",
      "unitRef": "Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "pbm:ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails",
     "longName": "41803 - Disclosure - Financial instruments and financial risk management (Details)",
     "shortName": "Financial instruments and financial risk management (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption",
      "unitRef": "Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw",
      "name": "pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption",
      "unitRef": "Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.psyence.com/role/DisclosureSubsequentEventsDetails",
     "longName": "41901 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:NumberOfConversionNotices",
      "unitRef": "Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA",
      "name": "pbm:NumberOfConversionNotices",
      "unitRef": "Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pbm-20240331xf1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AU",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccountingProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccountingProfit",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting profit",
        "terseLabel": "Net Income/(Loss) before recovery of income taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "pbm_AccountsPayableAndAccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "AccountsPayableAndAccruedLiabilitiesTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Text Block]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccrualsClassifiedAsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals classified as current",
        "terseLabel": "Accrued liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation, amortisation and impairment [member]",
        "terseLabel": "Accumulated Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r34",
      "r40",
      "r59",
      "r63",
      "r66"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share",
        "terseLabel": "Weighted average number of outstanding shares - diluted (in shares)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other operating receivables",
        "terseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in prepaid expenses",
        "terseLabel": "Prepaids"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation expense",
        "terseLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "pbm_AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in accounts payable and accrued liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments for Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_AdjustmentsForListingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "AdjustmentsForListingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for listing expense to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Listing Expense",
        "terseLabel": "Listing expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Non-cash adjustment:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share based compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "pbm_AdjustmentsForTransactionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "AdjustmentsForTransactionExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for transaction expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Transaction Expenses",
        "terseLabel": "Transaction expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for unrealised foreign exchange losses (gains)",
        "terseLabel": "Foreign exchange"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r169"
     ]
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r105",
      "r133",
      "r151",
      "r153"
     ]
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]",
        "terseLabel": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r85"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.psyence.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "pbm_AnnualInterestRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "AnnualInterestRateMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for an annual interest rate used as a measurement input.",
        "label": "Annual Interest Rate, Measurement Input [Member]",
        "terseLabel": "Risk free annual"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Applicable tax rate",
        "terseLabel": "Percentage of statutory income tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "terseLabel": "TOTAL ASSETS",
        "totalLabel": "TOTAL ASSETS"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r84",
      "r85",
      "r87",
      "r118",
      "r120"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AverageForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AverageForeignExchangeRate",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average foreign exchange rate",
        "terseLabel": "Average rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_BalancesWithBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BalancesWithBanks",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails": {
       "parentTag": "pbm_CashRestrictedCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balances with banks",
        "terseLabel": "Unrestricted cash held with chartered banks"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Loss per share - basic (in dollars per share)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "pbm_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Basis of presentation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings",
        "negatedLabel": "NCAC promissory note (Note 11)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]",
        "terseLabel": "IFRS Debt Instrument [Axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_BorrowingsByNameMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsByNameMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings by name [member]",
        "terseLabel": "IFRS Debt Instrument, Name [Domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, interest rate",
        "terseLabel": "Interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "pbm_BorrowingsMinimumInterestChargeablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "BorrowingsMinimumInterestChargeablePeriod",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum interest chargeable period of borrowings in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Borrowings, Minimum Interest Chargeable Period",
        "terseLabel": "Minimum interest chargeable period"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_BorrowingsPeriodToRepayAfterNoticeOfAssessment": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "BorrowingsPeriodToRepayAfterNoticeOfAssessment",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period to repay the borrowings after the notice assessment received related to the research and development refunds.",
        "label": "Borrowings, Period To Repay After Notice Of Assessment",
        "terseLabel": "Repayment period after notice of assessment"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Business Combination Agreement with Newcourt Acquisition Corp.",
        "label": "Business Combination Agreement With Newcourt Acquisition Corp. [Member]",
        "terseLabel": "Business combination agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BusinessCombinationsAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_CapitalManagementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "CapitalManagementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Capital management"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_CapitalManagementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "CapitalManagementDisclosureTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureCapitalManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on capital management.",
        "label": "Capital Management Disclosure [Text Block]",
        "terseLabel": "Capital management"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r37",
      "r59",
      "r60",
      "r62",
      "r63",
      "r64",
      "r65",
      "r66",
      "r103",
      "r108",
      "r109"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carrying amount [member]",
        "terseLabel": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r60",
      "r62",
      "r64",
      "r65",
      "r103",
      "r108",
      "r109"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "terseLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r69",
      "r81"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "terseLabel": "Cash provided from financing activities",
        "totalLabel": "Cash provided from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r71"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash used for investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r71"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "terseLabel": "Cash used in operating activities",
        "totalLabel": "Cash used in operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r71"
     ]
    },
    "pbm_CashRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "CashRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, restricted cash and cash equivalents.",
        "label": "Cash, Restricted Cash and Cash Equivalents, Total",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_CashRestrictedCashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "CashRestrictedCashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash, restricted cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_CashRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "CashRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on cash, restricted cash and cash equivalents.",
        "label": "Cash, Restricted Cash and Cash Equivalents [Text Block]",
        "terseLabel": "Cash, restricted cash and cash equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
      "http://www.psyence.com/role/DisclosureShareCapitalDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]",
        "terseLabel": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]",
        "terseLabel": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r110",
      "r111",
      "r112"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]",
        "terseLabel": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r110",
      "r111",
      "r112"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r123",
      "r124"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]",
        "terseLabel": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ClosingForeignExchangeRate": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClosingForeignExchangeRate",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Closing foreign exchange rate",
        "terseLabel": "Closing rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]",
        "terseLabel": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "pbm_ComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ComprehensiveIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.",
        "label": "Comprehensive Income Loss",
        "terseLabel": "Comprehensive loss",
        "totalLabel": "TOTAL COMPREHENSIVE LOSS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment [member]",
        "terseLabel": "Computer equipment",
        "verboseLabel": "Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ifrs-full_ConstantPrepaymentRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ConstantPrepaymentRateMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Constant prepayment rate, measurement input [member]",
        "terseLabel": "Prepayment Amount"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the constant prepayment rate used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r145"
     ]
    },
    "pbm_ConvertibleNoteLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ConvertibleNoteLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Convertible note liability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "pbm_CriticalAccountingEstimatesAndJudgementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "CriticalAccountingEstimatesAndJudgementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Critical accounting estimates and judgements"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CumulativeEffectAtDateOfInitialApplicationAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative effect at date of initial application [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "terseLabel": "Total current assets",
        "totalLabel": "Total current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r140"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentDebtInstrumentsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentDebtInstrumentsIssued",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current debt instruments issued",
        "terseLabel": "Due to related party",
        "verboseLabel": "Promissory notes payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current debt instruments issued. [Refer: Debt instruments issued]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current prepayments",
        "terseLabel": "Prepaids"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_CurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails": {
       "parentTag": "pbm_CashRestrictedCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsDetails",
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current restricted cash and cash equivalents",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted Cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_CurrentWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current warrant liability",
        "negatedLabel": "Derivative warrant liabilities (Note 10)",
        "terseLabel": "Derivative warrant liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current warrant liabilities. [Refer: Warrant liability]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "pbm_DebtConversionVolumeWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DebtConversionVolumeWeightedAveragePricePerShare",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the volume weighted average price per share in the event of debt conversion.",
        "label": "Debt Conversion, Volume Weighted Average Price Per Share",
        "terseLabel": "Volume weighted average price per share"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_DebtInstrumentConvertibleFloorPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DebtInstrumentConvertibleFloorPrice",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible Floor Price",
        "terseLabel": "Conversion floor price"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_DebtInstrumentConvertibleInitialConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DebtInstrumentConvertibleInitialConversionPrice",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Initial Conversion Price",
        "terseLabel": "Initial Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_DebtIssuedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DebtIssuedMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to debt issued.",
        "label": "Debt Issued [Member]",
        "terseLabel": "Debt Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deductible temporary differences for which no deferred tax asset is recognised",
        "terseLabel": "Unrecognized deferred tax asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "negatedLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "negatedLabel": "Charge for the year"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39"
     ]
    },
    "pbm_DerivativeWarrantLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DerivativeWarrantLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Derivative warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for earnings per share [text block]",
        "terseLabel": "Loss per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]",
        "verboseLabel": "Financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for foreign currency translation [text block]",
        "terseLabel": "Foreign currency translation"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "terseLabel": "Income taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for income tax."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for provisions [text block]",
        "terseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and development"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for restricted cash and cash equivalents [text block]",
        "terseLabel": "Restricted cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for share-based payment transactions [text block]",
        "terseLabel": "Share based compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for transactions with related parties [text block]",
        "terseLabel": "Related party transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions with related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "pbm_DescriptionOfChangeInAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DescriptionOfChangeInAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of change in accounting policy.",
        "label": "Description Of Change In Accounting Policy [Policy Text Block]",
        "terseLabel": "Change in accounting policy"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfNatureAndAmountOfChangeInAccountingEstimate": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfNatureAndAmountOfChangeInAccountingEstimate",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of nature of change in accounting estimate [text block]",
        "terseLabel": "Summary of change in accounting policy"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the nature of changes in accounting estimates that have effects in the current period or are expected to have effects in future periods."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Loss per share - diluted (in dollars per share)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of accounting judgements and estimates [text block]",
        "terseLabel": "Critical accounting estimates and judgements"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of presentation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [abstract]",
        "terseLabel": "Nature of operations and going concern"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBusinessCombinationsTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureCashRestrictedCashAndCashEquivalentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Summary of cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "pbm_DisclosureOfChangeInPresentationCurrencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DisclosureOfChangeInPresentationCurrencyTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to presentation currency.",
        "label": "Disclosure Of Change In Presentation Currency [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "pbm_DisclosureOfConvertibleNoteLiabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DisclosureOfConvertibleNoteLiabilityTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of Convertible note liability.",
        "label": "Disclosure of Convertible Note Liability [Text Block]",
        "verboseLabel": "Convertible note liability"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDerivativeFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of derivative financial instruments [text block]",
        "terseLabel": "Derivative warrant liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of derivative financial instruments. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [line items]",
        "terseLabel": "Convertible note liability",
        "verboseLabel": "Promissory Notes"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]",
        "terseLabel": "Disclosure of detailed information about borrowings [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "pbm_DisclosureOfDetailedInformationAboutOtherIncomeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DisclosureOfDetailedInformationAboutOtherIncomeLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.",
        "label": "Disclosure Of Detailed Information About Other Income [Line Items]",
        "terseLabel": "Other income"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_DisclosureOfDetailedInformationAboutOtherIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DisclosureOfDetailedInformationAboutOtherIncomeTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to the other income.",
        "label": "Disclosure of Detailed Information About Other Income [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [text block]",
        "terseLabel": "Schedule of information about equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.",
        "label": "Disclosure of Detailed Information About Reverse Takeover Transaction with NCAC [Line Items]",
        "terseLabel": "Reverse takeover transaction with NCAC"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DisclosureOfDetailedInformationAboutReverseTakeoverTransactionWithNcacTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to reverse takeover transaction.",
        "label": "Disclosure of Detailed Information About Reverse Takeover Transaction with NCAC [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent Events"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [line items]",
        "terseLabel": "Financial instruments and financial risk management"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value of financial instruments [text block]",
        "terseLabel": "Schedule of carrying value of the financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Derivative warrant liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]",
        "terseLabel": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r110",
      "r116"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [line items]",
        "terseLabel": "Financial instruments and financial risk management"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Financial instruments and financial risk management"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "Nature of operations and going concern"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [line items]",
        "terseLabel": "Income tax note"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of geographical areas [table]",
        "terseLabel": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNote"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income tax note"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of information about key management personnel [text block]",
        "terseLabel": "Summary of compensation to key management personnel"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfInterestsInSubsidiariesExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of interests in subsidiaries [text block]",
        "terseLabel": "Summary of consolidation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ifrs-full_DisclosureOfIssuedCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIssuedCapitalExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of issued capital [text block]",
        "terseLabel": "Share capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of issued capital. [Refer: Issued capital]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of material accounting policy information [text block]",
        "verboseLabel": "Material accounting policies"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments and financial risk management"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]",
        "terseLabel": "Subsequent Events"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income [text block]",
        "terseLabel": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of property, plant and equipment [text block]",
        "terseLabel": "Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "terseLabel": "Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]",
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureTransactionsWithRelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Transactions with related parties"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share based compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [line items]",
        "terseLabel": "Investment in subsidiaries"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of subsidiaries [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to subsidiaries."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55",
      "r83"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]",
        "terseLabel": "Schedule of quantitative information regarding Level 2 fair value measurements of warrants",
        "verboseLabel": "Schedule of fair value of convertible notes combined discounted cash flow"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [line items]",
        "terseLabel": "Quantitative information regarding Level 2 fair value measurements"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]",
        "terseLabel": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to significant unobservable inputs used in the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]",
        "terseLabel": "Summary of unrecognized deferred tax asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "terseLabel": "Income tax note"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "terseLabel": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Transactions with related parties"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_DiscountRateCashMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DiscountRateCashMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for a discount rate, cash used as a measurement input used in valuation techniques based on a present value calculation.",
        "label": "Discount Rate, Cash, Measurement Input [Member]",
        "terseLabel": "Discount rate cash"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_DiscountRateSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DiscountRateSharesMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for a discount rate, shares used as a measurement input used in valuation techniques based on a present value calculation.",
        "label": "Discount Rate, Shares, Measurement Input [member]",
        "terseLabel": "Discount rate shares"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_DividendYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "DividendYield",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend rate.",
        "label": "Dividend Yield",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.psyence.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.psyence.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.psyence.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.psyence.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r156"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.psyence.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r104"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
      "http://www.psyence.com/role/DisclosureShareCapitalDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]",
        "terseLabel": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_EntitysTotalForSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForSubsidiariesMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for subsidiaries [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55",
      "r83"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Balance at end",
        "periodStartLabel": "Opening balance as at beginning",
        "totalLabel": "NET DEFICIT",
        "verboseLabel": "NET DEFICIT"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r16",
      "r73",
      "r75",
      "r84",
      "r85",
      "r87"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "terseLabel": "TOTAL LIABILITIES AND NET DEFICIT",
        "totalLabel": "TOTAL LIABILITIES AND NET DEFICIT"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "terseLabel": "Net equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]",
        "terseLabel": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "pbm_ExercisePriceMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ExercisePriceMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise price used as a measurement input.",
        "label": "Exercise Price, Measurement Input [Member]",
        "terseLabel": "Exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ExpectedDividendYieldMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ExpectedDividendYieldMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for expected dividend yield used as a measurement input.",
        "label": "Expected Dividend Yield, Measurement Input [Member]",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ExpectedLifeMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ExpectedLifeMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for expected life used as a measurement input.",
        "label": "Expected Life, Measurement Input [Member]",
        "terseLabel": "Expected life"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseByNatureAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses by nature [abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions",
        "terseLabel": "Value of options and restricted stock units granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "pbm_FairValueAdjustmentOnConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "FairValueAdjustmentOnConvertibleNote",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 9.0
      },
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of convertible note.",
        "label": "Fair Value Adjustment on Convertible Note",
        "negatedLabel": "Fair value loss on convertible note",
        "terseLabel": "Fair value loss on convertible note"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_FairValueAdjustmentOnPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "FairValueAdjustmentOnPromissoryNote",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of promissory note.",
        "label": "Fair Value Adjustment on Promissory Note",
        "negatedLabel": "Fair value loss on promissory notes",
        "terseLabel": "Fair value loss on promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_FairValueAdjustmentsOnPromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "FairValueAdjustmentsOnPromissoryNote",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair\n value of promissory note.",
        "label": "Fair Value Adjustments On Promissory Note",
        "terseLabel": "Fair value loss on promissory notes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Interest income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "terseLabel": "Carrying Amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, at fair value",
        "terseLabel": "Financial instruments at fair value",
        "verboseLabel": "Fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "pbm_FinancialLiabilitiesFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "FinancialLiabilitiesFairValuePerShare",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value per share of financial liabilities.",
        "label": "Financial Liabilities, Fair Value Per Share",
        "terseLabel": "Fair value per warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r123",
      "r124"
     ]
    },
    "pbm_FinancialLiabilitiesUndiscountedCashFlows": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "FinancialLiabilitiesUndiscountedCashFlows",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to financial liabilities.",
        "label": "Financial Liabilities Undiscounted Cash Flows",
        "terseLabel": "Contractual Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_FirstTrancheNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "FirstTrancheNoteMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for First tranche note.",
        "label": "First Tranche Note [Member]",
        "terseLabel": "First Tranche Note"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) on change in fair value of derivatives",
        "terseLabel": "Fair value loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "verboseLabel": "Foreign exchange gain"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r43"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "pbm_IfrsOperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "terseLabel": "General and administrative"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]",
        "terseLabel": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r132",
      "r146",
      "r149"
     ]
    },
    "ifrs-full_GeographicalAreasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails",
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [member]",
        "terseLabel": "Geographical areas [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r132",
      "r146",
      "r149"
     ]
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross carrying amount [member]",
        "terseLabel": "Cost"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r34",
      "r59",
      "r63",
      "r66",
      "r103",
      "r109",
      "r111",
      "r150"
     ]
    },
    "pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "HistoricalAnnualVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the historical annual volatility for shares used as a measurement input.",
        "label": "Historical Annual Volatility for Shares, Measurement Input [Member]",
        "terseLabel": "Volatility annual"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "HistoricalDailyVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the historical daily volatility for shares used as a measurement input.",
        "label": "Historical Daily Volatility for Shares, Measurement Input [Member]",
        "terseLabel": "Volatility daily"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Historical volatility for shares, measurement input [member]",
        "terseLabel": "Expected volatility"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsAccountsPayableAndAccruedLiabilitiesMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Ifrs Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsAccountsPayableAndAccruedLiabilitiesTextBlock": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsAccountsPayableAndAccruedLiabilitiesTextBlock",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Ifrs Class of Warrant or Right [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Ifrs Class of Warrant or Right [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Ifrs Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted Average Exercise Price per share, Ending",
        "periodStartLabel": "Weighted Average Exercise Price per share, Beginning",
        "terseLabel": "Exercise price of warrants per share"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "IFRS Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of shares to acquire"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares issued upon exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsConvertibleDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsConvertibleDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "IFRS Convertible Debt, Current",
        "verboseLabel": "Convertible note liability"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsConvertibleDebtMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityTables",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Ifrs Convertible Debt [Member]",
        "terseLabel": "Convertible note liability"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsDebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsDebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Ifrs Debt Conversion Original Debt Amount1",
        "terseLabel": "Principal amount of debt converted"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsDebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsDebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "IFRS Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Note principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsFairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsFairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "IFRS Fair Value Adjustment of Warrants",
        "negatedLabel": "Fair value loss on warrant liability",
        "terseLabel": "Fair value loss on derivative warrant"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsGainLossOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsGainLossOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 10.0
      },
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "IFRS Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain on debt settlement",
        "terseLabel": "Gain on debt settlement"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "IFRS Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other items"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "IFRS Operating Income (Loss)",
        "terseLabel": "Loss before other items",
        "totalLabel": "Loss before other items"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsOtherIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsOtherIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other income."
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "IFRS Proceeds from Convertible Debt",
        "terseLabel": "Proceeds received from convertible note",
        "verboseLabel": "Total subscription amount"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsPromissoryNoteMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for promissory note.",
        "label": "Ifrs Promissory Note [Member]",
        "terseLabel": "Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Ifrs Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of reconciliation of the combined Canadian federal and provincial statutory income tax rate to the effective tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsSharePrice",
     "presentation": [
      "http://www.psyence.com/role/DisclosureCriticalAccountingEstimatesAndJudgementsDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "IFRS Share Price",
        "terseLabel": "Closing trading price",
        "verboseLabel": "Fair value of the common shares"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsStatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsStatementLineItems",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "IFRS Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsStatementTable",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "IFRS Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Ifrs Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Stock issued upon conversion of debt"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "IFRS Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of shares (in shares)",
        "verboseLabel": "Stock issued for services"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carry forwards, including an assessment of the likelihood of utilization.",
        "label": "Ifrs Summary of Operating Loss Carry Forwards [Table Text Block]",
        "terseLabel": "Summary of non-capital loss carry forwards"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsTaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsTaxPeriodAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "IFRS Tax Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IfrsTaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IfrsTaxPeriodDomain",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "IFRS Tax Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Net Loss and Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "totalLabel": "Income tax (recovery)/expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r28",
      "r29",
      "r30",
      "r51",
      "r82",
      "r117"
     ]
    },
    "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]",
        "terseLabel": "Reported"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial effect of changes in accounting policy for cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "terseLabel": "Change in cash and cash equivalents",
        "totalLabel": "Change in cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "pbm_IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in listing expense from change in estimate of share price.",
        "label": "Increase (Decrease) in Listing Expense From Change in Estimate of Share Price",
        "terseLabel": "Increase in listing expense from change in estimate of share price"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in profit and loss as a result of an change in a designated risk component that was reasonably possible at the end of the reporting period.  Excludes defined benefit plan obligations.",
        "label": "Increase (Decrease) in Profit or Loss Due To Reasonably Possible Change In Designated Risk Component",
        "terseLabel": "Impact to profit or loss from fluctuation in foreign exchange rates"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_IncreaseDecreaseInWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IncreaseDecreaseInWorkingCapitalAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Increase (Decrease) in Working Capital [Abstract]",
        "terseLabel": "Changes in working capital:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughOtherContributionsByOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughOtherContributionsByOwners",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase through other contributions by owners, equity",
        "terseLabel": "Psyence Group contribution"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through other contributions by owners that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "pbm_IndefinitePeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "IndefinitePeriodMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the indefinite period.",
        "label": "Indefinite Period [Member]",
        "terseLabel": "Indefinite"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense on borrowings",
        "terseLabel": "Interest expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_InterestRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate, measurement input [member]",
        "terseLabel": "Risk-free interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an interest rate used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "pbm_InvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "InvestorsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for investors.",
        "label": "Investors [Member]",
        "terseLabel": "Investors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issuance of shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share Capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_IssuedCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital",
        "verboseLabel": "Common Shares"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation",
        "totalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "terseLabel": "Share based compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureTransactionsWithRelatedPartiesKeyManagementPersonnelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, short-term employee benefits",
        "terseLabel": "Short term benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than one year and not later than three years [member]",
        "terseLabel": "Between 1 and 3 year"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than three years."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r154"
     ]
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 1 of fair value hierarchy [member]",
        "terseLabel": "Level 1"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r85"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]",
        "terseLabel": "Level 2"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3 of fair value hierarchy [member]",
        "terseLabel": "Level 3"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]",
        "terseLabel": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r85"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "terseLabel": "TOTAL LIABILITIES",
        "totalLabel": "TOTAL LIABILITIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r84",
      "r85",
      "r87",
      "r118",
      "r121"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ListingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ListingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of listing expense.",
        "label": "Listing Expense",
        "negatedLabel": "Listing expense",
        "totalLabel": "Listing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_LoanFromRhCapitalFinanceCo.LlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "LoanFromRhCapitalFinanceCo.LlcMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Loan from RH Capital Finance Co., LLC.",
        "label": "Loan From RH Capital Finance Co., LLC [Member]",
        "terseLabel": "Loan From RH Capital Finance Co., LLC"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_LoanLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "LoanLiabilityMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for loan liability.",
        "label": "Loan Liability [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax note"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_MaterialAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "MaterialAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Material accounting policies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r105",
      "r113",
      "r133",
      "r151"
     ]
    },
    "pbm_MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of rebate for the research &amp; development expenses under the research &amp; development tax incentive program.",
        "label": "Maximum Percentage Of Rebate On Research &amp; Development Tax Incentive Program",
        "terseLabel": "Maximum percentage of rebate on eligible research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_MovementsOfNumberOfWarrantsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "MovementsOfNumberOfWarrantsRollForward",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Movements of Number of Warrants [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "MovementsOfWeightedAverageExercisePriceOfWarrantsRollForward",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Movements of Weighted Average Exercise Price of Warrants [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_NatureOfOperationsAndGoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NatureOfOperationsAndGoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature of operations and going concern"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_NcacMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NcacMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails",
      "http://www.psyence.com/role/DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Newcourt Acquisition Corp (NCAC).",
        "label": "NCAC [Member]",
        "terseLabel": "NCAC"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_NcacSponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NcacSponsorMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Newcourt Acquisition Corp (NCAC) Sponsor.",
        "label": "NCAC Sponsor [Member]",
        "terseLabel": "NCAC Sponsor"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NetAssetsLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NetAssetsLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets (liabilities)",
        "totalLabel": "Net liabilities acquired"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets less the amount of liabilities."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r160"
     ]
    },
    "pbm_NewcourtAcquistionCorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NewcourtAcquistionCorpMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Newcourt Acquistion Corp.",
        "label": "Newcourt Acquistion Corp [Member]",
        "terseLabel": "Newcourt Acquistion Corp."
       }
      }
     },
     "auth_ref": []
    },
    "pbm_NonCapitalLossCarryForwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NonCapitalLossCarryForwards",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-capital loss carry forwards.",
        "label": "Non-capital Loss Carry Forwards",
        "terseLabel": "Non-capital loss carry forwards"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Not later than one year [member]",
        "terseLabel": "Less than 1 year"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r91",
      "r92",
      "r96",
      "r151",
      "r154"
     ]
    },
    "pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the scenario where notes be payable on the date that is the one-year anniversary after the Business Combination, or January 25, 2025.",
        "label": "Notes Payable On The Date Of That Is The One-Year Anniversary After The Business Combination Or January 25, 2025 Closing [Member]",
        "terseLabel": "Notes payable on the date that is the one-year anniversary after the Business Combination, or January 25, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notional amount",
        "terseLabel": "Notional amount",
        "verboseLabel": "Principal amount of debt issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "pbm_NumberOfClassesOfWarrantsOutstanding": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NumberOfClassesOfWarrantsOutstanding",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of classes of warrants outstanding.",
        "label": "Number of Classes of Warrants Outstanding",
        "terseLabel": "Number of classes of warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_NumberOfConversionNotices": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NumberOfConversionNotices",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of conversion notices received.",
        "label": "Number of Conversion Notices",
        "terseLabel": "Number of conversion notices"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of days prior to effective initial registration statement for first reset date.",
        "label": "Number of Days Prior to Effective Initial Registration Statement for First Reset Date",
        "terseLabel": "Number of days prior to effective initial registration statement for first reset date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSUs granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r173"
     ]
    },
    "pbm_NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of senior secured convertible notes collectively called as notes.",
        "label": "Number of Senior Secured Convertible Notes Collectively as Notes",
        "terseLabel": "Senior secured convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Number of options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "terseLabel": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance at end (in shares)",
        "periodStartLabel": "Opening balance as at beginning (in shares)",
        "terseLabel": "Number of shares outstanding"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "pbm_NumberOfWarrantsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NumberOfWarrantsExercisable",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercisable.",
        "label": "Number of Warrants Exercisable",
        "terseLabel": "Number of warrants Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_NumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NumberOfWarrantsIssued",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued.",
        "label": "Number of Warrants Issued",
        "terseLabel": "Number of warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_NumberOfWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "NumberOfWarrantsOutstanding",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants outstanding.",
        "label": "Number of Warrants Outstanding",
        "periodEndLabel": "Number of warrants outstanding, Ending",
        "periodStartLabel": "Number of warrants outstanding, Beginning",
        "terseLabel": "Number of warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_OnSecondResetDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "OnSecondResetDateMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands on the second reset date.",
        "label": "On the Second Reset Date [Member]",
        "terseLabel": "On the Second Reset Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Opening balance after adjustment, cumulative effect at date of initial application [member]",
        "terseLabel": "Foreign Currency Translation"
       }
      },
      "en": {
       "role": {
        "documentation": "This member indicates the opening balance after the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member indicates the opening balance before the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. It also represents the standard value for the \u2018Cumulative effect at date of initial application\u2019 axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r22",
      "r25",
      "r80"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_OtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "OtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "pbm_ComprehensiveIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]",
        "label": "Other Comprehensive Income Loss",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "pbm_ComprehensiveIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]",
        "label": "Other Comprehensive Income Loss Net Of Tax Exchange Differences On Translation",
        "terseLabel": "Foreign exchange gain/(loss) on translation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "terseLabel": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r125",
      "r126"
     ]
    },
    "ifrs-full_OtherReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReserves",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Reserves"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "ifrs-full_OtherReservesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReservesMember",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other reserves [member]",
        "terseLabel": "Reserve"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r20"
     ]
    },
    "ifrs-full_OtherShorttermProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherShorttermProvisions",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current provisions",
        "terseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share",
        "terseLabel": "share price",
        "verboseLabel": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ifrs-full_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParentMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementMaturityOfContractualObligationsDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails",
      "http://www.psyence.com/role/DisclosureShareCapitalDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent [member]",
        "terseLabel": "Psyence Group Inc"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an entity that controls one or more entities."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "pbm_PercentageOfReasonablyPossibleChangeInRiskAssumption": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "PercentageOfReasonablyPossibleChangeInRiskAssumption",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reasonably possible percentage of the change in the designated risk component used to determine the value of the financial instrument.  Excludes defined benefit plan obligations.",
        "label": "Percentage of Reasonably Possible Change in Risk Assumption",
        "terseLabel": "Fluctuation in foreign exchange rates (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_PeriodOfClosingDateConsideredForSecondResetDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "PeriodOfClosingDateConsideredForSecondResetDate",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of closing date considered for second reset date.",
        "label": "Period of Closing Date Considered for Second Reset Date",
        "terseLabel": "Period of closing date considered for second reset date"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for private warrants.",
        "label": "Private Warrants [Member]",
        "terseLabel": "Private warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Proceeds received from convertible note"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "pbm_ProceedsFromContributionsOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ProceedsFromContributionsOfParent",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from contributions of parent.",
        "label": "Proceeds From Contributions of Parent",
        "terseLabel": "Proceeds received from Psyence Group Inc"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromCurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromCurrentBorrowings",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from current borrowings",
        "terseLabel": "Proceeds received from convertible note"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from current borrowings obtained. [Refer: Current borrowings]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfessionalFeesExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "pbm_IfrsOperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "terseLabel": "Professional and consulting fees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "pbm_ComprehensiveIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "NET LOSS",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r0",
      "r21",
      "r68",
      "r74",
      "r76",
      "r118",
      "r119",
      "r140",
      "r148"
     ]
    },
    "pbm_PromissoryNotesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "PromissoryNotesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Promissory Notes"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_PromissoryNotesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "PromissoryNotesTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosurePromissoryNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on promissory notes.",
        "label": "Promissory Notes [Text Block]",
        "terseLabel": "Promissory Notes"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r37"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]",
        "terseLabel": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r38",
      "r134",
      "r147"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "% ownership"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r54",
      "r77"
     ]
    },
    "pbm_PsyenceAustraliaPtyLtd.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "PsyenceAustraliaPtyLtd.Member",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Psyence Australia Pty Ltd.",
        "label": "Psyence Australia Pty Ltd.[Member]",
        "terseLabel": "Psyence Australia Pty Ltd."
       }
      }
     },
     "auth_ref": []
    },
    "pbm_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails",
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails",
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for public warrants.",
        "label": "Public Warrants [Member]",
        "terseLabel": "Public warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Additions to equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "pbm_PysenceBiomedIICorpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "PysenceBiomedIICorpMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Pysence Biomed II Corp.",
        "label": "Pysence Biomed II Corp [Member]",
        "terseLabel": "Pysence Biomed II Corp."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r95",
      "r99",
      "r144",
      "r145",
      "r174"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r95",
      "r99",
      "r144",
      "r145",
      "r174"
     ]
    },
    "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]",
        "terseLabel": "Reconciliation of the statutory income tax rate to the effective tax rate"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "negatedLabel": "Payment of promissory note"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_RepaymentsOfCurrentBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfCurrentBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of current borrowings",
        "terseLabel": "Notes paid"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of current borrowings. [Refer: Current borrowings]"
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "pbm_IfrsOperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "terseLabel": "Research and development"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated Deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r127"
     ]
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromGovernmentGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureOtherIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income from government grants",
        "terseLabel": "Rebate amount of research and development expenses received"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "pbm_ReverseTakeoverTransactionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ReverseTakeoverTransactionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Reverse takeover transaction with NCAC"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ReverseTakeoverTransactionConsiderationPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ReverseTakeoverTransactionConsiderationPaidAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Reverse Takeover Transaction, Consideration Paid [Abstract]",
        "terseLabel": "Consideration paid:"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed consideration amount for the common shares issued",
        "label": "Reverse Takeover Transaction, Deemed Consideration Amount for Common Shares Issued",
        "terseLabel": "Deemed consideration amount for the common shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ReverseTakeoverTransactionNetIdentifiableLiabilityAcquiredAbstract",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Reverse Takeover Transaction, Net Identifiable Liability Acquired [Abstract]",
        "terseLabel": "Net identifiable liabilities acquired:"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ReverseTakeoverTransactionSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ReverseTakeoverTransactionSharesIssued",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails",
      "http://www.psyence.com/role/DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued as consideration to shareholders in reverse takeover transaction.",
        "label": "Reverse Takeover Transaction, Shares Issued",
        "terseLabel": "Consideration shares issued to NCAC shareholders",
        "totalLabel": "Total consideration shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ReverseTakeoverTransactionWithNcacAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ReverseTakeoverTransactionWithNcacAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table.",
        "label": "Reverse Takeover Transaction with NCAC [Axis]",
        "terseLabel": "Reverse Takeover Transaction with NCAC [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ReverseTakeoverTransactionWithNcacDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ReverseTakeoverTransactionWithNcacDomain",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for reverse takeover transaction.",
        "label": "Reverse Takeover Transaction with NCAC [Domain]",
        "terseLabel": "Reverse Takeover Transaction with NCAC [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ReverseTakeoverTransactionWithNcacTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ReverseTakeoverTransactionWithNcacTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcac"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse takeover transaction with NCAC",
        "label": "Reverse Takeover Transaction with NCAC [Text Block]",
        "terseLabel": "Reverse takeover transaction with NCAC"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "pbm_IfrsOperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "terseLabel": "Sales and marketing"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ScheduleDisclosingChangeInPresentationCurrencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ScheduleDisclosingChangeInPresentationCurrencyLineItems",
     "presentation": [
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information presentation currency.",
        "label": "Schedule Disclosing Change In Presentation Currency [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of accounts payable and accrued liabilities",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Text Block]",
        "terseLabel": "Summary of accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ScheduleOfListingExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ScheduleOfListingExpensesTableTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of calculation of listing expenses.",
        "label": "Schedule of Listing Expenses [Table Text Block]",
        "terseLabel": "Summary of calculation of listing expenses"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Thee tabular disclosure of maturity analysis for financial instruments (including derivative and non-derivative instruments) that shows the remaining contractual maturities.",
        "label": "Schedule Of Maturity Analysis Of Financial Liabilities [Table Text Block]",
        "terseLabel": "Schedule of maturities of contractual obligations"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrant transactions and number of warrants outstanding.",
        "label": "Schedule of Warrant Transactions and Number of Warrants Outstanding [Table Text Block]",
        "terseLabel": "Summary of warrant transactions and the number of warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants outstanding and exercisable.",
        "label": "Schedule of Warrants Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of warrants outstanding and exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_SecondTrancheNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "SecondTrancheNoteMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Second tranche note.",
        "label": "Second Tranche Note [Member]",
        "terseLabel": "Second Tranche Note"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Services expense",
        "terseLabel": "Services rendered"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from services."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "pbm_SharePriceMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "SharePriceMeasurementInputMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for share price used as a measurement input.",
        "label": "Share Price, Measurement Input [Member]",
        "terseLabel": "Share price"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for information pertaining to shares issued to the third party consultants and legal advisors.",
        "label": "Shares Issued to Third Party Consultants And Legal Advisors [Member]",
        "terseLabel": "Shares issued to third-party consultants and legal advisors"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantInvestmentsInSubsidiariesAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiaries [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55",
      "r83"
     ]
    },
    "ifrs-full_SignificantUnobservableInputLiabilities": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantUnobservableInputLiabilities",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant unobservable input, liabilities",
        "terseLabel": "Warrants, Measurement input",
        "verboseLabel": "Convertible note, Measurement input"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Changes in Shareholder Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Condensed Carve out Consolidated Interim Statements of Change in Shareholder Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]",
        "terseLabel": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Financial Position"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_StockIssuedDuringPeriodSharesIssuedForDebtSettlement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "StockIssuedDuringPeriodSharesIssuedForDebtSettlement",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued for debt settlement.",
        "label": "Stock Issued During Period, Shares, Issued for Debt Settlement",
        "terseLabel": "Issuance of shares for debt settlement (in shares)",
        "verboseLabel": "Shares issued to settle NCAC liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails",
      "http://www.psyence.com/role/DisclosureShareCapitalDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued during the period for reverse takeover transaction.",
        "label": "Stock Issued During Period, Shares, Issued for Reverse Takeover Transaction",
        "terseLabel": "Issuance of shares, reverse takeover transaction (in shares)",
        "verboseLabel": "Shares issued to NCAC shareholders"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_StockIssuedDuringPeriodValueIssuedForDebtSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "StockIssuedDuringPeriodValueIssuedForDebtSettlement",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued for settlement of debt.",
        "label": "Stock Issued During Period, Value, Issued for Debt Settlement",
        "terseLabel": "Issuance of shares for debt settlement"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued for reverse takeover transaction.",
        "label": "Stock Issued During Period, Value, Issued for Reverse Takeover Transaction",
        "terseLabel": "Issuance of shares, reverse takeover transaction"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_SubscriptionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "SubscriptionAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the subscription amounts.",
        "label": "Subscription Amount",
        "terseLabel": "Subscription amount"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_TaxEffectFromChangeInTaxBenefitsNotRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "TaxEffectFromChangeInTaxBenefitsNotRecognized",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to change in tax benefits not recognized.",
        "label": "Tax Effect From Change in Tax Benefits Not Recognized",
        "terseLabel": "Change in tax benefits not recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax effect of foreign tax rates",
        "terseLabel": "Difference in foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "pbm_TaxEffectOflistingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "TaxEffectOflistingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to listing expense.",
        "label": "Tax Effect of Listing Expense",
        "terseLabel": "Listing expense"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_TaxEffectOfotherPermanentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "TaxEffectOfotherPermanentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to other permanent expenses.",
        "label": "Tax Effect of Other Permanent Expenses",
        "terseLabel": "Other permanent expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax expense (income) at applicable tax rate",
        "terseLabel": "Expected income tax (recovery)/expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "pbm_TaxYear2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "TaxYear2044Member",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteNonCapitalLossCarryForwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2044.",
        "label": "Tax Year 2044 [Member]",
        "terseLabel": "2044"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary difference, unused tax losses and unused tax credits [member]",
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "pbm_ThirdPartyAdvisorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ThirdPartyAdvisorsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfChangesInShareholderEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for third party advisors.",
        "label": "Third Party Advisors [Member]",
        "terseLabel": "Third party advisors"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ThresholdAmountForMinimumCashCondition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ThresholdAmountForMinimumCashCondition",
     "crdr": "debit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold amount for minimum cash condition.",
        "label": "Threshold Amount For Minimum Cash Condition",
        "terseLabel": "Amount for minimum cash condition"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold period for payment of price difference between VWAP and conversion price in cash or in shares.",
        "label": "Threshold Period for Payment of Price Difference Between VWAP and Conversion Price in Cash or in Shares",
        "terseLabel": "Threshold period for payment of price difference between VWAP and conversion price in cash or in shares"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_ThresholdPeriodForVolumeWeightedAveragePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "ThresholdPeriodForVolumeWeightedAveragePrice",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold period for volume-weighted average price.",
        "label": "Threshold Period for Volume-weighted Average Price",
        "terseLabel": "Threshold period for volume-weighted average price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails",
      "http://www.psyence.com/role/DisclosureNatureOfOperationsAndGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Range",
        "verboseLabel": "Maximum"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r95",
      "r99",
      "r144",
      "r145",
      "r174"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails",
      "http://www.psyence.com/role/DisclosureMaterialAccountingPoliciesHistoricalFinancialInformationHasBeenTranslatedToUnitedStatesDollarsDetails",
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacListingExpensesDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "negatedLabel": "Accounts payable and accrued liabilities",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureAccountsPayableAndAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r163"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://www.psyence.com/role/DisclosureShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables",
        "terseLabel": "Accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "pbm_TransactionExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "TransactionExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.psyence.com/role/DisclosureReverseTakeoverTransactionWithNcacAdditionalInformationDetails",
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of transaction expense.",
        "label": "Transaction Expense",
        "negatedLabel": "Transaction expense",
        "terseLabel": "Transaction expenses included other costs"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_UnaffiliatedThirdPartyInvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "UnaffiliatedThirdPartyInvestorMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for information pertaining to shares issued to the third party consultants.",
        "label": "Unaffiliated Third Party Investor [Member]",
        "terseLabel": "Unaffiliated third-party investor"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]",
        "terseLabel": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r172"
     ]
    },
    "ifrs-full_UnobservableInputsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityFairValueOfConvertibleNotesCombinedDiscountedCashFlowApproachDetails",
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [member]",
        "terseLabel": "Unobservable inputs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r172"
     ]
    },
    "pbm_UnsecuredConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "UnsecuredConvertiblePromissoryNotesMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosurePromissoryNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to unsecured convertible promissory note.",
        "label": "Unsecured Convertible Promissory Notes [Member]",
        "terseLabel": "Unsecured convertible promissory note"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_UntilFirstResetDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "UntilFirstResetDateMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureConvertibleNoteLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for until the First Reset Date.",
        "label": "Until the First Reset Date [Member]",
        "terseLabel": "Until the First Reset Date"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureIncomeTaxNoteUnrecognizedDeductibleTemporaryDifferencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unused tax losses [member]",
        "terseLabel": "Non-capital losses carried forward"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "pbm_WarrantLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "WarrantLiabilitiesMember",
     "presentation": [
      "http://www.psyence.com/role/DisclosureFinancialInstrumentsAndFinancialRiskManagementCarryingValueOfFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrant liabilities.",
        "label": "Warrant Liabilities [Member]",
        "terseLabel": "Derivative warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_WarrantsIssuedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "WarrantsIssuedNumber",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued during the period.",
        "label": "Warrants Issued, Number",
        "terseLabel": "Issued"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_WarrantsIssuedOnJanuary252024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "WarrantsIssuedOnJanuary252024Member",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrants issued on January 25, 2024.",
        "label": "Warrants Issued on January 25, 2024 [Member]",
        "terseLabel": "Issued on January 25, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "pbm_WarrantsIssuedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.psyence.com/20240331",
     "localname": "WarrantsIssuedWeightedAverageExercisePrice",
     "presentation": [
      "http://www.psyence.com/role/DisclosureDerivativeWarrantLiabilitiesWarrantTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share or per unit of warrants or rights issued during the period.",
        "label": "Warrants Issued, Weighted Average Exercise Price",
        "terseLabel": "Issued, Weighted average exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.psyence.com/role/StatementConsolidatedStatementsOfNetLossAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of outstanding shares - basic (in shares)"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "46",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "2",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_2_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG63&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "20",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001410578-24-001519-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-24-001519-xbrl.zip
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MS<'W!^!'.3EC1!38_+<C,NZ.BSABGU0_:%Z"\UU2QG^- .L /G65.2AOR9:
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ML\47RED@OE W$GCFM/3DBCP+?)^Z>+..OSV5A0<FU&;(8 [%)F(\I$LJ_MK
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MD6T9S6$-0N-3J:TIR*K95EP+2_3SW^H"/>R&ZX@9]Y'FRZ>REK59C5CE)ND
MJ\C=A49-+C LG./_S2NG;JPZ#E7X"%M%34$#UJJ(^+A9?R/"FGUYPDK\(VJ[
M.)(U.Z*E3FL9]AXF67T!6]F04K3Q^9:$VU6*Y>+HM3'_VYCJ:,]>9(G'8;0$
MC,/JD)@;N/:PP#;X6SW(H)^')J3Y0DR:HM>>(+#J $'E2"VL .WA@JWQRHN=
MZ5E)]M5X-5/ 9YX^V/*AD<J16A#^-@XG?.+:B_FI?VW*REK'NCJPZZ!$'./3
M #(D QO=KNXK,;J$7\X^#%4P-P^#-;4-A]<6_1QBA)N42-O#YG&S!>I@68(,
MM17Y_0C8HAC@R !;>;V>^@,MBP+_"0O[85N1M\G7[!EH(6'@-$GV4J8F?@5]
M>:N"^MSA%23?T]OTBF3<@I4-[_*B+T/-)[55,VA6[='MX&M =MO .H#-M]RV
MUFOG^XZK2:]]NMIKSPL!HUDIJL.&LW* ORQH^WVV5;>WEZE?4%8!_5B 9O*E
MUT9IRM/^S;E(]-9R0K1J+%"*>!I0%@2(#;N,OF%YSE?S99"$!%5A.Q<^J^(I
MLK3Q3-7;I_%HY&/$BG5F'S.IBDFLC=D\&F)K/L!ZGR\W\ E:1ZL^0;10\"Y*
M%;,Z5:QP$E2Y0D84#99E@T7A5OL)R?J4]PTCH1"IC]0&ID]:*I]!7]U%7WH[
M'/ETBM 5(LC#&?.+-?*,-[\#T?QVOWADQFA2Q[-I15CEF9B _[!PMI9%?<CK
MZUF2B0)*,)N=76/P#"=R^RS?$'6R.D3-<@/"8@$1^5D]ZBPT$^XRR .]F(PQ
MZ8>+U5E^O4GB4HT\RZK.JGX97$H?S)%NF7C7@RN;TKG2EK']FW*4Z,06A&S5
MF"%!>AYR@HX7!B"&T#(F-*E)JF@!.9!^TH?6(K7R=0%\J;+5H"H_Q$\Z4A:I
M%)5S8.% #"%97@"5M-NE35-)SG) W7P8?39WZB8'%8Q]+QO^?*(@O*CPNR-_
MK7R*,G?Z"G):&+9Y2'N2JWS>F!$1^I@__0U02P,$%     @ RX 364S=1@O\
M,P  :%@# !0   !P8FTM,C R-# S,S%?9&5F+GAM;.U]6W/CMI;N^U3-?^#I
M>9GSX+;=G>RD4\F>DN5VQZ?<ELM6)S-/*9B$).Q0A )2MC6__@"D+B2%*\7+
MHJ*7I&T#X/K6#0L+"\#/__4V#[T7S&)"HU_>7;Z_>.?AR*<!B::_O%LFD[,?
MW_W7/__]WW[^/V=G_WWU>.<%U%_.<91X/L,HP8'W2I*9-Z:+!8J\KY@Q$H;>
M%2/!%'O>Y<7[']Y?O+_TSL[^F0YQA6+>A49>.M:']Y>;/PS7H]'H)^_'\\M/
MYQ\N/GSG_?#3Q8\_77[P'KYNVGWEE$V(J6%(HC]_$O]YYM_S.,(H_NDM)K^\
MFR7)XJ?S\]?7U_>O']]3-N7=+R[/__OKW9,_PW-T1J(X09&/WWF\_4]Q^LL[
MZJ,D94^N^]LS"S<#?#S??DO90OQTMFEV)GYU=OGA[./E^[<X>+<F4?S9XB.;
MYF][[=>8+C]]^G2>_G7;E ]$-$/G8&_;!\FV0[[Q]^?9']_]\]\\[V=&0_R(
M)U[ZM9^2U0+_\BXF\T4HADI_-V-X\LN[Q?/\3$CJXF,&^3^>$BYOH4A#&L4T
M)($0__:7\6AR0R).$4'A XV)8/\[3WSLV^-M <<B7G%]Q>]].C\7?S^O,G *
MVHKSYPVC'LY0-,7Q;?0T0PS/:!A@]OFO)4E6=<'7?:$U/ER3V ]IO&28D\F]
M3T*>0WQ/$WQ'T#,).3%CQ'\36X*V'ZX#A/<HX?\=348+S%(_$@^BX OE#I83
MZV,67>,$D= =J_W ':#FGIYP;7M@..9ZEY)7%:=NJ Z0?>6VQ+C[&/@^748)
M9_<#MS.?X/A7$B>4$1^%6Q]S&TTHFZ<T_XKB*XRC,4-1' JK'--O$=E89WQ-
MPQ"QN"J36J*J WX_8A&>X#'Z$U/^KY12Y O:?^>AQ[V/_*H\<Q@9).X[+EDN
MZ,]O"QS%N++J5/]0!UP14]5"3&55T>X/ &C6JPK*.!X@C#>(L-]0N.0S5ZE)
M/*3S9Q+A0 PBO!@.ABB>W83T=;!8,(K\6=T,JH>8#KA[S;W]"_?@+_AWQ+C%
M)AM(I+HCL!H3&-:M +]B)-JF46X3#-!_"!A7UK_)N?)&>*+[##".C):)6.**
MO :/DC^_8>:36"P*FN"+^6,=<.>!T3F)8\I6J7NKBELU3 >(TA7L$"U(@L*J
M<*1C=(!EE,PPNXTXA94U4C9$!T@R"L;H3>A'52SR0;I&\RUBV*?3B/PO#PMP
ML/33:&&,YPO*$%M=D\D$,P&ILG4=^KFN.71/H[4QW=$X'G+/N+JA[!6QH!Z6
MV(S? 0]R*^LX86F"7"1CMK]^)/&?7U&$IEEJ3I#-YX9UX"GK7)59S1$"GJM?
M13J,A_1I))\P'H\L43AZ#LD4'10 -41%%_/E\CG&?RTYE9]?#E$RY3BNF%*R
M-\!<B1 !%K=[+HKA,D[H?/!&XFLZ1R2ZQA.T#)/8GC'V8Q49GX.!F+]!LOYG
M'LR6#R1*S@,R/U^W.4=A*!\Z3[J"H9NM&+&=]'T**1WM<*+XOW$D=@3/@I0)
M-5*X/W0-Y*8CG<WQ_!FS.FDMCGLXH3-.$_.7S_ALRX8:R96.7JLR9+;0C#9L
MQK8F6(R.XSEZCY>,+L3_TN'/<8PG6^)?28#96<3G.?I:53="QK;CB0^>K7_@
M,"Y_/+N\//N0^9/RMW)(.#H2I9N-=_S']1?%& UXNPP<?DMP%.!@^UN2B*]]
M^O3IXL([\W8C\Q\V@WM\="\;WA/C>]D'O.T7!* -I)#ZA0^&8I><LGUVQAOE
M(A,6IPQ-T!N-Z'PE]NX_GEU\//OP\7RR#,,_1(O=O\Y\RO[8-4EYG/X^;?%$
M>& \(3Y?>=]&+SA.THGY-A*3$PD(8GP=+D!L" K1,PY_>><^P!^7)1Y6&^(<
M$O,^1QS+*AY3'DCS^#E/[]>"%]WCFK&GAEU6?0M\VMG-@!4YQFUP\YT)H_,#
M!4N=R5S&G BZ$*2A[0R^=@R'^-2,9SO</U7!Y8VIYXB',NZ\?GD'35$EB]UO
M$>=]P->#8@6(12B^_<V0X8 D>K.O/*)&L0\:L__\-KB, \:LF^=UNIDZ%(G6
MB*@#CW0 "XHNZD#H0)W7%TRG#"UFHO9BP##2.R9I:XT!*-O#YH'!62C:N_"A
M3B,W"85:4M*!<2I(+QJ>AF2@1K5)L&EM*=](HSKE9J" #J93AJ=I2187_Q5?
MHIEL1]E#PP)MG\/M1R$(:DU"!X93I+EH+UI::[.8"8J?4SPQ2U(=.L=\^2U^
M$AG,3%'X#W\\BE)>B2$4_K8G_+V_@E+[E#*3IN<;:92[W*RJ/JOX274?:TUS
M2]05%;9,%5"O/N0F-:5B23J:/.*T$/4!L<24P]%WTVB&N2,H]I26\$6*W3(V
MLK[V.1M5[\-G"FM1ZG(U*O(ZF$5,>+0Y&A4.J-8;(K%&R^T@YXJA] 9LZJFS
M89N^H/@D(]1@O>HN&L[H.]5@JPY2H_:$=6&E9B1%0]4C &J?=_@%AP+DIH;U
M5X(9Y]M,OXK2=]/HG[DC*/8,PE!-L6G-9>ZK6WW9]3[<8JU%22N0UX'=FO"4
M5FUV. ZQWKWJ$OZ+/VXY!:F'&4W61<(C]DBFLT1B=L;V>VIDU:-I)->% A$;
M+%D/-S2[/E5-P86]U)J:UC3?@GRA\I9D YVFAG2^H%%V3#D[DJR/':7-=0&C
ML@,H-F2DF59UN4:ZY5NI60VQGXGK5/?]+D(\!<&E!5B)T-9S></TC!E;\"7?
MZA[-56D]63-IAD_5L*W4)%XL^>R*8CR8,KR^D:!(D73J<.HK3VVZ]#XD(V@0
M!:U 3JLY0SG]PBR<Z08ZH5PM8Q+A>'V4<WU'@FY*4770>%A=%U#,**689'2[
M91+5(]CG$_5C'#Y;60A4ET_4D]?!9*;&H\TGZG$ M5[5[I:DA6D/"*1!NN]T
M?;#;Z?I0A^6X[7=]Z,0:[':]/C2TLK_&S\GN3)!F2;_?4+GZE3=MC&AE&&9J
M;@F@GF#+BH_4CH;65^PRHO-+=1VQ0!WS%15''$@TC:]42Q5]8UTXI6@.F@$&
M'RYO[L"$6B,BO3RH'1U=A#Y2PHM^7TUPZ^OY[9U[3SZ.$"-4L:"7MI,N;)4M
MVT*T_NRW*%Y@/[V&4[F$5[:5(].U/F2);F(NM?A^JVMR!<&;1;F6T-J#'//%
M8(J@QZZC-(:P[]H:2&6 9-NU(M!Z B=G65!W^EH-JFP!;8(L%R!  Z[]*H7\
M701N]36EGD[U-9*^_>&3(4BSZ%N55\V6WJ@%2BM0"*(&9P]2,<JSA +4F+]%
M]#G&[$7<!W8;+98&"Y8WUZBBN@-P-A@,5-7!B15UFJ)1,M26E@Z,3D5\T=)T
M1 ,UKWO.P^!?R^S"VO1ZFL$DP>P1+RA+KT7&/'X.M"9G/X1&]]P& <Y"@VFJ
M.CBQIT[3K"1!:DM?!^;J JAHPCH@0$UX.[\_,+K +%D]A"A*Q$V:F[N;[6)>
M;7>;8,XX "BV*:DU6*^AGX91%CUKC'AMQ4D=2>PRY#5@*IJR!1:H%KV^:' P
M%R4D ]]?SI?I"9=KO&"81_"I3LR%+XNS?T?![7R!"$MY$05?V.:ZQ]TH^H-A
MS7Q0>Z2LN4\"%J9I62UI;,W$>L^7-:X1U 9))T?1FH)>6I<K(#>R^SY&;\I0
M7MI&N66]UZH)*K6[[*569DKKVU-7L8AJO]KZ+GJ)S/P&NH2\VF;!&/OOI_3E
M/, DVQGC_]AMBO$?UH56@R!@.+VF)OO'F(\OT4MSASW1VW5I'&;NFU)-EK:1
M@I&VJJK%3@RE&@):4V@;BH5V*RF%&N%M(MK\A?IVR[1R#YN5F:P/?'[8;D'L
M]W'E22,+,(V@Y%L-<HJZ7&_M0U!L+<A)AVI\64!'7O#GR03[R2"YYN'=:'(K
M&,&!+A8AR=XPU5NDTS ZE70>"!0[1PL<\3#V"H7B3=0K/*$,#](<6GH*PAJ<
MP=SK_8Q&'/5_J :G4E77:+/(NG!.CJPH>JSZ65!R<C^?EZ1\QW],_U#Q5NM*
M+_3FM$IQM?7%Q65ZM?5V)/[O_!=V?X@].O&V'_$JO .\4?^#UH9;>M+':15+
MPW*C<Y=/]^W"IAT\*Y]B;9;2F_%W:BY;%\N%4T[QZ,&4? D4T35\F5130MQ_
M.4(N05<==;Y0ZC#!2MV!J$)[6@AGQ:0"4+1IB-'%9R],7'90ITU620(%J*UP
M&!8;:(5&;0KE0TU"46&I7=$+KI5'#?B6_U.5OI4U;(:[Z;LYEA/"'M7Y7&EY
MVBB'D^G[)S_Y-$IX%/,Y3)O^\B[&4_&/W=]#&N/@EW<)6P*:\@=\99S$@^<X
M?=9*:0WE9AW:@YWLU*0O&*'B)MA4*8!ZJ.&2"8NU%(ZB-8B)1 ZA%'+)Z>^%
MH% \$\_W\/^)C?L7%(JEB"92EC<'(2JMTI6#9#F.7H@L@_F(.4#BKU\ =Y&A
M;7\0,8.+4&V!]4'*Z;NY6T0^)FFYJUJJRO9M2O%C#5)4 NF#U-9T/S"\0*NY
MC1D6FK8IJ^_JL[@"AAZ)*8-H%Y:T*YSOZQ/.AOP^R.6>1KY3Y*CN &+RLA&3
M&D(?)*:L_E3G)=0]0$21)AVTK.3MA_@,'K +UZ>,(6S$T2=GE[_3V^3GI&T[
ME(IK#D-*?Q^$M)Y$762EZP+"PVG 2".(W@IOS%" N5/.+RD>T$J_D-)W B%
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M31TL[*XO;)$][U[<!)"LRZQZ@7N2JJ*LK %W5".07@,S1 N2H-"M0.##?H%
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M XADD ,?!<U ?4<ESZF=.0X8$>@[577/+@=PZ)BTR#!+'30FE)GL8/.J07.
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M.O]4&U<JE'__?)[)AV0UT__\_U!+ P04    " #+@!-9R]JW+2YJ  "K=@8
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MDVP%<"LI<268W+)7]559;9-6G7%Z5#<;)"%:\YZX [,.>O0/QWSV6K/].FI
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M(DZ\M&BMZAWNQN3FLY7512E[.^()'G$_AT<ZV6 6-HI,!!0[6V.:+"E;9[(
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M]#@XL*U/@'0@;JB1>&B=N^\B:Y+QIOH%E(M-9"-N3K@+:)&*IP(9G@JH_MR
MB,0I$IQXI??_FQTMI-=%E>6-YP6EE?%D2<OY0)BM^.ITV$X<1DZHX\3.68)T
M-1Y:U0.[F]9J6_158W/,#ELO=-<1_5/YE#.M[PZG[C((D2V.VD8R-9[<F1QV
M-^]GIY.B9IUH80:(GAIU?M_0*=2=&%T0V"K/%Q<<-3JJOS'D9^U!!CO\=+-+
MA\LO-SC2J5JX '.NR=27.CQCQ7!4-V'L&0[IAO#"==73^_ NVC+QM*7^TU8$
MA\WVTR&$"B[A,M@]<U\7<#&:R0SPMLAC!R6[=CR)D:S0Q@QBEC7L'!<D8I
MY(!B0U":2$E"GF-1(.]+*LM%-<Y-%58A,R<NR,M'?.T1K6EO[(#5R@HGP5.3
MKICAIIT"W7-(Y5=AX^%$F_P0XUABN:5"U^E6B;..C I<D/ DJ,NDR@HOEP<A
MI-;W] @7C\.G0'W[>-CO/2ZQUVC+ED2P T07FQ1QH@T%S'#128_.OJ+IJ^K.
MC.QC-A,%$J-J_E2E\=3+),<1!^J%ZO8Q7W/F+L+8'E6;6Q5]L+M_ XW/=G)-
M'3 [=Q.Q>^PS*MK$28FKD@.:_'1[KL,J+)7,):+!Y<<*R!ZW@8BDI78RXGGA
M(:Q0C-:JZ(#=@^MT+;JOJ35FWZV5N>LX5H03/X70/28\D<L.IN>]2;/6;KJF
MX;/B$(I(>>@'YD4A_ 4)#+0;RC_^_@#92TINC)Y^A].Y2C4 /RI\@<]ERL7K
M.FH>(5E!&'&'>N0SH["%KC?UQZ]$/:%B@[D(2*'X/CK,IX('!G<QM</K.I6:
M)6Y4V@BG2U6+VGD4QL2F\J<IM!K.F6*V7_QPSQP5[I;6;J]KB]BIZC1,'<O4
M$*ESU8K;?RA.45!\6MTZ9YWZXD?<N^8BC!Y8R*)+B1'&DN%5;7$Z4B,-DZ12
MQH:X,TG5B]T]?51IN?$#,%0[_HHK46P)\!TU;]1P>G\Q*CA=-?(IM+6%,7?^
M(Y-.ZM8CC+DE7GRIT2Y!%T,SW-A2)[1%9($JK7(,AHH?9*F3@] =&U.&TO=.
M*Z>)H\"3L37%M5^<U4]8^9#*4Z*JE-&X46=LCA.5FNIIJN.1;XMO$=%8XLYY
M;5.R%X3'A(DX'\-C;1,/I.:J0K7.4_TE>XY6?A@)-:TL _^%B8@_>VP%I:"H
MIS\)U;64\NH![2G@=,(>UDA"AI;=<8<2797ID_M6)4XG>P@R5"+U8!U7^$M8
MD36C$5QZA\G/==6-=]7$E=+*?R?BCAJ$C&TIX$<RAJH$<,+R@L1,2<9UHAS^
M8YNEH>+VH?+:"P+1&AX+O68(B>=:U\)@UF6FT%>B0!^X6P.YWQKH6;11%= 1
MQ0<;M%E4/@=CN7%B"\QN#[!ZO%M?TF,HY0W$4W"U7C,GXB\)/C^P#8>RD. D
MZ5G4=2"*FUHEUK%)&R\P6K=@ I_6".,&6?MJ]H%B7TFCWE)*><#7X))\0%@B
M$N%Q>"%R0L%>F)9*;;2OU7[L1%MA>.QYF]H29"'WB2U3<=(8-2\0>2S8LF9O
M>WB,QVA/BV/3UD1RSZ0X[MUZZ04A]S>@<%(=GKG2%B>[EB6&;D\![Z30T1H)
M]+?LCAO@NRK3:P-!\53%<S17-=8AEH[Y*E^8]LQB;+O<IS:).>J3C&71)G4'
M ,,#[G1V:356; 'GD_PNW :>J^60"M[3(_@3I$&0D?XEE_ NF(2;3RQZ9<S_
M^97NH<10<=MDY4/-H3NQ\E7UP[**8\-QP@O$ ULW >R!V. &]J&5[C,!1(EL
MR50 /KS7XNE:%;#9XJ82DF<M(OGYE\6]KJV6K;MU8^[K>FN2D/RGVJ,9M^ :
M7GLGMK[/;'V?V5IQ)9ETY-.IK4^W:L' R\S66L[1)R+\]AYT; \WP?T<>!)8
M?F%\LXV8NY"BT(VQ*GG+[G.:BNKM8)Y?S'WG-FDTT,3Z3/"B>+Y[C9D2JKE.
M4"!\9'N4(/7/)[:(.4ZTI3Z1/9J.#5S7H;[XP7/(Q M5IZG[0Q16%G\P-L<)
MFDWU+%Z'*F^+^3I4C<3=[P=G9.6L#G2GK5,PM9[HG+4F87%%A_DY;%7285/K
M>3FMM6O])<-YVK3 &'3MO/Q0BRX5+N2>$"LMC*\9&G3!Z8!M]$V6%G7M<2\G
M&DMO^2V5OJ*C%\^'4.>1H;)=]DA=#>=1EQ*#VT(QT.N"B\*#?,5DNC<1(RF.
M< $ !R-R4$;W@L4;0 _J24@#H.M,!"?T];/):1',YA0PQRB=].AQ3TTQDVZ2
M<%,O%"[.47'J>&94NV1,B*[78NT>,@\=H >RZYWEQ@%.BZXXO;V+_NFUY(;]
M< <^K;6P' !1XL82Q%ZN#PVJ@B']'??)"_4.^FY2Q)RMS_]YD!V!FPNO22D@
M2 B]H!TC#O4<* XBVX][LWDL"R>,R(,RI.95&F!- 9O3F +&E.5SJ+P2<"+7
M"2TK.\X#*^MU+T-*<Z_YX&0#'89&277*^MO$R &M>X*0P G5 G1L,RATA*%D
M"QO_RD/9$!+M+7S_0+V? QA,'H^.<.&N77#9AQ9>!.UMH014.Q/"C;/]U;(,
MO? P;IL*1:B2"@YW8[&R;;S*H'54.)W.B!EGHEF3GXN6JHA*IT+=Z:R5LXT>
M5_9Q^))R[V@'AEN3F@,*=[//.0BWHS,7#.ZHU; 0[()0LT'@D4V8 V#%>5;X
M.[*M<J918\H6^NII))^LIS':MNB*%UW;ZI^@:=-^N-&SM1:V]PK\)$@M)*]"
M XVCV2<.0-,\5WK1CPCX1K/$ P]_)6O!6/<P<\##YT>^\?E:XK\?G=T0NLDJ
MSAB/X9KWQPF9G2U1/&UNV!GS07-;%3K?P\CXD,/9W;&+BCI'8QTMCV6)7Z@0
MDL=)0*C,,(3F+TP\!UATSV?_\8/3N:',!A,#Y37WJ>]PZN6LL(BN*1<_P^Z]
MT:#U_; #8T/-BX!8TPDS$#85O>O03^GGH>Z"T(BL)0]]&#01\HVG>I;I+!Q>
M\T;(-[CN)A6G+MW-0\B9(*'W;IW:($N(%CX!_ANMUK0W=I!K9863TMU-NF(&
MO'8*]#GXU%Q4]B,64>ZI8W*Y;M[I4W+Z',@EX;H4)+Y&(,54MPUG;**I;S=#
M2506EINM\J5CDY[88:6Q]B>7E^NZ88:3YL)W7CQH#N D!D^8\HDD5OTQ T'=
MZX9&?6<-!I5O&>H[SA80+.VREJXL+G21\,F?*B#5OWN>R,.SQYUD^\IXGF9H
MAM--Z_1*TSJ6M,%])E8IL>7SK[WB15YC9N/F8AQ"3TV4)%2G.Z\:4KODY[*&
M#X*_T(C5 X2A'6*$J-(LA8BR1L@QHE)DVR"AF4V$$H-H&E/%@!.#ZM<#*2;<
MPKSA/EM%;&?>:VA# 2<Z];!&N^W,M#OF)4=[):;:LY.4&.$@"M:]38NV8@I&
M(,M]#"05I_V]RZ&DRZX$"^\.D9J%N+\I <Z&W7!Z?UN]3^N35/7!';FTTJ#K
MP,VJ-CC9UELR%Y(@XS1)E9"15,_M.J9A3H[39$4]</SRMM$K4685A@?F5JA_
MUA _0I7K=HI)Q5;S0"&#S/U'7SKDN*(\"<X,IEP*)YKR9$@RUJ\W%%8T"W#F
M&M>T"&=F&\4,.X6AB5B&57.LZ$3GF[[RW::X,MZO>D&N!E;[,:(BPJCX)[;A
MOC]E0#J^UK8FE-5:A"J<3I6X$P^00CU1[9$Y!Z%6ZTOJ><S]=$R5U0W+:A;9
MH8IW@K)HM60BLT 2]X1G4\'^/A6FS.#=7D!>M]S9ZLK-Z@ ]<SNHKB* /=G1
M(WE.2CM',B0GU_([]HWN]E"Z_?D0P<,&XO$=APH$47!!_O#]]Q???_]]YL*G
M-#3WC]!(-9R@0!&&'P9DT-L-N>D<+*_H7Y#LA\N$(5H:\GS,YO^DQ_AEAS!8
M,3>\]?M\O?@@AWW@RW'*A,-#EI]1!I]%KF*F*LUO;I[L,'74DYKA?-'0/K63
M1 V=F<X,3;7JZB\)_3@C^)XE&<+AR%K^<?!Y5 S XJE@NO749+:J0^C4EKH4
M7'Y1-B@HUR[))K/8+Z>EF4Y,E ZWB9=N<S#0=$L\+."4AZ'4,/:2K+YPE_GN
MWSCSRDX>3K_'.].6:I)E1LU]B7M.+!>U^Y4%34VE)ADYU>@@>BAR$R0,'>Q'
MP7N]JBH_0/@E9.[*3Y_,YE[TWZUSKVJ;ORBUR0TG2HUD9?,5+VNLYG(=S+["
M=JZ.A95Y4<(TJ73V5+Z02TI2R-VE0O1<]K^RO3N'8%??]LR1P7!ACFF<R*Y=
M;YS V-$*27#7HBONT*^+(I;OZ[-8!.(F,<H1A$"3U&Y,$R6\2#'X1)7:;A)[
M%,>&/1S,+:M;X%^37IAQK['6&=[5=L&.<\T5L(YOA;T5/+ VO$6*>VS(4&Q$
M]1&6A6R=PKAE5YSPUT7_XN(6>PKCZI7J" EI5_G,Q @K.XZ4D_>=RLE;2--L
M>_5VP]=M@I8&G7 Z;3N=3Y=HYA[8(Y;&\@^U(/,D:T3QRN#V2%<;P -9M#*>
M\O"KXXI5LBH27:O=]*6%$QBM6*@8WG0@A#G>Z:-.5T?*E6DI+62#,"::PDPI
MWF1&PH4Z-^R%>9!6*SD^^"MG0GKE]EB95[*V&W8L::9W$3:J^V!&B(:2=QWE
MFKQ*I9@=]&P3%M-FDD2H^L0NO_ \LU%J HMF?;$[?PL+%!&@04?,,-!&_*X.
M(7D0K\8IIHT#<%L!0SSP0P=D:- 1.RPTU;TD*JCHA1D0&LO>:WHD/V"%@K'T
MQ^7CMF\6W;1*#6>;(W94&=S:P]Y+O)E;JKIAE$9Y7\Y#E?<.E^'_XR#EX)'.
ME)?/)"C8A@IX'$22R:G<VM:><I8514H-<<_T!E3)=GC3?C@!L+7FR9%6HTZX
M3[7:J= Y77TV;'/O+//E+')@,>HIUDCZIWK>Y&O *;,H3D2RTO7"1S_*FF0$
MQ*_9< 6;/U'NAS>!RB[H+[=249:;!^[663Y3<_C8C@9./.QED6*(UX( YJ"M
MBQI=/47Q(F\\Q>TMD6& HQB>!%LJ^W#*=:*8:DR[Y! $;&,KY/D<O.@8ZFY]
MFM#I(?"\ZT!(K"I[%MNX(TXG;Z][$O4TZX4[[&FI0^><+(%T4AGD<)T8_(5R
M#]89HT8X(ZF:L@%D*DG.]Q68D9C;^!=VQOK!SQ2WA5/%9*6:3XF>AF9X,:A*
MKP1QRMK@QI=*B:TGF"7N0< N 60PTSD_1D68090]21*<9 $;'3@&4:XT\;&-
M$";)JA(G53&D*6D<V'0AAQ=J;-BI) AJ30LW=%G1[#<2,(UO@$(859<C"6=\
M-;[1:NPT3 A6I6;M/%+3&2^&MK=!>1!7U1,W/G;0H_>XIO&X/GFZVB9G(<)(
M<5C;G<:/[4!B[,!R4%N<F:!\/ V#DW?^_Z3^@8KC#W^ EL8'<<UZS049*[4N
MA\32+G/"PFH%+#^*.UT"RW QYDY^^,,% 0$FA+9A3'&":64Z3_<D;@P#F/4>
MJL9.#,0E*>SJ6^/%J@9:FFKLY)KBQJ8F@EO<B6,9^4EK[ RC9HH\.?*3%UP9
M^!<UJ]H97;[XJO0$<Y>Z! 27M.^E5\HY+!#'VR!BYNKI;?KB19[6%DAPJ'%'
MW*C47HW.22_87BJ@MI+R=PKEJB^BW%>+P$ N&&-QDJ(D((]<#20"04V3<?%L
M/ .EG$B.%<EX$<5LNH!J"DM4C )K$18(?D^/@*MW_B6-V-WZ:4NC57CGL[\Q
M*A:^SZ40H0SO%FMIH4^'D/LL#)?![IG[:A3?B7QT^8>E%\@F&R-TCL 2+^*.
M9>\T8!R8'VY\'TU["],"; *&#O.IX% #BPFF'#V$&E5[K0(LM:"9*Q61_Z"1
M7&ZK#P*?O3M*=0C-]"$4%%)?)UJ1G%H7L!MYLF[[P[BQ,O8?1\\XL83DSB=/
MTI8@)[E;$Y!4KOS59U+>=R PR4E,E,CJZS+SD[MSZY-8_.DFN9G\)&.Y ZX+
MT1(KZ#$^U5L>A)#_^A0($;Q*\YJO0-?UPCE5MM2Z>,VYL@OFB\W-!.\QU\34
M86'M:/KD.64PT:WE895. (-WN=\STE-:5=.(2?75XXXEW?.(>LWK=%1VQ^[>
M[>Q@?K%J[HO9X5MJ8.<MJ:,9I;4IB:-Y]2BC,*6CW+1Z1%Y+8O8.<V:/EDYS
M,[=WVPVU&-IY/%1OJ@<VRF->=UR D1;Y5>GY]!FET62&QMA!H$K'HKN7M<3L
MV)7R]C].*A1CGLA-)U1Q8M=\$M1E"]^]DZMP$6\SF*=M4VOLSEFI9=$[2YMB
M=L]J@3M?*@*JA/HN"8!NLK\SU8IT&"47CA,<5,E831&7:][3RK0BE0VQ.Z1)
MMZ(OGK;"[(9&6;L.3DGP-"/(1,YG734=II==J;6BT@L3S\'H2M7_7A/CR2,3
M+]+B(>2Q]D,SG)RWPXXF!LV*8'+2"#.6F$3MO#2,Z:E"&9+@1#@RF%J"^2X3
M]MZ+YE?MERRBW(.$9^D5H<5S<(A4)++RG6#'RO:%>Y#!Z6U][9)5F6]/ _>-
MAEX:=1[[SI:Y!X\15W.',^IB9CR/PD.6*-#'KRJ(YTJ D2O<3V"<XOY@PI;D
M^!+%F"C.1+,F7Y^LEBR^":A_+5WG81MO]>D\8FP9O+_Q'.-5K(;=\()$&[T3
M4&C2!S<(M-+ TM4D\ZU5D(; 3T(>_DIB@4@L$9$B79";F^6H.#"*?93:US5J
M3W>5!X\-)@J4SL[!ND\4-^C/!VW8IV/0='ZHA!(S>VO5V4?2<T$9)\602N*?
M$AX#.-[!U<F;*5$'\._ATF#(LC:P?Z$2/$NPC2,P!K0"$<4YH#-HIF$8.%Q%
M8Z\\VL9/-4.=QT.S"7SU0GU'_2.AW_19)B!\-/IKJ<E^DUS,=M<B9E,_Y6K\
M(]Y);767B^9Q[3$]L!?F'QC,/S\%+TSXX/\_J>=BQFV!ZCXXP;V5QJ=7(8T=
M,.])-1&[\ZME[<PJ8-VDQ,FF+#_@>'<@A]/W@3W#_6BZ@],GP'J8@J!4B3IP
M<R&5?;!7)H@W[&"><AA_P79ZG)2FCG?T[OP&MY^K^V!W]P8:EY=?+^F V=V;
MB-W=W>,:X_'HAD<#D]]Y'E-A:WD-Z3>^.^SNF32'#+,W,@[1T'+G/\2(<IF!
MR1/])H%6_D/BR+T()+KN2H(:&S1Q.K%5BZ5I#OL2Q+U$LZ=>]^PV3*Z+E!2P
MR16+H2=--8M"KAM8*Z5SZ/]-=_O_MWP6/< Y45UK.3-";*W5@$>^H,>X"18G
MMWHL <E$@%59'+?<^>2A:+Z<-$2*0U)Y2"S0^.D6T9BP=-#*&8]Y?*.>D=<&
M?[:FBVQ&^\Q]D"V9EY9;*C8,]AKN5<J[$GNVZ8L7_EM;(('YQAUQPWE[-7K!
MMN8AP30.?YR42YQ;$3PBB_Q@)^QW]_[?_,_^Y9/_5_F?Q]\1O9URH6">?9-H
MX[$+V>KCW_[P^>/O+W^7;>"%\?X;<\F:.FI9!=MJ\.A4]@8LV@5^M TOE)]%
M6RZ;,I^X]#AN0:7Q?H.,TP6)>9$T%,VX$<UN=(@>SQ"?:P>B?8C5HC\%ZBVE
M>IA]&T0JP>\"7H&$X*:51FE(8 Y@V\86YXC;I/=<8+>5+GVP-\;7* !4I$<5
M\^:0-GMY[RO^A*;LTZVFTSLDQCA%NH,,K*="T5%,FH=2S9 \!42QC+-*:*80
M)6=L)X344:R2OA-/AIL>5O&0DA,P-9EBXGW+?V?'S]27(3F()DT5!K[/O&6P
M@X!;>?'C5H824IG=E8PX@B-CGYC/UKSB&*,?39PP;M5BQ7W1'@0Q[YO:4*NK
M.TK><(0<,P>?U-R)DV-_04(0X!U(0%@L GF.99AH\W5*JRG*1)G#8(49@!6%
M?860N?<:CWL9^IS6;P&<#!9J#THGA.8.1B9U!@<AR?B=XDSB( (Q]M@VDGZK
MK[7/VV5NP-/#J+\)6.F*(O,&C7$P8A X""#EQM3J/P7H,G3$I]YPV^4,[9X$
ME9H[H'JX\G_9<F?[4Q"XX9U('F ]Q#L&E]R5J\S_.%"/KX_7@9"?!QM=JFP1
MPKJS8ODTI@38@6?T7Z.(7Z.QQPR#XQNA*YS$DNKK<R5Q%8ERXDX49,W'FC\G
MQ>.#O9)([7;"H8'@#FR&AE'@_*KJB(7Z@B*V.WF%7#9W6HF?M*"K\U!V ;4<
M]&1G_/'Z4,0.M;VM59';J0TYS%#87RE+*912GXP=#PZ,RP"/9B)@2"@UD<E.
MC(43I5:^1-:#SC4+KQJN_GG@T3'W:6RU6DNW(#073&IKFW(H:DIE#@C46A<+
M7J3>VC#%2.)-RFD^&#2!T1X>OR#%G?R;K9\8W/3;RX"32N]F-&R>X-G8%3NV
M--??G*.VO!]F_&@AO9V<$YL<$W@L2D-#*N>QP "O!28&A#-C++YQ\RZ5J35V
MMZ_4LNCII4TQ.W>UP%U'\T\EXY=*PE,Y\+1:8G/2TO0Y3=K/SE'/$^;4-IZ5
MLUI*>U(VD'<3Y'G!I&EKIPV9\WX3O'Q067&%=MGD#[CKK-TR_N#OR\6)[H4O
M<#K:N>S@4=FG^%RG1+:N(V>YN%U<+D9U!YO24Y^Z%->\5!E5W[2J@E+9':<S
M=;5#BY7E#8Y,1CU6E^<:#+>^\E#5.QG0%''"$'BIV['R[H"@L-CO/:FS7.H^
MT6\/-#+O*)6UQ.[J1NV*7GW6#+,#FX7M7%D@I:@&J:!G@W0LC[2OVWWA07,8
MT>@000ULGCEEB;Z3)Z:"T<T]K@NBKN/2#]S?W(M@S://!R_BTE+,_70\,UFX
M> XC01WS$;DU\MC=WZX=3S-CV:"-&6@L:]C]W59>#/50*Q4$$EY(2<@N%84\
M'PD]QS/8*8H%FBK:0&M.53C<!(S)>TJV7C-')<G "9FGUC1/,><-L<.82;>3
M(.:D%69H,<K:.80YA82I AC;BMVR*$X?^N'-31"&;\DS6P<"'C@[D.GO"!Z<
M^6RG_"L#NJ6$K_@VI59B$35?<#3KB]UY6UC@I+9;?4?,+MY&_,YO$^14E*3E
M>Z.=X"VA45D ,%4IN!&L  P<?;DGG;K?)/#P]D/W-'X#XX***.[6UQ+-^,9/
M IU*4QJ[S $%JO4]=_[R]MA]OD;J7JZN:,.$M];4L_!^0O<>2.%++@D+!H40
MN%^K<.<<0#D-/!Y"X%)><:VN+4X';*1ADL3'V!!WOIYZL?NDYHG3/D=;&N6S
ME\&2T,U&Z#.+7B$_F2X#4#8IJRQF*D&E>] ^#'_6K>15F_/)_(T,@V.)/+6X
MEXO46/>$]:CY?0;\":3&5RGLW<0Z7DU0&6]8/6^*O]X Z*:N1M\SL:.^',&Q
MW&6U79KTF07:56M<@GKE'6:#?C7B_Y= P;C^=6*$-"OK5' XU&]2@$5=823E
MDL#CN$'A.(K?&7Y?ZX )CU^76W@4LH*8-DE@=!M$\3O6_SQ[YM2E_PR M(TE
MSD"U2>>9 &PK5?Y+@*VCK '+,VB5Y.."2QYJ=U:;9!KD'>?'RE!8U?!;IO:
M;Q*>D&R29%RG ^51;+)L,B9P[<4EQ6R3G<IE .YQD!YR)R<:A0M5!7(:=<:)
M\]UL<%HRI[XGYCV[5O+;W*B?*&72*/JNYK,3G[\$^<1V^T!0<<PV'[_X4#E2
MF@L.'UFX\-WTDZ5@KL2VYN]0>Y''CB!V[6B^==R=-F84LJRAG5O+42)(+NZ\
M( =?UU*5ONTI:52DF?O4T1(A>D.+QJ+#O;-M]QIH\>7$;H4O<$+-N>SYUT"+
M+_C<NT2VSO=[OCP^/2QN5M,\"+*AP 'N[WD<V9N@3LA0^>B\#T6<CF?16B>'
M_%W)X7-UFTIU7F3TG*ZG?##_V[+:'$&MYI%^/YJ_26"K>NS?@^!O#MPL/:7O
MZZC3)ACX[5FN\QG;34#]&TZ?N<>C8RGLF%OA!)(:K9)3L9(FN,^^J@3N?L+%
M0Z)'%+RZ\=U058OT)"OB);Q&/30:0DN@25*BY.OGX<#GA8GGP'S\,X1VZA0>
M5\QS J8UT8RI-4YX::AE,0(I;8HYMJ@6N.M0_7(VRTT<" RCYFW@OW/HGD?4
M2_1TJ!!PIB_1]94*9&>NO7=G;UKE:^G- CLPV+>GY1.8F[GEAK&D)8Z3& ]5
MKIF)38LZ'\TE@\M:')['G5LIO Z$*KEQ&UPR^9E0!E*U-%9A?(DGK$B_;HDX
M>C"T:,,3&+1 &34 VM2O,_2E0I3BGEXOOH(@TG^)&XNB_!E*&$=$+C!%*LY4
M>(?!DE_\[,Y=B:%L;>BLI-92?EW%NN1PS-0&)XY4:I1LY9PUP+V18Q:W\X+C
MPR!'T:8]&OL*K*X?'M4]W;A"_-=%QX.<>I>X#':4U_XL::N9N$51JU+'T$UF
MY!HG L_1.2RI<.8>FJXU!Y&D_\:H^.'[?_U7XQ% 61N\SF'4*/<HIM@ MV.8
MQ>T\IES)CJ]A4XJ&*@PY2@8$.(S]2L2R9N H?TMT&72WO^ZIAV7%@)2U.=&7
M(2CW><0TIAC]WM@0K_-7ZY9.CJ6M<,- C<S=T_ 5'K;QE L\[I1L1@6$@73,
MR*:SZ%3(,+B&MD#B-O"7^AP#=@*75 BH'0L'&&6KRNK6>.&B@98)9E0TQ0T<
M303O?)M8/Y$-UL0_.?A2QU['Y-!KW'?_0VJ</^ #ZD21)PG]T0%E+%U+?E-D
M&_:Y@XUKRH4J2?V94?@$W.-NG=R^X*S%6['&I'""G W[F$\@F]%!O='>71L[
M)XIKR92\J/+INXPM?.-EC'$6 ;QA+\S[F+/;7SD3<DQNRR\3MNJ(W9N:ZE[T
MG;I>F#VEL>R=K^H! _+QQ"FV"9>I[PN-I3]"'_]]5Q^O[C@+'V^@>XF/5_1"
M[^--9.\WQG^/VL='T!^7CR\].(4.I=K<I[[#Y5(B"STJWU@VZ8G=RQMK7W3S
MVFZ8_;RY\)W3#VD.RM$3'L6(%N%[O3)KU$QSE5VP#_UZ?8MCWMP>\V!O('77
M47Y=-K0OB .#W_ISK5^H$-2/ZL9F35.<8[*)?LE&K*D=[EW86JDMO^-ZU?SR
M W/4/=C!](T)DYO\9#+5<<Y@6EXRP5^HJG-5\DO:O!UU+QV0AV$@CK=!Q,QG
MP>:F>"&E3K_\9:FR=K@AI59JRY"R3WFI^_KCG@P/I2L0)AEE2!+*)CP>'DK-
M$PUM H@*]>_6,13>B0>^V485MX^KVN.&DEI-\WAB;(P?5.I%[WY/00+)3E=\
MA!S'4@U8(B93G 09 ;R('*J'D5,6#ZPXP(PB#_K^DNFK6 QPZ;E4E<H+T-4]
M9NB9YHO1%<UGZIVV+DS3'4L2E.M5K!RB1B\-#I$*#[B_>9^,:?WV47T?9EG3
MB9O%LR%S#D+'[2J1^485<Y4,MX$GFZE_:OI10/;2@ELI6K[7FT-XH)YW).R?
M!QX=WQ(8"_KV&L"&4)7W2+AG#E]S1X8MW)%1-(^VW)>?.TQ$%-)B<ZGJ6DB%
M\[*K0]F(^5##SCNXJIB=[.2S5ZG"<PQ,(!C<H%4EL5Y8*+TR5/5^R5;*+040
M+#H(G^SE3"N;4>\]@7SR\ N598Y_S5O.D9J18*_2_\(#*F6BU[Q\&AM5X\V!
MPN<LRQCO!+L]]8\7Y%7* 6DM$U+0DWU+,\6'D5 #33.%+R$S>$RZ2.L]67AA
M<*$^\OB:*<-!]>-T0/ P-EI\@JV,!E>*0Y"#>ZRDKQQ4*OFFEH^H@#/KO O\
M:#ON@G5HUZJ; ;K?ZY_T4HUZ+-<R"T!32CCG' O6:7NCYH0,YMW6[LH,?9]&
M/;5$]P9_'!ME&]6GT)^=S@@>_BKG*)]NE!"(@:AD0[_%A;Z*WK,"G#HK5(",
MJ>ML@*56 4M@4GYTB?$RWF<:07Q\K#RO/VF$?;B7Z50<U?D6F =OJ9Q=QVA"
M#.49^F*S$6Q#(^8^R5C_$VP>UQRA5_7 /D)KM2T.5V-SS&.W7NC.KT=2RGHU
M_JR.&GJ<FP\XKF^#Z$9**I[D"OK.9_"\LV9<5_7 /JYKM2V.:V-SS..Z7NCN
M[V8B L7Y8"^+^B20ZPWUP'KBVXW#*7S#PE#K^E%IBLMU3Y5>^&[>%$]2 /5Y
MW435G@YV-^]HF9,+S^V(8(:$KJIT]IL2D(!%N5\$D CXZ@W5J3%D; M]BO?(
M/RJ[_+XKNAB/R1:Z"FMX3X^PJ)/JR$_$@;E-KMFU)H 3#[K;(G^FUKPW_B.V
M#KITOYC!=Y!7+]MJ"*5H>M/2H?IPA/GJ*"8,H5AP7#<X)'LMG#[ T>)-=MMO
M9*.ILY2$'[G/&2)FB>-VX,A6630<&;;P\Y(]1RMU8FA$R)(F>#'0I$^"<J??
MX\8QH[06,L7PW#6>O3Y/!VB*@MPA^;BW=ZQK"P2)IC@=@ RI%:XU6MWN_DV[
M ^8:"C@QJ(<UVIWUG)\K(ER+M5=BT#,?#]>I\: &F?UI<9EYC'8U-,:.$54Z
MUC_;P^SYE?):?:HWD2</HJ!*_011F,[)92O(+Y/UB^]*+ (NS%W2<'OM!:]E
MM_W;],7I;ITLD*P7&G?$O9!HKT;W=T=RS9IFE),_2R2H$QVDSQYR_(@C&9(U
M<(2KHH)Y>B$B5Q^E<_>HZY#QC)4!6GZO(\^+ #.BN(V^<AG/#LO<,#$JW!G^
M[IFTBO2-C0RZ'A@- Y\^>\?[( RAI,127:=>^0\R&%K(5=5N;_"ACF3P@F(?
MNR3XV(4&;JCLI5$?U!0I,[*/N<'&3"Q,^J(CN?VO_G)9R#>^NGVA@GG88PY\
MV'?6=:M@,T?Z^ X6/M!>7ZJ-2:U+E@CO";GZIEY-A$2EHX6G!,R7_XK(WH,S
MKF>/;Y3MQ@7E27Z6^X+Y,[8DX4N6Z<\!K$G&>W2TGL1 U]X!4%L___#AA3&3
MXS%[I"+DT S)&RI7GLE8?FLO!;H#+L,NF?[ORK\7@1RG=P*RJ%X>V%-@ML-E
MZCA@D67B-F4' ,.PP3LM#&G7+'F[?1ZXIY5!->XS[?!8,/+&C45["ZZ\5]*I
M#2.5-EBYL#3,P=,/,?S<3$0KYJ'X[5M8.KW12$U$3#*)YR3!]H&(8 D<IZ['
M.A^A_#U7Z6]YF?\MM63P3DUENY;"D:>@:CI;^2034<]LJ9 3I-O':.G=7JY7
MU.O6U+C*3]0[UG63:1'7=FM^9_I6VM+]QR$$/[QZ@8WCQ5K^1 ^);^JR!\V?
MZ[2CAW-FM&8I\S%/"V*8MW[[JF3G" AJ&:2L"7O1QQ_ _&R.P?D8J)GI*I\*
MM2*!W>W:V^/T?GO3_IB=JX,6?2I'-/8@A*^8SDU5^]C#V&%^SE']U*.\];P&
MOK6''BV&N>5TH(],_KKNDZ"^LV65J?O,+7$.S0;:)7L!AF:XE_-U0EM.VZ?9
MD4CS&S]UWU#JQGK%A"=.W#>BDK8 Y(M/UVON<?6R<\N%>T]%=%S%"8V,:-*P
M&UYH::-W@C--^N &G58:6$8@\W7A<$NELDG>*?D![.-%(![9@WQP"0"V#2'Y
MU:B@-8JY\DR(XD(4&Y+PF0[/QM=?_>KO]*^>9%6S%BNI8:;O/3\%F3[+;'0M
M?/>&;:BW<%]X&!C>@O:EA1<4>ULHC<BZ$L(-G_W50HFI^HP&I"8T%GO<V' R
MLVK.R0L/::4\_N;8$\F?* %((L&$4>;4YLH/J@RNJP<4KIV=]CO,-ZV>GK2G
MB7-2L&JQON<6-W-[L-)5K0G.+SQ4#UO&-MSCX3ED_SS ;0/-#A=:W8O 8<P-
MKZ5/?@J$"%ZE#72:6K[FS%V$\45;?[-P(OY2_=*E*S7L"-7+2D5LZD0*,RKU
M4ZA'N0G%55]I>$[YQK6Q%&>X%K1.>!.:,I\(A28VE& .XR_2*LIB<MB_R*!>
MW:OQ+>[YW1X@&KQ;+Q7]4"X>;@/(8U[V>J>J+4Y$:*1ALE U-L2]$*T7N\^%
M/E]1CU_?Q/1A  *#=(B.ND(<3M_;5->,-HF)C[ZR&T/-\Y_49B8E2"V027\G
M^$;"I0>?Z@>)'TNT;MH/+]RTTCR?+JFV$VX8:J>"G0>!L(\5Q%QTHI%G!J%#
M/%FFM3KD+P;OP-Y R3(JHN2#M^H(-(1 (_#?D^_N<]]])\%M+?70.QLT(FJY
M(1TE9IOKJ9*SZ<O,P%RR5-P4..XC53!%?;"GQUV<+$61B.\DCYV5:?@?225C
M4HE%<CB:,-)?Q*PF2< TO 'N!9=AX1ZVO-*QJH9G.C!M9ES*=/DY\*2/_L*@
M?HB,3^6G=,/NH=J-7"6K#;L2DW0@@1=]N]HCG]&I37_<F-Q9&PL9H=0#0<61
MO,8L"=4\XP),>SB_V*H"1AH0U;[4B:^ X*/GC1K59B= >4$T3Y(P)3%7HM@2
MR9<HQI/DGAK5,C\W&SXV8];'*'!^U<<IEP>1;B_JPX[<I!&'Y6H]_I@6(C-,
M.+V)XL5;>S;+A\+]*.+&9(OZ]5\ %D^&725++C8]?:>G:\"E(5VZ@M3;4EE!
MOM%CVHD-J@)>)4-R?*RE(%J,"PW8X44^'DYW&;3Q,FDFB8DG-J"V73P,#WMI
MGN(P@X @9Y<_?<ATN)'_^LN_))_$%/_R_P%02P,$%     @ RX 365OP+ #Y
M20  ,&T% !0   !P8FTM,C R-# S,S%?<')E+GAM;.U];7/;.++N]U-U_P/O
MW"_G5IU,_)+7J=T])<MVQKN.[6L[DW,^I6@2DC"A2 U(V='Y]1<@*8F4 !
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M,*'1[0;[@VTYGMU FAZE2J LY7='QR?'G<-3+5ZM'?U AY0F@/H+%P-P#*3
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MYN,:!YIJ6>$'EC[)I)103YER%X\HCSB<LA)E7,GK.$,UOP#1/@E@IVNMJLG
MLUW6L2.V;8;BZ;BE>U@^Q>BO)6/T6?W"SS$GX6]+R=F0ZK*EHEI,GUU@=T-3
M?D83JJ1[M(A(>GL\K2"E9YHT24*T1>)QZYHC)4KE*7=\='SR!I)%,L*(V 29
MBZ3C5DA<X$&K?,G)T>G1B4[Y$N??U_3_[R'/BQJJ9*)]?;A)FX%BC^!%5H=G
MM^;&942,4Q_KT85B3]05RK49#0CA0'G2T*'Y&)TCJI8Y#E%QRZQ9K=/>)P8
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M$E^%+&,(^]@EJO%=+3*09GV%GJK3;HV8[6U2B-9T/]V?[O*4D!9F?5,)(2>
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MT]\='9^\!;2);/H9GGIB N435H14/S-)LCQ).L!56B!BP_'N8:):7-6$X$#
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MHR!PV3&Y3A3O=#^*MQX>>V@\'Y^SR =(?SW;C+%06!%O1^G,W-AYHN-TDLU
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M%?/,D@+GH*X>-KK[9T),%"'#;0T%.5KZY6_95;D;##K<>#8*??;'!75:G]V
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M(0&K29&M47CX=Z'^]CJ#!<ZNMO[C_P-02P,$%     @ RX 360)W7\'$'
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M4^[XVA" J07=^XD_\@,_75Y,?0\6F%2=\Y/&J=9UY"@IOBW_G<;ZYA%W?Y^
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M+=;YNQ4S48GN"9$L.N$-S5EENA/_T$5PRI12?\0C7]GK\$!BMLBR=+T<:K1
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MPN3SSZ]25"O@5L"M@/N7G9X5P/T:A]?@UFEUFC>L=WO;ZP_ONAUL5E0YORI
MVP3HBA/_-8%;^;HJQ\&+ &KEZZI\715DK5(**E]7A4G;,%DIJA5P*^!6P*V
M:X6UU74^MWIW_2$;W#9;\$^O.^CUV<U-J_)F59"U8WX5K_WK /=OZ\WZR&.7
MO>?![WY8@=-2<%8>+%;!M(+I<PM_Y;7ZR$,^>> \_=NW%Z24?D^XD3S8ZA";
M_EW(DXWAM\ORUW37!?&9;^GA5'4F?"F="8U2#SSN7L1E/-%)5(]J+&7\K&[I
MGP#?WI7S[P^=]YTA:WZ_<YK6S_Q\EXGO75WCH?'16!\(7AC /X@>_BSX[R-8
MYD>P?S2*O"7\F*:SX.K_ 5!+ P04    " #+@!-9@(<[@$D%  !O'P  %P
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MG8W3OSP?A0,0--MRI *B%A% ^CJH:0,_\:(O6!L7F(',N70:/%-9$_"%)4[
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M-"KV[D I/T(5]*9B8F(5NHQ2KD*7,?VT1%TN0?KI-A9+DQW92;8A\C8VO\5
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M>Q\I[L/@<K4+E7DP0D2J+\(8]$F4Z#% PHD]FDRU^E(ZM6>Z!D94G0QI!"7
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MD/D5DAX-A3N#7Q/E>Y?_!U!+ P04    " #+@!-9O8JHJ'Z+! #2(BH $P
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ME]_*#7'E_$?-0ZA/JV>/#^K=8! *QWJUXG6Y<-W[1@;DQ\]#6);EX9U5/>_
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M;)C8/IY]"]>:/4E7G^C?O[:@' J:-YJ$G\42VVYC.S-O'[3]LV:J\,5,<'/
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M@SF[+]E@2Q#,CEN":J,*QI;K*NI;EQ$LQ*HDRV";82<D=HBJY25*"IE,#>,
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M0(*]'K 4SS#Y-BRS#;,N8D= A,)(,H6QI %[_N3^UK/ 6X$8][A^T3>ODH>
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MGJ.Y)(U0^4>]^*6+>+X)S 69T":+;BS#L-P[ATC5@B$#OR+;.9H"0,4ELE
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M#0"\![C74E16R(RC(G&DJ(UOU*0)3H:$]RGP2N-8J, G DH!X$#G08]8)32
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ME=FC981VGZ=\X'V5;"9[Q+[#C[S EE5 @&4XIKG3^7IHOHP]$A]!)+ 0P3'
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M<&;NGN?KXY*6?&3:?Q_O4\%=4$UZB9M+Q=/&Z.YADI#F,MR!P_[H,8I\WMD
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M)<8*7*8",#S;!87:S+.!"$[4EC$/9K@S,&&%E/WYR260 8KA@.X+=<"&48[
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M[0M3W_4T;9SZ3Q/UI.J5\0-N& </T#H!H-5D"< SYD5P5!H\EJXB91[ZRN3
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MI4W3*<UT:*+21AJNA"O84-T>M(VP(1^8+=@@U&_)',5@*BSSK)[S7!OTP2_
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M#J.;^!OF,C#KI*?!6U0)ZI+;@/@AB<#X>2LARD-MWPD"($-S6:C=C[,J.+'
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M>7@Y2PGJ<VH+KCUW3*E:W%U0^604J?LG7=4@4J2T?3BICE[\ME(BB%L&3<7
MMZ(Z9$FP@GDPUIO2NG%'D+#8QF[I=%IW?;Z)9"M-KKDQ]NFYG.%,H%R8\&_1
MU?/*ZI"]= /NZAV=T$42[P^2F!=)..QQ=-&\L18CR!A8%L,5IA+?HPY#KI=:
M%>"8^1>,FUFTG4@BA!%='\;UT*2AU/&=Q$J#X>4\X^& %PT>[Y-(*W]_$C:
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M"3NV:H,#!"MP!SW!DGQP=3YTGDUIPI26==_M)4](JE)0D@#_WJP_]+MJT[-
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M>>PVF#PMVC;[7:<TS:0?VW:[]$5N2VEQ@D[L^.XH%,B@EH.T[FU2@M8K,MX
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M'WC9_KM:B)Z,S"NY_ICOPG-,N7@4U7A=>!;:4C5+:-/DL\'O795X?> A%X#
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MJA%I&W;%B;4#@L^9L# U/:^R,=8%CGJM-2@Y4NT;_8?S+P-KG,8_&Q9IPN\
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M Q2Q%N$/F:<3YDAG(??B'WR[_4";V2LK"(<Y9:E:IV<KP 3*-\1MBG<<XRS
M.HJ]R<&NPE3\F?S(:QV?YUZ'-7[!?(_<XBJXP%X+79E<<ZL.Z7ZWA;>Q4*UX
M 6IN4\D4,8[CXU!F%&5B+S4%T(6AJY0 (]BV!*72&0E0N92LW.T$%<G[ [M3
M@I4-'HK61LW=MJ\AQ<I[R&B::0HVPOLK,0X.=.2;P];BKJ@VD&Z:=23^WD5"
MCYPU56L955A4^DXGVI>J)N<MUIA1^F#[@QNP+B)P&8!&QQ]31@@YGW@2'FUZ
M3L-F78<M2LN6WN_NVL4OP9EH:3$W <^SZT"*2VO>;L-J_MVS+RZ?A#-H<-Q
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MWL!1L2#4V9#.AG1'_/P+\5:H0M_97L[V,A4,C<M09]C0V71.3'06LVV[$SF
MMK,.298<ZMKP>;F 2)70G7<5-9TS;4(;)FYSMJ^S?=VUE3D3VG8D+[@%<^"V
M79-0'-=FK_944J1,X]F@S@:5,R@^FD4D5(8LAO2SJ5"M\$CPT1![T8#VMFY
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M+\TOF&PZEA,DO:1N%6-EY X9&EQ2BBN;AMIBA#)+-ZO@994WBR&?Y2;L[P)
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MVN*$01+]UP^?POU^N+6Y/_C4.^QM?]H]VMO[U OCHT_;O?UH:S XZ._L[?W
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MX6#BN@'R(@OY01]^I5WIF,[<Q#UX3#H6W2]6##-*=\&N4=*W&=#C2VF#"!(
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MSO5EH6-OA1C>0V[9M>_R,E[4H$KW#\I]FU6*Q,?%#2F13$G)L/V9X$C,UC"
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M8_HBG]SPRW:J,U;Q%):!;238/8VIH=#9$T)*!@&[H"@+/Q^8*"K#)7X@1*_
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M#&J[&C//^^Y.=^\G6/T>]1X=3<4[+NDMI]@Q&>,>16UFP_ SD;B7A@@>NW^
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M%&.(:E3ZK&!0DBE]?E.H.[#['\V5SQJ<^J;PJ4GATUSYW*"-,E<^GW"55UP
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M!07*?>'DEY,3>TT">7U*(Y=3<UQ S^ "ZH$+D)D(UR1L-2]4ZI!CV#W^&F2
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M%=B9>J,.H?Q>2($!"]22;5HKKP$+U+<\:)H*Z*?4.P 6.#.VO8[6P.G8;]+
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MB\!A1-WG16-R.;2#S^DJ]9IA>H50F_K/81B&YH!@W@A9$JX0S2GQ@K&?RFU
ML$:SG]*$)M14>=6OU7"=ANLVW!+._BR$0W'@K8Q04[O'6BIE@>!DC"ECLX1*
M:Q1Z4\?4F4"T:D7X.\,;K$7$CO1"E.@T:#!'&JCPJ?C6!M%RXN%%U$$:!4"2
MXE=12I80A-[0PP:<6+7'I!$:IA$9(83)DFH5H8=,E"2QA=-G[$.;Q6V*]E62
MO--PNPWWL.$>-=S>\N'W3D&X+C/P&H: V56]B\\(K26YN,X%3.1?1#+SM]3#
M9@80H%:XYN/R.49C"@/I=WCCO"(OD7@\PSRJH79ET5=YIF+0ZJJ@539ZI2E$
M$M>$G3M$JVK$E(I'PVFR]N-9>CB>TB.P7SRYFR,1>S.<A/0E5<SP::6F(L5[
M&/+N"]WS$%<VF.I9LK">2X?C"RT!G_UZ]O(6#:3T.%X8O-$.X(T<A9XX UNT
MP#+3>3BE7MW]I@  0N3B>\6>-R*SH\(=NXLC]A0@(4_QN#ANX^1X?1;NN([
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M'-\7)L_2J?2AV /QMCB!1>5R,(OR?_*LVEL$$OZ?5/0T"YB'O<,4=#T.9_A
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M]T4\Q&Q(.,=9RP0CR@[/5?P*V*QV#VC?:3T$,73JB&=K9UB(*!Q89S=8Z V
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MFJPMNLUDM4($4$6IJ&(TK?Y(-2WR%PUJ[4T0AJS561$=MM1KC9=B[N6C/\O
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M"VA:!@FEB%GP3D,JGR EI+15&J?0M"X%>]9- A$#I].H.)=!#CH44S)HC-J
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M,5#UK(TS( 2P-LV%<6/* PYP4]:XF;C+[V!:9-+$#('WW;:E2$>Y]!]R5/
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M_4T#*=0D4PN:YSQA5Z<Q6'">H^"IFJ!=H?E+9^DS_DXW8\(V$22$9T#"ZKQ
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M\.K9"W0(UE>(]83*%'T+_WBT^JJ:J[VP5_7M(3L1T?$5]6Z*/A;MBWP-U**
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MOY!#<1=*F:S_BC*^9M;-\JQ-37;DUI8+%S;;*@/%%.R.E8DNDHRH%>;]<08
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MB<&-,6)T#^HC[B=@?YB20!E9R.DB]O;D>[+VKGPPM'%46:"C[0]@'@\!S"&
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MLH-: X<4LF5H.A#2E[K0CTK7*;W9W$Y@$CC[>D;%('Y!&[$+DY41.OXWJ0G
M2 $A76)B%O4;WCG:M4:!)&>%NC1;[=6S%![>.?CE:-<H:#0>U9!AB89K<NAV
M"6!6()JF$WO63G[QNVD0#S6/&+:4W&HVS=Q_!P^;"8P &>B;E!'!6[F001^%
M.:BTM%BI8T$;UB1-N?%/[LVV7'/QA6E>RXG\Q"SB+4G!7DSSFA%S_$[ZUDJ^
MK!E]7N3210X=67H=-(,EEHID-UP+!:FP/HC/F0DFP_I?)*55K,^9E3\<,D^"
M$+#^;0JY&QB^&T0,1\&;OL4)7W9&I>JFGG GVA-44+=>5]A@95I;:Q"W@*>
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MT&[\GWS"S*>"NTO@*9QCT/JP**=1;I_ C_>:!?XKS?>*R21T#3=\0+<)LXJ
MR%OR^>D6)W#+FIC<BM%DHKB=0(>46>F>1Y_2>3/7-(_$^C$EH&_-%$HNM$W\
MA&GI->GV9?&<5RU#Z-H\/E8C^1:4:D)=)3F/ZY+=VV)FK I=4.$X U=8NI&
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M3"4@38(=]J_GF"R%>5,PGQ1Y,QZ)U=3-Y&U1-,]S=Z#V@=I;U'Y%Z7,KN.I
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M^3O+VAZP>"X=-B6W]T!CZL#Q_7[7(!N>ZN1@;*Z _3" )B[C:8&;O'OY*N0
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M7+7)SI0^_T\I[YFN85.%GI([BQ*))FNUQ,7:C/UE.LF%1EQ9O!J^[L@@5O7
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M+5ANF/2T7.;0U<-Y:&4U'GK?AQ[+4)MT+#_^_1?#73D-K,)A[UMTP6X7L%O
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M%%3(I:1<DD4S?_S+LAQG-!(T@NE^STD@]YM$R[:D^9OQEKI.K%4NY>S/)K=
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M#6I:%RF1!LGW-XXDB(P;8*Y;/9D^?'9RL2,%$14E2C\F4%6-J+SPX;D?K]!
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MFPPB\O<C6KN0E?P/.<JJA%FDPB55\Z0U6M9K@$"FB3".+*Y*:Z2&2YUX$W,
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M0X7>5F%B*#Y&,R>TS)'TG+?T7('3^XXSL*<Z"'*VT_YA!V%#*_!33L9^[V'
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M+[M=.#J'O*M=\,EX"@#0YUMTOLK04,9F!-"UB/84CG@-*8LO,7()=&@8SM6
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M]3(Y4^^ZEGI?_P02WX:6]\QVWH)6'+R&9[@95?*MDLE*6;;$2+F[S5+D1$5
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M-E<:VQD=:':PA3V.K"_R\\''%/I+#MY3-7I(-E0<B5"$)%"3) L4CNWS"CL
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MSB@>7RI">$8K=4SEBEDZ.5EO5&K2UED^/:HKR?#;36&9&>?3:V8"1H-BVLJ
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M&D#2\,04EVGX9+J1JZ[R0JI7:\"Q'I!7+7>OSM2B+LO5Y)K*='J5NIV&VO>
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M#]&-?<C79Z-,\@5R\76Z^9"E 1PJ 5;:2+6&T1[EBT"JT8G9*R3J#[.DLN4
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MUT_MT&C3%65S.4.$_(H[4Z/&*\"5@NCV#-X;9U,A-7TRVR^E\78N,!&AL->
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M("J!6?.L B_ZXIOA:E-H-T+_V*0%VYUE6QE'0:>@/PNZ7"MU:\\+GD;IR]&
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MCY3E(V7Y2%F^WRK+%R5E^4A9/E*6CY3E(V7Y2%F^NRO+]_FR9_?9[S[OUI]
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M+IJ &LQBQ:2!>]A!.SF9#%,G_3??VQ'=UBU!=0M#;*_>D!/TI7U;1&H06_M
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M33IC/T@!3E)O\_O0FA1;#5PCJ:%ZB\[BZ_6W%DP36*2U]2W[^:ZCN@@5;U.
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M^^@]>@8P"[2<9C*QGC(93WL4,TKV4J4&@C$IH7?Y%-(; ^MW,._?56PU,P(
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M927,EB_=!8];(.Z.5/7LRW)@OII41$A%WCH,G1Z]-'C<BVIWI,74ET_)>KO
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M4#8. XGLYJ')R F.LRC5%9:$AK2-"QW9*D>..(\?K$+"=*JN/%D$EJ)SV=9
MXF$ K 4 QQ_FQ4 .INA**\DG8WRSOM(NLQ^0Y1-H:UJ(@7"(Q9'>OM;,WA<W
M>@ZS+N)K. %] EG+Y>R]'9'=<(R'SZU =UX<09/:V?N?H2JT?]^;SN$ST7=Q
MS 7@5-L=2FQ"1V9H > W!=%1@^&#YUXY0-C&M$$6B!-A<O<%A4]-9*^@."9>
M/=24<(#NAD&Q)L=Q+$BFS=;)$.3X6VB8)Q_AM_8&;/9.DN'.85V)*R5:8QU*
M#?A7A];P12MG]WS[CH#HH-"S1AP#"Y''C:1AKM@$:C\2IW5![.IV^)MO FCE
MX$K$R:-P-9J8;4S1UL"EN$+=%2)'A&S8SW]'<.63X'NLC:TK1U]XII ?+B:V
M4@7X.!0^?!?H/U&)>7WBQ-@W$<Q@A KPX"]L7C/T5N\^![&JQS$HDNOPC(_-
M-DO"N#)WA#3:-F,.;M7*X@0#A5_-.C!:8[@Y0;95MKB6;#'>G'?DYV>=[>M\
MIXK\ZG=O6Y41!B&50R9:^G6M*4_=N#@S0P/!A"R!H_<R<MM)CLC83!?)>VPY
M8+L()3I $87_ H\8&?SEO2_(**="%6V']:%9@"T17S!_*%N>Z(7(<(KX.H<_
M?><%8[A]P#C0E/")Z%=GCQ&X7%1I-KKQ@4;OS#*DVY:7]A*2;&,S$1=VN>!E
MPU5(P (&U,3.*ISCD/?M#T_>,VQ^9[KA[1G,$Q:.+L9[XB14P,DC.3_5D7\9
MB<F=IX5=48^5 A3T"/O8^XAF+($!_([M#!,,*&E<<>KL@([AC"2-:1]+C+BZ
M8,'2!/(PD.K""BF']M8X#/0E]2-<1I@OA3)5:";T'+L2(O-UXP&D#-Z)$-X*
M3&ZHB&[@]#849",T%U1[ZWMQV0HQ6K/5,4,CQ'@.QOPPATSH>7XV7AGD4-(\
M+>N9->]ZH?<$B*-IO8<$O08%0? WYL#T>T5V5^ >(GT+=%>V>:1/@-BF)SDR
MJB JD98(!03<^(DN ?5&L>48-FUA&82C^=*LO*:M%$]E<V]\(B>WM+S<./1@
M!X][F/12U_BSA"6XH@]W.XN-I#<W?CHG,P^:E=A-*2PW%BL:[IJ1VRS0/?T,
M36, 7P.5FV,H(RWC.&EEY"]5L24+_^J<?'R/<K+[4-+EKD)TW3+X3A-R&VQ.
M(R*47/@E\L[L!-74CSW7>08^D.'\Q=VCC_.<R[_A2H>GK$M>=Q4[SE?TV518
M.5%M1TK"C_"O[MI=>^)__A%-4'^ANV1A3T3!KSKG$Z )HN_P<M+9@?W%FF<D
M.5(7\8QO'LXAQ<M?]B(!VPE >>I?DN]T)_H^WG=9X+Q>?3B$@U$T07 B$? S
MH,$EB@"_&N<RP-V136=:[GAKX_DW]W-P21HH20,E:: D#92D@9(T4)(&>MTT
MT"1) R5IH"0-E*2!DC10D@;Z#=) 3R1VGG2F7>7Z[=:M=.A*\AWWD4-T9D,^
M'SKY(6 RA10Q5CL!3R\([\\500]&/FTGXG$D=<$YN\M&2!0, [_ .]:[+N(@
MIOP9VLQ^UQ_D\]JBM+T0Y)8(M-^P>Q2YJ043#MKZ<[<.$SPO86$Z_K&Q,$=I
M+W =GB,%W;NU!RBX@Y@#^R@^ZF%Q'"R&W\6C.^DVVRQ-OX_/V2KLQ7,W:H66
MYN0U2+ZE^UTMR)WB>$:\9SIQL%-.%9\W9==ILT^@X&D.G"IOINM*]/R,IN"0
MP\V<M*VQ;L E7.V2>?!F^;A]US_JYCZBOT,9O_(GN/X,L=:1G$M(_G  $;UW
M2;9X\"+/$0M?H.DA5==&P-C+I?5=$O=<@, -QF]R:P64[N %,2&A]04&++KS
M[M9HW>1;H!&#S=+\8<'W"GE</IP!,:KJZ!*_/YKQ;$LC!_"L)G%NMFI@9'!N
M3)C:BUAZZ0B<V&^W]76G- B*: 2.NWQ$XV/QB]C/4!9B!1> $#:[L,G3=<#X
MMMF4ZT4&IQ  @D-XQ&'#C8CVU:! ?3IT)',F2(#A0ABHZJJ7=6V&X+P$9R6(
M,2>" D)N?O1VQ6&\7#=O%(E1T[0G;J@./AV.___LO6F3JDK3+OS]_ IB/<_]
MQMX1Z@TXH&N?LR-PGF?4]HN!@(H@*(.*O_ZM*D!1Z=FQ%U_6ZK9+J*H<*C,K
M,R_%U>6VX (9Y0P396#!Q#'X%O>@<A.Y8&;2_@7V1: 3.=ZGG7JF9J=>ZZ??
M\TPL=#8SE- ._IVJZ$B$AT[(N=U5[2M0383')OJB?3DQ :>)JNDA)U',;:G
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M'X!@M%:C5"%3G#.K-2^WZK/I*EQK^<$"9EIR<4?O1J-<8J?6DHO-P*#JOK"
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M+A7VSM&!P0U,@,>#)BQ5&U-EB: B0K:?::,%(R!0#[][LOL<4=/WT&E@&Q7
MY+8  ,L$683"3%!T&$""']N4.K2H/V]J?QIFLDXP+FT25H4U6!X)I@#3G2.
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M0+*X*9)%(AD)\!-ND37[?MD0102$> 1"1"-D(!(/08E )!Z$$(%(/ HE(O$
M9.>"A/AD9?][UM*? .WRGE9^$"R/ZT&[O*<,[[X!3F0)LQTTX$=>#,7ERI1_
MN_SE4>7A#^:'MP^CNR_\ J@^@<8/Y/Y-N7]BB*\RJYCP/H",VZ'%X)@(V.4-
M=D'!:,R-0S_+&7)/9OG267/OOF>7!9"SE<&]UW2YOF*.%#]QX\3OY L1(S)^
MFL:'KK%@%I][!504!0VJ"NL$:@0-)/T&7A17;B')VRU>-M=XI5[:ICH;F=!6
M=^D^QF>F9#W-CK.X52Y*O7*J*(?G+1O&*1:A4M?I/O8(\G;YK@R!8'X:V?'1
M!%,:Y+(+C64S.:N3Z.6+1JLUZ]VE,3U1M3+E352P<N8BD=06 RM?BD_!)L:N
M"?@8OT_'W<L(YN.[S3DW>^<X1^II')JK&BR/HP0O74KY,(:)RW]'V4VOJ,)>
M?AU^*=86.E,9[;JK>"DS*YM?R5^_A#;LYU6Z6RF036D58SN[<G&H3<<.EEK=
MIR'=<TK4W4R2GRYZ#V!Z?$;T.F6ZV)Z2B5VND]H*ZFHT*+XDIW<2O:Y9K8J;
M?'DL"<T\/BK+>+VZFP+1BUU1]&X1<+FCT7%O$\LM<PE"*(&G]JB6BJ<0ZQ4U
MN94ECAI4>H9$5J8L7C/7:X&Z2Q2E5X\6$U0LP3*+:D(Q,UM%$58;&RG1OPSL
MQ\A<$$;Y\\(H'Q'.FI[+UZEV+\OT>6E$-+E*O1&[2R1EH[YLAS$N'F,R>6$5
M[BT;9H&= N&,754X@U#*U<%D?&JVGM/Q^[FAE"O5?-W90CD,^ #4C))5ZKG>
MLJ#A5J:2X3O\<LLP=P'*6E>E-EEM%LNY57*Z:C2K+!FN3VVPTU@$)WY(&.4_
M@2!]"YSI405IF(BOLUJ4MJ1.DK;B@_F2[Y;N@XR^6.M<S2 [.9B#W@C+NX4U
M:0%!BD%!(J\D2#</BGP=7NY1PAR>8ND?XW$%40X?M?<R*IBU)E%3IE6)U(QQ
MO2LE=C/!MT?/0X0W;,ZL L9\1=O%UNQ 21;H&=XGM$9<G28IF?U"@[I+Z+MB
M.Y,9Q:>4Q9")=3T:8YHC06C9H,+QR+50A1]!V(+PQJVD\B'B&N]*92]3[:6[
MQ=I+KE'J5'=]*;G-R&]>S5Q/*BO#P7J]ZVS6N8K>'TD=<S O3J= *F/7E,H@
MKG$;F^70W>8YO; @IO&L,8T#)/C'T< S%+>;;5:C 2-N1^M4LD*5UI.[!#ET
M93TIMW=TATF0V\Q\(>4W2]U! R>H2.(<2/(YY2N(<CQAE.,KHB5N5JOT*%5@
M<@DQIC:G"3YME>\2]NAORM4$45WGI$).2T_,:'>[)#9 M*#!D8JDDD'<XU'B
M'J)FH=YS@2/VHQVQD_+(5$#N@-Q_GD/G(J.=0DW?I/#]"X67MT?B\&W3B)IV
MGG>D=7J_PE:NI]W6$=[]I8'4[P1T\!%H^X/1M)^!QT*BC;U)Z-L8?)(WEU66
M;&;P1#HN%IIR-,XJTU__)JFX?R?^]S#JOY8V]$ZWS8ML=RRIA34NJ?>9OEX5
M58%3B:CX:?</X=7[;/1^FYN";2K[;G=.+JO<M%LP)6O>XPI=E<_2E<VO?_$(
M?N[S_=?IF?LW]M=IBP$L?"46]W/PO['GD^%&))-5)25EAN%5)3]8M"?:C5D\
M)C93+#V(AYD.UVLU*6HU+81IX TDDB'*)[/*!H9Z. WR1?R.Z^\OGVUD9V,]
MGF$*)I^0Z\E&LKT%/$TF0@G\W-UZ$@WBN]WQ1,IHU5JE,6-FVILZ/]2+V\:1
M"HE=7X7TJ?9HK-54W.IMZ=QHGF=U":F06")QOMU/ID1\MYU>D.7$IA.O,^2R
M,FIM!EPV:DQOR^7%]3*)[UYBC-0O%FLSI;W9)*:O<_G?(0B: </DXEJ0K0A&
M>ZT8U(W_?4B23V__M_$0/[>/!594]*J*Z*ID$#2!IX6U%Z73'Y5$F!9'JTJ=
MR$ILN,=E2B^38F4--',43X1(/UP2:-IYP [4+X =V&;YB1'^-AHPM%C=3C,^
M".C/@!X>C4:BT=<B5%@\$G/L<?33/]=O@/E1//&+>D=D[."H8J^Y2M?K27I,
MC5?CA0],C:^NE?P):_T,TONGQ>VZ09KW&/\BL:MOL/>5FU/Y+5]<3#%=XY Q
M%H:'(QZ-$ML)@9/QR'P); M6!F=@ 3#73.1^N?/C17T)%/1O48& \^&QK'*2
MJ\K)9"0.GFWC#?QG#S?@U^IWSYK'K)>D(A1\Q*__?B96^#4INSG#D=%7 F*/
MWN#X_QPU;M['(.$1KVJ_W7YS'H/!Y0=$A"G@$J2<V G@R-^LO&$MW:5W,D+&
MW%9VO_<]ZZ(VH9+)_V"''P\JR3,;:#UXM-81Y(7]K6/0"^>S=S2D8_! WO2Q
M=BY-+CL,F#A()HO--&C+_D^WD?$E)?SY3?S%+C+(@"V8L2VK P C^^]%,4:N
M:;&A1[P>W_X)I^0[2[R&8GBK+V.S\Y*K9W)8NM2HY;*E#%W%JMULY+-M;T_6
M=\=&E9]</Y 6-#4$O79 *>RXWI7NLQ.W4N+HH %^J&K[MV%X_$(/3OB<0G_-
MPSM6HWZRP;KY!=&H&8]J<ZZ"9\;+Z3#;K3'+RA2ZV[]L!;,?*6\J\UG;DD=,
MA2XE.HN&/)ME6V D=3IRU,Z9QF96RN<*ZT:3*+:23"T]'9&C^.G(>9FL;Y:2
M$64:<4)N+QJZT&ZTP$@"/QU*UTA-[<@UA1$HWIJTE'ZJ68'-N<X>*LX946YU
MA4K.7(<S<J<SC:Y$&HP\?VA#?(DNM2QG,HMYGNJ%>8J96;3=X^9X9%(4YZDF
M8^'2 @\KJQYM+MI#V WG[/4=L3>)ZV6E++'A9JJA=U21RL)GGNU3I9 ADX8^
M6.<:>&U03TB+056%(\\G2A!+G$IIZPV328_#-9:12)9OV=7NQR/Y<M1B4O2H
MP(1KI9>54F_%EDLX\FRB#;+(":E5O"NM6)%H#G5V4$W#(MVSB3*Q=,LDZJ.2
M9.ZX-3=ZF=>V'3CR?*(R41GJZW9,RPFDU<(7K6&A5-V,$J.SD>5:OSBJ]/-]
M)E%:U MR>D!UB(U=&7<\<HF31&F<(PTFTQO@*['<*VY)VB[].1XY-:-<#9?;
M.)-(4+TXU6NJS1XL$CI;_(J3*Q;>IW9XAZ-X<I#"NQL%/O-L\5:;'?4D(Q:5
MPCV<XC@B55VMX3Q3IR,34STK#LH5'.\+9',PPJ7BK@N?>;Y-?&JRZE*]6AT7
M)ULFJHOS97H L_O/1DZS,9/7C=Z *43GC=(N-5&;<YA;=S:2:<FCF3'*%YD,
MF:($K1?N)<$SD^?;5)ELZ[M1-;G%K<ZVE&32+5E@8%+1V9*&E3S=ZNKT0 K3
MM-#8YJG2RJ3]A'ZBYR>KC/ 2DQ8MH?>B#1;55A<JDO-M:B1ZA7E8SC(KF7G9
M%==*O+#S50]6LI38,6T^EQ,(=5#9Z6M<S6_ R+.W:U)5HCJ[(</TU76S0'$Z
M/M?@,\_>3M(D5=O2I954P&<361FUB6P=ZI&S_8Q1)7YA3D91J5_L%W(+,D',
MRTZ?SN.1F[[%I#.T;.'L*#,I-Y>I_F+5\M--J>F<*1;3.4EB!_T,J[RHI#B&
MNNE<YH;DDE<HEL(;L6ZJTXLKX3*_ 2//5M00"O2L$JM7<XEJO579*3NAW(*J
MZ6Q%;;+=4JEX=Y8S^02=SB[507_LJ^[Z#9R:SQ.;E91AZYT>*6HEQFC9'8B.
M1ZYC26+9YULO4J7VHJ\*7'/=[\,^'#XZ+&_DTT#>F8Q:#(^GH\3+<+"QFP*@
MD>+V-S1%1<4!F'7P (O]F1#-Q.A=KA^KZ,6:U>]VY,T(#B4NZ_I][&;?Q4TP
MP+^Z'<JUP[,P>*L@<'!HK>\10H$UK</(-T+DU("A;B[ PU'$E]4=J$C]JOB-
M\(:FP\T$WI0/"-M=S_1IA3^%NV\<9HT<D"Z821H&"/8XC0(N4NL7G8_B8C\V
M2"6ZC51!VOSA.(V.MXE\5M8T5/<#VV-%G]P8RC%.1(A78RDW\+U^'#A4 %SW
M[(1(15(!;MTC$ )(1*":'H,0>#(@Q ,0 JBF1$"(!R!$H)H>A!"!1#P((0*)
M>!A"!(?U0Q "J*8 =OF"A/ADY>>[D8W;HG &H)O+[Z,H<JH,/T29YU_;(9)$
MY]03(RHZU6!N)/9R^)LW$):O<\Y=&(5X;D8YJ17\%J1QH$T?3R:^JTVO$QZ]
MTZZX+\J +XTU$3RX*,AK :X,OH15]+"OA-V*DQY1NS[XGKWMQ_RQTO=FO./.
MIXYWWDM-0$X+O!1'0P0>P_X0<^6',L>/5#,/R4D/OF>!:OY\O.?153,6. B!
M@Q X",$I]#1[%IQ"3^<@_/J7!@MBIT+@"3PU%_Q(??*0G/3@>Q;HX*?S!/8Z
M.##X X/_&0S^[[)[?5]V$Q@=P6'PTTRQ[TJ'"QX<R,:?S 6!C@QT9& P?TY'
M!A;S_2WF[U+6[L!^_N^%M*!M&S]Q%MFSY1D^.#_8^O_>?9*>\'Q(/+44-361
M>QH#^\%%Z.F9(5"I@4I]!)4:>VHI\E&I7[/'[P"U=-3DA8J0[E8X+8;"]D='
M>Y%F95;AA)"-&X0YD$'1BYGH]X79>E=D;AC(?FC ,0PNFB O N-K5T(%='=/
MD#M#KOWOY6RC@(/_, X.Z/YGTOU'::[[P%Y^AX,?,P#\!>NRI.NFP#]#O/<Q
MY?#N8=XKP;H[F'3Q";=3N^N7@<3RT0J[9?M62=D\(JIEJ9[_("B=^VB;]>WK
M3Q^(]:(T*KP02E'#&V/-B,X;Y=5,W8PHV!67($-Q'/>%#GV&N,YCBM+SA7/^
MC!#X937,8^!>7A<Y]UC#N(563NZE>Z.,PE@^>J=;&Q"I\#S)2HU9H=C2=W@]
M7H<]X.- [Q 1'\# 0.4$LO4PI_<7$64O?GS/PY46KQ87O+1J]LTM)2=["8,&
M8D3]^C=.!6=W<';_"7<M/_'L_J*&N<GAG6H/1ZS:S[-,I58(6UNBM&S34.M
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MGJ(_NQN+>78VA*F:KTD5MT\F8"IQ@L#KV 2P#G@*>!,\XNPVWJRL"2QO89K
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MU,\O"V:ML&B-DGR53]S)N>0#5.-!8)3E M'H$=T!WXS5^MA^3)_U(; ]]/3
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M!KCH/F7L.NV^M6R($W:3/O>^_:*+4ZH"?-9(W+<?M.&H6HN8'84M".W9Q7&
M7G\ZZ=:>&H\L%\KD!@^A2+Z22M&";LP!(K% -.&'K?Z2PI0CRVB1FZ>>EO>%
M(3O*I"M*]95?EF*71Q+)QW@MFDZFT^Q]H6@.R_A9@WB*SL8,!>(P2SFY+V3P
M%U?S?'"&GC5'UIXAS2@;IC>M:;'-;IV92;(,W5(D#4%M#0P %.TAQK3 H8L@
M6?,D,\C,$=[<HM*KC!$\3NF# IB!!>>M]>X8/+8<I_.<,6MU6HL8JM6*3Y7\
M_/Y8XQ6OI:[$+QHY53HP9?@W;-0AQ4O*T_Y[$^8O&RY_<4G)90/&)YC+A,M?
M7'!R$L!<>?V)QQGMRR5_1KP&U==$^5U\EQ*##Q["7U]^\L'SLI-7?&3Y&\M3
M/GA>KICVE9>L;&^<8R.1[^&RW-[;WY#2Y=[O>YV4F52V4U<[4:5;O9L-.2$U
MBD@OX7)2.EQ6%V1\@BNHR<^K>&.JZ.2!XBL@L0'OK(!@>Y:+R$_]V&,NEFLB
MM5CMY6H?]WV"\ZFL*AGJ(]MR.'DX,XLU;MFH50:Q5N;EM5L39SH:WUN3U+Y[
MNM5QB>52LZ_6B.7J$K"V85941-23,&U?XS"!$_#K2P\O[<=''Y*7H$M>KQA.
MM?:(X17KH%]8LOB)G;^$7\?<:#CIA,WG1D(O/\Y.((O[R4*KOT3(S,7FTN.3
M:6@/[6:*EEB\G>?V+33QIHK/RM<N?%7\P*IXO?CZ& OITCUKRN@111X:3XV'
M#^?;?9RDGV,)W=2?N%"N,IC=USDY'ZE-_Y)J!E^]OA0"P$*07\1B_69\^<*:
M]5PMOJ@762%U IE6K<>KA5XEWLBU9XV7V&-]PLT+,)ON_3+-3I4Y? K*.K[N
MCT/0^QSMB_M :&(CQ>?4*3\?BJ"X(D2"C'@-2'&PL?DPNYUM<: T#_*<H,PO
M5-/XW9/F2/QJ6H>AVDPC'+X)[[15F>A-Q&)9Y-,)(G#;83>\5H],EH/B!V?O
MDCU+5'0=&I$KA,9G][K3&+VFO;YM8WR!W(XKH-]"_(/D^7\!O0^^^_6 C]?V
MI5&?T36!B/4@*!1L.!R:]T(L%[UY'6/MF)>Q,E"@>L4/>WVBI(\Q@_XM*;*D
MH& 7<A=M5LXE;K#V\X<FZ?W7R='SRC5P4',=]1+QFS@\XL<_']&"/T=E)T<X
M+GY4U>:]JLS'N?K_6<L<<;1N$/&J]MMV0+D4!AL?"!#Z&$L(<^)[&"-_\_*,
M7^@VO!,W7,3V;?UVG%AA"JA$XK_,ZN.*);E6 ]J#BVNMY8G27ZUGBEK7WN"0
MEL(#N.FA[1S%4@*5R*9,GAEHH/#_IUG)>((2/F,E$JOK\A]WL-:Z].-?DEL,
M&2$9JEGI#F3YPR;F'E-C(X\X6X;42:3D&UL\!F/8%^6O-IYSY4R.21<K#[EL
M,9,J,:5F]N:C,?^-_9W;<_W^_6-J(4OCH7(@+RF\(DB\S&!+W4 C2D9;)W$J
M)DX$#3;(55J=$ 3Q"X8D^AA#WV7AK;-1+]K@':,^E\NIO592&E:ZP^?(+,4]
M%94^%$O\H S&N=.8RTVNJI0CPTGF+CZOO41B,Q;NC&S>.3.F&2Z2F<=;#7[T
MO AR"S[]#'?&-N_,I(56EP]W>RS'2=-IYZ$^+H9F^,[$YIW9Q=-P4,^5$JRD
MSU'U]E'O: ,(;K.;=Q8K7*@\C[/-7&&ZC.FFWAHU!:LOX_J=]Z-;]H6K90=L
M^S434R./[8<>Z>"XM<Y'E,NFNN-;(3<)SFM:M_X2'BS G;_U=NXIGQJ-6J5\
M+M906+7T&'T1XC7J^%^_<Z+WTF*Y\%QG1[?AT-/R/OGR5(8N3%MOOP^U=7VF
M9N368AS+&-%8;1ZI]SN1[;>/N]4EV\V'ND.36X3J:;76;3=JU$>Y?F?E(?2B
M3#ML.1=L3).AQ\:P6WZQG#GK=ZJ5]E.]%:ZR.:X5C<1#':78FL*([>VW]PM)
M]#!OQ]E)(Y&<I"6V'6Q9P[C7[ZRW:]KKBR[-6ZB32O*U?&P8E6:T&'G]SE'&
MB)0*_>8MR_466J;\G-,+&.MBVV^/O+R6M+P9F0X7\T?^5:^D=)ZWYM6NWYF<
M2EGAI9G.MD9+/93E"WE46<YHU=?ZG<''0?HNK.:-EJDG^@_)NUFJ\P13Z>RW
MGW3<C</$ZI(^?. 5K(V-Z S?K8$VO9?PK#H=1N.M0B[6,D>-0B<TZ%,7I*28
M2$P9>^[KP&VA(Y4I;;'JW85CH<2-BW-+BHX70E@W&7/4<[[1\'DP(^= #CVS
MZGV+Y7]YKI419%[7I1X6J<1O3%;.2QJ=Z<2,$ _ /?"R/U"<YWV^UJ0J1(9#
M:63 E>%>MDHK\02WC-4=R0K*Z@HZM@ BS[-/ ]]OZF2$E?NQ PEIO"8,%G0!
M6'&6D4"6@_5;K(V08U0$9$^GDI2QB;^&M@Q0'#CBA_!(^,9UKOK-^<H>W4?6
M<VUOP.L;X[5D-$6R-43K PK]UW23-1^XRU B.]UK#=A6GF4 K&F0UFT)R_9?
M??&E%6_JI0 (HISNC)N%MI30__U/,A9/_MET16QHJELVV@$FWNTS\$H >B9D
MIRXGN%#H#S,Q2<GK&,L5_$Z,W!!1F6+$YK4AS'#KJ1IF]A@-X4Q<U.:BXAM'
M8]Q2<'T,^PLQC-N'88!/NH17P6MKDF +\[Q^N$+$W4\A7-E"7D>\P!!"^O@_
M1#*.5!')V#+2\!61,$XB-<D#9E#BS_"R[!(%ABT"X,?NRY3GBO <C8YJ5+OX
M"*<$[[?V=$F4POJ$<FY"":\3B@L-;<SL:>IH=9TQD#!0I(F)7(B*K7F@AI&J
M(2^$)82R#U]-986Q>_#3V]-)V*WCT#J+ZN/JTH!9!=(MO=(UO=31BPR/!A&>
M$NT,,T;S6(-[A(6Z[*_B:D5>QI=<B2='=ZWI*(?X68$U^ZV*F?[;IXF>N.M#
M-'Z3W!FT^]XUN9=6'7T3^TNKUB\,$(D;GR N 0X^05P(('R"N PX8(+X2QLT
M71@@DC?AJ ^("P"$3Q$7 @B?(@X+B ]6MKUIQ9UNUXD/[/JHZN'9A]T>N=T*
MT<HNN-G*6\=C17,.U7S&QX9O@ W<X;#AN"T:+AP;J#B^>G0(^^C@HP.<CU4C
M_[&,7"\-Z=S-];,0%R,:+#/C-0TB6K(U'%/"3[4C:6-REW./?C !>>[]'ZP<
MFLJ[JQXM<+C&+SYL+PVV)QNJEH$\0:2[@JZE%3]QNKZT*1]Q?67U?5D]B$A<
MW17'O;63\#:F.Y$;.:\;K6?:S6?(TBH]Z]T5K0YGYBRI2EF<]:V]GMM(.U)(
M/!7N6U*G5!G6XYRLU[XP0-OS5 QGZ1[5^\V>AA+)>)#+F3UEE&U%>22W(8$>
MAO[& C$V<8S>%51#^384;"D<5TW"!V7//G O"[C7PI^_PDM9HRA*M7BOE;L?
MJN7P.#@HJ<$OC+K\."^=BT_+6I;MA(=F33**6BLACH44YJ6)=_#2*W"!OE>;
M-[NR)!Q>F;].]G%N3]5W916?5>5"7U?E"'YO<!]Q]I)]C6:>.\/V:ZP\?)GQ
M>C3RA7&?'^<^K+KHII2$J;=BC?&LEF\9N6P?2@RY'_\FXM$ QK,CJ7(^;5ZI
MCG:=4#N[>\\'VU\!MFN1A%^06B_%PI3EIP\"6WA^3J!*EEUD)U^8Q_EQJ54/
M);5>]>FUV>(J3UDN$JZ/*J]0[IYXC]2Z3J]X1E7(*B&#'B98^O[N[^@3]?W=
M/FQ]9]D5 O?"Y#X1[2N)D45=XXLF<'B/"1R=C=3*:RH<9X/I[.MH+#R_-(V3
M:@3%GA&[ZSX.9FRE@UJLJ9;1:Q#:VL1^_!L/Q*"A=O(H#;5]4O1)\;.D>+LL
MIJN88AJLE!9:<OYN]#R?GM3Y' O6ZP_1V_ MVVYEAP_QV#AY7P2R2;R/;*[
M_US.I#),8PS-931FK*DC2<>?%D2'ODY/UCNRI+Y)PN0'*7_OP:S4K^O(I?7A
M?JEP]YUIWT^2\P;JJYH$PKP.Y3-(K/+:FA@O"[Q@B9$C:M)\+%LOU-EAE<T8
MPZ=)*C=NWG9/JDG?9I+/6K!2F+=,N2%&U7J)#]?ZG2AHTJ% )!X)<-'8\31I
MG[)\RNKH&>E%8$O#94[JQ=*%4:=BR+V39KAQ85-H95)29M@P'J>W^FU&3-Q!
M4]'$^ZC@.GW,U4+Q:"KRN?=V:NWIFDWHTRO2/G;XV.&[UZX!^I?H7JLZ,JN,
M1=81U?/0PP05^)=:<SAZ29IJ+++0"Y&3>NR6KZFL436->B[3[J0[9DYKCAJI
M3HRJY^%0+,"%CZB>^Y3H4^*'*3'9$.Z?XY7TM!6;W W50G/ZLKP_J5$[:T0>
MB]IS(C1$X7XKFKB#>1(U3#6)]U'-%?BY]TKE-"]#J_, \P#<C F' @R V/>%
M_F6^T)-QC,.E5_?'K;ND=*]%V$6O/TJ+Q4%"2IQ4Y+;"I67([#P4V$(V&QY&
MPIGAK#/KQ/?G2/N4Y5/6^2EK7PUJX7%<UHO=<I(MW$V#);77>GZHG+3ZX#XM
MR95X<&P.T937AVTTF@H&C,395T=ZK6&<TQ'6M7FCKY*R]IF)R7;\MC$L!U]R
M[4&CT91+=Z6'YY,JO(O7X-VBQ)8R0\3EE/DB*3\\UE.8LL!,9 .12#R02"1]
MZO*IZ\C4Q6>-Q'W[01N.JK6(V5'8@M ^*26D64Y Q;K&M3)<28I)P?F8>ZAA
M2@#3#]M^D60@XIGCM-5(QYZ2\,_:S( 3]0UT@^V=K0//-*1*0.O#&%3\/\U[
M! /#C\>:.L>@-I UPVHUXTK$_QDJ'=<U4#4C:"!MQ.!;30WO'&,&_N"\9-?,
MHC,= U[8#)&1-(RA\8K>@T$<$AW8IIH&K%JFW;OP-C5[SM@"\=HAU[R%.+O7
MW/W%U(\V^.X#9U>DLWWH#!7,64Q-)S#NPH WI.L!]WP/1M(9-!^K,+$-8PJ/
M$4>3$,:-M9%Q,-!/_\T(&A(E@_P58&1I8DHBH!']&W,@?$P*?IHPX)4^HE,
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MSDPIVIWDJMT4.WH:OO1[G#G*YZ%+\M8Z\XI<C+#I<BC7-E/M=@HEBX/.C/8
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M%N5F/ECH#_FBUI*K?#CZ5#QYB"16$EK!>DCE<Y/FL!9-],M&\"F%B0L;&9$
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MSWA=#3@/3SC-A7;WN7U;F+:D7IQ[?N4G.AICGLK>1,.Q[3:JQ =.3C=@57R
MY]9V4[OB3.\D(0M0T9ZP5)O3YZ<A+X;O^3G?7A25V:4#:E/0[:>CAJ$*0]K,
M"F_%608!C>XBL)[+3[[*:_,$7KVR? E.Y;["%B*]?*=9C@^E,22EA]E -+X]
M4I%"3O>C]%<=I;=3XCAV)>MT&M(]NLC[1!H=Q[K2Z.P_#A[L73;SV06KO+9&
M[5?QJ6W.T_?+SY6 ?5KDZ5.ARH_S+R;+\>W*_6,CJB86-5(B$N<"W&ZI=Q9Q
M=S& .:FX$U_SR7I0R#[D[G6)*[6>BX_B0^I=X@Y;E4#T7C4#1Q1V%P.FLPN[
M8+-M+/5AK9U;-*;U!UV^K=[I4.2QNP)KO[@[N0F/]TK+H0UYL5XP9*797)'2
MM'L05Z'=#"]EE'YL3=K5ZG0R?QQ6\OW/H=)>-*+7\ZH&+V\@PY"),\L3>;0E
MKY;FL=<&6QEK8G*@IRIZ 1(]8H%X<B?F,*JW::D<%52')OG=H!(KS6(V]EI]
MSIEE+?5<UF=FNO9)JC\8J)K2I%N[?7HUV/N:&'O5IHMZ@UB.B4"4VZG3 JB\
M5"/,K07PE4/M"/2D$*F]8N5-J58=B>L[EW9TO;;G5ZCSM/(X;8P7U;:LM1IR
MK!MEQ6GB(9[Z\>]5J3Y?(;"3GK9:C?,U,7BKY*1A_KG\Q(F#9&ZW]K-''3I3
M.P^:;K:R<F@;!(><;9V,YIY!*PI!P-8J4=.<M#'O4K*]%63D+?#(#0_R1S+:
M: Z?W4OEO>EL1S]ATL>(I'Y[%3)#@PD9$<L$6Y*P&V/5_</)1J1[X(%*^5Y/
MDNDVC8&DB4%( (060%,,'VQ]8DYJ/4>'0QS;1^UZ*>F5'/\#9M%HA ^(4GC@
M#8G[.99@)[=^N8"SY=IY$S8.S="QC*?;MBM*$K&G7J:TS++20V; "J/BHSKZ
M3.C$E87.:X_0_&<OV0O5AY=E?,QIN<(@:B["M_EAH8O)7O$(FV!X6;VJ7*;/
M;" )@Q7@@!(<198Q-&H789"4>5WD)S= 04"(3JIKVT*=G(TZ#F5YJL'6KVY5
M&?*BCZAIQ3NKPGDO)'!ZN.B57FYB;O>JHWI-AA]#=ZFM%O7'P*'.8%K-OBY?
M2ZU%)I/M1>^X06]Q+*\DYC#DJQU5]_)3KO:X&->'DU?]_NXV%DTFY=J/?V.Q
M'>98AA(T?3:P08>5V)4*.L$JD>19BXP C%N6:5CVN&;VFYBP-:Z@Z#326HTK
MJ)I=61(L;-=/@@_-3D/K5M*5=&NT3&8KD>SSK/M9:^N+^%#C:O-@Y'[Y,#0;
MC[%25^SV&\^I/?A C\OF#CHS0+)3PT*)_^;_[VK_?"JC\>2JR5H4,N8E3"WN
MMEY7=50[,A1S5S#'OEK X3+EFNH*(R&[Q)2AWY^>4L02ZO-R2L1@4IT6G??#
M83(3XB+WN<8=2E3J24X--X_E7=J/I/'7VN-+M'"GY;@J_]R<11753$#(!)N7
M>WQ(5":M%!IAM6?"JF38-88KW?:N+EP.4MK9IB3/Y6,82M)3K<2P]Z9'LA]-
MC_3K)2XN:]VOE[@D:/CU$GZ]A%\OX==+? ;APJQ?+^'72^RHEPB[*/,$]1)?
M39[FB6;=$9-=,<G'XYT(ZO4ZD:@0[202L5"'%:*)>"^*0GP,NK+"6X_,X3PL
ML_VE :EZDQIMQ:*3!7]A:\3&4:7^D&H6*V6F7&DR]5RM5:SGLDRQS%3KE48U
MEVFV&@=>_6?7:J 1/<\8]"<0T8BVG+=].%E)0X*!;21B-E5Z^#NDZ<<X^?>9
M[2VG]T)%,7AL13)I4\<23=<QS6ACJRI!9U*"P?P$]LBQ?RKI3(I\#/WY%6!F
MB!GQM,L]['7!J*9FNT>AG3Y8M?@5HK-QX@:G^X;/O*)"AWUX /BP87#>;* R
MV/ZD7PM68A \5H,J>YUTQN.=)[H>&* /=#\+[%B:HLDSNH3/D\>KX\>\@!E_
M@'2'M]Z/ETLN\7UHR8??(<,T/]W0 ]"R7^M;TP#0?(P4'1SRDB+()G']@DN#
MII*->8GX;W42XR5?4+\&7I>.CU+'Y\,SKZ;8I]Y?S>FF#8^#0W,\0*X]X,5;
MW>7I@K']C;^2\<(T"3K4XT^\B#](NJ$1UA2P(@YD_. 4D1,BF[3ZIE@G0OW:
MFR\#U^14E4E#E=7$!4C4PH^!A_"ZK@H2OPK?F&N I =)&ZH JM F'_C-$*&P
MFN=;2$.^X<4IB5"-5 4MB*=A!=N #=G5%EQ+!;?I'A"MCM0CY*2;>.N\ZT#.
M%-*[56=H"I@K;3 +?-YX<0.LHQAK74#)D9J*#"2Z#KJ/E&L<.55SOP?#UG,L
MI\6N)-KUQ-DOK?@06;?_^Y]D+)[\\T8RK%M+L11#+ASJ8;9YJ$D>^Q0>RBT'
MF))TB$W1Z##35U41)F5@M*>A2F8JX3=C2@.FVB6A8RN&K!,6"GBU?MEN8N(F
M<4)_GCS$8MJZ%X^&CY[<>(/)_X'5._K:)Y.UCUM[XV/Y>;#<RED0>"J:>$<.
M$C&T)@E=\M<E^X@,P@P6*1B%!2IS>2* L ZT8+#XP$:_E:/H0NL!+ZXD-F*H
M^:<3,N@B64)3Y]DN:0F)Z2:6W)")+O.SGBG?[,9J;^.+<%C'[#M]: >8Q *O
M72>TB4D:)#YI3&3K?(C'3 "#XB.Z'Q'5\#M?\_M>FM_9+1FL(1&[A'3@0MI(
M,JRD)2??!N )K;<-_!_,A#(UHH+V'-FGH)Y$SOQ+F(U?KL-1G0^KSP2,*K8D
M-3N1Q<JBLBQ@DH.VRO,".(&6H1  $3^!W?6,,!?0"^QL&9TB'9R<N&9'XZ,B
MD'0@0/';LCD"0*.0H4/.Q1A =[: 8X>0,6 .)W,3=]<TH(R(D?$QNZ<E. M;
MX9:Y@7P#:633#. 4C"8B!=B>-$\OP]ET$<DDPC_DB2SI(J1X8\8?>W,BV0A!
M=WT G M6O&+,Q,QQTWC/^S1(-WG\!(1?)I)GP,"EKRB2\)L XQ+5Y\'$4^H'
M]M%AZ*%#* H!^]QUU:9[,AA"8<"33/D24<J[,N'WX*A98:(' 9UK"AT6CQ@G
MB-RSV#+!L!E\LN0:3$BTD-\8X-UACH#/'<8P]GD/"%%!147PPN;/#E-PW ;X
M$\+,1UT@1+EOG[ 11P)N&MUTEEL7V8J.2%YKDSD]/LOGFPPG$[%>LM<1^4@/
M'+^)3B+!<9UP7.B&>VPT%ND*!_7Y?MDC&;]AZ@A<L4R#E^F\Q):BH3[T6H6M
MKG* S^>/= 2'A?F;;AN2>#(:T;&;@.4N=^6H"],:\:T!:R!CGY#YJHVOODIR
M-M1U/@AI+1+H=O:TJC'TC-%H 84E7:8814'BK"ME;EFV4A%YJXVMB*@'E= ^
M/ITIZ<0!2.7*$;7R9MR2CI(^?@I9WDS281ZECOE8%[2'KCI%=!DRFL)#='I&
MEIE.74=DA5A!^TEDP&KO6'G$YC$=56D78EF>W0P65'"P13N1W';S4F^>Z_RL
M$P7>!$_?^B&F<XO*70BVXDVN='/P+-.M2+2>D$H,-$=TCB-M-FL#DUQQ1!]F
MRPVZ<XKAD9_\KY_<+_K'JMNS^U7X6/_!QU]'?=/*K,S"\T:FW+?2MO%2Z4*)
M5N8&+T@!A6Y=L^2LPX4P0$DVGPI300FGQNBJF@9C=:(> 6@P]\'X()-&25AA
M<QB;?1TC ICP^NG<D4[F'L,E]R3MA2$Y;#.!U<E6SJJ*.E 1D[+Q.&79"?BN
M4BE#9F>:6#4!E.X1.:P[-5"$_Y/VS:)-'Q3U[6?U$+1Z?L\B:9?IG:NLF ;0
M(\'DK^=ZG3Y3H5@,AOR0M!^2?B,D?6QE(ZW.&2OCGRDJPLV&.!SSNN$0LHB9
M.N9H"T*_*;-OZO"H=R<'A^)<@.42[Z+H3RWK;*G2]EE$O<YBK?DW#*^&/ET\
MI*B(YHCYZ9+7*>NB+:9=LS9W5W,%&-H([XY73+!FU@M[[1(OMRKBU&@-2%:Z
M$PS8K%C"&KY$0G(;?<0@$NZA#L$C9CQ @G+\+OZ_JMA"P?4^ZP6,(//2R'*O
M@'=#MKP"5-DR0-.W*\S@U_;IK)\NM9+'_&)M1SS(&2^%TYHH;HMU\K(>UI_4
MF?Z;BA$7J1XIJD8SR3SB#YLXM\&2/)/4L/4;='G_W<\@#'4[5D#SHKB8G1?%
M6_/5\8%A*PG3&\:Z*/M?&VA\'Z,.*%-@]^KZ:E:'QF,UEOB^B/$J6#JC90!N
M'#16%@U)9OXG%HT&8EST!@MV:/M'/"*VKW55**&O_"$!#%,KI$HL;&ME1$V%
M)4/<N8OH,RQ$L=6SC8H[_"VVU4WR#=YP@%9$C\DP RB)9F^BK+M,S'H:@E("
MR[TD@7^%,68J. ^,@;Z:G(#P/NFT>'N&@AME/0_2\C1;QP@>P.UC _;(6+%A
MC C_$[6[0_S9%BQ_![9NTSX1(#;^."R-\"-)LX4&@0R9: ZN V?,\3J.6#'*
M(QXL^[W/U;,8-NIUU &GRA9;AIH !O$N2KSQ4D8O)9C6MM*ER%F98]CX_P![
M8_";9<M%OJ[OX#O:  ZF1&S?S=K2U5=>A=N@V*]-:MGP#IQ)!6H0M_2YG 6,
MY2=@?!?!.[.FW2[%4U12G<6ZYGSKVK>NWY?P'4N$PGR83W:B73;9B711N-/M
ML5PG%([T8N%$E&=[X<MR_B=NF-R<9!-2 \JC#3K3$ 9(-&67__]0%8UK^,FN
MDHXL[-S&M7<WHK^)1[=:T=_ $9VL&?V60W4O1"P@4*"4U8TF_/NWO"N-B[N)
M1(\Z;V!KBW3Y'ZH%2\1NXHD+ -6^LH2W@)<E(1BB:7QE> +%64>>_/Z/@ WD
M7L\^&Z*EGO9@-L4EJ8KO+=:/AKL)_><PJ.JQ]Y-.B_@"^EX<U-:QE[>?":US
M@AB@4,C_&U&FLY:<^;\34S7^O/DZ>MN?'Y9H'AC&6/_]SS^SV>P&O^&FKT[_
M26&S XM'_1\D]GGM'VQI\/^$DHDH&^/^P2<0"K&16#3)A4.A&+[XCS'BPAR;
MC++!$-?I1?B;@3'ZCY$JEU,A+Z'_P7-Y4T5(C:##BDB$8!WI!E'IO:+(VQY3
MGG@^H5D41:!PB'A.PP&J]HM61!FO45!-S<#&Q,24J!)!JFD"JZ\:U53&#C)#
MC"S 5/4% I.F@+%K;)5D*<+-ZHNTI(Z0",A)ORT9HNO;GQE^@8_E%_. M#ZV
M/1IF=_.G9 TW9*$;7Q2+UG<_)46PRG[LW"1LJY!;L;VY)KNX&V[5!VS=#UQW
MVU\K]0+_D<=0L+J$!2/,S[Q$.H?=6,<9#@>Y>#@:#?]B>F3^I^-X;N0RI,&2
M.B4=-:PV(V%Z_+]NMK2\3_+D\W-8[N)U@4-R4Y\WOILWGH8YTIDPA$42DK4(
M_,L\<YUPDW\UVPQ_.[9Y!G7N;4X:]E75\Z[\<OAM(I*,Q*-N?AMAV7""BP&_
MC82Y9%P,== \A+DN,-Q3,-IW1>@M?9/&Z3>[<*_QSO<QNTVV!;^GF<*TIY[.
MT.Y>Q,&-F=0'V!KF!"&XN).).UQNQ<L2P?M-7H8A%(RP22ZYBY6M'X;59^[[
M*(#AFY"O 'Y_AO0)!3!]$OTO _ BV?#$BUYTZ-^*3.[C,Q]A%^%O:#Q>H!84
M/I0]>6Y=PM>"SL)TGCS#<*?QR-&"XX/RG.]G>9V;P42N15]Y:R.^"G,(;A()
MQY,K;B*&6&Q5A8.1DQE58^B7C*S,*69#F3D<'XD<@X]@3LQ%?UT>B[E M29R
MQ6K-\1B1K^E\F#=%3NCPL7F3/0SD2-PI0OTP?PMW.C>Y1J]% ?*U'0^.LM;R
M&<VCXLG8064L*99/I8TD+0]]!Z!8MOK_?6.Y#4[BJQ7<OI0^NI2.L&PB$>=(
M5"82#7$D*A,YG?VP$H.8+ LF#W)Z\3'AN],T2"D*E,K1X3+K,I=C@WG/0$@H
M&8Z_*Q!B)2)]HT (7H:?"O-7,H$=JGJ(#7)GX0,E51@&6V-74=7'PJ)^H.,T
M[,+/]_ UBT\PE?#I'  T:ZUACHD*\%E^X@<QCL \(KZNX;,%-ULXF<U1Y4E+
MV:]RA:.$)'PM8XM11$D3A,B[R<Y7-OXBKA()L=%X MP8H5"(^V?#NQ@1$R=C
M*ON""4"F#!WG#0E>T$EIBIBJC-?T(5='XF2N#E->=?[[5FI'[*#<Y$I8A\\G
M]KL[DV=Q<]B#R=QSR;8&F'U*.XG<)+^)4_0R59*XKXOXNLC'+9SHJ=A,'>F(
MQZMEBE5WB8M5O])%Q@QZ^MDJ"^U-(O.?L(&BW\X&N@#NDO!U$Y]ON/E&[%1\
M [K@0:<_:.A;99I(&S&- 4)'81VQ;\<Z+E-72?JZBJ^K?- >"ITL[KO6]R"G
M]/D^I?82,@SH)[RS*I?;K,JU6=/=S>--^L;5;(VT*0C0U@762!]C@*_U!PQT
M9LNH V3-LOA??C3^XW18M5N;/_#:$!DP6!/:,*H*>9M3=+N;>=@#!J^O*V/8
M[\KH=V7<UY416AE;( Z%;J)TT=?2N/#]XN"?DXG,-]]T10+M"L321Z??;G96
M^&AYP,Z$I"OSQEV .AMB?>O8UU17+.%DR41YA)@'5?3PS']&2\WP"GC^\Y*Q
M[$.3<7%= [U95S*_RG]V)C!=&?^Y3 L[Y%=87+9&<I&,ZV3I3H<WL1_XN32B
M=C49-NCNT[?1%/"#C,JOY3@<5_*+.7Q^X^(W)PL^KN4XK#GSZW"C_CG%Z>VF
M>X?LK8=9T<[0YI6QH@O5F?S:$5]G^C /.UD@=+TLU9H#93407;@9&)KCBQ8[
M>9,Y':"7,69,.P.G5\:8+H$+^44H/G]Q\9?X992['D(O"NSS'MF:D@JJ$=&2
MH"ORY_2D^#=A1Q>J)T5]/<G7DS[*QTY6];+&QQIT%CE1D\@,A]5,\K)JH'=Q
M-6O2_%O:E,5RBHZE]S&>=;HZFN^O0L5\%>K[LQ[/<0Z8]20IZXE'PO8XAY/%
MXZJ:.L+<0M46:]SE3;ZR4RU:FZ6P.?7F,QT#3CJ8X:]1B+Y)[<T:@;QWOK.O
M.1VP8)B-AMA5P7"(% R'6/&T1B!)T>-EF:F,-\O];,@??1WOX6P,(;V=:I,3
M8L3<B_"^_4G\3#X8^B=EL345 HH+_(+OJ!U=8RW/"5B3SX?>:ES G<S7;7='
MSLV% :_TT4=+CIG(#?<QGS2S;DLQYVI'<*$:SC>IV/$UG#/[AA)<.$KG[862
MH412Y+"%EDR>SD*S)IL"M$5S9'.(DB0@Q3UZCWBC796'[K+#S2'0#,=Y^K]=
MK&=C/BE#LI#6ZA1O$2]C_D)LOO=QN&1R=P^XC*F1=E(;+"Z&#;I]S"SR#;4=
M[AISLWUMYZ0\*1*.4*<1QT:C2>(UPCSI9$W@@<\0BT05AGO&@%(:W97_Z&(#
MY'H;T!DS-O6=[9R G^P<&?$Y?O*WN'^X;Y)K[2M'E\F(3E;X_*[$R..SH9V5
M:9?"ABZ!YUQC)K6OUGR0FVQX8$*LR)VN^[VGI;1W8#FA^#<B[CKSG4?;<"%_
MM,VY5W[9,C[$);DPD?'1<((FQW"AT]D:)2S@P7'1,+NZ)$J\!I3LFCOW/B$-
M:/ZY5DE,G@DR(9>?-1P.XRM</):,[VR2E$==#:+*S+=K_LJ%_<%Q5\P)-N0S
M%S[=Y#@L5W5"5SWFH5R%D7%.;-;\\E'&2?^4=ZU$EA3D]%V!YB?0GP:.WP,3
M?OP+LM\<>].MO6CK8=&;" 7B=2L$!QN-?6ZQ>M4*@=6ZJ('7QQM8+]4_U\&H
MJLZ0!B27,@Q54]!B%\V=CXJN2?J%V ,E3ET)(7QKX==#2#^=;2I#RSQH?T*:
MBMEDV#W&6[NJ+%*BZ^YKJ>=J6_9Y(-ZLP&@WX'-=L9F"N]7932B)1A[MT-;;
MD;VG59[]1,#.K<>15]_$\*LLNHO>L$Z+/$55D(-\#&]BRX!EV#].:SSZ__?U
M8G.Z[KW91 V8RU[>$$H<E]#V0.C'O__Q8A#G6DP3VU(6X>O$2:,+ R2:,A18
M@14GZ>O9P@-^BI@N^'/5D62 )2@I#"]@RU#DP10D!EH16W;T]A@;^MG]]9/[
MY2ZQ-V5B M)+C>"]E4$,2[%-1/ 8@>^(K*)G:HJD#Q@LV<8RL1EY65XX?B=L
M"?*,H(X7('XA.=%>V8Y]F6-L.,)E#4U,I!LW.\CV[\+*/8-&SK6DH@*%-. 8
MY!G\2+L3#'1>!('%J!K^/!HC1:<NA;',*SXP#2J1+@>,>>*Y@6I-8 Z[ '0I
M086K:W\;\=O?^NUO][6_)4N4Q/_[H]-C(_&X(,0[W9B(.I%8)-+I1L*)#@J'
M^"X;PY^CB1_TK4<YM1"W.K5UA7Q=H5[I#\D;IJ5@9#/X(<8*G2K:XZ^S\UT\
M>F]GVXOA^7".VWSV)__K3&S?>SV@SYD /!V?'I8 VDJW V'07=!O,6B1_OM(
M8IO")1S[5G .71B<51*<"3"BJ8'M#0D>8_PTE=@&^!"% >9M/8P'H+'I/.C@
MO 96!-P]XD7\4Y[!?,L((GR;0*8-\NXV@,0,T=S1(]V.'AT7<;X9@Y N#G$D
M19!-$5&<T51]C,%O4LM,TFB840>,P" /L9C!_0RO+,F-I(.48-A?686MR7#X
MCX\>'T"/R\,/K%C)&/[ 2 #<+A0!C.EA*Y P%30%K0ES%:SD P<"U97\8,50
M($6-L;#&FY4P/U7ZHQ%F1?@>4+[WL"6086KO%V5P ;Q"F+@AFL0U@1]DK9CO
M]_';>*CXUM!80R0RQS,]+/IXZLE@K#HFZP>2T@.UD"X-&0S^RQC87WHO_ ;2
M9\"VPE<44;(*#/ /45_%?P7(66%*PVJ]CF!M(K(^X\=.5=D<D9/15[1$V#4F
MOY\2/3!#A86*0!<:,^5E<]</9JHIBXRB&@R:"PA!WQ[>L&3 C+>9.-SZB]9#
MX)6):"K1'?4T=43>)ZLS6.< *X4,/G ;;D@WI!%)/QA!3U=S1-\+.];(&8[X
M!18K-M90YY1U%J1VU84_&_D$D&DMZ61@RMC4=).GDJ=NRLCJP\%%?G8MYB/U
M A[PA3\I+'77P<(NQYHD(!?\%17C&): ^' 4C P<^]\-)+"WYSQ]M5'ZK"W,
M(.X;]D^&EP7+O<9L]K/,(T3N"OUA*/NS?KK";F_T^@-[\/GH1_CHY3%2MZ %
M$M*@=LG-:P@E8/P$\K!=J^!0 S02 2NDKDEN!.+&B#R55%/'K Y_)\BJOJ*U
M'<R5#(YUO=M">/PFW10&:TO9S^Q\2^']F,A=&!YB81  OD6QR]2P="621$08
M*T:28IL/LL137QTU$=^EZ@48Q L#BDT[I;8^@  !%A$BY*6*@'[X#YY1\#YW
M("[UHX!0I43A(?6(+B I@56G.IM;@Y2$!;E^Q!M4*&)1AG:LA^H!^'9,)UU5
MP>J")+H>:JD>/B5\@!+"%T8)H-J.5(R;1.=90SUL\XP0KY#DRSUV,=")I1>Y
ML(L:U2LUR]*]\,MXS%9-15>Q?D90$*,9H3E'67 CKH];'\"MR,7A%BBW;_I4
M=HIJ8UU=Z#FS"9U;UBWTE;LV<9,"3-IH0V>A&_ZU1K(2J=(O\PMHI^)P2LV>
M<ZB:!@GH*ICKFEC)\)'R,T@9O3"D?(_H7XE]BQVYT@'>KP@ _A)_DE6%HJU,
M:RI2U]39+19*3#L>[*P1)):OB7*WZ"<_V^'?=IN0>YR7X!/H\YHH(WW]B3-X
M"SA'D3%01<;4J6J@(ZPL;#!\6U6W-XN7OR44P-MJZRK@@@498"O>JU-:DSLK
MX=+#!*3.8#4"MI%-Q1HHI0?V'<!,HFH-3]8,@-M8)E&5[+LPK>M8P]'H+LE*
MR3IANYOJT]:Z?0_P]7J 4\3MBV0)]!!MS06,X>_^:R^Y;:KH*Z^0+:6H7DU]
M/CO].[ZS^(J=Q8!*/0TAQN:=:^&$'?B!<6_,6UH,1CA0OA&VR'IOX!N^E;!D
M_"\I@K(Q;+'G1SYR7;4'#627JMD: Q&/I!O]AU$.]%J>JCN>?CB^"_KO?N2#
MY$672,2OG6+Q^4$L]MVZ'T7*Z67A9,I!PC7%C'J7)(B06:J4I?XZ* @A]_W,
M:DM=\TVO#R!*[++PY*A>URUCRW+#]F@=QD; 53&<8F">MEK4:,,.MT[F!/S#
M/WD[VJ^MKD9_BCMS .RFD/1[KP5'F)^8[068&?A0&7X\EC%F=2%[96/9F'K^
M7WO7^M0V#L3_%4T_P4R:\NH!=W,W$TIZI=<"0^!N[KXPPE82%<?.6#8T__WM
M:F7'>2>0AQSTA=*0Q*O5[NJW#^V*3C>(>@(K54+1E(G.ARRR@%>2NINK\N2K
MU].3+F\AW%V^BMV/KF+75>S.J-AU"&S,P?I@U\%Z$:JHR6-L^"GAP.R$_6GK
M>-IFQRE%X*@R:8&#U=2R=/&(UM>9P%CZ,H:S)8I5!<VC]+"F$HVPOA(#0J&=
M$'@Q"M7HT3L4E2Q4")$'H2BJAQX$FMQGJ4Q12[%PERNZ_<5]^$!6WY,!S"Y8
M\7Y(M;!"I#%OV%PHM3&I_T'>(71M@8NDD.('.)_!\X*?/>2S^(DU-(5J ^"=
M_G9)\4A0:UA4!?@LT*?R!*I1E5V82I<GJMSB.L$0<-G1&S5,0/9T35UQ%W<(
M;NNR'8VE>$^?F09+%YVT)I**G6/UX9W&)O3:Y5(?X#S?RGPGZ3K3\#Z.V4:S
M<J#. U8TTP!.TZ9N4FL\4Z[A1P7>(1,31\-:+/C27<U<X%]L@(1>XKRDP(/A
MU="@F[QT:DKV<41^,.*+NZ,CWJ-B@XZM!T>?$H&I@\*AWWVI4R)) J)\@#XL
MUO-U0%VE#Z N&I4R&F>"3.D""[K@:B>"_0!:E2\]XRH)IN\ Z@6UA=[>L4()
M3Y3)RT0SBW*W(K"W(5&OU4^& 'BX_R/ULZ=D^$G/?UFMS[5E1X.PZVA8Y.X#
MI33 $^G-G?H/!F-&H N@M>3',7R*RDQ AM ]TWB1%)1[)BPNPZ<H>"I">JK7
M!''&,B\R,P\_L"1,VQ8_2PS/JO8"7<([MO \#\CNEQ@ZF5Y IIMEEFF0(W>I
MI[R7>A 7F5"1>EFL"#]%=7G#9>W9_?R\W'MB>3;8H:XI&IF21D=;A$E$W8!
MW^['M!X[.MRKY>@8#FW3JV#RTT9AW'"JD%$5.(/=0HRT<Z3_.3H]WFGO3F;$
M^*C'/ OC.8S7X1-)IMD7@%W1?.=F=?6Q_"W3-LL*8Y<2G.TKG YE3KFYPI-,
M)]1X?7@+<<-5-QP8N=>\M1T(?G'Q3!?/G*\#P;%_>'IZ]%'<\^.F?W_4W/OE
M_F%?-.^]O4/_<'_O6!R(CZ8# 7UBH"_?\AH33)3PC+TG\W4J:%S\>5F[O;NI
M-_+6!$LD$(,084)GY43ZKH>B>J;FB<ITQUZ3'1O5\[$AOL>IU' *)"'3:UP
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ML>L2?#4@_21.Z1L#_HSI9&Y:F"M8]7OLL4*/:Z%'8;Y')W_AO0'K9HW/5?I
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MX<WP*,YW.:T/D=^#?]I))_CC?U!+ P04    " #+@!-9OALYRO^1  "BRP
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M!A$0WRHL_CZI'S@Z-H/29KB3G2E:I+D9NW9%0,R&.ZQ,)''4Y[\E$=;-3+*
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M@FM>C]6I[AZ;?%;J6:]%@Z,)'!#:)9W&)04P$]B*3E]$,^NK9PS='G^E_]R
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M*.#8Y!>33#_#O%HC(N J7@BM$[?$0VM6@U[Q171PORO-&5U*6?.L3ME$*E6
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M)\G036JBY&YB TTSN&?N><[9>^;./O?N>V>>\_S^6']VJ/755U7OJG>]95X
ML[K@+!R\G4+[^95SM1\/58JB9R=;P')D:IABD[F8K-:$@:0NF5^^8IA8NP)[
M+9W+V O-:T!A$E82.21%!+6X@1[Z%KB7S^":]34"KVQO,>XG#<;>^N)35+<Z
M%:'"F8Z>0.E[<J)KC1UMLO6V>27C\&?C[^W[SS-R+L< ?.5Q-Q9&[.L.'ZBN
M[+6&2O)M>?/,I-=73QR??X+86&N:?N=2;G[,-4#T(4JUOBUS=;1+B@BC.F-]
MDD(G+ [.6]:S_-CL*_PZ/<'OM@[EYD8/?P14G^FU>C*9)M1E:#?UV<-LW0^6
M.O6Y9.=5K<7$#FC0RF4]U'S/0R^!*65/>:U,=TA$FCIO/A(GK>XY_J[H5K<)
M1/'0+KSU5M-K+'/XXL[[B50'L#O#>Q.34/G =0"A+<QATOE,DKBY CM$SR@"
M9HY+Y_5<]_>M-_ 35\###4^XW30PN+(8M+SDKYO[%2-\.]W5M5 HS:IE\I.\
MYJ-)ACO?#M*^&T>),5]J/\\>%COD?E^[ZS)(DC^1M:.TX+0PXSJANMW[?>:?
M0/<N9E)MWGF'_YJSPT90@#Z0[.:K;QVT7E9W:SLBX0;(UD#$-- P7DM@26?X
M8[GEZ=CS E'0HIW;^[6'W@9URXXC!#!--%U$O_WT:<'^8FZ%]T@:>7&37 X0
M $EF1O7?ES9G7K-)%.#[:.<)C)]TF"1$M=*UT$([[A+[8Z3 HJF+>H,SU>8C
MRU%"XIK-O6_#ZT9NVTNX(U8J)W6.=Q(6GRXY49#(,L2'2Y-IV>3^[MTQZ.T:
M#7F,>3OFR5?;MU.XY3!,-]R+PS:O 0YUDF+OZQ&<*"$ 3LUSYD^@#7=&1C4F
M(;/3'8IA7N8TS)>%A:5M9ZKTNEO7  )GX*T/EK"3TD A<3=J);2IKWFT^LL^
MYJ7U+D2_^KP8)1=_Z"VQ@T#HPV,@L:=SM#*R^J+6KWJEKN91D]JKS]JX5G5X
M)&U$ $IG8 >^,21D-=!/DA7]NJ.W)Y&U\*K<K)5E(V;,:Q?0)9B*^Y$D6Z_V
MI_"J;DY#);@_SS(N<HN_K<_&*##ZX5L;EM:@NG[CR<T:0$\<U0B1L$9SHH>>
MU\B0BJ1004\.72[IA(+ACI+P',]._BE%P*<TQ%EWBCM<?7*?N1S%O5T3CW=$
M,;]"<EA#_+(NG"$<_NHW9V\+MU(11M"OA]IRJ@2.)5'^\&-JW3A))E0PK4EU
M>*/W$5M>4.!$ CH-5;':TR+\RQF.ESCE]&,%8I1$JW+'DGAP]CM!G5K;""?G
MJFI7+#IS57;*9B7N_IV?2AX6YH#G>536RY%10TL![&J=DQJA.;6Z%\5^%!&9
M'!JY"MM9YUXL'MC6+[NI$M70+Z![&#K>P-ZY_;467Z_7"$GM!@<J%UFCD8Y7
M-- &_IWDM #V3$\7]+!#B2'$>TFEJJ)<)ZM<FT3.0?1C^M(:(/1Q9 1"?S-Q
M>!S[ FW7)46(0*:%.X6]/H;WE,NXYL;PN!#*GIO1Z!/=/:\<D6/6ID#P!M=<
M XB;7&V*(% %"Z&Z)\_LP!+M.0W?4KJSHFU%XNYYOP/ "-Y&R8:I*.0T7SD?
M0'?6GO\HN%?,SLZFM-!D4P!>/_+"C)JA+5UYNTJ_@1YAQ%9$GN=\JY#_KC-T
M>_!CI0!OC-1ZPOUP;;SO=_LWBK #ELY95O022$R\G:-EMF$OK>+\4YL)SC*Z
M6C=P;[7;8A JMU,2;[I)NQ3M/OJ^<>JDUCSX@0Q3.(W!D$'%P"YH0PSW?AON
M"V53SP?H.>).93N]^FGN$N<[PC91RMPM$T\C=<)W^0&;0]:'XEJ.Z>KO-S*J
M+'7<"O6GPP7\GQ^;BBWDBK>R>;"=G]-'(HW?U;=<)4C8QC_N%]#MSGMUQV4T
M'CA'5A/Q*LXXPKWTDG))GP^E')DPG.&5:OJU=J $WLE'%W3OY\4>O6^%IPBJ
M$+$4T/2@%*T^J(3"+TG+2_BE\D90L>.#+X5U7[K\;U(3H_?146#<98KNT@<8
M-@,K T5N]?V5\U7YZ>E%@1!JVW:6+ (''DC/;0(V";'QY/PI15ZM(M)RTOR9
M3A$U7?:<@[6.WE7/<DL'B*K2Q,_R&F5UJ3(K<MM/491X(?[+I@D^XLDU*J<C
MX*:KLI-A.15)^LJJ29YB&YZ5>KT0B)E)^$=""-%/1$-J2_51>+JSL>F*&$^5
MM."';M&X64/91VT$#!]NVZ8(-B:;ARZ[C_;PAM%3H+-_;NT[&<@(7UHD"A^9
M:M9\;1G?O9<R_JCV_O?,Y._NVF_RGD[GBLHIVQV)IH<Z=DQG:^4V9S<_GON
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MJYR^)[G8(K?ZX,HS2M(EHR7XJK2J4!G8Y4TSN?M12?SRV[K _,MG@C$FL[W
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M0%*JM(R7\<H#ZA?FIZ9-T=JM$5VZX<G,AR<J^D$D7EE,9?,OUP4QTK-^ZI[
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M"1%66L;\!*+#5E&+**^=*5A4UU+1;AV%[N1*+RRM;/JV(A2N 1V 0-!H_#4
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M93I_GT \M,2K5N78(Z>+TM/TWT_72V .GJ\C42 A<-8_U%1XUT7D$YFF-MV
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MGO0S@5"^T$D$'R1;ZF(VOY&UV#I3\,EM75@2R!M/[+^C-3%2[>))@GWC;R
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M]3JLB&T:::%V>;HN\CN62"QUW,>,K?D$.>S\[1A49P4_0;\1TSL=$;H@R]C
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MEW8I]5JIYM; #96/]B>,9#941W*LGV+%7K\S\8@F)_3S'V*BMR/O,NW^3LU
M3 =SVKWV5_8%R#7D_LL@U,[6YJQX@MPVR(BY>KC(,U9*].5@3(B (*FEHE'W
M68@!%BY[S\O0=F1YM=O78,(@W,UNNE#%WMX-<A"JMD$GO(J'_&%YX8*L[RH=
M1B[I0\UD-^=7_)^+L@\B.902+P<# N,##?_41E>)[>NH)^J.H2;4).?4J^Z]
M20'LD#ZD)\M>DSNUO.VVATTM!K*OHDJ'H089HTT0!8Q=$2;+X:Z2(Y?=\0V
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MXL<H".;\?9ZM(RNQ3:QW^ZQY.[L.$U^R.04U3TTJR[6X/V,_91K^5-P__=*
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M/E4BZ;)B0Z\W1K9Y$?TMZ>5RE&B?YCDJ_FI;9'4I7'"?\$H(S76:^RBW:'J
M9@A=R<RFL:6T(U;F<FHU7%8%#V*X6]424OKKDOU#ESI?F&F;5W P,G-;!M:Z
MT\R23M^ 7@IZ,&\V+!1JX_^Q@E0E(3MFGM$H+-=[1$+!7^V.3?LU8[S-I8Z/
M0@09+5VT\*A"^R +8)'G=!9FO!EQYD'W(>H.) CZS".34!VC=B6,1U2^^;XM
M3FN?^07NCJP8N7^'QTKY!;5K^151Y T047*&T5HA"#=2NN+*[CTD.Y28D7^5
MP<J)$!M4.KG:A*]H()BO0[BH;@#@EN?B R.WP[_?:7S,NVF,H;O]ED(U$6E$
MQ^:T2L\A'70AF9'_\U'8U2,>;/_AW*P;8)G0?^6)#_.!#'8L[N^NF(X>;G]E
M )7[)[>)-1]Q<=DI7KITZOWX96=!\*]9-=S!A>VXTB$?]W+-L1,)5>U%NL_Z
M[_=>)SDG=%QFVX.68Z"WZGNQR51]1J C-3_ZA-Y&,YSQV8>"X*=5X2;5S]AP
MWALIL8KU(8TX9EQ]&88>CRU_'RLUK?@>[IY;I4SQW"D 6'Z.LV4;V62W 2DD
ME/W#/CYI6H=B%A4$'2KTB)5?BU\/WW+ KW7I4[*CI_V^ZU%K)V:;:< =!?]<
M7YX51BS+=,B8Z=BQ'?_BCTD2K*0H!S/DSX&)<+$^UF^K+5;?QC574G:S"UL*
MGKJW,+\G\/R$N][&G%'0(Z5N.S7I%!#@N,33RY]]1$V/.;W-1D1VI&V'9DPH
M,8UI)V,NO]GP[Y<K!Y$$7YX2;<<H(I!,?H:B0[6,FI57^300"".[%'P(==ML
MCD7XZ\$9-B/F8WS;O/I@0)2?Y^D X"MA9W=W3D:/>MK3+"$;OE$JOCHJK,:U
M&G> WQ"CH'YTG*]W51-7HX9M%B"0CJ/29 $[03ZYI0;GWJ?YF <6N9:C/H\/
M<HRG4R<_;C]HJP1A1]:!F(P^![9?4.[9S$D3(]:N%#'>V8B0]E=E*_??T.!_
M+YS&P-PXTM-<M@UJ=U50JO!.QCLG!?9O-)P*D:>B]]Y.KU6L?_-LH_<'+>;]
M29$4\US)"&IAK&W1CEEU>C!W#V7ISH*%B^TH>_TV0,K\[VR>IN$=Z).&2^^\
M4_RVNE.R&JA].R:-=MU'XZ"QTTBH)>A(?XSL8FN!T$EY5#P)0B/ZXH[_D!>P
MV3(#N3J+O;XD]_T./=]G_'/*$6@\<]2&*[\$?9J) W".FH"&??>",WZ.W@"=
M< SNAC1C5'"ZY*9$6OQ9XS#$^[07OM'D?S9=IK(*[Z:G6_'+L"K85G\T8V 0
MJ?F@X3Q4(&CFS78,L2/>YJN-94C Q0U@DBGELJ&4AJ*Y7/#OJ(>&P[\O!J]*
M/?PQU*D].8N]NB6<_CLEKN01]$>1&I3%3#HO0,JFTXAS5-+8)&56.M>N8+87
M1$08&)$ Q2:673[PW-9;7DMO<AIMVEZQ:,L@]'GX*F?4)%EE<\K\3(>H/@<&
M1LH03\ #+G2R<#98<4(=G>:N5F_UP[V_S056X""G(3]D-4#,+R^"Y<P/5??Z
M):EBL;(/?7;-,?&U*FAU +_TLL=#GNZVA9HZ-9A5BB.?F%C\4*!7J//*IK[N
M.\:AV%!/55+$\5$?7HVVA06Q:$>0(C-3% ,18#^/\5:8+-O9M^?D<N#6>-(M
MV4LSX9(DN7SM"RU]XK'"A7^P169@.>DLG5W-?84)M<>%LYG%.!W?:@T]]!>S
MKHOHO-I5@EZW+[8*%@56Y3:VW_I86'^"AT#*:7E*0WFRJ%+KH0+K6Z70H>KD
M5F3C3CM0Y?%><%MT^BD3?L],EFF=9IS8"S5GJ#)P@B=)M;(=%J14-2?V3D,)
MFR53VD#UK$T:LR%==U&$X'D<S:1XK$*N>$_X(.OIG5Y=L[>\PH4]?+W;2#UT
M\>>,NTHY"&=_C+*0KN 7HQGNG''NW5\\#JX%PLAW^#_JM>U*>)7:>]N*:_U8
MT3BM,8)]M#> EF(IMYU=^:@B_?UTJLB-3\Q:;]H=FVITG:4-AB%%4"R$I9Y^
MEZ#-/2N*AG;:]PA2:,-'<"WUH+I>;A$&WI&JEN'FSQUO@QLX>P/LXCG\4H(5
MP2>7S2N#(,RS3=^7]-#1+2FE33H>*3I8*NZ)&HBUPY5W/U9JNJ9?/\I;)'UO
M0BQ^9&M@\WS&RCTUM+%PWI)_;F%WO)0K5R7\0<<Y;\U.2UMN[$#0P!)PVQG$
MG<%157+K^,7N8O7B^X:J/G&X30<O<<X=B0%JFHU2-XHN'ZJ/(K=YE2@_1="!
M/JO[_F!4V?>R)Z$X\F*0-).-&#[#;Q)A_FKR;*!_+HZSTP0%*0'$2E*%ULT#
M?YJ3JE*HR'(HT>R>#^*#BJ ^Q]LR9"5? YE@YH!,[ZV8F4M=]A.VGDSUZ)R;
M+N,FPWMXV"&_X=(Z6'_[IZ3T3H..5G0]XD-1^C\.?.OT37EG][+IN.H-TDW5
MSRT7Q)B@N<9C+3"Y7-^\V]S#TR0KSGL]-?[R&3H9]G[XJB"_H0P""Y:AE\K+
MM2K2Y^K._3'_N%>Y#S2/>T*-VM1^%_@9S.*/<-T.XNC<*W5HNNLSY*K94?N"
MS&_.NE0XTL=3+)7GW 0Y;K8]VFC'O&J@XN;P9E612KXQR85\5?9!=(_8$OET
MC[B),+0:\'@L9VO&*NFZV>-Y?&55LC4BQI0$CNNDH3XK$]Y?K8EXZ&W'-K]]
MYO0E;TGU?7\MO4K?V4M?14F/H@$/E*\VY$U-Q<% FE7C8+V9BR.P=A7^CAH\
M?GR6"?GM.=7R<%L\D=?2M>#NLX",!G-6GR["D\OL@PVA19V4*[X)TQ'[7\/K
MS?KK+3S^^=8SU.-:G[GQD,1AT2UI@=U>#A]QL;':XD"PX/WC3,BHL*.CC%0X
M36Y6 "]/$[N=[RH7_%57\MGDFV$5 M1 =-B\TY5*NL+7S1X;OW]LM5(ODX%8
MW.FW2.UI7[H_76!XG'@$,RM39SJY&E#_G_;NI];I@A"_B8G$(X!#^*Q(6VI8
MQ!4IT74DC:]+YY12D:Y\W9_-)T?R4OSUC %G99$K/-VJS*NMH5PGJM(O]=?I
M>&S-;56MV%;B/T3%R)QN",V+W:-SX(KAZ&OROA3&>'3/SJ>>IGAXK_"0*GHH
M%5H>4L]J]X#<!JG_^+*!)WVZVR0/1<Q@J,W))JHN.%&3V0$2*9X1Z0>;T[=N
M<"]9-53O]%!C7N#Q-'493K.@V;-V_9/19$?5FT%=O4)M(LM[SY;8T?/DRI-5
MJ&VKA0S=\AD=)GO :4Q^4A_SU>S!<>W#!SHAF@# +\MJ[P]]+4/_L![:O1\]
MR;.RO8#/"&#\ECV]0N;F/6O)OL+%Y26P^,9=6=XVSW4RT%0=Q(8)_J%2?4+T
MY</]12%1"&#"A_23:IB*CPV0%C]7P@RM$DW3F#G0,&\.G?=M+D!W_J <I8VC
MTIE@,+]5:5'4(9-_O Q#?^EO=[][HWO'N_(XC=\:H[J%&J-"(<'7<@CWC(/@
M59V.Y=,,J(^.A??*?/R=I')Y_9VF8P6#-3>IYJUMOZ%%03'&@[KJU7Q)WT\
M_1WI,R;0>: !9>D*(VS3F-I5';L/K6Y(:JWGDU*Q2/V!?+K+T]N#='-LV"+&
M$EQ7B;F[&DNW+9R:WPTE19;HZ8FF+LF.W3_<]?EY8([M@Q253L/RGBK ;"!I
MH9W&Q ;6M-T_A;4=\YC?UVG'U^'&EQ>*@NF)/(NOL-#MV-"HEGO,#\+V-,M9
MZZ6(E]JTAO#]?M(2)Y;J;S/<'Z^&TEE_BQL9*!%UE:<YKW&5:MC(&,:JW5E:
M67AQZD#J\WC*+J=R_$K+\6'HX,M'DZ=%?-32&\&Q#M9G^.&O<;'R]T:< II%
M4=1(<+YR\O^Z^68;&$'R[LZ.ZE_>.11S V"YW@#1XC"GIG"S$CU[X900#V*9
M'Z+7FSU2<HC%^%5X["U;?4W[[!IF3*6GGQ!O:,M/GY/^-$*V!VA[W7-'U==Z
M.1Y9L!]S_-$7Q1K3!!V^-CO,A":;8]#H_M=+!U58T@Z8TXS,]MZ^':7M/Q,G
M0FU7+YLQM6@O7S)#]97=]0^I<LCT2!L;=AV[']-BNP&0;6/G!,QE<;I_Y.&N
M[ OU1>9\V'-(/^F5"V:YZ+,?)<YNQO>!UKK?=!!J(XBDRQC.0\P*>O:0F="8
M,)GF < 9;<>NQ=I"\#HE3CQP3^*/1A7ZB*%^=ZB:$(\I%%DCF@E-:F*_A"/&
M5O.CN*[4T=J7;YJ(O\ME%6HV6LW?&4F2ZZ-I[T-:7R3,SNLC8:9LJ*<P3I]'
M!Y ??&W;UZK*P2&7;:#HG(VC_'_WPBFV"Z],B=)SJ $9'.9OQ!$"IQ2LWQ?$
M^28W[KJ@?6@CW! 5<BE8L<_2D.[T83O*I5&T;.OET9V.K_%U)M.S"H^A&Q<Z
MH3,^8I,EJ(/UM'3Z&$7!!>=?>_[<NAWJX-!IQ2&XKSSTS+-M /#6.?U2\AS)
M,:^PWA^=8']N<'SN>7KE+/[K\\-L*Y86W<;:Q=*J8D5^.ON5'D]4FI]4<8?M
M-9G-0(YE34-,BMA8*:JUVI=_\N3N#[(?1NR0GR\#ZHUR0]4DM*N1'9?UDG*K
M-CD'$]EW\^8>)KDYB8=0:<AKPD@Z'[R?=THC/,F$&H;I?DM^\(E[M^O!##A<
M?M)$;5GLLBW&5XRAJG4VV73:H'F@-JX+*I8#PH/D[9C%++:6^J!7_0GF$?#.
MJ2,;2J?9N<6M5(.:?JDNFT\?[))XTXAEQ6CF<;'355T],@A/YCX-'&M'$Z==
ME*2PRE8VQ$A]J_(&!\G*2P3:Y:]O,$41 MZPAM+4DL^YX8X_8DHZ)3XZEDCU
M\$5M;.J*9\3NH*X7:\>8?<VT1I7QJK85='_%+^V%+ 6H4V]'!4%S/?/#KTFW
M1JT:0O)2LA[,Z\P^J$[PS=OTD./4I,229^$[5SH/]1RB<.DRA@IY7SK0Y4C3
MUGXZ^:SRMBH^)_*^EAR4SH*:J?!>@Z,$6H:AG2$77SF^G^7YO'++Z\ <!A/J
MC2AS5%3ZS&F^DJ=]++:1N0I+!J=3"LT0MD_]!F!Q@"KUK E;CL0T:3EY%E@Z
M+:8TA)Z.O4A>AE1BD83>NS+F80+PT_-3P[IN.<8)D=DJ_?J?B>9?V;D+ODF9
MO$;OD^>[YC[1*/6^D#'5*5]@)@>YO, ,6=@X^277W-G4]M^YU-%_GZW?V/KQ
MX_C>H.C@4<AYLTWKV EV,L51LH1^*Y>1BLQ*.NGOZ1V!J5Q$%2.QF_FA^M7]
MY&ECBH$BI8KEV=-WPG3,7Y#.5]FB[=TD/K#)W.^3K^,MPKH(>9[23M=IQ1B+
M%A)3^)DX"@=,SP7&L(&GJGEH?C<\.R4UM";IFAJKKH*X/U$4+Z^F^%4+)RZC
M=Y6XA$/T9I6(KC2-IGUS\7SD1ZH"$K^9K4LZR_0-.N(#IWI_34@K+3R9B6V)
M"DS$+'6UJK$]R^;/7Z*"X]3/*>:GH&BGB2L*I[0&W[SIXU[F 35(^0U@%,"-
MX=%LF#!'$U)Q)LB]*13*>119K2WT]-Q9/#[Q5ERF;GVTQX8MH]N[G>#0!;,Z
M=*2BC$;)0'W[\E7X\,F50(]-S5M\/!9 C.4T$W]LEFM<LYM%0UP97]05F[=]
MB]C#G5KZY->B],'#I$P?4?1CW:?]-H) Y$/?R9&6O6?6SIII&Y#Z<K7+QR;I
M[C'1,5"U]&:;!$Q5FX\X&JO1;J#%"P5V_(VX ;8M-F7H+KB^O]H4=FPGT^NZ
M)Z<X1A#[P2+*C;H4=!CU!6G9X^M[\"COTT/!?LI[WTQ>N)<SNC($7UTGV4UC
MVYUKP>[^06S*,$B@U EBB;;@%J%.^;_/SN[K$XP/"GY13'@9.,LN$"1N?HJM
MX[;L0)YQ5U<YA9? T'I0T\'?4HV6';0>N*41@.T5Y;Y97/9J>DM/:IZVRM+V
MP8M:+$< +\A32E0R^(_7(1S*N3;IYKU$7EU?6=U<J\+!H<U"PV4F]BJ'J,\L
M#6IK40IX/?BW+_O^&Q Y*@LOTL%T@OMO@+N,<_<?W "Z#?YA2LR7G^?&I*"P
MBZDF19EG::=M$!JI$(1\$O]F1@UE78J]F9V"3-B.]X4BR=4R:1M3?/M&ZSAX
MT3(/3]ZI.DR4D7WCZ@9(9_>(,H=%H6*\5P,@_V!6"'BWY,SUF#%^N2[VJZ^-
M5?/R:HHLSA*,_AJ]FT:[+!%U$'<E:G K_(^];W%[B_!/(7B,/Z[KW(OR0EE/
MJ;6*\J4(*&<0LFRDG69/831 :E=^5 ;@,9+R'BMZ8%:O&T*'V0B>OP'BYU*3
M_]WA%9*_J^R40DR^PLA;13<BY=D?.CA)K''W3,3CH/F,'TM%7K29L--@AY8S
M8#HY-1$;;:1/I-[1%AO,/Y*ZTI\0P,/'CUJCZN'W.NL&O&HR2F:L)TWW>GY)
M])OBD76TQZ%&&CR*I9VCW-K7%3<\:%",&Q$'I?;[KPZLZL923Z7PO0VY')9I
M[8I*])(N88IU3%$P4(6,9&*:DXK;*B.)T58+YZU LQ?,&RV]WV0GS*81)#!G
MCYCB2&=A+F05NW@.:718BR*3%^W][7T#P'^DOJ7^42RZ\])M,\K/UTMG8!]5
MZK>DW)1Q?9>FJ5>0SE"?Q[;HV65'[SO;RQ)1CG$WZK7)I0A)ER(KG8MOM"?=
M6>>SAA,YKU]F=7*362+[?]SI8Z6A 8\!#-U9F$HE-'UUUX7=CD?\K6!1'DDG
MDQ-]I+0,.Q7Z^F"'CZ-25$LVV52F#8*=(</75PYF8*L/VNZ:O%"]FO3026=)
M%4I>D)G/(NKD7G[7;T+(/HB[Y4R3N56YO<AY\*O<L\QHUM 881A*JO7:"I4(
MI8XJ YNO!7E94'<#WCTI9;K;>CY4DR+L+F\<T\T%>IP3'@K4,:I[?1\KPC(@
M!WFX8- GU.7I5:UT-OR8)\_82UJ23AV@I1/Y,W8ON4Y^OR4B-7#]4=Z;"1-V
MYK4V)L7L&X_9-ZGZN)WOK(_%I+@P?&"6)WQ#L"'WY=/KH7$S,'V;=#!1<@^4
M7MW:3=9VU3Q&IG<YSX.=%7L9G8Z,'<W_7U\DB(N*[Z/^8V69>:> :3F9"=2'
M%-QBR\1/F76E3>.@GVBZ&]C[*IL,Q[[+8K3D::@000"%/#FQ$^8/GWI6 %T=
M^C"];A?9#!J41KD?WP ,XUML(%#O;X7)Y%M]DJL$1\3<>D*,4A\REXL<^+@&
M2_/24/F[+&&V@&"#I^-3V]'EH3EHX]"]JM]Y^J_6WKBFT("2 E_XW],_?@[Y
M\GM1(+)3)]IBU9!?"NMZRQ2I$>WQ:J&OC451>IN^;G;^@*,Y>8\Z\TC/$A55
MML+!F$@]Z#*V5/JDT IM[9ZH-]^6(GQ8-G,_Z0ES.9Q=LWUW\Z3L_L;*=6&F
M/!KQ=HO=%8EC/GSREG\VB35+A#.8_N7:_ZCEJ\.BBM=N-PPP2+<TZ* @B*0P
M-(@2(HV M*)TYS T2 \MH,30)=T-4D-)=Z>DQ-#-]9XO[G?O]YUS[G.><_Y8
M_^_GM_=^U[O>W[N6<2A@4X?FV6>N8V0(O,=)+NY5EP>B1$!!$%8<]5E\O?'B
MR"+8AM+8;Z>=AH(DL5<O]&%!;PEIN1FH)@!P7_)U%X-PK+Y7^ %*0GADOX.O
MN,K5^L^QG'8C%</S5C&ALE@1G16CX54SGTTT9"3)J9GI,7Y<1\"-;L780"%A
MZFCOH!9G]TRIXAFVZ=/=QZKT&[9 I6*KJ*-_I$4_.A=5( &&O1CM,)P6#NA0
M]HIWF.%GU$#OL=3->!W0,XKQ&7SS6R/#.X#.#ZY&IMU8!IZG+N_LDW8NIUM%
M"U5.&"&=XMHX4((X/XR/&%.YA ;A0';ASHQ6I/,\7QNBQ#''(M%A^PZPJDFR
MZ*?MQD4@-BSIUYQ^=,&/J7<[="$O.?",V!'6 !'T-PY _8=.)B//^98C\I=:
M$'QZK?SD,#&G"YQO=- C3@-Y05%F4W$#):DN.^&3T[^_\6BY88YR@'6C9%N>
MKZ=2>Q%[MW77C-H>7ZT/-[[-;$G*V<X3=#,-[^U59I]#.)Z4*&9](L!E)H$Q
MGZ418U2C)[N(B;_K6$@0_WX^O:(6I%+9C%?N.UQ]VKT6J;H8&N6A==ZM17R
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M-*U$Y\B5"#?2AJ8FPC_Y['1G=$>2?C#,Z]$?;JNOKFQV^]640I Q,8*#?(O
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MT>K5W\-\'GD+" ==QI--*UY<+#_WB+'Q2$M0L@\W7P^#R"U%<2N.<A[3MT[
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M)9>UU?Q]W7]8 V+<3?\O4$L#!!0    ( ,N $UDQ(UW4):   $BM   6
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MXXC3C&'(:359<D06Y=C*30J(S(U[SL5?F^=/)JS49WJ<0Z]4!?AQ*,7'?51
M1"C,=@8H%VM(6#*D6OD8T4T&[2MI]+ZG>MX%;6<*9H:0U^1J]J__*N8K2(D3
MQ%?@_?BP-O(&&:R]ZD7 ;+(@=W07[;.)GQIXKG(TA_OFNQ@RJI+UE2^BM3/O
MY,6]$Z90&9LHF-3]XRWG(.E)L5E!CWUE%?_Z,/Z3O'"A\J5(K=.%XR@ WRE!
M]FD_8'60DVUP_$&*E5?CZ, $#9)*XQP&5,"-VZXIDB99*1],0M3M;>%S=;A'
M">XEQ7\@NS*"HV/CBSQP5LJJ[@[\/6$G*1.S@1 LJL9MQW>VNKE]=L&6O2VA
MYA>'J5N33EGTT<G+QTRR&8IY<IBR6:'#UTD%:X492[#-TX[&HRW16$*&B==B
M%Y5OB5/$>#J/,>=NBDB\EP4PL2UI#!D!-SH2II=8/7\J)&=3+$$>UW2 9M-[
M&Z9.-3N#YW%'X5\>ZE107E87YK@_I'PF)\^G?37QKJ!W?^2VV$H_9SXJBVA5
MKRQUN30VJS7K(:*31!*,;L!^JB](B6QU4P%\C"1B"IYEMD[&$Q\[(FO@"2):
M"WX>H(3%[,T]3NF9HE%$XU^LR_Z>KZ14E[(8,5(%&]$4U(154U(]XF?ZC^*U
MLDBE70+Y;M?+(__\T&0L#5<!12J <=B(: CUC.X7X^Z UY3HB^+[I.+P@I_?
M-'@>[9+OF( &AQ7;#A*H\BAI7HM1!X-FU(I:AV^5MC46-$7O[:OV97KU5RU-
M3_3-6>)6@EU;J]O#5Q;5,/<6!@L+VJ;,%%0K+$%]2)=!3XPW]8,L/JB J.*5
M"E CC&$(AF1:\C7;G'62]11'F@<5R*B*Z8 YR#N4=A9UP$$^%#+R*I\X 21B
MGA,(HI T>^;.:0?6D[;XL8Y3,=%O[A1N.RJVJSSHJ*C/?(3<\.O0'3Q7PJE[
M+7LJPOGTQH1D\.(R[ 0G9F8%QK]6Q=SH(;Q>.47K7LF?KR S@T+D47B/]E%3
M624O1/2BCCI(M_Y6.99XN7?PV$)M\W5;<TP+Q?O&_%QE4(KX"2\NK7F]F#;F
M4#>&61N$9[2YK>N!8VUMYD;W7,WZ<#SPWA=X/FW2!]I]Q./F.)REOOX/94$S
M=ARG@:?#?^!\.WAL_<1HS4N47>/5J@.V[ P7W$HV%4+,#;GS,:RAOQ#:PE<N
M"+ZIKT3:WA?Z.OS]AOR7S$,<=7*8>WQP^?>QI%;* C<-^D'A(<L6=4GRQ8]$
M>\N?AYLA$IU,35H?"^01G=@#\SGGN10UA9)52++6$7X2N^<*LM5YT!^5$2=-
MUW)Y(\;HF>OZ[@:3RS9&\G[=!&XK/ ,RE$V,->'T\1Y>4&^OY2/>J-@.]3^8
M<&"BU=\NO\C=,6&8>D2GME[':D=VRAT7O9(OF+=61VH$@Q=H'SZIU5$Y]S7M
M-L%=M,@39EHW(XLN?O.+(QX<@ O&&@*KK'6=KF>#P^&+Y.UX#3XU0WQ3\J<8
MD41PXK+RWF45EZ;,SQ>E50DMTO?XQUH17GUHHJL \5E-BL)*22::$C#BBV[&
M/9$Q:,_+_![RW-C TM,Y.CNRY5KR1Z^6\% U3"%2X*+(*7[2C!%)E(;F@B&N
MS"_!BP2AG7N6E0E=[O>1JTF'X25RR3.9WW@FL@VQE5$KL$N0:Z-\Q)2/Y[H,
M^MR?U'+ _B--$X'I^95W&F01XAM,B9\8_G8?77^V;X9:8.XX=<$C8\Z;I:0$
M^]V1SF<SOD#?GA<)8&;0D K0IIO@2\^)!FL2RJB,*V$&\K!!I^".CW7'++L;
M?TQ;Q&*>,AH/J,>;6FB:@,E44"^_O8)@D0@?%H0@XP/BJQT-%@Q-FQ3=']JN
ML<;4(.XD-B/)<?BVCJ$\[78WTT91X'T2MO)GS/[J;4.$4QAG&482)WOZG+!&
M%O;*?:RRLB7A+[I;LUB;>>]:=#I?,E L[P&W*!)9FUR%?)R 5!3!K2MM9^HK
M#O6/LCL@ UK:1-]RY89T?G>!CT_8;[\G#@8.#"C,E*]=-HDM+XBF[F)\U6+A
M;M.YOBL-::5]$TF]D'M6-#<XNW]/$SJ. PGBX1U/Z7NASQ@-NL-UF;/E77[_
MG TV&IWPI2=&<"8XQQ6Z925@-1$Q!8TP$X*5V$?8D37LYU4GFN@*&]U>7V!S
M[;S/\*7&WCWN.)EN[6?-H7HO=^!:N/' _=^QXW0ZM2[BJ4O9NH6*'1AYY1M%
M]Z^!X*^.N;X190$FE7:+D3_J5<N\Y9\:5OQ&FYTEWT3:G9EJ$ F7_YH1V\2+
M_TV\-^\;PZDK'(HP4!,M3?)M>^%.65W7('0P+&>(&-=Y=\#%,D2-]FX,UV;?
M+!5 V%._9C6DC!#LP-T6G6C(_O6^"FC-99U??3EJE>&=/">!?(5//G!:H"DN
M)C=OT?2*Y*NHD;"F45;\/%3J-$K:4MOX2Y_QC'-"5L'XWZ?\B=AT;J(/XWXS
M5<YS2.'IL.1CTC;FG#R!8\;D8:%LFR+WA3.,@VY"*1V4S] C>U.2GT";.'RT
M]C_\T?A6N"&KC=P9V62;#=9;H#&.T)JF8(!("1W=UQM3F=&$UC[W0;+P>:Z!
M1FL\%;0!FJT@Y;P*7QTD/?^"3"S'H,,&O<"J-TW9E]/ T6OD!]?=3&57>#H*
M_=T\ZM.Q;G-NFR2@- D>M#K:X5#59Z7(LG63$QCQE2^5# **U[T7=C\ E=KL
M6#1KN%KR9O1$$;^RG-\3/>V%&.3LP<P25< '\H)R!E@M.C94S]4-FU:S#,.\
MXGP1S=#[98VC8E/$.Z(3U#?.BWL0#5\KN])Z*Z4=ENKT42<&6QBV\ JY3FLP
M?@*7K6>OQB31&?_K5\3DSGQ3!R'R35^N?VW!L!W2K[9O.,B28]/\@Z#6@3TD
MHPYPTX/V491_JH#(;VX6^,^HL#&<GBPP^B1E7.,][E+TPRIJ(",NEJFX==LU
M?\Q18!4C1G<$F:LGA<*@ J_QCJ4?YCKX]%8K_N4=Z&O-&895^I0 @67H!$+]
MBP3C0#/>T=.#2#X,H30EY\#L!;$".;=-2E^^&@!QB&9#2]QTHOGGI;3J9LVQ
M%D?!-GSK"3:N;!2[@KU\PK-[T6!E=KR<KD^(ZP-#M!$=XW^Q3B,O5:G+I\MM
M'Z3F)6F5)[DMV,]8.=V7^R1.=%;S&[Q3K?Y]N\:>"5-<$*5X\*R8_)!P?#[/
M[_X2U2?'!]-BU93X]Y!\X)/"1EEAS]U&\*7);HHU>055(FG[4 XYH?3OOF)!
M-@L^VEY6%+$EHIUP4XP^TP.Y$0R5Q?#?&G)Y!4V\D-[J922^@&?W=&)TO)LM
M];LYI^X$UT-ON?4ZJ800^24\^H1(IZ/[&-\OR=ZJLJL[Z,.0^\DJNS\<G(\9
ML1PB@R>(..D^C<\N"#4(375NDZ4+6Q%KED&]Z0"STI@25'Q$%;MDY;?K#OU7
M.4&S<@0AJ@<,Q=UWPCVH-TG(<$;GYFRZ/C^DRT:98/&D$6/%H@PM2N%;9D(Z
MBFMBG3823)9R8B!::#23WPPO94X$A!\@-PS=4'19E;\32L[1>Y3W%.YCJ*W$
M3_2=9D ?R;T/&]>1\)*Y*X<_N!@G?!R">YH?Q5$CE)8-D'"B9MQ4\W CK7X@
MILKY3%,#7RNAZ0T_GC'BB\MK3I'D*$N+9-M GJN.9\^/8GB: AD[2*4>G'ET
MP7UMQ?S!+BME/SE+<5H%;+:!+*!>I/S8,3U9+_H]R-L)#:;[Q?41R$N8UR"E
M":>&;_Y,2V=;,GD:5G,7U+/;OJRS-<+1SSCRE7TH;23P0L4A5D=4DQ#K@6HY
MXC%*,G!SN$ PE-DCL@A^(=;FHZP=>_JLB_TG(LIC#Z#;54 ,%,MN*A7[F:H5
M>U&C[([8_#MC>N"B74YP$C^>[JH<GF;=:_>NFLAWXWR;5H0ID*PJXI=10U%)
MC=P.7\CLV%^!_F;X3_<HR;,M;&93;2C'I>$<@K])@9F+).>HI87 5ZX&_]R7
ML@GB+K"5V=O\$V_'D(_8OB1?8F5UN:,YWP?#SXVPJX(&A?-G3ZVN&=<QG [2
M$%'+^38WYET1'GT_)N17/B5^/=DR.RG<2!R)I3O*]%7 MGH5H,FIZN:F/6EE
MG<FRYU=>9.XN/-[;5;<-SFR@2SC9W0K\D (C/Q,&TZ:0[KF9)O,1K<G1J]32
M,)O5:0;KT%O;+S_F=J\TOXP9G:Z;9%_,FK/AG8(.*BQE63R,L<QMGXL5/ -N
MOY&BA3W\JB;<C2A-MVD*LKPSX/#A]S4""8-2A"'\(\,WH_4C >>8QG[;@[\8
M5&G=6(BL/5LGF-SCN2!D2\_1'P2RC<#OOZ!@N"QWY6-2L&09^R]?<8 ,_=:I
MF:@KDI26.0<>S<M<[K6M>?5I;C@[%\QN8<N"Z"1E-GU?!$G?90>YNYKK/QMG
M#$_%+?ULSW':IDTOU=>A1!KX#!,CB<*NA<^:;WK<]0&O_[+.'SRVLP-9V'!B
M)#^%$YZ7#NPK_-]?"S)&")@B4@20^!C%[O?PS.! !NLFRIJ.Z:)%AW[T,L%)
M?5N.IN\#"O_7:ZUEYK43OF?_YL8'E&7JH!Z:A)X@7?^1BOWL_M7V2[[\O9+5
M5WA[OZG#,-E7("A,H 16_K.G>ADS/U^!Y+F:(2B"WNN(WN+%4A7@CAIE2$E9
M3UMFP].!PNA9WQ8TE7JONBBP\I?,N JU6(_QJ/A&->84L<(=8EGWZJA"\WF+
M;!W%^LK3Z0 S^51=[=.II-[M>X-]0M+M?8,QC?6"8ZCZ 6P :W70I"M$_GGD
M>'6F"E@3WN(.!)>F++WL50%UN<AZ3V>8>.JK9;9Z-(]C+\KM@OP>39"S:9'=
M#%ONZ1IWX&S6B9H,E/$M?W15#H=Q[<+O[NH[^P,<4^HY:S>DG.ZKLOORE'8P
MX'"-%5$KX/>SZTU<#S(]_0RIG]G6F2UW?ZJ8QPG/^8?YYH7D2YPO8%V&N/!'
MNB63T*+/ZCX-*V_1?&[E1?9(T'1.[B*[)C3X#<T_:#?4]H^5\(1,)];\!8L\
MUOYB&K;'^=VK'IK<4A:^K+]&/[7.:O>^:%QV=L7][.?3C19% =.K,<7WZDR[
M#5YJZ3HJUD><2P=*KUS"EJ)?&O[+ [=6)V??D\MDQ8;'79Z4ONS!099)=.SH
MK/ZE.$=IA4!_S1VCY"7GQ V>AJ;&;^U"?#WZKE!1=8TU(^,?Y(R?NB_VU <B
MVE:QE/NYEW#%7]#5?V.MQRZ\2$O<YC<1H,[NYGW_'UI6'\!Z,F)J$I3/9PFT
MF"N*7$C^/'F@C+P?^MRL DCO06$CCBW\[W?<=KV<OD"BC5[G2)ZJ &&%&Q=/
M6EA$*)</FU6YQR.YHY:C#<\08^<3Z8O7A/5,%9!X5K/2*\A'(F>NK) @^4MY
MXK@*Z/JH J0#P"V*P00<Q).(ZIUG<@52TJ)Z)^EALTKW>!1[7@5,3:+D\__Y
MO!];J"<,1*GW/0>&!H',KPPIY_L^7U4 [KNQWXUJ!/_#6M_T!9S BK2R\@1:
M+7?CQJL Q"$5P(U>,U/O]T0%A*FW^&X+QUD@53-9^/=KY]?,]/MEJQV B"$J
M@#[M-AS/P)'4+AX)^3]Z4O3O=AW1K.@).I<KS9+:?K^_G,'R^W>#:]2.2.Y-
M*2"DVN >Y8OOKW_\WU_?[_<$_/[V?K4#MWP?SJT&5C;AKF6&6C/<]<^N^7]H
M:?Y+!9@:K.2IR:*W,*W<2@5T_,)#*=:35,##'A6@XR;+5P%'N?<0(D-U5AX.
MI.Q?#4:AGD'JV$L0+9BG&-&B,(VQ9"/S5J-,)$(F@/W7$VL^) ;R4-M/W8S@
M92*]& /V-F#[5DP'X3WYNJ>#$CN_0P!#0ML+%ZA".9MJ?U$$ZQ $,8^*/E@W
M7AQLC [:V1?<9RNEEU;83[30Y:FD.%$\@X.%SC<]C1C'R.(U'R(H%OTJ@*<I
MLI3\65F+%LZ]DQ^O5';F$J=*P;:_%3$2.5(H.TK0D; O-%>B&7/O"6P\XTT6
MXP99_KOF_N7..W2;&3<#455AN/%D&EA:;SQ2:>>%C(HK=:V:;X^H>@PMH[O=
MV0L"+,F-Q1'%95$0QH3#HG_U^^]JJ&T2F^4?0!.G+1=L!/ZF?/]@']RHDM--
MI>]+@38?&4\-$A2*$'<N)70L5#^S>X>JMY1:K$#!*H#X3%T'Z_>*Y_/UO?QE
MA]XZA!D*]]LL35]>H"4J\X-7P*3;$V[=:!6P54UT/XBI% /)BTN%LIN!V133
M$U*OQ>BEOLM]_&S!N?>86 &3<<M<!;3X3XL1/N)GH]FX^ -%TZ.[TBW>U&?,
M,<+3$PUGHKFZ77 UNP+E)',*X7>2R#LK;>-"K0S3NFF2NA+KWR57*VR<E&'O
M\UH%)/T+/W[ZSH]U:LNM!3VT5PZK5]I3U:.(V '..W\O3774A'?IEIA0:&M-
MDM:W/I_<4Y\O4_+F]^."IO-/QW._)J1F$^<EB5TJ8.VMT@J"CSBRJ6@F;TI2
M\C2LB''7#@O*UWG \UQ6 H,7J@W/Q\A)"?(F(Z7P234X]M+LYV:*W [2%.T9
M5'?;?''?CKX).6FO"AB#=.;[2-!FC_'R/,,G;]TTX]+A=>W"$D27D51O:L5/
MF:[QNQRC9GVFRXD;,(8!MKDA495XE ##WI1RH9 3HQ^00.Z6!NTG2-6$9:^<
M4@>.XPR/B9([C9NIGX_QM<VMR*]' HYG3544'KR8^"PX-V*O5#DH40$^$(=P
MX'M_8%*S)/=QFV6_C,8,.[<\8$QODL8BA$2<S/20FMTFY>!5P!$*$GOH[>BF
M/NPV6G%+YH.:O4*I88#:L*QSXBV/QEQU>PCP\5]B6HZ=S]F3MFPR->3"Y2#A
M>:E#&VMPY^-6.-Y?5W1?7Y*)^<[,S3-F^Y)1O6#=$O>'Z5O]C;>LR=8TH_RA
MK[G$@21+3Q4P+U0!M^APE&Q?:<8N2DXW$49P0YX*EA^G3A?1WP=#\A(5\)3!
MKORL MXB(?.C#VOPR+?_+"+__G>.;N%!\*82QUGA?GW^"ZKIFAB7>DV&%&N<
M[1_4<CV&K&'(39<SW(WR,B):++[4=DT<1,C!OS*#/*L(Q\1>LL1@W@6*\BAL
M*SX(K<6YXK\(]L*M)W*X<V@N5&#(4\=WJ&GH(Q4F.H<P#?/5N7)EC*SQ)4S8
M%%-,?V;MY29D+%@WA:L;("E7<>2I*;K53"OQ6QE[+GBEA\A'",%D&:+I\ W2
M53Q3<J=_R13S#C:<43+CZVL<6Q[SFS!\\%O=\(B[7KMPLNETTT1,W+#11]+>
MU9S%3J>I9,@AW/A$R>!05LS++R[2J./B@/B*W%IESNC>.+;KN^X*=<1<2$*W
M#G(Z@_?5[.?%^7GP.W"PX.#X#&[N'3=*!01BP&X5H%&I![[]E6[^ZZ=>&>IM
MG7.MF[0NF_.4>%4%Y##^4C>#O%[=!6V* /%\RQC:,VC3$D['8F P)<KPN6CW
M2V1,%!4=AZI'?$B?E@^QFZ8"TP>F@_X1/T_\4:;UZRD5$"T.SY6;8QFA!5KG
M3S*67K!#Y)LPSZ;5F& DSG,O.TQ?*UKK#BZ.'LU#SC6J@.IRQJ0*N-.W#)?M
MU\Q2XY'9 JB-]Q88VPFC0NS.GBGPMD/IE:YR&V?D#F"#.G;!WPH.T8>:+405
M6HCM506E"3S.B4"45T)Q[EQM54[[FT;4:O _54"GPN<,$W-_?K&5N)TQ$&-C
MY@QN[0JN[M9)GWA#:\3-#;U!J0O_!N/W[IKF$C9E]NO/_]:@U ()WD5G[$(P
M0P5DO7_1M\-L%FI4J !'Q987*B E5=:R]*;^G2Q1))<?W+MXN0;J!.N*P$1S
M+BU&/0QHY7B2=[XD4LQ9,MO5DC]WD\N:=MMS*C:0>96V2=]O$USLT#VM=M>P
M>R#KYCA)=]:8F;RD.1 Y!R=8\:VT=W<<9-.9- XR1H(O!(76KZT^J8#E :NO
M:M6?E*<XD:=3A^2!FJYT#BDDX9=8+#3)=8QD1:A[0)U.YR;'NPK3EF)_?ZC-
M5II-5(^T*C5=7U4WJ%D;WZQAG*DU@H[(+&:'03^*Z'7E ?0_:CMLDOV[)@B?
MF(N@%J')H1$TN,5-ML]XEO"6#AO &05SH*<1,4Y@GV_:#A4@EI(_*G'09OAX
M5<*QEE[;9DO>ONO55<&UN7,YM>W3^HQ9+]/@E3@58!!6JM 7\@/,#\@B6D^F
M-AGH#HY?ME0JU>W8%V"UZ B9)8H=H7N,S>"8C=HSTZ+_>N+[C9IDKQ[$UVWJ
M5KJ8PX Q>%-</? ;6E0*K1T!Q2REO3*'N'<&W ZMP2/>&;>T4$J**P+J:]LN
MOWK]PC_P'TV,D;(MWH/?_DT4-6#2,-OLP'O$=8/-:+++=-&TP^3,A*!P$?-;
M)P?#?[ZE(ETFA\Q*1;LA,$8%*/2Z/!2NJ#$/!32K F26.;?=WA;2W=39+U=L
M5),L#J@"UBU\)Q#>LFUJ2J,N8FC3Q'.=UZ'D+ 9O!ER+F))BU#EQJ0?;^J%U
M('->74M)\:$:<\96XT+9+=)?62M*]4P2H6Q@HF7$'=BBG*P> 04!@'S#_V_(
M_UL,T5$#UCG9UK0F >M_;O(*L0F?PWU'-.J-4=IDA#46O_*COHO>-_F+OM/7
MV)_-TP%%J'JP7R/I? O2'JC*_56,2E-<*L5?@^N&W[K_-#X8%UR\(A%&Z286
M8$8_59!F P_@=D*=B.NRE(0KO.Z;2-&[M*B82R]#R\F!IQ=FG'ZG>EUT;3Y3
MK@(\B7(!YIEA\R2,E?MN<'1K;EMO1V$04ID%3[D\.+_T!\D[P_,J2U(>):7.
MK2"&JYP1;!.^Q3,E9ZGR!8;3,M"BK.2&_814/HLW:#R<Z]M$GZ.?LU2*CQ!7
MFL81PU[>/%I*3+>F3Q^VV1W'.Q73'=<V-)0E&294EB;Q^1;#E,NHW*]<A8Z?
MPD+^H\.SBFDIT:+_MT&%?=FWO.Z.^L9;S/#I^)#@J=)5V2,6_"GZ%B'S(J L
M5^!=MM*-%^T8^Z^#M;F^T">,8#U%[E$@3BP28N.)(568K= PN(W@$2_)S^EY
MGJMTS9]CQ3(=T%U@'><T%S$:K184^S3>\F+QC]A"07EY:GIJAO)#XOKU^EZ'
M_VT9<!6FLO7C8%9C3O&5,>PN^X06)XLW#1Z-Z=SP.BR*$52I K;PE,\9WT[3
MU&FGJ+-M='@'K*8@S8TBWLLK%<6F\5':_NVY = +<ECWK;R8)(:0\!*S@H-S
M4,U<F3(!DT+?+CMT3I38' MN>5XG(J=%DPUG5A]6E0\SV/6GKG.@#MR46M)M
M2(M5,#KH;U#:4"N7 DLVXS6[O@S\!H^B=2<Z8]*YW<-21VQ.:;YDM[+2-IJ#
M0N6T>>6C!BSEGLHB60[\P Q*^(&.^]BOZR][5#(B0_Y%VC0X/B:]CX7V8V9,
M^+W8I?W$UAR]CHD UN@\.,IQ9N1+I3;Q<8)$>(J ^--(J-G.GOI$&\(O5S;D
MEM.3(R0)"=WN?LH#YU$\Y6PM^)=5/QEQA<&:.H=T;S;N^.#_*=>0'I?6HTCS
MFW<B2B>"(>5--2OX106$1J0%\<??BCVMLQHXRQ&QL:!0N0JL%*:O>D.F;?(C
MX.=LG I(C@ AV[HY=9.JQ=1.X7+F,63R6XDP_K='+F(P'*THB%22.J&NLUZ+
MG$1[N?FWG"$W,_%],C\KY18F3;'^TCH&R^D!ZRHMX,_%>C1V[A55.<BMX?2X
M^<B%T@,P69R.8+U:FODP(.TJ=9\W?G-QE.M" P4ZE 3LAJYS/39?07M^7_,I
M@T:U9$VXW'7$TB]>5-HV"-MD69?!@YY%A93BG=N@/7W+;:5(^]$7E8&!!RZB
MZ\L7SY ;^ M&4+S?,3[NOMG.P"W,3B>_.]&>N""J:&]Y>=A@QG-D:5L9]VV"
M/IJ+!/.59ON)F)9)I7",;*L"[ALKR[DGZWL9=>H0U%E/R7VJLA1[O.+_<3%1
M!=CK=:]@XL0##8S+0M:GJ78JM"N'ZYO?;C@[X5Z!2.L3;(-+=3&.L2Q@ <[J
M:VWT2'9SB;AU+:7D2&& _;-[_:O!C+]SXLZQ.FS:3Y+::IY!*![9G%P*9XP5
MP.J#2A.BXN)XQUN:GHWZ1]K:Y\?%!S+2V&"WCUH>CB#JC92;?-6!<E!7.?^;
MQF3C5>;7=H&2]0W:A=>X* L<MT&VTBWJT-IQGE>1^='9P:R/:M63B/@271W5
M$^CPV4L(&KAMP5OR!)/YHOGNYE.O"!>:*7W!\@"7326N Y.=<J<.B!9N72[G
MJ.,MLZ*+<^?\GP\3O$0YV86SK$*\PP+S//:*;PM%!9Q,'_^5(^F_XQ;(EA2Y
M0\OQ]_/E:/SXKRB=3X/$'8S!)8,D*]=;<O?T0-2'9,BU9]YM\;H*&-8M#\-0
MXCIL#C!_S8)T*Y^='O<<8%#FA!3$4F6JQ4*!99H_8R*YZ& ])J9LSS)S,[&+
MN$7,2"/\+*&;B$O2>$K,L?[EA*M-@]:VL'-RNU/62(-60LTAW,K@^17'8CQ3
ML$O4>5*&$!_%:(?2<F^:7V!Q+K+"K;.B2IC6Z-%!/TSV4S?4,P0CH#%7$#CN
M_'>5X)4:?K2_.06W/"PJ[2@)93FQV0*Z)PU7)V?601I!B>.,U#QF>_P2\AGV
M><XLLN_'7O,W]VT>=ZV#60=%@"85BJ9O&OGD$:;,4JIX.M6&6!7GJH#3%N0V
M)^5']=0!P?<%!'7YDG> 2X4!:ST^_^[EOFX]WD/P7@7LS1(CH;\65,"WB"!A
MD([\)OB^2'%.!;QV(:T:?];DN1HP^*24T3VB$\]>S)C]V&.[E&$3RQ;D7:=I
M46Q_@]0/<L,NSB]!"Y_#W=+G7"Q$8$?0+Y^QRXGF[S;5OU\V[,WA1_Q=U<=$
M@ZY]DVHW<S#V4?E]\GY@U0KI(7I72497=3\DN0QZQANDL"!!(PJ^6E;@N^)#
MBE 7^KQ/8H)'@^A=0UF8<7KGEA>7G ,^I1TXG?I!CKE"_L 5%@,^A7\\)*.>
MKTW?]W]>69)]Y)?@)5=$AS?!B]%OIWW"QO%D[UBZ-/!\TJ9(H<V U":[$:DX
M5SL'P7*%GS6[$U2 ,-U1R91 $\0TV2T\ZJZMT';)=7<;<<N?^,;QSCS+5?BJ
MZ>(ARKTF-;%>/I'\81@:9'TE6I#2H1TR/U'6J?VX^/'W,:G5-@K/=881N*+$
M$GC=VY(.FI#0-.H[3 E(BL]*"27?5-:Y@+"';@??EP9@W"N&\4&?;-;$A%Y.
M0]0'9T!NMB:X#^QB=?FO&0[:<>3(]Z^8?N7ZUG]]MFSB0TV[UA@V8.XA?\"&
M4"T+RAFE\< K%U1IA-N&'H5?6,FLF7.?"Z+*LP1?Q:^[/XJ-1"=*<@R;B+X+
M1K&#,>Q));?I,"P_ 5(!<D2",MUQ:-JOK71 ;SRS<J0],+^-=37HX)MZ["_U
MRP/T3G@>Z[OV+?3L:OH0O$(##?YIW&^<F#(W4'ZX=MH1H0WR,.MI.6PU-+>(
M$6SH&F8E8DHIE <?<>EL77K/&'"4UZ]>Y<[D*UF;$<_5?=<'G=1I(\F-7B&6
MCGIYS*EUVAY-'E.9,0A;W;7O^=^*2_V,JS"3+_#[MA,D9 )\6ZA1P2YJTZEG
MO19)7,$Y=M<"H78%[1:P*)2=#W*"WO78QXIBJ7G7&@ZPIW/!2XFYYV@CQU4
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MWD_R5)8X1@)D64=Z74RKZ2_ TG"G\P'4HGA<5%240?_)U(4/[QMBU4/&QW
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M? MKA:/],$'SW>M?_;&[!AL'<'#"59;<CL<#VFK9"W:0ZX(-[,_I"B?PS3^
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MZ%V4$W6POY>KOK?70#+!=9[]&LAH$;2&Q8"22Q5&WOWC2P$)Y!L&%86=.*;
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MM" R2%F[3;D1,5I$J1EQ:$B8)VT:-%Q[XQNQ@#I1MX3U9EV[E MTR',3J^Z
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M6ZS[<=JL,/+<%,&FMFX  58.-E+\B^6I=GUY8EQ9-:4/_E56A&=AA _+.:E
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M+O!U2]WZN]OS#\*ADNB0HU^K/GQC&OY_4$L#!!0    ( ,N $UE3V7X=67X
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MQPF)27\^24[/>)[Y(BL[)[>XI+2,2'I57E%575-;5__V74-+:UM[1V=7=\_
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MG@2T.S\L@N4U^E4I$5_:_<W8:3A00;C7R%!R2X<V[UMI^TTI/O2%K+*;F4Z
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MSTAOKO%@^A3F$(GM=.>WM7O2__DU25T/OCO7"L_.;:%+QU>=.UR"W]"%^YQ
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MLW'8J6]?KVD]Q!&'2UA#S%E:HS,:L8%R*5+9@_J/!ZP3UN&V%='&SA;VX+[
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MM2PES^V&'>+# U)@G;-7B;/'-:]%'!V6;(B4PDU[3[:+<J,9M!Z&BT(5-L8
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M9.D4O[R4BIV5D8<?J_ _-T$N,LOL0"NWY+++O>;2]LB<GLL^0?G?)+;)IT%
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MQVW:.+[E-:@Y';]$#D6UY &WZ)J/'!5MCQSGC?!+-*T #RI!";&02ZFR&4L
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MJ;RV_F%=)DN$%V24Y"K(N]*S)Y:3AL16]]/L\FSZQ<D&5O1%/\5\W%+HO &
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MMUX)<5="&F\K#""5GS.MHQW:!)6<*8%WUYF*DF=>2Z3F;]GT8#1OP.<]3#N
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M$582M@=(@(]WG )A\AH 0;/J#!*:2J[DQQ434)8)EVKZM)N<WW7XV"X0[RF
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M3EI/ZB)KV)G D(NP,:E@D#WA:L4)L9JO)%NF9/<@)*,9E\@&I(OH2BZCUQ=
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M.3[&R3='MZKBEW'8^Q9G_&ZDJ&>SW>(H$?:[Y&ND54K@^M>S460'D4O:PX*
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MGER":LK4T C4_0M:\69&B9<^&*0$2 N=WP8=7:+!L\[7'3>8RS>D8V.0JQ\
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M4DBI,B6SY_!>OE>_JNZ6W6D9-I8OIV2A)N2CO>Q!3;)""7ABN9O;P5%SE/S
M[LM[MCFKC]UYS,:[S'B.!.8-O.)D@O/Y4F2*E?T$W[<I*SLEQM;5=%4+;9OJ
MC(3)&AK,1%P0@<AMB1)8OCD.)0]O+*($J,;RC?,8Q9(P)2!#[BVB>OAL5 (N
M*)HWWZ!+]?Y\--M/YJ!X?9H63CX'Q]7/[V]X'-P5A$,V1T#3 UAHKX&]=WNP
MGLRUHM)]0V9K,&-3>C,.UG+;C>KY)A'5$X.1(>5@K?-#2-XPNZ"F?-%8613A
M:"PE.)")]PXZQ7C&GB'$HH6('6"74*S=VR>#RVN^<:<R?Q'Y&.T5V$G.(1:]
MD#Q?U(/V@N5V_[(]#R.\.PK.:G<J <'\L:45Y]%U7#01H 1PW="\53JBF:6+
M7!5C)0K\+B^178*X,C,\QAQ&*I1 &AJ7/2<NVW@R<GH5$&KY=&YF:.Q+W^F[
MR-*N5[_'O* $W?EVQ'Y0"5P*ROZ\<Y,TF)K>BL\J3(_<34)Y^@(39)2-%"D(
M!SJ*9K.^C@EP,>L6K0D>Q&5O88)W_1 LPO\;]B-C3Z JG!^B*G!HDD$3>_4J
M[M/ IB1( :);X^CKQ[^WP&]BT+C=IYD30CNG!,;24*^#(X7'5!W=RAT2##S;
M\Y]Y_?4X$Q^7V-J+]K1B\#?<_K]/'V VOZ<\,<W>Z\?M$F>H-:$'3)UA2D]>
M!$//@#5R;3)U(L(ZP[)_C<5R$V_;DDV/CF8RP:%^<B0!V7/:7+[)QERQ9!(4
MS+=_'-B*+P)<S1/!=RO)<U+4_7G+7;'<K?]*TA*Y%\_IR]GK[,)>[+PO34['
M2>$C#VSH,KZ;A8DS':]3.7@J-#I)LNENLS.LY:H"4^S1?B*R1AD*&D-9_'KF
MQ];W" ?OF[<$!S'QI_FG&-5HTH!HG?7VSKC@5H]FN&3'70@]SW2J996=*Y6C
MVD-8D()#5@)^-#05KY-1(G]0C+X%.]#,B-5 KLZ#'\1V%8$Z2N %.JQ,C/<L
MK-^/?^^U)I%;_&Q<>Y:;2PG(82N!%K14R-<?K*(BLE.5JQ6/D4%SDU><;?EW
MIB<'E( *HM<$:OLS.,CFA0AL)0OO^D.SNB4?PFR8'LJMV:$YY]I+:M="1VS7
M^H'IH -29((!*40NEA/JV"/TUSR$E62V)B?!^# J[M++F@$[< YG+$([3+7L
M'X97+1A^! <?GK50 C]^P-1]V1*OUHB;WHY>T^,%*K8D%($?I]!9F%6?L1^^
MR'=S*8V<^59J._L/$+4$&$Y7C)O>?5453Z3M#MT6-% 6*5]5MEGDFO@>DCM-
MDB1RR9'$CU)*I9-@:_UXOSA/ME.18YJ98L9$F7!SO;/8FXXZ3KPU(SENMF"[
M9>3J[=;'C+39=L,.O7*L]4"$#(J)E%F^)W]4!<=_7\T WM4M 7KGS50"E;AY
MRZTH==X;_=5W'G;&: DCF!J7[NU9"$X: LUT;5&A9"KP8(UKN1>6'MA=V;(V
M-)HJ^4 _^JYK![>U$]%XQM<DHRF5/8;V%>><7QGHWJ(QNL_GG>NU@TW1,B9O
M/3$^0VBMD>2"X<>M]KCTE.\Q9!]@9"_+Z.-ME1?<\8ADH/F$%2D&(&L)!:4'
MKG$;6J8F*#ER9G,_C@G07433!E\\BT%X"W7\!_8DU\^;P)?FW-Q*(OO(:!DS
M[RWJ:D4JH$&*IS99_#V5$%3B8)W!N>A!?(2V',OOG'A4W580SGRC$$BG4G51
MJK96+/D5@9:_S8D#_"79$IEK0P)OXBP=M:Q*I@0&^C@R2S?1YO@\]P"Z9B]_
ML&S2;48"<6)%06A7BJB(5@+RC1F_<OX'9OZ8B9)1TZ7:EH1YM".6Y6$_8E&3
M1D/C#DQM1F$QY8S@'<@*0^:/J7J8SX]A!ZD8#8^&Z MA5,W^_HWZ?*JA=_QV
M1OH[M+E&NNTRCY_%[8!X!%\)-%+5B:N?UU<"OYS]AS[#R]F&G9AOGLZ,W!R<
M;9[)V1_^7GK,9%NIN83IW:H$%E%H#\9T!HDSU+SR0W>DAZ;+&5T>$4=DN/=2
M+Q@K]IPQ1ZN ,*^&\KE$L>5#F3M+$SZ\\U?)Z:'FE'<+OKT2X=5@LO$P([(%
MF3L7"(FXYC)TCWB8=^KW!),@JZ^RK:1]?HF:R[ X5'B7UBKK>J!17I"3\*+L
M/2M1V(CN:7-)[>A_HQ&X6&N0Y3E,:E65"Z\A"M-P2!=\1YG S(WX*8&*P+@X
M9NNPMY1Z)AVJFL8<0SMJ&2@ W^(N%EQ3G6P#6<NP@HYVL3]VY#I&,H:G.EG7
MO<S+^X5N8MG=ZTWEDL^CKBFQ(]Q'6]D;1$]VZDC535EDJL113$V6QVB=9Z62
M1EC(P%_^B@8(G4_LVD#.H]P%L>6H-!-"O56?"[VWYVCJXXC^:48+Y,>:-E;,
M>%CNM5_0V*<AF[T7FZ$A%:-V;W*T!_[-T=3(.G$;9AWL)ED-OCBC(3T'\;LN
MT;D"Z>=$=$#^[A96? F8SY?9<9!8-&&8]IA>L1*8$6@HIK=U175U395P!;<C
MT^_:42]PQ3?.G/,WEFW*X+NX)N*C3S":91&3@] 4]9S'!/BOR[8@+#I*3E&@
M(,5'C?LCT2LZ1W_"A*;=AT9JN<'UNB-=[4B7&&>IB;/L)4TD=90V3-,&$(67
MT&M"C*P6V6>7,[=616-V<!K4Z]V*^J.?:%K0*DZ^D^;X<F:"I&F7]]3)[-A(
M[!!J+/Z>:"ZK=-]#_DVL=*4'J*&P+$"TU,_!*@ZX-6IW"Q\%W=G#F>_QYI>\
MB1WN9WS3(VT2$7LIX&IHB/.U$OBI*QU)>K#J[K_$^2.LR@7+46[+*/.Q-LLK
M]L>NL_2:**,,C#IK-LSLL^GS>/PF5<^TZ*6)1;&,Z32!C+>I4M$.Q099U:"D
M%?4=9T: 4<S@MH^)B![),NRK9)]TWQ=II$W.5C,2KQP99SMF HQ!GD#/O)UJ
M. DAMFN&=ITANN%#(\/BSQ*>/#?Q9C<67_6(1"F4P6Y.G"HD9GJ/JG# ,CXT
M,HB5O7]&-NCS,KV96KD,>F?J*U=#:6WY<>(VY(TAT'ZP.@2JT+'RT$-+7;VU
MA(PLH@N(G$%IF1L1E6>HAU/<*()F+QU;*A#'0G)9G1(@)M@UH$W?[B>4"-5<
M*?5)Z))L 29E9$T55J7+-RR7%=CFI4]20MKM2Q#GU'>[RI^4A<S)V)5MJJ7@
MKYB-?Q,F-+C4V52IJ:H%Q[G>T5@]Z+2DM/$%/84TT1P_'-_3?.U]>LAPF)1T
MJ4OX*E^TTU2K,: @X&3R&N_ 9QUIO'"\OY'_E^;#U@.]NBPZ.!@>"(AIDS*"
M5)*,2(L)C>*(L?P 6? 9)?!#5KJ\;&$02>2>G, )J7(KXCZ#?AO.FS->%<SP
M@/JG4CI?&AF[C?.]$GBGOS *>Z)T<43SLC7J1B4P,HB1O3NE'R9^AC]3R?%W
M&7@G9Z!ACPGVMSXB>B@4U.L9-\3B&BHI!HJ*EEV%T4.MR]KM=>\4OIP.\L_V
MEB'!LH@VU8+8W",$*?X<&",&F>0)\!DBD5E:E(RU.VR_0ZW:?E92S"7A))3W
MF81>1KWHC9>7?N:6#*M#AJ)\3;J\E!-&KI)-MF_NDKV<(2H!R_ =<D.1+^V&
M+>'1 &>L+ZOIEN5?:<RNU3&1%RD$*$)@C;>^XP+>L,.E,OE S'4K<>C!4OO%
M9L6,U"ZW]\5@4T3$6 Z;?Q7=O+74L-+ST(PP5:-6H.X39?USE6O2I1<].A=*
M,:9T<\YY69,@%C7,+>\T?$4)?.%%D"WS0&?2KX\ME8ACZ7)9$QK'=@49'8GM
MT(F%8WF^NG&^>8K%2Q(_"XTN\AA-NT0\'NUH2R6$A^Z>["^YF-]\"L>5=;2I
MYJ )H018U5C)B]S?R(3X<C<LYG4W#QTBK/=D9[GD?=]YTL.':Q5]Y(F)$NC$
M#4*BO5!$%6'Q81X;5(=+,9KT>*>B)#UV2V!IQ<0ALD@H"I&F>+WKHR"<U+V&
M_(\L>P6/=PS8[G[V;3*"W8XV6W"$MRU?F!6>"H.YR:L5>7,N26F'S1I?^NIG
MXFV4P*KAO@BHE=4Z<[Z\.D8)&*&C-JT%B\Y9EZVQOQ97\J_I1K$<PJXN5QS1
M2)A?Q32OMC_+Y6LY5KT.WS(K>T)J"3LC/4.7V<B+^>\9:-Y(#I4OFB#_&?WA
MOH"9SM\W(!MI-X9ZS/DAJ0U4R8\ECCICOBF>K[:2<'.&IW"H&RHDB.=D6 TX
MI(*'-#''VBJ"]]#""AX(Z[>U.^/QX:5#A%^H$G+0T2G.MK*<-M5VZ%^Z3-+A
MNV>#F*L8OE>Q<V@._PS-#)BHO$7G#(SP1JNB1E&23'=2H$OH<E7Y=;N6:?Z,
M$DB,0&L@!HYP<Q)AD0,3T/P$ 9W=UK2IVO_F7 ORQTT 2C8C>@2+P'V,"N0U
M3MVSEA9J4+5KGQ%)PE^E!.JF::G3E2,$J:\\;-$$YT_]\!<\2V0VC[;HC&[O
M6 L9I2E@4WG"D,25,2PS[^W"C0PR796 20AG:, [_\J4//@1WG!SQGS3J2ZS
MQ]=:KZ+3O\V6;ZO0K<^UX'F?=7+Q6+N;@E:SU[#WHW1H(3J553HO#ESYDX,D
M!\',!Z:2A=]&_3W*M"GQQ"C>L<!G*;[R8(3S'O%.OC0B6 9-\JF$!,STAD",
M .U+N>@NB?TU^H]^L]R54C<5KJ'C#ZZ?4WL)E9\75E%LJ48MXK]1USHN/FYF
M%3(3&1(N948,3%.!&.R_*J@C-J$'B?T.K0 =IK^ZZ**W-_E$11=51'EI>\&S
ME:D3X7AR[8KVV!9?Q;P@_>+40 W>S?%N8]WS[(W?@_#A)+::%=8_ ?=5\9H9
M8MHD>6=]2\7Q= 7UWJ)9S+]4])B([%[UVJH_*7V.D9<N "XG;O.^8*N2B\ZL
M!S?J/4VZS@P-"??FEUU Q .,FO&F!HQTC256YOL/M&ORV=^"N1^,_:U_N1LL
M(0[Q\,ZWK/JNE["]H])$4 4-XYQM4)A]UC$P6#X F?=60Q7FK&DTURJ/J;9!
M?]KU#7@3?#=W$9E=GB:*@4F\6I<:KW5Y!]2FHYU5Y<O7>^@&0;NL!]@>T,IB
MTI=><*=S9KTC[>6W&6"JS>F#K5K(6$2+8N 7&=-YCB(/KKQL=_VCOCR,;.[S
MRK]BF>:^80 =3R,5><7[WP;YF&M-C/%.%L2F^&RLC#U,)G;*!XD4QE0N:2+0
M^ 5DU<>W,T9WQ#@JV&.NN(].EGJQE:KSMBAD\W]YM.M*FZO&[>\?,+6Z&V_?
M85+$6Y$7/^VDE"->07VMTU,#=,&%O7J_ =[ZKY[,=+HYPLN7;UD?]/>H9]4.
M.@]''CU>[CHUWCDE]4("SBB&0J3TRBYD@LCP-&AJP"V)2K>OZG;S%OE7I;UR
M.MC1>^"8E[,MZ:01-!"5(QVHY'L/N@"Q.S[*[;BAQ-UAPL>/6Q;'5-.F>AQ/
M*X%D[+OC7>!$_ /UPBTYE^V"8,@B0(1S']@8@,3Y2C@$^5RQ&_\O("L**QCO
M5@*-5)6C77;;QTMQ 6F1DVE6@<D7/CLR@=!E7;^X$ZW;YC:FYK3-'CJ3>'ZL
MV/3, 6_.!;OAXTN2RY\K@3UOT5F6XM"']MUL(<AY_03W]MWJANU4KKKUL+17
M\Y4Q")7)R(-''I'5+21.+=S=#LXFZ-S_P\58ED#1_-/VV,<:4H&J0N%IUZDJ
MEUQ#$.K..FX$^<DV2_J-,(F#6Q1Y<D=0.H'3.WWR)#?\-ML*MFF7E*$[5WT)
M-DZ@!)8 CN(?L2/5&,F<O^PH9F900S9?H4FTZ+3:2.5ZVZV[[^,2V9FRINLD
M*-E6,W+9(F;Y"1.RVICXU01TKB_L\#3(6;LH\E=/M/\J"K\+6<W2 -M4CZ")
MO Q:>.)GI5"B ,)H<B!1"=QZH([]#;QKN<D+K48?[?/9&M*5Z+QNZJ:HJD57
MCUUUG-E%'9#P,W/$B#KJLU(HBX)J*8IK>9/!9Y809O\*H0WQS&4[)O(:W8#)
M+:!LOAP,=$>;Y#"$^J-!"=PXR\7,:Y?C/NB,ST6TDZ^#HZ[MX(+$S:7;^_Y[
M%UZV@BJV@R/3'-37%YG8UU0]SGYVM*K\)MHEAPM1*9YMGTHHQC6!J^2FA*7Q
MPU'X0T[S#1E6+<N84^@6YJ_2]ILT3%\:=D:*M@O0M03DNL,.R(U@724 &"D!
MGO^G,A^HT_B.&*F<_B%_Q'G)<L0+3>:N(ASL:K<&7=^\[/_A^PSLIZ)4\+(3
M30AHBM;[>(_U4,W!]B*+&OH/X O/%L23)I=O\OP# $(CM,K6A'#VL=1G?<=J
M.\JYI-):<\9[FLQB$><CWV'_A07-Y]H28;)B19\Y BS\P62[$EC15(N=-?&'
MX$6H*5I[]7&_X4W^#8L[)"PB;E "7U>BFB^O 446X.\EM2WM^0UN<4R37FKN
M6!^)_0+[SMAO(7L0DF;^'P"$+@ P)N2_L2"M[] BY9^CH@"DL+/87Z7F/\R#
MA;N./RT84O5/0XXM'?G-D-S??-J-D9MH+%,";12TSMXNQBT\ZDBU_0 IZ9^0
M%CU3/#F++A=I: [,X;-$[W,#K!)#*&@:7?\UC6I/<?[I".;"53M D24K:HC;
M=)U?'A.17*>WTYI=U(/8&BW<J%("YR_OYOR7^>"CB>8#[N!_D@_M']NE^_O,
M3_XTLX"/2JB"!4^<* <UM+V>8A1F/1\2R?[D)Z'KP0Z!<89:]#8U!R[U2WU^
M1,WV!?MO0;T/5DW\/V#$?[N.E8!FN+Z#,)Q'?:=?S0:E@>BDMTTB-\$LA)'Z
MSS ZA6+7V'T.?\.IM;ZS8#^FE2Z]@V;1%'FR3?7!?UD&I<)TQ8IYZ__9,CC+
M"\GU1Y:_UB9\$3&@:QB(FG**\JD(RU^(#G X=S>X9%RS"05@X&E^?[L1:_[U
M0O[L4?VO Y!^'1IU:X?^!P/ T9K3_XJH\:1P<"]?1EOP?]<V)?"' & T20:P
M*^NYS;V?8/RA&SW-'P(P_B$ 22>:5!0[/R52ASKSY=^"#>:YX <)F$^]NJCB
M(ZS^'^5SXJ>1<OC4&B#X([3O[38'NB:_]?[.=5J58(Q<HDG2BC_EP!YSD?%"
M <O5*2V8F^6W!HRD'MN-T-6V?-'H_E,E/RN!HW\HWWW"EEIWC,AQ5 G\PPS'
M_YD,*G+6&W=-YGH?=IU2/9\X):7\08_[H!D<S<6;JP=J/>=2C=;S$B_9N-L_
M\T*D#U:-)VQYH)&)F"F!EV[=V(E7+"40V.T:'QK]ON5LL)_.H_2CF=3WWJ.3
MT(6)L[SFW<13W96YV'F#=*2K2 EHX"/M#&<J/<I?FI@H1IRS(I7 $(3M+_RB
MQ#I^[I97V$\'IHL*^-:IDDPP(WY:#C4=Q\%D-Z@T;3E/:D!J,9$Z(74H!)R1
MZ]6H]_,8:1REZDAIL=C/ON\6%(DL6OB>Y+U(Q\5+9[#C$9.0P4;<G,C/D2;.
MXZ5^XH%9*^9^S^+9:Y-.)O4R=/C\#!R:LQ@T?6WWAF^[>C>_K]U)*P>DSH"S
M-FV93=:OOJ?D2[&0S&'* WHC0U.FB5-D$#+M33B1-C,)GI^)(,:C.^#/HY_-
MP.R3T3ZN_MENWK=EX)MP)= [L<OE=:9+U<QPPC(<7)TGFV+5#%(4&3CI.XZD
M 7,^'8FV5HA.J6S)__38WI44DJ$22&FJQ8G774/7";0]_/,CU_(MCYS7P8=^
M?*/!OX6-4\P#\XW5WP@:248==M:<_=$7;.VTOS<W/9.F:80;.'#"6Q;!#_"X
M&Z%@,YW(#3Z]QZL=C8)]!R&^JSUYQQAFM=U6XYN3+6/S%8J9\>[@@M.F&4%7
M/'@SP<<-UC!G;!CR9HK$I](B>3U<(U?A!:A/4:VHPY[EA%#?$FI()H(]DRC!
MC?,0<3=;OGMBU/O>/,!E:HU[5E+?.FT>.;W+ZI%+RB#7JJSPQ3A-HB4PZV2<
MF9JHB#D-WU "AO.ZBIM%T&QP>,5+XC[<;*P:4N<*SEM=MND3F22OCTH_ +?'
MJL^6H26U0X^>X;DG373@3.*+WGO2X8"!'A(?JI-K\ROT&TLW]WBW(%T \95M
MJ,B(-XU/^H;MVGG;L]/6TZ8O&%_@LV6%9\,%S2IY9EZ_@!X*/O.VRAHBK]G/
M91D,1!6:K_9/UA;&K"L*.CYE1)_.,3*YR.AVE;X:\X*SH&?3LN*^D&;@'6F]
M8T%_E/ZA3+<:;^=C:3NG^Q=)F!%;['@AVQANI*X!>KBGB"./"@#%.J5*H'W,
M>T^H(;ID)ZN;([7=N/D]6U3R:5D5:,N!)4Y0]17:W/KUX8ZIG8,]CK6G*R=P
MFP>0@XKNGJ=2.I%-DKS$'6C?:Z@R)%@WD6ZX.:5Z!W5<Q:FJL[]EYYOR[FY\
M1<3IS6^8Z-+IR:#O(B &3TY$;6CT,0+1G3KH:;=.LY/-\0*/ :]=&WTCI+K+
M!D_(2^4C@A!I>X19L^14_/&O\U]0Y"8G@A]H[(#W\'!K)R39)H9;.PGE].1C
M)WWQD9\9-:D<^/% >,1,!,H 8'12^ *2'T(R%[Z_-U=L.3(VD2'JVS561>+,
M+^\%1V<?K$JI<DOTDIMU\2OJ(I(NBAIX2H ?)6_=QPDOZRO<O7-*BL3*3L+8
MFS6%"8!4T&BW1)2>*#\<6QB%1QGG>DBPP]$['=-3B S_*GF82!DFBHXP#, J
M<BSI? &B*]\CBKMAZ[N*2G'?"'?PRI_*+,6SA &OIE)3%N-2^0D=#KHZA[X/
MG#=* *:AJW:ZKVVQC_&:@9XJ\'DO=ONV,<K%N\]7;-M6W.,6_.KKJ4A"=6,5
MYQ9F>@FZ /]T@XS<VQ0V]PL\MW[6W>HVF:]FOG #RR90*O$4F2<667X5-D%;
M'?B7\3OP]^YA8W>/VI?*S-B1"L$+CA'E"&4F))(@MG-^4/! 8YD(6X_3;QGR
MX-39F(KSN",=^0@K;1DW;9 7VTY29&5&OJSI.B.-#+[4"A.&"(;>,+GN)<WL
M4=#C3J/,8[J5H)^[[N182:\+MKNB4<'&A72SZ>]H#T]8)EGE\''BP"/HCGRC
MLJ\V_Y9Y^)[])ZKHZ2?3]-=9?L'@7=T\38]MD$VAO6=JDLI":>-%)3@QO?#<
MM%%QVC.:(3K%KEH-S4C]%NY*'5-UQ.V0GQ2YU0>K(CJG72\5TS[_X;0[/0YS
MM-WVS0_EFO1>3M )@?<H@R/[)7':Q*WSWC'57YAF</K0'@=>T\VB\F2^?[6Y
MY<-*)O*JHK[$FR0-H9<=F$"2*S>SGY$D+56E1',>E*"G>HNXM*H5@4"_Z/,9
MJ>_<;#R;$Q>3 Z,[>.XY3J5>]95'H/#[ XC;P+3"-67C7K[+-^@D?[CRLJTS
MU^^V)4%+?D94D1M8E==XQ;_PB_*N\D:Z8DI0$X*<((T=3R'Y19SOYYA>TJU7
M E(M%/D$%4+N.7A[7X0T#PI4?<"%;WP-[RWJ<KM&/-1MZY?/B<KZHKN8/YE3
M59+6^:*3K/!R,).%^:=DAMHTS- EXIYJM.26\*!;>I,9BNN5Z9[%6<$&Y4N]
M''=C*X()@XH:7]]X)1#S6?11BD(@"&DX+I0DR@]1N;M3BO&Z[4X%E4$A023"
M3[NL!'ONF%)M<2;6OV2ZR?@2)"Y)6[69$2#S5VFR,XA*;/"D-V"TGL=:LD<#
M-^*C\NA]*?ST(._C?S,TOQ_!F,+L"N+BG\(/E8"1U4-D%C=O:5)4[,Q#A]4&
M]8(E'PYL42FB9<KW\\!X*]V_L14Y\^^7])C?;:7_-.T3YD"7[:DBC:7C39QG
MH&:VG2+V2]2C=D01+KGBKT0OZN#SPG$)<UU:@RUYTLO*K\+[R<SCT<KF:28L
M"9%BWYH>A2/1VM7#Z >(\!*Z6X9;;V79?I5H9]U[166,:/?S,[AFJ8?7145K
MQ:S>P9*F"C=TZ Q'4Y-;O<BN*ARSSH$ZL*=C'W6G>W4:\VOJDZLZIYP%A676
MK<B<#YR+8MJ,;FE!T&R@F]OI_(8EG+=.1Q?N'NFA<5IUE?DWD5N"W0;_^=M_
M\QK@>&_#]VQ)7I558AP73DO5-&L:F';$<LX-E+#!%IS#]U>3RA?QR*OE+KP-
ML1>BN0K7<7!52V[T>%"0)#BL.MXW/!V/B'@!7\L9;N?'7\*A0YQ;UCX[VGDB
MG_M/W/VQ;WJ.]I@')J_MH-;[G"JMDC?+]$-:$^7!B #:B/\\QB6")G%]]$##
M$-;B:6CC\32T!3F9OF,;QS^8>3M=_=@W6!3;($T?[B?OI$GZ&#@T,Z:_G,#-
MM:!-VG/"Y!Z<-1.EBF[4Q5C97QZL*@C3OC:T/GP+T9AJE[2M@9)WC^^[L<2B
ML&PR^$8*"1Z@#U.Y;2?:5%]<)'X#_TA:Y'VD%*\SN 7IPI4.5/Y]NA_T([CL
M;"GER&0]PXFD <A<Y"J^*]+EZ=X@.N6R>%9=<XGJ]I/#&8V=3J?26D<2 _>9
MOY1C=^VDQ [C,D=Z<<XHUR\I!IO(TUO&H;GZGGWNAE^AHX6#"UL)V*H#0>WV
M:Q=-2QI9ZF-5K(8:5R^9Q=/PDC*7\Y$XZ82BN]@<64W00&?@G5B9;.%)0I_$
MWSTQ5Q:FC]]-YFM4[MO.\:M(XT8X#\=RWLI2#WSN)_]B$*,$'IP#)>(/?]>P
MKQJK!/:^0+>-24CN?8D@_T)?A^LY[5&L=>9 O"J'8+F&H\B3(HKS\-TZ->Z$
M.W2I\\C,)(?NUS*\(?^E0I!=M$KK$V,<?J^#[O]@I?DG>C#":U$@<B4%'1=[
M0;AJ(.?R7R#N4J$24*B@DS)4^N$/'6K5N4I@?JD#.D]_>*HQ(@%8N!^ECPZ9
MLRN3$63A(=LNJNK/)$-0!_8QGWQ164GYS%J GDM05'5^,JL]T'B Y3JC"_=E
M]#)PX7GK,9![+&H_<GGBG^\II;0?;1UD>Z/H7U<R8AC4I:QC9:*[_IS>@+6E
M-</D>3/;QX.W.W).$X(+?N'\G(DW8@6CF]4^KL:\"DVA!-*50 *Z6:E>QXZN
M@B0(#ME6;=*(*4^.YS.-X,Z#0CXKKCAL8H_)JXYBL^%>C<S2@>I>7PY"D=!F
M^.Y,)X8DY#'16)$_A],F'J[HJ'AF6F2ATZGI7-'/-F7T.Y;%](-4J:EDRA[,
M\I)Q+(&8)ODVC65@FP$HD$-REXO(;MB-ZX6/U6KI<(F<T GD0.GH7"QPS:^E
MZ4X,;JD6Y3VN69):/6_UM(^H]JW'W1?37Z9:[XH=40A:$WI_-_DM["0KKM5B
M9E5QJ 0TH-H.OU,5X3+=E&B'A8>^CBEGQ&J^\(BJBC4;#G9KS2KJ7F:X\>I6
M;ULIFZ5?"?[L>GE/S^\\D@R?,ER-9H8-&G<I"!?.T&Y!NM4G<^'$$Y7"#G^]
MFVFV)@435KN:IY_>&>]S3ZGN=G[K))C.?_5+C2N92X[/WOC:-G(EO:HQ$W/C
MC' XC1(;TGW&.&%\9)A^PWB&%#QYA]Z/;$F'"U3:H$^"FR6BU9)7L-^,,<)N
M2"MV6R@!G+E<C!-/8,2!<$4QT:TM/";+=_O1RK+GE3'K?"P.IBU.Y6-"Z8)O
M(W<\FU,9]IS%&2B!IIOI_YBXT#;FC*Q%LQ$<7?D!FUGZ[Y RMDFM&[#E4)+M
MKJ+]OC'?Y?U,X26V6D53C:)U)T6F3Q*VT*NB2ZOZL0-2IG/J%I51C4]<@_W$
M_GK$&&F[)+AI]Z7WV+P3DF1VQ?+>TL8HEQ#YXTAGF^F)H,)VK_JD9UY3=@.,
M[G)D'?&,")<@/YD_&%A5?#> ^^.L!?1Z"*\;%U3:;ZM3G*[^OWK[\JBFKK7O
M6*=;*:(,6E&D11$E#%49*J-6HA6*R)0 ,:2"R!!#JLQ"<JQ6$!"Y:"$5+@1!
M9"8R!A)(*H,#$9%9 B$,92838!+(]!W:WO56^[ZW7>M[O^^/G;7.R=E[/^/O
M>9YSSM['E$ULCXE<6/&\G\$YOK?Z0Y6?YZ<0-"5G.6=[6+:?$[!G7]H/,-<>
MPBO8NAME9\;1&B0M%(::?;>P$#FO,9L9T%9.'/3.V'3XFU>6#%GM2*EB6NK9
M+^$K3E!QOSZ.?WCP(Y+LD!*R5KCO^M6.0 PH:@2=_3CHKPPP6Q1Z#EJRS1<-
M[M0P[F1TOSU1R)'DR<>%MR:2ZT6F) Q5[= NC9!'GTI/#6!?T @!D1&Y:GG
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M?;_W.^O<L[YUUKF_V<]:^Q=[[R=^3^Z9N9V]709(7R@H*P 8F " <?<!;N<
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M/VV_.^/X5Y@N'=4$^LH3,9Q4 K5U=CI@JVW(ZGHU#_&A=ND++HE_*3H,8&F
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M9F!  RRWHDYLVX([-J$V_ND0L?(Y]<:6(W!W;^?"/':6.DHH[K3[1+#5WO1
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MZC-O73<-D]@Y'^5?RKQ+<L4A=U-3ZG<#8QL!0>(T]R]2ZR<]YK)T:(\T0DY
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MR4'1G5B]A3VE;22]+@ $S=GMK)-,DL$"_J#KP)%Z&$=T;+$$$R;U/SC.DB/
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M/()UHCS]FA*T34D&>.S=[V_R?@1LN+OU=HX.^#E,''Y)NJ)K,E1">JLS6)7
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M"YM:78I/A"1SZ>WC][[2HF?"-?EOD4YB[BJ_IW]AP,_%9=2Y02,X8W7N>I=
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MUT,!OC>5"'NLLY.K >^[QOL<;A4YJV$LPMLRJU$K112 6 RI#N&F %<VRBE
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MN><___1PAI' >^":0Y5L'L,>?74S@+LCAHS]^AN,70O(!,1SE)9?8H2C!8_
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M\9T[[ACGQUW9Z\<>>ZZ9^>PUUYS/DQ\YG3U=!O#<,38U!M#1 P!T9Q_ Z3S
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M"B.'=E4B>Q U^W(%2':)#5#0N<VLYR'5%866]EM!#8VACK%N-3)C-YZ&T;\
MFZ ,G5T_DDSZ1.W0R:K==MJO$_N??WB?'5V)RIS+%!Z3.'+SE]!:[3Q'DAN
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M)52%DSRX>9F/]C4H$?MI?:MDY.)0$33FS^#;LV(;%6*ZG\_>JC( B0(W/(+
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M,A#7C$-PDPW[37%>#2Y\.FAB0Z_+^N98W^]:J6A;9\FG /&?WC06\L754\"
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MW ;= OW5O].)F1+7ULQ0/=.I&TW9K=!TAX*AFN'G[Q0NB+4PR$136K9=1XT
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M4\1M59*?A]7UQ0N?3["<Y5?6V 4CTB_I'*NX_G"I/O^<TG$Q=TF+;T"M<4?
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M^3^>%"M_MO-A9WWQ/VY63P$X#[(%+>H+$GOM3/,C>X>)[PB4YT#*JL590U:
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M;F;%L EMQ65EPWX7MTI3"77]Y26SAW/5&_6\*+[,5T+KJKTN^R9-OT?'PE=
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ME(2F\YA((>&&OG/G702U#?B?07V/K*R9SDS[(^R&.Y(R<JQ[,W)QCH4.;=K
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M*B?GNV530DVX.9'<WZT)EDQ71X&M$37,O"S%SW6P_$W%5'Q6U#N\YZPM-YI
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MLX9@Z?N0H+=CVS9L4>J5)GXDMBRVHN6:FE,XON6OEA<(261 6E= B^2%!.B
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MQ,_,/W<Z/I3T@D'2S,Q+LX?7D?L9%\1'  F<'-4D!]S J*Z $SONX)31J1?
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M%W]N=RG?&<7I.$H*FG.<]3+4F2[\FGEZ^^I/0R9>679=F,71($[D_)VB!/K
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M!M,4WM8U2O[CBO3HE?OH6['7LDJ,9Y.;MIRE!GKSS<(?AZQ3*[L(KL.O!TW
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MK.IH[[AG3"[N2^/L^$&9B4^P)BAVJ$8@IQZZ*=6K2''7\]C#E*?_Y0MMK;C
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MLJAQOWF^OL?]1(LG^\D]%)P59_1$RCOK,P==2DJ)Z4-6 X3EJ?/=97K(_*/
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M?'>>WJD>PEII2TLO)3B"&'OD]I?'#@DS^5=LZ2 %;55.=07O RVA$&DYR@A
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M(Q8A>$#+6W&_)@4D_1JO+-CK)=U+J2V'HS(5%STL\C*:S'+KUY<?^2,N!7-
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M>RPFLT#MC:P[4= MH'6*Y)"3+32]IK([M*2RT\0U]5QUUH E-G<W&^O54K.
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MAI@L&&Q#_UA9PMW\B(YI4T^J_*3YK;YCY/N=C6\TVIU5'N1E= L+8P"S)8P
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ME%59>@]N1^1E)!KDOL,0S+LH_^NTK1VL70D,Z%CE9 (Z+% C6$)/;_\[M92
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M([G!YI0S&3R&3J>^E:C;GU]$5JO=$QK!ZVQ=/''5+6M:_]Q%2[H\O8 XD1;
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M_-+$1K@@CF7A2?'.X]+S!P;;1^4F,M1ZOJB437,9O;=,Z_)@IDH#-A,,&"O
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M+O$#9.(S,R!;G0LU\BJ@ ULKO?%F@S0HH_-5O1Z]F%3.X:\5_Q,TC*1.5>M
M=VNU6 2=1B/&)>;;)P7))<\3\[>R+ .,X+^KRPBAC5@AS]56-O&T;]<IKL-(
M39PE/0$\._RS,E&9Q_?519HA_"+V+C=P"EV-_F+]*5EQN81RU?N$L#_'U,AQ
M^@)O*[HW).!@?_<,NBX),I@E.(V3Y:XO+CA5MM@VH;RO7NRSPQUJ,#J^EPI)
MI?V!W=;PX#&Y[S8A7_OJ/FX>9L,:8=*A\.:)/25"2@9]B [X'1GT4>*RLB\#
MEIY,_&C^EWU5R]G3^ ^#<PF;Y33.107L4/,MJ0^ONTA\VLL>SVD1A#C,$@XX
M0Z2E!$"\_5Y^._T 9@@*._L"HC57(&=#<]Q&K:-SQ?4T%J[7<'YEIBC0Q5'K
M-GG8'_HDL!()OL#,/XV96Z/?_-F[C:!Q:@P^ '8+VP(VS.56:%;J?E?0SR 5
M)8+]4P'@P)IF!DQ#VN?K^+8W]1#=%7*Q*9TKB*A%Q*1BS.LUC@@?.!WP =W?
MVPSX]F\84]Q ;<T8Y#*K[S^<+,41V:?8T]_U ,D.JMIB-FS!0Y UB2@V$*@;
M4$#K^$/X[4/?&Q\!:=P?OR"!^%T*LL KDD0$N"*SE!-+]94*$D]I5S\0@[U"
MY%0XYXX/5SE3_7XU<=KH:RSN6VP^53;QHKP!Q'[O@@JT&3_5STFZ%%+XBIAJ
M7'W.B,BYY9LQU@_O8-K_7'+;%%7D'+[H\,#K331G](WF2</^[(!V;,E<.-$1
MR6_I95'/:^Z>E7DD?IRG9\9KV@ZE+LRM<:WZL<\SEF0JJ\X%?:.!^-\,6!F!
M.+<V#8+E4+PO\(?B?1)B>Y/85 V1_C!M/SL&[ /Q!9%\%0M>U*1=U9T6HQ^@
MG8'B13<#1HF<H8XA=CJ6_6S^]9>QFY(M1_-']7]JL)6^"$)>W54#!<]0XL$@
MD!/BY L096]$D!=DHO$;O.0DD 72XTWB_SB/*9 <N6O_/QY\CNX&I\U+^<OL
M?>C4-]>CP@Q$UJG>NG2R6TJMV\]I;E-A%D\V_:[K3JJ/.C(BY7EGA?H:34^L
MCJ<'81_BN /: I@H0A%3E2FRBTNW>T)&I#/;UH0-SJ'8S7A9A+<([XD313Z.
M)H!KCO-E&\^#I*RF9E#9^LPY#2_081&_ _^XDPOY;W<<5FU\WS.'*F7RG1J?
M1Y)ETJ771)N)<6^1J9B*0OC$V3+></"0%XM12/F9WR%V?^8NNYY2A.=<081X
M)NS02&VKIH;JW+" )]C:^\_>#-\ O'.7Z8LC(Q8L6Q+\B,R ^ZB%.1J/&"KB
M&3PLV9HRI_"K\8?^KFI(^RQFG:.Z&7IT#US[^IF0?Z_S[[00YH<GVVGQ)'8&
M;$ 6TD?JTH__DDMIK[[DA3"D8$-.578HE5(>ACQ-+GRYEI*WWOR^[M?@&:/.
M^ $57Y/Q>BS"D0$[7L67!43IF=E$+AQ*[)OT^(61C2NNE6# #J>'F@BE53A1
M9$X.6ONQ4P+2*<Q:I8E+M=183@!_JU25Y#*-6SGTRET8^^EP"[.GZ,DA%>J?
MI6Y:X-:01&K,IP&O*.V27OG*'PI'KJZ=21U;'+I.:>5GSY?D."0\I_"TZ+\5
M/ L5IYIQS?5$EG8L._)1;Z&=A;1LH\$O=\]3PUSW/.?BYYF4\]T:5<YU57%_
ML%XR[UTV#WCG$*IM__8S;)DE5RSP:MQU@CS@/3EZ9\H@RAD4!0J[= ]]B)DF
MCP5?GFT2FRQ\@%@?4Z]I)LL(ZII\C@0RBYD+ +6)2X#G!$99=M;0/:^-Y)UK
MM?VU,B'JYY_MG0CF ;85\;02YY;1O=)OX'\\" )M@*U5P/Y9\X,S8)9E</JI
MU&H;@@$].4 >6Z_B]Z"#YDE_2R?0D\L/;R'E6L=G:T71OBPGQB'5Y4-QRQ1O
M]GB#FS\;2>N!O+210#\>S( %P\$F'.!G#L6VRTC@ D3V,#/($@JR%?@X0I=,
M(RH@)RD8Z#B>B3D!;$,]D;YN&1;)@$T04B_U2,V$W2![Q&:TU;.Z/9'\W4(J
M#W3\5'D4;)_B5?E!)U;+.Q)9D?8RQ\UUG^9_ EYV69VN&T"DT'K/2?IS\[WT
MUR+4)R^KB-,L*:Y-KIS5E=-'G*;->@X-Q9RKNTD<51<0W^)N[N^<((^;9/\<
M'1ZY@=:#]&(IGSMQ:+B.4R,SL=;E_,CT9</C,I.MD3N)Q-O07<4CF%8WG'G-
M 7S>L+QD+F'@6=HT_Y0)?3EXX/,PWE;C4EJVJMYF-VE_0&3_#(K&<QS4L0\D
M+O,BP1AN:CX:$I"F!COG4O<Q8)\MH1<BC_H],TZ2G-LY\K_-&E61MM+(IX#X
M7:37TO6;ZV)?N\]X:<CZ-?#W"^V8;^@Q@]?-/>F^$ 7Y$%FEH0'7H8&RC^/B
MYLUH/2W\-Y=?9EII'S"X[2BY@![>W@J(GT V%V@N>S3)L -A'MF9%;A83T62
M#4NOP :X)%;@UXOVU$_+/W!YN06IO=<;BN3Y4([EHRE6?37]D])MWIWFHOBE
M4[!&:->$&7>]N2S@3?]Z"KE[ZGPY^5WS28-(FO*SON3"=Q<2Q01//+-S-;9Y
MI?F1,#@^6+E%!IY0EK1*OGSK75&Z.#6U3R_=R>U0-.[EYVLV=OOG8(+U B]?
MT%9M0^+>Y1]XMGU2Y75:LJ#.GPO-EK-5!M.$E3!RZX30.Q]W_#%S-.9SEFW'
MLYU$S+<3&^P?:,&C1<T%7ATO\E1,\XM2!2']9@E\9WFA<G#0Z^R8^TE"I$M'
MRU&D[)"J6B7BUH_3ADOK/B=IH81;](_52ICQ4H.&?!(/)J;$:^W1<L^,]+W]
M*S%86>U5;859]RTO'00JX\/V(B3:JZ!(ZN:U#\T$MJKP*U[8430O:<U5\4GP
MV(&H/],^XAGL0W10^3BB6@[PK;L4^ZTLU54%=.<[:I[]2P2OKV*XV);^/8 V
M7Z&<'58:)7V^CKN\J"1$>B+BX+[3@5P!JE4C?7F&=Y-R.CW^=_FAI__,#Q$*
MD1.0:Z^Y4SWI003D!C<A=NE_IB__RE:H!H39^KN0P:6,TSVP]$/]'3/\[3/4
MB(3\53S$A&E)Z&,0@$,\8KZ1$/(W^U#\( EY U&P8:CNIZUYYN])RL:=_]_D
MY3GZQ7AY6/TT>7HKB_(]4G-F:&PD1G]<D$T_35\EV@P[<9;H@9G  1*D&B2@
M"R(6L)REE1I)QN1MZOD/MD:Z R6<)Z9+7;2W."^N6!^T,C8JL"_I>$1+)60@
M)U+'CYT"W';O $93JW9!K7?6GWU+^0U;1[&VN[X_19.<I29VK6(.Y[@X_W&P
M#VF(_1%VP%0@2"6T.B^#6^NR2@:^*X6;3-QK2SD@2DZ*H2EG VY3UKF\H57&
M+E&P'A+'L.XR^T'99S%TSWL(ZR=HEX7DLI?EMMRK*=ZN6'OQ-D^>XD^Q7S?9
M,X+1QTRBYUL3'8I';V#]7;/,+*VMVA*WOE!*BW^=JDMCBFO8@K$U4Y)P- 7R
MNHZ_00-U*^6#J;!H>\Y(AH1_Z)2L?YC"3L*N*[96_0,0DX[V@D^^[\H*?LI^
M-?3+3UO?#)+ ];4<W_@@30'C27+O1<Y2DY2:W7!P!+&/203D<8EHWG7]YZB-
M(_5D$3!R;\B1/T3"CZ.#%7IIYP"W?#]+(.H#H';S>:&"H,G,/77F$.O"N4YC
MM8LJ@?U?URHNHIYB PNQJ@%P2F(4!&\<@TMC0CVG>Y_Y-LJX>A_TT&)JTKB^
M>L0O'EHI"[*:%V[+I;S_5%C;N^N]-JF:33IJXA<5095.5%_ 07((+E!), UP
MU3,XWZQ;^K+K5+2=Q//X51]0 =Z 98;H&2?MP!2<;3%<J-ZT*/&WM>S=JZ].
M^.;6,P\\MSXB$9GP0*$8&]@^)Q$YKR(,(.X"F&EG3!VU3?I@=J:5\J>?]7P2
M7C;+]>S*X84!U0ORO9TLRWC:<>;I T0<T7Y 24ZAB8ZN6RO+;UI)O'!1AM__
MRH.M&NXM:2P268);@2X\2)S2PT?*:\C5/#D"IOX*)PF+O58)^ZJ,FT:7(ID8
M,(Q!&*)4*!8C$[:YA/%W[.#;D!PTN?;#0B PC!2(C7BJDB(Y<Q$PNY.SJ.[[
M*<-7FJOEX<M#R=IVIM.&B9[",&5M0@P6@P;$DX*KN0$?!NPF68A@/X7CTX]A
MT[,Y_<OY?H.M[]>?)>SD#ZF:EPE7$\[U)4EQ-_EY0BNK#>2SX) .#SJDLH\/
M>5EWF%VYD\#+X?F3I?O/G=4,#\)+B;Z"O#%,1>9L9HYEBS?64Z[]R1,Y%V^[
M^V9O<4^US^;U#W=FY71'\ZK^OR8[]C:O[]OUQ*-^0CVKF_C0OA;LAY&?_;QC
M;.>+-+^_M-8]>]GT39QV]"2KV&J\%;Z>&#7&#[PY/]%]_D%IWR/3,V!8[DWG
MS<-G181U#_O5'-4X\<#@/J:L4 :23X>49"BG=3$%)HT?^Z19J&=+;$Z55Y<Q
M8(5N9T_ M_3O;A_\,GL' ,G7="1_A+VHEO22]I@/D.RFV=I]'7:>PF#/3L -
M5(XR45]G-U,,ICC>A+AC7_2O5SSN<D@N**M3K(A@MT<4R-AC0[+IWL^7[J(@
M6ZW;[/EM&,#M]:>-@^V=Q6WB=O_0!<?L*=<&9QNV!21;H90E?=!]Q?S07=^$
M\!\.6T_!9.:^_!= " 6G"F ],9F**05>J=O(^^2MQ#3,(*7WB_V?&[%)C\0W
M"]VK6"@R3;DX3J +<<3LB^< 8'2D^)4O?\33^I>+'W;[;2<0(0$\@+VS4H!0
METU)ZDSY*/J*[*@5<3OK;80W?+=AU]!!T_/Q90*<)MM?Y4\8!-*G+%]]+7VB
MDC2IZU;15;NK*X=M]0Z['V ,'DO%##BD91D]'=D7*?Z/GKZ_[8E-DXD9XR=2
M<+7C_ [F=U7]=8TZ"U>DTZ2XE'#'):)36411T]NT:Q;3XW2VQ''@8MC>L)0/
MK1+=V:SG6J1OMB?E$'*PDT/C0M#Y[N[]A5?T/X:KK+CBL!L2%MB))@0H\9WP
MJ0-TWP[?\8FDAH&"!102&*+K2CM1SX U&D*HT0=L,V"JF>4@N\W>L!7J+_@<
MV@LA8XB&V%E]6;4R%"YR(=,+/H$%\LIM(2W6#%"\)M&JW05,))6T-XCMWX[^
M#\/6"57PU_.$*AH?=$0D$)QW M^0*MY9JO7[</,CH9F:#18V.;29W\F]NHG?
M6<#,$Y/K9%("M)H$AIDIW&=GF_[ZPB\;3WKX+>\AU[D"P?%7IH#<UB7Z"Z4;
MNZI.'M7"%';>JXA VWNS"QT921-"1@*;UA?0'U9^!;3.7^4."Y77/2*B4_:R
M6:_HN?1*P<<36M.W]^4(U1@/3&O9FDX;:W4<,#8,A,W#LE&_II[<:?BY-IPF
M+KF6#QYF9<#.R-6@MP[C&3"-2+HQX3EV(AU?7-[@.L3<+'2\QX\[O3'7?,!4
M=S_I3,\3YZ<3ST-%E$S>L#9Q]V0LEQU'BCN2L00<?9*VM$ "/,J;B51N:2+9
M%B+[W/I1(&L19>6!JI^D<V -'GBSM^*HWG\NEN;*WO<>PM+7P._IT JKH_.2
M;\$QF69JP@VQ=>'U'2&PW@K@H>$?8FG_\F8:V(5F=_63RY.H]WF+UR,VF?=-
M<)SP%7KA>9!XI%J&)D!!U8R?M/*R;1RRJW"GH97TZ[=1%^U"$L_._WSL+7A(
M>")(DBI"4 &ZR?RU6$25;(58=.F+GGL14<.6YP:52V*#.K_.N#V/[9BP$T!E
M!C=5R<TD%G'O#7O:G9NVIW&Z-0DA*E.W)YOR7:>L%!,M#F\?M1+;/54]#9[!
MS"!X MH@L:$$%RDL(Y,:/,)3[*VN:D.V1 SGNR:TN;%!D7?*;]+2A"7W?>3.
M'C2BSD@3YR+;:I&D]U.Y\?'F!9/*SF)K%AH]/*X[L\Z6BC.1BS2Y766:/N5U
M4584&0J125,&E5(^EG4R3:H?-:<P]N+-)@W>=!<OD1HJJ0'+9>KE6>_SH(GP
MR9J8=*2@F,=VT2#M>8M8(-/9ZFK@&F2.GX"D:?Y67]S)=LS$+_'W+7RQ+N=_
M3 ?FZ>!R7>N(6DA[!FP04X,N"4B0$N+JELL9$=8M,%^"NUT66!FE2:9Z1'.D
M/+%V$;F0J6T.?PLR%_T(:$06^^.66\B[SE-J;M/2AL:;NCU\PR.J,?1&NH%*
MPH8S%^IG3ZY$L5OB\H>_]K11N0G-^&@\V0 7,R8-E$P?<;U%_E4UY/$QWW+4
MXH?KI%%G5?3/QQ8B09)]K1*J[__,+I_ULT!;8FNE&; _2QNDW0/6V'E)LW_S
M\^HP^@NDK4SD^'X&S.$P\CA0?B.T7O-EW>S!MS(BK\(>7XH^)U;F,_!>G<\P
M^0ZJ_ DB"PH<?MXWT+]"<QFP4]>(U&5(/QTC+*@0CY/V!N=AA1X2O\4J23_Z
ML29W#NP,>P4I%J?O;<6?SJVOEWZAWVQ/6/HK7U6$="K&#V*A'XV&&;"#D#JE
M&&^B:,?KMW2 MV3>J2]EGX!V]2C][M5GW:X"L:.:YV2J!&RTE0_XF%9L9*KJ
MR.I1P^E'H-CV1^>*3!1^34?)$8J&NN-[K1=+VF!1=18Q'1WNH_>;. $_[IBH
M)5KUO?N\\T?5QWQC9XWY5EJX 4@ID_6PN <#.+;A>WCJH7]X'3'1.%M?=BY.
MU;ZUC'H1L@DW!BSV':3B?<R@VWZ*>H']=ZC;5019*W<OT%3I>(5V?DNO82W<
MK2BC\B\O!]._:7N^MI?>UFX>XQZ.(>AX>6M =[T3@7 WMKISJZRO="G_\#SG
MXN_%2Z$.=GPHC1/"N,=.O=QK#Q"1Z"]SRZ@"L%U(_#OE8,0#Z>WZRL%U5V]$
MVR,SW-%67(5<7;E:S6\O0H(D5;?O&09^S!'E\S#7GN-C]FA31SOF\?/IA$.U
M)BQ!DA,R0W"052W=*]1[TS6D(MF!5V]=D/>VU-X?M!:)21'58M':(6UI72'.
MNY'-,S'FGWL)I<5Z"2N-'Y5O<1;;KRFL"*G0P\%+?E<3#;$31^[<+E=K[,/Q
M#J?;+.U^^HP@,5D;^D]@CRW$O2$H(?/,M3C8#!Z<%J#>*_ US&7-;\P2D5C=
MF@+1LK/>+J(@K= 4?/BQL%(-0$X3CX]D5L=.$(\ZN2%OEG6?C:=,^CR]0OC'
M_/']@T OY:#7& .FAJN[Q'X#$_/P-NXE$/%T<.MRYM6>!8*/-M/:S/>J<L]C
MM?M=Y;L^WWRI(-76, %C,<)LDD#6P5U^7?(=596K%/?8L*;DC(.7I1^BWQF4
M/^+,\(C]+#?"H8SY0G\#F0N""6QW&\9XGF/ 6#6CIM!)1E77;<M=9D]0H3T.
M?ZCWJ],)*4W3O<;+"\[C7[O8Q-.J;N /0.%3"VE[C11IHD<1JTW$.E%X4IS+
M#;OOW6KQ95O_#MO]G8Z4,6&.?L^\HXCN:O1SW#6"?J+H)T))PQ"/>BE/D+%1
M9VU%TRY#9K3Z9DTWC=XG!H0%:"FL3A0M)F^Y>\PW= (SZK[C#:X#Z&G[>HM<
M(U)-Q<L2IQ<A51WIBD5?-P\+6<*W7Z-PHU[\#8F*"/MO9##?5<5CQVA0JP!_
MB_N7/[N3JA/%,>YV15_9X>%G05/46:^C-J<3'SXP7&:MR7.?3X734U3$O:AW
M]5AJA$[U</_>OY3]X]7<F D3RQ1F!3[8#;+JYH\Y7:H@-D9]_?1(Y-Z<ZN<D
MOV(&K$0T.$2H\JG_DL379'GCF5/X8Y:T4_V? C@M_-0J X?F43X1W04GU85'
M+ABUM2ZFGV@G=/0?0Y<@RK.7.Z?@D=@#-)%)>&CRD=PHC>\'I.['2D^''HC.
M"VG95WWH;P"A78U?/^-*MFA5(8^*]5\3F0$*?_%&>BK9&J\2/T'G:%I0JGR'
M.7$J02[E4PX3'S5R7>[JYYR/+:+;)R\YI$62-?;H,)8Q^'\ 4$L#!!0    (
M ,N $UGA- B14!8  !D7   6    <&)M+3(P,C0P,S,Q>&8Q,#(U+FIP9YUW
M>3Q4_[__L366D*U%92)9&B)$A E)2%HI8I*$)(E"-&-?(E.$0M90&&-?A[%/
M%,K26&+,C+)GQC(.,V;N?+Z/W^_>Q[V/^\>]]WG>C_-XG,=[.<_GZYS'\_5Z
M<48YT\ >J_.6YP$>7@#@X5X 9P(P _AX>?\97/!SAX"@@  _OX P!+)+<+?P
M[MTBPB(BHF*2>T3%),1$1/;LW2,A)2TC([-;?-_^O=+[):5EI/\YA(>/NX=?
M0$A 0$A:5$14^G\-3BL@(0CH ^5\/ H KP0/GP0/IQ. <GD*\/P+P/\##R^7
MXRZ(H)"P"'=!S1Z EX>/CY>?[Q_6W-D7W'F 7T) 4OZDR2ZI*RX0!5]IK; W
MN8)'32O:9*[^H"EJWWT2+B2\=]_^ [+'E)155(_KG-+5.ZUO8';._+S%!4NK
M:]=OV-G?O.7@>L_MOKN'YP,__Z?/ @*#GD=$1D7'Q,:]3$I^FY*:]NY]>E[^
MQX+"HD^?BRNKJFMJZ^H;&ML[.KNZ"5]Z>@>'AD=^$D?'QLD4ZLSO/[-S\POT
MU;7U#<8FN+7]CRX>@(_G_^._U27!U<7+S\_'#_E'%P]OP#\+)/@%Y$_NDC2Y
M G'QE5+0"A.4-GV36]$F=%3[*DWF[I,?PGL5=<C'Z/](^Y>R_YFP\/^3LG\7
M]A^ZQH'=?#S<C\<G <"!#<3$5[8PWZ<0%>(C)#3D3+H*RUPX[-/"4IYM19+6
MT81#X>"1)+^$]3[DPT740:1\(/JZM\4U.B'6QR?^T5K!\!^UHIWLC-]R'3)1
M5*B4$SC4U=B/1QVU"2YVM@G2KNC1.)H*[Z^$+=/ !_Y'DAPVE&9'H57*+&DO
M @<0VF"JP[O3,;,)./FCD1]\9K2=)C1LZ+TD;5=FZ:7@NW@7UAF**+PK72P;
MXVFO&E1(:DW3)4IDEKXI%[C $D7IR3!M.0!_)UV=&(MW.ZP$^RQKN]1GNM"N
M0#B=(/,8+JY)3'[ODKN_N-SNKT[(%0X@@$B_P $>P.Y4:J%!"\QI?O26I]%M
M&HHE2:7 $UC0CV#TUZYTM<<+NA637;O1FD_%<D*1M]W3<[E;[W* Y/Q:#E#Q
M?(@#G+=UWJ%QX_:!1FB#BQGJYTR"J,ZA*<_&$-U*'4V3B@][>$VT(A+05J1T
MW./AG? FB=7-Z!95%F(GC*U#(/?Y76O*OA1&35JS2/U=5-U8Z\JNU+04?BPF
MV/:E#3NF =KHW PYXX:97'B6:N#]2U4G8)^VFL>-M,<S;T:)%%1W-G21 ]2Y
M+T,]_<@D\:_>Z@MFA6/C&BNR*F^SIRYTA&V^RVJU6UE^3W&ZBA@W,N2C8.S8
M'6U9!QP/']^OT*]0N\>\\4[S@8QC51'#8B,R--+-M]+5*65+VAMK%F#?M UR
M9:DQ(+[:J^G#Q+DK4]TWL\]J#Y =GV,3J@\+SS@N./S,=M&_3(%EO'T5:R0F
M-(]X;ZRR$\V68IG1HLIR:?LH-\IR*8$7KQX,GKRJ*:O=H7UGUZMND[;U;EC&
M3@42"+&@H9>VIK&2@7\7#NZ@3!M>* 1/6$=H9'AP !V!B2;5W0U&%<[/VZ]F
MOKV^_$+M9PZRKD,G8,_'"H,>J4]N_OJ[Q4U%[^F]"C%.SV9X>:4_69"[$[-4
M.&\X.3-]XM>L_C)"E]V%JA:HB^4 K@<U)!;2Y,M8\N[&'SYI9S%ZWL5M?#M_
MXH4E-IP#W"OY;.A.)Q*@LCCK/[_F6D2J<'3SWJ8[ED_,=M(U-N/=8G!WJZ)%
M\9[?EK^"Y7"7$!LJ2AS4^F53MFAG<,XBQ>MK%#I@2#G=4)OJ(P[V_QK(]=(U
MP)V]5_.AO:=N,:(+Z<+N1^P:6!ZAB$N$6(+-E,]I%ZVK! I31+_'^1$?S/[-
M"X<<RG:(8"2 W+^RW">>=9*^CZS\TCWM?$,3TV@J[=B79"^>)B_7E?.]^Y]H
MB>G/QF]GZC>GP?'S106M.[8-Q/6O1I=$#5Z8_CQLZML(NZ5T(]5DX/C'F74C
M(]&["-9UVJ.4SX>-U[H,C#!SIS6M@V7KC2.ENI"/D"-(M9](3?8P@N>4+1^I
MI^"!LPIM,J>J\?:?B8$LLMQ%5&4IP7@,^[$,/_T.+XC%G3I5,[A =)9/E3SH
MG+Y]_MTWB^WVAO&@V?VE4W(?3G>-)-NO'MC 21'\A*UWQZM=XH/E?KGS?(]7
M%AW>B1<.U+H1[T3?^_YC[VAG0(#EP4/KTYG$V8 E//,BB"9K+'V@.X]OSV\X
M76N7S7Q^/W&H(EGRU[YS)EE6,::MJ!J$%4MR)P&G$"+O6<:R'KI+GWVU$9NZ
M=J7EI]]I"]^FKZ]LA?-/4PH#GYKC/=:;JQ<@@[+*L?YXR;'X9N4K-<,86TN,
MTJU]:_S#VXF?W?/'F_MVAG7M>C8+ZU\KB'\VM/]FAZI*;:99,*)I [%(Z;']
MAGS%,;7T$]%U5J\=$T*2NQ,[,JE1_+077GDT0LPRW ,=ZPRC0^(XP!#K&'G2
MP5OD_(^/KHP@I3KY1R?N.2=>S'CCURJT<LO %WQ;S7H!,# 'N]ER=)D.DP*O
M]&?Y!@GOEA\EG><C B-?FX-M*M(OE/E@II-.G?BJ&&;U22!.?SG4]KOLFD9L
M=M5 ),LBSUHWRM6'C)8<ET^S&5E_N\>&/S^%6?_K8UB*H<1UY ''>52U<CM&
MV8%^[)U!=2SC^<OVWT"6DD<!WV'T-\'UN\?U%8A:SWG H^8O9@M0;0JX@.+Y
M9P&?J6BQO-OMR<>KK\WLNGP6KM'LP %BC,!-=@Q>#$4J0;.56O"+]:A9)4+K
M#2:4Z[ ?N=[G@&**.W& N3W$/CQM%B_' ;YOD@>8&[X<H),X@:^P;>VS9CP#
M+5],]SE>J1GQ4=\(FM73=8F\9^B[9]>T:% ]R^9X=9 +K.D5- M!L]/8,CCC
MP]R'@:_?XZ:EMNQ1[#0VMD4*M+@^'"+@^A054.@X8-BGEM-4R6O9L7F*FEV7
MW0Z/:-$#R6+Y5.S+05#;4=8<9V9C+:%Y$O*V-"->[&,YH2;8/I0#>*-"V1#:
MHSCR7,N1"2>+0@<+CRK<Q8)V%:?.9_TPX>3/:D:G!YM_,NKE)FG4Z9A0MH2Y
M0J!9^S@R\E[_EC?U6ZGXW>540JTO0I[]'2$)=X<F< #9&3"(#C'%E]/=/FPR
M[!F#!,:+CWJ]%S\(RPDJ^AO>;?D,!C,M65I@27'M>S+BP/SS[IS/N D3S;63
MZT9>K:A''&",.5T4)U])CT$_[3$4P4P:C'9@QI56C-I3KRCXWY5QA!RASL$2
M(Q[4K3S*6*Z'JK&)I/*T*"1?B"&.OA)IZ/.G //-*MV[,WY6[]U"L8*;OB+O
MS76RS?/-)1=X'/P!?I1)@8>Q'(-T/\F[>A8L[/O8H[2:=9=W-KEF)&@QW M.
M)K&DX&THF6I1Y4X[Q+ZG6$GP;A!?7OSE/#>[#L#Z0]&G?C'8@FA =[80_@XJ
M&BDW>&)PUN)[F9*'^OC49)EB^IV<IB_77U#T^YZ-8/L$K-3[ X:L'5J1YP)A
MU$LUM&QR0)=&=(%B9&!L!W]QQZX#"F]+<Q(G7I?#31#^[ %HU:OE&)94/L%3
MX#,'B$SN-G#KSOM<IZ&@\#?\))MV"5*2#BYV&9Q/8UYCCS6^=>:O>N]O*[D8
M[M'YZ7IL_Y!A*3SRI*2QN,T(,RYG[EG6H>^E.O$JJ3 8S+_VI:8F[_'0TRS8
MPZ<^[OL_E>C=9Y]%]_B,:C.>@.9T9OOV"#9!8\7;\(;+TZYJ^SQ1VFM-TS?]
M8B;8*^ 64YO]%5$U8X!@*=:U'&EJ&%8\V>%>-%6Z2C.F7\;MIF^<6LK>CY].
M=Q8&XZBJ.!LR!G69MC?_R1_K@J'+AE=/ZJN5I(Q;SDQ3QS-H:6RA_.D!7K 7
M*@D6=3JDH;'+]R3'"9^/7,AW24YUZL-G2GR9GZI(/2Z95LUXI?&; X1#7H$=
M'8T647#O@;%@J^_RC74_,#BCA[5O$*BRFZRO>;D[-*_U8IPV!;I4XTKE ..P
M5I(,R2FK>[;]YU>?O6F'&ZO]HH(<CZVE<  '"[Z:X ]!-0O%+_?.U3!'!PBV
M,<C#+40D+_*'GD.(N)\NFM('OQYX+>E'A^$2!\C!_H1&9>D,&<N'&-(X0*Q.
M?&1#17/5RW/^^H1>+?%<2(+].W8_JA*9QH2+RRDL:@4FDKKJ[BY01)K<S!.0
M:ZJAEZ9#AHB##8NVHZ2K-"7,)TM:!R6Q;EI4<@LWIG-S.1]7EVCSS3+^&_S(
M5J/XI9JAV))+N/3FFA\L+EMYN1BZ,O4W.A2I DJU/IY??;!-?'GBL&'](3Y/
MX83J?GA3*.KX*G9LDPR)VGC/EI]K'&"D@Q$7Z/<+&+$Y(V68#A/#92-<KN19
MS1]?]/F21 -(N_!ND]ID],L5G O&B\C6HS=3WF7?'CDK>NC>SI?7]XYLVYM0
M5\)]P;0NB4!LQ_@R*=+PYIM2R0>Z'I7'OIV=L="Q"3MR:'I&(DO4;ZT=EB0^
M.\LV._X@FR<$DN]99[_I4VKBY2UEK8;&3H46YRLFSP;;Q2QM[$3HM6.4UCH,
M#,?EXI\/3CI.V!X]4^ZN_.U8G#)J:F83*T@G)K+D*>)QOBPC,([^FG1!*;$7
M)>(Y'EAAW?#^QQNWQ]^^%>5>/BM?LA@/4]&9.*VN[F(=[+''0OI*PG&5_8!8
MJW!ZYH^75[U)Q V^,VVD594YU 85PHYW&"U%07S)ZGL"]EZ.6#(%O.XV9"WQ
M5JQ#0181OLCD !Y=CC)O<M:>8C3U14,>HY;?NFZ]W -]@_K/YKN^$LK-\AQ
M..0&;:UC&],YGFF?'OU!X%MB4@(D<"01+H4XB6J[B9^96\8O.5=S@!_)1#<R
M=%29RL"3C:!7R\%$]24--4J6(*KZOM.;2MZ2T,!6A9:4VO)AS+5D4UL!\#/M
M-]X=.CY%ZF@1'"D:/C94 SM?E:ZT\W?V>$CA!"E38@51Q %J4TCM'LB#H#=;
MR]'IMJ<H$G_?\:J92/:Q;6KMY,861AT=SP%<$.-G+@WC_/)& _-8 HV2DR??
M78R<[CF899889+2XL (>#WA9BO-C:K.TZ'O3N]9W[&]$,R;1UPZE/JED1Z=X
M-*9X+!:MG<@W;MQYKTP[ERW@?\!8CJ F)S'^Y\<CH5^[J$V*S#\MB)T*^ .-
ML:&N33OD/OJ+YLV$B0L- 7P7DA^8R1]TG)V;/-GUI)8DL6$;C:!965OOR+K7
M#/N$#DE2M*/C[M?#Y"'#.8_%O<>*X33K@;&J-O8IFFX-=4#:@[']>PV1<<8<
MYS0O:"[P3O6OM9B-;W>"JA\QX_D9F,]F& G9!9?B /=OLJX<JPOS)] (+WVT
MI<UN>0\VTE>[9\,RUU=>;F.I:00?$?8 4K*&#HU72A4U^+.A=M3C6I!6Y9DP
M]$=O1 :)=@T5.@4%Y2D<8%<@H97A1:86'\BOC_ZV="Y+(2'IR&&AW6.$3?.
M[#J-5UCCHZ@V0[8$F'SY#+;FL*-M^K,-5(53.,KJ2:[P8-$5/<\S7O5R.]RC
M0%5H.UP$M+CXDX)K&%$<UMM?JIZ\V9LS7<6W&213Q/4_81%:/B4KI<2IMI M
MEW8QJNQ^W3"M],<)K5Y4/-:D+]"=)97,N T&4VU#8[J,56F_LV-/V5@Q/"*F
MRNC2EJ$R%@]GDA&R<PA!?QMK!K4!]/F-<SXHI]4X&,G3C_R6=J(X<G/KNG ]
MN7S(+[R9.BS^79KKH9@091\)E'N&^JV'N!48TZQ7SOG7#NMIUXL@,G3OO+$!
M;3*Z.7>*@"I G%,*IQQ]W8O"UH1 N!V=RDZZL5P@'P-508=&X?3<<QX\DZUI
MQF?<S[A8WFCPUL?9-),93(338)2_6!J5+11#P3AT_QZZ&KU-O529;=CQIU'U
MZ)!POT4+[(#+YQL%LF\?E2U_@EJ%>'))Q;!@H![6.J_G*3SVZ6FH6Z?#3;'R
MK"<B_HH2"<+#H! S($0;9)86QA=.6><O)B7)EP^?/9]Q^/6Z\L0X_A3*%<^M
M, 61LK5UI2Q+&H8#Q#\=*[QROWUBX*5T]ZU8>+?ERFCP3^5E;>H*7V R)?45
M53QB>U<1V3YNK_4[XWZ7&PT6O3UR!O=<X7^91/MAU=KY,=)6H\# !/0PN&8*
M>I*]5O: Z,OQ%P<?#OE7]?JN P'*Y=AD^7^%4RFM$S6V[%YBX3:[GP-47S2[
M_Z]XAI"X,8."Q!)P@DQJ:]:]I1@N:F_N=)]QY%F<\A'Y+PSYV&TB$5$YNQ1$
M&SJ_DQURO+$N:GW'_=K/]8S@Y?.K?X^L'.V3_7)=KK>I-N&YO6RNU2N9JS43
M/CG0; X@A;,M#!Q@"\NXE7D0?4GS 5-'AV;KZF-_.XF_-<&.I[/.TN$=,&@$
MJ0Z#CM)I)XW5&BM7Z183CBD$28SX+>T7;\?[+*R)/!G\/=Z:P)^".^5WW"IA
M_%[9H&*L]HSVH?(C*"'%3$:?M^.D68!@JM!5#[3%JP@^\*4U'F0D[PRQ2CH,
M;W"3T@0ZCWMWONW:KSWJ<^IWRJNR=W:K]!:G7K]#SG\M#CU_6M)HE]7HE/!L
MH=NTP?U-8Y-4JNN&8GH?#<V*D)J#O\:,IQ6&(@W^JU]^ C78P@1W,APREZY*
M.Y=<^\%-M"B#D>DS&N8WU (;QC_D %MJ$JA1+?$=,2O:\VV58(-J>=DWS6F^
M<F?HR12-1+@/-B']7CHT6E'27'+,T=&AQ, TJM+98L[(TCAE?9,EC6Y3ITTP
M3, S9(NT@1=[5W^V%;"W$GO/*=,56E)WDE S@O!)>'\&TQ?U)2R' XS:<@!/
M(S^<[0KYTLGJNY#$$!7PI!X!#RIYHR,?3KJ.' O[6WH@$3*N\*Y1E?%09L![
M9&UER9MY6V_I&5N!)MYIPW>EMLX+:WC$IG+BZZM2X:R<Z2=&L/4(QAT.D*1*
MY@";" Y@=HI&8LE V&:I<"N5ZS>*+T42FY119PVQC$QP!(-J.VNL#CIV&/-^
MUX!7Z4S36\NTNCZZD70B'Q?S)KB3?C9S +:P]K1*RSYD!UX4IRRR%9>_F*J;
MP0%P=KTKRFM]WAR@39,#S-@U;Z-_.Y.9W.<>U4$.L*2]CQV7E;FP:A^UO^2\
MFM@UMA": RA]R$,1-XCL2!@9"D'U7OZ+6LI%H.:OUVQ[,Q51/?N&., BQ6<6
M8>"!6 U8Y<9H@-O;Y&?EI5A?+UUNO/,,2KL!WSH%0S-%;W%?L3%#JIAMOT;O
M8 M1*21(Y]?#OQFY_C^3X.8?A V#&,<>OXC#%L,?HK:.7N4 1!:4><J,>8#+
M3\%GFP-D;-MI%I.C+!\5^&9G<H!*+,'H*,.2&&([C8\WWI7DHTN^)VI4^1XS
M<_GZM.;6FVA-$X+,?,N1G<H3;*V0*S]"8#0S<LM[1>WL$YY/1?6/W5=$3^GN
MDI!V3UYT@K)D]NT@L]?9X8T^H!*$%;_);>Y6R^9[)0LVB@XCK.<4TEC2),;3
MGZQK-&*[L<:/)20IF-SD4_G@\LV.A'-GE<Z9L.377AOPW28L<4M4 6/:;!AR
M]UR++!WYYH4OQL/.T]5'O5#X%T%V&:T_9QH%F4?D;V^RPC3PB]P$?9QU.X-]
MB<"F()A&KE&^G5?]BTM6%T)GT[H=2)WPB6NF=&-\44_! UE\;"G6/+/8S%RJ
M4<<,DEUOA_=?G%[A=I4]_9ZDC0UN03!77[(B.]L]?$/F#,P#PAG[-U!+ P04
M    " #+@!-934PW/A@,  "U#   %@   '!B;2TR,#(T,#,S,7AF,3 R-BYJ
M<&>=E7L\T^_[Q]^SS9Q9-J>P#DHA<JR<E@I1C@D14TZE)(J-9BN14PBASRH:
M%B5\Q$:1L_FH)))%!^98<M@HO;/3=WT?O\,_OS]^O]_KOOZ[KON^7\_'];BO
M6_1!- $H.3LX.0 0"0" B!<@^@@<!* 2$G]"+)@XX%)P. P&ET$@)*7D9.3D
M9&5D9>45-BC)*R 59&655)20RB@T&BVGJ*JF@E+;@$*C_AP"@8KWP.#2<+@T
M2EY6'O5_EJ@=0$H!!L E*&0+((&$0)$043> $?N$0_XMX#\$D1![E$1(2<O(
MB@OH2H $! J5@$'_N!9G$\5Y (:$;]AL;">I['$*L24:97(MERJU]4!=!]IS
MD*-C>CHF25I&155-76/;=MT=._7,S"WV[-UG>?"0O8/C82?G8U['O7U\3_@%
MAX2&A9\Y&W'I<FP<GA"?<#TYY49J6GI&7O[M@L*B.W]12LO*:0\K*A\]?EK?
M0&<T-CU[WMG5W</L_:?OY="[X?<CK ^C8^S)J>F9V;FOW^:Y*ZL_?J[] G^O
M_^&" %#(?^I_Y$**N21@,"@,\8<+(H'_4X"$P3<;2VZP\T"<BE;>8G)-"G4@
MEUK7(;W5U).#/ATS**.B8\;>QOV#]F^R_QU8TO^+[+_ _IMK#)"#0L3-@R(!
M+"#P-$#XK9+3, U17>24A,DS0GUN0&'FHQ;]BXQWJ0;!.E?']8II;C.!F9L[
M:GM$P,?&GB.3 V-7>E9Z=Q;J[\GND+8V*KRJA)WP?U3V\G5T#L+)56^Q&5/A
M/<[ =YQ[=:=Z@BN\JS/4E*4D;?+:%>"UTA>^ZSU/4I1L*SZG+K>'L;)SS-L^
M*''WN77)MQ>$H]2SO_P;TZNG\B\N%R#,3$L,7NMFS<XY^7U$M>"YBEUM<GP;
MPV>3B=[R&.?T$8MG3;IGPO9Z7,MSLDUJ&1!NQ$T4"5"[3(6_BT1 6FT:>8(F
M K2*F-K8!HYDD97%??;J+ [9?H6!P7_:@@3K$WQZ)).S-<,NZ9G?M_1P,7HM
M^$P7E-IJ!X*2J\RWA.(A-YG1U[OFWN^>U+GUM#+0P>E5Y02^!O?GGELB@)+R
MD#QN(@*X:$XM<R^B*PK47>X4 ?++6U:[G^>.Z+H3C-F?H"(@L0O, %ET*V3Z
M&WWWVZ=+:X:B9LG[A0I<1CH7VL6@_$JE2]%=MBPHPX<1>A,;*M3GDJ3X>CG=
MV QM5="CM*<*K/>];O\NY(X_K8<9]Y>4CA%PC^W$UY\>![<U9HL AA#YO5@C
M]\ZKTGGMTR'34K/J:B+@FKXP5MRM#E_K@$PL! S;I^!W),O!MV/J:AT5^VOX
M=DX@8>FDZDC>R'AV+^N+C*"B58WHP)734+W1@@NMFG]791;'^+Y]5L:DMP!Z
M[<18V^(U#G[_^UJS_H.]";'5@GL#,,[?MV[G.LE5R#C"D+B2-HZK/Z2,4#6I
MFCV;9MYX@VAED+E5$UX@#,*B,^Q 5I]?UH]U9L6E^)A9_ZI'E+.:*R=&TW57
MS7Q7=.\=3U'SFO$I$$Z36!V\,T144T&P6UJ">]BWIN<YKRO1WVPW@.GL'&T_
M^D"JN<#JY+7=6C]XY7=/V4 C=1'?<7F!.T5 $HEX@E.;-,<U8"0D_J2]>-1,
M^?+F^^5O:B[]*VCU37$P"C?J!D[9VHZ3WS-BNX4SPV?L&1F2#'H2=_2O&:T$
MD^)DC3A]'@[I$.U+\3XJ $OK^%HU.2C"D4,CATB'APVHS2M];P:,H<&VHZ7E
MZPU+-9E^3*ID0<7GP$__U/G['WIW1 Q[')9'NNHSX9-)_XL8.]4?[.7>;UA=
M^<I27YL<OWD3Z8'/POAB^A06M&L+QVCAJB*+(_<MG-+EK9*^DNS2^?HKX6N^
MG!"2C8!*1)2]H2Z6',N8#+V0I>G8'XIUO\,_6S9=_W!^A&9']GD[(S0@F/$M
MP?Q)1?G\_(<!&XGKBU"*X/RPK?4)HI'@UF6<5L#>//+"QI#ZM)*?K%U*OJQO
MS?D+\J1HTN<$[-J>1<<IW[5%Y5?H?WZ-;[ @6X^0F;4Y0\3]X"G.N_8U@SX:
M&.64=2%U:W_S-*;22S8G+D)]SKW; /:])^HI[TT4>SF9KGBSU8)E'N :=\[?
MZMP+O$]+]*T-YF>E;)<^V E_T2_Z'<^<7Z?3[A$48TT.E?UMT*XXAPNRYTSS
MY01)YN-*$9@FKF[.4N2#]&CZ9/TJ]$DX]HM7G.V;,CH!MT!CH[D#B^@)FVU3
M)@?&\DXZ/PB?3E/WYW1JA,L?M3I&0W"/^*PF:'\6 7#UX<@? 5'L\:N+%FE$
MJP=,=9^Z\SLPMX.$YI.V&-#*L(VWCU#6R['3R3\SUD]OR+;]VG@Y:$Z+LZ@Z
MYX]C]&;Y]V(;!K(NU//NZN<^[+11@2-+^J]CF*V?! 6MLC4O>(CQ,WCCRJ*>
MW8$!$O?NY7EO210!<0U:\QG,*3W:4]?Q7<A51;YR\*0IB%U+<E$YVQVGO;D^
M;S W1S+D]R0V4(W<_FB<X[F,WM[&LV?<WR@9L-4E:?3O!*NP UA=]&ICEPA
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MYQ(UGY='UR(MJJO;=&(W1SLG>-U%T#8B:%N_IFC!40WN"-'HOP!02P,$%
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MO[]I;FEEM;5W_/&VMZ]_8'!H>&1TFLV9F?TT-[_PF?_UV_+*ZIK@^X]=+Q
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M]JE XR68"=3I-\GMD;\#4$L#!!0    ( ,N $UFW3P1MY0<  'H(   6
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M !               ( !     '!B;2TR,#(T,#,S,2YX<V102P$"% ,4
M" #+@!-96MG&F.4*   NE@  %               @ '1%P  <&)M+3(P,C0P
M,S,Q7V-A;"YX;6Q02P$"% ,4    " #+@!-93-U&"_PS  !H6 , %
M        @ 'H(@  <&)M+3(P,C0P,S,Q7V1E9BYX;6Q02P$"% ,4    " #+
M@!-9R]JW+2YJ  "K=@8 %               @ $65P  <&)M+3(P,C0P,S,Q
M7VQA8BYX;6Q02P$"% ,4    " #+@!-96_ L /E)   P;04 %
M    @ %VP0  <&)M+3(P,C0P,S,Q7W!R92YX;6Q02P$"% ,4    " #+@!-9
M G=?P<0<   +&@$ &               @ &A"P$ <&)M+3(P,C0P,S,Q>&5X
M,3!D,C(N:'1M4$L! A0#%     @ RX 368"'.X!)!0  ;Q\  !<
M     ( !FR@! '!B;2TR,#(T,#,S,7AE>#(S9#$N:'1M4$L! A0#%     @
MRX 365C8-M[S$   GGT  !8              ( !&2X! '!B;2TR,#(T,#,S
M,7AE>#5D,2YH=&U02P$"% ,4    " #+@!-9U2"#(<0.   ;2@$ %P
M        @ % /P$ <&)M+3(P,C0P,S,Q>&5X9F5E<RYH=&U02P$"% ,4
M" #+@!-9O8JHJ'Z+! #2(BH $P              @ $Y3@$ <&)M+3(P,C0P
M,S,Q>&8Q+FAT;5!+ 0(4 Q0    ( ,N $UF^&SG*_Y$  *++   6
M      "  >C9!0!P8FTM,C R-# S,S%X9C$P,#DN:G!G4$L! A0#%     @
MRX 368ZQ5.&G:0  '74  !8              ( !&VP& '!B;2TR,#(T,#,S
M,7AF,3 Q,2YJ<&=02P$"% ,4    " #+@!-9,2-=U"6@  !(K0  %@
M        @ 'VU08 <&)M+3(P,C0P,S,Q>&8Q,#$W+FIP9U!+ 0(4 Q0    (
M ,N $UE3V7X=67X  %Z>   6              "  4]V!P!P8FTM,C R-# S
M,S%X9C$P,3@N:G!G4$L! A0#%     @ RX 363+-J=<F;0  WH4  !8
M         ( !W/0' '!B;2TR,#(T,#,S,7AF,3 Q.2YJ<&=02P$"% ,4
M" #+@!-93S N:/9=  !;:0  %@              @ $V8@@ <&)M+3(P,C0P
M,S,Q>&8Q,#(P+FIP9U!+ 0(4 Q0    ( ,N $UE<YFJIX;0  $O&   6
M          "  6# " !P8FTM,C R-# S,S%X9C$P,C$N:G!G4$L! A0#%
M  @ RX 366)DJ7 !<P  2WL  !8              ( !=74) '!B;2TR,#(T
M,#,S,7AF,3 R-"YJ<&=02P$"% ,4    " #+@!-9X30(D5 6   9%P  %@
M            @ &JZ D <&)M+3(P,C0P,S,Q>&8Q,#(U+FIP9U!+ 0(4 Q0
M   ( ,N $UE-3#<^& P  +4,   6              "  2[_"0!P8FTM,C R
M-# S,S%X9C$P,C8N:G!G4$L! A0#%     @ RX 36>DNB6VL"   1 D  !8
M             ( !>@L* '!B;2TR,#(T,#,S,7AF,3 R-RYJ<&=02P$"% ,4
M    " #+@!-9MT\$;>4'  !Z"   %@              @ %:% H <&)M+3(P
F,C0P,S,Q>&8Q,#(X+FIP9U!+!08     %@ 6 ,L%  !S' H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>pbm-20240331xf1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pbm="http://www.psyence.com/20240331"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pbm-20240331.xsd" xlink:type="simple"/>
    <context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_z-3r1zgdRUar9YFq_BAsYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="Duration_1_15_2024_To_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_t2bpJrv-CEWvzpwrJA9aDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-15</startDate>
            <endDate>2024-01-15</endDate>
        </period>
    </context>
    <context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_xeKCbUv1EkKwDZisFjFScw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="As_Of_1_23_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_1M028Mwq5kytRxpB_bSdUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">pbm:BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-23</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_EDSUwdQ36UKTQvA2QAr00A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_0wYG8t1HXE-O2rRhbaBJaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MgMsfnVGck2AmUnYInyYOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_bvPGj60BfUSrD5EMG-60sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_TE-tT_L3DE-Ydn-lI9Eu5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Hjb5c9ngrEaYgdmgugFj6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_ThirdPartyAdvisorsMember_mC8mvXWyOki084m60qbTKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:ThirdPartyAdvisorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_KTMtplbPx0WC_t5qQhav6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_RC1H4ZLwU0apeImJQBE_dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-15</instant>
        </period>
    </context>
    <context id="As_Of_1_15_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_AFjT0Vhi0UeLxeHCocK_EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">pbm:BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-15</instant>
        </period>
    </context>
    <context id="Duration_1_25_2024_To_1_25_2024_eZQ4RlMJqUmySF9gmBlrAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_pbm_IfrsTaxPeriodAxis_pbm_TaxYear2044Member_WwE4lXg6VE6ETeoIPfEQ6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:IfrsTaxPeriodAxis">pbm:TaxYear2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_pbm_IfrsTaxPeriodAxis_pbm_IndefinitePeriodMember_X0xZ3jp2mkq_3uYS8sNVww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:IfrsTaxPeriodAxis">pbm:IndefinitePeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_RIjV61siK0uleVe4MSXSMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ay66gT7zZ0uREQ7yRI0cAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:ReverseTakeoverTransactionWithNcacAxis">pbm:NcacMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember_T_SrbOBOBUmz9DO4DYwbFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:UnaffiliatedThirdPartyInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember__hvPDjzjLUyCCDf5J2hfyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:UnaffiliatedThirdPartyInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="Duration_6_16_2024_To_6_16_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_Kkk9C124KESJe8OR92o3TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-16</startDate>
            <endDate>2024-06-16</endDate>
        </period>
    </context>
    <context id="As_Of_1_26_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_lrZq_P2lj0W1n0ER5UZe2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:ReverseTakeoverTransactionWithNcacAxis">pbm:NcacMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_LZT5nK0-7UestTgckCLkuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:ReverseTakeoverTransactionWithNcacAxis">pbm:NcacMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ZZfEBp5vhECip57BNE-wtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_EyC98DIUWkSnV6ZsDXjDuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="Duration_1_15_2024_To_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_TVvUizpQt0O2JuSrfGUeqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-15</startDate>
            <endDate>2024-01-15</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_w3jAzl07ZUOTF5NYOWIMug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_snyZUpSh_k-8or2abjhYpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-15</instant>
        </period>
    </context>
    <context id="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_T9W7od1CnEWSc0EL6UeLCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">pbm:BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-15</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_H47wk_lCv0mLLYxNgeLpyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">pbm:BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_WarrantsIssuedOnJanuary252024Member_Ge_kREe1AE-p07ojtGFkCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:WarrantsIssuedOnJanuary252024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_fldBCEgE6kSkrzCFgPayzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:DebtIssuedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o-z_ZS_GkkqdhTX8BnXnaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:DebtIssuedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_cEdgQ5bJd06uTqKWAeXLww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_CBu0LGH96Uq1bwkLGIZIlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_0Qw1JPRffk-sFJICGMRYNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_-EyNTF-GgkaIrUlPa35XIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_Se9-CIpcRkaZzb8oP9NClQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_569tQMQIbUuCRwNdZsHxOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_SZy8rGHGj06aGJODffVKug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_srt_StatementScenarioAxis_pbm_UntilFirstResetDateMember_xUD9ygGdy0ikpiUdFa3HuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pbm:UntilFirstResetDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_srt_StatementScenarioAxis_pbm_OnSecondResetDateMember_xTV-TVOmlEOSuiCCH637yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pbm:OnSecondResetDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2023_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_wL0j3sQ_P02l4cmD5Xha0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-25</instant>
        </period>
    </context>
    <context id="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_dOTID6jPYEuNrAYNswuBQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RzTFDy0njUmWjdXWuxBKzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-20</startDate>
            <endDate>2024-06-20</endDate>
        </period>
    </context>
    <context id="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_GWT3zleBVUqWPPvqxVkOFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_w55DsmyS8EihPG7FoizvZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-15</startDate>
            <endDate>2024-05-15</endDate>
        </period>
    </context>
    <context id="Duration_8_21_2023_To_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_4lNLIUCIGkWdqrARdGf_Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-21</startDate>
            <endDate>2023-08-21</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_FIOBwMXOW0G4Rh9Kg-g5zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_8aaTSxqRuk2-CUB0EpgfuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:HistoricalDailyVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_0n6lL7b98kK_7fXZv3ARAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:HistoricalAnnualVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_DiscountRateSharesMeasurementInputMember_T-qLZ5GLyUqYuqKzU6A99Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:DiscountRateSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_DiscountRateCashMeasurementInputMember_9zeIuNj3jkeNuHkmFUSZww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:DiscountRateCashMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_AnnualInterestRateMeasurementInputMember_rlp9Ay7neEuAWClA72ZtUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:AnnualInterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_ifrs-full_ConstantPrepaymentRateMeasurementInputMember_OOYtrkOvCkOAIWIIs2K24g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:ConstantPrepaymentRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_kXEDmraaCEyS6VFHtQQhVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedLifeMeasurementInputMember_VCLVBTHMYEOISLzWk8xClg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExpectedLifeMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedDividendYieldMeasurementInputMember_SJAHRg26zES9xeoq_XHY8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExpectedDividendYieldMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExercisePriceMeasurementInputMember_MsEFN7RVDUWdk_1PcKNO4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExercisePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Z65vDr3AykS8Ay5XjpdTIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_iwqqB_9GUE6i4oPg6dByJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_mklxx0Juv0KNIx9Swl1rqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedLifeMeasurementInputMember_4vaXn8GAh0W1rO5og87law">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExpectedLifeMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedDividendYieldMeasurementInputMember_VFv-YHMmsUK_zTq5IChJuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExpectedDividendYieldMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExercisePriceMeasurementInputMember_xlkc7XKVtk2Kga0Muvve7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">pbm:ExercisePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_nDnNEVpGr0yCKCdSdpxUUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_C7czhwq_XUix_v98K7IvfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-05</startDate>
            <endDate>2023-10-05</endDate>
        </period>
    </context>
    <context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_-EfQBvs7Lka4G6nGPl75Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_Rt33JWhG7ku7cESAe2Q9TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-25</startDate>
            <endDate>2024-01-25</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PysenceBiomedIICorpMember_G26BZFrZI02CLYH9Vu0ViA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">pbm:PysenceBiomedIICorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PsyenceAustraliaPtyLtd.Member_6XWCmWdVH0epdAirb_PHmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">pbm:PsyenceAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_NewcourtAcquistionCorpMember_RS2hbyZeVE21RshMW0SvfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">pbm:NewcourtAcquistionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_1QeYdHjl3EWi94YMiSvNOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_ipePrLsiFUeta9xYIvy-Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_xjrxvVhFRE2AUu-5qZqFxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_BDylPQLgv0aDtOticTwZeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Y8ha6ksYVkK1MvnJV2HJKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_zZkoynDJMUmruO9PlmDnHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="Duration_6_17_2024_To_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_TakD6semK0yRl952XvE8qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="Duration_5_31_2024_To_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_n_9pkBhIOEaocJLzvCa1KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-31</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember_P86XfCLzD0iMCh0cmIVomA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:UnaffiliatedThirdPartyInvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_DRqwp1PzKECgohUZ8NbYwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_G3Bu9s5MGkyw9paFYnaXQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RxOFqjiYkk-14gPIVMGVgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_BJrV3lqLKEyRyjAj25AV4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-17</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_WCUD7D3O30eL671BNA5zOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_dXrtFPMS3U-OLj3sZ1COaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_p40vy71k1EO-ouLsmL1rWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:InvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-15</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_Q5QpV3tf5Ea3fIz2QATK7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pbm:ThirdPartyAdvisorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_hsBM3S00RUmiCZS-VgNMhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pbm:ThirdPartyAdvisorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_3f-lrQXd4E6JrxjlD7INuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_qlM5Q3rZkUqmLNL6sPVskw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3QvCsKmuG0iNZ278OZUdsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_H4W4G8XGKUi_LOkR72lsQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:IfrsClassOfWarrantOrRightAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PublicWarrantsMember_dwZDj5CY_kWj6NkZwas54g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:IfrsClassOfWarrantOrRightAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:WarrantLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PublicWarrantsMember_ZIGv0avMc0GYY8eOD0yDqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:IfrsClassOfWarrantOrRightAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_0tIdiQ7fUEKkoN3p-hLo-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:IfrsClassOfWarrantOrRightAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:WarrantLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_0gDwTd2QTkau6NL_MH7NiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_a6DRGR0kP0CtkXqAEpTHbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsPromissoryNoteMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1MqeGaZQTkmZ9uo64ysG4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_5wmoOjA370-BDjmpcYZTtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsPromissoryNoteMember_9ScKY7OBvU6qJkoGTvZzKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_DrXtvzbxdUuHFqH8Mzx6Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_9W7HSkN-ZEWhSSTlLJLMYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_GVpNsIbN90GJv-LofUYMOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_gpUJ9iKr40yfgmBdIh8i8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_fZwi28Ln9kCZ-qKFXmRfrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Am2J6wS5NU2pK_QwXcD3tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">pbm:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_h3aSU-K3ukq60Id9Kf0N4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:DebtIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_aKXOxKCzikiefTsqg-KknQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:DebtIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_HzIBP-BDS0iBcUlFJmYxvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_AmT7G0GxkU2kHfFmvoXWyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">pbm:IfrsAccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Pj4XiiixQkW2C1vuJhevIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_fDdHxo-EdE-nSoM7ApAHWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4Ep3QBgg9E-C5EIM6WXlUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_tuvfzSbZYUSwJW82QolpRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_I2azYclQNUyISbz7ooT7Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_c2lWJEMjh0WThzeAGu23wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_5KKmfXcG5UWbCL--sLIg7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_Dw3sdk3PW0qHioYev-uYqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_-XClE6sYLESe4Ac51L39fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_XpSCtJGVFEW3JU9sTAbAHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:IfrsConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_1-dfoVe4v0uYJUHIYSGRgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_ebbDbrQcZkK0zv4fy_SFHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_nAJQDxrBpkSuuvZsO96n0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_pbm_LoanLiabilityMember_Bfg_MzgGgE248VkLkaHv1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">pbm:LoanLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_ComputerEquipmentMember_7jZCSqZ_9UaOraMsvT_DUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_ifrs-full_GeographicalAreasAxis_country_AU_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_oXkJbW1flU65sYmCYJGLPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_pbm_LoanLiabilityMember_IYWYvzYJfU2ryBzR65Zllg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">pbm:LoanLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_tIiRp3n8-02l_21JjlykGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_sCiZc0LkzEif6BGm_OtlfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_gwAintdcuUyQ_JwYJbceZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_srt_StatementScenarioAxis_pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_miXMAYbfxkOSULYF69B0Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pbm:NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_srt_StatementScenarioAxis_pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_5hN9t5cHDkWZRJOTiq9-ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">pbm:NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_nExNeJnlAkCUbDgmBzFjag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="As_Of_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_PM6a_iQxqU-pxFt4cy2t8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:SecondTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-17</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_xbkoUUMcMU-zQH04gc1B7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_nXcMNI1ydUezo0_dxGEwgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">pbm:NcacSponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:UnsecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_Ov4A1NkLkEa1t15pEcI7Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:FirstTrancheNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-25</instant>
        </period>
    </context>
    <context id="As_Of_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_ieM9jWT5V0m51QaeqASX4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">pbm:LoanFromRhCapitalFinanceCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-21</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pbm:ReverseTakeoverTransactionWithNcacAxis">pbm:NcacMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_3_31_2022_JQf3C7gGZUeF0m5KrvQUIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA__NbCY8cPYUCtxWf2hnkGgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_GeographicalAreasAxis_country_CA_ipl1RTFCVU6OA2u7sgwd-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CumulativeEffectAtDateOfInitialApplicationAxis">ifrs-full:IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_ZRqYyGoYrU2C6-I2Wd8ynA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001985062</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Options_7uzaMjMwKkiCpqW1np5Gkw">
        <measure>pbm:Options</measure>
    </unit>
    <unit id="Unit_Standard_AUD_jW69VxHF6ECitQL_0ZsRRw">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A">
        <measure>pbm:item</measure>
    </unit>
    <unit id="Unit_Standard_Y_GuMP1MngLk2rtbNTk6zhew">
        <measure>pbm:Y</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tc_RFvFL2GgeUuceS88mbiQjA_2_1">0001985062</dei:EntityCentralIndexKey>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tc_s9Hfb1wgCkiM6ZGrHI_0uA_3_1">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tc_1j4CdkyFU0q7femyEQfxZA_4_1">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentFlag
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tc_l1v8oTwaGUSYK_npxsIYUg_6_1">false</dei:AmendmentFlag>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="INF"
      id="Hidden_XxB_F4KMEE25cXOfcM4pEQ"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <pbm:NumberOfWarrantsOutstanding
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="INF"
      id="Hidden_s2yDhvbquUGMuaS1WGntNA"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13070000</pbm:NumberOfWarrantsOutstanding>
    <pbm:NumberOfWarrantsIssued
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ"
      decimals="INF"
      id="Hidden_x8bw_yf0B0-hUxug_gXzGw"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">12500000</pbm:NumberOfWarrantsIssued>
    <pbm:NumberOfWarrantsOutstanding
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ"
      decimals="INF"
      id="Hidden_zlOG_EIIqEixGctRvHNJ-A"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">570000</pbm:NumberOfWarrantsOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="INF"
      id="Hidden_t5Q4ViJtT0a_n3x8PTtDQg"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13390659</ifrs-full:NumberOfSharesOutstanding>
    <pbm:ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_xeKCbUv1EkKwDZisFjFScw"
      id="Hidden_8zLKxnneHEOziY32s6_j8Q">P35D</pbm:ThresholdPeriodForPaymentOfPriceDifferenceBetweenVwapAndConversionPriceInCashOrInShares>
    <pbm:ThresholdPeriodForVolumeWeightedAveragePrice
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_z-3r1zgdRUar9YFq_BAsYw"
      id="Hidden_bgTt3-yaZkufZ6GsyM4Hmw">P30D</pbm:ThresholdPeriodForVolumeWeightedAveragePrice>
    <dei:DocumentType
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Hidden_dYH7SUvFfk6sgj6PCvfaJA">F-1</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Narr_EV0phqS2LEax6jJgabd8IQ">Psyence Biomedical&#160;Ltd.</dei:EntityRegistrantName>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_x1Qqh41E9EySCcsjAdCnHQ_8_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">733188</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_cBQGQakoJEGBp-shHNeB0Q_8_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1334280</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_I2I4XH94rEKkz-msI5eaeg_9_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">29611</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_5TVU4BHinkuP-Dq66iUt6w_9_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">29556</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_vEhB1tfjdEevpaGpg1t_pg_10_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">41747</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_OEe7XPRpZ0-mSl207ldEIw_10_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">149369</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_K0phNwiZvE2iFSGQILUA0g_11_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">322126</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_WollwDf_J0eucPQvbjGY5g_11_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">77050</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_KYT_vcT9aUe-iGuhDd43YA_12_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1126672</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_mTjigcqlKky1754_XE6ydg_12_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1590255</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_UozzWbkWzUu-ghyVoe8TDA_14_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5487</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Assets
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_rkj0VOxzJEiO1VzQ5m3prA_15_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1132159</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_RdarLxAC0ECNHBqQHJpoJA_15_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1590255</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_yiugqf9410Km0b70lXrSbw_18_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">755202</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_0MMbr6MISESwpAvwGvitZw_18_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1790700</ifrs-full:TradeAndOtherCurrentPayables>
    <pbm:IfrsConvertibleDebtCurrent
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_iQvdW3uYTEu1kP9ra2PP6w_19_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">7657397</pbm:IfrsConvertibleDebtCurrent>
    <ifrs-full:CurrentWarrantLiability
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_15a9ouhNv0uGp9QxmohdUw_20_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">901608</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:CurrentDebtInstrumentsIssued
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_sCiZc0LkzEif6BGm_OtlfA"
      decimals="0"
      id="Tc_cny4Y5hJQkSli0uNGxSqgQ_21_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1474256</ifrs-full:CurrentDebtInstrumentsIssued>
    <ifrs-full:CurrentDebtInstrumentsIssued
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_gwAintdcuUyQ_JwYJbceZQ"
      decimals="0"
      id="Tc_zqr0RMAjPkKkJn5SUKovyg_22_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1316236</ifrs-full:CurrentDebtInstrumentsIssued>
    <ifrs-full:Liabilities
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_xLvSlovEpU2nSvS5B9LONA_23_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">12104699</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_ZUycRYiCxEGEk5FKuQNloQ_23_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1790700</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_jM6P7uzdHEm-AZY7wGlHvA_25_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">46125397</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_i4mBk0MQREKCg-rDqP5gRw_25_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5934141</ifrs-full:IssuedCapital>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_Yvs2uZlXnEqhkAC44HsmDw_26_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-57458994</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_DETrI6rbeEqaRxIdERL9mg_26_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-6299946</ifrs-full:RetainedEarnings>
    <ifrs-full:OtherReserves
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_CpOVcLYHykSq0s1ZCxzpxg_27_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">361057</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_pydrKyEZHkqNB1Uval3M5Q_27_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">165360</ifrs-full:OtherReserves>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_kz5QRndsEkCXfUMoSMftZQ_28_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-10972540</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_Wac-HDGemkeGVsWzoifqIQ_28_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-200445</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_daLrV5cDBkWxydAJ61ysww_29_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1132159</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_G7CX-pLhrUqAqVC4nyUt1A_29_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1590255</ifrs-full:EquityAndLiabilities>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_-GwANUxouUu4mzcBt-4b8A_6_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">80603</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_dp-BnDU-sUCVyKaAkld6hA_6_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">7029</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_ariiDjc7hESj0vw6ZLzijg_7_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">954593</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_myuQM4DO2kKv0GvKdmxdiw_7_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1608895</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_VqYnTSwGz0qEc4J1UvaSQg_8_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">557904</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_RjzuJl9eyUW38RBdNhmfxA_8_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">366435</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_MZTxMt71MUSWhi9kRoNgmw_9_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1158484</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_HzaXmUkRZE2ifIgU3_5sbw_9_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1252510</ifrs-full:ProfessionalFeesExpense>
    <pbm:IfrsOperatingIncomeLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_CrRVNtlMkU-eLMMjykkMRw_10_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-2751584</pbm:IfrsOperatingIncomeLoss>
    <pbm:IfrsOperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_m3aVq5U3nkeQl8U8tIvktw_10_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3234869</pbm:IfrsOperatingIncomeLoss>
    <ifrs-full:OtherIncome
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_5BudOsPnC06C937i6wfbvA_12_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">879344</ifrs-full:OtherIncome>
    <ifrs-full:DepreciationExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_wssUoKDrFU6qHY_S56scBQ_13_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">240</ifrs-full:DepreciationExpense>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_mmNADUFe0kmk6r8x__8HFQ_14_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2134</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_LIHz6KqAFEGFDCkQcrksHA_14_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1554</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_4jNnV1F5RUybbsHD5LktEQ_15_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">52941</ifrs-full:FinanceCosts>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_kUwtxIgdsEqwAuNBbe7N4g_16_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-2695</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_WCuqShgJJ0av-2KejZUOZQ_16_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">26912</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <pbm:ListingExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_czD3PX8SBk27g06icrhgMg_17_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">41481605</pbm:ListingExpense>
    <pbm:TransactionExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_eyWMNnhYUkG8VHtIzmGGgg_18_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2461025</pbm:TransactionExpense>
    <pbm:IfrsGainLossOnExtinguishmentOfDebt
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_ZgzYRvaYJ0-a1LshWuEjbQ_19_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">281500</pbm:IfrsGainLossOnExtinguishmentOfDebt>
    <pbm:FairValueAdjustmentOnConvertibleNote
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_IxgOy1ONGkqOXkkfRWCbPw_20_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5157397</pbm:FairValueAdjustmentOnConvertibleNote>
    <pbm:IfrsFairValueAdjustmentOfWarrants
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_r_3bQOL5i0ap86vTa2Zb1Q_21_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">306250</pbm:IfrsFairValueAdjustmentOfWarrants>
    <pbm:FairValueAdjustmentOnPromissoryNote
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_tnqyqWeX202v1DqosvLnWQ_22_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">108288</pbm:FairValueAdjustmentOnPromissoryNote>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_Scq2r8kJOkmhVNiba8d1pg_23_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-51159048</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_sbceRfRN9Eq0L9h5CwGD2g_23_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3206403</ifrs-full:ProfitLoss>
    <pbm:OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_GRhJt7qTj0WM7-aQ-5MoYQ_25_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">3715</pbm:OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation>
    <pbm:OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_RQS_6iigDkaxFSwCm_ADrA_25_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-89828</pbm:OtherComprehensiveIncomeLossNetOfTaxExchangeDifferencesOnTranslation>
    <pbm:OtherComprehensiveIncomeLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_g6BP2kqc6UKoYVD4uo0nAg_26_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">191982</pbm:OtherComprehensiveIncomeLoss>
    <pbm:ComprehensiveIncomeLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_ypEFobEqtkeO0rhxx1UAMg_27_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-50963351</pbm:ComprehensiveIncomeLoss>
    <pbm:ComprehensiveIncomeLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_Xi4BOgkNGUSv9jkQrz4EXw_27_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3296231</pbm:ComprehensiveIncomeLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="2"
      id="Tc_-pB7pOv7_kuUDtOUmaid8g_28_4"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">-7.82</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="2"
      id="Tc_-pB7pOv7_kuUDtOUmaid8g_28_4_2"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">-7.82</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="2"
      id="Tc_MJX0vlDD4EOszXJ8RDUCVw_28_6"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">-0.66</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="2"
      id="Tc_MJX0vlDD4EOszXJ8RDUCVw_28_6_2"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">-0.66</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_-MMMbjvTMES-QJ-k2bLZEQ_29_4"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">6517215</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_-MMMbjvTMES-QJ-k2bLZEQ_29_4_2"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">6517215</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_eiS64Hjb8kCZx78FUvvSpQ_29_6"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">5000000</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_eiS64Hjb8kCZx78FUvvSpQ_29_6_2"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">5000000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_-XClE6sYLESe4Ac51L39fw"
      decimals="0"
      id="Tc_Sp7ozIRsBUqIPKd4mzYEUQ_5_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">4537055</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_Dw3sdk3PW0qHioYev-uYqQ"
      decimals="0"
      id="Tc_CsFrENtTiUWdjMuWJyRHXw_5_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">255188</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_5KKmfXcG5UWbCL--sLIg7A"
      decimals="0"
      id="Tc_vHTiQyNH0E6ThJuwGl3V8Q_5_10"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3093543</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_95xhTU7Cu0K8ydaXh1K7bw_5_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1698700</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3QvCsKmuG0iNZ278OZUdsw"
      decimals="0"
      id="Tc_Ub3E3nYZx0qwYQ4l6pBhkQ_6_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1397086</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_H2gxdyFu6kGZ-aUMyPG2ug_6_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1397086</ifrs-full:IncreaseDecreaseThroughOtherContributionsByOwners>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Y8ha6ksYVkK1MvnJV2HJKw"
      decimals="0"
      id="Tc_pVC85iJrXkWVLKvd12FgNA_7_10"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3206403</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_qzB66dVrv0uk5Tyu0doUdA_7_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3206403</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_G3Bu9s5MGkyw9paFYnaXQw"
      decimals="0"
      id="Tc_5p1LunLl4EG4L3EHFzwA5A_8_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-89828</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_x28UOzLG7ku41sGz_N5wug_8_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-89828</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_c2lWJEMjh0WThzeAGu23wg"
      decimals="0"
      id="Tc_CiV6iQ7NXE2wyOc5ePVWMA_9_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5934141</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_I2azYclQNUyISbz7ooT7Zw"
      decimals="0"
      id="Tc_Y0AjnR-9aUKhNQuP5pzqqg_9_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">165360</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_tuvfzSbZYUSwJW82QolpRg"
      decimals="0"
      id="Tc_nZ4U7ozTLkWemiLqsYyDzQ_9_10"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-6299946</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_tW2NeXKnHUGEHts6g3lugw_9_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-200445</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_c2lWJEMjh0WThzeAGu23wg"
      decimals="0"
      id="Tc_NIDw4N1MqUuQB4b9xdpIKA_11_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5934141</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_I2azYclQNUyISbz7ooT7Zw"
      decimals="0"
      id="Tc_g0G8QoUY4UmQnbxgXo54sA_11_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">165360</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_tuvfzSbZYUSwJW82QolpRg"
      decimals="0"
      id="Tc_ML7vBaGMdUa05QSRHKeK8g_11_10"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-6299946</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_FRAukmpN80255D7csUL27A_11_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-200445</ifrs-full:Equity>
    <pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_bvPGj60BfUSrD5EMG-60sg"
      decimals="INF"
      id="Tc_ev2Pzg6XsUiKotQN_LvjCQ_12_4"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">5000000</pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction>
    <pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MgMsfnVGck2AmUnYInyYOg"
      decimals="INF"
      id="Tc_u0sKKoj_wEydXTi_4qli7Q_13_4"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">7794659</pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction>
    <pbm:StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MgMsfnVGck2AmUnYInyYOg"
      decimals="0"
      id="Tc_UXL0xskJdU6kGEptx37FoA_13_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">37336416</pbm:StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction>
    <pbm:StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_EDSUwdQ36UKTQvA2QAr00A"
      decimals="0"
      id="Tc_iGxCJKTVWESneNXQHpMrOw_13_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">37336416</pbm:StockIssuedDuringPeriodValueIssuedForReverseTakeoverTransaction>
    <pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Hjb5c9ngrEaYgdmgugFj6g"
      decimals="INF"
      id="Tc_0QGOa1iJcUiK0hUhfdp7eQ_14_4"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">150000</pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement>
    <pbm:StockIssuedDuringPeriodValueIssuedForDebtSettlement
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Hjb5c9ngrEaYgdmgugFj6g"
      decimals="0"
      id="Tc_2L4uwagbuU-PQ_klIwbMeA_14_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">718500</pbm:StockIssuedDuringPeriodValueIssuedForDebtSettlement>
    <pbm:StockIssuedDuringPeriodValueIssuedForDebtSettlement
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_b0AykaJ3cEWZikUlQAdwPQ_14_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">718500</pbm:StockIssuedDuringPeriodValueIssuedForDebtSettlement>
    <pbm:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_Q5QpV3tf5Ea3fIz2QATK7w"
      decimals="INF"
      id="Tc_lbi6nFaGS0ODvtBpLGzIww_15_4"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">446000</pbm:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_Q5QpV3tf5Ea3fIz2QATK7w"
      decimals="0"
      id="Tc_C8nmBzRWrkSd2Cj55DZ9XQ_15_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2136340</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_4_1_2023_To_3_31_2024_srt_CounterpartyNameAxis_pbm_ThirdPartyAdvisorsMember_hsBM3S00RUmiCZS-VgNMhA"
      decimals="0"
      id="Tc_-DB9nxVPYUKWQ5QIWZUGYA_15_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2136340</ifrs-full:IssueOfEquity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_BDylPQLgv0aDtOticTwZeQ"
      decimals="0"
      id="Tc__-9jr2M77EOj1VG5t7N4ww_16_10"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-51159048</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_U5UBfmrtYE63RyDuttVbyQ_16_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-51159048</ifrs-full:ProfitLoss>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4Ep3QBgg9E-C5EIM6WXlUw"
      decimals="INF"
      id="Tc_g_qi3VQNDkK8jwFMuSBKgw_18_4"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13390659</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_4Ep3QBgg9E-C5EIM6WXlUw"
      decimals="0"
      id="Tc_hPvKUfjf_Ui9DtwCgXIFyA_18_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">46125397</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_OtherReservesMember_fDdHxo-EdE-nSoM7ApAHWw"
      decimals="0"
      id="Tc_D6_TbtSfWUKiechjvm4Ulw_18_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">361057</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Pj4XiiixQkW2C1vuJhevIg"
      decimals="0"
      id="Tc_PLXCpOjZz0SUfTdtBUUALg_18_10"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-57458994</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_94IEf8UzGU2agk7Zxo5fqg_18_12"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-10972540</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_9rIwSR9HEUaajH_tS7iz_A_6_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-51159048</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_MZ7DaHxzOkG-ABCFw7GtOQ_6_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3206403</ifrs-full:ProfitLoss>
    <pbm:FairValueAdjustmentOnConvertibleNote
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_qNUvAmryOEOrT0UM5K1rnw_8_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5157397</pbm:FairValueAdjustmentOnConvertibleNote>
    <pbm:IfrsFairValueAdjustmentOfWarrants
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_ISxQsm09dUy93CYPJTET8Q_9_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">306250</pbm:IfrsFairValueAdjustmentOfWarrants>
    <pbm:FairValueAdjustmentsOnPromissoryNote
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_duFuPaOYLEO4DJy-tPUevQ_10_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">300270</pbm:FairValueAdjustmentsOnPromissoryNote>
    <pbm:IfrsGainLossOnExtinguishmentOfDebt
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_eNJ33QMqi0K44e282bZ2hA_11_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">281500</pbm:IfrsGainLossOnExtinguishmentOfDebt>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_3ARRTokHjUa03XrM5Fs54w_12_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">317882</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_gpcs3HqT0kWxue27ci0wjQ_12_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">221287</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_j_2wF71uDkyXyiXA0jOu6g_13_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">240</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_1OYfnIXNjUmntuzViu4-6w_14_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">3658</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_waSx_0oBK0mKN_d343MpWg_14_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-84499</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <pbm:AdjustmentsForListingExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_D4NKY364FUy4805od_SYvQ_15_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">41481605</pbm:AdjustmentsForListingExpense>
    <pbm:AdjustmentsForTransactionExpenses
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_tgDPoRmLOESCr7NCQVtp9w_16_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2100830</pbm:AdjustmentsForTransactionExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_p08izjJ860aG_AcKe-bimQ_19_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">107622</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_7jjLGhxfDU2dhF0fYt10fQ_19_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-109858</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_aIFywVCNdEmV4jzLjzlJRg_20_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-245075</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_aJ3VHK9QskCYyNIwnMwWEA_20_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-71665</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_1beH3rPyuUS1H5cPgYda7Q_21_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-1035498</pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_H4OkgX252kaSRfZt4hTjTw_21_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1659058</pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_MmzGa86g3U2mzIgFwooEmw_22_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-2945367</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_szJjnhbJ00ODKdG8hORI9g_22_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-1592080</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_glBp8BCymUCSH34R7ADMAg_24_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5727</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_zjTJ6O8J80qy1LdQhBhMJA_25_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-5727</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_icnTyGNyEkOwrTjH1MzZlg_27_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2500000</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_pvbErN5f3kqMnz1T4ddwog_28_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">150000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <pbm:ProceedsFromContributionsOfParent
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_P3nERFCapUCuA6N1E31NpA_29_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1172923</pbm:ProceedsFromContributionsOfParent>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_Doi3rODe4kK6Mpbid9YWHg_30_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2350000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_G6OvkXgPkEOF8ndQnekG3A_30_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1172923</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_EASUPucocUK4Dpx_UDepLQ_32_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-601092</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_G3wwFZOeI06QIJQbThPIow_32_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-419157</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_rpw0qex-AkK3RWsEuq-h-g_33_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1334280</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_YDWTsPAVwEW7TUEo4DCmgQ_33_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1753437</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_qO0jaYrqike0QZcrri-aUA_34_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">733188</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_E_mJN5w6Q0azMMxy5mJ2nQ_34_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1334280</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_2TPafptSuEaAfUFv9m8wmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Nature of operations and going concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Psyence Biomedical&#160;Ltd. (the &lt;b style="font-weight:bold;"&gt;&#x201c;Company&#x201d;&lt;/b&gt; or &lt;b style="font-weight:bold;"&gt;&#x201c;PBM&#x201d;&lt;/b&gt;), is a life science biotechnology company traded on the Nasdaq exchange (NASDAQ: PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The Company is working towards developing safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. The Company is initially focused on mental health disorders in the context of Palliative Care. The Company is currently conducting research through clinical trials to evaluate the safety and effectiveness of natural psilocybin in treating adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context (the &#x201c;&lt;b style="font-weight:bold;"&gt;Clinical Trials&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s registered office is at 121 Richmond Street West, PH Suite&#160;1300, Toronto, Ontario M5H 2K1.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company listed on the NASDAQ exchange on January&#160;25, 2024. (&#x201c;&lt;b style="font-weight:bold;"&gt;Carve-out Financial Statements&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On February&#160;15, 2023, Psyence Australia (Pty) Ltd was incorporated and registered in Victoria, Australia. It is a wholly owned subsidiary of the Company. It was incorporated as a wholly owned subsidiary of Psyence Group&#160;Inc. and was transferred to the Company concurrently upon completion of the RTO Transaction as described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Business Combination Agreement and NASDAQ listing&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;9, 2023, Psyence Group&#160;Inc. (&#x201c;&lt;b style="font-weight:bold;"&gt;Psyence Group&lt;/b&gt;&#x201d; or &#x201c;&lt;b style="font-weight:bold;"&gt;PGI&lt;/b&gt;&#x201d;) entered into a definitive business combination agreement (the &#x201c;&lt;b style="font-weight:bold;"&gt;Business Combination Agreement&lt;/b&gt;&#x201d;) with Newcourt Acquisition Corp. (NASDAQ: NCAC), a special purpose acquisition company (&#x201c;&lt;b style="font-weight:bold;"&gt;SPAC&lt;/b&gt;&#x201d;). The agreement aimed to create a public company leveraging natural psilocybin for palliative care treatment. PGI is a listed Canadian company that contributed its clinical trial activities to the Company as described below. After the Business Combination Agreement closed the Company became an associate of PGI.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction concluded on January&#160;25, 2024, with PBM&#x2019;s listing on NASDAQ. This transaction involved PBM acquiring the SPAC through a merger, thereby making the SPAC a wholly-owned subsidiary of PBM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Transaction Overview:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;25, 2024 (the &#x201c;&lt;b style="font-weight:bold;"&gt;Closing Date&lt;/b&gt;&#x201d;), the Company, a corporation organized under the laws of Ontario, Canada, completed the previously announced business combination (the &#x201c;&lt;b style="font-weight:bold;"&gt;RTO Transaction&lt;/b&gt;&#x201d;) as per the Amended and Restated Business Combination Agreement (the &#x201c;&lt;b style="font-weight:bold;"&gt;BCA&lt;/b&gt;&#x201d;), dated July&#160;31, 2023. The parties involved in the BCA included:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Psyence Group&#160;Inc.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Newcourt Acquisition Corp., a Cayman Islands exempted company.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Newcourt SPAC Sponsor LLC, a Delaware limited liability company (&#x201c;&lt;b style="font-weight:bold;"&gt;NCAC Sponsor&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Psyence (Cayman) Merger Sub, a Cayman Islands exempted company and a wholly owned subsidiary of Psyence Group.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada (&#x201c;&lt;b style="font-weight:bold;"&gt;Original Target&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;Psyence Biomed II Corp., a corporation organized under the laws of Ontario, Canada (&#x201c;&lt;b style="font-weight:bold;"&gt;Psyence Biomed II&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Key Transactions (collectively, the &#x201c;&lt;span style="font-weight:bold;"&gt;Business Combination&lt;/span&gt;&#x201d;):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Formation of Subsidiaries&lt;/i&gt;: Prior to the execution of the BCA, Psyence Group formed two wholly owned subsidiaries: Psyence Biomed II and PBM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Amalgamation&lt;/i&gt;: Prior to the Closing Date, Psyence Group amalgamated with the Original Target. Consequently, Psyence Group transferred shares of Psyence Australia Pty&#160;Ltd. and related business assets previously owned by the Original Target to Psyence Biomed II.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Share Exchange&lt;/i&gt;: Psyence Group contributed Psyence Biomed II to PBM in a share-for-share exchange (the &#x201c;&lt;b style="font-weight:bold;"&gt;Company Exchange&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Merger&lt;/i&gt;: Following the Company Exchange, Psyence (Cayman) Merger Sub merged with Newcourt Acquisition Corp., with Newcourt Acquisition Corp. being the surviving entity. Each outstanding ordinary share of Newcourt Acquisition Corp. was converted into the right to receive one common share of PBM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrant Conversion&lt;/i&gt;: Each outstanding warrant to purchase Newcourt Acquisition Corp. Class&#160;A ordinary shares was converted into warrants to acquire one common share of PBM on substantially the same terms as the original warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;15, 2024 and January&#160;23, 2024, the parties to the Business Combination Agreement entered into letter agreements (the &#x201c;&lt;b style="font-weight:bold;"&gt;Closing Letter Agreements&lt;/b&gt;&#x201d;) pursuant to which, among other things, PBM, Psyence Group, Original Target and Merger Sub (collectively, the &#x201c;&lt;b style="font-weight:bold;"&gt;Psyence Parties&lt;/b&gt;&#x201d;) agreed, on a conditional basis, to waive the closing conditions contained in the BCA that, at or prior to the closing of the Business Combination (the &#x201c;&lt;b style="font-weight:bold;"&gt;Closing&lt;/b&gt;&#x201d;), (i)&#160;Newcourt SPAC shall have no less than $20,000,000, net of liabilities, as of the Closing (the &#x201c;&lt;b style="font-weight:bold;"&gt;Minimum Cash Condition&lt;/b&gt;&#x201d;) and (ii)&#160;the PIPE (Private Investment in Public Equity) Investment in the PIPE Investment Amount shall have occurred or shall be ready to occur substantially concurrently with the Closing (the &#x201c;&lt;b style="font-weight:bold;"&gt;PIPE Investment Condition&lt;/b&gt;&#x201d;) and (iii)&#160;to waive certain deliverables of the Business Combination Agreement (the &#x201c;&lt;b style="font-weight:bold;"&gt;Closing Deliverables&lt;/b&gt;&#x201d;). Upon the Closing, the Psyence Parties waived in full the Minimum Cash Condition, the PIPE Investment Condition and the Closing Deliverables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Convertible Note&#160;Financing&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;15, 2024, in connection with the Business Combination, the Company entered into a securities purchase agreement (the &#x201c;&lt;b style="font-weight:bold;"&gt;Securities Purchase Agreement&lt;/b&gt;&#x201d;) by and among (i)&#160;the Company, (ii)&#160;Psyence Biomed II, (iii)&#160;Sponsor and (iv)&#160;certain investors (the &#x201c;&lt;b style="font-weight:bold;"&gt;Investors&lt;/b&gt;&#x201d;) relating to up to four senior secured convertible notes (collectively, the &#x201c;&lt;b style="font-weight:bold;"&gt;Notes&lt;/b&gt;&#x201d; and the transactions pursuant to the Securities Purchase Agreement, the &#x201c;&lt;b style="font-weight:bold;"&gt;Financing&lt;/b&gt;&#x201d;), obligations under which will be guaranteed by certain assets of the Company and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up to $12,500,000 in exchange for up to $10,000,000 in cash subscription amounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Note&#160;for the first tranche of the Financing (the &#x201c;&lt;b style="font-weight:bold;"&gt;First Tranche Note&lt;/b&gt;&#x201d;), for a total of $3,125,000 of principal in exchange for a total of $2,500,000 in subscription amounts and was issued to the Investors substantially concurrently with, and contingent upon, the Closing. The Financing closed immediately prior to the Business Combination (Refer to Note&#160;9).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Merger Consideration&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As consideration for all the issued and outstanding Psyence Biomed II common shares that the Company received in the Company Exchange, the Company issued to Psyence Group, 5,000,000 Common Shares. As a result, Psyence Group is the largest shareholder of the Company as at March&#160;31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These Consolidated Financial Statements (the &#x201c;&lt;b style="font-weight:bold;"&gt;Financial Statements&lt;/b&gt;&#x201d;) provide historical financial information of PBM, reflecting PBM as if it had been historically operating the Clinical Trials conducted by Psyence Group prior to the listing of PBM. The Financial Statements are carve out statements up to the date of listing of PBM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Going concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These Financial Statements are prepared on a going concern basis, which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. During the&#160;year ended March&#160;31, 2024, the Company incurred a net loss and comprehensive loss of $50,963,351 (Year ended March&#160;31, 2023: $3,296,231) and the Company has not yet generated any revenue. The Company&#x2019;s ability to continue operations depends on its ability to secure additional financing. There is uncertainty regarding the availability of financing at acceptable terms, which could impact the Company&#x2019;s ability to continue operating. These conditions indicate a material uncertainty that cast significant doubt on the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These Financial Statements do not reflect the adjustments to the carrying values and classifications of assets and liabilities that would be necessary if the Company were unable to realize its assets and settle its liabilities as a in the normal course of operations. Such adjustments could be significant.&lt;/p&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <pbm:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_1_25_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_H47wk_lCv0mLLYxNgeLpyA"
      decimals="INF"
      id="Narr_tnMIQ5SRGUyby41JQx5nDQ"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">1</pbm:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <pbm:ThresholdAmountForMinimumCashCondition
      contextRef="As_Of_1_23_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_1M028Mwq5kytRxpB_bSdUw"
      decimals="0"
      id="Narr_28Sr7G0qrU6Y9NfOQehTNg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">20000000</pbm:ThresholdAmountForMinimumCashCondition>
    <pbm:NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes
      contextRef="As_Of_1_15_2024_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_AFjT0Vhi0UeLxeHCocK_EA"
      decimals="INF"
      id="Narr_HHWMQfNP502w0Ih76MkX1A"
      unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A">4</pbm:NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes>
    <pbm:IfrsDebtInstrumentFaceAmount
      contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_T9W7od1CnEWSc0EL6UeLCA"
      decimals="0"
      id="Narr_o315IfNpPkCePw3iWZ38Xg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">12500000</pbm:IfrsDebtInstrumentFaceAmount>
    <pbm:SubscriptionAmount
      contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_BusinessCombinationsAxis_pbm_BusinessCombinationAgreementWithNewcourtAcquisitionCorp.Member_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_T9W7od1CnEWSc0EL6UeLCA"
      decimals="0"
      id="Narr_ttNWWx6hnkaar3MKeImtEw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">10000000</pbm:SubscriptionAmount>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_p40vy71k1EO-ouLsmL1rWg"
      decimals="0"
      id="Narr_5IPCxpwz1kCHSLmT5yc6UA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">3125000</ifrs-full:NotionalAmount>
    <pbm:IfrsProceedsFromConvertibleDebt
      contextRef="Duration_1_15_2024_To_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_TVvUizpQt0O2JuSrfGUeqw"
      decimals="0"
      id="Narr_Hif-uL_rP0CnHy9nYlxefw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2500000</pbm:IfrsProceedsFromConvertibleDebt>
    <pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_TE-tT_L3DE-Ydn-lI9Eu5Q"
      decimals="INF"
      id="Narr_FNyu3nbPxUKCWA1mIF-2GQ"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">5000000</pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction>
    <pbm:ComprehensiveIncomeLoss
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Narr_AN_2ltFwpUyWzjtIfeaPAw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-50963351</pbm:ComprehensiveIncomeLoss>
    <pbm:ComprehensiveIncomeLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Narr_XyZK5Lj0UEqw5xzQJzX15Q"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3296231</pbm:ComprehensiveIncomeLoss>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_a3n4H1gnzkC7vTiZrbcbCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Statement of compliance&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Financial Statements of the Company have been prepared using accounting policies in compliance with International Financial Reporting Standards (&#x201c;&lt;b style="font-weight:bold;"&gt;IFRS&lt;/b&gt;&#x201d;) issued by the International Accounting Standards Board (&#x201c;&lt;b style="font-weight:bold;"&gt;IASB&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Financial Statements were authorized for issue on July&#160;25, 2024 by the directors of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Consolidated Statements of Financial Position&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Consolidated Statements of Financial Position include the assets and liabilities that are the Clinical Trial related assets and liabilities, which have been determined in the following manner:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Cash is comprised of cash and cash equivalents which the Company utilizes for working capital purposes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Restricted cash comprises a guaranteed investment certificate which is held as collateral for a credit lending agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Other receivables are comprised of sales tax receivable from the Canadian Revenue Agency and the Australian Taxation Office.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Prepaids consists of D&amp;amp;O insurance fees prepaid.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Accounts payable and accrued liabilities consist of audit, consulting fees and legal fees related to the Company and its Clinical Trials.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Consolidated Statements of Net Loss and Comprehensive Loss&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Consolidated Statements of Net Loss and Comprehensive Loss include operating expenses that are related to the Company and its Clinical Trials.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;The Financial Statements up until January 25, 2024 were presented on a carve out basis (&#x201c;&lt;/span&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Carve-out Financial Statements&lt;/b&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Financial Statements have been prepared on a carve-out basis from the PGI consolidated financial statements for the purpose of presenting the historical financial position, financial performance and cash flows of the Company on a stand-alone basis. The accounting policies applied in the Carve-out Financial Statements are, to the extent applicable, consistent with accounting policies applied in the PGI consolidated financial statements, and as a result, reflect the carrying amounts that are included in PGI&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In determining the perimeter of the Carve-out Financial Statements, the activities related to the Company&#x2019;s clinical trials were considered to include the operations of Psyence Biomed Corp. and Psyence Australia (Pty) Ltd carried out through PGI directly as well as through legal entities of PGI as detailed above.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the Carve-out Financial Statements of PBM, all intercompany balances and have been eliminated. The transactions and balances with the remaining PGI operations that are not part of these Carve-out Financial Statements have not been eliminated.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Carve-out Financial Statements present the assets, liabilities, expenses and cash flows attributable to the clinical trial activities for the year ended March 31, 2023 and from April 1, 2023 to the Closing Date, and include allocations of certain transactions and balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company believes the allocation assumptions applied in the Carve-out Financial Statements to be a reasonable reflection of the utilization of services provided by PGI. However, different allocation assumptions could have resulted in different outcomes. The allocations are therefore not necessarily representative of the financial position, financial performance or cash flows that would have been reported if PBM operated on its own or as an entity independent from PGI during the periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company believes the basis of preparation described above results in the Carve-out Financial Statements reflecting the assets and liabilities associated with PBM and reflects costs associated with the functions that would be necessary to operate independently.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of consolidation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These Financial Statement incorporate the accounts of PBM and its subsidiaries performing Clinical Trials. A subsidiary is an entity controlled by PBM and its results are consolidated into the financial results of the Company from the effective date of control up to the effective date of loss of control.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Control exists when an investor is exposed, or has the rights, to variable returns from the involvement with the investee and has liability to affect those returns through its power over the investee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The subsidiaries of PBM have been consolidated commencing the Closing Date and on March 31, 2024 for the purpose of these Financial Statements are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Name of entity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Place&#160;of&#160;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;ownership&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting&#160;method&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Psyence Australia Pty Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Australia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pysence Biomed II Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Newcourt Acquisition Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cayman Islands&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Inter-company balances and transactions are eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The financial results of subsidiaries in financial&#160;year ended March&#160;31, 2023 and up to January 25, 2024 were presented on a carve out basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Basis of measurement&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These Financial Statements have been prepared on an accrual basis, are based on historical costs, unless otherwise noted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Functional and presentation currency&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These Financial Statements are presented in United States Dollars (&lt;b style="font-weight:bold;"&gt;&#x201c;USD $&#x201d;&lt;/b&gt;)&lt;b style="font-weight:bold;"&gt;,&lt;/b&gt; which is also PBM&#x2019;s functional currency. The Company&#x2019;s functional currency before the Closing Date of the BCA was Canadian Dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;This changed upon consummation of the BCA at which time the USD $ represents the currency of the Company&#x2019;s funding and is the currency of the primary economic environment in which the Company operates in, except for the Company&#x2019;s Australian subsidiary which has an Australian Dollar functional currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;See change in accounting policy in note 3 for further details on the change in the Company&#x2019;s presentation currency.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_wGXAwa7k7kKAJkNJGQ3frw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Name of entity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Place&#160;of&#160;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;%&#160;ownership&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting&#160;method&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Psyence Australia Pty Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Australia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Pysence Biomed II Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:44.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Newcourt Acquisition Corp.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cayman Islands&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consolidated&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PsyenceAustraliaPtyLtd.Member_6XWCmWdVH0epdAirb_PHmQ"
      decimals="2"
      id="Tc_fuUxTkh1eUGoJaoiOKWOJw_2_4"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_PysenceBiomedIICorpMember_G26BZFrZI02CLYH9Vu0ViA"
      decimals="2"
      id="Tc_s9xhNLKKZUuBgqqvetIUXg_3_4"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_pbm_NewcourtAcquistionCorpMember_RS2hbyZeVE21RshMW0SvfQ"
      decimals="2"
      id="Tc_m-oa5JvCxkuv0UuiNCWBkg_4_4"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_fcMOFmZi8UKkW_jQRkrtLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Material accounting policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets and financial liabilities, including derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument or derivative contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Summary of the Company&#x2019;s classification and measurements of financial assets and liabilities:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"&gt;&lt;tr style="height:4.8pt;"&gt;&lt;td style="vertical-align:bottom;width:50.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial Assets and Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Measurement &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5.75pt;"&gt;&lt;td style="vertical-align:bottom;width:50.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5.75pt;"&gt;&lt;td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Derivative warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;FVTPL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;FVTPL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;NCAC promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;FVTPL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;PGI promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;FVTPL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Classification&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies its financial assets and financial liabilities in the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (&#x201c;FVTPL&#x201d;); ii) those to be measured subsequently at fair value through other comprehensive income (&#x201c;FVOCI&#x201d;); and iii) those to be measured at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair value, gains and losses are either recorded in net loss or other comprehensive income (loss).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reclassifies financial assets only when its business model for managing those assets changes. Financial liabilities are not reclassified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Amortized cost&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;This category includes financial assets that are held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments of principal and interest (&#x201c;SPPI&#x201d;) criterion. Financial assets classified in this category are measured at amortized cost using the effective interest method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair value through profit or loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;This category includes derivative instruments as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL. This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest (&#x201c;SPPI&#x201d;) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets at fair value through other comprehensive income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Equity instruments that are not held-for-trading can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable transaction costs are included in the carrying value of the instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets at fair value through other comprehensive income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Compound financial instrument and derivative liability&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined that the warrants, including public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized in net loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Each embedded derivative is measured and presented separately unless the whole hybrid financial instrument is designated as at FVTPL.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All financial instruments are required to be measured at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payments of principal and interest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value are attributable to changes in own credit risk which is recorded in other comprehensive income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include cash on hand and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three&#160;months at the date of their acquisition.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Restricted cash&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash comprises a collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment certificate with the bank.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Related party transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be a related party transaction when there is transfer of resources or obligations between related parties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in accounting policy&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to completion of the Business Combination Agreement and NASDAQ listing as explained in Note 1 to the audited consolidated financial statements, on January 25, 2024, the Corporation decided to change the presentation currency of its consolidated financial statements from Canadian Dollars to United States Dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Board of Directors believe that US Dollar financial reporting provides more relevant presentation of the Corporation&#x2019;s financial position, funding and treasury functions, financial performance and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A change in presentation currency represents a change in accounting policy in terms of IAS 8 &#x2013; &lt;i style="font-style:italic;"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/i&gt;, requiring the restatement of comparative information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with IAS 21 &#x2013; &lt;i style="font-style:italic;"&gt;The Effects of Changes in Foreign Exchange Rates&lt;/i&gt;, the methodology followed in restating historical financial information from CDN$ to US$.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The average and closing rates used in translating the historical financial information from CDN$ to US$ for the various periods were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The closing rate used as at March 31, 2024 was $0.738 and as at March 31, 2023 was $0.7389.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The average rate used for the year ended March 31, 2024 was $0.7415, for the year ended March 31, 2023 was $0.7559 and for the year ended March 31, 2022 was $0.8003.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The change in presentation currency is a voluntary change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated to United States dollars which is disclosed in the tables below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,805,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (471,485)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,334,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,444)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 202,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,782)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 149,369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,152,192&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (561,937)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,590,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,152,192&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (561,937)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,590,255&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,423,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (632,767)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,423,467&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (632,767)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,790,700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EQUITY&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (271,275)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200,445)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (271,275)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 70,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (200,445)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES AND NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,152,192&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (561,937)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,590,255&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&#160;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; $&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,191,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (437,658)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,753,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,990)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,862)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,510&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,287,196&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (456,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,830,342&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,287,196&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (456,854)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,830,342&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 164,500&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (32,858)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 131,642&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EQUITY&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,122,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (423,996)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,698,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,122,696&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (423,996)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,698,700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES AND NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,287,196&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (456,854)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,830,342&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,263)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,126,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (517,867)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,608,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 484,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (117,947)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 366,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional and consulting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,655,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (403,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,252,510&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss before other items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (4,276,099)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,041,230)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,234,869)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign exchange gain&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,662)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET LOSS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (4,238,471)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,050,392)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,206,403)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,238,471)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(3,206,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-cash adjustment:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Share based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 292,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,469)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 221,287&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84,499)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(84,499)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Changes in working capital:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (152,778)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(109,858)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (97,547)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(71,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,258,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (599,909)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,659,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash used in operating activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,937,073)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 344,993&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(1,592,080)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Proceeds received from Psyence Group Inc&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,551,744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (378,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,172,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash provided from financing activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,551,744&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (378,821)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,172,923&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Change in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (385,329)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,828)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(419,157)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents, start of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,191,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (437,658)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,753,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents, end of year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,805,765&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (471,486)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,334,280&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Research and development&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and comprehensive loss as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Provisions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Foreign currency translation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Financial Statements are presented in USD $ which is PBM&#x2019;s functional currency. The functional currency of its subsidiary consolidated within these Financial Statements is AUD $.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In each individual entity, a foreign currency transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency and the foreign currency at the date of the transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the end of the reporting period, monetary assets and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The resulting exchange gains or losses arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition, are included in statement of net loss and comprehensive loss in the period in which they arise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the purpose of presenting these Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries is recorded in reserves.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company presents basic and diluted loss per share data for its common shares. Basic loss per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting the loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Share based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the options and RSUs granted by the Company shall be recognized as an expense in the Consolidated Financial Statements of the Company. The expense shall be recognized over the vesting period of the options. The fair value options shall be determined using the Black-Scholes model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Income tax comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders&#x2019; equity, in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also recognized directly in equity or other comprehensive income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Current tax is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect of previous&#160;years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the amounts and the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax is recognized in respect of all qualifying temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Financial Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.&lt;/p&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_dSYkwhi5SEqi3by8h2oc-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Financial instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets and financial liabilities, including derivatives, are recognized on the consolidated statements of financial position when the Company becomes a party to the financial instrument or derivative contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Summary of the Company&#x2019;s classification and measurements of financial assets and liabilities:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"&gt;&lt;tr style="height:4.8pt;"&gt;&lt;td style="vertical-align:bottom;width:50.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial Assets and Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Measurement &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5.75pt;"&gt;&lt;td style="vertical-align:bottom;width:50.36%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5.75pt;"&gt;&lt;td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortized cost&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Derivative warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;FVTPL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;FVTPL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;NCAC promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;FVTPL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.36%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;PGI promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:21.58%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;FVTPL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:2.87%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.29%;background:#cceeff;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Classification&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies its financial assets and financial liabilities in the following measurement categories: i) those to be measured subsequently at fair value through profit or loss (&#x201c;FVTPL&#x201d;); ii) those to be measured subsequently at fair value through other comprehensive income (&#x201c;FVOCI&#x201d;); and iii) those to be measured at amortized cost. The classification of financial assets depends on the business model for managing the financial assets and the contractual terms of the cash flows. Financial liabilities are classified as those to be measured at amortized cost unless they are designated as those to be measured subsequently at FVTPL (irrevocable election at the time of recognition). For assets and liabilities measured at fair value, gains and losses are either recorded in net loss or other comprehensive income (loss).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reclassifies financial assets only when its business model for managing those assets changes. Financial liabilities are not reclassified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Amortized cost&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;This category includes financial assets that are held within a business model with the objective to hold the financial assets to collect contractual cash flows that meet the sole payments of principal and interest (&#x201c;SPPI&#x201d;) criterion. Financial assets classified in this category are measured at amortized cost using the effective interest method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair value through profit or loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;This category includes derivative instruments as well as quoted equity instruments which the Company has irrevocably elected, at initial recognition or transition, to classify at FVTPL. This category would also include debt instruments of which the cash flow characteristics fail the solely payments of principal and interest (&#x201c;SPPI&#x201d;) criterion or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell. Financial assets in this category are recorded at fair value with changes recognized in net loss. The Company records its financial liabilities including derivatives, convertible loans and promissory notes at FVTPL. Derivatives are mandatorily recorded at FVTPL, whereas the Company has elected to record convertible loans and promissory notes at FVTPL.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets at fair value through other comprehensive income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Equity instruments that are not held-for-trading can be irrevocably designated to have their change in fair value recognized through other comprehensive income (loss) instead of through net loss. This election can be made on individual instruments and is not required to be made for the entire class of instruments. Attributable transaction costs are included in the carrying value of the instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets at fair value through other comprehensive income/(loss) are initially measured at fair value and changes therein are recognized in other comprehensive income/(loss).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Compound financial instrument and derivative liability&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determined that the warrants, including public warrants and the private warrants are derivative instruments and should be classified as a financial liability and are measured at FVTPL. Derivative and financial liabilities designated at FVTPL are carried subsequently at fair value with gains or losses recognized in net loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Each embedded derivative is measured and presented separately unless the whole hybrid financial instrument is designated as at FVTPL.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All financial instruments are required to be measured at fair value on initial recognition, plus, in the case of a financial asset or financial liability not at FVTPL, transaction costs that are directly attributable to the acquisition or issuance of the financial asset or financial liability. Transaction costs of financial assets and financial liabilities carried at FVTPL are expensed in net loss. Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payments of principal and interest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial assets that are held within a business model whose objective is to collect the contractual cash flows, and that have contractual cash flows that are solely payments of principal and interest on the principal outstanding are generally measured at amortized cost at the end of the subsequent accounting periods. All other financial assets including equity investments are measured at their fair values at the end of subsequent accounting periods, with any changes taken through net loss or other comprehensive income/(loss) (irrevocable election at the time of recognition). For financial liabilities measured subsequently at FVTPL, changes in fair value are recorded in profit and loss, except where changes in fair value are attributable to changes in own credit risk which is recorded in other comprehensive income.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_YE50mDVzX0ePav8tg3_rhA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Cash and cash equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include cash on hand and, when applicable, short-term, highly liquid deposits which are either cashable or with original maturities of less than three&#160;months at the date of their acquisition.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_abw6gUgbJESXKOHDc33s8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Restricted cash&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted cash comprises a collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited in a guaranteed investment certificate with the bank.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_WnQykXTwKkGXsiIZvf6k4w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Related party transactions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. Related parties may be individuals or entities. A transaction is considered to be a related party transaction when there is transfer of resources or obligations between related parties.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForTransactionsWithRelatedPartiesExplanatory>
    <pbm:DescriptionOfChangeInAccountingPolicyPolicyTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_Q1PZdTY2VESz2FNZjWwBGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in accounting policy&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to completion of the Business Combination Agreement and NASDAQ listing as explained in Note 1 to the audited consolidated financial statements, on January 25, 2024, the Corporation decided to change the presentation currency of its consolidated financial statements from Canadian Dollars to United States Dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Board of Directors believe that US Dollar financial reporting provides more relevant presentation of the Corporation&#x2019;s financial position, funding and treasury functions, financial performance and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;A change in presentation currency represents a change in accounting policy in terms of IAS 8 &#x2013; &lt;i style="font-style:italic;"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/i&gt;, requiring the restatement of comparative information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with IAS 21 &#x2013; &lt;i style="font-style:italic;"&gt;The Effects of Changes in Foreign Exchange Rates&lt;/i&gt;, the methodology followed in restating historical financial information from CDN$ to US$.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The average and closing rates used in translating the historical financial information from CDN$ to US$ for the various periods were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The closing rate used as at March 31, 2024 was $0.738 and as at March 31, 2023 was $0.7389.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The average rate used for the year ended March 31, 2024 was $0.7415, for the year ended March 31, 2023 was $0.7559 and for the year ended March 31, 2022 was $0.8003.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The change in presentation currency is a voluntary change which is accounted for retrospectively. For comparative reporting purposes, historical financial information has been translated to United States dollars which is disclosed in the tables below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,805,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (471,485)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,334,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,444)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 202,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,782)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 149,369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,152,192&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (561,937)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,590,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,152,192&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (561,937)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,590,255&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,423,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (632,767)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,423,467&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (632,767)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,790,700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EQUITY&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (271,275)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200,445)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (271,275)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 70,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (200,445)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES AND NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,152,192&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (561,937)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,590,255&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&#160;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; $&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,191,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (437,658)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,753,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,990)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,862)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,510&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,287,196&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (456,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,830,342&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,287,196&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (456,854)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,830,342&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 164,500&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (32,858)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 131,642&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EQUITY&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,122,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (423,996)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,698,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,122,696&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (423,996)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,698,700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES AND NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,287,196&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (456,854)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,830,342&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,263)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,126,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (517,867)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,608,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 484,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (117,947)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 366,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional and consulting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,655,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (403,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,252,510&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss before other items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (4,276,099)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,041,230)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,234,869)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign exchange gain&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,662)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET LOSS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (4,238,471)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,050,392)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,206,403)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,238,471)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(3,206,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-cash adjustment:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Share based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 292,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,469)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 221,287&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84,499)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(84,499)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Changes in working capital:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (152,778)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(109,858)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (97,547)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(71,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,258,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (599,909)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,659,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash used in operating activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,937,073)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 344,993&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(1,592,080)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Proceeds received from Psyence Group Inc&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,551,744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (378,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,172,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash provided from financing activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,551,744&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (378,821)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,172,923&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Change in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (385,329)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,828)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(419,157)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents, start of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,191,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (437,658)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,753,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents, end of year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,805,765&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (471,486)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,334,280&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pbm:DescriptionOfChangeInAccountingPolicyPolicyTextBlock>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="3"
      id="Narr_sXvkkmMUnUSr30Zs70-JhA"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.738</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:ClosingForeignExchangeRate
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="4"
      id="Narr_IhiczHR5bkWIWCRXodMxug"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.7389</ifrs-full:ClosingForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="4"
      id="Narr_BYV1ua7PEEq0BzHyYWZHqg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">0.7415</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="4"
      id="Narr_vt1YLxO6PEqraStpzQOdDA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">0.7559</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:AverageForeignExchangeRate
      contextRef="Duration_4_1_2021_To_3_31_2022_JQf3C7gGZUeF0m5KrvQUIg"
      decimals="4"
      id="Narr_Y7GXQnasd0-kR1Gp4Xt1Kw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">0.8003</ifrs-full:AverageForeignExchangeRate>
    <ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_kMe6bp-krkeeVp_UXNU6BQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,805,765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (471,485)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,334,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,444)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 202,150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,782)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 149,369&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104,276&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,226)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,152,192&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (561,937)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,590,255&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,152,192&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (561,937)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,590,255&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,423,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (632,767)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,423,467&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (632,767)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,790,700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EQUITY&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (271,275)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,830&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (200,445)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (271,275)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 70,830&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (200,445)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES AND NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,152,192&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (561,937)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,590,255&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&#160;Restated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; $&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,191,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (437,658)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,753,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,990)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 32,010&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 49,372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,862)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,510&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,729&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,344)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,287,196&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (456,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,830,342&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL ASSETS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,287,196&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (456,854)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,830,342&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (32,858)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131,642&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 164,500&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (32,858)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 131,642&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EQUITY&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,122,696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (423,996)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,698,700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,122,696&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (423,996)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,698,700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;TOTAL LIABILITIES AND NET DEFICIT&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,287,196&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (456,854)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,830,342&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales and marketing&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,292&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,263)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,029&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,126,762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (517,867)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,608,895&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 484,382&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (117,947)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 366,435&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional and consulting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,655,663&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (403,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,252,510&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss before other items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (4,276,099)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,041,230)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,234,869)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (500)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign exchange gain&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,574&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,662)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NET LOSS&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (4,238,471)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,050,392)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (3,206,403)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Foreign&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Reported&#160;CAD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restated&#160;USD&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Change in presentation currency&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Translation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,238,471)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(3,206,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-cash adjustment:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Share based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 292,756&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,469)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 221,287&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Foreign exchange&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (84,499)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(84,499)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Changes in working capital:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Other receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (152,778)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(109,858)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Prepaids&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (97,547)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 25,882&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(71,665)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,258,967&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (599,909)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,659,058&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash used in operating activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,937,073)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 344,993&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(1,592,080)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Proceeds received from Psyence Group Inc&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,551,744&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (378,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,172,923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash provided from financing activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,551,744&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (378,821)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,172,923&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Change in cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (385,329)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33,828)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;(419,157)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;Cash and cash equivalents, start of year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,191,095&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (437,658)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,753,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash and cash equivalents, end of year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,805,765&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (471,486)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,334,280&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DescriptionOfNatureAndAmountOfChangeInAccountingEstimate>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_FjOeHoSo3UK_2gVgXNMksQ_7_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1805765</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_Y8mye1y9xEmyTC35aY1e3Q_7_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-471485</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_U6dlW_OCyEmc8pKMfik6AA_7_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1334280</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_wybS7hCqAE-cVBbJqaF_0g_8_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">40000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_ZA6YaTktr0aB2q520KC54w_8_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-10444</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_LsTlHHbON0eKN5Yd0I6uBg_8_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">29556</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_qvS6DRXdh0qFEBszgJyEyw_9_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">202150</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_TsnO1fWH4EmdvjnUKRZiCQ_9_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-52782</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_7GoXqDxtWkGQWBwphxoGcw_9_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">149369</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_m87rTGjyN0mgv1ms8D3-gw_10_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">104276</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_Dwhb1J1qhU-vyQ6RIKnrfA_10_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-27226</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_5rOCM_l9WEuIse0bq4I7rQ_10_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">77050</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_KuWECQC8-UmbtTFFXMxEfQ_11_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2152192</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_X2Nm0x1Z2kWMN7uY0Ic8HA_11_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-561937</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_l8Zz6F3twk-Iicyeo5WCEA_11_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1590255</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_rrRhLWL6_kqs7Ti8ERPECw_12_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2152192</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_IMp7r_rU3kq4JOS28zhNzw_12_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-561937</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_QU3iqN-EO0eGAJby96I6hg_12_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1590255</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_47gZbSlWH0OgQ0siDmK0jA_15_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2423467</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_UxQIrOTvsE2pfwBk9ebDPw_15_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-632767</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_SkxV3ZMu60uT0dQOhM_qDA_15_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1790700</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:Liabilities
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_myY2kNmZQUCWuKC1SEmX8Q_16_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2423467</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_Mp-fbAoZdUe2xLB7PF0zbw_16_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-632767</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_9tq2E3K6vkKrVD5vvjrnlw_16_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1790700</ifrs-full:Liabilities>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_Wbbzer8UWE-ZKh9dUybeEw_18_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-271275</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc__TO72iCTT0qOazWiVBKtvg_18_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">70830</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_bU80ATKWQ0uhK-fkCcLCOg_18_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-200445</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_q2y963a4P0SgasGGjzngmw_19_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-271275</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_B7VaVRVfQ0KGGSPNmI5R6A_19_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">70830</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_Gb_BKiwaFkKGzdFfg_FWmg_19_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-200445</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_X-SSmyRxxE6fMq8owho65g"
      decimals="0"
      id="Tc_I6krmRJHrUuhvm8LJo5GtA_20_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2152192</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_2H9FRCMOlUaJuISlv-oUwA"
      decimals="0"
      id="Tc_7IHG10dYPkeZhyAxLpTMLw_20_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-561937</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_5gXTAeZEeEiyQSyWkHRMIg_20_6"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1590255</ifrs-full:EquityAndLiabilities>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_X1MnZeLvd0yY0PeyjodYJA_7_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2191095</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_5hX1XKjQ50ye1RPLyHZHEw_7_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-437658</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_nQ0cWMOIh0C3SwTJhK6l4g_7_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1753437</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_Px8gMGgs10m3_6Ct-YpSJw_8_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">40000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_vw0I8gekOUeOsVF1yd6SHQ_8_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-7990</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_QNDDB1G4MkWESfJEQJK5CA_8_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">32010</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_5_M-0yWjeUqb-u1veOmEyA_9_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">49372</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_j91Rl9zGAkaAZxycsp-9Gw_9_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-9862</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_LdVg54mzkEeuHral4T8xDg_9_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">39510</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_7nkK4ielHEKWT9Gdq8QDhg_10_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">6729</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_23H2T4pCbEGhoI-1ebEjAA_10_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-1344</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_N8u094Wrik6GqrQPcppRRA_10_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5385</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_XgCaHxXSzEKAUXWoUpPw-g_11_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2287196</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_Iz3re_IfqkCrjY-olgN16g_11_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-456854</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_x-TKCMXdl0KI_DFMk3cB_w_11_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1830342</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_9nFVYo4AjESW2-QWlNqGTg_12_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2287196</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_C62lemubyUiXFLptkE7_DA_12_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-456854</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_p9VncCi5_0CIS_pjsSNiNw_12_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1830342</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_iz6hDW51s02wyyfmfZCsvA_15_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">164500</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_BTGfT6jTHEOukgAKOXjRUQ_15_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-32858</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_BAS801EX_kKEKDHzqiEA6g_15_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">131642</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:Liabilities
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_9h7lBd6b20O5Dv0oTTeeRA_16_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">164500</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_KB5L0D0cIUC68N7LXfMrDQ_16_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-32858</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_KmFY4ivQyUK4fLMj2rmYfg_16_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">131642</ifrs-full:Liabilities>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_7RvoJcfyOEi0-qMr6WhlVg_18_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2122696</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_6pcbFsUlVU29GMlJZwDLzg_18_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-423996</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_FoGKgkGHp0aWEudjDpZAQQ_18_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1698700</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_OcfUzFnQAUCyThwBmJKNFw_19_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2122696</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_TgjzwyE930ul5qlsDjrM_A_19_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-423996</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_3x37JFi6PkeIC4C72NPilw_19_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1698700</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_09TIiTvkVkSeRGvEzlqifg_20_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2287196</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_sG2i93B4XkmhpX03g7X8KQ_20_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-456854</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_Os-ee_9mZkO4KMwZAYYzbg_20_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1830342</ifrs-full:EquityAndLiabilities>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_r_xC98wlwkecN8vlp1B7sw_6_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">9292</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_j1Zd0Vr_F0iZ4H0W8ZRIOA_6_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-2263</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_d_0uaflwqEG1Mwkk4iEG3g_6_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">7029</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_eQZdyNBEG0GiLFJqB0aSYw_7_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2126762</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_g0QaVPiaEEyVksb3cc7Bsg_7_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-517867</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_j10Sev3fkEeEY8qgC_O2Ow_7_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1608895</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc__iBEZ89EMkWuDQbBfYKPFA_8_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">484382</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_L2J0Be06NEOCGm5SSZjipQ_8_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-117947</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_q7Piv3KmgkeYanXdD2ZvQg_8_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">366435</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_3f5IfTdMcUOGd6Hxzct5_A_9_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1655663</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc__WZo_BLqtUOk-R0LPkMG4A_9_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-403153</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_64WA_lfrQU2nVDilEbR3CA_9_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1252510</ifrs-full:ProfessionalFeesExpense>
    <pbm:IfrsOperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_xEcsYGR02kmAGIoElLU--A_10_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-4276099</pbm:IfrsOperatingIncomeLoss>
    <pbm:IfrsOperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_WPlgpsKX50eCTxQvu8o6MA_10_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-1041230</pbm:IfrsOperatingIncomeLoss>
    <pbm:IfrsOperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_lW2wWpsXFEWkT2SNxmp-_A_10_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3234869</pbm:IfrsOperatingIncomeLoss>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_YCgQtolG-0KXXXUGrNuZ0Q_12_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2054</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_VdBM3JE7l0ynqRXm0VrATw_12_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-500</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_Rt88LYw_Rkm5lH40EtZjKw_12_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1554</ifrs-full:FinanceIncome>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_M5NdwuLPEUaBgeAW4WtkjA_13_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">35574</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_uMIBRwe6NEGTdhxNkhMxBg_13_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-8662</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_1Ed1Gs8LlUWIzh0Odko1zg_13_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">26912</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_Bw3jO0ecN0mMSIeQ1Nzlqw_14_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-4238471</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_Eu-HxIPJfEeKX1e_SJshnA_14_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-1050392</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_WME3iaiZoU6izXosf2onOA_14_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3206403</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_IKzBO4tWz0KVoh6SjYVOhg_7_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">292756</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_CeQduK7jJkamdaiWMIwfMg_7_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-71469</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_jvVDoCoPCUesLfxsG_5J8g_7_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">221287</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_IQ48OgQpgUCxVF3IIhQ6aA_8_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-84499</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_Bq0GW5_SR0aqtnNUMAuKfA_8_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-84499</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_aqF-leFBCkKzl2WaLegmoQ_11_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-152778</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_4iPfgOx9KUyTOA8NlEaBog_11_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">42920</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_0UH41OOrtkuk_EHlK6YGKA_11_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-109858</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_LCWESRcysE2DIoVFMS2sog_12_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-97547</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_JSGiq8Cy7Eu1URBWxPLzSg_12_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">25882</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_nQ5Y0Rw_sUC-jKL7mewDcw_12_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-71665</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_6Vy8K8UFUEi0yTkpRiuf-Q_13_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2258967</pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_ZISC8yBH6k2QNtRJawlrJA_13_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-599909</pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_27A0iePANkSqk80_xz-52Q_13_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1659058</pbm:AdjustmentsForIncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_FkW6NW5Uuk6sIto-FR7IWQ_14_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-1937073</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_PcbqzFcbbEa7J4KUYZh6lA_14_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">344993</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_pgMYZa3ZFUevmB-Nqvtc5g_14_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-1592080</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <pbm:ProceedsFromContributionsOfParent
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_GXjPfQ5PqEu_O67UnI5FUQ_16_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1551744</pbm:ProceedsFromContributionsOfParent>
    <pbm:ProceedsFromContributionsOfParent
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_KMYK2hDABU6CIm1kEUziKg_16_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-378821</pbm:ProceedsFromContributionsOfParent>
    <pbm:ProceedsFromContributionsOfParent
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_bv-yNKIbykCb_xt0Qw4SGw_16_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1172923</pbm:ProceedsFromContributionsOfParent>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_k7g-eRg950WwTlxa3iHWtw_17_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1551744</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_QnZimVmsmkqK5Wb_oyQ9nw_17_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-378821</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_aAzdOBkoNUyTdk9uJQVzCA_17_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1172923</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_pT8Hyz35tkSGt8snjX6OBg"
      decimals="0"
      id="Tc_roWbW0tChEmw0bg8EFRK-A_19_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-385329</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_J6R5_mXDGkKZsL6g9zWZsw"
      decimals="0"
      id="Tc_ck-Kkr2_X0ijXPKF7O4ZcA_19_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-33828</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_qEF8gBwdHU2_C4v8R7aD4Q_19_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-419157</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember_GELDWclzukCzsf_PXetCFQ"
      decimals="0"
      id="Tc_rG-SfbmN7USJOxAcrFF7Hg_20_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">2191095</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2022_ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis_ifrs-full_OpeningBalanceAfterAdjustmentCumulativeEffectAtDateOfInitialApplicationMember_lvm5TrAjEE-rdMDwg9SxHQ"
      decimals="0"
      id="Tc_imSgiZN0qE2Oc1_-Lx2dtA_20_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">-437658</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2022_N0hE7KYg9EG3Sd3tKVLzpQ"
      decimals="0"
      id="Tc_Vhud2QPOr0Oh2gyckKwFBQ_20_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1753437</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_3qBYtWxRgkiCFbTzd8u9uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Research and development&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Expenditures on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, are recognized in the statements of net loss and comprehensive loss as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to complete development and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are expensed as incurred. Research and development expenses include all direct and indirect operating expenses supporting the products in development. The costs incurred in establishing and maintaining patents are expensed as incurred.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_jAACk6tMBEONYqcTeN_39A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Provisions&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_Z5FfFs4FL0e3LHGXlmpsaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Foreign currency translation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Financial Statements are presented in USD $ which is PBM&#x2019;s functional currency. The functional currency of its subsidiary consolidated within these Financial Statements is AUD $.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In each individual entity, a foreign currency transaction is initially recorded in the functional currency of the entity, by applying the exchange rate between the functional currency and the foreign currency at the date of the transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At the end of the reporting period, monetary assets and liabilities of the Company which are denominated in foreign currencies are translated at the period-end exchange rate. Non-monetary assets and liabilities are translated at rates in effect at the date the assets were acquired, and liabilities incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The resulting exchange gains or losses arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition, are included in statement of net loss and comprehensive loss in the period in which they arise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the purpose of presenting these Financial Statements, the assets and liabilities of the subsidiary are translated into USD $ at the exchange rates prevailing at the end of the reporting period. Income and expenses are translated at the average rates for the period. The differences from translating subsidiaries is recorded in reserves.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_CIzduc5RvUiJJoAZo_UNpg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Loss per share&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company presents basic and diluted loss per share data for its common shares. Basic loss per share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the period. Diluted loss per share is determined by adjusting the loss attributable to common shareholders and the weighted average number of common shares outstanding, adjusted for the effects of all dilutive potential common shares, which comprise convertible debentures, warrants and share options issued.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_Z-EBavxaL0GR6oDAya-vzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Share based compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the options and RSUs granted by the Company shall be recognized as an expense in the Consolidated Financial Statements of the Company. The expense shall be recognized over the vesting period of the options. The fair value options shall be determined using the Black-Scholes model.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_vxsMY9t8_0CDj_6DiSnFiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Income tax comprises current and deferred tax. Income tax is recognized in profit or loss except to the extent that it relates to items recognized directly in shareholders&#x2019; equity, in which case the income tax is also recognized directly in equity or other comprehensive income, in which case the income tax is also recognized directly in equity or other comprehensive income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Current tax is the expected tax payable on the taxable income for the&#160;year, using tax rates enacted at the end of the reporting period, and any adjustments to tax payable in respect of previous&#160;years. Current tax assets and current tax liabilities are only offset if a legally enforceable right exists to offset the amounts and the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax is recognized in respect of all qualifying temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Financial Statements. Deferred income tax is determined on a non-discounted basis using the tax rates and laws that have been enacted or substantively enacted at the end of the reporting period and are expected to apply when the deferred tax asset or liability is settled. Deferred tax assets are offset when there is a legally enforceable right to offset tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets are recognized to the extent future recovery is probable. At each reporting period end, deferred tax assets are reduced to the extent that it is no longer probable that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_vrm3OVcKVUaEcZTTozUKbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Critical accounting estimates and judgements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with IFRS requires management to make certain estimates, judgments and assumptions concerning the future. Actual results may differ from these estimates. The Company&#x2019;s management reviews these estimates, judgments, and assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted prospectively in the period in which the estimates are revised. The following are deemed to be critical accounting policies as these require a high level of subjectivity and judgement and could have a material impact on PBM&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Going concern&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These Financial Statements have been prepared on the assumption that the Company will continue as a going concern, meaning it will continue in operation for the foreseeable future and will be able to realize assets and discharge liabilities in the ordinary course of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management routinely plans future activities including forecasting future cash flows and forming judgements collectively with directors of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Judgement is required in determining if the Company&#x2019;s has sufficient cash reserves, together with all other available information, to continue as a going concern for a period of at least twelve&#160;months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As at March&#160;31, 2024 the Company has concluded that a material uncertainty exists that casts significant doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Reverse takeover transaction&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The determination of fair values of consideration paid and net assets acquired is subject to significant estimation. The Company treated the RTO Transaction as a capital transaction equivalent to the issue of shares of the Company in exchange for the net monetary assets of NCAC. The Company determined that the original shareholders of PGI became the single largest shareholder of the Company after the RTO Transaction, therefore the Company was the acquiror and NCAC was the acquiree.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has determined the RTO Transaction did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was estimated by the closing trading price ($4.79/share) of the Company&#x2019;s common shares listed on the NASDAQ on January&#160;25, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Convertible instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The valuation of convertible debt instruments is subject to significant management estimation. Convertible notes are compound financial instruments which have been designated as a FVTPL classification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The identification of convertible debenture components is based on interpretations of the substance of the contractual arrangement and therefore requires judgment from management. The separation of the components affects the initial recognition of the convertible debenture at issuance and the subsequent remeasurement. As the Company has designated the entire convertible financial instrument as FVTPL given the embedded derivate liability that was contained by the convertible financial instrument, the debentures have not been separated into debt and derivative components. The determination of the fair value of the instrument used a combined discount cash flow approach and a Monte Carlo simulation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Contingencies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, the Company is named as a party to claims or involved in proceedings, including legal, regulatory and tax related, in the ordinary course of its business. While the outcome of these matters may not be estimable at the reporting date, the Company makes provisions, where possible, for the estimated outcome of such claims or proceedings. Should a loss result from the resolution of any claims or proceedings that differs from these estimates, the difference will be accounted for as a charge to profit or loss in that period. The actual results may vary and may cause significant adjustments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The rebate over the tax claim is subject to inherent uncertainty and could be subject to being denied and clawed back by the Australian Tax office at a future date. The Company expects that a claw back of the rebate is highly unlikely.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Deferred taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Significant estimates are required in determining the Company&#x2019;s income tax provision. Some estimates are based on interpretations of existing tax laws or regulations. Various internal and external factors may have favourable or unfavourable effects on the Company&#x2019;s future effective tax rate. These include, but are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, and results of tax audits by tax authorities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Inputs when using Black-Scholes valuation model&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimates used in determining the private warrant fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes valuation model. Inputs subject to estimates include volatility, estimated lives and market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Income taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Provisions for taxes are made using the best estimate of the amount expected to be paid based on a qualitative assessment of all relevant factors. The Company reviews the adequacy of these provisions at the end of the reporting period. However, it is possible that at some future date an additional liability could result from audits by taxing authorities. Where the outcome of these tax-related matters is different from the amounts that were initially recorded, such differences will affect the tax provisions in the period in which such determination is made.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;Government grants&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Government grants are recognized when there is reasonable assurance that the Company will comply with the conditions attached to them and the government grants will be received. Grants are recognized as income when they are received. The Company has recognized the government grant received during the period as research and development grants as other income in the consolidated statements of loss and comprehensive loss.&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <pbm:IfrsSharePrice
      contextRef="As_Of_1_25_2024_ZZfEBp5vhECip57BNE-wtg"
      decimals="2"
      id="Narr_lwYGRlcR40CBnCJenyw5cw"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">4.79</pbm:IfrsSharePrice>
    <pbm:ReverseTakeoverTransactionWithNcacTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_BWyn9IlEAkeX3rrF1M96Yg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Reverse takeover transaction with NCAC&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;25, 2024 the Company completed the RTO Transaction (See Note&#160;1). As disclosed in Note 4, the RTO Transaction did not constitute a business combination as defined under IFRS 3, Business Combinations, as NCAC is a non-operating entity that does not meet the definition of a business under IFRS 3. The excess of the consideration paid over the net liability acquired together with any transaction costs incurred for the Transaction is expensed as a listing expense in accordance with IFRS 2 Share-Based Payments. The fair value of the consideration paid was determined by the closing trading price ($4.79/share) of the NCAC&#x2019;s common shares listed on the NASDAQ on January 25, 2024. This was initially estimated by the Company as the opening trading price ($3.55/share) of the Company&#x2019;s common shares listed on the NASDAQ on January&#160;26, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accordingly, upon consummation of the BCA the Company issued 7,794,659 common shares in exchange for the outstanding ordinary shares held by NCAC stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The calculation of listing expenses is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Listing&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;Expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consideration paid:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Shares issued to NCAC shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,794,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Total consideration shares issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,794,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value of the common shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Deemed consideration amount for the common shares issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,336,416&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Net identifiable liabilities acquired:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,136,505)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;NCAC promissory note (Note 11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,413,529)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Derivative warrant liabilities (Note 10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (595,358)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net liabilities acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,145,189&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Listing expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,481,605&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The listing expense has been included in the consolidated statements of net loss and comprehensive loss. Transaction expenses included in the consolidated statements of net loss and comprehensive loss are others costs of $2,461,025 in connection with the RTO Transaction composed of legal, banking, professional fees and costs related to the settlement of carved-out assets and liabilities from Psyence Group. Some payments to brokers and advisors were in the Company&#x2019;s shares upon RTO at the closing trading price on January 25, 2024 (Refer Note 12).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The change in the estimate of the share price used to determine the fair value of consideration paid resulted in an increase to listing expense by $9,483,945 from the amount previously reported.&lt;/p&gt;</pbm:ReverseTakeoverTransactionWithNcacTextBlock>
    <pbm:IfrsSharePrice
      contextRef="As_Of_1_25_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_LZT5nK0-7UestTgckCLkuA"
      decimals="2"
      id="Narr_0WEuh-iRiUCIzILyr-AnXQ"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">4.79</pbm:IfrsSharePrice>
    <pbm:IfrsSharePrice
      contextRef="As_Of_1_26_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_lrZq_P2lj0W1n0ER5UZe2A"
      decimals="2"
      id="Narr_eX4tBak_J0-18MCcisHPLA"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">3.55</pbm:IfrsSharePrice>
    <pbm:ReverseTakeoverTransactionSharesIssued
      contextRef="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g"
      decimals="INF"
      id="Narr_JwnLb-89PUSS8y9HhXs8xQ"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">7794659</pbm:ReverseTakeoverTransactionSharesIssued>
    <pbm:ScheduleOfListingExpensesTableTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_iKjR4PRojk-oWnKzq5VQzw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Listing&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;Expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Consideration paid:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Shares issued to NCAC shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,794,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Total consideration shares issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,794,659&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Fair value of the common shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Deemed consideration amount for the common shares issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 37,336,416&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Net identifiable liabilities acquired:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash and cash equivalent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 203&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,136,505)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;NCAC promissory note (Note 11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,413,529)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Derivative warrant liabilities (Note 10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (595,358)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Net liabilities acquired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,145,189&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Listing expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 41,481,605&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pbm:ScheduleOfListingExpensesTableTextBlock>
    <pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction
      contextRef="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g"
      decimals="INF"
      id="Tc_-BjWvLiSA0uAa1dNIk1dYA_4_3"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">7794659</pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction>
    <pbm:ReverseTakeoverTransactionSharesIssued
      contextRef="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g"
      decimals="INF"
      id="Tc_TXp785p3IEqmDUyD2al-oQ_5_3"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">7794659</pbm:ReverseTakeoverTransactionSharesIssued>
    <pbm:IfrsSharePrice
      contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A"
      decimals="2"
      id="Tc_pqohAcBV5EyVjPvWrf8lzg_6_3"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">4.79</pbm:IfrsSharePrice>
    <pbm:ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued
      contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A"
      decimals="0"
      id="Tc_69yGwjEhOEuumPS7cILh9w_7_3"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">37336416</pbm:ReverseTakeoverTransactionDeemedConsiderationAmountForCommonSharesIssued>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A"
      decimals="0"
      id="Tc_rNlmj__gsUGj_kUuzOlk2g_10_3"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">203</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A"
      decimals="0"
      id="Tc_NDLwPDdV50m_ECSmk7Hdfg_11_3"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2136505</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:Borrowings
      contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A"
      decimals="0"
      id="Tc_nop5FXgbrkmzjRpvy2soTw_12_3"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1413529</ifrs-full:Borrowings>
    <ifrs-full:CurrentWarrantLiability
      contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A"
      decimals="0"
      id="Tc_ICafjLWRGk2I_CefezI0AQ_13_3"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">595358</ifrs-full:CurrentWarrantLiability>
    <ifrs-full:NetAssetsLiabilities
      contextRef="As_Of_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_7YZUhAW05kmWVj2huC7l3A"
      decimals="0"
      id="Tc_dHa-M3NepUmjH5DeZS897w_14_3"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">4145189</ifrs-full:NetAssetsLiabilities>
    <pbm:ListingExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_pbm_ReverseTakeoverTransactionWithNcacAxis_pbm_NcacMember_dOFEGy0oN0O1cYXo8nz08g"
      decimals="0"
      id="Tc_5wEbPcPEv0-y3tJmQF3jaA_16_3"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">41481605</pbm:ListingExpense>
    <pbm:TransactionExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Narr_kTin9rQpbUGB4fEQ7MoTbQ"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2461025</pbm:TransactionExpense>
    <pbm:IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Narr_gyCs3x1VnEKed-WDjR67mg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">9483945</pbm:IncreaseDecreaseInListingExpenseFromChangeInEstimateOfSharePrice>
    <pbm:CashRestrictedCashAndCashEquivalentsTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_r3rP_ietpEulc4gw7LJC9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Cash, restricted cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include the following amounts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Unrestricted cash held with chartered banks&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 733,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,334,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 762,799&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,363,836&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:20.9pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;unrestricted cash held with chartered banks and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Company entered into a cash collateral agreement with a major chartered bank in Canada with regards to a credit card facility against which the Company deposited Canadian Dollars $40,000 in a guaranteed investment certificate with the bank. Amounts are presented as restricted cash on the statements of financial position.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;</pbm:CashRestrictedCashAndCashEquivalentsTextBlock>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_inq7zBjgF0WXHm4mwqHzlg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Unrestricted cash held with chartered banks&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 733,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,334,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,611&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 29,556&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 762,799&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,363,836&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <ifrs-full:BalancesWithBanks
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_z1mzuvkeoU666LaXIiwa2Q_3_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">733188</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_zRND7SJdFEGuRcvqYyTtDw_3_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1334280</ifrs-full:BalancesWithBanks>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_jAMPZdck00W2iXXfuHrkFQ_4_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">29611</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_Xix5mS_MWUqGnjBZARimyA_4_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">29556</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <pbm:CashRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_IpCtr2u9R02-QsyRtx5LPQ_5_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">762799</pbm:CashRestrictedCashAndCashEquivalents>
    <pbm:CashRestrictedCashAndCashEquivalents
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_2VQ0UQDZ-0qONC_9DfTSjA_5_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1363836</pbm:CashRestrictedCashAndCashEquivalents>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_3lU0F8ptSkiJRa7vNXJTmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Equipment&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Computer &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,727&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,727&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Accumulated Depreciation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Charge for the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (240)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (240)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,487&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_9Io86Wf7rEyehjRGbwdG2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Computer &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;equipment&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,727&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,727&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Accumulated Depreciation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Charge for the year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (240)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (240)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:86.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;At March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,487&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_ZRqYyGoYrU2C6-I2Wd8ynA"
      decimals="0"
      id="Tc_CJJbGSr0VkK9fJtOR3H1pg_5_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5727</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_1QeYdHjl3EWi94YMiSvNOA"
      decimals="0"
      id="Tc_6jJS-agAw0eZx-gxQicuNA_6_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5727</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_1-dfoVe4v0uYJUHIYSGRgQ"
      decimals="0"
      id="Tc_Y5Egrd_v8k27jp2leAOZMA_10_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">240</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_3_31_2024_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_ipePrLsiFUeta9xYIvy-Ng"
      decimals="0"
      id="Tc_FlR8Xkt9bU-lYyj9Tx-tGg_11_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-240</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ComputerEquipmentMember_xjrxvVhFRE2AUu-5qZqFxg"
      decimals="0"
      id="Tc_aWkNjH0TvESlsi4DbZDiNA_15_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">5487</ifrs-full:PropertyPlantAndEquipment>
    <pbm:AccountsPayableAndAccruedLiabilitiesTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_0_x6xjXoUUm6gBXH31vmnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Accounts payable and accrued liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts payable and accrued liabilities include the following amounts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 562,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,628,143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125,951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 162,557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 755,202&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,790,700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pbm:AccountsPayableAndAccruedLiabilitiesTextBlock>
    <pbm:ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_ghm-zAIfPk-am8mTInAclA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Trade payables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 562,352&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,628,143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 125,951&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 162,557&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provisions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 755,202&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,790,700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pbm:ScheduleOfAccountsPayableAndAccruedLiabilitiesTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_HpPd2Cq8KEmvwA_CFfrw7A_3_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">562352</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_Idov-lG6xEySJMIRjlLNBQ_3_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1628143</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_T7NOixjv-UyuNos4oDidXw_4_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">125951</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_NJGGPWj-BEuXSzu1_PAvVg_4_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">162557</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:OtherShorttermProvisions
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_XjsviK0HEUOHwu89amMXrw_5_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">66899</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_PWduBNAEBUqk318cKOCjVw_6_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">755202</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_-rfnC6A61k2exnk5AID4dg_6_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1790700</ifrs-full:TradeAndOtherCurrentPayables>
    <pbm:DisclosureOfConvertibleNoteLiabilityTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_3t-spL67a0Srimx3b33_cg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Convertible note liability&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;15, 2024, in connection with the RTO Transaction (Note&#160;5), the Company and Psyence Biomed II entered into the Securities Purchase Agreement with the Investors and the NCAC Sponsor, relating to up to four senior secured convertible notes obligations under which are guaranteed by certain assets of the Company and Psyence Biomed II, issuable to the Investors at or after the Closing, as the case may be, for the aggregate principal amount of up to $12,500,000 in exchange for up to $10,000,000 in cash subscription amounts (the &#x201c;&lt;b style="font-weight:bold;"&gt;Convertible Note&#160;Financing&lt;/b&gt;&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The First Tranche Notes, for an aggregate of $3,125,000 principal, were delivered by the Company to the Investors on January&#160;25, 2024, in exchange for an aggregate of $2,500,000 in financing, which occurred substantially concurrently with the consummation of the RTO Transaction. On the original issuance date of the First Tranche Notes, interest began accruing at 8.0% per annum based on the outstanding principal amount of the First Tranche Notes&#160;and is payable&#160;monthly in arrears in cash or in common shares of the Company at the Conversion Price (as defined below). The maturity date of the First Tranche Note&#160;is January&#160;25, 2027.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The price at which the Investors can convert the outstanding principal and interest to the common shares (the &#x201c;Conversion Price&#x201d;) is determined as follows: The initial Conversion Price of the First Tranche Notes&#160;was $10.00; provided, however, that such Conversion Price is subject to certain adjustments according to the terms and reset dates included in the First Tranche Notes&#160;and may be reduced to a Conversion&#160;Floor of $1.00, until the First Reset Date (5&#160;days prior the initial Registration Statement is effective), then to $0.50 on the Second Reset Date (3-month anniversary of Closing Date) and no floor thereafter. The Conversion Price is the lowest volume-weighted average price (&#x201c;&lt;b style="font-weight:bold;"&gt;VWAP&lt;/b&gt;&#x201d;) of the shares up until conversion date subject to the conversion floor.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is obligated to make a Make Whole Payment to Investors within &lt;span style="-sec-ix-hidden:Hidden_8zLKxnneHEOziY32s6_j8Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thirty-five&lt;/span&gt;&lt;/span&gt; (35) Trading Days following a Conversion Date if the &lt;span style="-sec-ix-hidden:Hidden_bgTt3-yaZkufZ6GsyM4Hmw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;thirty&lt;/span&gt;&lt;/span&gt; (30) Day VWAP, starting from the first Trading Date after the conversion, is lower than the Conversion Price. The Make Whole Payment can be made in either cash or Common Shares, at the Company&#x2019;s discretion, subject to certain conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;If the Company elects to settle the Make Whole Payment in Common Shares, it will transfer to the Holder the number of Common Shares (the &#x201c;Make Whole Shares&#x201d;) calculated as the difference between (A)&#160;the principal amount converted on the Conversion Date divided by the 30 Day VWAP, and (B)&#160;the principal amount converted divided by the Conversion Price on the Conversion Date. Alternatively, if the Company chooses to pay in cash, the payment will equal the number of Make Whole Shares multiplied by the 30 Day VWAP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Total proceeds received were $2,500,000. The Company has designated the entire instrument as FVTPL instrument. The fair value of the convertible notes was estimated using a combined discounted cash flow approach and Monte Carlo simulation with the following assumptions as of March&#160;31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Note principal amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepayment Amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility annual&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility daily&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free annual&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value was calculated to be $7,657,397 as of March&#160;31, 2024. A fair value loss was recognized of $5,157,397 during the&#160;year end March&#160;31, 2024 ($nil, March&#160;31, 2023).&lt;/p&gt;</pbm:DisclosureOfConvertibleNoteLiabilityTextBlock>
    <pbm:NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes
      contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_RC1H4ZLwU0apeImJQBE_dA"
      decimals="INF"
      id="Narr_e_cWzvqSGE2O7TBFGdoH5g"
      unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A">4</pbm:NumberOfSeniorSecuredConvertibleNotesCollectivelyAsNotes>
    <pbm:IfrsDebtInstrumentFaceAmount
      contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_snyZUpSh_k-8or2abjhYpw"
      decimals="0"
      id="Narr_9QWx06s0m0eX2j2ysk_2Mg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">12500000</pbm:IfrsDebtInstrumentFaceAmount>
    <pbm:SubscriptionAmount
      contextRef="As_Of_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_srt_RangeAxis_ifrs-full_TopOfRangeMember_snyZUpSh_k-8or2abjhYpw"
      decimals="0"
      id="Narr_UKwzcE3Fo0ij3_NdzonpUQ"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">10000000</pbm:SubscriptionAmount>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_dXrtFPMS3U-OLj3sZ1COaA"
      decimals="0"
      id="Narr_FZN3RKKtDU6DeSfAXl2l6w"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">3125000</ifrs-full:NotionalAmount>
    <pbm:IfrsProceedsFromConvertibleDebt
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_EyC98DIUWkSnV6ZsDXjDuA"
      decimals="0"
      id="Narr_gCqLi0zS2UOaxRlA1H-dHA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2500000</pbm:IfrsProceedsFromConvertibleDebt>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_Ov4A1NkLkEa1t15pEcI7Fw"
      decimals="3"
      id="Narr_VqUH2Wwa_UW4wu2-nk2zbA"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.080</ifrs-full:BorrowingsInterestRate>
    <pbm:DebtInstrumentConvertibleInitialConversionPrice
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_Ov4A1NkLkEa1t15pEcI7Fw"
      decimals="2"
      id="Narr_Qn_DZuCtbUucUHeQxvZz5g"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">10.00</pbm:DebtInstrumentConvertibleInitialConversionPrice>
    <pbm:DebtInstrumentConvertibleFloorPrice
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_srt_StatementScenarioAxis_pbm_UntilFirstResetDateMember_xUD9ygGdy0ikpiUdFa3HuA"
      decimals="2"
      id="Narr_L8dpvR_ys06KHyZOTWglZQ"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">1.00</pbm:DebtInstrumentConvertibleFloorPrice>
    <pbm:NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate
      contextRef="Duration_1_25_2024_To_1_25_2024_eZQ4RlMJqUmySF9gmBlrAA"
      id="Narr_WCzkzFWlH0usR5SODD2B2A">P5D</pbm:NumberOfDaysPriorToEffectiveInitialRegistrationStatementForFirstResetDate>
    <pbm:DebtInstrumentConvertibleFloorPrice
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_srt_StatementScenarioAxis_pbm_OnSecondResetDateMember_xTV-TVOmlEOSuiCCH637yg"
      decimals="2"
      id="Narr_coy_2Wo1lEqQlvmXd-HNVQ"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0.50</pbm:DebtInstrumentConvertibleFloorPrice>
    <pbm:PeriodOfClosingDateConsideredForSecondResetDate
      contextRef="Duration_1_25_2024_To_1_25_2024_eZQ4RlMJqUmySF9gmBlrAA"
      id="Narr_duyFQZ5KI0aaguvecSFPxw">P3M</pbm:PeriodOfClosingDateConsideredForSecondResetDate>
    <pbm:DebtInstrumentConvertibleFloorPrice
      contextRef="As_Of_1_25_2023_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_wL0j3sQ_P02l4cmD5Xha0Q"
      decimals="2"
      id="Narr_QnCbSR4AK0uE4dcBboeuDw"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0</pbm:DebtInstrumentConvertibleFloorPrice>
    <pbm:ThresholdPeriodForVolumeWeightedAveragePrice
      contextRef="Duration_1_15_2024_To_1_15_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_t2bpJrv-CEWvzpwrJA9aDA"
      id="Narr_oek72jkfq0CVDPYMjc6VQQ">P30D</pbm:ThresholdPeriodForVolumeWeightedAveragePrice>
    <pbm:IfrsProceedsFromConvertibleDebt
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_FirstTrancheNoteMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_InvestorsMember_w3jAzl07ZUOTF5NYOWIMug"
      decimals="0"
      id="Narr__Mh6FK_RKUqOTh05wuF7Mg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2500000</pbm:IfrsProceedsFromConvertibleDebt>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_XpSCtJGVFEW3JU9sTAbAHQ"
      id="Tb_XKycgw6Ickm8w9oikyfuPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Note principal amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,125,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepayment Amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 130&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Discount rate cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.83&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility annual&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Volatility daily&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free annual&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_FIOBwMXOW0G4Rh9Kg-g5zw"
      decimals="2"
      id="Tc_XD9o7XbreUWZro5fK31-iw_2_2"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">1.14</ifrs-full:SignificantUnobservableInputLiabilities>
    <pbm:IfrsDebtInstrumentFaceAmount
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_DrXtvzbxdUuHFqH8Mzx6Eg"
      decimals="0"
      id="Tc_AHtYULc9yE6wv6NV8VXnHA_3_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">3125000</pbm:IfrsDebtInstrumentFaceAmount>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_ifrs-full_ConstantPrepaymentRateMeasurementInputMember_OOYtrkOvCkOAIWIIs2K24g"
      decimals="0"
      id="Tc_cyvgatNCXUyNemm0Y-F7lQ_4_2"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">130</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_DiscountRateSharesMeasurementInputMember_T-qLZ5GLyUqYuqKzU6A99Q"
      decimals="2"
      id="Tc__Tgn55z2vUSxXDF7axX1XA_5_2"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">4.43</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_DiscountRateCashMeasurementInputMember_9zeIuNj3jkeNuHkmFUSZww"
      decimals="2"
      id="Tc_jqZgM7QLf0yshQFgV4kUDw_6_2"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">20.83</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_HistoricalAnnualVolatilityForSharesMeasurementInputMember_0n6lL7b98kK_7fXZv3ARAw"
      decimals="0"
      id="Tc_LR0N_YSBHke73UtzhX3OOA_7_2"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">100</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_HistoricalDailyVolatilityForSharesMeasurementInputMember_8aaTSxqRuk2-CUB0EpgfuA"
      decimals="2"
      id="Tc_GxejfoDEIUqG8cRxlkdH0g_8_2"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">6.30</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_UnobservableInputsAxis_pbm_AnnualInterestRateMeasurementInputMember_rlp9Ay7neEuAWClA72ZtUg"
      decimals="2"
      id="Tc_k1XKzxD2lke1x8JL5XyerA_9_2"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">4.43</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_DrXtvzbxdUuHFqH8Mzx6Eg"
      decimals="0"
      id="Narr_lHEkhRARLUWt-Vpf9IhXKQ"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">7657397</ifrs-full:FinancialLiabilitiesAtFairValue>
    <pbm:FairValueAdjustmentOnConvertibleNote
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_XpSCtJGVFEW3JU9sTAbAHQ"
      decimals="0"
      id="Narr_ZCtbfiQFv0WTn-qtsmQEFA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-5157397</pbm:FairValueAdjustmentOnConvertibleNote>
    <pbm:FairValueAdjustmentOnConvertibleNote
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_BorrowingsByNameAxis_pbm_IfrsConvertibleDebtMember_SZy8rGHGj06aGJODffVKug"
      decimals="0"
      id="Narr_k4SLVqeU8UieX7Uvc1FQUA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">0</pbm:FairValueAdjustmentOnConvertibleNote>
    <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_HWhe3C4AzEW4KsHMyWTSlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Derivative warrant liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the RTO Transaction, NCAC had two classes of warrants outstanding, which were assumed by the Company upon completion of the RTO Transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Public Warrants: which had resulted from NCAC&#x2019;s initial public offering (the &#x201c;&lt;b style="font-weight:bold;"&gt;NCAC IPO&lt;/b&gt;&#x201d;) and entitled to registration on the Form&#160;F-4 filed in connection with the RTO Transaction. These warrants were listed on Nasdaq Capital Market under the symbol &#x201c;PBMWW&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Private Warrants: which had resulted from NCAC&#x2019;s private placement prior to the NCAC IPO.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As at the Closing Date and March&#160;31, 2024, there were 13,070,000 warrants &lt;span style="-sec-ix-hidden:Hidden_x8bw_yf0B0-hUxug_gXzGw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; and &lt;span style="-sec-ix-hidden:Hidden_s2yDhvbquUGMuaS1WGntNA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;, comprised of 12,500,000 Public Warrants and 570,000 &lt;span style="-sec-ix-hidden:Hidden_zlOG_EIIqEixGctRvHNJ-A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Private Warrants&lt;/span&gt;&lt;/span&gt;. Each warrant is exercisable to purchase one common share at a price of $11.50 per share. As a result of the potential cashless exercise feature included within the indenture of the warrants, the Company has classified the warrants as a liability measured at fair value through profit or loss as they failed to meet the &#x201c;fixed-for-fixed&#x201d; requirements prescribed by &lt;i style="font-style:italic;"&gt;IAS 32&#160;&#x2013; Financial Instruments: presentation.&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Since the Public Warrants are traded on Nasdaq, their price is observable. The Company valued the Public Warrants using the closing price of PBMWW to measure their fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes a Black-Scholes options valuation model to value the private warrants at each reporting period, with changes in fair value recognized in the statement of net loss and comprehensive loss. The estimated fair value of the warrant liability is determined using Level 2 inputs. Inherent in a Black-Scholes pricing model are assumptions related to expected volatility of the Public Warrants, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on industry historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides quantitative information regarding Level 2 fair value measurements at March&#160;31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Inputs at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Inputs at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 25, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Nil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Nil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expiry date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;January 25, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;January 25, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;At March&#160;31, 2024 the fair value of the Public and Private Warrants was $875,000 ($0.07/warrant) (January 25, 2024 - $568,750) and $26,608 ($0.4668/warrant) (January 25, 2024 - $26,608), respectively. A fair value loss of $306,250 was recognized on the statement of net loss and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Warrant transactions and the number of warrants outstanding are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Public Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Private Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Weighted  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Weighted   &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Balance, March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 570,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Balance, March 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 570,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following warrants were outstanding and exercisable at March&#160;31, 2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiry Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 25, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;January 25, 2029 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,070,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,070,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, March 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,070,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,070,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
    <pbm:NumberOfClassesOfWarrantsOutstanding
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="INF"
      id="Narr_LFIh6KbWcE-yhpBb4LEesg"
      unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A">2</pbm:NumberOfClassesOfWarrantsOutstanding>
    <pbm:NumberOfWarrantsIssued
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="INF"
      id="Narr_3h4UB6ZRzE6sXz8ItRJqWw"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13070000</pbm:NumberOfWarrantsIssued>
    <pbm:NumberOfWarrantsOutstanding
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ"
      decimals="INF"
      id="Narr_RLicSE_z3EaM_7ZCm8QSTg"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">12500000</pbm:NumberOfWarrantsOutstanding>
    <pbm:NumberOfWarrantsIssued
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ"
      decimals="INF"
      id="Narr__b_D9jet80GTen9MsMMIMg"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">570000</pbm:NumberOfWarrantsIssued>
    <pbm:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="INF"
      id="Narr_IXYPE_1mkk6TSkVplYffEQ"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">1</pbm:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="2"
      id="Narr_xzxcF3QISkuIqHVit09KEw"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <pbm:DividendYield
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="2"
      id="Narr_xlrDw4OJc0WL5OcdEftiig"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0</pbm:DividendYield>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_GyYh-yIlLUqkWocMNDUSDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Inputs at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Inputs at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;January 25, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Nil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Nil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.21&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59.98&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expiry date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;January 25, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;January 25, 2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_mklxx0Juv0KNIx9Swl1rqg"
      decimals="2"
      id="Tc_dCg2NBabD0yJHkVJ9Hl-jQ_3_2"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">4.79</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_SharePriceMeasurementInputMember_kXEDmraaCEyS6VFHtQQhVw"
      decimals="2"
      id="Tc_1LyCJw3eyEum68rmXyFI5g_3_4"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">1.14</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedDividendYieldMeasurementInputMember_VFv-YHMmsUK_zTq5IChJuw"
      decimals="INF"
      id="Tc_WFoATKG2Pkq4aSzJHZrgbQ_4_2"
      unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedDividendYieldMeasurementInputMember_SJAHRg26zES9xeoq_XHY8g"
      decimals="INF"
      id="Tc_TuLLiwFJbkePF0_Jl0NLzg_4_4"
      unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A">0</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExercisePriceMeasurementInputMember_xlkc7XKVtk2Kga0Muvve7g"
      decimals="2"
      id="Tc_VN3H6746aUmL6nuCxnneqw_5_2"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExercisePriceMeasurementInputMember_MsEFN7RVDUWdk_1PcKNO4w"
      decimals="2"
      id="Tc_woYxZ4c54UCFeq-VpOuGag_5_4"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_nDnNEVpGr0yCKCdSdpxUUA"
      decimals="2"
      id="Tc_vLkR2LPHJEq8gqOPLa2-Ng_6_2"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">4.01</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Z65vDr3AykS8Ay5XjpdTIQ"
      decimals="2"
      id="Tc__mvscMt2SEelatO-lzmyfQ_6_4"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">4.21</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedLifeMeasurementInputMember_4vaXn8GAh0W1rO5og87law"
      decimals="INF"
      id="Tc_HRCC_5g7yU26vN34UP_eeQ_7_2"
      unitRef="Unit_Standard_Y_GuMP1MngLk2rtbNTk6zhew">5.00</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_pbm_ExpectedLifeMeasurementInputMember_VCLVBTHMYEOISLzWk8xClg"
      decimals="INF"
      id="Tc_KZXvvzSwvEKsW_kSuXjHgg_7_4"
      unitRef="Unit_Standard_Y_GuMP1MngLk2rtbNTk6zhew">5.00</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_1_25_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_C7czhwq_XUix_v98K7IvfA"
      decimals="2"
      id="Tc_snvfJRzASU62xCjmkFwpsg_8_2"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">17.67</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_iwqqB_9GUE6i4oPg6dByJQ"
      decimals="2"
      id="Tc_WwJL61LvEkGErBfu3Txp1w_8_4"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">59.98</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ"
      decimals="0"
      id="Narr_fFupLa2PC06B5iGPl35ang"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">875000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <pbm:FinancialLiabilitiesFairValuePerShare
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA"
      decimals="2"
      id="Narr_ElJocgTGukyjVcGTodDAKw"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0.07</pbm:FinancialLiabilitiesFairValuePerShare>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_1_25_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_fZwi28Ln9kCZ-qKFXmRfrQ"
      decimals="0"
      id="Narr_4iP9aAX5-UScVQP77qgG-A"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">568750</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ"
      decimals="0"
      id="Narr_dDODhbs5CUGud6lN8O8Rxw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">26608</ifrs-full:FinancialLiabilitiesAtFairValue>
    <pbm:FinancialLiabilitiesFairValuePerShare
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_569tQMQIbUuCRwNdZsHxOA"
      decimals="4"
      id="Narr_EW7R_brMo0yVxAE_jFaskw"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0.4668</pbm:FinancialLiabilitiesFairValuePerShare>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_1_25_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Am2J6wS5NU2pK_QwXcD3tg"
      decimals="0"
      id="Narr_Hvp80zY4UkWHHMhnRww6gw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">26608</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Narr_egH_qKN1Dka-VcCIYfHKvA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">306250</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <pbm:ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_e0i7vYsd30iW4X96TO9Gkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Public Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:22.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Private Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Weighted  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Weighted   &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Balance, March 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 570,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Balance, March 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 570,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pbm:ScheduleOfWarrantTransactionsAndNumberOfWarrantsOutstandingTableTextBlock>
    <pbm:WarrantsIssuedNumber
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA"
      decimals="INF"
      id="Tc_Hk_GY1nHr0Obrt3jOJqhow_7_2"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">12500000</pbm:WarrantsIssuedNumber>
    <pbm:WarrantsIssuedWeightedAverageExercisePrice
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_48r-rc8sWUWsLioeco13iA"
      decimals="2"
      id="Tc_TMX19-j8akOhGHQsz0N5NQ_7_5"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</pbm:WarrantsIssuedWeightedAverageExercisePrice>
    <pbm:WarrantsIssuedNumber
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_569tQMQIbUuCRwNdZsHxOA"
      decimals="INF"
      id="Tc_j-KQdoHmdkqPWux7l8V6tA_7_7"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">570000</pbm:WarrantsIssuedNumber>
    <pbm:WarrantsIssuedWeightedAverageExercisePrice
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_569tQMQIbUuCRwNdZsHxOA"
      decimals="2"
      id="Tc_9RZ_aoWFaUKMG-yx1IpRAA_7_10"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</pbm:WarrantsIssuedWeightedAverageExercisePrice>
    <pbm:NumberOfWarrantsOutstanding
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ"
      decimals="INF"
      id="Tc_tcVgqDgPmUWsALZS2I4fOA_8_2"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">12500000</pbm:NumberOfWarrantsOutstanding>
    <pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_W2-YQ1ilgUmVOCTaYwVeJQ"
      decimals="2"
      id="Tc_ktaFz38LL0iZp6K6spvckA_8_5"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <pbm:NumberOfWarrantsOutstanding
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ"
      decimals="INF"
      id="Tc_TtQfaNn8Fk6PLbHOdW3uug_8_7"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">570000</pbm:NumberOfWarrantsOutstanding>
    <pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PrivateWarrantsMember_Q-LmDvPnq0aRulWgHSWRvQ"
      decimals="2"
      id="Tc_OzV3jZ4jeUKNyi20q47bKQ_8_10"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <pbm:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_Z6aoDVz1tkmDMoj-hSj50A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issue Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiry Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;January 25, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;January 25, 2029 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,070,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,070,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance, March 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,070,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,070,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pbm:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock>
    <pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_WarrantsIssuedOnJanuary252024Member_Ge_kREe1AE-p07ojtGFkCw"
      decimals="2"
      id="Tc_3pwsGfnLjkSZgffBShi4zw_4_5"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <pbm:NumberOfWarrantsOutstanding
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_WarrantsIssuedOnJanuary252024Member_Ge_kREe1AE-p07ojtGFkCw"
      decimals="INF"
      id="Tc_nnuU_ZaU40S2zUQHbgPT3w_4_7"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13070000</pbm:NumberOfWarrantsOutstanding>
    <pbm:NumberOfWarrantsExercisable
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_WarrantsIssuedOnJanuary252024Member_Ge_kREe1AE-p07ojtGFkCw"
      decimals="INF"
      id="Tc_eUKevFAI0k6uRL_CkWLyPw_4_9"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13070000</pbm:NumberOfWarrantsExercisable>
    <pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="2"
      id="Tc_3xSVeqQ3Nk-ROl2Nh-Hq5A_5_5"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">11.50</pbm:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <pbm:NumberOfWarrantsOutstanding
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="INF"
      id="Tc_GFQBI6kN9UKT5kSZa1wYFA_5_7"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13070000</pbm:NumberOfWarrantsOutstanding>
    <pbm:NumberOfWarrantsExercisable
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="INF"
      id="Tc_aVST9ijzJEO7JPvymmFvew_5_9"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13070000</pbm:NumberOfWarrantsExercisable>
    <pbm:PromissoryNotesTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_Jr1avuuqeEm9_ECxbFH9PA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Promissory Notes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;25, 2024, the Company issued an unsecured convertible promissory note to Psyence Group&#160;Inc. (the &#x201c;&lt;b style="font-weight:bold;"&gt;PGI Note&lt;/b&gt;&#x201d;), in the principal amount of $1,610,657, which is equal to the total amount owed to PGI in connection with loans the PGI had previously made to the Company. The PGI Note&#160;bears no interest, and (i)&#160;$150,000 of the principal balance of the PGI Note&#160;was paid on the date of the Closing and (ii)&#160;$1,460,657 of the principal balance of the PGI Note&#160;will be payable on the date that is the one-year anniversary after the Business Combination, or January&#160;25, 2025. The proceeds from this loan were already received by the Company prior to the acquisition date. This note is convertible into shares at the option of PGI. The conversion price will be mutually agreed upon and such conversion terms will not be less favourable than the below NCAC convertible promissory note. Given that the conversion price is not fixed, the conversion feature has been determined to be an embedded derivative and thus the entire instrument has been designated as FVTPL. The PGI Note upon initial recognition at fair value was $1,418,675. At year end the fair value of the PGI Note was $1,316,236. A fair value loss of $47,561, after factoring in the repayment of $150,000, was included in the consolidated statements of net loss and comprehensive loss relating to the PGI Note.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The fair value of the notes was calculated using a credit adjusted market borrowing rate to determine fair value. Since the PGI Note is from a related party the difference between fair value and the face value of the PGI Note on initial measurement was recognized in other comprehensive loss. Subsequent change in fair value movements is recognized in consolidated statements of net loss and comprehensive loss.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;25, 2024, NCAC issued an unsecured convertible promissory note, prior to the closing of the RTO, to the NCAC Sponsor (the &#x201c;&lt;b style="font-weight:bold;"&gt;NCAC Replacement Note&lt;/b&gt;&#x201d;), in the principal amount of $1,615,501, which is equal to the total amount owed to Sponsor under certain existing promissory notes previously issued by NCAC to the Sponsor (the &#x201c;&lt;b style="font-weight:bold;"&gt;Existing Notes&lt;/b&gt;&#x201d;). The NCAC Replacement Note&#160;bears no interest, and (i)&#160;$100,000 of the principal balance of the NCAC Replacement Note&#160;became owing on the date of the Closing and (ii)&#160;$1,515,501 of the principal balance of the NCAC Replacement Note&#160;will be payable on the date that is the one-year anniversary after the Business Combination, or January&#160;25, 2025. As at March 31, 2024 the Company had not made payment of the $100,000 owing to the NCAC Sponsor. This note is convertible into shares at the option of NCAC Sponsor. The conversion price will be mutually agreed upon and such conversion terms will not be less favourable than the above PGI convertible promissory note. Given that the conversion price is not fixed, the conversion feature has been determined to be an embedded derivative and thus the entire instrument has been designated as FVTPL. The NCAC Replacement Note upon initial recognition at fair value was $1,413,529. At year end the fair value of the NCAC Replacement Note was $1,474,255. A fair value loss of $60,727 was included in the consolidated statements of net loss and comprehensive loss relating to the NCAC Replacement Note.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the notes was calculated using a credit adjusted market borrowing rate.&lt;/p&gt;</pbm:PromissoryNotesTextBlock>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ"
      decimals="0"
      id="Narr_-fS2Ulmor0yJbZC9hB8gyA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1610657</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ"
      decimals="2"
      id="Narr_sF4JSFQmwUC46-vUtMA9HA"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_Rt33JWhG7ku7cESAe2Q9TA"
      decimals="0"
      id="Narr_uxRhJY9rSUSKBybFkLJSQA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">150000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <ifrs-full:CurrentDebtInstrumentsIssued
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_srt_StatementScenarioAxis_pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_5hN9t5cHDkWZRJOTiq9-ZQ"
      decimals="0"
      id="Narr_R7EkraA580OUPkN4VST8hg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1460657</ifrs-full:CurrentDebtInstrumentsIssued>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_dGoclaX5NESGtpH14gxnGQ"
      decimals="0"
      id="Narr_SxklkCSwtEOOA-C1-coX_A"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1418675</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_0gDwTd2QTkau6NL_MH7NiA"
      decimals="0"
      id="Narr_xfc1thKO0U2QhEET7eI-7Q"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1316236</ifrs-full:FinancialLiabilitiesAtFairValue>
    <pbm:FairValueAdjustmentOnPromissoryNote
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_Rt33JWhG7ku7cESAe2Q9TA"
      decimals="0"
      id="Narr_DqXzZ7xYu0SdK31jban7_Q"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">47561</pbm:FairValueAdjustmentOnPromissoryNote>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_Rt33JWhG7ku7cESAe2Q9TA"
      decimals="0"
      id="Narr_Rhqhs6V8S0ycNrRzT4WUKA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">150000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_nXcMNI1ydUezo0_dxGEwgQ"
      decimals="0"
      id="Narr_grp58mLg3kGfdbI_c4XnOA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1615501</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_nXcMNI1ydUezo0_dxGEwgQ"
      decimals="INF"
      id="Narr_ytYqbyxkOU-sCC59nwc7DA"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:RepaymentsOfCurrentBorrowings
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_-EfQBvs7Lka4G6nGPl75Bw"
      decimals="0"
      id="Narr_cWv8oJ1w3kmN7VVWIh89Og"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">100000</ifrs-full:RepaymentsOfCurrentBorrowings>
    <ifrs-full:CurrentDebtInstrumentsIssued
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_srt_StatementScenarioAxis_pbm_NotesPayableOnDateOfThatIsOneYearAnniversaryAfterBusinessCombinationOrJanuary252025ClosingMember_miXMAYbfxkOSULYF69B0Hw"
      decimals="0"
      id="Narr_GkhLFY6Qg0SVkHtnRv7JUQ"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1515501</ifrs-full:CurrentDebtInstrumentsIssued>
    <ifrs-full:CurrentDebtInstrumentsIssued
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_tIiRp3n8-02l_21JjlykGA"
      decimals="0"
      id="Narr_DwO74JaS3kqGAEvVK_ZnwA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">100000</ifrs-full:CurrentDebtInstrumentsIssued>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_nXcMNI1ydUezo0_dxGEwgQ"
      decimals="0"
      id="Narr_RTL-lWz84UaLfrmqRNC_kA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1413529</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_tIiRp3n8-02l_21JjlykGA"
      decimals="0"
      id="Narr_xPpIlpbJf0egkNxe-tCVtQ"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1474255</ifrs-full:FinancialLiabilitiesAtFairValue>
    <pbm:FairValueAdjustmentOnPromissoryNote
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_BorrowingsByNameAxis_pbm_UnsecuredConvertiblePromissoryNotesMember_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_-EfQBvs7Lka4G6nGPl75Bw"
      decimals="0"
      id="Narr_Sj0n-FPaT06Stg0opc3rDw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">60727</pbm:FairValueAdjustmentOnPromissoryNote>
    <ifrs-full:DisclosureOfIssuedCapitalExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_xKncB5O7XUWGz00o3vFefQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Share capital&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;a) Authorized&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is authorized to issue an unlimited number of Common Shares, each without par value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;b) Issued and outstanding&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As at March&#160;31, 2024, there were 13,390,659 (March 31, 2023 &#x2013; nil) issued and &lt;span style="-sec-ix-hidden:Hidden_t5Q4ViJtT0a_n3x8PTtDQg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt; Common Shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January&#160;25, 2024, because of the completion of the RTO Transaction, the Company issued 5,000,000 Common Shares to PGI, 7,794,659 to the previous shareholders of NCAC and 596,000 to third party advisors (see Note&#160;5).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Payments to advisors of NCAC was settled in the Company&#x2019;s shares upon RTO at the closing price. Accounts payable of $2,136,340 acquired from NCAC as part of the RTO transaction was settled through the issuance of 446,000 shares at a fair value of $4.79 per share on January 25, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;An amount of $1,000,000 owing by the Company for services provided in relation to the RTO transaction was settled through the issuance of 150,000 common shares at a fair value of $4.79. A gain on settlement of $281,500 was included in the consolidated statements of net loss and comprehensive loss relating to this advisor settlement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The prior year equity is the net parent investment which represents the net financings that the Company received from Psyence Group to fund it&#x2019;s operations through contributions to the clinical trials, cash extended to the Company&#x2019;s subsidiaries and the net effect of cost allocations from transactions with Psyence Group, all of which did not require repayments.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;c) Loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The calculation of basic and diluted loss per share is based on the loss for the&#160;year divided by the weighted average number of shares in circulation during the&#160;year. In calculating the diluted loss per share, potentially dilutive shares such as options, convertible debt and warrants have not been included as they would have the effect of decreasing the loss per share, and they would therefore be anti-dilutive.&lt;/p&gt;</ifrs-full:DisclosureOfIssuedCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="INF"
      id="Narr_TaJIUzhq4kWCHqW0pJNhrA"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">13390659</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="INF"
      id="Narr_Um3_ydiilkmD8SnGymuTuA"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">0</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="INF"
      id="Narr_6NH2QaU5RkuqTD28a7mc5Q"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">0</ifrs-full:NumberOfSharesIssued>
    <pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_0wYG8t1HXE-O2rRhbaBJaw"
      decimals="INF"
      id="Narr_BDxcY74D8UK_DqcupXCpmA"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">5000000</pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction>
    <pbm:ReverseTakeoverTransactionSharesIssued
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_KTMtplbPx0WC_t5qQhav6w"
      decimals="INF"
      id="Narr_kqNbPCj6i0yLZqxoArc1-A"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">7794659</pbm:ReverseTakeoverTransactionSharesIssued>
    <pbm:ReverseTakeoverTransactionSharesIssued
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_ThirdPartyAdvisorsMember_mC8mvXWyOki084m60qbTKQ"
      decimals="INF"
      id="Narr_DjTSbSzLKUKlhjm7dYt7Cg"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">596000</pbm:ReverseTakeoverTransactionSharesIssued>
    <ifrs-full:TradeAndOtherPayables
      contextRef="As_Of_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_DRqwp1PzKECgohUZ8NbYwA"
      decimals="0"
      id="Narr_Z80Rv8zOa0OpKec-6AFOMQ"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2136340</ifrs-full:TradeAndOtherPayables>
    <pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction
      contextRef="Duration_1_25_2024_To_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_KTMtplbPx0WC_t5qQhav6w"
      decimals="INF"
      id="Narr_nS6IhhZ04UWPXyy0H0suKg"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">446000</pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_1_25_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacMember_DRqwp1PzKECgohUZ8NbYwA"
      decimals="2"
      id="Narr_VA1ZTw3bqEWVJRP0h7HzFg"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">4.79</ifrs-full:ParValuePerShare>
    <ifrs-full:ServicesExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Narr_mSxw3Vb3OkqHvgNoClLwQg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1000000</ifrs-full:ServicesExpense>
    <pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="INF"
      id="Narr_YSmQMG_t8k-npx-9L4UYaQ"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">150000</pbm:StockIssuedDuringPeriodSharesIssuedForReverseTakeoverTransaction>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="2"
      id="Narr_2SQoqYWg3Equ3pwQaDuhMQ"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">4.79</ifrs-full:ParValuePerShare>
    <pbm:IfrsGainLossOnExtinguishmentOfDebt
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Narr_KbvQmOV-hkqiYz4mGXtVVg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">281500</pbm:IfrsGainLossOnExtinguishmentOfDebt>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_tYvmM4zT7kqIK-hpO9LvqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Other income&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company received a research and development rebate of AUD $1,336,622 ($879,344) from the Australian Taxation office. The Company benefits from the Australian Federal Government&#x2019;s Research&#160;&amp;amp; Development tax incentive program, which provides up to a 43.5% rebate on research and development expenses in Australia.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;This rebate represents a government grant aimed at supporting research and development activities. Therefore, in accordance with International Financial Reporting Standards (IFRS), the grant is recognized as income when there is a reasonable assurance that the grant will be received and that the Company will comply with the conditions attached to it. These conditions were satisfied when the Company received the rebate on October&#160;5, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On August&#160;21, 2023 the Company entered into a loan agreement via its Australian subsidiary Psyence Australia (Pty) Ltd (the &#x201c;&lt;b style="font-weight:bold;"&gt;Borrower&lt;/b&gt;&#x201d;), to borrow up to AUD $1,100,000 by way of a secured loan from RH Capital Finance Co.,&#160;LLC. The Loan is secured by way of a General Security Agreement and company guarantee against the assets of the Borrower and the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The loan was granted to the Borrower after it successfully registered its research and development activities with the Australian Federal Government. The Borrower benefits from the Australian Federal Government&#x2019;s Research&#160;&amp;amp; Development tax incentive program, which provides up to a 43.5% rebate on research and development expenses in Australia. The Loan bears interest at 16% per annum subject to a minimum interest chargeable period of 91&#160;days and is repayable at the earlier of: (a)&#160;21 business&#160;days after the notice of assessment (in respect of R&amp;amp;D refunds) is issued by the Australian Taxation Office to the Borrower for the financial&#160;year ended June&#160;30, 2023 (b)&#160;an event of default and (c)&#160;30 November&#160;2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The loan with RH Capital Finance Co., LLC was repaid in full on October&#160;5, 2023 when the Company received the research and development rebate from the Australian Taxation office, which was utilized to settle the loan payable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;$29,697 (March&#160;31, 2023&#160;- $nil) in interest expense was incurred during the&#160;year ended March&#160;31, 2024, on this loan. The loan and all outstanding interest was repaid.&lt;/p&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw"
      decimals="0"
      id="Narr_8CHaM1nCTEWI0gPCd1NU7Q"
      unitRef="Unit_Standard_AUD_jW69VxHF6ECitQL_0ZsRRw">1336622</ifrs-full:RevenueFromGovernmentGrants>
    <ifrs-full:RevenueFromGovernmentGrants
      contextRef="Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw"
      decimals="0"
      id="Narr_lRB0hHrEI0GMfJQfAy3ENg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">879344</ifrs-full:RevenueFromGovernmentGrants>
    <pbm:MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram
      contextRef="Duration_10_5_2023_To_10_5_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_cW3WpCf9GEi9oAtFbn8_cw"
      decimals="3"
      id="Narr_h12y_8jr-Um6zhPPyo3W_Q"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.435</pbm:MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_ieM9jWT5V0m51QaeqASX4w"
      decimals="0"
      id="Narr_8IgELxvGNEK7rN-Kal_Rqw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1100000</ifrs-full:NotionalAmount>
    <pbm:MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram
      contextRef="Duration_8_21_2023_To_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_4lNLIUCIGkWdqrARdGf_Vw"
      decimals="3"
      id="Narr_Ji-LpXlBLk65BJswQaZhZQ"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.435</pbm:MaximumPercentageOfRebateOnResearchDevelopmentTaxIncentiveProgram>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_ieM9jWT5V0m51QaeqASX4w"
      decimals="2"
      id="Narr_tkSAuSjgbUCKNWWEsUwkkQ"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.16</ifrs-full:BorrowingsInterestRate>
    <pbm:BorrowingsMinimumInterestChargeablePeriod
      contextRef="Duration_8_21_2023_To_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_4lNLIUCIGkWdqrARdGf_Vw"
      id="Narr_6A9MBUvLuEq_WE3MTYWANQ">P91D</pbm:BorrowingsMinimumInterestChargeablePeriod>
    <pbm:BorrowingsPeriodToRepayAfterNoticeOfAssessment
      contextRef="Duration_8_21_2023_To_8_21_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_4lNLIUCIGkWdqrARdGf_Vw"
      id="Narr_FOHRsQAquEKcZo1PsgsIcQ">P21D</pbm:BorrowingsPeriodToRepayAfterNoticeOfAssessment>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_3f-lrQXd4E6JrxjlD7INuQ"
      decimals="0"
      id="Narr_WJnFB5YgPUetVdEohHnh5w"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">29697</ifrs-full:InterestExpenseOnBorrowings>
    <ifrs-full:InterestExpenseOnBorrowings
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_BorrowingsByNameAxis_pbm_LoanFromRhCapitalFinanceCo.LlcMember_qlM5Q3rZkUqmLNL6sPVskw"
      decimals="0"
      id="Narr_qZsxVk22uUazyzwF69RsYQ"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">0</ifrs-full:InterestExpenseOnBorrowings>
    <pbm:CapitalManagementDisclosureTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_7gX-S4-Hg0irHiZ7RLI2eg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Capital management&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s objectives when managing capital are to safeguard the Company&#x2019;s ability to continue as a going concern to pursue the development of natural health business, to maintain a flexible capital structure which optimizes the cost of capital at an acceptable risk level.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages its capital structure and adjusts it considering changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may obtain additional funding from equity financing, issue new debt, acquire or dispose of assets or adjust the amount of cash and cash equivalents on hand.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;To facilitate the management of its capital requirements, the Company prepares annual budgets that are updated as necessary depending on various factors, including successful capital deployment and general industry conditions. The annual and updated budgets are approved by the Board of Directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Management considers its approach to capital management to be appropriate given the relative size of the Company. There were no changes in the Company&#x2019;s approach to capital management during the period.&lt;/p&gt;</pbm:CapitalManagementDisclosureTextBlock>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_h-iJYccXpkW6hVyfGHvLaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15. Transactions with related parties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All related party transactions are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties. All amounts either due from or due to related parties other than specifically disclosed are non-interest bearing, unsecured and have no fixed terms of repayments. The Company incurred the following transactions with related parties during the&#160;years ended March&#160;31, 2024 and March&#160;31, 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Compensation to key management personnel&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Key management personnel are those people who have authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include the Company&#x2019;s executive officers and Board of Directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Key Management Personnel&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short term benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 465,702&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 593,729&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 233,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174,782&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 698,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 768,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Short term benefits consist of consulting fees, director&#x2019;s fees, payroll and other benefits paid to key management personnel. Share based compensation is options granted to key management personnel.&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_9TujsyO-FEuRALAGP8aW9A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Key Management Personnel&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Short term benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 465,702&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 593,729&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 233,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 174,782&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 698,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 768,511&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_h6CYSEgHeE-rjv9vhAKjIw_2_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">465702</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_ruWF0B5UQ0iZ7eE0Jam4Iw_2_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">593729</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_1NBh9nOPrE-kcQaee-BoHw_3_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">233295</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_kKR39HHap0GvBLZNYjgSCw_3_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">174782</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_TTGziQSk8Ey2vHBpig-fuA_4_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">698997</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_HPpzIjye-UaIQXSqlqCVjg_4_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">768511</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_wot1bC_4ZkGBnnQcst3VEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;16. Share based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;During the&#160;year ended March&#160;31, 2024, $317,882 (Year ended March&#160;31, 2023&#160;- $221,287) was recognized for options and restricted stock units (&#x201c;RSU&#x2019;s&#x201d;) granted by Psyence Group under professional and consulting fees expenses and general and administrative expenses on the consolidated statements of net loss and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"&gt;This share-based compensation relates only to the historic carve out pre-combination period and does not relate to options or RSUs in the Company. No share options or &lt;span style="-sec-ix-hidden:Hidden_XxB_F4KMEE25cXOfcM4pEQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;RSUs&lt;/span&gt;&lt;/span&gt; have been issued by the Company post transaction and listing date.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Narr_k23fy62TT02TcaVMbSib1g"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">317882</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Narr_qve3RMyOfEqZg44EuuOVXw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">221287</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="INF"
      id="Narr_cS3c1YLOpEGPY5zqKrE9sQ"
      unitRef="Unit_Standard_Options_7uzaMjMwKkiCpqW1np5Gkw">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_6RHmZCAQKEG1spBFvgbCOw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17. Income tax note&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The reconciliation of the combined Canadian federal and provincial statutory income tax rate of 26.5% (2023&#160;&#x2013; 26.5%) to the effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net Income/(Loss) before recovery of income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (51,159,048)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,206,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected income tax (recovery)/expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,557,148)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (849,679)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Difference in foreign tax rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Listing expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,992,625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other permanent expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,061,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in tax benefits not recognized&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 502,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 849,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax (recovery)/expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Unrecognized deferred tax asset&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred taxes are provided as a result of temporary differences that arise due to the differences between the income tax values and the carrying amounts of assets and liabilities. Deferred tax assets have not been recognized in respect of the following deductible temporary differences:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrecognized deductible temporary differences&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,035&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-capital losses carried forward-Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,357,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-capital losses carried forward-Australia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,699,257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,646,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,721,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s non-capital loss carry forwards will expire as noted in the table below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year of expiry&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Canada&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Australia&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2044&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,357,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Indefinite&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,357,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:ApplicableTaxRate
      contextRef="Duration_4_1_2023_To_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA__NbCY8cPYUCtxWf2hnkGgw"
      decimals="3"
      id="Narr_r3UmBuDbjEy4FsIyCpP5Jg"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.265</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="Duration_4_1_2022_To_3_31_2023_ifrs-full_GeographicalAreasAxis_country_CA_ipl1RTFCVU6OA2u7sgwd-g"
      decimals="3"
      id="Narr_i7zNbyVzbUeRiFDoxEkCwg"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.265</ifrs-full:ApplicableTaxRate>
    <pbm:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_DmIzE4iLS0CIS_a_zFxsPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net Income/(Loss) before recovery of income taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (51,159,048)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,206,403)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected income tax (recovery)/expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,557,148)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (849,679)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Difference in foreign tax rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Listing expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,992,625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other permanent expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,061,001&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in tax benefits not recognized&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 502,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 849,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Income tax (recovery)/expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pbm:IfrsScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <ifrs-full:AccountingProfit
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_lbzVtJnSCUKqTta8n9Ydow_2_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-51159048</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_OWGnjgJuX0SvghqmWnJmeA_2_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-3206403</ifrs-full:AccountingProfit>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_Vc8H6LHXNE2TFEAYZuVdGQ_3_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-13557148</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_evdkFlrxpUiKMYi7wEnJXw_3_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">-849679</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_YeFXCGYX6kKEoRpi6DY-BQ_4_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">966</ifrs-full:TaxEffectOfForeignTaxRates>
    <pbm:TaxEffectOflistingExpense
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_Lgy2DU9JAEezR28PGOEcSQ_5_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">10992625</pbm:TaxEffectOflistingExpense>
    <pbm:TaxEffectOfotherPermanentExpenses
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_KBabWDCviUOxjfg0-d2X3w_6_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">2061001</pbm:TaxEffectOfotherPermanentExpenses>
    <pbm:TaxEffectFromChangeInTaxBenefitsNotRecognized
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Tc_OgFzGuQGyUm9aPa8JlE9MQ_7_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">502556</pbm:TaxEffectFromChangeInTaxBenefitsNotRecognized>
    <pbm:TaxEffectFromChangeInTaxBenefitsNotRecognized
      contextRef="Duration_4_1_2022_To_3_31_2023_7zRphJB1KUCYcPWaQnRfVA"
      decimals="0"
      id="Tc_1XM2wKwNaEqm0TD_PIvGGg_7_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">849679</pbm:TaxEffectFromChangeInTaxBenefitsNotRecognized>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_iV4aqMeHE0-r6AG7bhYwJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrecognized deductible temporary differences&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 240&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 124,132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,035&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-capital losses carried forward-Canada&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,357,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-capital losses carried forward-Australia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164,861&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,699,257&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,646,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,721,292&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="As_Of_3_31_2024_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_ComputerEquipmentMember_7jZCSqZ_9UaOraMsvT_DUg"
      decimals="0"
      id="Tc_zqjpnTabjUCbJGoTWGi5lg_2_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">240</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="As_Of_3_31_2024_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_pbm_LoanLiabilityMember_Bfg_MzgGgE248VkLkaHv1A"
      decimals="0"
      id="Tc_aZ74Q6NyhEyIj0EZ5i0fdg_3_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">124132</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="As_Of_3_31_2023_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_pbm_LoanLiabilityMember_IYWYvzYJfU2ryBzR65Zllg"
      decimals="0"
      id="Tc_XC05k7wybkib7tu6qEAgzg_3_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">22035</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_ebbDbrQcZkK0zv4fy_SFHg"
      decimals="0"
      id="Tc_fPa5mQkVu0mlJuMJUBSOWw_4_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1357347</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_nAJQDxrBpkSuuvZsO96n0Q"
      decimals="0"
      id="Tc_stkYiZEbFUqXPo6FZO0iKw_5_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">164861</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="As_Of_3_31_2023_ifrs-full_GeographicalAreasAxis_country_AU_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_ifrs-full_UnusedTaxLossesMember_oXkJbW1flU65sYmCYJGLPg"
      decimals="0"
      id="Tc_Q03xLiiDfkadmAdf4w8HDA_5_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1699257</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_fgvqbQXSV021CEhM14FOAA_6_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1646580</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="As_Of_3_31_2023_d2xAXzKGk0mCBOnPjazL6w"
      decimals="0"
      id="Tc_9V7Q5B9BB0KGIukNcesh7A_6_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1721292</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <pbm:IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_zpBF2twU_Uy6eQQIXOFxKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year of expiry&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Canada&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Australia&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2044&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,357,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Indefinite&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,357,347&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pbm:IfrsSummaryOfOperatingLossCarryForwardsTableTextBlock>
    <pbm:NonCapitalLossCarryForwards
      contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_pbm_IfrsTaxPeriodAxis_pbm_TaxYear2044Member_WwE4lXg6VE6ETeoIPfEQ6w"
      decimals="0"
      id="Tc_IQ2zSQOh6UCZjbQdwsepKw_2_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1357347</pbm:NonCapitalLossCarryForwards>
    <pbm:NonCapitalLossCarryForwards
      contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_pbm_IfrsTaxPeriodAxis_pbm_IndefinitePeriodMember_X0xZ3jp2mkq_3uYS8sNVww"
      decimals="0"
      id="Tc_g9GUgzeeuE6xiVXutrMWTA_3_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">164861</pbm:NonCapitalLossCarryForwards>
    <pbm:NonCapitalLossCarryForwards
      contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_CA_RIjV61siK0uleVe4MSXSMg"
      decimals="0"
      id="Tc_Y68susX21EOhwKR2lF4Qvw_4_2"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">1357347</pbm:NonCapitalLossCarryForwards>
    <pbm:NonCapitalLossCarryForwards
      contextRef="As_Of_3_31_2024_ifrs-full_GeographicalAreasAxis_country_AU_ay66gT7zZ0uREQ7yRI0cAw"
      decimals="0"
      id="Tc_PR7PGfO7SEWwSZ6VRq2xGQ_4_4"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">164861</pbm:NonCapitalLossCarryForwards>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_fZ3wPvk57UGE6UumSG_1hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;18. Financial instruments and financial risk management&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;a) Financial instrument classification and fair value measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that are recorded at fair value on the consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of hierarchy has the following levels:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1&#160;&#x2013; quoted prices in active markets for identical financial instruments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2&#160;&#x2013; quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in the markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3&#160;&#x2013; valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The table below presents the carrying value of the Company&#x2019;s financial instruments:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative warrant liabilities &#x2013; private warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative warrant liabilities &#x2013; public warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 875,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 875,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,657,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,657,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;NCAC Sponsor promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,474,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,474,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;PGI promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance, March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 875,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,608&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,447,889&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,349,497&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The face value of the other financial instruments approximates the fair value due to the short-term maturity nature of the financial instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;There were no transfers in and out of level 3 during the year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;b) Risk management&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In the normal course of business, the Company is exposed to a variety of financial risks: credit risk, liquidity risk, foreign exchange risk and interest rate risk. These financial risks are subject to normal credit standards, financial controls, risk management as well as monitoring. The Company&#x2019;s Board of Directors has overall responsibility for the establishment and oversight of the Company&#x2019;s risk management framework.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Credit risk arises from cash and cash equivalents held with banks. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The objective of managing counterparty credit risk is to prevent losses on financial assets. The Company minimizes the credit risk of cash and cash equivalents by depositing with only reputable financial institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company manages liquidity risk through an ongoing review of future commitments and cash balances available. Historically, the Company&#x2019;s main source of funding has been through investments from its parent. The Company&#x2019;s access to financing is uncertain. There can be no assurance of continued access to significant equity or debt funding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table set forth the maturity of the contractual obligations as at March&#160;31, 2024 and after&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between 1 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Flows&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and 3 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accounts payable &amp;amp; accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 714,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 714,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 714,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible note liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,657,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,875,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,625,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Due to NCAC sponsor&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,615,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,615,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,615,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Due to Psyence Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,460,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,460,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,460,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total contractual obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,447,737&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,665,340&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,040,340&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,625,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Interest rate risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company has no significant interest-bearing assets or liabilities and therefore its income and operating cash flows are substantially independent of changes in market interest rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Foreign exchange risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As at March&#160;31, 2024, a 10% fluctuation in foreign exchange rates would result in a $4,139 impact to net loss and comprehensive loss.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_lO79mJUvmEeawG0ugUOuBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative warrant liabilities &#x2013; private warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,608&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,608&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Derivative warrant liabilities &#x2013; public warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 875,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 875,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,657,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,657,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;NCAC Sponsor promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,474,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,474,256&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;PGI promissory note&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &#x2014;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,316,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance, March 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 875,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26,608&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 10,447,889&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,349,497&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_H4W4G8XGKUi_LOkR72lsQA"
      decimals="0"
      id="Tc_Tfre897-2EufnmDU5aelWw_2_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">26608</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PrivateWarrantsMember_0tIdiQ7fUEKkoN3p-hLo-Q"
      decimals="0"
      id="Tc_xdXzQD0_3kuQitIrU8dpcA_2_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">26608</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PublicWarrantsMember_dwZDj5CY_kWj6NkZwas54g"
      decimals="0"
      id="Tc_0oybAn8usU6SpwQFUtEDgQ_3_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">875000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_WarrantLiabilitiesMember_pbm_IfrsClassOfWarrantOrRightAxis_pbm_PublicWarrantsMember_ZIGv0avMc0GYY8eOD0yDqw"
      decimals="0"
      id="Tc_R19rfPXjTU2OXD243RmOjg_3_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">875000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_5wmoOjA370-BDjmpcYZTtw"
      decimals="0"
      id="Tc_Ift6JbVhw0O_eU0uoNej-g_4_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">7657397</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_HzIBP-BDS0iBcUlFJmYxvQ"
      decimals="0"
      id="Tc_6-RRM5H3H0WUDkM76p9KIg_4_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">7657397</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_a6DRGR0kP0CtkXqAEpTHbw"
      decimals="0"
      id="Tc_HC9Yr-OGxUulSd5oRLa3Qg_5_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1474256</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_sCiZc0LkzEif6BGm_OtlfA"
      decimals="0"
      id="Tc_23ucUCAiCkStVvHsHCd8Jw_5_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1474256</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsPromissoryNoteMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_1MqeGaZQTkmZ9uo64ysG4Q"
      decimals="0"
      id="Tc_zjADtPutRECW_B_uErTmSA_6_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1316236</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsPromissoryNoteMember_9ScKY7OBvU6qJkoGTvZzKw"
      decimals="0"
      id="Tc_wS4VIrY81ke3gU58Jx7USQ_6_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1316236</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_gpUJ9iKr40yfgmBdIh8i8Q"
      decimals="0"
      id="Tc_U3Lz1u_MG0GDD3k43Ckw_w_7_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">875000</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level2OfFairValueHierarchyMember_GVpNsIbN90GJv-LofUYMOg"
      decimals="0"
      id="Tc_KBilO7-pukevaskWemvctg_7_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">26608</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_9W7HSkN-ZEWhSSTlLJLMYw"
      decimals="0"
      id="Tc_yj-JyL0LCke2Enxy9lMVRA_7_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">10447889</ifrs-full:FinancialLiabilitiesAtFairValue>
    <ifrs-full:FinancialLiabilitiesAtFairValue
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_B02ceIRr2UC2Li6i-xp2MQ_7_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">11349497</ifrs-full:FinancialLiabilitiesAtFairValue>
    <pbm:ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_b1lSi6mWy0iSW4LxBedeFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Less than 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Between 1 &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Flows&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; year&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;and 3 years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accounts payable &amp;amp; accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 714,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 714,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 714,182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Convertible note liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,657,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,875,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,625,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Due to NCAC sponsor&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,615,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,615,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,615,501&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Due to Psyence Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,460,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,460,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,460,657&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total contractual obligations&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 11,447,737&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,665,340&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,040,340&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,625,000&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pbm:ScheduleOfMaturityAnalysisOfFinancialLiabilitiesTableTextBlock>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_AmT7G0GxkU2kHfFmvoXWyg"
      decimals="0"
      id="Tc_4TovZc-9TUm3gDm_WDLLUw_3_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">714182</ifrs-full:FinancialLiabilities>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_AmT7G0GxkU2kHfFmvoXWyg"
      decimals="0"
      id="Tc_YBE6XTNZfkmcou8qY9Btog_3_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">714182</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsAccountsPayableAndAccruedLiabilitiesMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_0Qw1JPRffk-sFJICGMRYNg"
      decimals="0"
      id="Tc_ONjfTP7d2EyOyc8b1Fkyaw_3_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">714182</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_HzIBP-BDS0iBcUlFJmYxvQ"
      decimals="0"
      id="Tc_byXQSjIYHkyjHe6wFUEfJw_4_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">7657397</ifrs-full:FinancialLiabilities>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_HzIBP-BDS0iBcUlFJmYxvQ"
      decimals="0"
      id="Tc_GjNbjL4Pi0uME7FT6AXUZA_4_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">3875000</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_cEdgQ5bJd06uTqKWAeXLww"
      decimals="0"
      id="Tc_1wsW8QGVbUSPAFSrp4f42g_4_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">250000</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_IfrsConvertibleDebtMember_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_CBu0LGH96Uq1bwkLGIZIlw"
      decimals="0"
      id="Tc_HBrd8r7vrEqgm3iY77uNpg_4_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">3625000</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_h3aSU-K3ukq60Id9Kf0N4w"
      decimals="0"
      id="Tc_7Ue94PVWZ0GYQ5ZgShzctA_5_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1615501</ifrs-full:FinancialLiabilities>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_h3aSU-K3ukq60Id9Kf0N4w"
      decimals="0"
      id="Tc_BRAHNF_ou0O2OJKa05SeNw_5_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1615501</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_pbm_NcacSponsorMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_fldBCEgE6kSkrzCFgPayzg"
      decimals="0"
      id="Tc_IYDkLDcrP0OYOn44J8WIvQ_5_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1615501</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_aKXOxKCzikiefTsqg-KknQ"
      decimals="0"
      id="Tc_0ICYLiIGdUu8XrJV7JoGZw_6_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1460657</ifrs-full:FinancialLiabilities>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_aKXOxKCzikiefTsqg-KknQ"
      decimals="0"
      id="Tc_UrPqlRU3U06ksaUAXeOYhA_6_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1460657</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_ParentMember_ifrs-full_ClassesOfFinancialLiabilitiesAxis_pbm_DebtIssuedMember_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_o-z_ZS_GkkqdhTX8BnXnaQ"
      decimals="0"
      id="Tc_AXaMaramB0i-s0duI0t4Bw_6_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1460657</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <ifrs-full:FinancialLiabilities
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_6ru2r3WaDkeRNluTPaMf9Q_7_2"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">11447737</ifrs-full:FinancialLiabilities>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="0"
      id="Tc_PmKF-qH0fUy_eNo1LsGKIQ_7_4"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">7665340</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_-EyNTF-GgkaIrUlPa35XIg"
      decimals="0"
      id="Tc_6LcU-R1oaEqTkQ58gNt-XA_7_6"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">4040340</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <pbm:FinancialLiabilitiesUndiscountedCashFlows
      contextRef="As_Of_3_31_2024_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember_Se9-CIpcRkaZzb8oP9NClQ"
      decimals="0"
      id="Tc_2Oy9JEaweEevqLeFBkHV2A_7_8"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">3625000</pbm:FinancialLiabilitiesUndiscountedCashFlows>
    <pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption
      contextRef="As_Of_3_31_2024_iaDt8KWMrkmPQ4u_n0GcWw"
      decimals="2"
      id="Narr_ayDNJG7jeU6AIzvfXnr2Uw"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.10</pbm:PercentageOfReasonablyPossibleChangeInRiskAssumption>
    <pbm:IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="0"
      id="Narr_NIPG85VJkUGEqIPBAGzwtg"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">4139</pbm:IncreaseDecreaseInProfitOrLossDueToReasonablyPossibleChangeInDesignatedRiskComponent>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      id="Tb_-8wbqtV5ZkC80XdpNqlxdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;19. Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received additional financing of $1,000,000 related to the Second Tranche of convertible notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;On May&#160;31, 2024, the Company received proceeds of $250,000 related to the issuance of the Second Tranche Notes. The principal amount of $312,250 was issued under the same terms as the First Tranche Notes, with interest accruing at 8.0% per annum from the issuance date. The Conversion Price remains subject to adjustment as per the terms outlined in the original Securities Purchase Agreement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;On June&#160;17, 2024, an additional $250,000 in proceeds was received by the Company for the issuance of the Second Tranche Notes. The principal amount issued was $312,250, also under the terms consistent with the First Tranche Notes. Interest accrues at 8.0% per annum from the date of issuance, with the Conversion Price subject to the same adjustment mechanisms detailed in the initial agreement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On July 15, 2024, an additional $500,000 in proceeds was received by the Company for the issuance of the Second Tranche Notes. The principal amount issued was $625,000, also under the terms consistent with the First Tranche Notes. Interest accrues at 8.0% per annum from the date of issuance, with the Conversion Price subject to the same adjustment mechanisms detailed in the initial agreement.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These subsequent financings are part of the Convertible Note&#160;Financing arrangement entered into in connection with the RTO Transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has received two conversion notices related to the First Tranche of convertible notes:&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;On May&#160;15, 2024, a conversion notice was received for a principal amount of $70,000. This amount converted at a VWAP of $0.5361 per share, resulting in the issuance of 130,572 shares.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;On June&#160;20, 2024, a second conversion notice was received for a principal amount of $1,072,200. This converted at a VWAP of $0.5361 per share, leading to the issuance of 2,000,000 shares.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Concurrently, the Company issued 86,790 shares on May&#160;15, 2024, and 78,522 shares on June&#160;20, 2024, to cover outstanding interest on the outstanding principal at a VWAP of $0.5361 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;These conversions and interest issuances are in accordance with the terms outlined in the Securities Purchase Agreement and are related to the Convertible Note&#160;Financing arrangement initiated in connection with the RTO Transaction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In July, 2024, the Company completed a warrant exchange agreement with an unaffiliated third-party investor of warrants to purchase the Company&#x2019;s common shares, no par value per share, which warrants are currently trading on Nasdaq. Pursuant to the Warrant Exchange Agreement, the Company issued to the Holder 660,000 Common Shares in exchange for the surrender and cancellation of 660,000 Public Warrants held by the Holder.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On May&#160;16, 2024, the Company issued an additional 178,000 shares to third-party consultants and legal advisors.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_3_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_WCUD7D3O30eL671BNA5zOQ"
      decimals="0"
      id="Narr_LJ9pdFvQdEypOet19sw5DA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1000000</ifrs-full:NotionalAmount>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_5_31_2024_To_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_n_9pkBhIOEaocJLzvCa1KQ"
      decimals="0"
      id="Narr_si0jORV7_EeHmZMmXnVz4w"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">250000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_xbkoUUMcMU-zQH04gc1B7Q"
      decimals="0"
      id="Narr_KXaYmdQII0evGHRvEggxpw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">312250</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_5_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_xbkoUUMcMU-zQH04gc1B7Q"
      decimals="3"
      id="Narr_J5jsS-KbRUWwKjXTkHMFgQ"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.080</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_6_17_2024_To_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_TakD6semK0yRl952XvE8qg"
      decimals="0"
      id="Narr_BYUIGXDRlkSd7TVTX1jgrA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">250000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_BJrV3lqLKEyRyjAj25AV4Q"
      decimals="0"
      id="Narr_o3MVvcO-okWeXbcpCERDng"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">312250</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_6_17_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_PM6a_iQxqU-pxFt4cy2t8A"
      decimals="3"
      id="Narr_QrG-qNIC0kasRW2y2-qbUQ"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.080</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_zZkoynDJMUmruO9PlmDnHQ"
      decimals="0"
      id="Narr_bhpFkTUWpUuBAgOLvQr_uw"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">500000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:NotionalAmount
      contextRef="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RxOFqjiYkk-14gPIVMGVgg"
      decimals="0"
      id="Narr_-v568Oc-Zki7nbgVhScmBA"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">625000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SecondTrancheNoteMember_nExNeJnlAkCUbDgmBzFjag"
      decimals="3"
      id="Narr_bsPzsLA-UUyHaxeVlTPDCA"
      unitRef="Unit_Standard_pure_a1C9kKmC1kyoNP-TE4zegQ">0.080</ifrs-full:BorrowingsInterestRate>
    <pbm:NumberOfConversionNotices
      contextRef="Duration_4_1_2023_To_3_31_2024_Co7qpkKwh0i0zaLzBG3ZNA"
      decimals="INF"
      id="Narr_zSc7fozTTUeGkVT4CZJmaQ"
      unitRef="Unit_Standard_item_UvXiJIoL7UuisD9QxiYQ7A">2</pbm:NumberOfConversionNotices>
    <pbm:IfrsDebtConversionOriginalDebtAmount1
      contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_w55DsmyS8EihPG7FoizvZw"
      decimals="0"
      id="Narr_uixnfqiS-UWbiCLQeqbFHA"
      unitRef="Unit_Standard_CAD_Ro_5nbPJwk2cAm4iZ3N9iA">70000</pbm:IfrsDebtConversionOriginalDebtAmount1>
    <pbm:DebtConversionVolumeWeightedAveragePricePerShare
      contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_w55DsmyS8EihPG7FoizvZw"
      decimals="4"
      id="Narr_xcWbYWHGvUif72YjaqsepQ"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0.5361</pbm:DebtConversionVolumeWeightedAveragePricePerShare>
    <pbm:IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_w55DsmyS8EihPG7FoizvZw"
      decimals="INF"
      id="Narr_ROzZ-vlgn0G4fF_TN7kipA"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">130572</pbm:IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <pbm:IfrsDebtConversionOriginalDebtAmount1
      contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RzTFDy0njUmWjdXWuxBKzA"
      decimals="0"
      id="Narr_svcPapFZu02aWOKVS5o8yQ"
      unitRef="Unit_Standard_USD_6ubx0K8fgEOLhz9OoojAtA">1072200</pbm:IfrsDebtConversionOriginalDebtAmount1>
    <pbm:DebtConversionVolumeWeightedAveragePricePerShare
      contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RzTFDy0njUmWjdXWuxBKzA"
      decimals="4"
      id="Narr_djF9R-cDMEKsi2LUYIVdMA"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0.5361</pbm:DebtConversionVolumeWeightedAveragePricePerShare>
    <pbm:IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_FirstTrancheNoteMember_RzTFDy0njUmWjdXWuxBKzA"
      decimals="INF"
      id="Narr_-TWtzskQWEySvRMslHPJsw"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">2000000</pbm:IfrsStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement
      contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_GWT3zleBVUqWPPvqxVkOFg"
      decimals="INF"
      id="Narr_rzaoLx6jS0Oprd9hsAOsGA"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">86790</pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement>
    <pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement
      contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_dOTID6jPYEuNrAYNswuBQA"
      decimals="INF"
      id="Narr_TiqbQHXjt0KQd6jrvyRSHA"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">78522</pbm:StockIssuedDuringPeriodSharesIssuedForDebtSettlement>
    <pbm:DebtConversionVolumeWeightedAveragePricePerShare
      contextRef="Duration_5_15_2024_To_5_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_GWT3zleBVUqWPPvqxVkOFg"
      decimals="4"
      id="Narr_dBtpyPWlrUSl6b50dv8M7A"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0.5361</pbm:DebtConversionVolumeWeightedAveragePricePerShare>
    <pbm:DebtConversionVolumeWeightedAveragePricePerShare
      contextRef="Duration_6_20_2024_To_6_20_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_IfrsConvertibleDebtMember_dOTID6jPYEuNrAYNswuBQA"
      decimals="4"
      id="Narr_oP7aQd-HnEikFYNX2dh9EA"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0.5361</pbm:DebtConversionVolumeWeightedAveragePricePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_7_31_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember_P86XfCLzD0iMCh0cmIVomA"
      decimals="INF"
      id="Narr_cPMZz7p2rEGh5uy3HFkGbA"
      unitRef="Unit_Divide_USD_shares_Q1veB1Wi1kmzQdybtG_2Fg">0</ifrs-full:ParValuePerShare>
    <pbm:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2024_To_7_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember__hvPDjzjLUyCCDf5J2hfyw"
      decimals="INF"
      id="Narr_slXEQVypRkqjsKJH6599lQ"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">660000</pbm:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <pbm:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2024_To_7_31_2024_ifrs-full_ClassesOfFinancialInstrumentsAxis_pbm_PublicWarrantsMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_UnaffiliatedThirdPartyInvestorMember_T_SrbOBOBUmz9DO4DYwbFg"
      decimals="INF"
      id="Narr_Q2Qx-4KzMkuSV6LbdbgSYA"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">660000</pbm:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <pbm:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_16_2024_To_6_16_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_pbm_SharesIssuedToThirdPartyConsultantsAndLegalAdvisorsMember_Kkk9C124KESJe8OR92o3TA"
      decimals="INF"
      id="Narr_7jQVZ5GJrE2PaYTw5nou8A"
      unitRef="Unit_Standard_shares_5fczoTvYXkad3KaxaWyInw">178000</pbm:IfrsStockIssuedDuringPeriodSharesNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
